<SEC-DOCUMENT>0001628280-21-017141.txt : 20210816
<SEC-HEADER>0001628280-21-017141.hdr.sgml : 20210816
<ACCEPTANCE-DATETIME>20210816171341
ACCESSION NUMBER: 0001628280-21-017141
CONFORMED SUBMISSION TYPE: 10-Q
PUBLIC DOCUMENT COUNT: 76
CONFORMED PERIOD OF REPORT: 20210630
FILED AS OF DATE: 20210816
DATE AS OF CHANGE: 20210816
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: ROCKWELL MEDICAL, INC.
CENTRAL INDEX KEY: 0001041024
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 383317208
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 10-Q
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23661
FILM NUMBER: 211179755
BUSINESS ADDRESS:
STREET 1: 30142 WIXOM ROAD
CITY: WIXOM
STATE: MI
ZIP: 48393
BUSINESS PHONE: 8004493353
MAIL ADDRESS:
STREET 1: 30142 WIXOM ROAD
CITY: WIXOM
STATE: MI
ZIP: 48393
FORMER COMPANY:
FORMER CONFORMED NAME: ROCKWELL MEDICAL TECHNOLOGIES INC
DATE OF NAME CHANGE: 20120530
FORMER COMPANY:
FORMER CONFORMED NAME: ROCKWELL MEDICAL, INC.
DATE OF NAME CHANGE: 20120525
FORMER COMPANY:
FORMER CONFORMED NAME: ROCKWELL MEDICAL TECHNOLOGIES INC
DATE OF NAME CHANGE: 19970722
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>rmti-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:3c1f30ef-dd44-4e46-abb9-054971f79e00,g:61350dd9-1066-401d-a0af-504d0c113dc8,d:1d62b4adfd9b4f4d858c9a9ca79e3e49--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:rmti="http://rockwellmed.com/20210630" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>
<title>rmti-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80L2ZyYWc6M2U5OTdiMTU4MTQyNDdiZDk1YWM1ODJlZDI5MTE5ZGUvdGFibGU6NzkyZmU2YmJlN2NkNGY5MmE2ZGY1ZmFiZTdmNDVkMmYvdGFibGVyYW5nZTo3OTJmZTZiYmU3Y2Q0ZjkyYTZkZjVmYWJlN2Y0NWQyZl8zLTEtMS0xLTA_b372fc19-76bb-417b-8fc8-a4d7b561d798">0001041024</ix:nonNumeric><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80L2ZyYWc6M2U5OTdiMTU4MTQyNDdiZDk1YWM1ODJlZDI5MTE5ZGUvdGFibGU6NzkyZmU2YmJlN2NkNGY5MmE2ZGY1ZmFiZTdmNDVkMmYvdGFibGVyYW5nZTo3OTJmZTZiYmU3Y2Q0ZjkyYTZkZjVmYWJlN2Y0NWQyZl80LTEtMS0xLTA_50b33b83-b6e3-4c71-b110-8c78362aa71f">false</ix:nonNumeric><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80L2ZyYWc6M2U5OTdiMTU4MTQyNDdiZDk1YWM1ODJlZDI5MTE5ZGUvdGFibGU6NzkyZmU2YmJlN2NkNGY5MmE2ZGY1ZmFiZTdmNDVkMmYvdGFibGVyYW5nZTo3OTJmZTZiYmU3Y2Q0ZjkyYTZkZjVmYWJlN2Y0NWQyZl81LTEtMS0xLTA_b5659930-9da6-4cc9-8a9a-53269aa5c928">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80L2ZyYWc6M2U5OTdiMTU4MTQyNDdiZDk1YWM1ODJlZDI5MTE5ZGUvdGFibGU6NzkyZmU2YmJlN2NkNGY5MmE2ZGY1ZmFiZTdmNDVkMmYvdGFibGVyYW5nZTo3OTJmZTZiYmU3Y2Q0ZjkyYTZkZjVmYWJlN2Y0NWQyZl82LTEtMS0xLTA_67bb139e-e206-4cba-962a-6228e726b7fd">2021</ix:nonNumeric><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80L2ZyYWc6M2U5OTdiMTU4MTQyNDdiZDk1YWM1ODJlZDI5MTE5ZGUvdGFibGU6NzkyZmU2YmJlN2NkNGY5MmE2ZGY1ZmFiZTdmNDVkMmYvdGFibGVyYW5nZTo3OTJmZTZiYmU3Y2Q0ZjkyYTZkZjVmYWJlN2Y0NWQyZl83LTEtMS0xLTA_a7d1abed-c406-44b7-9b06-45fc43d02e0f">Q2</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rmti-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i179f99b00109446d8a4f4d374551db0b_I20210813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i55273b6777354d8bbb4e783f2786d443_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i544f39c3225445aa9a9903581a14c535_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i736a800e19204a58b4825177573a05a2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b07a43b8619400ca8c95f27f08d1ba5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ba271b9447b4d5f949594629592652a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9807fc3339154e519ccef4517a1e8357_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf30cdc4b4b9449e8880eba00e1e682d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf754b423a114a0597693457a11d520c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73e508b6a03f4f7b8143e955a745dbfa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd51386c0f204b70ab961d89fac6b414_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea063dee27124e3cb8e847225bc9a727_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81559f9595424094af9504f5e9176fb6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bbc1a5a98724c2f8dca606328b38948_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56d558368b464ba98704441dbcaaabf9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabe3c25da72c456a845f39add7002756_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fcb676677b441d99b1a3adf52053525_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic460d5f9387a4d06b4cc0bc019a1734f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dce86a076074a34ab97dd39cec92b15_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9474a82666f14c4a96556216f214b159_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09f5e26ca97b4ed5a7c42b24779e77dd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic407fb18061d4956b9355d05fc844063_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idef3faf9cfc649c7b67efb0ea9882617_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b87d1b1f1f141b88fbbb40d8e3f5d32_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i974b2e044bfa4a0385fe4bbe668091b8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b18e138a6594afba9bdaa869817c283_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1331b5ebfa64639a2e460e5675967a1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib996a5fca98d4d6fa54ca00eb94caa3a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i569ca4d2801b45ef95abf90a705c76df_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib10111ed45264e43ba61d121ddd55efd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43c45a3bec674ffb9577158bb599935f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic19a9d3e1a27430b8e5242841760bea9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51f3e4812fbe47e5aa54eace8ed662e8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7e74f88217d46d08457f4184133e631_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3de306d20bfc41faa248fc7b78c41c67_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:BoughtDealMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0115d005cfa0459aa5a4504336d80145_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:BoughtDealMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id97b06daeb6d4f0382282fc44378994f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:BoughtDealMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08bdbce20f8c405a928c41402ca43cde_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc8684882fbe48c186518ce3c43ea805_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc14b52f677a45e8953c87dcfa86734e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7f30c59a79940599a681143825fab90_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d6b6a4094954db59808d66f399716fc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a4f7793fa564ff88ca3fbead5bfdd86_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1859822b74774adfbfa6ba5fad1b506d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i500b8c7b421a4b73a7804aa65a26c308_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25489ab4a8544c46b57a6837b6d94fb4_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eed6445722d476897f396e3b650e2fc_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b404b31727244c9a3dafa0dfaa79147_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b376170a7a3481b9e8ceaf392294f49_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aa75d0adc8143288bf6adb66cdca8b3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id26df19b9a654c2c8b37f4d6700c1341_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27fe27368b2b463192fd03bba6ea7fb6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07c59fcd42914f3b85721e88dd99ea93_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60accea2370749c788fcb682961480d2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i071f7359c8ca4332a2fa89ffb08ab774_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia37f306f86304d1db38e7502e2c78594_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f360d22e2b9419f8e68140a6ac31e88_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i362afd3374074c7cada0c9ce798f3143_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b04f90c66774760bcf6df9405476edc_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60a1e178baa84a468624d0acac59ece5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>rmti:employee</xbrli:measure></xbrli:unit><xbrli:context id="ib836387b9dbf4d2194d1f2d0760e18fb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4213fa50227d476f94ac06eb631a5c6f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f359e12f74143a3aecd3e1aea69c9f6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib187f06d4c2b4b44a5076ea0d0b431b5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i234e6a6e01d345a2a2a9ecbd74387219_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cb310df91c047af8dd3a11fd4886ab3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied0dd598d05f4288a25014c07eebd870_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22e74f63f96b4ccf89d59802612fc8c4_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>rmti:agreement</xbrli:measure></xbrli:unit><xbrli:context id="id817573b63f545c4b0779381d9eecaa4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9a3833807ea4f74a7a1f27cf203fd5e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4a5ecfa7b564990bee4389ba90e2ec4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieca9a4e9f9244e53bbff8d044bfaccc4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafedcd0ea4794c7aaa56752656d24c74_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6cb7e08ae2d49e6a5b26d9d272b9f1d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4ae2a5c5baf465e84899070e8d326d6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if096b68927464500b4e88829e37637c2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f3b0b018abf4ad28e152dd527bf3362_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06a344e202084e8db05b539ad000672f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if238d6f15fb74086ad99dba36761f71f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i745d398121d3420c9e3c52c10191697f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a076ec540424aaca3aa0743cc065e09_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02702a823cf648519e82be8308bd7596_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6922c012b894f83b88c3ade46b3691c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c130100b8bb44d2a7a09782e10841de_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3053c900b0b4cd6b2f2b892bea072a6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i292ea93b319445a483177b398681ba09_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ce20ced6701401694822bf3176021b8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42661da0c9dd422d99f958a822e76c80_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic569e934568a4510a8431b3e9b0cce78_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4ccc0ab30cf47169a22197ca958e494_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a7ed85229724ee2a7a0722168d880b7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4f4a67681724daaa3e7eeed7f750918_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i923167f606cf40d7a53bb0e1fbf64893_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ddb390e46cf4c218e6473e46dfc5e7e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8be39cf73a5645cfa4869eccd7ffd140_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i499887d5bc04466a881225c24de111c9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1b0c675ad3a4dc5a6cfbdb5e8eab0ba_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72196e4fcc3d4c68b85555ee776e8323_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fc604f0bbfc49e0af5bd3f913f7bcac_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9afd3e3be09480b93f86d7baf05a03e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19717f382ea34d3a8d3ba919c064ab70_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04631d2e7a6f46958f2abcf1c20c0165_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46c0764450934a84aede084a08f162d3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i453a3991692c48d196c8d65dfcef5486_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib211340e5e4741839359edb488b6820a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if69d4f2ec51d4ebab66a7c6c0b08fd69_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if84c75bc21bd454e9387eea17889b736_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica982797685d4867885a3bbb4e1799f8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84f272a5e5e04e439fb8926e0ca1edf7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4a510f683e7412cabff75b22f5281da_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f3b95dc158544189ce6a5d99f57cfed_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if572cd5222f042df8163eeda30992465_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c202ad8a44b417c93e84a0b4edc89df_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33e8984dceec4885937bef7aade6f1bf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id52be33547c9431b85a4342a2f2a4c9c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0da48e7639534786971c53ed0c8a8b79_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3579aee169c40d1b1ebf79b3f56a3a3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00411df7d3c04001838b0d136b05ff9c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1fce7f95ed24da2bedbd4e38c03b866_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0315167a57d743cb8c4cccfeed4f43c9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id72af55606eb4c8eb7cfbe2a7544505e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40b91f57dc5345558f46f78c6e809cde_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0480fc74d5745178e00498bd3c64905_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5145ce2ef7ad4c80b3936b501436c3ca_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9090f1f2b024e1fa299abac8f5b8a94_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff460b44d83a459a91b73a4e4bf3b9a6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6593dca464b48b688b4062dcb38e469_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3c726d6f00c48748ecb13e2df4349a0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if40ef0e6f3b34b859ff96c8f94e67052_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab0454faec22428e95ed05ab8e5b75e4_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57d87eb7fbd94c44a05255171f31ec4f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i855c474985a24e75a1db3f85ab19407d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fd60db6aa864ebda72c4b973f6bb595_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c57eb7213114137a35dc2e9414b8ad7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b9266a45b8644df99c3c3cc5a340793_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a6c6fed0fce4b14a3c5bd84ed2eb65a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e0a6c01cca24e8fa233e43822d66e39_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i666be76116bd4dbba8fd86f8788fbd2e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87b28ce51d1b45beb18577ab76dfd443_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cc214e4793343a9a278e81b78adef30_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c637418d7d54d0eb1be550eeadc155a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i333c560005714b44882c1307abb33985_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4800217e44243a0a6c3800959e5d3bf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6b367e5e5f34fc1abc31941f97868c3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeea20075b5643f2bc9e29ae4bc8bb9a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21c4c64e4427462690f1cc8ac29aba99_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2537301a83f4c34b4d7b41169bbdc07_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5323b8c605048f9883ce2e0cf2efc2e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2221de36cdaa43edb16860bc141df763_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i531d67a3cb074164b661fe82095b4e11_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffc4d933f9f0489188683fe4b938ade0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5da195dc185f4ad2823040c5515d8512_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">rmti:TrifericInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideb44eb229184ecda8a91c6139e0d759_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">rmti:TrifericDialysateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90a1bca35c1243f08d1d94a939cef6c4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">rmti:TrifericAPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b0b6f74a05044e4873509f11c7db6af_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d0128a643514513b686ad5149092728_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i465a7180dcdf4d2b801c1f4275cbdb15_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2878341b4b7445749e3907105900094d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16b1bae1038f45d8bacf79228eeb50a8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i283693a6ea47413b8d27e797fcda6960_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d2310b000e944b4a1bafa95387c732b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9904a6ff79bb4fc3884be08d20ddd455_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib41a5b0fba4342b8a42fbf0205323776_D20141001-20141031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-10-01</xbrli:startDate><xbrli:endDate>2014-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a444cdf60204392ba5ee29a80d7a166_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i108ba00af91143ca9c3ed9b4e9bb5c39_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d78ddfa8815448196febe7de94d00ab_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeff68f2861040f5976c97fb25345bac_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib11ae81bd8164d54aefe2b07a1acc333_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="id44e4c40542f422392e127f7e00d1cef_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6b9801f65854970b5da63868031cd71_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97d0767332814c26b7040a7f42da83d7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29a9d581630545e5b9d979ee4a331a36_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib261789f13ed45118a64720f9ece6816_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1200549772a41baab582b78ceebca58_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia416a305cef740509c44aa63f6654918_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cbe96745d4a4ee7949e736eff90fddd_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7f108a122f849b691d34141d686f377_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bbf0986a8a141be81ed18c1868716dc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf5243f34d8c414c9014f13c02e11602_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i979ffd2d5930459a8fee1a724d668606_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic278353975334c0eb61849b38be42f55_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1509c49ed2945d6a5a0f7728fe181ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4698c56f368245e5b301c41e5ecebf1c_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2deedffb02b34d8da21c7fab0fe0b691_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5a61d1ec2a6474a931f248906e77c43_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i765972d583d94402bc7862f121892b89_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4081bbacdfc8425bbf6a232aeb6f1b27_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f97c0f7f55d43f9b70110bf979d68b5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91bb067c41004b14ad33a703a367c7da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2770d871f3fc4222a123073cfdeb613a_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:DrogsanAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4046492d81c4dcfbc80f8128d23a0e8_D20190322-20190322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-22</xbrli:startDate><xbrli:endDate>2019-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54ebd73955be4ec087f2c3127f7aef9f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c4394b8322844b885708d0a121c0250_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i328ca3ef8e144273a05211111c192e60_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacc309a401f7466cb3e18730470f3752_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if90c1947aa9c420f9f93f64285facd2f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55e1c1131a084252abc713575b403ea8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9f58870aefd4e5f887f2aa505cf9e96_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4015b62fa1a0414b80069a233cc0d05e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i812bfc33e296453fa2415e929c6925d0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e0e7f5848454b9ba1e6e17804b0edc3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e07dbab6dd248f6969e269920c504d6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if12de0f76e944b3bb7b40b44269dcce8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5595532179db49e29df13d2e4d7388be_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9c93c9caba84edd95b2548a2b744445_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6edb07a7cf7d4dfd9ea0c2aa04d300be_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6ebf042a7d748bc926786bbeaa6e5be_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8068b0b08b04c629bb3323c7e3c6b00_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i233d9a246600434d8e13d460c3115a63_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18efd6bca7ec4a579e596234751a12c6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee6f8140c1524d41888a692944254bf5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeb306a8995c48b88ea62ab0a33622a3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3796b585b2249e4a838d2e201de472f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f0a1cbef1614ce18f5c5d366eca4edd_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08c773fc721845f790f8ef203229134d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6519cfa82a8542f3bb0c56cb262141f8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b89ee6dba67472bb93b39369d3a62e5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cc879ec3d384c4891fc21ec9fe0b853_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf99680c33194615a4cde239ceeb4697_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1222c7a7994947a5bec3e3f85f308708_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a4f48e172c544ae980c5a5322bd7e1b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23d7d82cf9a64899b7f1206eabcb09ba_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dc167d328cb46c68fb83fa95a614259_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59ed53d4977e452abe904ab6ebf547cb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccc11aef27a949598168c7e139f011cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e71868a215c4613b29c948c789638c1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2bc1e2e4f8f4649bbe2dfd466d3ec82_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f366d79a6c6435a80da6fa75f516bb1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d18ac7044704140bef4ab937ea9ab1d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c44b152081048d6b3e5aa2d27e30992_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd51c0a0b5b34333bd95586be0b8d818_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i377ec7f50aff44afbeea1a0fddf83054_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4500479b46394800b4b9f21530bd9449_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i387b50c6a04b446ea4adc3f7f089a489_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0d53e2aa30e4cb2be00af8ad6ff6d23_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie590926897c544debd71e35ba26b6cb4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6070dee6d0e0457e9691825bf5ba3091_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72d3d3d7938c411bb6ffd58511f24608_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic639b26ebf744397b60970c46c3ac479_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c8dbaa25e2e4cac985ded30596cdaae_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7b50de406504a1199ae8a1f61a650ac_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12f2cce783ab4aa19f82d7776112d561_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i218c5ca968e448d4951556a9ac1e5e79_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5a5a222803a4f01af33dfbbd4edd90e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbc5ecc328954a549da54b7fbbe4c241_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ec99fab2f214abe99616df767617659_D20181007-20181007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-07</xbrli:startDate><xbrli:endDate>2018-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i460677d97abe4d1e8cb8e4f651ec0039_I20181007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>rmti:installment</xbrli:measure></xbrli:unit><xbrli:context id="i759627e2f50f423aafc0dfcca70bfd78_D20181007-20181007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-07</xbrli:startDate><xbrli:endDate>2018-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i809ecae77c69447cbf9e47687819d366_I20190115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97f806f584404ce2871df7a18de3ca11_I20190415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0e0b072a5234c05bc5ad0336ebb3ec8_I20181015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia12ceffd5d8641e892942dd059f10047_I20190715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3906b27be7c4423ae983ce14db75f27_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie29e7d1c982f494cba429b4a0196ff5b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic98fba3f2dc143ee8df5663a86c4661c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ic51c88898b0b42d4b034d35705eeaf8a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MI</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">rmti:WixomMichiganPropertyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5db4542d469452c8d4313a5744d4574_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MI</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">rmti:WixomMichiganPropertyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91c605c7aa7a4caebb53cdfdd424223a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia59cfceb831d4c4ba96a80f128ab4ead_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2aff2a50c9f45c59831b6c31dde2cc9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc87c3a83e2348a693051682f6add7a3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4304315a451412aa6227dd3d7825bbd_I20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fdc6c38a5ba44f4b1470b93d16d3808_I20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9301ccf847b14601a0409335c024832e_I20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7283d6d91074cb3b430c6bac11ae64d_D20200316-20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-16</xbrli:startDate><xbrli:endDate>2020-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fa07c9abdfb4de9a8f92bf2cb718792_D20200316-20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-16</xbrli:startDate><xbrli:endDate>2020-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf213bc00b65407ca919f5dd19c8467b_D20200316-20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-16</xbrli:startDate><xbrli:endDate>2020-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff0f4151e69d41f1a37b619b32340008_I20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fac8535567243c58d7ee0b17a853032_D20200316-20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-16</xbrli:startDate><xbrli:endDate>2020-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cc94eef73f94e268d7a68b7dad267bd_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie79abc16084e479aa59aa703cef935f0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i718b2b1115aa4464937e15a664860aea_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0e9b928a38b40e7850ffdd7b26ec0dd_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ee87b88447b43f4bf5d2a2510a5ede7_I20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheTwoAndTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58f2d0162acd40c0942ea5380b124712_D20200316-20200316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheTwoAndTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-16</xbrli:startDate><xbrli:endDate>2020-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia82218c7009949eebf722cc90aec1835_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i909302a232e445a29fbed3c3520b5158_I20210703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:A3925NotePayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41920f2da0c24c9ea164cc61d469bc9b_D20210703-20210703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:A3925NotePayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-07-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">United States</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTA1_790650b5-69e5-47f2-85cd-a211c8cd89c6">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">__________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6MDY4ODI0Y2E4OGE2NDQ3M2I2YTJjY2Y5NDM1Y2ZlOTQvdGFibGVyYW5nZTowNjg4MjRjYTg4YTY0NDczYjZhMmNjZjk0MzVjZmU5NF8wLTAtMS0xLTA_b4e3ff48-01b0-44ec-8d8d-81513b222dd5">☒</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8xODU_3837efad-7c8f-4411-a947-f2682e941a12">June 30, 2021</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6ZTllZWY3YmJiOTAwNDhlYWJkYjFiM2EyYzc3MjQ2MDIvdGFibGVyYW5nZTplOWVlZjdiYmI5MDA0OGVhYmRiMWIzYTJjNzcyNDYwMl8wLTAtMS0xLTA_9c94251c-3a17-4553-b968-edd6995d94de">☐</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from                              to                              </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTA2_b1b47560-8962-4b9e-ac67-712c1ba53c46">000-23661</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTA3_a96506b3-43f9-4dfa-8c35-1dc08eb82fcf">ROCKWELL MEDICAL, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.886%"><tr><td style="width:1.0%"></td><td style="width:36.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.090%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6ZjU1YzZkMDk2ODU0NDk2ZGE4ZjA3ODljMzQ2MGY0NmUvdGFibGVyYW5nZTpmNTVjNmQwOTY4NTQ0OTZkYThmMDc4OWMzNDYwZjQ2ZV8wLTAtMS0xLTA_2cbc9f22-8d1d-4f32-83e8-05c1111d3ca5">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6ZjU1YzZkMDk2ODU0NDk2ZGE4ZjA3ODljMzQ2MGY0NmUvdGFibGVyYW5nZTpmNTVjNmQwOTY4NTQ0OTZkYThmMDc4OWMzNDYwZjQ2ZV8wLTMtMS0xLTA_a10ac2a1-a91c-43c8-a2c0-e81df63b59fc">38-3317208</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of <br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer <br/>Identification No.)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6ZjU1YzZkMDk2ODU0NDk2ZGE4ZjA3ODljMzQ2MGY0NmUvdGFibGVyYW5nZTpmNTVjNmQwOTY4NTQ0OTZkYThmMDc4OWMzNDYwZjQ2ZV8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpmZDYwZTI5YTMwYzY0NGZkYWUxYjBiMmFkMzhmMzEyMV80_771714d7-586e-401f-8382-2b284af6aee7">30142 S. Wixom Road</ix:nonNumeric>, <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6ZjU1YzZkMDk2ODU0NDk2ZGE4ZjA3ODljMzQ2MGY0NmUvdGFibGVyYW5nZTpmNTVjNmQwOTY4NTQ0OTZkYThmMDc4OWMzNDYwZjQ2ZV8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpmZDYwZTI5YTMwYzY0NGZkYWUxYjBiMmFkMzhmMzEyMV84_ef00368c-c14a-42df-917e-696a1fe3084b">Wixom</ix:nonNumeric>, <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6ZjU1YzZkMDk2ODU0NDk2ZGE4ZjA3ODljMzQ2MGY0NmUvdGFibGVyYW5nZTpmNTVjNmQwOTY4NTQ0OTZkYThmMDc4OWMzNDYwZjQ2ZV8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpmZDYwZTI5YTMwYzY0NGZkYWUxYjBiMmFkMzhmMzEyMV8xMg_704b2b7a-ae3b-4b37-80e8-af18afb02278">Michigan</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6ZjU1YzZkMDk2ODU0NDk2ZGE4ZjA3ODljMzQ2MGY0NmUvdGFibGVyYW5nZTpmNTVjNmQwOTY4NTQ0OTZkYThmMDc4OWMzNDYwZjQ2ZV8yLTMtMS0xLTA_ccf8cad6-674d-47d3-a869-afbf2c5c5713">48393</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTEw_d645d7e4-3e79-45ec-b383-b0bb00519ff3">248</ix:nonNumeric>) <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTEx_3d139111-d99a-439f-a258-70f32486008a">960-9009</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant’s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Former name, former address and former fiscal year,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if changed since last report)</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">☒</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTA4_35787535-0a10-4a25-af7c-0f78f8025021">Yes</ix:nonNumeric>    </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">☐</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">☒</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTEy_15c0a9ad-be04-4f75-8a59-f60afd819c2f">Yes</ix:nonNumeric>    </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">☐</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.625%"><tr><td style="width:1.0%"></td><td style="width:20.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">☐</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">☐</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6YzViZGMxMzM3NjBlNDllMjk5NTYyNmFjZGJhYjM2NGQvdGFibGVyYW5nZTpjNWJkYzEzMzc2MGU0OWUyOTk1NjI2YWNkYmFiMzY0ZF8xLTAtMS0xLTA_2ff59092-fa0b-410f-94ab-0511549dd9d3">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">☒</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6YzViZGMxMzM3NjBlNDllMjk5NTYyNmFjZGJhYjM2NGQvdGFibGVyYW5nZTpjNWJkYzEzMzc2MGU0OWUyOTk1NjI2YWNkYmFiMzY0ZF8xLTMtMS0xLTA_0d76418b-099a-4f9e-b2b4-3b6fe9307726">☒</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6YzViZGMxMzM3NjBlNDllMjk5NTYyNmFjZGJhYjM2NGQvdGFibGVyYW5nZTpjNWJkYzEzMzc2MGU0OWUyOTk1NjI2YWNkYmFiMzY0ZF8yLTMtMS0xLTA_0f50c057-9beb-45ea-8f33-8201777abf26">☐</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">☐</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTEz_9c542c34-65d6-4684-bbcc-44b08aa295e1">☐</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Yes  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">☒</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:30.941%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.941%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6NmYwZWE2MmFhMWE3NDJlMTg0YjA5Yzc0ZGM4MzQzMjEvdGFibGVyYW5nZTo2ZjBlYTYyYWExYTc0MmUxODRiMDljNzRkYzgzNDMyMV8xLTAtMS0xLTA_dfe1c0fd-1005-4109-b933-12cee601e8c9">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6NmYwZWE2MmFhMWE3NDJlMTg0YjA5Yzc0ZGM4MzQzMjEvdGFibGVyYW5nZTo2ZjBlYTYyYWExYTc0MmUxODRiMDljNzRkYzgzNDMyMV8xLTItMS0xLTA_f2996f45-fdf6-4080-bea4-f131a5507c66">RMTI</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6NmYwZWE2MmFhMWE3NDJlMTg0YjA5Yzc0ZGM4MzQzMjEvdGFibGVyYW5nZTo2ZjBlYTYyYWExYTc0MmUxODRiMDljNzRkYzgzNDMyMV8xLTQtMS0xLTA_978ac096-94fd-4e09-9e75-0a70dcc3b57b">Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock outstanding as of August 13, 2021 was <ix:nonFraction unitRef="shares" contextRef="i179f99b00109446d8a4f4d374551db0b_I20210813" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTAx_f9b9526d-73f6-4e79-a80c-dc3edcdc81ef">93,888,881</ix:nonFraction>.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rockwell Medical, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Form 10-Q</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_10">Part I — Financial Information (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_13">Item 1 - Financial Statements </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_16">Condensed Consolidated Balance Sheets as of June 30, 2021 and December 31, 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_19">Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_22">Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_19">June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_25">Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Six Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_19">June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_28">Condensed Consolidated Statements of Cash Flows for the Six Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_19">June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_79">Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_97">Item 3 - Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_100">Item 4 - Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_103">Part II — Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_106">Item 1 -    Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_109">Item 1A - Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_124">Item 6 -    Exhibits</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d62b4adfd9b4f4d858c9a9ca79e3e49_127">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I – FINANCIAL INFORMATION</span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_13"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Financial Statements</span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_16"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Thousands)</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMy0xLTEtMS0w_8aef98d0-6bbf-41b1-981c-5a86ccab01a8">32,378</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMy0zLTEtMS0w_95a11550-11ce-4e80-96d7-a096f32c4a12">48,682</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments Available-for-Sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNC0xLTEtMS0w_97bf2254-c2a9-4472-b711-b73b39f87ff1">8,574</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNC0zLTEtMS0w_2871dc25-a508-40af-9146-88d4edbddd0e">9,997</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts Receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNS0xLTEtMS0w_711662f3-0fc9-478d-895c-7014a6bf388d">5,357</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNS0zLTEtMS0w_c7ce00e8-c6d6-4dc6-aa28-a777a89dc595">4,171</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNy0xLTEtMS0w_ea0a59a3-26e1-4ae5-9acc-e224d9074d83">4,677</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNy0zLTEtMS0w_5580baf7-698e-4964-baba-cc06f3dcc89e">3,913</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and Other Current Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfOC0xLTEtMS0w_1000b112-fc4d-4055-a8ef-5350097943a7">1,413</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfOC0zLTEtMS0w_59cc201c-f3cc-49bd-882b-ac8a771da952">2,706</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Current Assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfOS0xLTEtMS0w_4a42267f-c5db-44b0-b768-87f8ed65b735">52,399</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfOS0zLTEtMS0w_88ef6cf8-cd29-41c0-9c80-a0b1b21133c8">69,469</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and Equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTAtMS0xLTEtMA_67ddbec7-3d5b-4760-90bb-02b6d00032db">2,529</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTAtMy0xLTEtMA_978cc32d-ef78-42d2-a0a1-8fa755e0104e">2,642</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, Non-Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTEtMS0xLTEtMA_45dc4deb-f96c-4b5c-978f-ad5bf2000792">1,122</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTEtMy0xLTEtMA_4cb9729a-eee1-4fe1-a147-c4c8d3c3483a">1,176</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of Use Assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="rmti:OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTItMS0xLTEtMA_9ecbd122-9f11-4a9d-90a0-5e4fcca03a3f">6,085</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="rmti:OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTItMy0xLTEtMA_8914f530-2f05-425a-8b4b-e8700f00c92b">2,911</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTMtMS0xLTEtMA_4ac5661f-5dc3-4d14-9386-579ad00dab9a">921</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTMtMy0xLTEtMA_ecffaff3-b8f5-4591-9f50-9b5e4b40a5b7">921</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Non-Current Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTQtMS0xLTEtMA_3d1421c9-84a0-46ee-ab41-43f7930689fd">628</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTQtMy0xLTEtMA_f5a809ba-4b4c-4923-bc01-ff4dca213f70">629</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTUtMS0xLTEtMA_2cd4422a-068e-4108-ac75-6924dc899da1">63,684</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTUtMy0xLTEtMA_a05332b5-03f7-4ed3-b5f0-4b6b63f564d8">77,748</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS’ EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts Payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTctMS0xLTEtMA_22a26562-3a88-4c7f-a7a5-ae9aaeaf18a8">4,932</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTctMy0xLTEtMA_22e5321d-3037-45de-8ea9-dcd23fee5e9e">4,155</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTgtMS0xLTEtMA_9ab5656e-4988-4e07-805d-6b46bba87ab2">3,993</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTgtMy0xLTEtMA_c4cb5871-b3f8-40ea-867b-e99806924e7e">5,013</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease Liability - Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="rmti:OperatingLeaseAndFinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjAtMS0xLTEtMA_7b09337a-5bad-4747-b68c-91004cca454c">1,674</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="rmti:OperatingLeaseAndFinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjAtMy0xLTEtMA_f7b30fbb-728c-48aa-9374-04c8b7a94ddd">1,167</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred License Revenue - Current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjEtMS0xLTEtMA_6753c184-401b-4ee3-acc9-9968fec6310b">2,166</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjEtMy0xLTEtMA_5714cecc-0498-4a77-aaec-08ff74ceafb8">2,175</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan - Net of Issuance Costs</span></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjItMS0xLTEtMTU4OA_03707826-461a-4bbd-8f90-d23bbcd629d3">21,133</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjItMy0xLTEtMTU4OA_7f0dea5d-f27b-4f45-af9a-3dd4a8d16aa3">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-right:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Deposits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjMtMS0xLTEtMA_152733de-fe26-4b5d-8975-0ee6ed5c9257">140</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjMtMy0xLTEtMA_0f87763e-7869-4fd7-8784-00abbea56bb2">152</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Current Liability - Related Party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjQtMS0xLTEtMA_72ae555c-152d-46f2-b30a-a5eed8f9cd1e">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjQtMy0xLTEtMA_17336d47-9227-4106-84a4-66b66062b028">131</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Current Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjUtMS0xLTEtMA_8b1f2875-4f6d-4d01-ae5d-947ebac67138">34,038</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjUtMy0xLTEtMA_c2d9dde4-89d8-4f91-ad31-43fd7655d2f4">12,793</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease Liability - Long-Term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="rmti:OperatingLeaseAndFinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjctMS0xLTEtMA_51c63fd2-bf17-4fa8-9ab6-766630acfded">4,506</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="rmti:OperatingLeaseAndFinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjctMy0xLTEtMA_374fb97c-f12e-4f74-847d-ba536bbfdee3">1,821</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, Net of Issuance Costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjgtMS0xLTEtMA_39cc2de6-7a42-4b81-aab8-15c534c3aab3">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjgtMy0xLTEtMA_b523531d-2930-4d47-b569-6d5116ecceca">20,949</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred License Revenue - Long-Term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjktMS0xLTEtMA_93f5b4cc-0562-46fc-aa95-d68cec6a824a">6,937</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjktMy0xLTEtMA_4cfae6d9-04a0-418f-b78b-467a786a1ed8">8,015</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzAtMS0xLTEtMA_5c62f7f8-1e9a-4d0b-b1e0-14a455482405">45,481</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzAtMy0xLTEtMA_62242f38-b9f3-488c-ac39-da2a8e40889e">43,578</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and Contingencies (See Note 14)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzItMS0xLTEtMA_177c71a6-078c-4033-92b5-caaf0589195e"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzItMy0xLTEtMA_ed3471fe-3854-4ba3-b0a7-4a2e6ea8cd4f"></ix:nonFraction></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders’ Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjAzYWMzODlmZDAzNjQzMDliMTllYzlmNTZiNjYyYTVlXzIx_add399db-bb82-4458-977d-81ddbfa02e77"><ix:nonFraction unitRef="usdPerShare" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjAzYWMzODlmZDAzNjQzMDliMTllYzlmNTZiNjYyYTVlXzIx_fb83f3fa-d2c4-4c0d-8fe3-0bb6a014916f">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjAzYWMzODlmZDAzNjQzMDliMTllYzlmNTZiNjYyYTVlXzM1_13880135-d9f4-4e5f-812a-6af9b81661b5"><ix:nonFraction unitRef="shares" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjAzYWMzODlmZDAzNjQzMDliMTllYzlmNTZiNjYyYTVlXzM1_6ae34b84-014a-43e9-9520-f9050a50f08a">2,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjAzYWMzODlmZDAzNjQzMDliMTllYzlmNTZiNjYyYTVlXzU3_41fe5f61-9330-4162-ad86-50e1cb4bdfdf"><ix:nonFraction unitRef="shares" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjAzYWMzODlmZDAzNjQzMDliMTllYzlmNTZiNjYyYTVlXzU3_61569094-4e18-43cf-b3f5-af2110ca9d9c"><ix:nonFraction unitRef="shares" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjAzYWMzODlmZDAzNjQzMDliMTllYzlmNTZiNjYyYTVlXzU3_cfbaee82-fe5e-41ad-9f0d-1e1a5abc2fc8"><ix:nonFraction unitRef="shares" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjAzYWMzODlmZDAzNjQzMDliMTllYzlmNTZiNjYyYTVlXzU3_d135d0a9-4dc1-4ed6-83bd-1fb52c0eab2e">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at June 30, 2021 and December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMS0xLTEtMA_2693684c-1627-4c7c-8276-b037c979d6be">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMy0xLTEtMA_fc02d642-7ccb-4529-9876-c5c53c665978">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFkY2VhODk3M2M4YzRiOTVhMDcwMzg3NGUxMDVjN2VhXzE4_76d37be6-11eb-4c50-bf2a-e40fd65e7606"><ix:nonFraction unitRef="usdPerShare" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFkY2VhODk3M2M4YzRiOTVhMDcwMzg3NGUxMDVjN2VhXzE4_a250472a-e858-478e-a44f-2c989c7cbfa2">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFkY2VhODk3M2M4YzRiOTVhMDcwMzg3NGUxMDVjN2VhXzMy_20a9d7c4-165c-4d41-9255-61ba68148793"><ix:nonFraction unitRef="shares" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFkY2VhODk3M2M4YzRiOTVhMDcwMzg3NGUxMDVjN2VhXzMy_61e4c894-acf5-4279-9c3f-07ffde12daab">170,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFkY2VhODk3M2M4YzRiOTVhMDcwMzg3NGUxMDVjN2VhXzU0_28c638ee-e217-431c-845a-3cc23b9354ee"><ix:nonFraction unitRef="shares" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFkY2VhODk3M2M4YzRiOTVhMDcwMzg3NGUxMDVjN2VhXzU0_c372b1bf-8188-40b4-9882-6b8ae1d909a2">93,811,381</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFkY2VhODk3M2M4YzRiOTVhMDcwMzg3NGUxMDVjN2VhXzYx_8c9343c9-c4ce-49dc-b55b-05d5940cc1e7"><ix:nonFraction unitRef="shares" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFkY2VhODk3M2M4YzRiOTVhMDcwMzg3NGUxMDVjN2VhXzYx_de8897fb-cd63-4883-8e4b-759d04ee2172">93,573,165</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMS0xLTEtMA_d192f36c-bd58-445c-9982-3edf467ac39f">9</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMy0xLTEtMA_da7a7209-b8bc-48ae-b8c7-37048d75b1c0">9</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional Paid-in Capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzctMS0xLTEtMA_0d9f36d1-eedb-4397-9502-4f03fa6baa17">371,700</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzctMy0xLTEtMA_a50a3fc0-78bc-4e87-9a07-ad235480263e">371,510</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzgtMS0xLTEtMA_42deb260-ccd4-4b29-8b9e-360f906cd260">353,558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzgtMy0xLTEtMA_d28ebf8a-0251-425f-80db-937129c1d0f4">337,406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzktMS0xLTEtMA_cc728859-8f19-499b-bf21-cee2ebda4c6a">52</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzktMy0xLTEtMA_30d2bfa9-03f7-4eeb-80c3-487c16362290">57</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Stockholders’ Equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNDAtMS0xLTEtMA_17aabf73-67f8-42aa-9a78-0d4f7c24d9d1">18,203</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNDAtMy0xLTEtMA_701569c8-dd01-4851-95f5-51e1427cec7a">34,170</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Liabilities and Stockholders’ Equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNDEtMS0xLTEtMA_b7b48893-db48-4ad9-bad4-8248e8560adf">63,684</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNDEtMy0xLTEtMA_f7cdf411-26cb-404f-83a9-8de01d43c630">77,748</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Thousands, Except Per Share Amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMi0xLTEtMS0w_0e6a05a6-6038-4178-a6cb-697236a32e99">15,137</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMi0zLTEtMS0w_acb0c615-d741-4e81-9de9-2dfa270ecf22">15,896</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMi01LTEtMS0w_723bcbb4-5236-4ec3-9db3-9c4c64b0825a">30,611</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMi03LTEtMS0w_41afce49-b13a-4089-9397-562ae6caf20f">31,753</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMy0xLTEtMS0w_285881a9-b280-4b15-a4d7-f9cf31dab77d">15,399</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMy0zLTEtMS0w_d091ade4-2343-49a2-9a7d-b177f2c706f1">15,015</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMy01LTEtMS0w_bc554b2e-134e-4323-91fa-474f290f2897">30,471</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMy03LTEtMS0w_7b9d345d-d9aa-43a9-90d4-e55d6664831e">29,759</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNC0xLTEtMS0w_78b0a1f7-4707-4033-aee5-835b1f29549a">262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNC0zLTEtMS0w_233ee0bf-37ab-4c84-9db4-449860ac66eb">881</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNC01LTEtMS0w_21d8ab45-c43d-4ee4-8c6b-46f7647bbf8d">140</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNC03LTEtMS0w_368a303d-7760-4c72-97cf-1ae7c0a52311">1,994</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Product Development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNS0xLTEtMS0w_9925b325-0257-41ae-a9f1-916cad4c2371">2,416</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNS0zLTEtMS0w_196778c2-ae74-49f9-82a8-40cb9b23f9b1">1,616</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNS01LTEtMS0w_f4d36f0f-c2a5-46cb-965e-d7d318b6fd14">4,224</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNS03LTEtMS0w_4fc1e3f9-b2af-45bd-a587-1b66e6502766">3,438</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and Marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNi0xLTEtMS0w_bc78781b-3ba1-4179-8567-f3a2b3bc09a2">1,468</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNi0zLTEtMS0w_3c32d1ac-ca92-4cb9-a87e-e55ebf8390fc">1,997</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNi01LTEtMS0w_956f7627-e4d5-421d-9ded-7332e5e23cb3">3,319</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNi03LTEtMS0w_9176264e-a6b3-4055-8623-2905cac8f90c">4,069</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNy0xLTEtMS0w_59c17b2c-f793-4672-9594-ff3347fa9d1a">3,677</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNy0zLTEtMS0w_2240d8ef-6bed-4706-862e-d9dd1233dbaf">2,871</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNy01LTEtMS0w_575abd00-2869-4a34-a5a0-52c99db93e95">7,602</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNy03LTEtMS0w_65941157-6757-4dd2-abd1-ff0cb62df9ec">8,145</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfOS0xLTEtMS0w_bbc107da-e1c9-4569-a05c-05b201a6bcc5">7,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfOS0zLTEtMS0w_c17d6639-6b1d-451f-bc1d-42b3681e125c">5,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfOS01LTEtMS0w_d281c70b-c462-4a13-9e0c-8937adc7b8db">15,005</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfOS03LTEtMS0w_0cf77902-843d-4eec-baec-e1e22db46739">13,658</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other (Expense) Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized (Loss) Gain on Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTItMS0xLTEtMA_4564c216-7649-462b-b1be-39ae3649c380">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTItMy0xLTEtMA_131dcaff-7390-44f8-beed-afde7d1c76dc">2</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTItNS0xLTEtMA_1ed726ba-c263-4615-9c9b-b15f75bf8103">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTItNy0xLTEtMA_17a5a348-4586-4d5a-ac92-3dfc9ff156de">4</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant Modification Expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTMtMS0xLTEtMA_bb558222-60e3-4d57-84c8-8125e17acd71">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTMtMy0xLTEtMA_b62266a2-0ed3-4bf2-b0a9-c4f5e872e20e">837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTMtNS0xLTEtMA_aa511b59-ded2-4ca3-b243-61eed1292034">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTMtNy0xLTEtMA_df7e5c25-ad86-4ea6-bac0-411b41e76437">837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTQtMS0xLTEtMA_738ee7e4-0e82-4882-8cad-3b35493e3f1a">583</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTQtMy0xLTEtMA_af9192ff-854e-4d1d-91b2-c414388caa32">521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTQtNS0xLTEtMA_5b05b094-4b93-4e1a-9d28-b8daae645573">1,164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTQtNy0xLTEtMA_d80c9ad6-7dbb-4415-9fbf-72b7515af9ed">623</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTUtMS0xLTEtMA_3da0de97-b5a1-44f1-a1df-e8dae5d7635a">7</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTUtMy0xLTEtMA_3c18f389-dcb0-4db5-9376-e1da5e806f8c">67</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTUtNS0xLTEtMA_53e3dec4-62d2-4f90-9a29-e272e249d32b">18</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTUtNy0xLTEtMA_4b7a71c7-563d-4519-ac49-992cd89fe046">238</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Other Expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTYtMS0xLTEtMA_1625ddc1-fc4d-46fc-be9d-3c911c0e59a8">577</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTYtMy0xLTEtMA_26927ac8-e176-47ab-bef0-61b006a6b87c">1,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTYtNS0xLTEtMA_dd519299-c7be-4867-a599-1ba47065ce52">1,147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTYtNy0xLTEtMA_e444850f-d2cf-47bc-ae0e-c14a63539859">1,218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTgtMS0xLTEtMA_7ee192d5-0b84-4a80-b961-9f5e7412b66e">8,400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTgtMy0xLTEtMA_23a30af1-16d1-43d3-b824-688031ec1f25">6,892</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTgtNS0xLTEtMA_21a7b3f8-bc27-42d7-b2a5-83fdd13972aa">16,152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTgtNy0xLTEtMA_fcd2a68c-f2d8-44d6-8804-07dbede5bcea">14,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and Diluted Net Loss per Share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjAtMS0xLTEtMA_81ef95eb-4198-4a42-a26c-99085d166317"><ix:nonFraction unitRef="usdPerShare" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjAtMS0xLTEtMA_af5735a2-5efe-4978-b11e-b01c08de8b82">0.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjAtMy0xLTEtMA_155cfecb-b85d-4ba9-948a-16b32bc38e8f"><ix:nonFraction unitRef="usdPerShare" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjAtMy0xLTEtMA_863f016c-376a-48b7-b8fb-5ec0c722b993">0.10</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjAtNS0xLTEtMA_6b432fba-cc89-4840-9d3c-84d6b1292352"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjAtNS0xLTEtMA_bb629987-68f0-47d7-9b3e-cc880d992823">0.17</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjAtNy0xLTEtMA_174c0a10-1b67-4a8d-987e-5e2ff4820fbf"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjAtNy0xLTEtMA_261d7516-9f25-4239-8288-170a54e43c1d">0.22</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and Diluted Weighted Average Shares Outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjEtMS0xLTEtMA_dff1628a-f4ca-4ee5-b838-392bd9081616"><ix:nonFraction unitRef="shares" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjEtMS0xLTEtMA_ee5feb45-84dc-4801-9c49-d900fde0f740">93,703,492</ix:nonFraction></ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjEtMy0xLTEtMA_1cf8b857-d1d2-4618-95e9-4b51da526727"><ix:nonFraction unitRef="shares" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjEtMy0xLTEtMA_846c314c-be9d-4c0c-b275-ef2b29ca62ce">69,428,574</ix:nonFraction></ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjEtNS0xLTEtMA_68a59e2a-b15a-47ba-b4d9-8ef337c83f78"><ix:nonFraction unitRef="shares" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjEtNS0xLTEtMA_818a8b37-daaa-41d9-8c28-43fc150929ac">93,647,583</ix:nonFraction></ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjEtNy0xLTEtMA_211b9b7b-08c0-4cc4-8bfd-fa9ed31c3204"><ix:nonFraction unitRef="shares" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjEtNy0xLTEtMA_8ef289af-fdf9-4fea-985f-45721009077d">68,473,407</ix:nonFraction></ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfMi0xLTEtMS0w_0889a067-c7cf-4921-bc85-fe3828ca57b4">8,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfMi0zLTEtMS0w_fc7c577b-7e30-401b-a649-f35f1d427be3">6,892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfMi01LTEtMS0w_caa825e8-def2-45e6-8d2e-04fca3e1dead">16,152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfMi03LTEtMS0w_fe1ddaac-431f-4692-92c4-cd01e055a48e">14,876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss on Available-for-Sale Debt Instrument Investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfMy0xLTEtMS0w_8b450d4e-d0d8-459b-ab9a-a5565ed0674f">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfMy0zLTEtMS0w_22333dbe-1ef5-4653-bddc-2a3e0243a188">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfMy01LTEtMS0w_bede23e9-f08d-4fda-905e-de15283c6d99">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfMy03LTEtMS0w_7f2a20a5-529c-48cf-b839-f71356617389">13</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfNC0xLTEtMS0w_4032d4ac-3208-434f-be56-815bbc485093">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfNC0zLTEtMS0w_136f8b39-bddc-4cb4-b82c-6e4f84627168">1</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfNC01LTEtMS0w_1264dacb-ebc9-4a0d-a7b0-516d73bb0890">3</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfNC03LTEtMS0w_2ace87e3-25a1-457b-aef9-c172b7dd608e">7</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive Loss</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfNS0xLTEtMS0w_32b0f472-2f17-401c-aa6c-e17b6eb3acf6">8,401</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfNS0zLTEtMS0w_32bc428c-5cb9-4102-bf9a-a6ef9e5296e7">6,897</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfNS01LTEtMS0w_72b2314b-889a-4b2b-86d4-4850143d79b8">16,157</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfNS03LTEtMS0w_a3277203-fe26-44bc-8229-193944022c0d">14,882</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Thousands)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr style="height:54pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMON STOCK</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ADDITIONAL PAID-IN CAPITAL</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ACCUMULATED<br/>DEFICIT</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ACCUMULATED<br/>OTHER<br/>COMPREHENSIVE<br/>INCOME</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL<br/>STOCKHOLDERS'<br/>EQUITY</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SHARES</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of January 1, 2021</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b07a43b8619400ca8c95f27f08d1ba5_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMi0xLTEtMS0w_5b9fbc37-a5d9-45d8-88eb-c9301b94bcaa">93,573,165</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b07a43b8619400ca8c95f27f08d1ba5_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMi0zLTEtMS0w_a1a97c00-9854-4ffd-a47a-bc4f3c3db671">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ba271b9447b4d5f949594629592652a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMi01LTEtMS0w_58d080cb-777c-4d24-a3b3-da9c04220805">371,510</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9807fc3339154e519ccef4517a1e8357_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMi03LTEtMS0w_e6810945-1599-4fd3-844e-18517179522b">337,406</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf30cdc4b4b9449e8880eba00e1e682d_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMi05LTEtMS0w_175841c3-59a7-41f3-8755-d39f230cbf16">57</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMi0xMS0xLTEtMA_7ffba2da-8d2a-4913-b83d-6d288f1dbc8c">34,170</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf754b423a114a0597693457a11d520c_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMy03LTEtMS0w_d80d9946-eb9b-4bd0-ae84-8042eea22062">7,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73e508b6a03f4f7b8143e955a745dbfa_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMy0xMS0xLTEtMA_2cb1eb87-ad93-44fa-a2d0-0b838556d4f1">7,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss on Available-for-Sale Investments</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd51386c0f204b70ab961d89fac6b414_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfNC05LTEtMS0w_e8ca996f-8c43-44e9-8583-78bef887ac39">7</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73e508b6a03f4f7b8143e955a745dbfa_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfNC0xMS0xLTEtMA_f269107d-e4a7-4033-9c28-1ea166600c0d">7</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd51386c0f204b70ab961d89fac6b414_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfNS05LTEtMS0w_75f5ea86-4975-4cc4-902d-01c81be3f402">3</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e508b6a03f4f7b8143e955a745dbfa_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfNS0xMS0xLTEtMA_935b9080-c103-4cb2-9edc-91315872cabc">3</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based Compensation</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea063dee27124e3cb8e847225bc9a727_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOC0xLTEtMS0w_f1534f74-8172-4157-ae8e-124f39a34ce4">26,354</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81559f9595424094af9504f5e9176fb6_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOC01LTEtMS0w_66e50118-8620-4294-914c-e43daa389567">236</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73e508b6a03f4f7b8143e955a745dbfa_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOC0xMS0xLTEtMA_4a13da0c-2824-4ce7-8e95-735b01acd260">236</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bbc1a5a98724c2f8dca606328b38948_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOS0xLTEtMS0w_789fdd86-ad49-4868-a767-32e6d69e653d">93,599,519</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bbc1a5a98724c2f8dca606328b38948_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOS0zLTEtMS0w_b81c1e38-83aa-4f51-97a3-86b0a4f710d9">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56d558368b464ba98704441dbcaaabf9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOS01LTEtMS0w_0661a420-1b14-4d51-9107-da09c13c0c5a">371,274</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabe3c25da72c456a845f39add7002756_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOS03LTEtMS0w_4fa161bb-4607-4347-8e08-7d44a9040566">345,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fcb676677b441d99b1a3adf52053525_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOS05LTEtMS0w_fb88af31-2346-4f62-a0cc-24a132dd4981">53</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic460d5f9387a4d06b4cc0bc019a1734f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOS0xMS0xLTEtMA_23546d95-d23f-4403-9e8b-34a65bd349d3">26,178</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dce86a076074a34ab97dd39cec92b15_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTAtNy0xLTEtMA_598a7fd2-a2ce-472c-8ff5-9da72f6937dd">8,400</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTAtMTEtMS0xLTA_efd6984d-1901-48d3-b19e-fd2b8a918ebe">8,400</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss on Available-for-Sale Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9474a82666f14c4a96556216f214b159_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTEtOS0xLTEtMA_ddec8497-96b3-4772-9cf4-1935e6806dc2">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTEtMTEtMS0xLTA_6cd86713-7162-476c-ba07-eec61e6f3e13">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of Restricted Stock Units Issued, net of taxes withheld</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09f5e26ca97b4ed5a7c42b24779e77dd_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTQtMS0xLTEtMA_b011f6ce-18f1-4003-bdf3-5c28ac8a9db2">211,862</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic407fb18061d4956b9355d05fc844063_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTQtNS0xLTEtMA_c8b5f83c-c241-4601-b616-ab5644579e01">7</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTQtMTEtMS0xLTA_652bcf6f-185a-4cf0-baff-0470fba2a367">7</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based Compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic407fb18061d4956b9355d05fc844063_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTYtNS0xLTEtMA_1ae09864-a0a6-4123-9b25-66e6d397bbb6">433</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTYtMTEtMS0xLTA_bce46f2e-39f4-4afa-a862-29afc7b2747a">433</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></td><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idef3faf9cfc649c7b67efb0ea9882617_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTctMS0xLTEtMA_9c26c191-f38e-4331-a73a-e775ce82994b">93,811,381</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef3faf9cfc649c7b67efb0ea9882617_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTctMy0xLTEtMA_d6567b02-947b-45f9-962b-7a0c502f320a">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b87d1b1f1f141b88fbbb40d8e3f5d32_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTctNS0xLTEtMA_9304227e-d19b-4808-96b4-9e7416e716b8">371,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i974b2e044bfa4a0385fe4bbe668091b8_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTctNy0xLTEtMA_07ff12b2-781f-4843-9ce3-ef576f991cbf">353,558</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b18e138a6594afba9bdaa869817c283_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTctOS0xLTEtMA_ca0b664f-9f0c-425e-81a8-d1f09628de81">52</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTctMTEtMS0xLTA_812844b2-a4a2-454f-9320-12d1fa813f52">18,203</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.358%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMON STOCK</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ADDITIONAL PAID-IN CAPITAL</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ACCUMULATED<br/>DEFICIT</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ACCUMULATED<br/>OTHER<br/>COMPREHENSIVE<br/>INCOME</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL<br/>STOCKHOLDERS'<br/>EQUITY</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SHARES</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1331b5ebfa64639a2e460e5675967a1_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMi0xLTEtMS0w_498df6a0-53e3-4b79-970d-f5cc7c58948b">65,378,890</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1331b5ebfa64639a2e460e5675967a1_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMi0zLTEtMS0w_f8f2140f-58cc-4b92-9221-d687246f546f">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib996a5fca98d4d6fa54ca00eb94caa3a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMi01LTEtMS0w_50dfb0c6-8801-4f6f-b76d-84d3964ca428">326,777</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i569ca4d2801b45ef95abf90a705c76df_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMi03LTEtMS0w_00eb001f-3302-484f-b1db-f656134772be">306,516</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib10111ed45264e43ba61d121ddd55efd_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMi05LTEtMS0w_14c62219-0076-4577-bd42-fc2ed5618217">52</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43c45a3bec674ffb9577158bb599935f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMi0xMS0xLTEtMA_48678a61-cf89-4ee8-83bd-1cf3f59c3864">20,320</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic19a9d3e1a27430b8e5242841760bea9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMy03LTEtMS0w_99d2f459-9b24-47c3-946d-8d4367c470c6">7,984</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51f3e4812fbe47e5aa54eace8ed662e8_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMy0xMS0xLTEtMA_cb229ae8-558a-40c3-8eba-304b5f39e515">7,984</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss on Available-for-Sale Investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7e74f88217d46d08457f4184133e631_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNC05LTEtMS0w_bb7c9541-2535-484a-be22-c3c7f70ae1d3">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51f3e4812fbe47e5aa54eace8ed662e8_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNC0xMS0xLTEtMA_4ab3694e-1b3d-4ed5-8412-f49be7cefea1">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e74f88217d46d08457f4184133e631_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNS05LTEtMS0w_895b1327-6e43-453d-9e79-758d34032f50">6</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51f3e4812fbe47e5aa54eace8ed662e8_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNS0xMS0xLTEtMA_5c9a8b4b-0d77-4e8d-93af-75b9ba78de6b">6</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs/Bought Deal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3de306d20bfc41faa248fc7b78c41c67_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNi0xLTEtMS0w_8eecddec-4bd3-40aa-853a-32680e86d6df">3,670,212</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0115d005cfa0459aa5a4504336d80145_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNi01LTEtMS0w_0bd0674d-0834-49f3-95ba-ccc96f0467f5">8,003</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97b06daeb6d4f0382282fc44378994f_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNi0xMS0xLTEtMA_00986a3c-cf90-48a8-827b-f573ec5d2403">8,003</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Warrants related to Debt Financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08bdbce20f8c405a928c41402ca43cde_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNy01LTEtMS0w_dc0c412e-c053-404a-bb4a-8a277b8d9906">501</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51f3e4812fbe47e5aa54eace8ed662e8_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNy0xMS0xLTEtMA_4f217f7a-4a9c-48e7-9b4b-62c7f97b0eac">501</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based Compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08bdbce20f8c405a928c41402ca43cde_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfOC01LTEtMS0w_e68032d8-591a-44e6-8dc3-4fd7a21cf490">935</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51f3e4812fbe47e5aa54eace8ed662e8_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfOC0xMS0xLTEtMA_dcbb5c9e-9b77-499c-99fa-b6f4bd5f1ae0">935</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc8684882fbe48c186518ce3c43ea805_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfOS0xLTEtMS0w_eb3a0376-52ed-45d7-a03b-b4483381f1f6">69,049,102</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8684882fbe48c186518ce3c43ea805_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfOS0zLTEtMS0w_f817e316-5b53-46c4-8fac-d598f976e90d">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc14b52f677a45e8953c87dcfa86734e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfOS01LTEtMS0w_7cb729ca-819e-47de-a1fd-4912b5d0832e">336,216</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7f30c59a79940599a681143825fab90_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfOS03LTEtMS0w_e70c2a4e-574a-49bf-be99-2311ee2c18de">314,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d6b6a4094954db59808d66f399716fc_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfOS05LTEtMS0w_933c1145-6293-4348-9170-09aedfce0f23">51</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4f7793fa564ff88ca3fbead5bfdd86_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfOS0xMS0xLTEtMA_07fa45db-10e9-4f07-a938-acc4f08392b5">21,774</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1859822b74774adfbfa6ba5fad1b506d_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTAtNy0xLTEtMA_779b4ac4-501f-4142-9c82-413c74751622">6,892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTAtMTEtMS0xLTA_c834e046-c7a4-4495-87cd-4a313463d9ca">6,892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss on Available-for-Sale Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i500b8c7b421a4b73a7804aa65a26c308_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTEtOS0xLTEtMA_2b20f4d4-c81f-44ea-b6fe-fa2ebd29ac63">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTEtMTEtMS0xLTA_72f11256-aeb5-4cef-86a0-b8ffa456e0f2">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i500b8c7b421a4b73a7804aa65a26c308_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTItOS0xLTEtMA_516ff471-55b6-4ad8-8057-b11f4bf9f9d0">1</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTItMTEtMS0xLTA_141f21dd-7c32-43ae-a926-e33dfdf2ecb0">1</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs/Public Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25489ab4a8544c46b57a6837b6d94fb4_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTMtMS0xLTEtMA_415eb207-faab-4662-99bf-2bd4b5556fb1">987,716</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eed6445722d476897f396e3b650e2fc_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTMtNS0xLTEtMA_98078af6-b7b3-4c9a-aa24-545a7c64884a">1,978</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b404b31727244c9a3dafa0dfaa79147_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTMtMTEtMS0xLTA_6a1f4b52-a098-4f0f-b0e1-2e9c8be33110">1,978</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of Restricted Stock Units Issued, net of taxes withheld</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b376170a7a3481b9e8ceaf392294f49_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTQtMS0xLTEtMA_b45869fd-95e7-4efe-b30f-d1dfd179ba39">120,104</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6aa75d0adc8143288bf6adb66cdca8b3_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTQtNS0xLTEtMA_0f80f922-570b-4c33-abbb-fe529c7a1383">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTQtMTEtMS0xLTA_3e7a7925-0786-4f61-8ea8-a6d814d32667">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant Modification Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aa75d0adc8143288bf6adb66cdca8b3_D20200401-20200630" decimals="-3" name="rmti:AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTUtNS0xLTEtNjY_415084d5-99bc-4ea9-8b20-4d48898473a9">837</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" name="rmti:AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTUtMTEtMS0xLTc1_7979616f-ff34-4a7c-9eef-bc5ca3839822">837</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based Compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6aa75d0adc8143288bf6adb66cdca8b3_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTUtNS0xLTEtMA_fc47044d-ef26-4024-9eeb-7a97f0c4653e">1,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTUtMTEtMS0xLTA_ee2681ab-68b0-453e-a94b-cc5085eacfa2">1,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id26df19b9a654c2c8b37f4d6700c1341_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTYtMS0xLTEtMA_a67f23eb-ae81-47b1-bc1b-e4f4475b63e7">70,156,922</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id26df19b9a654c2c8b37f4d6700c1341_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTYtMy0xLTEtMA_063b72d9-7524-439e-9672-5896442a24bb">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fe27368b2b463192fd03bba6ea7fb6_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTYtNS0xLTEtMA_721c086a-04ba-4ecb-933b-5c15ab8c3243">337,551</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07c59fcd42914f3b85721e88dd99ea93_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTYtNy0xLTEtMA_e80269fc-a813-4be3-886c-c5d6dc824eae">321,392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60accea2370749c788fcb682961480d2_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTYtOS0xLTEtMA_1f814b63-2906-4119-9a58-e3b89ee474e7">46</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTYtMTEtMS0xLTA_600a4cdd-f813-4c6f-8842-679df6c2e04f">16,212</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Thousands)</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the six months ended June 30, 2021 and 2020 </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Flows From Operating Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMy0xLTEtMS0w_80c394de-d564-4003-aba2-9189873fdb1f">16,152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMy0zLTEtMS0w_a7f2bab0-005e-4102-9466-6816bdd9c2f4">14,876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNS0xLTEtMS0w_82c3315f-d0e5-4a45-8052-1b89cbfda44a">385</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNS0zLTEtMS0w_774683f4-d4f0-4962-a822-ec46e9905e3e">408</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNi0xLTEtMS0w_ddf5f5fc-c4d3-48ab-a556-bbc2149cd75f">197</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNi0zLTEtMS0w_669fc3f6-eb42-4a2f-95f5-78755e160687">526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant Modification Expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNy0xLTEtMS0w_4c440928-ec16-4922-8389-d3db7b6a60f5">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNy0zLTEtMS0w_db84fa6c-6641-4090-98e3-889d8ac51dcd">837</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase in Inventory Reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfOC0xLTEtMS0w_8bb8b882-0602-4c9a-bbc8-6ea48172dcb9">89</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfOC0zLTEtMS0w_8cbc322d-7057-435d-9731-3cc53cb936f1">12</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of Right of Use Asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfOS0xLTEtMS0w_a6fb5469-a7d5-4764-8462-125707672cf2">857</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfOS0zLTEtMS0w_45fe040b-d9cf-4d77-a3c8-3dc819368da0">748</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of Debt Financing Costs and Accretion of Debt Discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTAtMS0xLTEtMA_5d298b53-b4c8-40d7-8d8f-65d45799cc29">184</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTAtMy0xLTEtMA_2581884d-9d77-45a5-b7f1-e773f523f9bc">108</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on Disposal of Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTEtMS0xLTEtMA_f6161ac9-893e-482b-98da-3671f63f87ae">8</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTEtMy0xLTEtMA_e76a690e-9962-4d81-acc0-4f8d7c79d32e">6</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized Loss (Gain) on Sale of Investments Available-for-Sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTItMS0xLTEtMA_d85bc737-2a8f-46ee-81f2-c5442858b5ac">1</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTItMy0xLTEtMA_8f49b86c-35a2-48bf-b010-b5a4d6411917">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign Currency Translation Adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTMtMS0xLTEtMA_5db5f8fa-1562-4cd9-be9a-388884b17c2a">3</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTMtMy0xLTEtMA_ce6dde98-7a8d-4e52-a56e-ec256acb44cf">6</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in Assets and Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Increase) Decrease in Accounts Receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTUtMS0xLTEtMA_adbfd084-b137-4d24-b0f1-f1a0feec0857">1,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTUtMy0xLTEtMA_26f32889-5c7d-45cd-8fe2-9a6166715406">637</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase in Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTctMS0xLTEtMA_1ac921d4-8707-406c-a8ea-954e03b9142b">799</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTctMy0xLTEtMA_42956bc6-5a00-4797-abe8-c4e54d019f56">1,302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease (Increase) in Prepaid and Other Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTgtMS0xLTEtMA_375d07da-c1c7-467a-825a-2e0bc621c35a">1,293</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTgtMy0xLTEtMA_77aa7679-e7cc-45b2-a4ff-d4b35623cb6c">608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase in Accounts Payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTktMS0xLTEtMA_0e64dbc8-229c-4bed-92b7-ab54679167e3">777</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTktMy0xLTEtMA_2c4c585d-4f15-49d7-827a-11911bcd92bd">295</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease in Settlement Payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInInsuranceLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjAtMS0xLTEtMA_56a1a95e-83ef-4b11-888e-3ca118b9fee0">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInsuranceLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjAtMy0xLTEtMA_672e306e-9357-4d0f-81a8-64b7d068eb9d">104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease in Lease Liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" name="rmti:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjEtMS0xLTEtMA_32535d52-2c0c-44ea-bec0-791792e11c9a">839</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" name="rmti:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjEtMy0xLTEtMA_ffbc3b94-b3a2-49af-bed7-55aa937ff50b">703</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease in Other Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjItMS0xLTEtMA_2b2def1f-e1dc-43d5-bccc-c34a9dd08f9e">1,163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjItMy0xLTEtMA_f06266e3-c666-49b6-a54c-d0bd8427be47">96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease in Deferred License Revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjMtMS0xLTEtMA_1b23e862-ac6c-4078-b831-f0204490f524">1,088</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjMtMy0xLTEtMA_c80f8747-ba91-4e1a-a83c-19d84265c6f9">992</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in Assets and Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjQtMS0xLTEtMA_4f3cf5cf-efd8-4d22-b06a-cb228c52a2db">3,005</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjQtMy0xLTEtMA_2500d6f5-07d2-4ba9-9752-6510719db8fd">2,873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Used In Operating Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjUtMS0xLTEtMA_a3f28297-0b29-45ee-a440-9ecac6001c2a">17,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjUtMy0xLTEtMA_b5202e5a-a377-4155-a150-2889e2f08249">16,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Flows From Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of Investments Available-for-Sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjctMS0xLTEtMA_ff2e5b45-87cc-4d7e-a0c0-6070a4bd50f0">13,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjctMy0xLTEtMA_6453ed3d-fd8c-47a3-81a3-0563baf17384">16,514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sale of Investments Available-for-Sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjgtMS0xLTEtMA_6f2d3002-a5f7-4ed7-adb0-7b78354d31ff">15,181</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjgtMy0xLTEtMA_4749e678-b4da-4157-a138-2a54eafee679">17,497</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjktMS0xLTEtMA_246257b0-1cca-48f3-b0a0-cbf26c580846">281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjktMy0xLTEtMA_95573c7c-b5da-4e2e-b783-457ffa7a6fa0">283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Provided By Investing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzEtMS0xLTEtMA_677528b0-d9b9-48bb-9424-4d91b562b432">1,135</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzEtMy0xLTEtMA_d9c9dfe2-5a30-488f-b1a9-da830e71cb1e">700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Flows From Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from Term Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzMtMS0xLTEtMA_10d2dbf8-ff19-49dd-8ea3-99326475a771">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzMtMy0xLTEtMA_ecc06a6f-8482-4bfb-b6d6-b2ae05789cf0">22,500</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt Issuance Costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzQtMS0xLTEtMA_dbf8e2bb-adaf-4bfd-b910-d82f7e3956a0">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzQtMy0xLTEtMA_5e409802-581b-4171-8074-aac5503286ac">1,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments on Short Term Note Payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzUtMS0xLTEtMA_8fe744a6-4d4d-4f53-81c9-5527fecf9d11">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzUtMy0xLTEtMA_b2c7a15c-519e-4a4a-a7f7-54b98e78ccf1">763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the Issuance of Common Stock / Public Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia37f306f86304d1db38e7502e2c78594_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzYtMS0xLTEtMA_f445a591-6843-43ad-8444-a8425a8fc703">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9f360d22e2b9419f8e68140a6ac31e88_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzYtMy0xLTEtMA_4af69281-3d46-4a10-9641-a407ec225c38">8,148</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Offering Costs from the Issuance of Common Stock / Public Offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia37f306f86304d1db38e7502e2c78594_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzctMS0xLTEtMA_7408d153-a2e0-49d3-af9e-ea28f71efe22">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9f360d22e2b9419f8e68140a6ac31e88_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzctMy0xLTEtMA_1b5c1090-ca28-4684-a1c9-b43815906fb1">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the Issuance of Common Stock / At-the-Market Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i362afd3374074c7cada0c9ce798f3143_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzgtMS0xLTEtMA_e29fa80e-448b-49c9-bfb9-1923de19d6e4">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7b04f90c66774760bcf6df9405476edc_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzgtMy0xLTEtMA_4f118137-954a-4a53-a9d7-802eb6960ceb">2,034</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Offering Costs from the Issuance of Common Stock / At-the-Market Offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i362afd3374074c7cada0c9ce798f3143_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzktMS0xLTEtMA_1426c4a6-84e5-41eb-88ba-705ee549294c">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7b04f90c66774760bcf6df9405476edc_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzktMy0xLTEtMA_729879b1-ffc1-40b3-a01c-155414c92eb5">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchase of Common Stock to Pay Employee Withholding Taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="rmti:RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDEtMS0xLTEtMA_89c9d409-4ad0-4998-8ff6-202f096255ba">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="rmti:RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDEtMy0xLTEtMA_f059de88-920d-47b9-87fe-3b48dcf86b29">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash (Used In) Provided By Financing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDItMS0xLTEtMA_31d777a6-e9b8-4d05-8fc6-a9239541e873">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDItMy0xLTEtMA_857c56be-194e-4d2b-942a-6e8c9021fb39">30,357</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Decrease) Increase in Cash and Cash Equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDQtMS0xLTEtMA_264a00c2-7a68-467d-8a4e-753a5e59845a">16,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDQtMy0xLTEtMA_f18275e0-3351-40ba-bc00-96570348c78e">14,903</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and Cash Equivalents at Beginning of Period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDUtMS0xLTEtMA_f1496fad-dcb5-4cd8-b982-6e05920683ca">48,682</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i43c45a3bec674ffb9577158bb599935f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDUtMy0xLTEtMA_14156592-a680-40ed-bb9d-7b7e6b1d4b57">11,794</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents at End of Period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDYtMS0xLTEtMA_58765488-5900-49c0-abcd-452d4606edbc">32,378</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDYtMy0xLTEtMA_a8fd9381-9020-4bf3-862a-ebc12c339a0e">26,697</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Disclosure of Cash Flow Information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Paid for Interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDktMS0xLTEtMA_7a4e0e96-67fc-4bd5-94c6-63c3906b5d15">982</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDktMy0xLTEtMA_51aa0f84-8851-45ba-9b46-ddcb626e122b">410</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Disclosure of Noncash Investing and Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in Unrealized Loss on Marketable Securities Available-for-Sale</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNTEtMS0xLTEtMA_0ba5edcb-e18d-472e-b86f-d0dc97387902">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNTEtMy0xLTEtMA_9f6b3c66-5286-46c5-ad7f-c8e502c3c084">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value of Warrants issued related to Debt Financing</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNTUtMS0xLTEtMA_67845dc0-cf9f-4ef3-bfd0-06ee5b7581bd">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNTUtMy0xLTEtMA_482c7593-0a35-4368-9c81-3368ea23b42c">501</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><div><span><br/></span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.  <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNC9mcmFnOmRiZWExN2IyNWExNjRmNWQ5YzM4MDFhYmQzNThmMDg4L3RleHRyZWdpb246ZGJlYTE3YjI1YTE2NGY1ZDljMzgwMWFiZDM1OGYwODhfMTczOA_bf4656b0-0c1f-4c38-9a5f-0b6093b3587b" continuedAt="iec3669d5a9e141549e0bbc883783f62e" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="iec3669d5a9e141549e0bbc883783f62e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rockwell Medical, Inc. ("Rockwell Medical," "Rockwell" or the "Company") is a commercial-stage, biopharmaceutical company developing and commercializing our next-generation parenteral iron technology platform, ferric pyrophosphate citrate (“FPC”), which we believe has the potential to lead to transformative treatments for iron deficiency in multiple disease states, that we believe could reduce healthcare costs and improve patients’ lives. We are also one of the two major suppliers of life saving hemodialysis concentrate products to kidney dialysis clinics in the United States.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two novel, FDA approved therapies, Triferic and Triferic AVNU, which are the first two products developed from our FPC platform. We are marketing both products to kidney dialysis centers for their patients receiving dialysis. In 2021, we intend to advance our FPC platform strategy outside of dialysis by starting a Phase II trial for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving long-term and or chronic intravenous medications for various therapeutic needs in the home infusion setting. In our R&D pipeline, we are also exploring FPC’s impact in the treatment of hospitalized patients with acute heart failure, with the potential to begin another Phase 2 trial in these patients in 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the second largest supplier of hemodialysis concentrates in the United States generating approximately $<ix:nonFraction unitRef="usd" contextRef="i60a1e178baa84a468624d0acac59ece5_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNC9mcmFnOmRiZWExN2IyNWExNjRmNWQ5YzM4MDFhYmQzNThmMDg4L3RleHRyZWdpb246ZGJlYTE3YjI1YTE2NGY1ZDljMzgwMWFiZDM1OGYwODhfMTM4Nw_f5b1f8ec-dad6-44c3-89a7-c828d389ff51">60</ix:nonFraction> million in annual revenue. The Company's reputation for excellent service, quality, and reliability is based on over <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" format="ixt-sec:duryear" name="rmti:YearsOfService" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNC9mcmFnOmRiZWExN2IyNWExNjRmNWQ5YzM4MDFhYmQzNThmMDg4L3RleHRyZWdpb246ZGJlYTE3YjI1YTE2NGY1ZDljMzgwMWFiZDM1OGYwODhfMTQ5OQ_14ea2527-082c-430d-aaab-6ae84d141dbc">25</ix:nonNumeric> years of service to kidney dialysis centers. Our approximately <ix:nonFraction unitRef="employee" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-2" name="dei:EntityNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNC9mcmFnOmRiZWExN2IyNWExNjRmNWQ5YzM4MDFhYmQzNThmMDg4L3RleHRyZWdpb246ZGJlYTE3YjI1YTE2NGY1ZDljMzgwMWFiZDM1OGYwODhfMTU0NQ_0a7df9a1-828c-4274-ad11-0535093089b4">300</ix:nonFraction> dedicated employees, as well as a management team with experience in manufacturing, logistics, pharmaceutical development and commercialization gives us a solid foundation upon which to grow.</span></div></ix:continuation><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.  <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="rmti:LiquidityAndFinancialConditionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNy9mcmFnOjUxZDQ5ZTNjNTEyNjQ4YWY5NzQwZTIxNWFlNzA2MmQzL3RleHRyZWdpb246NTFkNDllM2M1MTI2NDhhZjk3NDBlMjE1YWU3MDYyZDNfMzQwNA_a26fb119-472f-4877-8d75-73253851deeb" continuedAt="i151e2108f0c445c7a274240d0a538ece" escape="true">Liquidity and Capital Resources</ix:nonNumeric></span></div><ix:continuation id="i151e2108f0c445c7a274240d0a538ece" continuedAt="i5e8b972eb78647dfbf487cb5365cd838"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, Rockwell has incurred significant net losses and has funded its operations primarily through revenue from commercial products, proceeds from the issuance of debt and equity securities and payments from partnerships. At June 30, 2021, Rockwell had an accumulated deficit of approximately $<ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNy9mcmFnOjUxZDQ5ZTNjNTEyNjQ4YWY5NzQwZTIxNWFlNzA2MmQzL3RleHRyZWdpb246NTFkNDllM2M1MTI2NDhhZjk3NDBlMjE1YWU3MDYyZDNfMzM0_8725fb9e-8732-4c1d-a5f4-d7677aabe687">353.6</ix:nonFraction> million and stockholders' equity of $<ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNy9mcmFnOjUxZDQ5ZTNjNTEyNjQ4YWY5NzQwZTIxNWFlNzA2MmQzL3RleHRyZWdpb246NTFkNDllM2M1MTI2NDhhZjk3NDBlMjE1YWU3MDYyZDNfMzY1_94562339-a800-4b32-a569-30af3e949dea">18.2</ix:nonFraction> million. As of June 30, 2021, Rockwell had approximately $<ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNy9mcmFnOjUxZDQ5ZTNjNTEyNjQ4YWY5NzQwZTIxNWFlNzA2MmQzL3RleHRyZWdpb246NTFkNDllM2M1MTI2NDhhZjk3NDBlMjE1YWU3MDYyZDNfNDA2_c30ef263-9111-45e8-a20d-233837a00fe2">41.0</ix:nonFraction> million of cash, cash equivalents and investments available-for-sale, and working capital of $<ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-5" format="ixt:numdotdecimal" name="rmti:WorkingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNy9mcmFnOjUxZDQ5ZTNjNTEyNjQ4YWY5NzQwZTIxNWFlNzA2MmQzL3RleHRyZWdpb246NTFkNDllM2M1MTI2NDhhZjk3NDBlMjE1YWU3MDYyZDNfNDk0_4fc4238d-9b16-47fc-8177-810173ec0e98">18.4</ix:nonFraction> million. Net cash used in operating activities for the six months ended June 30, 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNy9mcmFnOjUxZDQ5ZTNjNTEyNjQ4YWY5NzQwZTIxNWFlNzA2MmQzL3RleHRyZWdpb246NTFkNDllM2M1MTI2NDhhZjk3NDBlMjE1YWU3MDYyZDNfNTgx_a0269c16-1ae9-4a2f-8d42-38407d6aaf9e">17.4</ix:nonFraction> million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is subject to certain covenants and cure provisions under its Loan Agreement with Innovatus. As of the date of this report, the Company is in compliance with all covenants. As a result of the ongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company may not be able to satisfy such covenants over the next 12 months. However, based on the foregoing, the Company has classified amounts payable under the Loan Agreement as a current liability. If and when the Company reaches an agreement with Innovatus to avoid an event of default, the amounts payable under the Loan Agreement will be reclassified. The financial statements for June 30, 2021, have been prepared with the assumption that the Company will be able to agree to an appropriate remedy during the applicable cure period for any future breaches of operating covenants. If the Company is unable to comply with the covenants under the Loan Agreement, it would pursue all available cure options in order to regain compliance (See Note 15 for further detail).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company expects it will require additional capital to sustain its operations and make the investments it needs to execute its strategic plan, including the commercialization of Triferic (dialysate) and Triferic AVNU in dialysis, generating additional data for Triferic in dialysis, developing FPC for iron deficiency anemia in patients undergoing home infusion and for progressing our pipeline development program of new indications for its FPC platform. If the Company is unable to generate sufficient revenue from sales of its commercial products and from partnerships, the Company will need to obtain additional equity or debt financing. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the currently available working capital and managements assumption that the Company will be able to agree to an appropriate remedy, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i5e8b972eb78647dfbf487cb5365cd838"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic and resulting domestic and global disruptions have adversely affected Rockwell's business and operations, including, but not limited to, our sales and marketing efforts, research and development activities, and the operations of third parties upon whom the Company relies. Quarantines, shelter-in-place, executive and similar government orders and the recent surge in infections domestically may continue to negatively impact Rockwell's sales and marketing activities, particularly if its sales representatives are unable to interact with current and potential customers to the same extent as before onset of the COVID-19 pandemic. The Company's international business development activities may also continue to be negatively impacted by COVID-19, especially with the recent surge in infections internationally, ongoing international travel restrictions and quarantines or shelter-in-place orders. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic, the domestic and international surge in infections and resulting global disruptions have caused significant volatility in financial and credit markets. Rockwell has utilized a range of financing methods to fund its operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding, refinancing or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect the Company's liquidity and capital resources in the future.</span></div></ix:continuation><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.  <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RleHRyZWdpb246MTI1MzFmMTZlZjg0NGQxYzhhOGM1Y2VkODMwZWM5Y2FfNTgzMg_35030dd6-0ea8-4548-8f3f-4e4357bdcac0" continuedAt="idda35589f3d84261b182fe00e4aebb9b" escape="true">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="idda35589f3d84261b182fe00e4aebb9b" continuedAt="i3cf08100450845d4b130557710646dc9"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U. S. Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet at June 30, 2021, condensed consolidated statements of operations for the three and six months ended June 30, 2021 and 2020, condensed consolidated statements of comprehensive loss for the three and six months ended June 30, 2021 and 2020, condensed consolidated statement of changes in stockholders' equity for the three and six months ended June 30, 2021 and 2020, and condensed consolidated statements of cash flows for the six months ended June 30, 2021 and 2020 are unaudited, but include all adjustments, consisting of normal recurring adjustments, that the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and six months ended June 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021 or for any future interim period. The condensed consolidated balance sheet at December 31, 2020 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020 and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 as filed with the SEC on March 31, 2021. The Company’s consolidated subsidiaries consisted of its wholly-owned subsidiaries, Rockwell Transportation, Inc. and Rockwell Medical India Private Limited.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RleHRyZWdpb246MTI1MzFmMTZlZjg0NGQxYzhhOGM1Y2VkODMwZWM5Y2FfNTgzMw_64b5deef-8160-4967-bf44-08a4c77cc596" escape="true">The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RleHRyZWdpb246MTI1MzFmMTZlZjg0NGQxYzhhOGM1Y2VkODMwZWM5Y2FfNTgzNA_61dc653d-63ac-4544-9adf-b223c257f7a2" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RleHRyZWdpb246MTI1MzFmMTZlZjg0NGQxYzhhOGM1Y2VkODMwZWM5Y2FfNTgzNQ_bb5b8550-199e-40d0-900c-88a81f8f2154" continuedAt="i2df828a8826e425f8aa0aece774fac77" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i3cf08100450845d4b130557710646dc9"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2df828a8826e425f8aa0aece774fac77">In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.</ix:continuation></span></div><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RleHRyZWdpb246MTI1MzFmMTZlZjg0NGQxYzhhOGM1Y2VkODMwZWM5Y2FfNTgzNw_aebf203d-3f74-4fa3-a0e3-629b977cad81" continuedAt="ibe57fe1da79e419ba415ff2d520d487e" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibe57fe1da79e419ba415ff2d520d487e">Basic net loss per share of common stock excludes dilution and is computed by dividing the net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. The Company has only incurred losses, therefore, basic and diluted net loss per share is the same.</ix:continuation> <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RleHRyZWdpb246MTI1MzFmMTZlZjg0NGQxYzhhOGM1Y2VkODMwZWM5Y2FfNTgzOA_bbb973cd-68cb-4887-8913-33f3d61285f8" continuedAt="i5dca3a01c8ae4670b1678c1ae564fe44" escape="true">Securities that could potentially dilute net income per share in the future that were not included in the computation of diluted loss per share were as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i5dca3a01c8ae4670b1678c1ae564fe44"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib836387b9dbf4d2194d1f2d0760e18fb_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfMi0xLTEtMS0w_4f02b5df-8f2c-417d-9868-9aa471058791">6,070,801</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4213fa50227d476f94ac06eb631a5c6f_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfMi0zLTEtMS0w_02e7ea30-6e88-4f2c-a9d7-d1297e290cb9">6,225,562</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3f359e12f74143a3aecd3e1aea69c9f6_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfMy0xLTEtMS0w_2fd434cb-8610-4561-a863-4024092bc75b">78,300</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib187f06d4c2b4b44a5076ea0d0b431b5_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfMy0zLTEtMS0w_f32ca3de-8bf4-47fa-8fc8-a5cc26450c7a">146,800</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i234e6a6e01d345a2a2a9ecbd74387219_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfNC0xLTEtMS0w_56a3c414-ae82-4447-bc2e-635ad816ce19">342,604</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4cb310df91c047af8dd3a11fd4886ab3_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfNC0zLTEtMS0w_3223324a-92ed-4e0d-bef6-fa07013ba86a">503,395</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ied0dd598d05f4288a25014c07eebd870_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfNS0xLTEtMS0w_bc5ee3e7-04da-4b56-b689-43d47a6cc5d6">26,426,863</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i22e74f63f96b4ccf89d59802612fc8c4_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfNS0zLTEtMS0w_cbad3949-3e20-4eb4-8a5c-a9bb7fc79a06">3,248,054</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfNi0xLTEtMS0w_d6277d5e-1c05-4ff6-bce1-ff01c8801ea7">32,918,568</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfNi0zLTEtMS0w_3c700875-7ea1-4e74-8467-2c4e1a65118d">10,123,811</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RleHRyZWdpb246MTI1MzFmMTZlZjg0NGQxYzhhOGM1Y2VkODMwZWM5Y2FfNTgzMQ_6e279ab3-8f90-4337-96fc-2b95c36d0325" escape="true"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually assesses new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Financial Accounting Standards Board ("FASB") recently issued Accounting Standards Update ("ASU") 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_43"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.  <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNjczMw_2a3c2323-b103-40d0-b752-662e267c3ad8" continuedAt="id5f29df48c1940c7872990d47faebf48" escape="true">Revenue Recognition</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:continuation id="id5f29df48c1940c7872990d47faebf48" continuedAt="i3ee205aa7d8f478aa60cddd7c7e94d83"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 1: Identify the contract with the customer</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 2: Identify the performance obligations in the contract</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 3: Determine the transaction price</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 4: Allocate the transaction price to the performance obligations in the contract</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i3ee205aa7d8f478aa60cddd7c7e94d83" continuedAt="i8684a9bd373a4171a15193460808126a"><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 5: Recognize revenue when the company satisfies a performance obligation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Nature of goods and services</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of principal activities from which the Company generates its revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales –</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug and dialysis concentrate products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales.  For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales.  In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude that regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time that control of the product transfers to the customer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received upfront fees under <ix:nonFraction unitRef="agreement" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="rmti:NumberOfDistributionAndLicenseAgreements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfMjk1NQ_7738948c-0192-45e8-be2e-418436dc1027">five</ix:nonFraction> distribution and license agreements that have been deferred as a contract liability.  The amounts received from Wanbang Biopharmaceuticals Co., Ltd. (“Wanbang”), Sun Pharmaceutical Industries Ltd. ("Sun Pharma"), Jeil Pharmaceutical Co., Ltd. ("Jeil Pharma") and Drogsan Pharmaceuticals ("Drogsan Pharma") are recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China, India and South Korea, respectively, to determine that regulatory approval was probable as of the execution of the agreement.  The amounts received from Baxter Healthcare Corporation (“Baxter”) are recognized as revenue at the point in time that the estimated product sales under the agreement occur. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the business under the Company’s Distribution Agreement with Baxter (the “Baxter Agreement”), and for the majority of the Company’s international customers, the Company recognizes revenue at the shipping point, which is generally the Company’s plant or warehouse. For other business, the Company recognizes revenue based on when the customer takes control or receipt of the product. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers. There were no such adjustments for the periods reported. Customers typically pay for the product based on customary business practices with payment terms averaging <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" format="ixt-sec:durday" name="rmti:AveragePaymentTermOfCustomers" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNDQ0Mw_223d9cfb-6e5e-4543-a145-81be8393c589">30</ix:nonNumeric> days, while distributor payment terms average <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" format="ixt-sec:durday" name="rmti:AveragePaymentTermOfDistributors" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNDQ4Nw_2abd4625-91cd-45e4-a920-7ea1b5989780">45</ix:nonNumeric> days.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Disaggregation of revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNjczNA_c1a9e04e-ddc4-41c3-823a-0489d3828917" continuedAt="i9ea7e3618739408a8b9dfec8241af7b8" escape="true">Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i8684a9bd373a4171a15193460808126a" continuedAt="i1145f59ce98942c1b161df1432234a09"><ix:continuation id="i9ea7e3618739408a8b9dfec8241af7b8"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.901%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($) </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id817573b63f545c4b0779381d9eecaa4_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMy0xLTEtMS0w_a443c75c-f008-4633-bd27-32f64b4c0734">215</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id9a3833807ea4f74a7a1f27cf203fd5e_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMy0zLTEtMS0w_6d0344f7-d08e-421d-a775-b92703c46422">215</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id4a5ecfa7b564990bee4389ba90e2ec4_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMy01LTEtMS0w_272556b7-a2be-456e-83e8-7447bb5bc54f">—</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ieca9a4e9f9244e53bbff8d044bfaccc4_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMy03LTEtMS0w_3217775b-9b58-4145-9af1-0e7be8f1fa9f">439</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iafedcd0ea4794c7aaa56752656d24c74_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMy05LTEtMS0w_fbb2f16f-0d22-4107-9df3-dad79558374d">439</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id6cb7e08ae2d49e6a5b26d9d272b9f1d_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMy0xMS0xLTEtMA_33363a92-6640-4c20-8d1b-9185782da3d2">—</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie4ae2a5c5baf465e84899070e8d326d6_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNC0xLTEtMS0w_0b8b2377-10ae-41e9-a41b-55487f49a8ce">58</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if096b68927464500b4e88829e37637c2_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNC0zLTEtMS0w_9ae018bb-16b8-41c9-97c4-c198c9efda34">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6f3b0b018abf4ad28e152dd527bf3362_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNC01LTEtMS0w_28a6e6f2-f6dc-40ce-89cb-bed331ea7712">58</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06a344e202084e8db05b539ad000672f_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNC03LTEtMS0w_1c4ae436-49fb-46d3-8930-fb0209de5621">117</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if238d6f15fb74086ad99dba36761f71f_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNC05LTEtMS0w_8fe4bb5e-306a-40f6-9cb3-d9f2f4fe0420">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i745d398121d3420c9e3c52c10191697f_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNC0xMS0xLTEtMA_d26a5c3a-54bd-4840-959b-3f8daa1a0842">117</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0a076ec540424aaca3aa0743cc065e09_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNS0xLTEtMS0w_45e84179-d39d-4171-b67c-539364dbcfbe">273</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i02702a823cf648519e82be8308bd7596_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNS0zLTEtMS0w_c98280c3-0262-4b4b-ac09-dc2193896be1">215</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib6922c012b894f83b88c3ade46b3691c_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNS01LTEtMS0w_34cb8637-58f6-4199-85cb-d4f0d371d50a">58</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3c130100b8bb44d2a7a09782e10841de_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNS03LTEtMS0w_5a891314-639c-42e8-9325-1ba1b61d3cbb">556</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id3053c900b0b4cd6b2f2b892bea072a6_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNS05LTEtMS0w_37932e32-2dd8-4af5-9eea-9e1159dedca6">439</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i292ea93b319445a483177b398681ba09_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNS0xMS0xLTEtMA_025ea6d2-d144-42b8-9220-e3bfbf290f25">117</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrate Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6ce20ced6701401694822bf3176021b8_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNy0xLTEtMS0w_a8d4a726-fe10-456e-a72c-7df26ce902f6">14,379</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i42661da0c9dd422d99f958a822e76c80_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNy0zLTEtMS0w_1a3d8ac8-49b1-4499-a457-19f2b3a2166a">13,026</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic569e934568a4510a8431b3e9b0cce78_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNy01LTEtMS0w_c0c57c4c-b859-4ed4-9a9c-5a9e896680da">1,353</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4ccc0ab30cf47169a22197ca958e494_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNy03LTEtMS0w_08fc822d-da7c-4476-a575-ad6ecfa76d37">29,084</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1a7ed85229724ee2a7a0722168d880b7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNy05LTEtMS0w_3aea65d8-8231-4700-86de-b4757fa24359">26,227</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4f4a67681724daaa3e7eeed7f750918_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNy0xMS0xLTEtMA_c74b9ec3-30d1-4e03-a136-a3f7128e0c81">2,857</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i923167f606cf40d7a53bb0e1fbf64893_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOC0xLTEtMS0w_52d6ef00-f2df-47b5-9c6c-ecf8a195970b">485</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5ddb390e46cf4c218e6473e46dfc5e7e_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOC0zLTEtMS0w_41bb955f-26f1-4f61-af42-cf5f97e424ee">485</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8be39cf73a5645cfa4869eccd7ffd140_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOC01LTEtMS0w_f5613591-5d1d-4040-9e99-e10dcb85aec4">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i499887d5bc04466a881225c24de111c9_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOC03LTEtMS0w_bf9db88b-c681-45be-8e3a-54b3a67480f2">971</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic1b0c675ad3a4dc5a6cfbdb5e8eab0ba_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOC05LTEtMS0w_7984daed-efc7-4a39-a814-467ac38d6dcd">971</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i72196e4fcc3d4c68b85555ee776e8323_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOC0xMS0xLTEtMA_6591b40e-4740-4720-b747-7c71cb0dedef">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7fc604f0bbfc49e0af5bd3f913f7bcac_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOS0xLTEtMS0w_70ea1f71-067b-42bf-ae06-32b1bac30786">14,864</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9afd3e3be09480b93f86d7baf05a03e_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOS0zLTEtMS0w_0114f80b-bcc9-436d-a4c0-6208bb2cee3b">13,511</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19717f382ea34d3a8d3ba919c064ab70_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOS01LTEtMS0w_6986d41a-36c9-4fce-9cd4-4a314397e134">1,353</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i04631d2e7a6f46958f2abcf1c20c0165_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOS03LTEtMS0w_2b2c0f66-bd74-4ce6-befa-3a2a2488a24d">30,055</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i46c0764450934a84aede084a08f162d3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOS05LTEtMS0w_930d4c1d-afa0-4d2f-81ba-72f967c04583">27,198</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i453a3991692c48d196c8d65dfcef5486_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOS0xMS0xLTEtMA_f17b104c-7820-4c61-8c6e-f1101a693ece">2,857</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMTAtMS0xLTEtMA_79ae2d72-0b44-423a-8941-7d7d6aadb162">15,137</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib211340e5e4741839359edb488b6820a_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMTAtMy0xLTEtMA_a6e92871-d190-42e2-bfe7-62fe9c2d6bd9">13,726</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if69d4f2ec51d4ebab66a7c6c0b08fd69_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMTAtNS0xLTEtMA_67f02e11-3185-43c3-8a37-bf30ae7a0651">1,411</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMTAtNy0xLTEtMA_be08ce60-08f8-4203-a24a-aea399d96a8b">30,611</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if84c75bc21bd454e9387eea17889b736_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMTAtOS0xLTEtMA_27f76021-fe78-42d2-a2b2-fa5a6ac269d2">27,637</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ica982797685d4867885a3bbb4e1799f8_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMTAtMTEtMS0xLTA_3c7cc6fc-681f-41bd-9956-c4d7ec1fb664">2,974</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.179%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.179%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.179%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.179%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i84f272a5e5e04e439fb8926e0ca1edf7_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMy0xLTEtMS0w_d938308b-b805-404b-81e3-6c3c4ee2c09d">182</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if4a510f683e7412cabff75b22f5281da_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMy0zLTEtMS0w_a8f6aa83-c0ba-428f-9693-3d79c4775288">182</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3f3b95dc158544189ce6a5d99f57cfed_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMy01LTEtMS0w_ba95362f-63e9-4285-b6e7-8493e3f0e78f">—</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if572cd5222f042df8163eeda30992465_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMy03LTEtMS0w_d6867c41-24fa-424b-8e62-2a3a5b8b10df">381</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3c202ad8a44b417c93e84a0b4edc89df_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMy05LTEtMS0w_5021b509-5e8f-4193-97cb-1a223bd1c5e9">381</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i33e8984dceec4885937bef7aade6f1bf_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMy0xMS0xLTEtMA_e2cd3b7f-8841-49ea-9aec-f05ce53b7c53">—</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id52be33547c9431b85a4342a2f2a4c9c_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNC0xLTEtMS0w_90768a9e-205d-4af8-b1c3-7088812d73d6">56</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0da48e7639534786971c53ed0c8a8b79_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNC0zLTEtMS0w_56092e0e-ba88-49b3-a9d0-55a6eb232ef5">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if3579aee169c40d1b1ebf79b3f56a3a3_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNC01LTEtMS0w_9817e582-e1cf-4e6d-aaf7-4d2d5bf92ef4">56</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i00411df7d3c04001838b0d136b05ff9c_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNC03LTEtMS0w_7e7904ec-0b7d-46b6-ad2e-adf86f2ba632">112</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie1fce7f95ed24da2bedbd4e38c03b866_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNC05LTEtMS0w_2a4c79f3-90b1-4acf-9f2c-ec9167e66ff5">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0315167a57d743cb8c4cccfeed4f43c9_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNC0xMS0xLTEtMA_13e7bcc0-97be-4c3a-b6ac-922d0c110634">112</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id72af55606eb4c8eb7cfbe2a7544505e_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNS0xLTEtMS0w_40f9f0b0-5f72-4586-93fc-c1d4ca0c7d21">238</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40b91f57dc5345558f46f78c6e809cde_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNS0zLTEtMS0w_13327416-8234-4d4e-9c00-81483f220f88">182</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0480fc74d5745178e00498bd3c64905_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNS01LTEtMS0w_538690b7-2550-4f04-bb8b-3167302ad89f">56</ix:nonFraction> </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5145ce2ef7ad4c80b3936b501436c3ca_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNS03LTEtMS0w_7615483c-9f85-4d05-a9c1-6286f53e0a53">493</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id9090f1f2b024e1fa299abac8f5b8a94_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNS05LTEtMS0w_74e00632-6fe5-4970-8e75-134bab85f0b6">381</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iff460b44d83a459a91b73a4e4bf3b9a6_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNS0xMS0xLTEtMA_6a2fdfbd-7bb1-40e7-ab44-7aee060c0d69">112</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrate Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib6593dca464b48b688b4062dcb38e469_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNy0xLTEtMS0w_0d5660c9-73e6-42dd-81ef-d4239c65fb38">15,168</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3c726d6f00c48748ecb13e2df4349a0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNy0zLTEtMS0w_7f2bb593-7ecc-40a1-95a1-cf95b66ed58d">13,319</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if40ef0e6f3b34b859ff96c8f94e67052_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNy01LTEtMS0w_68db800c-a7b2-469f-862f-19e4fd5f4649">1,849</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iab0454faec22428e95ed05ab8e5b75e4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNy03LTEtMS0w_94929163-8fe9-411b-bd63-d3f6ee91c630">30,280</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i57d87eb7fbd94c44a05255171f31ec4f_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNy05LTEtMS0w_0e511037-ad7f-4552-8051-ab62240721b3">26,826</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i855c474985a24e75a1db3f85ab19407d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNy0xMS0xLTEtMA_74c9b646-4c5e-437b-a8d7-00c5e3693cf2">3,454</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8fd60db6aa864ebda72c4b973f6bb595_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOC0xLTEtMS0w_6229e380-4628-4de9-9b10-4e0cb0d8f6f3">490</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0c57eb7213114137a35dc2e9414b8ad7_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOC0zLTEtMS0w_c7f7427c-51cd-4722-b85d-6394c5409995">490</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b9266a45b8644df99c3c3cc5a340793_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOC01LTEtMS0w_7c3d3bb1-77ce-458d-b662-4d97dba9562c">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7a6c6fed0fce4b14a3c5bd84ed2eb65a_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOC03LTEtMS0w_142f40fe-60cf-4e6e-9b80-572c9753215e">980</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9e0a6c01cca24e8fa233e43822d66e39_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOC05LTEtMS0w_b88903c0-101b-4ffe-ba47-39646af95697">980</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i666be76116bd4dbba8fd86f8788fbd2e_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOC0xMS0xLTEtMA_34d24120-b23c-4a48-8394-f4812dbcb402">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i87b28ce51d1b45beb18577ab76dfd443_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOS0xLTEtMS0w_4c183430-c631-4959-bc81-906fb0149133">15,658</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5cc214e4793343a9a278e81b78adef30_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOS0zLTEtMS0w_b98e58f8-0d83-4db4-8446-e5b630e2ee19">13,809</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8c637418d7d54d0eb1be550eeadc155a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOS01LTEtMS0w_105c8951-a7c9-4dfb-b3cb-85a445d81df7">1,849</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i333c560005714b44882c1307abb33985_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOS03LTEtMS0w_b0e69f24-1ce7-425a-8568-6c018efb8089">31,260</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if4800217e44243a0a6c3800959e5d3bf_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOS05LTEtMS0w_e8f31f29-8c6f-4d5e-a889-4b78b6040f1f">27,806</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6b367e5e5f34fc1abc31941f97868c3_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOS0xMS0xLTEtMA_c739e984-1d8c-4353-a32a-38ba748262bf">3,454</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMTAtMS0xLTEtMA_6e35121a-0c39-4a16-a1be-94c7c962c680">15,896</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaeea20075b5643f2bc9e29ae4bc8bb9a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMTAtMy0xLTEtMA_fe5a4ccb-2057-41a4-ac39-51c73d4696e3">13,991</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21c4c64e4427462690f1cc8ac29aba99_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMTAtNS0xLTEtMA_67932275-cfc9-4cf5-994c-6cd1ab35291c">1,905</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMTAtNy0xLTEtMA_cb5d419e-5d6a-4f0c-b6d3-cc3c37210aac">31,753</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib2537301a83f4c34b4d7b41169bbdc07_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMTAtOS0xLTEtMA_334ae7cd-18fa-45ab-96fd-cee32f0a5aed">28,187</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id5323b8c605048f9883ce2e0cf2efc2e_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMTAtMTEtMS0xLTA_e991bf54-830c-466e-b118-197e4637ff95">3,566</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Contract balances</span></div><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNjczNQ_3ced42ad-a0c1-4764-a7c0-6cc2b9328d2a" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, which are included in "Trade and other receivables"</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmE0OWVmZjdlYjExOTRiNjQ4OWVkNjFjZjc0ODI0MjA0L3RhYmxlcmFuZ2U6YTQ5ZWZmN2ViMTE5NGI2NDg5ZWQ2MWNmNzQ4MjQyMDRfMS0xLTEtMS0w_31ca032f-ade6-4f61-89d3-783309e3d62d">5,357</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmE0OWVmZjdlYjExOTRiNjQ4OWVkNjFjZjc0ODI0MjA0L3RhYmxlcmFuZ2U6YTQ5ZWZmN2ViMTE5NGI2NDg5ZWQ2MWNmNzQ4MjQyMDRfMS0zLTEtMS0w_e9f12fdb-a867-471c-859d-27840290655e">4,171</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmE0OWVmZjdlYjExOTRiNjQ4OWVkNjFjZjc0ODI0MjA0L3RhYmxlcmFuZ2U6YTQ5ZWZmN2ViMTE5NGI2NDg5ZWQ2MWNmNzQ4MjQyMDRfMi0xLTEtMS0w_2ae1f2ac-f44a-49e2-97d5-6b91a80c8c4b">9,103</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmE0OWVmZjdlYjExOTRiNjQ4OWVkNjFjZjc0ODI0MjA0L3RhYmxlcmFuZ2U6YTQ5ZWZmN2ViMTE5NGI2NDg5ZWQ2MWNmNzQ4MjQyMDRfMi0zLTEtMS0w_3365f89d-63a6-4f09-831f-3a14168ebb5c">10,190</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetCreditLossExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNDc5Nw_560120a7-5dfa-44f0-9d59-5213517b9683"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetCreditLossExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNDc5Nw_bed2159f-f358-478d-b03b-43f45038781a"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetCreditLossExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNDc5Nw_bff59780-48d7-4f88-b1f4-3d81dc9e2b1f"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetCreditLossExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNDc5Nw_d2d0b65a-31cf-4b67-912c-59f8ee7ecc83">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> material losses recognized related to any receivables arising from the Company’s contracts with customers for the three and six months ended June 30, 2021 and 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021 and June 30, 2020, the Company did not recognize any material bad-debt expense. There were <ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNTA0OA_198694bb-dd29-4a7b-8e96-455e06f52c78"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNTA0OA_2ef7fbb7-79b2-4c68-b314-3c0923444123">no</ix:nonFraction></ix:nonFraction> material contract assets recorded on the condensed consolidated balance sheet as of June 30, 2021 and December 31, 2020.  The Company does not generally accept returns of its concentrate products and <ix:nonFraction unitRef="usd" contextRef="i2221de36cdaa43edb16860bc141df763_I20210630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerRefundLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNTIyNQ_63df5140-327a-48e5-a53d-425860ef623d"><ix:nonFraction unitRef="usd" contextRef="i531d67a3cb074164b661fe82095b4e11_I20201231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerRefundLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNTIyNQ_c916d351-2c90-4305-b975-c3240d8e00c2">no</ix:nonFraction></ix:nonFraction> material reserve for returns of concentrate products was established as of June 30, 2021 or December 31, 2020. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract liabilities primarily relate to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Transaction price allocated to remaining performance obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, revenue recognized from performance obligations related to prior periods was not material.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1145f59ce98942c1b161df1432234a09">Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, totaled $<ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNjAzOA_0dd8cb6c-864a-4881-b0a9-6e4cd1f9e6e6">9.1</ix:nonFraction> million as of June 30, 2021. The amount relates primarily to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The Baxter Agreement includes minimum commitments of product sales over the duration of the agreement. Unfulfilled minimum commitments related to the Baxter Agreement are product sales of $<ix:nonFraction unitRef="usd" contextRef="iffc4d933f9f0489188683fe4b938ade0_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNjYyMA_cef79bc0-48a1-45ec-889a-d34a0f7d833e">6.2</ix:nonFraction> million as of June 30, 2021, which is amortized ratably through expiration of the Baxter Agreement on October 2, 2024.</ix:continuation></span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_46"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.  <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RleHRyZWdpb246NWU1ZDYyMTMyNWMwNDFmMmIwMWFkZTc4OWI4YTExY2FfNTI5_7724449c-72d4-4025-9138-5906c5b34dd5" continuedAt="i69459e3841d34059a7d9d29ae6700aac" escape="true">Investments - Available-for-Sale</ix:nonNumeric></span></div><ix:continuation id="i69459e3841d34059a7d9d29ae6700aac"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RleHRyZWdpb246NWU1ZDYyMTMyNWMwNDFmMmIwMWFkZTc4OWI4YTExY2FfNTMw_893cdf02-1d32-484a-bb13-936dff78ccd1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available-for-sale consisted of the following as of June 30, 2021 and December 31, 2020 (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmUxMjU3MjE2NjJiZDQzZGRhNDhmNDQxMzZlOWRiMWY0L3RhYmxlcmFuZ2U6ZTEyNTcyMTY2MmJkNDNkZGE0OGY0NDEzNmU5ZGIxZjRfMy0xLTEtMS0w_53128432-da1a-4124-9421-fe331d30cdfa">8,558</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmUxMjU3MjE2NjJiZDQzZGRhNDhmNDQxMzZlOWRiMWY0L3RhYmxlcmFuZ2U6ZTEyNTcyMTY2MmJkNDNkZGE0OGY0NDEzNmU5ZGIxZjRfMy0zLTEtMS0w_6b60f970-5947-43f0-ab13-4b4d41e21f1b">1</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmUxMjU3MjE2NjJiZDQzZGRhNDhmNDQxMzZlOWRiMWY0L3RhYmxlcmFuZ2U6ZTEyNTcyMTY2MmJkNDNkZGE0OGY0NDEzNmU5ZGIxZjRfMy01LTEtMS0w_94f34428-c736-4985-af85-ac13f064664b">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmUxMjU3MjE2NjJiZDQzZGRhNDhmNDQxMzZlOWRiMWY0L3RhYmxlcmFuZ2U6ZTEyNTcyMTY2MmJkNDNkZGE0OGY0NDEzNmU5ZGIxZjRfMy03LTEtMS0w_8bec3560-de32-4f67-b749-2f9147a1dc86">15</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmUxMjU3MjE2NjJiZDQzZGRhNDhmNDQxMzZlOWRiMWY0L3RhYmxlcmFuZ2U6ZTEyNTcyMTY2MmJkNDNkZGE0OGY0NDEzNmU5ZGIxZjRfMy05LTEtMS0w_9f314933-7904-4906-8359-f8f93bb9abcd">8,574</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmU3NDRlMDhhZDYwNzQ0ODNhYjE5Y2M0ZGZlYjg4YjJjL3RhYmxlcmFuZ2U6ZTc0NGUwOGFkNjA3NDQ4M2FiMTljYzRkZmViODhiMmNfMy0xLTEtMS0w_228e358d-c609-4a14-83f1-6990c3be4311">9,987</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmU3NDRlMDhhZDYwNzQ0ODNhYjE5Y2M0ZGZlYjg4YjJjL3RhYmxlcmFuZ2U6ZTc0NGUwOGFkNjA3NDQ4M2FiMTljYzRkZmViODhiMmNfMy0zLTEtMS0w_78ef3231-60bb-4d98-a562-acf794de6eaa">3</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmU3NDRlMDhhZDYwNzQ0ODNhYjE5Y2M0ZGZlYjg4YjJjL3RhYmxlcmFuZ2U6ZTc0NGUwOGFkNjA3NDQ4M2FiMTljYzRkZmViODhiMmNfMy01LTEtMS0w_d7125643-c6de-4fd8-b92c-13687bb8e9b4">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmU3NDRlMDhhZDYwNzQ0ODNhYjE5Y2M0ZGZlYjg4YjJjL3RhYmxlcmFuZ2U6ZTc0NGUwOGFkNjA3NDQ4M2FiMTljYzRkZmViODhiMmNfMy03LTEtMS0w_b39dd637-a693-4e5d-81a9-05df76eee88d">7</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmU3NDRlMDhhZDYwNzQ0ODNhYjE5Y2M0ZGZlYjg4YjJjL3RhYmxlcmFuZ2U6ZTc0NGUwOGFkNjA3NDQ4M2FiMTljYzRkZmViODhiMmNfMy05LTEtMS0w_4525a6a6-151e-4548-85ae-0bb94a2f7afa">9,997</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of investments available-for-sale are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as a Level 1 measurement under ASC 820 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, the amortized cost and estimated fair value of our available-for-sale securities were due within one year.</span></div></ix:continuation><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.  <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RleHRyZWdpb246NTAwYWVjYjNlZmQxNDlhMjkyNDhhNmVhNDEzMzEyYzFfNzE0_ec84cb6d-df20-41cf-a1a5-532d2c55640d" continuedAt="ibbc6bb807d094640909d90f7a099339d" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="ibbc6bb807d094640909d90f7a099339d"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RleHRyZWdpb246NTAwYWVjYjNlZmQxNDlhMjkyNDhhNmVhNDEzMzEyYzFfNzE1_68ca10d4-5e3b-4237-95ce-64b6785436a9" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of inventory, net of reserves, as of June 30, 2021 and December 31, 2020 are as follows (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:74.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.912%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.913%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw Materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RhYmxlOjY2ZDJkN2YxN2U0YTQ3NzdiODdlZWUxYjQxZjNlNzMzL3RhYmxlcmFuZ2U6NjZkMmQ3ZjE3ZTRhNDc3N2I4N2VlZTFiNDFmM2U3MzNfMS0xLTEtMS0w_9dd26984-3550-4e56-9e62-5d9517b6454a">3,598</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RhYmxlOjY2ZDJkN2YxN2U0YTQ3NzdiODdlZWUxYjQxZjNlNzMzL3RhYmxlcmFuZ2U6NjZkMmQ3ZjE3ZTRhNDc3N2I4N2VlZTFiNDFmM2U3MzNfMS0zLTEtMS0w_06b0b534-82d6-413f-8eda-6a1664daf56e">3,112</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in Process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RhYmxlOjY2ZDJkN2YxN2U0YTQ3NzdiODdlZWUxYjQxZjNlNzMzL3RhYmxlcmFuZ2U6NjZkMmQ3ZjE3ZTRhNDc3N2I4N2VlZTFiNDFmM2U3MzNfMi0xLTEtMS0w_e69782ef-f027-4d72-afd0-b09b2aa05b69">265</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RhYmxlOjY2ZDJkN2YxN2U0YTQ3NzdiODdlZWUxYjQxZjNlNzMzL3RhYmxlcmFuZ2U6NjZkMmQ3ZjE3ZTRhNDc3N2I4N2VlZTFiNDFmM2U3MzNfMi0zLTEtMS0w_dc3a87a0-9cd1-4e17-af31-aad75d9eed88">172</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished Goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RhYmxlOjY2ZDJkN2YxN2U0YTQ3NzdiODdlZWUxYjQxZjNlNzMzL3RhYmxlcmFuZ2U6NjZkMmQ3ZjE3ZTRhNDc3N2I4N2VlZTFiNDFmM2U3MzNfMy0xLTEtMS0w_7d654f67-888e-41b5-8bc5-58d8195dba27">1,936</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RhYmxlOjY2ZDJkN2YxN2U0YTQ3NzdiODdlZWUxYjQxZjNlNzMzL3RhYmxlcmFuZ2U6NjZkMmQ3ZjE3ZTRhNDc3N2I4N2VlZTFiNDFmM2U3MzNfMy0zLTEtMS0w_9c2ec06b-7475-4b27-a698-8f58459e22c3">1,805</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="rmti:CurrentAndNonCurrentInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RhYmxlOjY2ZDJkN2YxN2U0YTQ3NzdiODdlZWUxYjQxZjNlNzMzL3RhYmxlcmFuZ2U6NjZkMmQ3ZjE3ZTRhNDc3N2I4N2VlZTFiNDFmM2U3MzNfNC0xLTEtMS0w_d19ab0db-3047-4466-9f20-1fe06aa9aaea">5,799</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="rmti:CurrentAndNonCurrentInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RhYmxlOjY2ZDJkN2YxN2U0YTQ3NzdiODdlZWUxYjQxZjNlNzMzL3RhYmxlcmFuZ2U6NjZkMmQ3ZjE3ZTRhNDc3N2I4N2VlZTFiNDFmM2U3MzNfNC0zLTEtMS0w_47c7ea11-7d97-423f-95a5-7c3d927532c1">5,089</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, the Company classified $<ix:nonFraction unitRef="usd" contextRef="i5da195dc185f4ad2823040c5515d8512_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RleHRyZWdpb246NTAwYWVjYjNlZmQxNDlhMjkyNDhhNmVhNDEzMzEyYzFfMTQ5_35187fa1-a0c4-4efd-95d8-0f085f89511e">1.1</ix:nonFraction> million of inventory as non-current, all of which was related to Triferic or the active pharmaceutical ingredient and raw materials for Triferic. As of June 30, 2021, the total Triferic inventory net of reserve was $<ix:nonFraction unitRef="usd" contextRef="i5da195dc185f4ad2823040c5515d8512_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RleHRyZWdpb246NTAwYWVjYjNlZmQxNDlhMjkyNDhhNmVhNDEzMzEyYzFfMTA5OTUxMTYyODU4NA_b5a599da-e71f-441a-bf33-24ce68a94d1e">1.7</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="i5da195dc185f4ad2823040c5515d8512_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RleHRyZWdpb246NTAwYWVjYjNlZmQxNDlhMjkyNDhhNmVhNDEzMzEyYzFfMzg0_b5a599da-e71f-441a-bf33-24ce68a94d1e">1.7</ix:nonFraction> million net value of Triferic inventory consisted of $<ix:nonFraction unitRef="usd" contextRef="ideb44eb229184ecda8a91c6139e0d759_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RleHRyZWdpb246NTAwYWVjYjNlZmQxNDlhMjkyNDhhNmVhNDEzMzEyYzFfNDMy_6e3766b1-eae3-4c37-a0b3-10420eba094c">0.3</ix:nonFraction> million of Triferic (dialysate) finished goods with expiration dates ranging from September 2021 to December 2023, $<ix:nonFraction unitRef="usd" contextRef="i90a1bca35c1243f08d1d94a939cef6c4_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RleHRyZWdpb246NTAwYWVjYjNlZmQxNDlhMjkyNDhhNmVhNDEzMzEyYzFfNTQy_9ba8c503-3b39-41e0-a21d-af88190b84e4">0.5</ix:nonFraction> million of Triferic API with estimated remaining shelf life extending beyond 2021, and $<ix:nonFraction unitRef="usd" contextRef="i5da195dc185f4ad2823040c5515d8512_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RleHRyZWdpb246NTAwYWVjYjNlZmQxNDlhMjkyNDhhNmVhNDEzMzEyYzFfNjI0_c7f7f19e-fd33-4546-9d70-5daacc8c1885">0.9</ix:nonFraction> million of raw materials for Triferic with estimated remaining shelf life extending beyond 2025.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.  <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RleHRyZWdpb246NWFmMDEwYTc1OWQ1NDliMThkMmFlOGI0MDFjMDk2OGRfMjA2_1620e5f4-2192-4638-b848-40800ee7ca85" continuedAt="i3a59d608a6484759be1b37c24897726f" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i3a59d608a6484759be1b37c24897726f" continuedAt="i0dbebe1ad38d45929a4a6f35474147d4"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RleHRyZWdpb246NWFmMDEwYTc1OWQ1NDliMThkMmFlOGI0MDFjMDk2OGRfMjA3_85261ab7-eda9-4370-a2ef-9424f3441362" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, the Company’s property and equipment consisted of the following (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold Improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b0b6f74a05044e4873509f11c7db6af_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfMS0xLTEtMS0w_811abbca-e661-4052-b777-13222caa3090">1,196</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9d0128a643514513b686ad5149092728_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfMS0zLTEtMS0w_3295aae8-cd72-46d6-9351-3f67c4734d0c">1,196</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i465a7180dcdf4d2b801c1f4275cbdb15_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfMi0xLTEtMS0w_834f0789-ba73-4da6-bcf5-660fef558c6e">5,684</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2878341b4b7445749e3907105900094d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfMi0zLTEtMS0w_5395191f-3d3f-425e-a4aa-510692f2197a">5,475</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information Technology & Office Equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i16b1bae1038f45d8bacf79228eeb50a8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfMy0xLTEtMS0w_df6dd156-b362-46a3-8efd-2d46d9fce2a0">1,847</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i283693a6ea47413b8d27e797fcda6960_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfMy0zLTEtMS0w_da18636a-86ae-4080-8cc2-606e6b0449cc">1,831</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2d2310b000e944b4a1bafa95387c732b_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfNC0xLTEtMS0w_29f715fd-810d-45f5-a8b8-724397f336cb">676</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9904a6ff79bb4fc3884be08d20ddd455_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfNC0zLTEtMS0w_c70d495e-7823-4049-af8c-df1caa5e9a29">676</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfNS0xLTEtMS0w_24b031c3-7770-4e77-bf18-a359bf5bc7d4">9,403</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfNS0zLTEtMS0w_a4d598a8-9f08-4c52-8872-db6fb52a7740">9,178</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated Depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfNi0xLTEtMS0w_e2838d74-bd80-4bd0-8773-a4b053253c78">6,874</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfNi0zLTEtMS0w_450a4583-821e-45af-af35-86391a9d4104">6,536</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfNy0xLTEtMS0w_48c6b941-0ac1-443a-9662-d180613fcd2c">2,529</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfNy0zLTEtMS0w_c3e4ea8b-4cc2-408a-b264-def6a4aca35b">2,642</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0dbebe1ad38d45929a4a6f35474147d4">Depreciation expense for each of the three and six months ended June 30, 2021 and 2020 totaled $<ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RleHRyZWdpb246NWFmMDEwYTc1OWQ1NDliMThkMmFlOGI0MDFjMDk2OGRfMjAz_19d0c4bb-c338-4faa-a7cc-5cd2ee258d32"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RleHRyZWdpb246NWFmMDEwYTc1OWQ1NDliMThkMmFlOGI0MDFjMDk2OGRfMjAz_6b4eb4ae-2dad-4023-9bb6-c49858c044cc">0.2</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RleHRyZWdpb246NWFmMDEwYTc1OWQ1NDliMThkMmFlOGI0MDFjMDk2OGRfMTA5OTUxMTYyODAwMQ_20504ef2-c897-4b03-8f5f-75de9ca76d3a"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RleHRyZWdpb246NWFmMDEwYTc1OWQ1NDliMThkMmFlOGI0MDFjMDk2OGRfMTA5OTUxMTYyODAwMQ_4bd33deb-d12c-429c-b50f-e6eb181211d0">0.4</ix:nonFraction></ix:nonFraction> million.</ix:continuation> </span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.  <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RleHRyZWdpb246Y2U2NWNjZWFiZDFhNDAwZWE4ODIyNDhkZjgzYWZhYjVfMTE1_baad0018-c781-4bfd-a0b4-0f94a9663498" continuedAt="i61261de77bec4d468cffc24901c4f36f" escape="true">Accrued Liabilities</ix:nonNumeric></span></div><ix:continuation id="i61261de77bec4d468cffc24901c4f36f"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RleHRyZWdpb246Y2U2NWNjZWFiZDFhNDAwZWE4ODIyNDhkZjgzYWZhYjVfMTE2_a00b06e5-049c-427e-ad15-ee3463d298c2" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of June 30, 2021 and December 31, 2020 consisted of the following (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Research & Development Expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfMS0xLTEtMS0w_0d92c9e0-ac9e-406a-8e7f-d77ea6dc7e67">315</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" name="rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfMS0zLTEtMS0w_38406710-bf0e-439d-b7f2-df6f6ad747d0">232</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Compensation and Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfMi0xLTEtMS0w_c205f2fa-0119-4bc3-bc4a-1e8c2bfa9bd9">1,420</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfMi0zLTEtMS0w_41f97a60-40ac-4396-ba89-813ecdff7f41">2,500</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Unvouchered Receipts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="rmti:AccruedUnvoucheredReceiptsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfMy0xLTEtMS0w_cbce7549-d733-4c0b-a7f6-1be076e3d43c">647</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" name="rmti:AccruedUnvoucheredReceiptsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfMy0zLTEtMS0w_f5a88b76-2c3a-4242-96d1-c675f833bc6b">755</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Workers Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:WorkersCompensationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfNC0xLTEtMS0w_db37188e-3371-4439-959c-f048781d7218">531</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" name="us-gaap:WorkersCompensationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfNC0zLTEtMS0w_fc9ef734-9b28-42c3-a759-e782ad0c5764">395</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Accrued Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfNS0xLTEtMS0w_db6e5b04-5d0e-4e5a-90da-0a760fa0b5b9">1,080</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfNS0zLTEtMS0w_6c5d13a6-7daf-447e-a390-ff8ef61931c3">1,131</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Accrued Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfNi0xLTEtMS0w_805ed2c4-21da-4e55-85d0-1f7d57ce655d">3,993</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfNi0zLTEtMS0w_10324681-b325-44dc-8c44-fa77d32dc2fc">5,013</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_58"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.  <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="rmti:ContractWithCustomerDeferredRevenueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMzUxMw_66754270-c53d-4247-9ff2-cdaa56c21865" continuedAt="ib1cebe78c4944723afd9692cf615f8d4" escape="true">Deferred Revenue</ix:nonNumeric></span></div><ix:continuation id="ib1cebe78c4944723afd9692cf615f8d4" continuedAt="i0a2a798957274269bc46795d1ad94828"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, the Company entered into the Baxter Agreement with Baxter and received an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="ib41a5b0fba4342b8a42fbf0205323776_D20141001-20141031" decimals="-6" format="ixt:numdotdecimal" name="rmti:RevenueRecognitionReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTMy_4bc7bbb1-287e-443a-9c94-3818080bac73">20</ix:nonFraction> million. The upfront fee was recorded as deferred revenue and is being recognized based on the proportion of product shipments to Baxter in each period, compared with total expected sales volume over the term of the Baxter Agreement, which expires in October 2024. The Company recognized revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="i5a444cdf60204392ba5ee29a80d7a166_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfNDQw_4e315e1e-523c-48e8-9f71-16846914aabc"><ix:nonFraction unitRef="usd" contextRef="i108ba00af91143ca9c3ed9b4e9bb5c39_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfNDQw_fbea279c-fddd-4be1-91db-24103e3ed93e">0.5</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2d78ddfa8815448196febe7de94d00ab_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTU3OA_7c0f9145-9cf9-43b0-91db-85a5ae693047"><ix:nonFraction unitRef="usd" contextRef="iaeff68f2861040f5976c97fb25345bac_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTU3OA_88524e65-8868-41a7-b72e-e9b593b6bf83">1.0</ix:nonFraction></ix:nonFraction> million for each of the three and six months ended June 30, 2021 and 2020. Deferred revenue related to the Baxter Agreement totaled $<ix:nonFraction unitRef="usd" contextRef="iffc4d933f9f0489188683fe4b938ade0_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfNTQz_6ee70b74-92e8-404d-818c-8bf44d82cd3e">6.2</ix:nonFraction> million as of June 30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ib11ae81bd8164d54aefe2b07a1acc333_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfNTU5_1ba4e6b5-e433-4297-8775-8ec9aea993de">7.2</ix:nonFraction> million as of December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a “Refund Trigger Event” occurs under the Baxter Agreement prior to December 31, 2021, Rockwell would be obligated to repay <ix:nonFraction unitRef="number" contextRef="i108ba00af91143ca9c3ed9b4e9bb5c39_D20210101-20210630" decimals="INF" name="rmti:ContractWithCustomerRepaymentPercentageOfUpfrontFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfNjk5_2e8ddfbe-3b34-4cb4-8fe1-bb6bb305b558">25</ix:nonFraction>% of the upfront fee.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into a distribution and license agreement with Wanbang (the "Wanbang Agreement") and received an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="id44e4c40542f422392e127f7e00d1cef_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="rmti:RevenueRecognitionReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfODYx_d267946e-e71b-45c2-8bbb-4152f4889de4">4.0</ix:nonFraction> million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="ia6b9801f65854970b5da63868031cd71_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTAxNg_7fec9268-3505-4d51-8c9e-f0098df71db3"><ix:nonFraction unitRef="usd" contextRef="i97d0767332814c26b7040a7f42da83d7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTAxNg_d435bcb9-9f0f-4f80-93ed-d63bfc9ebffe">53,000</ix:nonFraction></ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i29a9d581630545e5b9d979ee4a331a36_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTMxMg_9c4de17c-5fca-46e7-a5d2-0d6ae88bf522"><ix:nonFraction unitRef="usd" contextRef="ib261789f13ed45118a64720f9ece6816_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTMxMg_e89191b3-414c-4673-b59e-d99dba9d9b45">0.1</ix:nonFraction></ix:nonFraction> million revenue for each of the three and six months ended June 30, 2021 and 2020. Deferred revenue related to the Wanbang Agreement totaled $<ix:nonFraction unitRef="usd" contextRef="id1200549772a41baab582b78ceebca58_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTE0NA_36dc71fd-5add-4ae9-a410-c691f66e258f">2.6</ix:nonFraction> million as of June 30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ia416a305cef740509c44aa63f6654918_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTU4NQ_68d66757-1da4-4e81-b31d-9147fc9cb64b">2.7</ix:nonFraction> million as of December 31, 2020.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company entered into license and supply agreements with Sun Pharma (the "Sun Pharma Agreements"), for the rights to commercialize Triferic (dialysate) (ferric pyrophosphate citrate) in India. Under the terms of the Sun Pharma Agreements, Sun Pharma will be the exclusive development and commercialization partner for Triferic (dialysate) in India, and the Company will supply the product to Sun Pharma. In consideration for the license, the Company received an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i7cbe96745d4a4ee7949e736eff90fddd_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="rmti:RevenueRecognitionReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTY2Mg_de336da3-51c5-4ff3-a17c-13888fa009a1">0.1</ix:nonFraction> million, and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Sun Pharma, will guide the development and execution for Triferic (dialysate) in </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i0a2a798957274269bc46795d1ad94828" continuedAt="i3c679531fd2a49618ce6aa6ecb540016"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">India. Sun Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="id7f108a122f849b691d34141d686f377_D20210401-20210630" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMjE3MQ_7d2e66cb-4717-49ed-817b-f8e3e0cfd63f"><ix:nonFraction unitRef="usd" contextRef="i1bbf0986a8a141be81ed18c1868716dc_D20210101-20210630" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMjE3MQ_8ef95ff9-a9a9-4fd3-a3ac-7e1def4220dd">2,500</ix:nonFraction></ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="idf5243f34d8c414c9014f13c02e11602_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTM2Mg_096c3771-41e1-48c0-90e3-0834d9a72a96"><ix:nonFraction unitRef="usd" contextRef="i979ffd2d5930459a8fee1a724d668606_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTM2Mg_70e38c7a-05d6-4570-b2c9-d8e8f10b1d51">5,000</ix:nonFraction></ix:nonFraction> for each of the three and six months ended June 30, 2021 and 2020. Deferred revenue related to the Sun Pharma Agreement totaled $<ix:nonFraction unitRef="usd" contextRef="ic278353975334c0eb61849b38be42f55_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMjI3OA_b6d53acb-00b6-4725-948c-9c0fce71a999">85,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id1509c49ed2945d6a5a0f7728fe181ec_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMjI4NQ_34a2b2cb-206b-4ea1-ab33-b8ef3830a690">90,000</ix:nonFraction> as of June 30, 2021 and December 31, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into a license and supply agreements with Jeil Pharma (the "Jeil Pharma Agreements"), for the rights to commercialize Triferic (dialysate) (ferric pyrophosphate citrate) in South Korea. Under the terms of the Jeil Pharma Agreements, Jeil Pharma will be the exclusive development and commercialization partner for Triferic (dialysate) in South Korea, and the Company will supply the product to Jeil Pharma. In consideration for the license, the Company received an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i4698c56f368245e5b301c41e5ecebf1c_D20200901-20200930" decimals="-5" format="ixt:numdotdecimal" name="rmti:RevenueRecognitionReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMjg1MA_456c3f16-8311-4d60-8d3b-6cc7abf90593">0.2</ix:nonFraction> million, and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Jeil Pharma, will guide the development and execution for Triferic (dialysate) in South Korea. Jeil Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i2deedffb02b34d8da21c7fab0fe0b691_D20210401-20210630" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMzM1NA_cb1a188f-c26a-40d1-b6e5-547c93df386a">2,500</ix:nonFraction> and <ix:nonFraction unitRef="usd" contextRef="ie5a61d1ec2a6474a931f248906e77c43_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTU1Ng_2004a21c-8691-4be6-b145-0f22853cb7f2">nil</ix:nonFraction> for the three months ended June 30, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i765972d583d94402bc7862f121892b89_D20210101-20210630" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTQyOA_a38a4cb4-b792-40f3-97b9-1a93bd365080">5,000</ix:nonFraction> and <ix:nonFraction unitRef="usd" contextRef="i4081bbacdfc8425bbf6a232aeb6f1b27_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTU1OQ_2be743e9-5129-4c52-8ffd-b09df1b57d6e">nil</ix:nonFraction> for the six months ended June 30, 2021 and 2020, respectively. Deferred revenue related to the Jeil Pharma Agreement totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i3f97c0f7f55d43f9b70110bf979d68b5_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMzQ4Mw_9e6a8bf2-8a45-404d-95f6-fcc572dc7a1b"><ix:nonFraction unitRef="usd" contextRef="i91bb067c41004b14ad33a703a367c7da_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMzQ4Mw_d2807d70-407d-4cbb-8ae9-75c5f5538129">0.2</ix:nonFraction></ix:nonFraction> million as of June 30, 2021 and December 31, 2020.</span></div></ix:continuation><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i3c679531fd2a49618ce6aa6ecb540016">In June 2021, the Company entered into license and supply agreements with Drogsan Pharma (the "Drogsan Agreements"), for the rights to commercialize Triferic (dialysate) and Triferic AVNU in Turkey. Under the terms of the Drogsan Agreements, Drogsan Pharma will be the exclusive commercialization partner for Triferic (dialysate) and Triferic AVNU in Turkey. In consideration for the license, the Company is due to receive an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i2770d871f3fc4222a123073cfdeb613a_D20210601-20210630" decimals="-5" format="ixt:numdotdecimal" name="rmti:RevenueRecognitionReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMzQ2NA_730cd1c5-436a-481b-83d5-24ae98ddf6ad">0.2</ix:nonFraction> million, and will be eligible for milestone payment and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Drogsan Pharma, will guide the execution for Triferic (dialysate) and Triferic AVNU in Turkey. Drogsan Pharma will be responsible for all regulatory approval and commercialization activities, and the Company will supply the product to Drogsan Pharma for Turkey. The upfront fee will be recorded as deferred revenue and will be recognized as revenue based on the agreement term.</ix:continuation> </span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.  <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMjE4MA_b7b28c74-4c75-40cc-869a-ab463993475f" continuedAt="i636a94a7e15743399b0269abc866adb3" escape="true">Stockholders’ Equity</ix:nonNumeric></span></div><div style="text-indent:27pt"><span><br/></span></div><ix:continuation id="i636a94a7e15743399b0269abc866adb3" continuedAt="i8d47185792fc4ea98e6970ff27faa5b9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfNzY_62bc4355-2069-4196-b18b-a48e01a8c0e0"><ix:nonFraction unitRef="shares" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfNzY_e8f4baee-e419-4865-a366-176ce0976d05">2,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMTA2_48110758-36a3-4fba-b07f-3dc34cc45266"><ix:nonFraction unitRef="usdPerShare" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMTA2_7cd423d9-a265-421d-bdb2-b06c9c8575a8">0.0001</ix:nonFraction></ix:nonFraction> par value per share, authorized and <ix:nonFraction unitRef="shares" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMTQ1_167f4111-d041-479a-8417-b6d878e85463"><ix:nonFraction unitRef="shares" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMTQ1_71a51862-6047-4184-ab6a-bee6169432d9"><ix:nonFraction unitRef="shares" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMTQ1_8075f323-d42b-4342-80e3-438304f35cc0"><ix:nonFraction unitRef="shares" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMTQ1_97307b7e-3203-4773-b578-76c08a616b0a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of preferred stock issued or outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMjM4_152e80ea-29d8-4be9-abb1-f34ed283aa45"><ix:nonFraction unitRef="shares" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMjM4_f50127f8-a56d-4f9b-b05d-aa6ceae50a09">170,000,000</ix:nonFraction></ix:nonFraction> shares of common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMjY1_486ad204-3a20-4e90-8741-da31ed26743a"><ix:nonFraction unitRef="usdPerShare" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMjY1_ad7ba2ce-a140-4fa9-af13-4487b9c9d936">0.0001</ix:nonFraction></ix:nonFraction> par value per share, authorized and <ix:nonFraction unitRef="shares" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMzA0_3a4e793a-7e20-4e0f-858a-bcff302ca30a"><ix:nonFraction unitRef="shares" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMzA0_d76d7821-aa36-4a28-9a0f-7a34bcde8250">93,811,381</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMzEx_4cba5123-e5ae-4fb0-ba08-7e0740f0d09a"><ix:nonFraction unitRef="shares" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMzEx_5435f4b6-1e05-4ac9-8d0e-d045da6198e3">93,573,165</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controlled Equity Offering (or "At the Market" Offering)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2019, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time shares of the Company’s common stock through the Agent. The offering and sale of up to $<ix:nonFraction unitRef="usd" contextRef="ia4046492d81c4dcfbc80f8128d23a0e8_D20190322-20190322" decimals="INF" format="ixt:numdotdecimal" name="rmti:SalesAgreementThresholdSaleOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfNzAw_888ec7b7-9e7c-4b9e-a579-65ae590bf6f8">40.0</ix:nonFraction> million of the shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company’s registration statement on Form S-3 (File No. 333-227363), which was originally filed with the SEC on September 14, 2018 and declared effective by the SEC on October 1, 2018, the base prospectus contained within the registration statement, and a prospectus supplement that was filed with the SEC on March 22, 2019.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the shares, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an “at the market" offering as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Global Market or on any other existing trading market for the Company’s common stock. The Company intends to use the proceeds from the offering for working capital and other general corporate purposes. The Company may suspend or terminate the Sales Agreement at any time.</span></div></ix:continuation><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i8d47185792fc4ea98e6970ff27faa5b9"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2021, the Company has not sold shares of its common stock pursuant to the Sales Agreement. Approximately $<ix:nonFraction unitRef="usd" contextRef="i54ebd73955be4ec087f2c3127f7aef9f_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="rmti:SaleofStockRemainingSalesAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMTc3NA_24374772-0c4a-407c-9158-3eb1b72acc7b"><ix:nonFraction unitRef="usd" contextRef="i362afd3374074c7cada0c9ce798f3143_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="rmti:SaleofStockRemainingSalesAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMTc3NA_dc2a5750-936c-4035-85ba-712c812e8753">32.3</ix:nonFraction></ix:nonFraction> million remains available for sale under this facility.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not required to sell any shares at any time during the term of the facility. The Company's ability to sell common stock under the facility may be limited by several factors including, among other things, the trading volume of its common stock and certain black-out periods that the Company may impose upon the facility, among other things.</span></div></ix:continuation><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.  <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzg3MQ_3a5d2fd7-d22b-47df-9f8c-335423512e5b" continuedAt="id7343a431278462bb32df6452e0701fa" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="id7343a431278462bb32df6452e0701fa" continuedAt="iaffcb18c565349c291f3457e7ebc1e00"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzg3Mw_5da085d4-c263-448f-a7f5-156e10e4a0f5" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized total stock-based compensation expense during the three and six months ended June 30, 2021 and 2020 as follows (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Service-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9c4394b8322844b885708d0a121c0250_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNC0xLTEtMS0w_6a35791b-a99e-4038-9375-96aac301d4ce">78</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i328ca3ef8e144273a05211111c192e60_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNC0zLTEtMS0w_876a058a-129a-4298-8cc2-5d5a58158f60">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNC01LTEtMS0w_b825fdce-c978-4d56-bbf4-26efb87d66a9">182</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNC03LTEtMS0w_0f2a060a-4ea2-4cfc-9d56-51a9be35b627">234</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iacc309a401f7466cb3e18730470f3752_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNS0xLTEtMS0w_30924f9d-1566-4181-bdc3-7ad10b41e398">344</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if90c1947aa9c420f9f93f64285facd2f_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNS0zLTEtMS0w_afc8c84b-f8d2-4485-936b-63fbfd8fbfb8">336</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNS01LTEtMS0w_389d9080-18e2-4b4d-b377-d7ef1946e588">735</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNS03LTEtMS0w_f54167da-d042-4395-b9c1-73d3393ee3ea">776</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55e1c1131a084252abc713575b403ea8_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNi0xLTEtMS0w_cb6334ce-e7b7-4d7d-864d-76f5f97fd57d">422</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if9f58870aefd4e5f887f2aa505cf9e96_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNi0zLTEtMS0w_4b6eb81c-b509-45f1-9907-873df44daf9f">332</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4015b62fa1a0414b80069a233cc0d05e_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNi01LTEtMS0w_77844300-008f-4e41-913b-c4ca078b972b">917</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i812bfc33e296453fa2415e929c6925d0_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNi03LTEtMS0w_c5b95562-b297-447b-bb35-79c44cfcd512">1,010</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Performance-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0e7f5848454b9ba1e6e17804b0edc3_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfOC0xLTEtMS0w_505eaade-6c90-4226-8162-c65ebdd2def4">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e07dbab6dd248f6969e269920c504d6_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfOC0zLTEtMS0w_35a9864c-952c-44fd-9933-6e808cca1e85">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if12de0f76e944b3bb7b40b44269dcce8_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfOC01LTEtMS00NTA_92483f92-ec84-485c-b171-3b95417a69d7">390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5595532179db49e29df13d2e4d7388be_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfOC03LTEtMS00NTM_849eb903-9ac3-421b-b7a1-51f133536d95">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9c93c9caba84edd95b2548a2b744445_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfOS0xLTEtMS0w_c70e18ca-ed66-431d-868b-201228799c2e">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i6edb07a7cf7d4dfd9ea0c2aa04d300be_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfOS0zLTEtMS0w_813508f7-4d6f-4ca9-9ad0-a06cdbf4e780">1,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if6ebf042a7d748bc926786bbeaa6e5be_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfOS01LTEtMS0w_9a26fa64-acde-4271-93e6-0c65f224e486">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie8068b0b08b04c629bb3323c7e3c6b00_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfOS03LTEtMS0w_efdf7f6c-fcbd-4c05-ae68-d87c46d5e231">1,025</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i233d9a246600434d8e13d460c3115a63_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTAtMS0xLTEtMA_ab68650f-2b49-45b5-b048-29d8e31f0d3a">11</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i18efd6bca7ec4a579e596234751a12c6_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTAtMy0xLTEtMA_10cd5503-0675-426c-bb3d-b4d5e29b57f1">596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iee6f8140c1524d41888a692944254bf5_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTAtNS0xLTEtMA_03a58d4f-a790-4e90-84c2-ca8d9084fc52">330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ifeb306a8995c48b88ea62ab0a33622a3_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTAtNy0xLTEtMA_8ac6609d-860f-4006-b099-ca7d55c84c24">511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic3796b585b2249e4a838d2e201de472f_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTEtMS0xLTEtMA_51a1ed15-a9ca-483c-9605-e7ce3d681fe5">11</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i6f0a1cbef1614ce18f5c5d366eca4edd_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTEtMy0xLTEtMA_fc8c84c9-670a-4dc4-8eb5-bc38d39c0007">1,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i08c773fc721845f790f8ef203229134d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTEtNS0xLTEtMA_bf5e042c-83bc-49f7-a0e5-a0a2a3e9ac86">720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i6519cfa82a8542f3bb0c56cb262141f8_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTEtNy0xLTEtMA_2da5bd81-22b2-4e92-baf2-d1178ce6451f">1,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTItMS0xLTEtMA_aca56d81-eb8c-46e5-b827-1a66d305cc96">433</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTItMy0xLTEtMA_9df336bf-6685-4c79-ae64-996a5d00f734">1,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTItNS0xLTEtMA_48091452-789c-461f-ab5e-e959303206b0">197</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTItNy0xLTEtMA_6526a754-1feb-4d06-b9b9-dc143608a02b">526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><ix:nonNumeric contextRef="i7b89ee6dba67472bb93b39369d3a62e5_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzg3NQ_61986f8a-fb4e-4de7-8a45-5cab03a232e6" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s restricted stock awards during the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average <br/>Grant-Date <br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9cc879ec3d384c4891fc21ec9fe0b853_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjdiYTk2NTJhMDg1MDQxZTViNmIyYTBlNDYxYzU5MDhjL3RhYmxlcmFuZ2U6N2JhOTY1MmEwODUwNDFlNWI2YjJhMGU0NjFjNTkwOGNfMS0xLTEtMS0w_b107ad9a-77f3-49fd-92d5-f3ced8949397">146,800</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9cc879ec3d384c4891fc21ec9fe0b853_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjdiYTk2NTJhMDg1MDQxZTViNmIyYTBlNDYxYzU5MDhjL3RhYmxlcmFuZ2U6N2JhOTY1MmEwODUwNDFlNWI2YjJhMGU0NjFjNTkwOGNfMS0zLTEtMS0w_6c28dc03-1e9f-4c10-976a-545a0e13d4dc">5.70</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7b89ee6dba67472bb93b39369d3a62e5_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjdiYTk2NTJhMDg1MDQxZTViNmIyYTBlNDYxYzU5MDhjL3RhYmxlcmFuZ2U6N2JhOTY1MmEwODUwNDFlNWI2YjJhMGU0NjFjNTkwOGNfMi0xLTEtMS0w_273a084f-8dca-4b8b-b4f0-d37f16f76d17">68,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b89ee6dba67472bb93b39369d3a62e5_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjdiYTk2NTJhMDg1MDQxZTViNmIyYTBlNDYxYzU5MDhjL3RhYmxlcmFuZ2U6N2JhOTY1MmEwODUwNDFlNWI2YjJhMGU0NjFjNTkwOGNfMi0zLTEtMS0w_190c347b-30e1-4f0f-bd81-38664f226fbb">5.70</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibf99680c33194615a4cde239ceeb4697_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjdiYTk2NTJhMDg1MDQxZTViNmIyYTBlNDYxYzU5MDhjL3RhYmxlcmFuZ2U6N2JhOTY1MmEwODUwNDFlNWI2YjJhMGU0NjFjNTkwOGNfMy0xLTEtMS0w_0808a52a-0ab7-4fb6-9a3a-e778c521a1b7">78,300</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf99680c33194615a4cde239ceeb4697_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjdiYTk2NTJhMDg1MDQxZTViNmIyYTBlNDYxYzU5MDhjL3RhYmxlcmFuZ2U6N2JhOTY1MmEwODUwNDFlNWI2YjJhMGU0NjFjNTkwOGNfMy0zLTEtMS0w_4923da84-5a7f-4fa9-9afc-b9d2b83194f2">5.70</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s restricted stock awards during the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1222c7a7994947a5bec3e3f85f308708_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmEwYjBjMDYzYmU4NjQ2NGViYzNmMDliYzk1NzE2NGI2L3RhYmxlcmFuZ2U6YTBiMGMwNjNiZTg2NDY0ZWJjM2YwOWJjOTU3MTY0YjZfMS0xLTEtMS0w_6c14b041-b620-4d03-b55b-d2aba8fcb3b3">146,800</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1222c7a7994947a5bec3e3f85f308708_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmEwYjBjMDYzYmU4NjQ2NGViYzNmMDliYzk1NzE2NGI2L3RhYmxlcmFuZ2U6YTBiMGMwNjNiZTg2NDY0ZWJjM2YwOWJjOTU3MTY0YjZfMS0zLTEtMS0w_5e91d110-4f15-4a7a-8522-c0709adb183d">5.70</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3a4f48e172c544ae980c5a5322bd7e1b_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmEwYjBjMDYzYmU4NjQ2NGViYzNmMDliYzk1NzE2NGI2L3RhYmxlcmFuZ2U6YTBiMGMwNjNiZTg2NDY0ZWJjM2YwOWJjOTU3MTY0YjZfMi0xLTEtMS0w_8a27c1ca-5c4a-4141-9fba-54f22fc48ad6">146,800</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a4f48e172c544ae980c5a5322bd7e1b_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmEwYjBjMDYzYmU4NjQ2NGViYzNmMDliYzk1NzE2NGI2L3RhYmxlcmFuZ2U6YTBiMGMwNjNiZTg2NDY0ZWJjM2YwOWJjOTU3MTY0YjZfMi0zLTEtMS0w_88d1c15c-a0d6-4d6d-b37f-37c96321e3ea">5.70</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of <ix:nonNumeric contextRef="i7b89ee6dba67472bb93b39369d3a62e5_D20210101-20210630" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfNTI1_884864ad-a075-46f4-a931-0bd9a525c077">20</ix:nonNumeric> months. As of June 30, 2021, unvested restricted stock awards of <ix:nonFraction unitRef="shares" contextRef="i23d7d82cf9a64899b7f1206eabcb09ba_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfNTc1_c51633a5-5144-4d84-84e3-ddf6da2e1778">78,300</ix:nonFraction> were related to performance-based awards. The forfeited performance-based restricted stock awards of <ix:nonFraction unitRef="shares" contextRef="if12de0f76e944b3bb7b40b44269dcce8_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfNjc5_a735fbac-ef4b-40ef-9011-ac4e58597ead">68,500</ix:nonFraction> was due to the termination of the Company's former Chief Science Officer on January 19, 2021. These forfeited awards reduced stock-based compensation expense by $<ix:nonFraction unitRef="usd" contextRef="if12de0f76e944b3bb7b40b44269dcce8_D20210101-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfODQy_47fd8410-7beb-42e8-907f-eeb3d6500ffb">0.4</ix:nonFraction> million.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="iaffcb18c565349c291f3457e7ebc1e00" continuedAt="i569c006ab50d49329d8cb960bc646cb9"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service-Based Restricted Stock Units</span></div><ix:nonNumeric contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzg3Nw_fb23aa0e-70fd-4de9-910f-e73528b62342" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1dc167d328cb46c68fb83fa95a614259_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfMS0xLTEtMS0w_f0764a00-55be-415e-8585-0b09785c4bd4">265,494</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1dc167d328cb46c68fb83fa95a614259_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfMS0zLTEtMS0w_653f3942-2134-4281-8a89-56cfa45e5b07">2.60</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfMi0xLTEtMS0w_d06ea749-728b-41e1-8a74-804748c9eb97">310,050</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfMi0zLTEtMS0w_e14c3b85-848b-4f2e-905c-c9ee0a4c5193">0.90</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfMy0xLTEtMS0w_d9a5357f-30d7-43a4-93b7-915b20809ecb">221,474</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfMy0zLTEtMS0w_4fa6cc92-6319-4179-9ac3-90a3c0c61473">2.38</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfNC0xLTEtMS0w_e36ebadb-47f4-4649-be91-d6cfe0314c48">11,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfNC0zLTEtMS0w_3df7b176-ff46-4fec-b7e7-541a608991c4">4.81</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i59ed53d4977e452abe904ab6ebf547cb_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfNS0xLTEtMS0w_d2e45a96-28ce-4515-9573-8593db34f2ce">342,604</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i59ed53d4977e452abe904ab6ebf547cb_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfNS0zLTEtMS0w_a5789090-14d2-4b97-b9bf-922d9ded04d9">1.17</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:74.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iccc11aef27a949598168c7e139f011cf_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfMS0xLTEtMS0w_543922af-314c-4a5b-a02a-2a7a35efef7a">463,786</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="iccc11aef27a949598168c7e139f011cf_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfMS0zLTEtMS0w_234e3206-b027-430c-bd88-150d16e854b3">4.26</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfMi0xLTEtMS0w_3b9ec95e-0d3e-4ec5-a1e6-1b9eba39f27c">188,904</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfMi0zLTEtMS0w_4913ba05-4dc7-4a4b-a639-d687162fa572">2.09</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfMy0xLTEtMS0xMjg5_f15c0f94-51ef-41d4-b96b-af90178edced">104,168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfMy0zLTEtMS0xMjkx_bdfbb436-c7ce-4926-a17e-6b36a9688f9d">4.66</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfMy0xLTEtMS0w_8f46d13c-7f62-48e7-8614-11d0a2600cdf">128,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfMy0zLTEtMS0w_2e782ee8-482e-439c-90e7-156a2bb84229">4.30</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8e71868a215c4613b29c948c789638c1_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfNS0xLTEtMS0w_9ab87971-624f-4442-a0f8-f163f5c32d36">420,062</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e71868a215c4613b29c948c789638c1_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfNS0zLTEtMS0w_13da3fcc-9770-4501-b37a-a22774ced044">3.27</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of service based restricted stock units are measured based on their fair value on the date of grant and amortized over the vesting period. The vesting periods range from <ix:nonNumeric contextRef="id2bc1e2e4f8f4649bbe2dfd466d3ec82_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTI5MQ_95dc62bf-d737-4dd2-a0ca-e9f0d204e4bb">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i6f366d79a6c6435a80da6fa75f516bb1_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTI5Nw_389fb1e6-9c33-43b2-be8e-75a5072e6a98">3</ix:nonNumeric> years. Stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i9c4394b8322844b885708d0a121c0250_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTMzNw_f71d4aa2-32f5-4328-b1d8-c1ded2dc1ca7">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjc2NQ_fcb7ff8b-04e1-4727-896a-d03c5a3d0b1b">0.2</ix:nonFraction> million was recognized for the three and six months ended June 30, 2021, respectively. Stock-based compensation expense of <ix:nonFraction unitRef="usd" contextRef="i328ca3ef8e144273a05211111c192e60_D20200401-20200630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjc0Nw_29e4d686-0e03-4aff-8ae9-c3f828437070">nil</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjc2Mg_54872d54-6694-4b0e-9c70-90b4614edba7">0.2</ix:nonFraction> million was recognized for the three and six months ended June 30, 2020, respectively. As of June 30, 2021, the unrecognized stock-based compensation expense was $<ix:nonFraction unitRef="usd" contextRef="i59ed53d4977e452abe904ab6ebf547cb_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTQ3OA_2c174135-6fa1-47af-83ac-a0edac010157">0.3</ix:nonFraction> million, which is expected to be recognized over an estimated weighted average remaining term of less than <ix:nonNumeric contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTU4MA_72baed2e-4a37-4595-97ca-e5d3d6e2d30a">1</ix:nonNumeric> year. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i9d18ac7044704140bef4ab937ea9ab1d_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTY1OQ_96c8ad52-b259-4220-8049-482a6b37feb6">no</ix:nonFraction> outstanding performance-based restricted stock units.</span></div><ix:nonNumeric contextRef="if6ebf042a7d748bc926786bbeaa6e5be_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzg3OA_68f2179d-8fc2-4c8d-ad15-466520e5389a" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s performance-based restricted stock units during the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:74.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c44b152081048d6b3e5aa2d27e30992_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjQzMjRjODM4NGVjMzRmNTlhNDM4MzEzNjMxMTVmYWRhL3RhYmxlcmFuZ2U6NDMyNGM4Mzg0ZWMzNGY1OWE0MzgzMTM2MzExNWZhZGFfMS0xLTEtMS0w_f2b31ea8-f346-47ad-81e6-7c0c51cb4061">988,958</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3c44b152081048d6b3e5aa2d27e30992_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjQzMjRjODM4NGVjMzRmNTlhNDM4MzEzNjMxMTVmYWRhL3RhYmxlcmFuZ2U6NDMyNGM4Mzg0ZWMzNGY1OWE0MzgzMTM2MzExNWZhZGFfMS0zLTEtMS0w_929fe22e-b19b-46f4-a513-2bbf5a2ce904">4.48</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie8068b0b08b04c629bb3323c7e3c6b00_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjQzMjRjODM4NGVjMzRmNTlhNDM4MzEzNjMxMTVmYWRhL3RhYmxlcmFuZ2U6NDMyNGM4Mzg0ZWMzNGY1OWE0MzgzMTM2MzExNWZhZGFfMi0xLTEtMS0zOTY_49450206-e6be-44d2-96b4-631e4941e92f">905,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie8068b0b08b04c629bb3323c7e3c6b00_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjQzMjRjODM4NGVjMzRmNTlhNDM4MzEzNjMxMTVmYWRhL3RhYmxlcmFuZ2U6NDMyNGM4Mzg0ZWMzNGY1OWE0MzgzMTM2MzExNWZhZGFfMi0zLTEtMS0zOTI_316ce931-cf13-4e55-ae3e-cf3dd3f9ffcb">4.61</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd51c0a0b5b34333bd95586be0b8d818_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjQzMjRjODM4NGVjMzRmNTlhNDM4MzEzNjMxMTVmYWRhL3RhYmxlcmFuZ2U6NDMyNGM4Mzg0ZWMzNGY1OWE0MzgzMTM2MzExNWZhZGFfMi0xLTEtMS0w_1de5d4e8-095a-46f4-b399-d55d31cbde62">83,333</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd51c0a0b5b34333bd95586be0b8d818_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjQzMjRjODM4NGVjMzRmNTlhNDM4MzEzNjMxMTVmYWRhL3RhYmxlcmFuZ2U6NDMyNGM4Mzg0ZWMzNGY1OWE0MzgzMTM2MzExNWZhZGFfMi0zLTEtMS0w_b85a8bb7-ce3c-41d2-a1ef-1f6f02c8d344">3.09</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service-Based Stock Options</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i569c006ab50d49329d8cb960bc646cb9" continuedAt="i33b4a359ef8a42bd9e146872fdf5c23e"><ix:nonNumeric contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzg3OQ_4af89ee6-f909-42b4-8537-7c37ad13e331" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the service-based stock options granted for the six months ended June 30, 2021 were based on the following assumptions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.766%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i377ec7f50aff44afbeea1a0fddf83054_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmU3N2ZlZmExMDU3NDQ1NzZhMWMwZWZjMjM5OTUwMDk2L3RhYmxlcmFuZ2U6ZTc3ZmVmYTEwNTc0NDU3NmExYzBlZmMyMzk5NTAwOTZfMS0xLTEtMS0wL3RleHRyZWdpb246MDViYzk3NGIyMjBmNGQ5Njk3NGQ3ZjAxYzdlYzEyMGNfNA_eece4baa-547a-4048-8faa-2e368eab27c8">0.90</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i4500479b46394800b4b9f21530bd9449_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmU3N2ZlZmExMDU3NDQ1NzZhMWMwZWZjMjM5OTUwMDk2L3RhYmxlcmFuZ2U6ZTc3ZmVmYTEwNTc0NDU3NmExYzBlZmMyMzk5NTAwOTZfMS0xLTEtMS0wL3RleHRyZWdpb246MDViYzk3NGIyMjBmNGQ5Njk3NGQ3ZjAxYzdlYzEyMGNfOQ_cdd98a64-d464-4c9f-a124-195eb5c822aa">0.94</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmU3N2ZlZmExMDU3NDQ1NzZhMWMwZWZjMjM5OTUwMDk2L3RhYmxlcmFuZ2U6ZTc3ZmVmYTEwNTc0NDU3NmExYzBlZmMyMzk5NTAwOTZfMi0xLTEtMS0wL3RleHRyZWdpb246Y2NmYzNhZjE5MTI3NGI2ZjhhOWY4ZDEyODhhZGIwMWNfNA_b3c7343a-8ff5-4666-ac2e-a189076f90ed">75.8</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmU3N2ZlZmExMDU3NDQ1NzZhMWMwZWZjMjM5OTUwMDk2L3RhYmxlcmFuZ2U6ZTc3ZmVmYTEwNTc0NDU3NmExYzBlZmMyMzk5NTAwOTZfMi0xLTEtMS0wL3RleHRyZWdpb246Y2NmYzNhZjE5MTI3NGI2ZjhhOWY4ZDEyODhhZGIwMWNfOQ_622054ec-b591-47f7-a889-c64d3e65d0ff">77.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmU3N2ZlZmExMDU3NDQ1NzZhMWMwZWZjMjM5OTUwMDk2L3RhYmxlcmFuZ2U6ZTc3ZmVmYTEwNTc0NDU3NmExYzBlZmMyMzk5NTAwOTZfMy0xLTEtMS0wL3RleHRyZWdpb246ODIyZjdiMjRlMTU5NGUzNmFkOTA0ZWMxNWUyYTI5OTJfNA_2dd4eca2-bc76-497a-9440-3eb4dbaee573">0.47</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmU3N2ZlZmExMDU3NDQ1NzZhMWMwZWZjMjM5OTUwMDk2L3RhYmxlcmFuZ2U6ZTc3ZmVmYTEwNTc0NDU3NmExYzBlZmMyMzk5NTAwOTZfMy0xLTEtMS0wL3RleHRyZWdpb246ODIyZjdiMjRlMTU5NGUzNmFkOTA0ZWMxNWUyYTI5OTJfOQ_bba957b5-d899-4e6a-bb57-273caec01a08">1.06</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i387b50c6a04b446ea4adc3f7f089a489_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmU3N2ZlZmExMDU3NDQ1NzZhMWMwZWZjMjM5OTUwMDk2L3RhYmxlcmFuZ2U6ZTc3ZmVmYTEwNTc0NDU3NmExYzBlZmMyMzk5NTAwOTZfNC0xLTEtMS0wL3RleHRyZWdpb246NjU2ZDRkNTNlYzNjNDc4ZmJjNDgwMGExNWMxN2IwM2ZfMTA5OTUxMTYyNzgxMg_b84156de-8903-43dd-b5fe-4576d078c220">5.5</ix:nonNumeric> - <ix:nonNumeric contextRef="ib0d53e2aa30e4cb2be00af8ad6ff6d23_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmU3N2ZlZmExMDU3NDQ1NzZhMWMwZWZjMjM5OTUwMDk2L3RhYmxlcmFuZ2U6ZTc3ZmVmYTEwNTc0NDU3NmExYzBlZmMyMzk5NTAwOTZfNC0xLTEtMS0wL3RleHRyZWdpb246NjU2ZDRkNTNlYzNjNDc4ZmJjNDgwMGExNWMxN2IwM2ZfMTA5OTUxMTYyNzgwOA_f9ce8cdf-6623-49b4-8654-2dd48cda2342">6</ix:nonNumeric></span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzg2OQ_dfe4b8e5-9337-40e9-bf4e-e88c1d30ea21" escape="true"><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based stock option activity for the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie590926897c544debd71e35ba26b6cb4_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfMS0xLTEtMS0w_371e000a-c4c7-4d1b-b921-1cd2674c3d45">5,717,956</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie590926897c544debd71e35ba26b6cb4_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfMS0zLTEtMS0w_fbfae166-54ae-4b37-b2f9-e51a46b3c071">4.55</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6070dee6d0e0457e9691825bf5ba3091_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfMS01LTEtMS0w_7e98bcaf-c9df-4fa9-9bf6-56572be088c2">6.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie590926897c544debd71e35ba26b6cb4_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfMS03LTEtMS0w_3727571f-a5e1-4cd2-8d2d-b75978d1fe25">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfMi0xLTEtMS0w_021db2ae-5b21-4836-82f5-5aab4cf48f4f">1,522,162</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfMi0zLTEtMS0w_661cf7a7-1246-4f42-9aa7-6e9e7ff518ce">0.96</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" format="ixt-sec:duryear" name="rmti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfMi01LTEtMS0w_df986edd-c382-4505-a0a1-88eff66874c5">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfNC0xLTEtMS0w_44627861-a2ca-4b4a-ae9e-e10c56f45de0">277,764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfNC0zLTEtMS0w_89a397d9-e8b1-4e51-85f1-aa9785c6930e">2.52</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfNS0xLTEtMS0w_0465d5b5-249a-49a8-9d42-40b978f797dc">1,266,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfNS0zLTEtMS0w_3f21ff73-b334-4646-b4cd-70ed83f26a16">7.35</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72d3d3d7938c411bb6ffd58511f24608_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfNi0xLTEtMS0w_5171e05f-6b57-40d7-bd40-3e7b954bb2d1">5,695,801</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i72d3d3d7938c411bb6ffd58511f24608_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfNi0zLTEtMS0w_e35a51c8-de51-4e7e-9ad4-7019b6d4f8cb">3.07</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfNi01LTEtMS0w_ed5a06c9-9566-46b8-9664-ae008fb7fdf9">7.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d3d3d7938c411bb6ffd58511f24608_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfNi03LTEtMS0w_ed1b6416-3ad9-4a66-92ba-fc35be4151be">5,000</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72d3d3d7938c411bb6ffd58511f24608_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfOC0xLTEtMS0w_abad6964-0ce0-4c93-ab49-6cb05337456c">2,387,440</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i72d3d3d7938c411bb6ffd58511f24608_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfOC0zLTEtMS0w_158e19cf-b496-4fea-8129-e29e130746ff">5.25</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfOC01LTEtMS0w_0c921ccc-2bc5-40e9-9631-f962d45af39b">5.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d3d3d7938c411bb6ffd58511f24608_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfOC03LTEtMS0w_361ed554-3593-4a54-a46a-f8ab6d6e1a39">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based stock option activity for the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic639b26ebf744397b60970c46c3ac479_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMS0xLTEtMS0w_e99e5729-1a03-43b9-baf3-f72281dafd1a">8,210,024</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic639b26ebf744397b60970c46c3ac479_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMS0zLTEtMS0w_10041f8f-a72d-4c1d-a0ce-daab712c5dae">7.06</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5c8dbaa25e2e4cac985ded30596cdaae_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMS01LTEtMS0w_6d10a215-ab96-4565-91f3-b16bd62f55d7">5.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic639b26ebf744397b60970c46c3ac479_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMS03LTEtMS0w_93f85c2a-4336-4da6-93bb-3df2d0f3312e">107,000</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMi0xLTEtMS0w_836c1881-24e1-4613-be9e-603fc9274951">1,610,344</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMi0zLTEtMS0w_8b8d9f66-311f-4a08-84fd-f754577c082f">2.24</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630" format="ixt-sec:duryear" name="rmti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMi01LTEtMS0w_d4f6cdeb-0668-495f-9ada-0779ca2a219d">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMy0xLTEtMS0w_9ab6ac57-babd-4db5-b715-13ddc9aa6179">211,471</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMy0zLTEtMS0w_26879a60-806b-410d-b777-761dd9fdfe19">4.41</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNC0xLTEtMS0w_b56d98aa-f009-45b5-9fa0-73da7d9ce0fe">3,983,335</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNC0zLTEtMS0w_e91bc0dd-07ab-4e89-8982-a1910a4b321d">8.30</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7b50de406504a1199ae8a1f61a650ac_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNS0xLTEtMS0w_3caef057-42f1-4427-8083-9a9217dd9a1d">5,625,562</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7b50de406504a1199ae8a1f61a650ac_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNS0zLTEtMS0w_a69a3055-7a90-4e25-8b99-005edfca8208">4.90</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNS01LTEtMS0w_35d1128f-f13a-457e-b480-6e995bb1bcc7">6.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7b50de406504a1199ae8a1f61a650ac_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNS03LTEtMS0w_fd3dc108-8f81-4d84-92ed-e9b7b4f988d0">1,000</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7b50de406504a1199ae8a1f61a650ac_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNy0xLTEtMS0w_cdeba98f-2a89-4c58-8369-67667f65355b">2,809,954</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7b50de406504a1199ae8a1f61a650ac_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNy0zLTEtMS0w_1c0b515d-c6b4-4728-b52a-6c9cd5736c99">7.09</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNy01LTEtMS0w_1d9fa65c-a2fa-48c4-835a-a213ad7051fa">4.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7b50de406504a1199ae8a1f61a650ac_I20200630" decimals="0" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNy03LTEtMS0w_39f85771-1df9-4478-8dc4-c3f0f496c52f">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the table above is calculated as the difference between the closing price of the Company's common stock and the exercise price of the stock options that had strike prices below the closing price.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, the Company granted stock options to purchase up to <ix:nonFraction unitRef="shares" contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMjQwMA_b5fb59e1-e8ca-4950-98d0-210b82c84260">1,522,162</ix:nonFraction> shares of common stock to certain employees. During the six months ended June 30, 2021, <ix:nonFraction unitRef="shares" contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMjQ3OQ_45dc030b-14da-4ad7-8132-6bfefc2d9eef">277,764</ix:nonFraction> shares were forfeited and <ix:nonFraction unitRef="shares" contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMTk4MQ_9fe566cc-63fc-4ef1-b78a-9aac1b8b776c">1,266,553</ix:nonFraction> shares expired. Forfeitures are recorded in the period of occurrence; compensation expense is adjusted accordingly.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for service-based stock options was $<ix:nonFraction unitRef="usd" contextRef="iacc309a401f7466cb3e18730470f3752_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMjY4NQ_3bf9518e-0817-4466-b2cb-065c946a3b4b">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjE5NA_625497e7-b1d0-46cb-9ac0-5444c0870590">0.7</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively. Stock-based compensation expense recognized for service-based stock options was $<ix:nonFraction unitRef="usd" contextRef="if90c1947aa9c420f9f93f64285facd2f_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjE3Nw_eb1e7513-8473-4929-9882-26872020edb3">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjE4MQ_7f33b720-ac37-4040-a0ee-39bdf2e540da">0.8</ix:nonFraction> million for the three and six months ended June 30, 2020, respectively. As of June 30, 2021, total stock-based compensation expense related to unvested options not yet recognized totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i72d3d3d7938c411bb6ffd58511f24608_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMjg1MA_9b6ffc53-b659-4015-948a-61ba1d3e5128">2.0</ix:nonFraction> million, which is expected to be recognized over an estimated weighted average remaining term of <ix:nonNumeric contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMjk0Mg_c69c5d1d-552f-4ceb-953c-5528e9c524c0">3.0</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Stock Options</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i33b4a359ef8a42bd9e146872fdf5c23e"><ix:nonNumeric contextRef="iee6f8140c1524d41888a692944254bf5_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzg3MA_52d467ec-9eeb-42f0-85b5-de1d76d2aa6b" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the performance-based stock options for the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i12f2cce783ab4aa19f82d7776112d561_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRkYmY1ODhlMmU0ZjRhOTFiMjFjNjFjNjQxM2ZlMzBjL3RhYmxlcmFuZ2U6NGRiZjU4OGUyZTRmNGE5MWIyMWM2MWM2NDEzZmUzMGNfMS0xLTEtMS0w_3c813b48-c172-4c77-a4fa-8f94139b418e">750,000</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12f2cce783ab4aa19f82d7776112d561_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRkYmY1ODhlMmU0ZjRhOTFiMjFjNjFjNjQxM2ZlMzBjL3RhYmxlcmFuZ2U6NGRiZjU4OGUyZTRmNGE5MWIyMWM2MWM2NDEzZmUzMGNfMS0zLTEtMS0w_2ad77d51-83b3-4188-acc6-e12c51c3dd7f">2.20</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iee6f8140c1524d41888a692944254bf5_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRkYmY1ODhlMmU0ZjRhOTFiMjFjNjFjNjQxM2ZlMzBjL3RhYmxlcmFuZ2U6NGRiZjU4OGUyZTRmNGE5MWIyMWM2MWM2NDEzZmUzMGNfMy0xLTEtMS0w_78d29313-92d0-48c8-b45c-37466e7f9f27">375,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iee6f8140c1524d41888a692944254bf5_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRkYmY1ODhlMmU0ZjRhOTFiMjFjNjFjNjQxM2ZlMzBjL3RhYmxlcmFuZ2U6NGRiZjU4OGUyZTRmNGE5MWIyMWM2MWM2NDEzZmUzMGNfMy0zLTEtMS0w_21e9640f-1d1f-45fc-b879-ec487393d30f">2.20</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i218c5ca968e448d4951556a9ac1e5e79_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRkYmY1ODhlMmU0ZjRhOTFiMjFjNjFjNjQxM2ZlMzBjL3RhYmxlcmFuZ2U6NGRiZjU4OGUyZTRmNGE5MWIyMWM2MWM2NDEzZmUzMGNfNC0xLTEtMS0w_230d6850-02bf-4d34-9224-445ceba70642">375,000</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i218c5ca968e448d4951556a9ac1e5e79_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRkYmY1ODhlMmU0ZjRhOTFiMjFjNjFjNjQxM2ZlMzBjL3RhYmxlcmFuZ2U6NGRiZjU4OGUyZTRmNGE5MWIyMWM2MWM2NDEzZmUzMGNfNC0zLTEtMS0w_0afb7cb6-3e08-4f97-b8df-04a233be9989">2.20</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i218c5ca968e448d4951556a9ac1e5e79_I20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRkYmY1ODhlMmU0ZjRhOTFiMjFjNjFjNjQxM2ZlMzBjL3RhYmxlcmFuZ2U6NGRiZjU4OGUyZTRmNGE5MWIyMWM2MWM2NDEzZmUzMGNfNi0xLTEtMS0w_be313203-4127-4557-be57-7dd799a11d9c">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i218c5ca968e448d4951556a9ac1e5e79_I20210630" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRkYmY1ODhlMmU0ZjRhOTFiMjFjNjFjNjQxM2ZlMzBjL3RhYmxlcmFuZ2U6NGRiZjU4OGUyZTRmNGE5MWIyMWM2MWM2NDEzZmUzMGNfNi0zLTEtMS0w_3eed733f-b0fb-402c-87df-3a56bc8e4380">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the performance-based stock options for the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:74.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if5a5a222803a4f01af33dfbbd4edd90e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfMS0xLTEtMS0w_e4c05daa-9d05-4c93-8cb6-2104e30b4ff8">388,125</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5a5a222803a4f01af33dfbbd4edd90e_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfMS0zLTEtMS0w_94c83234-f461-4f2f-ace6-ab29168ae3e4">4.70</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifeb306a8995c48b88ea62ab0a33622a3_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfMi0xLTEtMS0xOTc_875383f9-f87c-44d7-b5ad-a326b0818432">600,000</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifeb306a8995c48b88ea62ab0a33622a3_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfMi0zLTEtMS0yMDM_c568b736-eddd-4d4f-b923-85e024732361">2.45</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifeb306a8995c48b88ea62ab0a33622a3_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfMy0xLTEtMS0yMDA_df607c12-6f1e-4883-a3a7-65bd59d37f32">388,125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifeb306a8995c48b88ea62ab0a33622a3_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfMy0zLTEtMS0yMDY_760d569c-ea69-4b7f-8c2f-f3f04ac77ded">4.70</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icbc5ecc328954a549da54b7fbbe4c241_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfMi0xLTEtMS0w_ed08f69e-8df5-488f-9597-29371cfbfa4c">600,000</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="icbc5ecc328954a549da54b7fbbe4c241_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfMi0zLTEtMS0w_676215b0-5aaa-45c9-8040-07db5e529cb4">2.45</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icbc5ecc328954a549da54b7fbbe4c241_I20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfNC0xLTEtMS0w_e55934ec-8671-447f-a9de-47714cf99c01">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="icbc5ecc328954a549da54b7fbbe4c241_I20200630" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfNC0zLTEtMS0w_ddd02e81-6cd9-4bf7-8c98-f76b25fe8540">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for performance-based stock options was <ix:nonFraction unitRef="usd" contextRef="i233d9a246600434d8e13d460c3115a63_D20210401-20210630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzI0OA_0fa36eb2-3583-4c98-803a-60d3e17ba0d0">nil</ix:nonFraction> and $(<ix:nonFraction unitRef="usd" contextRef="iee6f8140c1524d41888a692944254bf5_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjM3Mg_bad4c733-e399-4d46-bb48-263f28cdb622">0.3</ix:nonFraction>) million for the three and six months ended June 30, 2021, respectively. Stock-based compensation expense recognized for performance-based stock options was $(<ix:nonFraction unitRef="usd" contextRef="i18efd6bca7ec4a579e596234751a12c6_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjM2Mg_1dfada43-fe7e-4d49-96aa-2707719c0929">0.6</ix:nonFraction>) million and $(<ix:nonFraction unitRef="usd" contextRef="ifeb306a8995c48b88ea62ab0a33622a3_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjM2Ng_13643632-10c4-49c8-9df6-f9c5af995376">0.5</ix:nonFraction>) million for the three and six months ended June 30, 2020, respectively. The reduction in stock-based compensation expense was due to the performance criteria of certain performance-based options granted to officers of the Company becoming non-probable as of March 31, 2021. The Company will continue to assess the probability of the performance criteria until such time the criteria becomes probable and the performance-based stock option vests or continues to be non-probable and the performance-based stock option expires. As of June 30, 2021, there was <ix:nonFraction unitRef="usd" contextRef="i218c5ca968e448d4951556a9ac1e5e79_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzc2OA_0fe8c554-3ac5-44d4-ba93-844100d56338">no</ix:nonFraction> unrecognized stock-based compensation expense related to unvested performance-based stock options.</span></div></ix:continuation><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.  <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfNTM1NQ_957437c0-5327-465b-b720-592341f32d25" continuedAt="i1483d8aac78149c28a2fcfb5f393e9ad" escape="true">Licensing Agreements</ix:nonNumeric></span></div><ix:continuation id="i1483d8aac78149c28a2fcfb5f393e9ad" continuedAt="i7e83ce1dea9f4032aedc2fa636ff3548"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product License Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to a Licensing Agreement with Charak, LLC ("Charak") dated January 7, 2002 (the "2002 Agreement") that grants the Company exclusive worldwide rights to certain patents and information related to our Triferic® product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the “Charak MSA”) with Charak and Dr. Ajay Gupta, a former Officer of the Company. Pursuant to the MSA, the parties entered into <ix:nonFraction unitRef="agreement" contextRef="i1ec99fab2f214abe99616df767617659_D20181007-20181007" decimals="INF" format="ixt-sec:numwordsen" name="rmti:NumberOfAdditionalAgreements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfNTE1_990083ea-f17b-4f40-9cd1-5895e5a71ded">three</ix:nonFraction> additional agreements described below related to the license of certain soluble ferric pyrophosphate (“SFP”) intellectual property owned by Charak. The Charak MSA provided for a payment of $<ix:nonFraction unitRef="usd" contextRef="i460677d97abe4d1e8cb8e4f651ec0039_I20181007" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfNzA3_989ad485-195a-4c71-b94c-30dde438995d">1.0</ix:nonFraction> million to Dr. Gupta, payable in <ix:nonFraction unitRef="installment" contextRef="i759627e2f50f423aafc0dfcca70bfd78_D20181007-20181007" decimals="INF" format="ixt-sec:numwordsen" name="rmti:CollaborativeArrangementNumberOfInstallmentPayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfNzM1_2b905823-5c90-46e9-af66-665017a94890">four</ix:nonFraction> quarterly installments of $<ix:nonFraction unitRef="usd" contextRef="i809ecae77c69447cbf9e47687819d366_I20190115" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfNzY0_21ce538d-87ea-4f3f-bfea-c3132b180d10"><ix:nonFraction unitRef="usd" contextRef="i97f806f584404ce2871df7a18de3ca11_I20190415" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfNzY0_484fcbd0-b5e0-4647-8327-ae3553087cf4"><ix:nonFraction unitRef="usd" contextRef="if0e0b072a5234c05bc5ad0336ebb3ec8_I20181015" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfNzY0_d6134730-96d3-462d-be80-c0aaaa61afa9"><ix:nonFraction unitRef="usd" contextRef="ia12ceffd5d8641e892942dd059f10047_I20190715" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfNzY0_fa62df1a-9151-4faa-afb8-c46546c4cd8a">250,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> each on October 15, 2018, January 15, 2019, April 15, 2019 and July 15, 2019, and reimbursement for certain legal fees incurred in connection with the Charak MSA. The Company paid all four of the quarterly installments totaling $<ix:nonFraction unitRef="usd" contextRef="ic3906b27be7c4423ae983ce14db75f27_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="rmti:InstallmentPaymentToRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfOTk1_febc098f-fcfc-4749-9048-a55f15c6b548">1.0</ix:nonFraction> million and accrued $<ix:nonFraction unitRef="usd" contextRef="ie29e7d1c982f494cba429b4a0196ff5b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="rmti:CollaborativeArrangementAccruedReimbursementOfLegalExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfMTAxMA_40540873-6ee9-4285-833d-c4c4a4fe56e9">0.1</ix:nonFraction> million for the reimbursement of certain legal expenses during the year ended December 31, 2019. As of December 31, 2020, the Company had fulfilled its reimbursement obligation of certain legal expenses. As of June 30, 2021, the Company accrued $<ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-5" format="ixt:numdotdecimal" name="rmti:CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfMTIwOQ_d57577bb-696d-4eaa-82f5-6348ac41ef3e">0.2</ix:nonFraction> million relating to certain IP reimbursement expenses and certain sublicense royalty fees within accrued liabilities on the condensed consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Charak MSA, the aforementioned parties entered into an Amendment, dated as of October 7, 2018 (the “Charak Amendment”), to the 2002 Agreement, under which Charak granted the Company an exclusive, worldwide, non-transferable license to commercialize SFP for the treatment of patients with renal failure. The Charak Amendment amends the royalty payments due to Charak under the 2002 Agreement such that the Company is liable to pay Charak royalties on net sales </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i7e83ce1dea9f4032aedc2fa636ff3548"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by the Company of products developed under the license, which includes the Company’s Triferic® product, at a specified rate until December 31, 2021 and thereafter at a reduced rate from January 1, 2022 until February 1, 2034. Additionally, the Company shall pay Charak a percentage of any sublicense income during the term of the agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and be no less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Charak MSA, the Company and Charak entered into a Commercialization and Technology License Agreement I.V. Triferic® (now Triferic AVNU), dated as of October 7, 2018 (the “IV Agreement”), under which Charak granted the Company an exclusive, sub-licensable, royalty-bearing license to SFP for the purpose of commercializing certain intravenous-delivered products incorporating SFP for the treatment of iron disorders worldwide for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. The Company is liable to pay Charak royalties on net sales by the Company of products developed under the license at a specified rate until December 31, 2021. From January 1, 2022 until February 1, 2034, the Company is liable to pay Charak a base royalty at a reduced rate on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the IV Agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Charak MSA, the Company and Charak entered into a Technology License Agreement TPN Triferic®, dated as of October 7, 2018 (the “TPN Agreement”), pursuant to which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing worldwide certain parenteral nutritional ("TPN”) products incorporating SFP. The license grant under the TPN Agreement continues for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. During the term of the TPN Agreement, the Company is liable to pay Charak a base royalty on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the TPN Agreement, which amount shall not be less than a minimum royalty on net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div></ix:continuation><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.  <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMTMzMw_06e02ea6-71ba-49d7-b237-d8d272fb3446" continuedAt="i4aaeee0c61a74942b5a35d045fabb844" escape="true"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMTMzMw_1703753e-a687-4bfa-844e-4bc8f4b31861" continuedAt="ifffdccfbf738402f901239f1087f8082" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i4aaeee0c61a74942b5a35d045fabb844" continuedAt="iaaa92f9cb0f243399dc5a29407bf452a"><ix:continuation id="ifffdccfbf738402f901239f1087f8082" continuedAt="i6d5e6348f8e24deca872f94b2f2aa898"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its production facilities and administrative offices as well as certain equipment used in our operations including leases on transportation equipment used in the delivery of its products. The lease terms range from monthly to <ix:nonNumeric contextRef="ic98fba3f2dc143ee8df5663a86c4661c_I20210630" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMjYy_be484078-e9ef-40db-90d3-2d3294be7797">five years</ix:nonNumeric>. The Company occupies a <ix:nonFraction unitRef="sqft" contextRef="ic51c88898b0b42d4b034d35705eeaf8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMjg5_89b4d52a-0499-473e-910f-cb561d878599">51,000</ix:nonFraction> square foot facility and a <ix:nonFraction unitRef="sqft" contextRef="if5db4542d469452c8d4313a5744d4574_I20210630" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMzE5_417aa7e6-f728-4ade-9f83-2b2c4a8f4976">17,500</ix:nonFraction> square foot facility in Wixom, Michigan under a lease expiring in August 2024. The Company also occupies two other manufacturing facilities, a <ix:nonFraction unitRef="sqft" contextRef="i91c605c7aa7a4caebb53cdfdd424223a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfNDY1_3ce97fb7-7d75-4844-9793-e22593997db1">51,000</ix:nonFraction> square foot facility in Grapevine, Texas under a lease expiring in December 2025, and a <ix:nonFraction unitRef="sqft" contextRef="ia59cfceb831d4c4ba96a80f128ab4ead_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfNTU2_99493431-fd5f-459b-91a8-8088c75439a8">57,000</ix:nonFraction> square foot facility in Greer, South Carolina under a lease expiring February 2023. In addition, the Company occupies <ix:nonFraction unitRef="sqft" contextRef="if2aff2a50c9f45c59831b6c31dde2cc9_I20210630" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfNjc3_37a06254-740d-465b-9e86-ee17f22b6fa1">4,100</ix:nonFraction> square feet of office space in Hackensack, New Jersey under a lease expiring on July 1, 2024. This lease is currently being offered for sublease.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2021, the Company had operating and finance lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-5" format="ixt:numdotdecimal" name="rmti:OperatingLeaseAndFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfODky_5b860a2b-470c-44f9-a371-c7e51aa5bf2d">6.2</ix:nonFraction> million and right-of-use assets of $<ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-5" format="ixt:numdotdecimal" name="rmti:OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfOTIy_0dc2efe2-4162-435c-8e5f-c74b51e07138">6.1</ix:nonFraction> million, which are included in the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, the Company had operating lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMTAzNA_6df7bb6d-c286-47fa-8c47-738ac87d8d54">3.0</ix:nonFraction> million and right-of-use assets of $<ix:nonFraction unitRef="usd" contextRef="i544f39c3225445aa9a9903581a14c535_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMTA2NA_4608688f-7e6f-4803-8e25-35b93f18f889">2.9</ix:nonFraction> million, which are included in the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMTMyOQ_e5346430-887a-4650-8c7e-7365cbfbcf6f" continuedAt="ic270700383714c22b78147c88f87acc6" escape="true">The following summarizes quantitative information about the Company’s operating leases (table in thousands):</ix:nonNumeric></span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="iaaa92f9cb0f243399dc5a29407bf452a"><ix:continuation id="i6d5e6348f8e24deca872f94b2f2aa898"><div style="margin-top:5pt"><ix:continuation id="ic270700383714c22b78147c88f87acc6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMi0xLTEtMS0w_2e85bcce-87e2-4656-979f-d1b7eaa84c32">432</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMi0zLTEtMS0w_e6f572e1-c7f9-4835-8300-e7e5d8ed13db">403</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMi01LTEtMS0w_16f9813c-91ae-4a6b-9ce2-aeb22c4410fa">851</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMi03LTEtMS0w_5cb5aa2e-3b4b-410e-ab5c-1b979d0efea2">846</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMy0xLTEtMS0w_1374a097-0147-4911-82cb-5e09c1cd5d0d">90</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMy0zLTEtMS0w_180a12b8-1f93-4ef7-ba3b-a607b9314081">123</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMy01LTEtMS0w_f045be07-ef16-4ac0-80e8-9eb4af7a0a07">192</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMy03LTEtMS0w_dc48eda1-78ef-48af-95d3-bf67847ca6d5">312</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNC0xLTEtMS0w_331b49e8-c606-4053-a989-9a24792b9061">522</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNC0zLTEtMS0w_8d34b4e5-db6c-4eaf-afbd-c92a9fbf8f5d">526</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNC01LTEtMS0w_cf361805-7475-43cc-a5a3-9381568de1fe">1,043</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNC03LTEtMS0w_0908ffc3-d76f-4f32-909f-0946c8f2b638">1,158</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNi0xLTEtMS0w_00780186-52f3-4cf5-8b69-b8dd6db7e167">67</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNi0zLTEtMS0w_33014532-4d73-4451-9e4f-37cc78cb569f">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNi01LTEtMS0xMTM_8131d83f-fab6-46a6-a34a-418c102f1965">112</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNi03LTEtMS0xMTY_c21f133c-979d-4300-9b61-14a4a781f8cf">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNy0xLTEtMS0w_fd5d6c4f-641b-4960-8c56-1c678ed075ca">20</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNy0zLTEtMS0w_6123adbb-ea05-4f96-9016-6d26a08e78c3">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNy01LTEtMS0xMTM_6d71c632-cc6b-4067-ba9a-e7c2c7023247">33</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNy03LTEtMS0xMTY_36403b60-d196-4e85-8ae6-46fd5047e6a3">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" name="rmti:FinanceLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfOC0xLTEtMS0w_8d8808f0-868a-4176-b680-f2310d34df07">87</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="rmti:FinanceLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfOC0zLTEtMS0w_95a15b11-f3b5-4ac5-b466-e02494a6bb61">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="rmti:FinanceLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfOC01LTEtMS0xMTM_2065cddd-f0fb-4837-9abb-a77877075ca1">145</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="rmti:FinanceLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfOC03LTEtMS0xMTY_ed0290b7-9578-4b45-b0aa-867dd83c981c">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term lease rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfOS0xLTEtMS0w_d2bad35d-36f7-43cc-8d5a-45c184042a01">4</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfOS0zLTEtMS0w_c5795d15-52d1-47db-9c6e-6af961168be0">4</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfOS01LTEtMS0w_9f5b0b71-8fa2-4541-b598-bbb9043da49a">8</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfOS03LTEtMS0w_3001e290-78d4-44e9-86ab-aab3e1cb06f9">8</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total rent expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTAtMS0xLTEtMA_85d8f73b-fef2-4f37-b187-35c1fe04274a">613</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTAtMy0xLTEtMA_95e2e75c-5772-427a-9d88-204adc8cec43">530</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTAtNS0xLTEtMA_d4a3fcd3-97de-4bfc-b9b9-90eaab2c0c56">1,196</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTAtNy0xLTEtMA_57df3509-3d20-422e-a942-1fecd8cda315">1,166</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTMtMS0xLTEtMA_940a00f1-b8fa-47ce-86e2-b25363ef355d">428</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTMtMy0xLTEtMA_c4ed7539-5c6a-43df-b2de-4f00208594eb">410</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTMtNS0xLTEtMA_c2693fc0-6de5-442f-87d3-95ca1ca8687f">853</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTMtNy0xLTEtMA_d0db351c-0d83-415a-a198-9d57c22f2a14">855</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTQtMS0xLTEtMA_a2f8b2cb-5e9c-4694-92fb-9ab00e2c12c6">21</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTQtMy0xLTEtMA_3c46dd3f-4a56-4edb-aa18-b8b7923b6d99">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTQtNS0xLTEtMTIx_aada86f3-ebe7-4e43-be5b-0a3a5185e548">34</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTQtNy0xLTEtMTI0_418df902-13da-4ed7-8fa7-e0f6789e1ec2">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTUtMS0xLTEtMA_3093615a-6231-41f3-82ff-b4c2d22d7867">56</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTUtMy0xLTEtMA_bf12bce5-981f-4bd7-ac2c-b96a1456e53d">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTUtNS0xLTEtMTIx_856bc10e-f380-461f-af81-751e1b4f7f65">93</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTUtNy0xLTEtMTI0_c998f3e7-536b-4983-b268-36607e43affa">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTYtMS0xLTEtMA_145605fd-4872-4dc7-9e43-36487f801fcc">1,476</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTYtMy0xLTEtMA_e7f5caf8-c6e0-4d90-bf85-5807ced3d4d1">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTYtNS0xLTEtMA_733c4208-a3c8-4cc7-906a-ce6ec764f3a6">3,371</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTYtNy0xLTEtMA_50f1b52e-220f-42a5-bdd6-649f1446e237">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for finance lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTctMS0xLTEtMA_18810722-c665-4b27-9193-e189375f6995">316</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTctMy0xLTEtMA_68a30183-3511-4115-96a9-3ff5239f1c0b">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTctNS0xLTEtMTYw_fa23435b-5276-4162-b603-c15eb90b71e6">777</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTctNy0xLTEtMTY0_3e006540-6152-4da1-87b6-afd503910679">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTgtMS0xLTEtMA_57550dfb-9b8a-4d50-90e7-3d3ec5ad5db6">3.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTgtMy0xLTEtMA_5de0e29f-70e9-4081-8aed-ff9efd55cf01">2.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTgtNS0xLTEtMA_935ab327-9f15-4b19-bdc6-b66058fe32c5">3.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTgtNy0xLTEtMA_76660362-18e5-41eb-b3b2-cbea892a7d74">2.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTktMS0xLTEtMA_52db5839-8d27-45f4-8d42-127d1a5f4dbd">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTktMy0xLTEtMA_bbd5fb46-890e-4134-81c9-404191f2b0d1">0.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTktNS0xLTEtMTI3_16996486-cd8f-4823-9d70-a2d4f196bee6">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTktNy0xLTEtMTMx_316af1a6-2c19-44e3-99ee-c7e53898f6c1">0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMjAtMS0xLTEtMA_9fdf3e4a-bee9-40b1-836f-d1c29318972d">6.2</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMjAtMy0xLTEtMA_03047a5b-cb61-4693-baaa-6d97dd201411">6.8</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMjAtNS0xLTEtMA_2a9ef39f-ad1f-4c32-ba67-758ac3e37df4">6.2</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMjAtNy0xLTEtMA_a095fc93-6af2-43e8-9485-6d49c4be57ed">6.8</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMjEtMS0xLTEtMA_968556c3-2b49-46d4-917c-c0c7b7240edf">5.5</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630" decimals="3" format="ixt:zerodash" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMjEtMy0xLTEtMA_1dccfc18-c8a3-4026-822f-17cdefb25e4e">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMjEtNS0xLTEtMTM1_705f705d-6868-4cd7-9404-4b9254c9c8a0">5.5</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630" decimals="3" format="ixt:zerodash" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMjEtNy0xLTEtMTM4_4d25cdaa-c595-4e36-8cad-79ccb8a85dbc">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMTMzMQ_61f18f3f-9a37-463b-a23d-d5b6bd583509" escape="true"><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMTMzMQ_ca503818-8e15-47c3-a4aa-c456e161509d" escape="true"><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating lease agreements are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:71.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2021 (remaining)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfMS0xLTEtMS0w_fdf33160-a1e5-4c58-a65d-11c8721ff21f">865</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfMS0zLTEtMS0w_fc76902c-ac8e-4eda-8479-cb6091baf65d">148</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfMi0xLTEtMS0w_03bff1e8-b8db-4dcf-b97f-89afed0b574a">1,603</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfMi0zLTEtMS0w_24430f1c-5b19-48d1-b1e5-e627b7ac128a">300</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfMy0xLTEtMS0w_0647f299-29ba-4a43-9d1c-9dba5a55b73f">1,285</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfMy0zLTEtMS0w_ee5abe6b-43aa-4790-9003-18f4189fc152">305</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfNC0xLTEtMS0w_518c10d3-2b0e-4998-9a66-2884019b4d92">930</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfNC0zLTEtMS0w_6f21f4ba-38da-4aeb-98b5-727f63d4fadb">305</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfNS0xLTEtMS0w_ec919e80-4e2c-47d8-baf6-fc68c187f91e">468</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfNS0zLTEtMS0w_3f870bd9-39f3-4432-8112-3a95331364e0">305</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining future payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="rmti:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfNi0xLTEtMS0w_dad314b8-f427-4086-a6f4-faf0fcbe1c69">97</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="rmti:FinanceLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfNi0zLTEtMS0w_f2b339b5-aeed-4421-b6c4-5cea441528ca">319</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfNy0xLTEtMS0w_269739c8-66c4-444f-8f9e-ba7110362164">5,248</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfNy0zLTEtMS0w_490f5093-6cc1-4a0b-8293-7b0739938d0e">1,682</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfOC0xLTEtMS0w_c601ebdf-498e-48b7-892b-dbee76998a44">522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfOC0zLTEtMS0w_5706b9a3-ef8f-4768-b273-6a4bf0f978f1">228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfOS0xLTEtMS0w_3716f3fc-3ff6-4617-8e20-59a576c4d238">4,726</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfOS0zLTEtMS0w_532e6fdc-9d16-47ee-bc28-cf0442c3c673">1,454</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.  <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83My9mcmFnOjIyZGY4N2M4ZmM4ZDQ5ODU4NTlkZjBlMGUyNzU0ZTM3L3RleHRyZWdpb246MjJkZjg3YzhmYzhkNDk4NTg1OWRmMGUwZTI3NTRlMzdfNzc5_dadec3ce-0519-4cbb-a208-4abd4365d360" continuedAt="i06eae736224b4a4ba60444fc716aea7f" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i06eae736224b4a4ba60444fc716aea7f" continuedAt="i4e1dee5dba5c4d3ea86c44ebe693fe31"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SEC Investigation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a follow up to certain prior inquiries, the Company received a subpoena from the SEC during the Company’s quarter ended September 30, 2018 requesting, among other things, certain information and documents relating to the status of the Company’s request to the Centers for Medicare & Medicaid Services (the "CMS") for separate reimbursement </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4e1dee5dba5c4d3ea86c44ebe693fe31">status for Triferic (dialysate), the Company’s reserving methodology for expiring Triferic inventory, and the basis for the Board’s termination of the former Chief Executive Officer, Robert Chioini, and former Chief Financial Officer, Thomas Klema, in 2018. The Company is cooperating with the SEC and is responding to the SEC’s requests for documents and information.</ix:continuation></span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDk2OA_8b6694f6-06dc-4de6-b89c-ac1356a77b05" continuedAt="i0091d7cb158140b1b69f82c62e17ca2c" escape="true">Loan and Security Agreement</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i0091d7cb158140b1b69f82c62e17ca2c" continuedAt="ib3c0a54ede96470d8f02ff79b031f233"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Rockwell Medical, Inc. and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ibc87c3a83e2348a693051682f6add7a3_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDM5_f895bf87-2d53-4ab6-8f33-00fe15bd1d47">35.0</ix:nonFraction> million (the "Term Loans"). Funding of the first $<ix:nonFraction unitRef="usd" contextRef="ia4304315a451412aa6227dd3d7825bbd_I20200316" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDgz_b16c0453-d644-483c-9a02-bf468ad7cdeb">22.5</ix:nonFraction> million tranche was completed on March 16, 2020. The Company is no longer eligible to draw on a second tranche of $<ix:nonFraction unitRef="usd" contextRef="i9fdc6c38a5ba44f4b1470b93d16d3808_I20200316" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNTky_79ce1af1-6ac7-44fd-83b5-e103e87ef4fa">5.0</ix:nonFraction> million, which was tied to the achievement of certain milestones by a specific date. The Company may be eligible to draw on a third tranche of $<ix:nonFraction unitRef="usd" contextRef="i9301ccf847b14601a0409335c024832e_I20200316" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNzMw_0b613688-5549-4909-ae45-38df548adbea">7.5</ix:nonFraction> million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds. Net draw down proceeds were $<ix:nonFraction unitRef="usd" contextRef="ib7283d6d91074cb3b430c6bac11ae64d_D20200316-20200316" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfODgw_bb5c6a05-54e9-4a59-9ec0-9aed8d14a077">21.2</ix:nonFraction> million with closing costs of $<ix:nonFraction unitRef="usd" contextRef="ib7283d6d91074cb3b430c6bac11ae64d_D20200316-20200316" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfOTA1_c737b6ec-6754-4c4c-8f97-2c3deb779ccf">1.3</ix:nonFraction> million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to make interest-only payments for <ix:nonNumeric contextRef="i7fa07c9abdfb4de9a8f92bf2cb718792_D20200316-20200316" format="ixt-sec:durwordsen" name="rmti:DebtInstrumentPeriodOfInterestOnlyPayments" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfOTcw_8f1734c8-cea4-4359-b21e-6a6a65a7f5f0">thirty months</ix:nonNumeric>, or up to <ix:nonNumeric contextRef="idf213bc00b65407ca919f5dd19c8467b_D20200316-20200316" format="ixt-sec:durwordsen" name="rmti:DebtInstrumentPeriodOfInterestOnlyPayments" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfOTgz_ae14c457-93a9-4c29-99c0-8e7315609181">thirty-six months</ix:nonNumeric> if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) <ix:nonFraction unitRef="number" contextRef="iff0f4151e69d41f1a37b619b32340008_I20200316" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTE2Mw_700973a1-ffd2-4038-be50-909f39682d84">4.75</ix:nonFraction>%, plus <ix:nonFraction unitRef="number" contextRef="i7fac8535567243c58d7ee0b17a853032_D20200316-20200316" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTE3Mg_24699a1b-ba33-4250-b5ea-2a6b2b6e7868">4.00</ix:nonFraction>% with an initial interest rate of <ix:nonFraction unitRef="number" contextRef="i7fac8535567243c58d7ee0b17a853032_D20200316-20200316" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTIwOA_169c423b-8a91-42dc-a750-e8bb4e66d355">8.75</ix:nonFraction>% per annum and an effective interest rate of <ix:nonFraction unitRef="number" contextRef="iff0f4151e69d41f1a37b619b32340008_I20200316" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTI1NQ_317e016f-3a6a-49cf-b30a-4cfdafa16148">10.9</ix:nonFraction>%. The Company has the option, under certain circumstances, to add <ix:nonFraction unitRef="number" contextRef="iff0f4151e69d41f1a37b619b32340008_I20200316" decimals="INF" name="rmti:DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTMyMw_304d4de8-94ff-4d65-9a63-8cba2a3f7c9d">1.00</ix:nonFraction>% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For each of the three months ended June 30, 2021 interest expense amounted to $<ix:nonFraction unitRef="usd" contextRef="i6cc94eef73f94e268d7a68b7dad267bd_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTUwNQ_5dc964ed-dca7-4f29-aa52-33b293a22edd"><ix:nonFraction unitRef="usd" contextRef="ie79abc16084e479aa59aa703cef935f0_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTUwNQ_6da2b79d-e47b-47fd-b669-a2d9a8b89d7c">0.6</ix:nonFraction></ix:nonFraction> million. For the six months ended June 30, 2021 and 2020, interest expense amounted to $<ix:nonFraction unitRef="usd" contextRef="i718b2b1115aa4464937e15a664860aea_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTA5OTUxMTYzMjkxMA_7e7e0933-600c-4528-a144-cae2cee9a538">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if0e9b928a38b40e7850ffdd7b26ec0dd_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTA5OTUxMTYzMjkxOA_ba2ca52f-e8b7-4631-a304-4db67fc63943">0.6</ix:nonFraction> million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds are being used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of Triferic, with the latter beginning with the period ending December 31, 2020. The Company cannot assure you that we can maintain compliance with the covenants under our Loan Agreement, which may result in an event of default. The Company's ability to comply with these covenants may be adversely affected by events beyond its control. For example, the Loan Agreement contains certain financial covenants relating to sales and, as a result of the ongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company may not be able to satisfy such covenants in the future. If the Company is unable to comply with the covenants under the Loan Agreement, it would pursue all available cure options in order to regain compliance. The Company previously failed to satisfy a revenue covenant for the period ended December 31, 2020 and then subsequently agreed to an appropriate remedy during the applicable cure period. However, the Company may not be able to mutually agree with Innovatus on appropriate remedies to cure a future breach of a covenant, which could give rise to an event of default. If the Company is unable to avoid an event of default, any required repayments could have an adverse effect on its liquidity. As of June 30, 2021, the Company is in compliance with all the reporting and financial covenants. The financial statements for June 30, 2021 have been prepared with the assumption that the Company will be able to agree to an appropriate remedy during the applicable cure period for any future breaches of operating covenants. Based on the foregoing, the Company has classified amounts payable under the Loan Agreement as a current liability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If and when the Company reaches an agreement with Innovatus to avoid an event of default, the amounts payable under the Loan Agreement will be reevaluated for its classification and presentation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the “Warrants”) to purchase a number of shares of the Company’s common stock equal to <ix:nonFraction unitRef="number" contextRef="i7fac8535567243c58d7ee0b17a853032_D20200316-20200316" decimals="INF" name="rmti:ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMzIzMQ_0deb3e7a-b3f0-4bac-8485-4af941d823c4">3.5</ix:nonFraction>% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company’s stock for the <ix:nonNumeric contextRef="i7fac8535567243c58d7ee0b17a853032_D20200316-20200316" format="ixt-sec:durday" name="rmti:ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMzQzNQ_bdcf0947-6f5a-48ad-9acd-c7c2aef4151c">5</ix:nonNumeric>-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $<ix:nonFraction unitRef="usdPerShare" contextRef="i2ee87b88447b43f4bf5d2a2510a5ede7_I20200316" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMzcxNw_358126fb-a7a9-41a4-b246-6a9d14980950">1.65</ix:nonFraction> per share or (ii) the volume weighted average closing price of the Company’s stock for the <ix:nonNumeric contextRef="i58f2d0162acd40c0942ea5380b124712_D20200316-20200316" format="ixt-sec:durday" name="rmti:ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMzgxMQ_5106f7b2-2c6a-4dfe-945e-9b25887833e5">5</ix:nonNumeric>-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia4304315a451412aa6227dd3d7825bbd_I20200316" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDM4Mw_41148c22-dd33-4af2-84b8-26e4f6e324ca">477,273</ix:nonFraction> shares of the Company’s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia4304315a451412aa6227dd3d7825bbd_I20200316" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDQ0Nw_4336b2d8-28e7-41ea-9b29-764b97743113">1.65</ix:nonFraction> per share. The Company evaluated the warrant under ASC 470, Debt, and recognized an additional debt discount of approximately $<ix:nonFraction unitRef="usd" contextRef="ia4304315a451412aa6227dd3d7825bbd_I20200316" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDU3Ng_1f6e5501-5ce1-48e8-bf2f-065208e4a834">0.5</ix:nonFraction> million based on the relative fair value of the base instruments and warrants. The Company calculated the fair value of the warrant using the Black-Scholes model. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:continuation id="ib3c0a54ede96470d8f02ff79b031f233"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, the outstanding balance of the Term Loan was $<ix:nonFraction unitRef="usd" contextRef="ia82218c7009949eebf722cc90aec1835_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDc5MQ_bcd864cf-06b9-40ca-9124-478bd43f9f1d">21.1</ix:nonFraction> million, net of unamortized issuance costs and unaccreted discount of $<ix:nonFraction unitRef="usd" contextRef="ia82218c7009949eebf722cc90aec1835_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDg1Ng_060a0b3a-e093-424d-8afe-a30bde10a574">1.4</ix:nonFraction> million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDk3MA_42580795-a371-40e6-a3ae-48a27a802940" escape="true"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the schedule of principal payments on the Term Loan as of June 30, 2021 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.385%"><tr><td style="width:1.0%"></td><td style="width:47.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82218c7009949eebf722cc90aec1835_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RhYmxlOmIyODI0OGUxYzkwZDQ0N2JhMzU3ZmEyYTY3YmNhMjY2L3RhYmxlcmFuZ2U6YjI4MjQ4ZTFjOTBkNDQ3YmEzNTdmYTJhNjdiY2EyNjZfMi0xLTEtMS0w_e3f79436-61ee-4ca2-b1d0-b40523e0afeb">—</ix:nonFraction> </span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82218c7009949eebf722cc90aec1835_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RhYmxlOmIyODI0OGUxYzkwZDQ0N2JhMzU3ZmEyYTY3YmNhMjY2L3RhYmxlcmFuZ2U6YjI4MjQ4ZTFjOTBkNDQ3YmEzNTdmYTJhNjdiY2EyNjZfMy0xLTEtMS0w_e7d5b6b4-07dc-4b90-a8df-828f0ecd8281">2,250</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82218c7009949eebf722cc90aec1835_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RhYmxlOmIyODI0OGUxYzkwZDQ0N2JhMzU3ZmEyYTY3YmNhMjY2L3RhYmxlcmFuZ2U6YjI4MjQ4ZTFjOTBkNDQ3YmEzNTdmYTJhNjdiY2EyNjZfNC0xLTEtMS0w_645e72cb-2c36-4ed7-8cb0-eddb9c909a32">9,000</ix:nonFraction> </span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82218c7009949eebf722cc90aec1835_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RhYmxlOmIyODI0OGUxYzkwZDQ0N2JhMzU3ZmEyYTY3YmNhMjY2L3RhYmxlcmFuZ2U6YjI4MjQ4ZTFjOTBkNDQ3YmEzNTdmYTJhNjdiY2EyNjZfNS0xLTEtMS0w_146a54aa-cd06-4ee9-abdd-91b41d99dbbb">9,000</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82218c7009949eebf722cc90aec1835_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RhYmxlOmIyODI0OGUxYzkwZDQ0N2JhMzU3ZmEyYTY3YmNhMjY2L3RhYmxlcmFuZ2U6YjI4MjQ4ZTFjOTBkNDQ3YmEzNTdmYTJhNjdiY2EyNjZfNi0xLTEtMS0w_a56b5fc7-4e7c-4708-9c1f-ee1994239712">2,250</ix:nonFraction> </span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82218c7009949eebf722cc90aec1835_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RhYmxlOmIyODI0OGUxYzkwZDQ0N2JhMzU3ZmEyYTY3YmNhMjY2L3RhYmxlcmFuZ2U6YjI4MjQ4ZTFjOTBkNDQ3YmEzNTdmYTJhNjdiY2EyNjZfNy0xLTEtMS0w_75bc2850-8bc4-4597-9b01-9efded9702a7">22,500</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_1114"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xMTE0L2ZyYWc6NDEwMjQ2OWI2NzNiNGY5MTg1NjVkODU4OWU2MTc3ZGMvdGV4dHJlZ2lvbjo0MTAyNDY5YjY3M2I0ZjkxODU2NWQ4NTg5ZTYxNzdkY18yMTk5MDIzMjU2Njc0_087f8704-590b-4130-9e3c-202ce71d850d" continuedAt="i800224993308450ab40aeb484b8f2ff4" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i800224993308450ab40aeb484b8f2ff4">On July 3, 2021, the Company entered into a short-term note payable for $<ix:nonFraction unitRef="usd" contextRef="i909302a232e445a29fbed3c3520b5158_I20210703" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xMTE0L2ZyYWc6NDEwMjQ2OWI2NzNiNGY5MTg1NjVkODU4OWU2MTc3ZGMvdGV4dHJlZ2lvbjo0MTAyNDY5YjY3M2I0ZjkxODU2NWQ4NTg5ZTYxNzdkY18yMTk5MDIzMjU2Njc2_fdafa733-d7cb-451b-a974-9135ae118d7a">2.0</ix:nonFraction> million, bearing interest at <ix:nonFraction unitRef="number" contextRef="i909302a232e445a29fbed3c3520b5158_I20210703" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xMTE0L2ZyYWc6NDEwMjQ2OWI2NzNiNGY5MTg1NjVkODU4OWU2MTc3ZGMvdGV4dHJlZ2lvbjo0MTAyNDY5YjY3M2I0ZjkxODU2NWQ4NTg5ZTYxNzdkY18yMTk5MDIzMjU2Njkw_980f4dc5-b905-4ee6-b021-22a6a11274f9">3.925</ix:nonFraction>% per annum to finance various insurance policies. Principal and interest payments related to this note will begin on July 3, 2021 and are paid on a straight-line amortization over a <ix:nonNumeric contextRef="i41920f2da0c24c9ea164cc61d469bc9b_D20210703-20210703" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xMTE0L2ZyYWc6NDEwMjQ2OWI2NzNiNGY5MTg1NjVkODU4OWU2MTc3ZGMvdGV4dHJlZ2lvbjo0MTAyNDY5YjY3M2I0ZjkxODU2NWQ4NTg5ZTYxNzdkY18yMTk5MDIzMjU2NzA0_4cffae6b-9d2f-40b2-87d0-0888cc091198">9-month</ix:nonNumeric> period with the final payment due on March 3, 2022.</ix:continuation></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and related notes in “Item 1. Condensed Consolidated Financial Statements”. References in this report to "Rockwell," the “Company,” “we,” “our” and “us” are references to Rockwell Medical, Inc. and its subsidiaries.</span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make forward-looking statements in this report and may make such statements in future filings with the Securities and Exchange Commission, or SEC.  We may also make forward-looking statements in our press releases or other public or shareholder communications.  Our forward-looking statements are subject to risks and uncertainties and include information about our expectations and possible or assumed future results of our operations.  When we use words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,” “plan,” “potential,” “predict,” “forecast,” “project,” “intend,” or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. Our forward looking statements also include, without limitation, statements about our liquidity and capital resources; our plans and ability to successfully commercialize our products; our ability to successfully launch FDA-approved Triferic AVNU; our ability to develop FPC for other indications; our ability to successfully execute on our business strategy and development of new indications; and statements regarding our anticipated future financial condition, operating results, cash flows and business plans.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that our forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements, which are based on information available to us on the date of this report or, if made elsewhere, as of the date made.  Because these forward-looking statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different.  Factors that might cause such a difference include, without limitation, the risks and uncertainties discussed in this report, “Item 1A — Risk Factors” in our Form 10-K for the year ended December 31, 2020 and from time to time in our other reports filed with the SEC, including in this Form 10-Q.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other factors not currently anticipated may also materially and adversely affect our results of operations, cash flow and financial position.  There can be no assurance that future results will meet expectations.  Forward-looking statements speak only as of the date of this report and we expressly disclaim any intent to update or alter any statements whether as a result of new information, future events or otherwise, except as may be required by applicable law.</span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview and Recent Developments</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rockwell is a commercial-stage, biopharmaceutical company developing and commercializing our next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate ("FPC"), which we believe has the potential to lead to transformative treatments for iron deficiency in multiple disease states, that we believe could reduce healthcare costs and improve patients’ lives. We are also one of the two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two novel, FDA approved therapies, Triferic and Triferic AVNU, which are the first two products developed from our FPC platform. We are marketing both products to kidney dialysis centers for their patients receiving dialysis. In 2021, we intend to advance our FPC platform strategy outside of dialysis by starting a Phase 2 trial for the treatment of iron deficiency anemia in patients who are receiving long-term and or chronic intravenous</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“IV”) medications for various therapeutic needs in the home infusion setting.. The trend toward providing medical care, including the delivery of medicines, at home make the home infusion market a rapidly growing area of healthcare. We believe that the home infusion setting is a natural path for expansion of our platform as many of the patients suffer from chronic diseases that are associated with iron deficiency and anemia. We are currently seeking additional FDA feedback and clarification regarding the clinical development plan for FPC in the home-infusion setting. Our expectations regarding the commencement of a Phase 2 trial in 2021 is based on the assumption that the FDA agrees with the development plan as we have proposed. In our R&D pipeline, we are also investigating FPC’s impact on iron deficiency in the treatment of hospitalized patients with acute heart failure, with the potential to begin another Phase 2 trial in these patients in 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the second largest supplier of hemodialysis concentrates in the United States, with a reputation for excellent service, quality, and reliability. We believe that this reputation, which is based on over 25 years of service to the kidney </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dialysis centers, combined with about $60 million in annual revenue, approximately 300 dedicated employees, expertise in manufacturing and logistics and the added expertise in pharmaceutical development and commercialization brought to the Company by recent additions to our management team, gives us a solid foundation on which to grow.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Rockwell Medical, we are dedicated to replacing the currently inadequate standard of care for treatment of iron deficiency in acute and chronic disease by leveraging our proprietary FPC platform technology. We believe that our proprietary drug platform, FPC, is a next-generation parenteral iron therapeutic that has several advantages over other parenteral iron therapies. Importantly, it provides iron that is immediately bioavailable for critical body processes once it is administered. It has been demonstrated to be safe and well-tolerated, with a safety profile similar to placebo.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Iron deficiency, which is often overlooked and undertreated in several illnesses because of the difficulty in treating them, can develop into a serious medical condition when left untreated. It is a common comorbidity in many disease states, such as end-stage kidney disease, chronic kidney disease, acute heart failure, cancer and multiple chronic gastrointestinal conditions. Iron deficiency impacts patients’ health in many ways, including anemia, organ dysfunction, slower recovery, diminished energy and reduced quality of life.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy Evolution and Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rockwell Medical has evolved its strategy over the past year to develop into a more medically-, scientifically- and data-driven company. We believe future clinical, regulatory and commercial success require the right people with the right experience to navigate us to the right data. There has been an evolution of both our management and board, providing us with greater relevant experience. In particular, we have added board members and employees with significant medical and commercial experience in iron deficiency anemia and the dialysis sector, drug development and commercialization, small-cap public company finance and management and clinical nurse educator patient support. We believe these changes support an improved execution of our strategy to generate data that will support future commercial growth, fair reimbursement and regulatory approvals.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to accelerate Rockwell’s growth by creating and developing pharmaceutical products based on our FPC technology for disease states where patients can benefit the most from an effective treatment for iron deficiency or iron deficiency anemia, while concurrently refining our dialysis business to drive incremental growth and efficiencies. We plan to leverage and build on the foundation provided by our current dialysis business serving kidney dialysis centers by developing a pipeline of additional potential drug therapies in multiple disease states outside of nephrology. We have preliminarily identified three disease states where we believe FPC may have the biggest impact. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Dialysis Business:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are the second largest supplier, and one of the two major suppliers of hemodialysis concentrates in the United States. We manufacture, sell and deliver hemodialysis concentrates, which are used to maintain human life by removing toxins and balancing electrolytes in the dialysis patient’s bloodstream. We have core capabilities in manufacturing hemodialysis concentrates in three facilities, totaling 159,000 square feet, located in Michigan, Texas and South Carolina. We also have core capabilities in the logistics of delivering these products to dialysis clinics throughout most of the United States. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first two branded products from our FPC platform, Triferic® (dialysate) and Triferic AVNU® (IV), are used to maintain hemoglobin in patients undergoing hemodialysis. We are building on our reputation and industry presence by commercializing then to medium and small dialysis organizations. We began commercializing Triferic and Triferic AVNU in the United States in the second half of 2019 and in early 2021, respectively. In April 2021, we received marketing approval for Triferic AVNU from Health Canada for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease, which is the first international regulatory approval for our intravenous therapy. We expect Triferic AVNU to become commercially available in Canada during 2022. Our strategy for increasing Triferic adoption is to continue to generate data in clinics showing the benefits of Triferic in real world protocols. In addition, we expect to study Triferic use with the innovations that we believe have the potential to change future medical practices (e.g. introduction and adoption of HIF-PHIs), subject to FDA approval. We believe that positive data from these studies would better position Triferic for long-term growth. We are developing strategic alliance partners for development, regulatory approval and commercialization of Triferic outside of the United States. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Home Infusion Program:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We plan to initiate a clinical trial program of FPC for the treatment of iron deficiency anemia in the home-infusion setting. Many patient groups requiring home infusion therapies suffer from chronic diseases that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are associated with a high incidence of iron deficiency and anemia. Home infusion represents a large and rapidly-growing segment of healthcare where we believe FPC may have distinct advantages over currently available iron replacement therapy options. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pipeline Development:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are investigating the use of our FPC platform for the treatment of iron deficiency in hospitalized patients with acute heart failure. We believe that FPC may deliver rapidly bioavailable iron to the heart and improve cardiac energetics. This effect could help patients recover faster, resulting in shorter hospital stays and fewer 30-day re-admissions, which would be a meaningful reduction healthcare costs and human suffering.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Growth Strategy</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to accelerate our growth by combining the solid foundation, strength and reputation of our dialysis business with the high-growth potential from therapeutics derived (or generated) from our FPC platform in multiple disease states where patients can benefit the most from an effective treatment for iron deficiency. In parallel with continually seeking to drive incremental growth and efficiencies in our dialysis business unit, our strategy is to accelerate the growth of our business in large, higher-margin markets by creating and developing pharmaceutical products based on our proprietary FPC technology that address iron deficiency in patients who are currently under-treated. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dialysis Business</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are one of the two major suppliers of hemodialysis concentrates in the United States. Over the past 25 years we have developed a core expertise in manufacturing and delivering hemodialysis concentrates. Because these concentrates are used to maintain human life by removing toxins and balancing electrolytes in the dialysis patient’s bloodstream, we manufacture them under cGMP regulations as described below. Our concentrates are manufactured in three facilities, totaling 159,000 square feet, located in Michigan, Texas and South Carolina, from which we deliver these products to dialysis clinics throughout most of the United States. We utilize our own delivery fleet as well as third parties. We employ approximately 300 people in the concentrates unit of our dialysis business. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The “Rockwell Medical” name has earned a reputation for dependability, quality and service within our customer base. This reputation was further strengthened during the recent challenges presented, not only by the COVID-19 pandemic, but also by the multitude of recent natural disasters where our team has been challenged by hurricanes, flooding and freezing, while still meeting production demands. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our dialysis business in concentrates and our growth opportunities with FPC technology are synergistic. We are leveraging our leadership position in the dialysis sector to commercialize our first two FPC-based products, Triferic and Triferic AVNU, which are indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. We commercialize the Triferic products ourselves in the United States, and are partnering with established local pharmaceutical companies for the regulatory approval and commercialization outside of the United States. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Although we have an excellent reputation for dependability and service within the dialysis sector, with concentrates and Triferic, our growth opportunities for both in the United States dialysis market are challenged by the consolidated ownership of dialysis clinics, a capitated reimbursement model and the demographics of the patient population. The two largest dialysis organizations treat approximately 73% of the patients in the United States. One manufactures its own concentrates and IV iron and we already supply concentrates to the other. Through our partnership with Baxter International, we currently supply concentrates to a significant percentage of the small and medium sized dialysis organizations. In a sector, such as kidney dialysis, with capitated reimbursement for the dialysis procedure and all included inputs, new product success depends on compelling data demonstrating improved patient outcomes and/or pharmacoeconomics versus the current standard of care in practice in the clinics. Once Medicare determined that Triferic and Triferic AVNU would be reimbursed under the fixed bundled rate, market adoption became more dependent on the generation of these data, which were not required for the drug's approval from the FDA. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the growth limitations mentioned above, we have made progress and continue to be confident that Triferic has the potential to be the treatment of choice for the maintenance of hemoglobin in dialysis patients. Toward this end, we have increased our efforts in generating real world data in clinics with current protocols, which we believe will help with the adoption of Triferic and Triferic AVNU as these results are developed and disseminated over time. In addition, we believe the hemodialysis industry may experience a great deal of change over the next several years. We plan to take the steps necessary to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generate the data necessary to potentially allow Triferic and Triferic AVNU to benefit from these new innovations, such as the potential approval of a class of drugs, known as hypoxia-inducible factor prolyl hydroxylase inhibitors ("HIF-PHIs"), as well as the new, solid-state dialysis equipment in development. We are planning to study Triferic in combination with these potential new innovations as they become available. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our dialysis business strategy is to also improve the strength of our concentrates business by creating efficiencies and enhancing our manufacturing and transportation operations. We have launched projects to identify ways to improve the overall profitability of these core operations. Specifically, we are reviewing our entire supply chain to identify opportunities for improvement, prioritizing initiatives that will have the largest impact on long-term efficiency, profitability and growth. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Home Infusion</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our growth strategy is to go beyond our foundational business in dialysis by leveraging the pre-clinical, clinical pharmacology and safety data from Triferic. We are planning to develop an FPC-based therapeutic for iron deficiency to be given in the home infusion setting. According to the National Home Infusion Association, the number of patients served by home infusion therapy has grown from approximately 800,000 in 2010 to over 3,000,000 in 2019. The home infusion setting is expected to continue to expand, which has been further accelerated by the COVID-19 pandemic and the desire to reduce or eliminate hospital and or clinic exposure. Many patient groups requiring home infusion therapies suffer from diseases that are associated with an incidence of iron deficiency and anemia. For example, it is estimated that 40% to 55% of all home parenteral nutrition patients are iron deficient. We believe, based on our data with hemodialysis patients, FPC as a home infusion therapy for iron deficiency anemia may have distinct advantages over currently available iron replacement therapy options.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We plan on initiating a Phase 2 clinical study in home infusion patients with iron deficient anemia during the second half of 2021 to confirm the dose and duration of FPC treatment. We expect data from the trial in the second half of 2022. Prior to commencing this study, the company is planning to further review and discuss this clinical plan with the FDA. After reviewing the development plan with the FDA, and subject to clarifying expected clinical development requirements, we expect to initiate the trial in the second half of 2021.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Development</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our R&D pipeline, we are also exploring FPC’s impact in the treatment of iron deficiency in hospitalized heart failure patients. More than one million people in the United States are hospitalized each year for acute heart failure. Clinical improvement in heart failure has already been demonstrated with older first-generation forms of IV iron in clinical trials in the outpatient setting. We believe that FPC may deliver rapidly bioavailable iron to the heart and improve cardiac energetics during hospitalization. This effect could help patients recover faster resulting in improved function, shorter hospital stays and fewer 30-day re-admissions. If so, these outcomes would translate into a meaningful reduction in healthcare costs and human suffering. We expect to communicate with the FDA in 2021 regarding a development pathway for this indication. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue exploring other potential patient populations for application of our technology. We are considering disease states where patients can benefit the most from an effective treatment for iron deficiency, and where the development path, cost estimates and reimbursement are the most favorable.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Three Months Ended June 30, 2021 and 2020</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating results for the periods presented below (dollars in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.339%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.339%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.453%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,137</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,896</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,015 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross (Loss) Profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Product Development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,616 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and Marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,823)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(51.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,603)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Sales</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2021, our net sales were $15.1 million compared to net sales of $15.9 million during the three months ended June 30, 2020. The decrease of $0.8 million was primarily due to a decrease in sales of dialysis concentrates products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Profit</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales during the three months ended June 30, 2021 was $15.4 million, resulting in gross loss of $0.3 million during the three months ended June 30, 2021, compared to cost of sales of a $15.0 million and a gross profit of $0.9 million during the three months ended June 30, 2020. Gross profit decreased by $1.2 million mainly due to a decrease in concentrate sales and an increase in costs related to protocols implemented because of the ongoing COVID-19 pandemic, shipping, fuel and labor.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Product Development Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and product development expenses were $2.4 million for the three months ended June 30, 2021, compared with $1.6 million during the three months ended June 30, 2020. The increase of $0.8 million was primarily due to the Company continuing to invest in its medical and scientific programs to support the continued advancement of our FPC technology platform.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling and Marketing Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expenses were $1.5 million during the three months ended June 30, 2021, compared with $2.0 million during the three months ended June 30, 2020. The decrease of $0.5 million is primarily due to a decrease in marketing costs related to Triferic (dialysate) partially offset by a slight increase in costs associated with the launch of Triferic AVNU.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $3.7 million during the three months ended June 30, 2021, compared with $2.9 million during the three months ended June 30, 2020. The increase of $0.8 million is due primarily to an increase in stock compensation of $1.9 million, which was a decrease in incentive compensation in Q2 2020 of $1.5 million from forfeited equity awards of the former President and Chief Executive Officer; partially offset by a decrease of $0.8 million for the reduction of severance costs related to our former President and Chief Executive Officer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income for the three months ended June 30, 2021 was $7,000, consisting primarily of interest income. Other income for the three months ended June 30, 2020 was $0.1 million, consisting primarily of interest income. Other expense for the three months ended June 30, 2021 was $0.6 million of interest expense related to our debt facility (see Note 15 for more </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information on our debt facility). Other expense for the three months ended June 30, 2020 was $1.4 million, consisting of interest expense of $0.5 million related to our debt facility and warrant modification expense of $0.8 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Six Months Ended June 30, 2021 and 2020</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating results for the periods presented below (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.339%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.339%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.453%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30,611</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,753</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,759 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Product Development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and Marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15,005)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(49.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13,658)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(43.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Sales</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, our net sales were $30.6 million compared to net sales of $31.8 million during the six months ended June 30, 2020. The decrease of $1.2 million was primarily due to a decrease in sales of dialysis concentrates products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Profit</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales during the six months ended June 30, 2021 was $30.5 million, resulting in gross profit of $0.1 million during the six months ended June 30, 2021, compared to cost of sales of a $29.8 million and a gross profit of $2.0 million during the six months ended June 30, 2020. Gross profit decreased by $1.9 million mainly due to a decrease in concentrate sales and an increase in costs related to protocols implemented because of the ongoing COVID-19 pandemic, shipping and fuel costs and labor.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Product Development Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and product development expenses were $4.2 million for the six months ended June 30, 2021, compared with $3.4 million during the six months ended June 30, 2020. This increase of $0.8 million is primarily due to continued investments the Company is making in its medical and scientific programs to support the continued advancement of our FPC technology platform.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling and Marketing Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expenses were $3.3 million during the six months ended June 30, 2021, compared with $4.1 million during the six months ended June 30, 2020. The decrease of $0.8 million is primarily due to a decrease in marketing costs related to Triferic (dialysate) partially offset by a slight increase in costs associated with the launch of Triferic AVNU.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $7.6 million during the six months ended June 30, 2021, compared with $8.1 million during the six months ended June 30, 2020. The decrease of $0.5 million is due primarily to a decrease of $0.8 million from the completion of severance pay related to our former President and Chief Executive Officer (CEO); a decrease in legal costs of $0.3 million, relating to previous litigation that has since been resolved; and a decrease in insurance and accounting costs of $0.2 million, relating to reduced premiums; partially offset by an increase of $0.7 million for stock compensation, relating to a decrease in Q2 2020 incentive compensation from forfeited equity awards related to our former President and CEO.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income for the six months ended June 30, 2021 was $18,000, consisting primarily of interest income. Other income for the six months ended June 30, 2020 was $0.2 million, consisting primarily of interest income. Other expense for the six months ended June 30, 2021 was $1.2 million of interest expense related to our debt facility (see Note 15 for more information on our debt facility). Other expense for the six months ended June 30, 2020 was $1.5 million, consisting of warrant modification expense of $0.8 million and interest expense of $0.6 million related to our debt facility.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, Rockwell has incurred significant net losses and has funded its operations primarily through revenue from commercial products, proceeds from the issuance of debt and equity securities and payments from partnerships. At June 30, 2021, Rockwell had an accumulated deficit of approximately $353.6 million and stockholders' equity of $18.2 million. As of June 30, 2021, Rockwell had approximately $41.0 million of cash, cash equivalents and investments available-for-sale, and working capital of $18.4 million. Net cash used in operating activities for the six months ended June 30, 2021 was approximately $17.4 million. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is subject to certain covenants and cure provisions under its Loan Agreement with Innovatus. As of the date of this report, the Company is in compliance with all covenants. As a result of the ongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company may not be able to satisfy such covenants over the next 12 months. However, based on the foregoing, the Company has classified amounts payable under the Loan Agreement as a current liability. If and when the Company reaches an agreement with Innovatus to avoid an event of default, the amounts payable under the Loan Agreement will be reclassified. The financial statements for June 30, 2021, have been prepared with the assumption that the Company will be able to agree to an appropriate remedy during the applicable cure period for any future breaches of operating covenants. If the Company is unable to comply with the covenants under the Loan Agreement, it would pursue all available cure options in order to regain compliance (See Note 15 for further detail).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company expects it will require additional capital to sustain its operations and make the investments it needs to execute its strategic plan, including the commercialization of Triferic (dialysate) and Triferic AVNU in dialysis, generating additional data for Triferic in dialysis, developing FPC for iron deficiency anemia in patients undergoing home infusion and for progressing our pipeline development program of new indications for its FPC platform. If the Company is unable to generate sufficient revenue from sales of its commercial products and from partnerships, the Company will need to obtain additional equity or debt financing. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the currently available working capital and managements assumption that the Company will be able to agree to an appropriate remedy, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">General</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The actual amount of cash that we will need to execute our business strategy is subject to many factors, including, but not limited to, the expenses and revenue associated with the commercial operations in the United States and internationally (with partners); the timing and magnitude of cash received from drug product sales; the timing and expenditures associated with the development programs including our FPC technology for home infusion and potentially acute heart failure; the costs associated with our manufacturing and transportation operations related to our concentrate business; any potential accelerated amortization under the Loan Agreement in the event of a failure to satisfy operating covenants..</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may elect to raise capital in the future through one or more of the following: (i) equity and debt raises through the equity and capital markets, though there can be no assurance that we will be able to secure additional capital or funding on acceptable terms, or if at all; and (ii) strategic transactions, including potential alliances and collaborations focused on markets outside the United States, as well as potential combinations (including by merger or acquisition) or other corporate transactions. In particular, our Baxter Agreement prohibits us from entering into a contract that would encumber the assets used in our concentrate business without the prior written consent of Baxter. Due to the fact that the assets used in our concentrate business currently constitute a substantial portion of the tangible assets we own other than our drug inventory, we may not be able to, or we may find it difficult, to obtain secured debt financing without the consent of Baxter. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our ability to fund our activities in the long term will be highly dependent upon 1) our ability to execute on the development of the FPC platform for new therapies, and 2) our ability to commercialize and increase adaptation of Triferic (dialysate) and Triferic AVNU. Both of these strategies is subject to significant risks and uncertainties such that there can be no assurance that we will be successful is achieving approval of FPC in a new therapeutic area or that we will be able to have sustained commercial success with Triferic (dialysate) and Triferic AVNU. If our planned clinical program is delayed or fails or if our commercialization of Triferic (dialysate) and/or Triferic AVNU should fail to increase sales, we may be forced to implement cost-saving measures that may potentially have a negative impact on our activities and potentially the results of our research and development programs. Even though we began commercialization of Triferic (dialysate) and Triferic AVNU as planned, if the results are unsuccessful, we may be unable to secure the additional capital that we will require to continue our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research and development activities and operations, which could have a material adverse effect on our business. If we are unable to raise the required capital, we may be forced to curtail all of our activities and, ultimately, cease operations. Even if we are able to raise sufficient capital, such financings may only be available on unattractive terms, or result in significant dilution of stockholders’ interests and, in such event, the market price of our common stock may decline.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Used in Operating Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $17.4 million for the six months ended June 30, 2021 compared to net cash used in operating activities of $16.2 million for the six months ended June 30, 2020. The increase in cash used from operating activities during the current period was primarily due to changes in current balance sheet accounts in the ordinary course of business of approximately $3.0 million, including an increase in net accounts receivable of $1.2 million and a reduction in accounts payable and accrued expense of approximately $0.4 million. Overall, our cash burn for the six months ended June 30, 2021 was in line with our expectations, and we continue to expect, in aggregate, 2021 cash burn to be lower than 2020 cash burn.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Provided by Investing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $1.1 million during the six months ended June 30, 2021 compared to net cash provided by investing activities of $0.7 million for the six months ended June 30, 2020. The net cash provided by investing activities during the six months ended June 30, 2021 was primarily due to sales and purchase of available-for-sale investments during the quarter.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash (Used in) Provided by Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $6,000 during the six months ended June 30, 2021 compared to the net cash provided by financing activities of $30.4 million for the six months ended June 30, 2020. The net cash provided during the six months ended June 30, 2020 was primarily due to net proceeds of $21.2 million related to proceeds from the debt facility and $8.0 million from the sale of our common stock, related to our public offering, offset by $0.8 million for payments on short term notes. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Impact </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic and resulting global disruptions have adversely affected our business and operations, including, but not limited to, our sales and marketing efforts and our research and development activities, and the operations of third parties upon whom we rely. Quarantines, shelter-in-place, executive and similar government orders may negatively impact our sales and marketing activities, particularly if our sales representatives are unable to interact with current and potential customers to the same extent as before onset of the COVID-19 pandemic. The Company's international business development activities may also continue to be negatively impacted by COVID-19, especially with the recent surge in infections internationally, ongoing international travel restrictions and quarantines or shelter-in-place orders. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and resulting global disruptions have caused significant volatility in financial and credit markets. We have utilized a range of financing methods to fund our operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect our liquidity and capital resources in the future.</span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Judgments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">and Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies and significant estimates are detailed in our Annual Report on Form 10-K for the year ended December 31, 2020. Our critical accounting policies and significant estimates have not changed from those previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently issued and adopted accounting pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have evaluated all recently issued accounting pronouncements and believe such pronouncements do not have a material effect our financial statements. See Note 3 of the condensed consolidated financial statements at June 30, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per §229.305 of Regulation S-K, the Company, designated a Smaller Reporting Company as defined in §229.10(f)(1) of Regulation S-K, is not required to provide the disclosure required by this Item.</span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure material information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosure. In designing and evaluating the disclosure controls and procedures, we recognized that a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Management necessarily was required to apply its judgment in evaluating the cost‑benefit relationship of possible controls and procedures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision of and with the participation of our management, including the Company’s Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2021. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II – OTHER INFORMATION </span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disclosure set forth above in Note 14  (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies –</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) to our unaudited condensed consolidated financial statements is incorporated herein by reference.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may be involved in certain routine legal proceedings from time to time before various courts and governmental agencies. We cannot predict the final disposition of such proceedings. We regularly review legal matters and record provisions for claims that are considered probable of loss. The resolution of these pending proceedings is not expected to have a material effect on our operations or consolidated financial statements in the period in which they are resolved.</span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2020 under “Item 1A — Risk Factors.”</span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_124"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT INDEX</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="rmti-20210630x10qex311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="rmti-20210630x10qex312.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="rmti-20210630x10qex321.htm">Certification pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(b) of the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Database</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, formatted in Inline XBRL (included as Exhibit 101)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i1d62b4adfd9b4f4d858c9a9ca79e3e49_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:13.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROCKWELL MEDICAL, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 73pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: August 16, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Russell Ellison</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russell Ellison<br/>Chief Executive Officer (Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: August 16, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Russell Skibsted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russell Skibsted<br/>Chief Financial Officer (Principal Financial Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>rmti-20210630x10qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i5e1fcb2b050443cc966d2ce94b192e3a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULE 13a‑14(a)</font></div><div style="margin-top:10pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Russell Ellison, certify that:</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">have reviewed this quarterly report on Form 10‑Q of Rockwell Medical, Inc.;</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a‑15(e) and 15d‑15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a‑15(f) and 15d‑15(f)) for the registrant and have:</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:465.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 16, 2021</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Russell Ellison<br>Russell Ellison<br>Chief Executive Officer</font></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>rmti-20210630x10qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ieb689bb57d6347dfab503a8eb678d60e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULE 13a‑14(a)</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Russell Skibsted, certify that:</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10‑Q of Rockwell Medical, Inc.;</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a‑15(e) and 15d‑15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a‑15(f) and 15d‑15(f)) for the registrant and have:</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:465.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 16, 2021</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Russell Skibsted<br>Russell Skibsted<br>Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>rmti-20210630x10qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7efecabf10f64c82a56b8d95b650c8b9_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Rockwell Medical, Inc. (the “Company”) on Form 10‑Q for the quarter ending June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Periodic Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that based on my knowledge:</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Periodic Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:255.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:253.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 16, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Russell Ellison</font></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russell Ellison <br>Chief Executive Officer</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 16, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Russell Skibsted</font></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russell Skibsted<br>Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>rmti-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3c1f30ef-dd44-4e46-abb9-054971f79e00,g:61350dd9-1066-401d-a0af-504d0c113dc8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rmti="http://rockwellmed.com/20210630" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://rockwellmed.com/20210630">
<xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
<xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
<xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
<xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
<xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
<xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
<xs:annotation>
<xs:appinfo>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:roleType id="DocumentandEntityInformation" roleURI="http://rockwellmed.com/role/DocumentandEntityInformation">
<link:definition>0001001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
<link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
<link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
<link:definition>1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
<link:definition>1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
<link:definition>1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
<link:definition>1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="DescriptionofBusiness" roleURI="http://rockwellmed.com/role/DescriptionofBusiness">
<link:definition>2101101 - Disclosure - Description of Business</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="DescriptionofBusinessDetails" roleURI="http://rockwellmed.com/role/DescriptionofBusinessDetails">
<link:definition>2402401 - Disclosure - Description of Business (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LiquidityandCapitalResources" roleURI="http://rockwellmed.com/role/LiquidityandCapitalResources">
<link:definition>2103102 - Disclosure - Liquidity and Capital Resources</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LiquidityandCapitalResourcesDetails" roleURI="http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails">
<link:definition>2404402 - Disclosure - Liquidity and Capital Resources (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements" roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements">
<link:definition>2105103 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies" roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies">
<link:definition>2206201 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables" roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables">
<link:definition>2307301 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails" roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails">
<link:definition>2408403 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Summary of Potentially Dilutive Securities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RevenueRecognition" roleURI="http://rockwellmed.com/role/RevenueRecognition">
<link:definition>2109104 - Disclosure - Revenue Recognition</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RevenueRecognitionTables" roleURI="http://rockwellmed.com/role/RevenueRecognitionTables">
<link:definition>2310302 - Disclosure - Revenue Recognition (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RevenueRecognitionNatureofGoodsandServicesDetails" roleURI="http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails">
<link:definition>2411404 - Disclosure - Revenue Recognition - Nature of Goods and Services (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RevenueRecognitionDisaggregationofRevenueDetails" roleURI="http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails">
<link:definition>2412405 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RevenueRecognitionContractBalancesDetails" roleURI="http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails">
<link:definition>2413406 - Disclosure - Revenue Recognition - Contract Balances (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails">
<link:definition>2414407 - Disclosure - Revenue Recognition - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="InvestmentsAvailableforSale" roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSale">
<link:definition>2115105 - Disclosure - Investments - Available-for-Sale</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="InvestmentsAvailableforSaleTables" roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSaleTables">
<link:definition>2316303 - Disclosure - Investments - Available-for-Sale (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="InvestmentsAvailableforSaleDetails" roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails">
<link:definition>2417408 - Disclosure - Investments - Available-for-Sale (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="Inventory" roleURI="http://rockwellmed.com/role/Inventory">
<link:definition>2118106 - Disclosure - Inventory</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="InventoryTables" roleURI="http://rockwellmed.com/role/InventoryTables">
<link:definition>2319304 - Disclosure - Inventory (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="InventoryDetails" roleURI="http://rockwellmed.com/role/InventoryDetails">
<link:definition>2420409 - Disclosure - Inventory (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="PropertyandEquipment" roleURI="http://rockwellmed.com/role/PropertyandEquipment">
<link:definition>2121107 - Disclosure - Property and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="PropertyandEquipmentTables" roleURI="http://rockwellmed.com/role/PropertyandEquipmentTables">
<link:definition>2322305 - Disclosure - Property and Equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="PropertyandEquipmentDetails" roleURI="http://rockwellmed.com/role/PropertyandEquipmentDetails">
<link:definition>2423410 - Disclosure - Property and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="AccruedLiabilities" roleURI="http://rockwellmed.com/role/AccruedLiabilities">
<link:definition>2124108 - Disclosure - Accrued Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="AccruedLiabilitiesTables" roleURI="http://rockwellmed.com/role/AccruedLiabilitiesTables">
<link:definition>2325306 - Disclosure - Accrued Liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="AccruedLiabilitiesDetails" roleURI="http://rockwellmed.com/role/AccruedLiabilitiesDetails">
<link:definition>2426411 - Disclosure - Accrued Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="DeferredRevenue" roleURI="http://rockwellmed.com/role/DeferredRevenue">
<link:definition>2127109 - Disclosure - Deferred Revenue</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="DeferredRevenueDetails" roleURI="http://rockwellmed.com/role/DeferredRevenueDetails">
<link:definition>2428412 - Disclosure - Deferred Revenue (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockholdersEquity" roleURI="http://rockwellmed.com/role/StockholdersEquity">
<link:definition>2129110 - Disclosure - Stockholders’ Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockholdersEquityDetails" roleURI="http://rockwellmed.com/role/StockholdersEquityDetails">
<link:definition>2430413 - Disclosure - Stockholders’ Equity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockBasedCompensation" roleURI="http://rockwellmed.com/role/StockBasedCompensation">
<link:definition>2131111 - Disclosure - Stock-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockBasedCompensationTables" roleURI="http://rockwellmed.com/role/StockBasedCompensationTables">
<link:definition>2332307 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockBasedCompensationSharebasedcompensationexpenseDetails" roleURI="http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails">
<link:definition>2433414 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockBasedCompensationRestrictedStockAwardsDetails" roleURI="http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails">
<link:definition>2434415 - Disclosure - Stock-Based Compensation - Restricted Stock Awards (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails" roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails">
<link:definition>2435416 - Disclosure - Stock-Based Compensation - Service Based and Performance Based Restricted Stock Units (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails">
<link:definition>2436417 - Disclosure - Stock-Based Compensation - Service Based Stock Options - Fair value assumptions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockBasedCompensationServiceBasedStockOptionsDetails" roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails">
<link:definition>2437418 - Disclosure - Stock-Based Compensation - Service Based Stock Options (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockBasedCompensationServiceBasedStockOptionsOthersDetails" roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails">
<link:definition>2438419 - Disclosure - Stock-Based Compensation - Service Based Stock Options - Others (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockBasedCompensationPerformanceBasedStockOptionsDetails" roleURI="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails">
<link:definition>2439420 - Disclosure - Stock-Based Compensation - Performance Based Stock Options (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LicensingAgreements" roleURI="http://rockwellmed.com/role/LicensingAgreements">
<link:definition>2140112 - Disclosure - Licensing Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LicensingAgreementsDetails" roleURI="http://rockwellmed.com/role/LicensingAgreementsDetails">
<link:definition>2441421 - Disclosure - Licensing Agreements (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="Leases" roleURI="http://rockwellmed.com/role/Leases">
<link:definition>2142113 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LeasesTables" roleURI="http://rockwellmed.com/role/LeasesTables">
<link:definition>2343308 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LeasesNarrativeDetails" roleURI="http://rockwellmed.com/role/LeasesNarrativeDetails">
<link:definition>2444422 - Disclosure - Leases - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LeasesSummaryofLeaseCostsDetails" roleURI="http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails">
<link:definition>2445423 - Disclosure - Leases - Summary of Lease Costs (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails" roleURI="http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails">
<link:definition>2446424 - Disclosure - Leases - Finance Lease and Operating Lease Maturities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1" roleURI="http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1">
<link:definition>2446424 - Disclosure - Leases - Finance Lease and Operating Lease Maturities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsandContingencies" roleURI="http://rockwellmed.com/role/CommitmentsandContingencies">
<link:definition>2147114 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LoansandSecurityAgreement" roleURI="http://rockwellmed.com/role/LoansandSecurityAgreement">
<link:definition>2148115 - Disclosure - Loans and Security Agreement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LoansandSecurityAgreementTables" roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementTables">
<link:definition>2349309 - Disclosure - Loans and Security Agreement (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LoansandSecurityAgreementNarrativeDetails" roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails">
<link:definition>2450425 - Disclosure - Loans and Security Agreement - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails">
<link:definition>2451426 - Disclosure - Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="SubsequentEvents" roleURI="http://rockwellmed.com/role/SubsequentEvents">
<link:definition>2152116 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="SubsequentEventsDetails" roleURI="http://rockwellmed.com/role/SubsequentEventsDetails">
<link:definition>2453427 - Disclosure - Subsequent Events (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
</xs:appinfo>
</xs:annotation>
<xs:element id="rmti_RevenueRecognitionTable" abstract="true" name="RevenueRecognitionTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
<xs:element id="rmti_DrugRevenueMember" abstract="true" name="DrugRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_DrugProductSalesMember" abstract="true" name="DrugProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_CollaborativeArrangementNumberOfInstallmentPayments" abstract="false" name="CollaborativeArrangementNumberOfInstallmentPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
<xs:element id="rmti_JeilPharmaAgreementsMember" abstract="true" name="JeilPharmaAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember" abstract="true" name="ExecutiveVicePresidentAndChiefScientificOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" abstract="false" name="ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="rmti_TermLoanTrancheThreeMember" abstract="true" name="TermLoanTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" abstract="false" name="CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_ServiceBasedAwardsMember" abstract="true" name="ServiceBasedAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" abstract="false" name="DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
<xs:element id="rmti_TrifericAPIMember" abstract="true" name="TrifericAPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee" abstract="false" name="ContractWithCustomerRepaymentPercentageOfUpfrontFee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
<xs:element id="rmti_RevenueRecognitionLineItems" abstract="true" name="RevenueRecognitionLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
<xs:element id="rmti_DrugLicenseFeeMember" abstract="true" name="DrugLicenseFeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_LiquidityAndCapitalResourcesAbstract" abstract="true" name="LiquidityAndCapitalResourcesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
<xs:element id="rmti_ContractWithCustomerDeferredRevenueTextBlock" abstract="false" name="ContractWithCustomerDeferredRevenueTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
<xs:element id="rmti_TermLoanTrancheTwoMember" abstract="true" name="TermLoanTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_TermLoanTrancheOneMember" abstract="true" name="TermLoanTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent" abstract="false" name="OperatingLeaseAndFinanceLeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_ServiceBasedStockOptionAwardsMember" abstract="true" name="ServiceBasedStockOptionAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_PerformanceBasedRestrictedStockUnitsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_ConcentrateProductSalesMember" abstract="true" name="ConcentrateProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_WixomMichiganPropertyTwoMember" abstract="true" name="WixomMichiganPropertyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_FinanceLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="FinanceLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_NumberOfDistributionAndLicenseAgreements" abstract="false" name="NumberOfDistributionAndLicenseAgreements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
<xs:element id="rmti_IncreaseDecreaseInOperatingLeaseLiability" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_CurrentAndNonCurrentInventory" abstract="false" name="CurrentAndNonCurrentInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_RevenueRecognitionReceived" abstract="false" name="RevenueRecognitionReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_DebtInstrumentPeriodOfInterestOnlyPayments" abstract="false" name="DebtInstrumentPeriodOfInterestOnlyPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="rmti_SalesAgreementThresholdSaleOfShares" abstract="false" name="SalesAgreementThresholdSaleOfShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
<xs:element id="rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent" abstract="false" name="OperatingLeaseAndFinanceLeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_WorkingCapitalNet" abstract="false" name="WorkingCapitalNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_TrifericDialysateMember" abstract="true" name="TrifericDialysateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_AveragePaymentTermOfDistributors" abstract="false" name="AveragePaymentTermOfDistributors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="rmti_AccruedUnvoucheredReceiptsCurrent" abstract="false" name="AccruedUnvoucheredReceiptsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_PerformanceBasedStockOptionAwardsMember" abstract="true" name="PerformanceBasedStockOptionAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_WanbangBiopharmaceuticalMember" abstract="true" name="WanbangBiopharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_PerformanceBasedRestrictedStockAwardsMember" abstract="true" name="PerformanceBasedRestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" abstract="false" name="RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent" abstract="false" name="ResearchAndDevelopmentRelatedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses" abstract="false" name="CollaborativeArrangementAccruedReimbursementOfLegalExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet" abstract="false" name="OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_OperatingLeaseAndFinanceLeaseLiability" abstract="false" name="OperatingLeaseAndFinanceLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_AveragePaymentTermOfCustomers" abstract="false" name="AveragePaymentTermOfCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="rmti_TrifericInventoryMember" abstract="true" name="TrifericInventoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" abstract="false" name="ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" abstract="false" name="AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_PerformanceBasedAwardsMember" abstract="true" name="PerformanceBasedAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_SaleofStockRemainingSalesAmount" abstract="false" name="SaleofStockRemainingSalesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_SunPharmaAgreementsMember" abstract="true" name="SunPharmaAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_BaxterHealthcareOrganizationMember" abstract="true" name="BaxterHealthcareOrganizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_ServiceBasedRestrictedStockUnitsMember" abstract="true" name="ServiceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
<xs:element id="rmti_ConcentrateProductsMember" abstract="true" name="ConcentrateProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_InstallmentPaymentToRelatedParties" abstract="false" name="InstallmentPaymentToRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_ConcentrateProductLicenseFeeMember" abstract="true" name="ConcentrateProductLicenseFeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_YearsOfService" abstract="false" name="YearsOfService" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="rmti_DrogsanAgreementsMember" abstract="true" name="DrogsanAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_NumberOfAdditionalAgreements" abstract="false" name="NumberOfAdditionalAgreements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
<xs:element id="rmti_AtthemarketOfferingMember" abstract="true" name="AtthemarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_TermLoanTrancheTwoAndTrancheThreeMember" abstract="true" name="TermLoanTrancheTwoAndTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_A3925NotePayableMember" abstract="true" name="A3925NotePayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_LiquidityAndFinancialConditionTextBlock" abstract="false" name="LiquidityAndFinancialConditionTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
<xs:element id="rmti_BoughtDealMember" abstract="true" name="BoughtDealMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_WixomMichiganPropertyOneMember" abstract="true" name="WixomMichiganPropertyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rmti_FinanceLeaseExpense" abstract="false" name="FinanceLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" abstract="false" name="ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>rmti-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3c1f30ef-dd44-4e46-abb9-054971f79e00,g:61350dd9-1066-401d-a0af-504d0c113dc8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="rmti-20210630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
<link:calculationLink xlink:role="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8898d2f9-42c9-4c04-a728-76aa17f1619b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_4fa252af-aebd-4eb3-859e-f8cf18da714e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8898d2f9-42c9-4c04-a728-76aa17f1619b" xlink:to="loc_us-gaap_CommonStockValueOutstanding_4fa252af-aebd-4eb3-859e-f8cf18da714e" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_029ca59d-7c36-4bd4-80f3-a54cb9b8530e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8898d2f9-42c9-4c04-a728-76aa17f1619b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_029ca59d-7c36-4bd4-80f3-a54cb9b8530e" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_352983b0-7e5a-434e-95b4-ecb46a9d48bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8898d2f9-42c9-4c04-a728-76aa17f1619b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_352983b0-7e5a-434e-95b4-ecb46a9d48bc" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_24f20f18-7176-46ab-a1d1-deb1683b6941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8898d2f9-42c9-4c04-a728-76aa17f1619b" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_24f20f18-7176-46ab-a1d1-deb1683b6941" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_18c1d3ea-8bfd-4418-957c-5f63afca32c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8898d2f9-42c9-4c04-a728-76aa17f1619b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_18c1d3ea-8bfd-4418-957c-5f63afca32c2" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2461d290-df95-46f5-9917-8d1e968c229a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d5b053f9-18e6-402c-9831-505b95f9bea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2461d290-df95-46f5-9917-8d1e968c229a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d5b053f9-18e6-402c-9831-505b95f9bea1" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_78efae6d-eb8b-402f-981b-606f40ccb30f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2461d290-df95-46f5-9917-8d1e968c229a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_78efae6d-eb8b-402f-981b-606f40ccb30f" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cd7712be-01b4-495b-8a71-2835f68cc0ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2461d290-df95-46f5-9917-8d1e968c229a" xlink:to="loc_us-gaap_InventoryNet_cd7712be-01b4-495b-8a71-2835f68cc0ed" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ed82d818-b78c-470f-bdc9-599736e1e98a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2461d290-df95-46f5-9917-8d1e968c229a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ed82d818-b78c-470f-bdc9-599736e1e98a" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7473420e-fe09-46c1-801f-0f2601c9f433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2461d290-df95-46f5-9917-8d1e968c229a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7473420e-fe09-46c1-801f-0f2601c9f433" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6a325ee7-71a2-4135-a4b5-0ea4263299eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a2fe015f-6927-4829-928e-d839958b275d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6a325ee7-71a2-4135-a4b5-0ea4263299eb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a2fe015f-6927-4829-928e-d839958b275d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_8d26ce8c-1e19-4389-9b10-115c127a9851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6a325ee7-71a2-4135-a4b5-0ea4263299eb" xlink:to="loc_us-gaap_InventoryNoncurrent_8d26ce8c-1e19-4389-9b10-115c127a9851" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet_52778b81-efbc-4408-a237-83d2e0e50e9b" xlink:href="rmti-20210630.xsd#rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6a325ee7-71a2-4135-a4b5-0ea4263299eb" xlink:to="loc_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet_52778b81-efbc-4408-a237-83d2e0e50e9b" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_14baad64-8091-4ca0-ae4c-4490af3b46bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6a325ee7-71a2-4135-a4b5-0ea4263299eb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_14baad64-8091-4ca0-ae4c-4490af3b46bd" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_17515a17-b5ad-4c72-ba13-38ea932afad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6a325ee7-71a2-4135-a4b5-0ea4263299eb" xlink:to="loc_us-gaap_Goodwill_17515a17-b5ad-4c72-ba13-38ea932afad7" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_de460d2c-f48d-47db-bcd1-3539cc30876d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6a325ee7-71a2-4135-a4b5-0ea4263299eb" xlink:to="loc_us-gaap_AssetsCurrent_de460d2c-f48d-47db-bcd1-3539cc30876d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_28f08969-5fcc-4d29-afea-ecd991fdd3f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_285cbf76-09c6-4faf-9a47-7cd78832d878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_28f08969-5fcc-4d29-afea-ecd991fdd3f1" xlink:to="loc_us-gaap_Liabilities_285cbf76-09c6-4faf-9a47-7cd78832d878" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4358adfb-00b6-4ded-a020-c20fa6904692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_28f08969-5fcc-4d29-afea-ecd991fdd3f1" xlink:to="loc_us-gaap_StockholdersEquity_4358adfb-00b6-4ded-a020-c20fa6904692" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e48c58fd-4ced-47ac-84b1-03ebf98cd778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_28f08969-5fcc-4d29-afea-ecd991fdd3f1" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e48c58fd-4ced-47ac-84b1-03ebf98cd778" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1aecd9dc-ea51-4622-b221-0fd144b99f05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_4439c11a-6f43-4cc4-b95f-eb9f475d4134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1aecd9dc-ea51-4622-b221-0fd144b99f05" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_4439c11a-6f43-4cc4-b95f-eb9f475d4134" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c8abbd2c-6e2a-4f32-a40a-1bdb44cb36dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1aecd9dc-ea51-4622-b221-0fd144b99f05" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c8abbd2c-6e2a-4f32-a40a-1bdb44cb36dc" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_437eb0ab-4a57-4414-95ab-ddc8f44d664c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1aecd9dc-ea51-4622-b221-0fd144b99f05" xlink:to="loc_us-gaap_AccountsPayableCurrent_437eb0ab-4a57-4414-95ab-ddc8f44d664c" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_30bed6f2-0db9-47d5-a313-1beada424e33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1aecd9dc-ea51-4622-b221-0fd144b99f05" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_30bed6f2-0db9-47d5-a313-1beada424e33" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d67f218d-928a-41eb-a4d7-2edadb324974" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1aecd9dc-ea51-4622-b221-0fd144b99f05" xlink:to="loc_us-gaap_LongTermDebtCurrent_d67f218d-928a-41eb-a4d7-2edadb324974" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8115e8fb-9f3e-4db9-862e-306559f3d9ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1aecd9dc-ea51-4622-b221-0fd144b99f05" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8115e8fb-9f3e-4db9-862e-306559f3d9ac" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent_d1ebc0c6-9c30-40ad-a3c7-5b460b856f06" xlink:href="rmti-20210630.xsd#rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent"/>
<link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1aecd9dc-ea51-4622-b221-0fd144b99f05" xlink:to="loc_rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent_d1ebc0c6-9c30-40ad-a3c7-5b460b856f06" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d254077b-9088-4f6f-bc5f-484d1998245f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent_93ec5355-9e1b-441e-afd5-9647837cbae1" xlink:href="rmti-20210630.xsd#rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d254077b-9088-4f6f-bc5f-484d1998245f" xlink:to="loc_rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent_93ec5355-9e1b-441e-afd5-9647837cbae1" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e58f5ffd-ccad-4317-8da2-890896c1e176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d254077b-9088-4f6f-bc5f-484d1998245f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e58f5ffd-ccad-4317-8da2-890896c1e176" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_47599e98-b754-4020-b9da-85a241302185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d254077b-9088-4f6f-bc5f-484d1998245f" xlink:to="loc_us-gaap_LiabilitiesCurrent_47599e98-b754-4020-b9da-85a241302185" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9a4e227f-580a-442f-90a6-95ef710f7b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d254077b-9088-4f6f-bc5f-484d1998245f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9a4e227f-580a-442f-90a6-95ef710f7b1a" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="rmti-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
<link:calculationLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b5705ce8-7c8f-48f3-9410-937ae8678d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9dc3fd50-bce2-466f-a21b-30da96900202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b5705ce8-7c8f-48f3-9410-937ae8678d38" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9dc3fd50-bce2-466f-a21b-30da96900202" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_17d8a950-05da-4f80-aacf-98788ad6fe1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b5705ce8-7c8f-48f3-9410-937ae8678d38" xlink:to="loc_us-gaap_InterestExpense_17d8a950-05da-4f80-aacf-98788ad6fe1d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_69b6e4f8-e0cd-4ac6-8ea6-a4eeaf42961c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
<link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b5705ce8-7c8f-48f3-9410-937ae8678d38" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_69b6e4f8-e0cd-4ac6-8ea6-a4eeaf42961c" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_513dda18-1abc-41ed-a1ad-058af1fb57df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b5705ce8-7c8f-48f3-9410-937ae8678d38" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_513dda18-1abc-41ed-a1ad-058af1fb57df" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9afa3dbc-6e6a-4df0-9d91-f1d70e85a21b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_022596d4-1992-4bc0-917e-0ba572c8853f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9afa3dbc-6e6a-4df0-9d91-f1d70e85a21b" xlink:to="loc_us-gaap_GrossProfit_022596d4-1992-4bc0-917e-0ba572c8853f" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_561875fc-a12c-48da-8290-d7dd34c079bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9afa3dbc-6e6a-4df0-9d91-f1d70e85a21b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_561875fc-a12c-48da-8290-d7dd34c079bb" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9b8233b1-d9f4-4752-bfe8-916f5b44328d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
<link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9afa3dbc-6e6a-4df0-9d91-f1d70e85a21b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9b8233b1-d9f4-4752-bfe8-916f5b44328d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_a82db09a-6e9b-4d63-af14-83ca64071962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
<link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9afa3dbc-6e6a-4df0-9d91-f1d70e85a21b" xlink:to="loc_us-gaap_SellingAndMarketingExpense_a82db09a-6e9b-4d63-af14-83ca64071962" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_14179891-e08a-4db5-9be6-4d03f69c134d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c11915e8-d068-408e-a1d7-4938416caa89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_14179891-e08a-4db5-9be6-4d03f69c134d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c11915e8-d068-408e-a1d7-4938416caa89" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_78ad8694-ff14-48c5-b464-38f436e4754b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_14179891-e08a-4db5-9be6-4d03f69c134d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_78ad8694-ff14-48c5-b464-38f436e4754b" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f7e4a738-8941-4b00-a42d-dd4c47c61dc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3223e356-7254-4db2-9d34-0cf60fa69c12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f7e4a738-8941-4b00-a42d-dd4c47c61dc4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3223e356-7254-4db2-9d34-0cf60fa69c12" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_99e82f80-d5a9-49b3-9a87-d18f4abcdb8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f7e4a738-8941-4b00-a42d-dd4c47c61dc4" xlink:to="loc_us-gaap_OperatingIncomeLoss_99e82f80-d5a9-49b3-9a87-d18f4abcdb8b" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="rmti-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
<link:calculationLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_750d7827-2347-4dd5-88a3-4d2a93c81adf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eccc9b13-5257-4601-8bcd-c224c020000b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_750d7827-2347-4dd5-88a3-4d2a93c81adf" xlink:to="loc_us-gaap_NetIncomeLoss_eccc9b13-5257-4601-8bcd-c224c020000b" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_cdf836ed-d089-4bad-8067-157f839116cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_750d7827-2347-4dd5-88a3-4d2a93c81adf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_cdf836ed-d089-4bad-8067-157f839116cd" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d8454e2b-1a1b-4686-9437-9b32b01f7437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_750d7827-2347-4dd5-88a3-4d2a93c81adf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d8454e2b-1a1b-4686-9437-9b32b01f7437" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="rmti-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
<link:calculationLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13b0e856-d0ef-4680-80b6-0c1217c06458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_bd32201e-d02b-4349-b31b-ee3e9452f557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13b0e856-d0ef-4680-80b6-0c1217c06458" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_bd32201e-d02b-4349-b31b-ee3e9452f557" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b137e8b3-b01b-4873-806f-4d7b8478280e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13b0e856-d0ef-4680-80b6-0c1217c06458" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b137e8b3-b01b-4873-806f-4d7b8478280e" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4305f3a8-4ed9-423c-961e-601530648231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
<link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13b0e856-d0ef-4680-80b6-0c1217c06458" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4305f3a8-4ed9-423c-961e-601530648231" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_714f4f99-b382-4132-9370-2e57d35f7d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2b771058-50d2-43d6-9045-112105b3375b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_714f4f99-b382-4132-9370-2e57d35f7d5a" xlink:to="loc_us-gaap_NetIncomeLoss_2b771058-50d2-43d6-9045-112105b3375b" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5411af42-5319-4c96-a82e-838f28eb8aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_714f4f99-b382-4132-9370-2e57d35f7d5a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5411af42-5319-4c96-a82e-838f28eb8aa8" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_01d6f97f-813b-4f09-83a8-e9afcebc8fa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_714f4f99-b382-4132-9370-2e57d35f7d5a" xlink:to="loc_us-gaap_ShareBasedCompensation_01d6f97f-813b-4f09-83a8-e9afcebc8fa1" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_ba3d8ca2-2b02-4fa2-86cd-d0ff734cd6a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
<link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_714f4f99-b382-4132-9370-2e57d35f7d5a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_ba3d8ca2-2b02-4fa2-86cd-d0ff734cd6a5" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReservePeriodCharge_37ffa43b-0d37-4732-96a2-204babb49ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_714f4f99-b382-4132-9370-2e57d35f7d5a" xlink:to="loc_us-gaap_InventoryLIFOReservePeriodCharge_37ffa43b-0d37-4732-96a2-204babb49ef4" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_7461b9a5-3d4e-4f2f-bd38-1fd1bf22306c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_714f4f99-b382-4132-9370-2e57d35f7d5a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_7461b9a5-3d4e-4f2f-bd38-1fd1bf22306c" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4d685ee2-134a-40d6-98b8-08c1d7059580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
<link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_714f4f99-b382-4132-9370-2e57d35f7d5a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4d685ee2-134a-40d6-98b8-08c1d7059580" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_b7fb1d8a-9b33-42f4-9bc5-0ff53ac993ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
<link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_714f4f99-b382-4132-9370-2e57d35f7d5a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_b7fb1d8a-9b33-42f4-9bc5-0ff53ac993ae" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_3f98d31c-0a95-4f56-a61b-09d89b4af38e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
<link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_714f4f99-b382-4132-9370-2e57d35f7d5a" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_3f98d31c-0a95-4f56-a61b-09d89b4af38e" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_7bf60c6c-78a2-4d8f-9080-e68e3a4c0324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
<link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_714f4f99-b382-4132-9370-2e57d35f7d5a" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_7bf60c6c-78a2-4d8f-9080-e68e3a4c0324" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_7df4354f-ae6f-40ce-aa4f-93678dd852dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
<link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_714f4f99-b382-4132-9370-2e57d35f7d5a" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_7df4354f-ae6f-40ce-aa4f-93678dd852dd" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_ddcc244b-92c4-4ea7-b60e-88509c675346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3e71aa94-f5f3-4b1b-a1a6-8fef2f4ceabb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_ddcc244b-92c4-4ea7-b60e-88509c675346" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3e71aa94-f5f3-4b1b-a1a6-8fef2f4ceabb" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_IncreaseDecreaseInOperatingLeaseLiability_01675a03-ad40-4164-8d2b-7843cc59c4d5" xlink:href="rmti-20210630.xsd#rmti_IncreaseDecreaseInOperatingLeaseLiability"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_ddcc244b-92c4-4ea7-b60e-88509c675346" xlink:to="loc_rmti_IncreaseDecreaseInOperatingLeaseLiability_01675a03-ad40-4164-8d2b-7843cc59c4d5" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a6355965-7478-4fba-99ac-c0b9fb5108e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_ddcc244b-92c4-4ea7-b60e-88509c675346" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a6355965-7478-4fba-99ac-c0b9fb5108e2" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3c884140-853f-41b9-baf4-284a09332056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_ddcc244b-92c4-4ea7-b60e-88509c675346" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3c884140-853f-41b9-baf4-284a09332056" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6f413629-7870-4a63-a7f6-8465fef6df42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
<link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_ddcc244b-92c4-4ea7-b60e-88509c675346" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6f413629-7870-4a63-a7f6-8465fef6df42" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_0314ed47-895d-454b-bc51-18f63f46bcce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
<link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_ddcc244b-92c4-4ea7-b60e-88509c675346" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_0314ed47-895d-454b-bc51-18f63f46bcce" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e69403be-7fbf-476d-9578-2735ac09fde7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
<link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_ddcc244b-92c4-4ea7-b60e-88509c675346" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e69403be-7fbf-476d-9578-2735ac09fde7" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6941580e-cf6f-49c3-99b9-ea766a315063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
<link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital_ddcc244b-92c4-4ea7-b60e-88509c675346" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6941580e-cf6f-49c3-99b9-ea766a315063" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4b33d2ed-4a7f-4ac6-92ab-c4506b12fb08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_170094ab-29a1-43b4-9a21-1af4bd18720c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4b33d2ed-4a7f-4ac6-92ab-c4506b12fb08" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_170094ab-29a1-43b4-9a21-1af4bd18720c" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e7d89e53-46a3-488a-a57d-740ffd4233a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4b33d2ed-4a7f-4ac6-92ab-c4506b12fb08" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e7d89e53-46a3-488a-a57d-740ffd4233a5" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_18202ca8-608a-422d-9e4f-71f2651ed98a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4b33d2ed-4a7f-4ac6-92ab-c4506b12fb08" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_18202ca8-608a-422d-9e4f-71f2651ed98a" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d282c92-ab43-47d2-a64c-36ea74c3eb90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_51f133d3-a9a7-4c0d-a7bc-5420c05e4db2" xlink:href="rmti-20210630.xsd#rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes"/>
<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d282c92-ab43-47d2-a64c-36ea74c3eb90" xlink:to="loc_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_51f133d3-a9a7-4c0d-a7bc-5420c05e4db2" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7e2ed0da-0f89-4a79-b513-4b0785fa2b53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d282c92-ab43-47d2-a64c-36ea74c3eb90" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7e2ed0da-0f89-4a79-b513-4b0785fa2b53" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6ea2b1ec-8c55-4823-b8ec-a68e5728a228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d282c92-ab43-47d2-a64c-36ea74c3eb90" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6ea2b1ec-8c55-4823-b8ec-a68e5728a228" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_a14b7214-6847-4da9-8ff9-dd0d9aa11896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
<link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d282c92-ab43-47d2-a64c-36ea74c3eb90" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_a14b7214-6847-4da9-8ff9-dd0d9aa11896" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b66f34ca-6335-47b3-a860-50cfa878e114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
<link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d282c92-ab43-47d2-a64c-36ea74c3eb90" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b66f34ca-6335-47b3-a860-50cfa878e114" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_82cf948b-5015-4152-b5da-00d55dc9d743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
<link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d282c92-ab43-47d2-a64c-36ea74c3eb90" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_82cf948b-5015-4152-b5da-00d55dc9d743" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/InventoryDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#InventoryDetails"/>
<link:calculationLink xlink:role="http://rockwellmed.com/role/InventoryDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_rmti_CurrentAndNonCurrentInventory_72506809-2248-41af-a8ed-d8540a3d871e" xlink:href="rmti-20210630.xsd#rmti_CurrentAndNonCurrentInventory"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3c82de64-172b-47cc-8bdb-9e6a5c5fc776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rmti_CurrentAndNonCurrentInventory_72506809-2248-41af-a8ed-d8540a3d871e" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3c82de64-172b-47cc-8bdb-9e6a5c5fc776" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_e05a33bf-480c-4d9d-a700-a72cd4286781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rmti_CurrentAndNonCurrentInventory_72506809-2248-41af-a8ed-d8540a3d871e" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_e05a33bf-480c-4d9d-a700-a72cd4286781" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_55e153a9-8ceb-4224-8403-350e58ea4461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rmti_CurrentAndNonCurrentInventory_72506809-2248-41af-a8ed-d8540a3d871e" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_55e153a9-8ceb-4224-8403-350e58ea4461" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#PropertyandEquipmentDetails"/>
<link:calculationLink xlink:role="http://rockwellmed.com/role/PropertyandEquipmentDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_60ae4b4d-de09-4bd8-92f1-fc1209fbcce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cc2bc2c0-1463-4109-908b-70f003b796ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_60ae4b4d-de09-4bd8-92f1-fc1209fbcce3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cc2bc2c0-1463-4109-908b-70f003b796ea" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9830f403-aebf-4212-bef9-8c16d2f17f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_60ae4b4d-de09-4bd8-92f1-fc1209fbcce3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9830f403-aebf-4212-bef9-8c16d2f17f6e" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#AccruedLiabilitiesDetails"/>
<link:calculationLink xlink:role="http://rockwellmed.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_adbe205b-824c-4e3d-ade3-edbb4c716c0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_215c512b-b02b-45ac-a28e-b8543c7d7a1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_adbe205b-824c-4e3d-ade3-edbb4c716c0a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_215c512b-b02b-45ac-a28e-b8543c7d7a1d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent_695d1e8b-5669-48ba-8da9-85b80538ca31" xlink:href="rmti-20210630.xsd#rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_adbe205b-824c-4e3d-ade3-edbb4c716c0a" xlink:to="loc_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent_695d1e8b-5669-48ba-8da9-85b80538ca31" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5827c36b-8ee3-4549-b0fa-93d5e5c3a3d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_adbe205b-824c-4e3d-ade3-edbb4c716c0a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5827c36b-8ee3-4549-b0fa-93d5e5c3a3d0" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_AccruedUnvoucheredReceiptsCurrent_739b3ab7-6630-4589-b518-1118111d69f8" xlink:href="rmti-20210630.xsd#rmti_AccruedUnvoucheredReceiptsCurrent"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_adbe205b-824c-4e3d-ade3-edbb4c716c0a" xlink:to="loc_rmti_AccruedUnvoucheredReceiptsCurrent_739b3ab7-6630-4589-b518-1118111d69f8" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WorkersCompensationLiabilityCurrent_28e7c2d7-aef5-436c-a245-5d74cb3584f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_adbe205b-824c-4e3d-ade3-edbb4c716c0a" xlink:to="loc_us-gaap_WorkersCompensationLiabilityCurrent_28e7c2d7-aef5-436c-a245-5d74cb3584f1" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#LeasesSummaryofLeaseCostsDetails"/>
<link:calculationLink xlink:role="http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_rmti_FinanceLeaseExpense_a4f10c06-e108-4c62-8ca1-f68168c85117" xlink:href="rmti-20210630.xsd#rmti_FinanceLeaseExpense"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_d06e913b-0dca-4940-98d5-a4b9a55466bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rmti_FinanceLeaseExpense_a4f10c06-e108-4c62-8ca1-f68168c85117" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_d06e913b-0dca-4940-98d5-a4b9a55466bd" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_c49462bb-25bd-4277-9529-0171db7c9bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rmti_FinanceLeaseExpense_a4f10c06-e108-4c62-8ca1-f68168c85117" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_c49462bb-25bd-4277-9529-0171db7c9bee" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_43982c87-a9f2-4ef2-893b-120d8577f20e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_18a85a08-2c9d-4b16-b13e-a6fc00d51c10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseExpense_43982c87-a9f2-4ef2-893b-120d8577f20e" xlink:to="loc_us-gaap_OperatingLeaseCost_18a85a08-2c9d-4b16-b13e-a6fc00d51c10" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_d6897e47-348d-480e-86e4-b4d5a8372958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseExpense_43982c87-a9f2-4ef2-893b-120d8577f20e" xlink:to="loc_us-gaap_VariableLeaseCost_d6897e47-348d-480e-86e4-b4d5a8372958" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_abd85ee1-73b5-45aa-aab3-d9c21dd1f32a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_f75a75de-551e-46e7-8b42-6304a4668741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_abd85ee1-73b5-45aa-aab3-d9c21dd1f32a" xlink:to="loc_us-gaap_OperatingLeaseExpense_f75a75de-551e-46e7-8b42-6304a4668741" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_FinanceLeaseExpense_f92cc479-1eea-4e27-b386-1a2ca34d4c9a" xlink:href="rmti-20210630.xsd#rmti_FinanceLeaseExpense"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_abd85ee1-73b5-45aa-aab3-d9c21dd1f32a" xlink:to="loc_rmti_FinanceLeaseExpense_f92cc479-1eea-4e27-b386-1a2ca34d4c9a" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_ffface1a-3f2c-4fee-b9dc-15922d6e07de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_abd85ee1-73b5-45aa-aab3-d9c21dd1f32a" xlink:to="loc_us-gaap_ShortTermLeaseCost_ffface1a-3f2c-4fee-b9dc-15922d6e07de" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"/>
<link:calculationLink xlink:role="http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_14306552-091b-405e-861b-28cfd22df113" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_388b30d2-33ff-4905-a0b1-0cab9dd84826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_14306552-091b-405e-861b-28cfd22df113" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_388b30d2-33ff-4905-a0b1-0cab9dd84826" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_94b29dd5-64a4-48c3-8ee7-3215336fd306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_14306552-091b-405e-861b-28cfd22df113" xlink:to="loc_us-gaap_OperatingLeaseLiability_94b29dd5-64a4-48c3-8ee7-3215336fd306" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_12971181-0a78-4283-a635-ccdb3fe9ef49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_418c7405-2898-49a7-aa01-94baa0ef22e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_12971181-0a78-4283-a635-ccdb3fe9ef49" xlink:to="loc_us-gaap_FinanceLeaseLiability_418c7405-2898-49a7-aa01-94baa0ef22e6" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3472cf7c-241e-458f-87a0-2674a9e30814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_12971181-0a78-4283-a635-ccdb3fe9ef49" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3472cf7c-241e-458f-87a0-2674a9e30814" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1" xlink:type="simple" xlink:href="rmti-20210630.xsd#LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1"/>
<link:calculationLink xlink:role="http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d19b9047-d94f-4e0f-b374-881e539cc0ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_98c00a94-22e3-49ed-9d6b-6b36ceb68a25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d19b9047-d94f-4e0f-b374-881e539cc0ef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_98c00a94-22e3-49ed-9d6b-6b36ceb68a25" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_a08be75d-d057-47bc-a41b-9c49e69aba1a" xlink:href="rmti-20210630.xsd#rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d19b9047-d94f-4e0f-b374-881e539cc0ef" xlink:to="loc_rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_a08be75d-d057-47bc-a41b-9c49e69aba1a" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e778f30f-3135-47b0-9d31-5acf4deb0871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d19b9047-d94f-4e0f-b374-881e539cc0ef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e778f30f-3135-47b0-9d31-5acf4deb0871" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0a938141-6f91-4c04-8f87-9794665b261d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d19b9047-d94f-4e0f-b374-881e539cc0ef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0a938141-6f91-4c04-8f87-9794665b261d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8ee750db-880e-42dd-a076-6d628296a9a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d19b9047-d94f-4e0f-b374-881e539cc0ef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8ee750db-880e-42dd-a076-6d628296a9a7" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_eec5ef89-eb3e-4457-9206-bc19ee74652a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d19b9047-d94f-4e0f-b374-881e539cc0ef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_eec5ef89-eb3e-4457-9206-bc19ee74652a" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a4579dbb-35fc-4cf0-9168-0fd29155e095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_b6010802-fce3-49a3-92f1-311bf891ebba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a4579dbb-35fc-4cf0-9168-0fd29155e095" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_b6010802-fce3-49a3-92f1-311bf891ebba" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_ef74eddc-fb85-43a6-a1b5-512856156add" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a4579dbb-35fc-4cf0-9168-0fd29155e095" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_ef74eddc-fb85-43a6-a1b5-512856156add" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2cc260bb-3ba3-4041-acf7-75ea3b16ad32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a4579dbb-35fc-4cf0-9168-0fd29155e095" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2cc260bb-3ba3-4041-acf7-75ea3b16ad32" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_3f5cd165-f619-4436-b894-9e6f349470af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a4579dbb-35fc-4cf0-9168-0fd29155e095" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_3f5cd165-f619-4436-b894-9e6f349470af" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_FinanceLeaseLiabilityToBePaidAfterYearFour_bfa6ca7e-31fe-4c61-a89a-7d106fd28aa1" xlink:href="rmti-20210630.xsd#rmti_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a4579dbb-35fc-4cf0-9168-0fd29155e095" xlink:to="loc_rmti_FinanceLeaseLiabilityToBePaidAfterYearFour_bfa6ca7e-31fe-4c61-a89a-7d106fd28aa1" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_cc306ca5-fec5-46f3-9ae9-d24c1ab4882b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a4579dbb-35fc-4cf0-9168-0fd29155e095" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_cc306ca5-fec5-46f3-9ae9-d24c1ab4882b" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"/>
<link:calculationLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ed743544-c571-4cdf-9c27-7390ee56c80e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c018d238-917d-42cd-a7e8-c833100ee47d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ed743544-c571-4cdf-9c27-7390ee56c80e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c018d238-917d-42cd-a7e8-c833100ee47d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_991fb8aa-c6af-4a9c-bdea-6881674fa525" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ed743544-c571-4cdf-9c27-7390ee56c80e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_991fb8aa-c6af-4a9c-bdea-6881674fa525" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f3376097-5f84-46dc-a480-fbb4f3337b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ed743544-c571-4cdf-9c27-7390ee56c80e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f3376097-5f84-46dc-a480-fbb4f3337b0e" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_743c6f44-206a-4fc4-8908-93c0c39fa0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ed743544-c571-4cdf-9c27-7390ee56c80e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_743c6f44-206a-4fc4-8908-93c0c39fa0e5" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_5914be44-1095-4c76-8bfa-e5d8da1a13c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ed743544-c571-4cdf-9c27-7390ee56c80e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_5914be44-1095-4c76-8bfa-e5d8da1a13c8" xlink:type="arc"/>
</link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>rmti-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3c1f30ef-dd44-4e46-abb9-054971f79e00,g:61350dd9-1066-401d-a0af-504d0c113dc8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="rmti-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="i068d5cf414b54a46a15f26296aa87388_UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_859aa6a4-efc4-4a07-8380-205c91f2dcdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_859aa6a4-efc4-4a07-8380-205c91f2dcdb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c9f3a91a-42f4-4b40-ae56-88a58a7ad611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c9f3a91a-42f4-4b40-ae56-88a58a7ad611" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a0017236-be67-45cd-8e7c-f92f485cf04e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_StockholdersEquity_a0017236-be67-45cd-8e7c-f92f485cf04e" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f711cf73-89da-4ec9-a9e9-a2aa5ef3bf89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_NetIncomeLoss_f711cf73-89da-4ec9-a9e9-a2aa5ef3bf89" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7a9cd190-4271-44f9-b940-d8eb559c0772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7a9cd190-4271-44f9-b940-d8eb559c0772" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8b7dc506-88ce-429d-9ae1-78f285950551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8b7dc506-88ce-429d-9ae1-78f285950551" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_be67ce1f-7764-4f4a-bf4a-9222e09f3c35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_be67ce1f-7764-4f4a-bf4a-9222e09f3c35" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2b457619-0aa4-4e7f-94a1-6c528e567311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2b457619-0aa4-4e7f-94a1-6c528e567311" xlink:type="arc" order="7"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f4fb38d3-6fe9-4cc6-9581-f4bdc1f1d8b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f4fb38d3-6fe9-4cc6-9581-f4bdc1f1d8b9" xlink:type="arc" order="8"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a50c8863-3797-4ccd-9ffb-517fec4d901b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a50c8863-3797-4ccd-9ffb-517fec4d901b" xlink:type="arc" order="9"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense_7f935825-3101-4884-bd12-f082de81e177" xlink:href="rmti-20210630.xsd#rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense_7f935825-3101-4884-bd12-f082de81e177" xlink:type="arc" order="10"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_3f9ad7ca-4bcb-4be5-811b-2bbbfa7b910c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_3f9ad7ca-4bcb-4be5-811b-2bbbfa7b910c" xlink:type="arc" order="11"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a68c26cf-4cb1-483f-a2a1-859cd0f91686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a68c26cf-4cb1-483f-a2a1-859cd0f91686" xlink:type="arc" order="12"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1ea40219-331c-431c-aa14-666c5f473be1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1ea40219-331c-431c-aa14-666c5f473be1" xlink:type="arc" order="13"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a3f0c25a-a54b-4e9b-b274-5f3aa827d653" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0d5e1e26-4e03-42a6-8483-f756bab923dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c8b2df87-c271-48a1-8881-b9e9e52d47a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_859aa6a4-efc4-4a07-8380-205c91f2dcdb" xlink:to="loc_us-gaap_StatementTable_c8b2df87-c271-48a1-8881-b9e9e52d47a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_501cd21c-d7af-4bba-8e89-55b86f57273d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c8b2df87-c271-48a1-8881-b9e9e52d47a4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_501cd21c-d7af-4bba-8e89-55b86f57273d" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_501cd21c-d7af-4bba-8e89-55b86f57273d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_501cd21c-d7af-4bba-8e89-55b86f57273d" xlink:to="loc_us-gaap_EquityComponentDomain_501cd21c-d7af-4bba-8e89-55b86f57273d_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5227b286-e034-46ab-a851-c4d671a2e4d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_501cd21c-d7af-4bba-8e89-55b86f57273d" xlink:to="loc_us-gaap_EquityComponentDomain_5227b286-e034-46ab-a851-c4d671a2e4d6" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7fa94261-1c13-417a-9915-4c9f82a9346f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5227b286-e034-46ab-a851-c4d671a2e4d6" xlink:to="loc_us-gaap_CommonStockMember_7fa94261-1c13-417a-9915-4c9f82a9346f" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2ae763d1-0096-49ea-800e-311706377269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5227b286-e034-46ab-a851-c4d671a2e4d6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2ae763d1-0096-49ea-800e-311706377269" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d56ad182-014b-4b4c-9752-7259d3b2622c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5227b286-e034-46ab-a851-c4d671a2e4d6" xlink:to="loc_us-gaap_RetainedEarningsMember_d56ad182-014b-4b4c-9752-7259d3b2622c" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6cc9f9e-e4f0-4e5e-bb59-f885caf8ec5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5227b286-e034-46ab-a851-c4d671a2e4d6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6cc9f9e-e4f0-4e5e-bb59-f885caf8ec5b" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_83848190-b92a-4f35-b05d-9e21f7d417ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c8b2df87-c271-48a1-8881-b9e9e52d47a4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_83848190-b92a-4f35-b05d-9e21f7d417ad" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_83848190-b92a-4f35-b05d-9e21f7d417ad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_83848190-b92a-4f35-b05d-9e21f7d417ad" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_83848190-b92a-4f35-b05d-9e21f7d417ad_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5db25f01-4fde-4e16-9140-25c149a2df8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_83848190-b92a-4f35-b05d-9e21f7d417ad" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5db25f01-4fde-4e16-9140-25c149a2df8d" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_BoughtDealMember_5f9c59a7-c06a-476e-86c6-395d136835ac" xlink:href="rmti-20210630.xsd#rmti_BoughtDealMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5db25f01-4fde-4e16-9140-25c149a2df8d" xlink:to="loc_rmti_BoughtDealMember_5f9c59a7-c06a-476e-86c6-395d136835ac" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PublicOfferingMember_82aea572-7420-4bb8-b689-d40ac6b83aac" xlink:href="rmti-20210630.xsd#rmti_PublicOfferingMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5db25f01-4fde-4e16-9140-25c149a2df8d" xlink:to="loc_rmti_PublicOfferingMember_82aea572-7420-4bb8-b689-d40ac6b83aac" xlink:type="arc" order="1"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="rmti-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i50fbd4483f774547ad5d97f3e7724faa_UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_31d6483c-319d-4774-81ed-a53a94c0ba45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_31d6483c-319d-4774-81ed-a53a94c0ba45" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b75ed7db-0e60-4372-9247-77224ae13f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_31d6483c-319d-4774-81ed-a53a94c0ba45" xlink:to="loc_us-gaap_NetIncomeLoss_b75ed7db-0e60-4372-9247-77224ae13f8e" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_31d6483c-319d-4774-81ed-a53a94c0ba45" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_bf3c5f23-fc15-4a34-8b6c-88ce16805c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_bf3c5f23-fc15-4a34-8b6c-88ce16805c4f" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0527e997-7335-4cc5-ba21-3675c14ad1cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_ShareBasedCompensation_0527e997-7335-4cc5-ba21-3675c14ad1cc" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_b8b2c381-770a-442b-9225-31343a547e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_b8b2c381-770a-442b-9225-31343a547e74" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReservePeriodCharge_c3769e55-066c-4a2f-bc7a-3ed35ca08a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_InventoryLIFOReservePeriodCharge_c3769e55-066c-4a2f-bc7a-3ed35ca08a38" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_45e2fdb1-87bf-4cdb-8820-25bbe1d2e0d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_45e2fdb1-87bf-4cdb-8820-25bbe1d2e0d3" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_87c2d7f2-72bb-428b-ad9a-57138c54712e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_87c2d7f2-72bb-428b-ad9a-57138c54712e" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_4dc41c47-aad9-4836-93bc-ad8026295fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_4dc41c47-aad9-4836-93bc-ad8026295fdb" xlink:type="arc" order="7"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_fcffb9aa-1af1-441e-8c2d-994a969f65bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_fcffb9aa-1af1-441e-8c2d-994a969f65bb" xlink:type="arc" order="8"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0e1fa9e5-de30-4be6-a653-25db6bd3fc46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0e1fa9e5-de30-4be6-a653-25db6bd3fc46" xlink:type="arc" order="9"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:type="arc" order="10"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_88cb60d7-87a1-45f8-801f-cb94d2ab9950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_88cb60d7-87a1-45f8-801f-cb94d2ab9950" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_299f2784-2a2e-4702-b99c-1f3ab5046a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_299f2784-2a2e-4702-b99c-1f3ab5046a9e" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_87070fa3-d785-4958-8390-a841dc9ace15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_87070fa3-d785-4958-8390-a841dc9ace15" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b655e20a-3fa3-45df-9c4e-588385875548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b655e20a-3fa3-45df-9c4e-588385875548" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_fcbe5332-96f5-43bc-9a47-3b5ff260cbd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_fcbe5332-96f5-43bc-9a47-3b5ff260cbd2" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_IncreaseDecreaseInOperatingLeaseLiability_7fdcf459-dc2c-4b74-8c4d-313bdba90580" xlink:href="rmti-20210630.xsd#rmti_IncreaseDecreaseInOperatingLeaseLiability"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_rmti_IncreaseDecreaseInOperatingLeaseLiability_7fdcf459-dc2c-4b74-8c4d-313bdba90580" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_406ec99c-21cf-4392-a4a8-684cfc018cc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_406ec99c-21cf-4392-a4a8-684cfc018cc9" xlink:type="arc" order="7"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_29c78191-9f6c-4024-b239-ba88b5e3c8a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_29c78191-9f6c-4024-b239-ba88b5e3c8a2" xlink:type="arc" order="8"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_ec886356-0297-4dfd-b5b9-8ca8c386bf10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_ec886356-0297-4dfd-b5b9-8ca8c386bf10" xlink:type="arc" order="9"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_44a8da55-0edd-4b40-bb94-59984c3426b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_31d6483c-319d-4774-81ed-a53a94c0ba45" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_44a8da55-0edd-4b40-bb94-59984c3426b9" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f38c6af6-a658-4ea6-a4b4-8c314ed28b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f38c6af6-a658-4ea6-a4b4-8c314ed28b0e" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_cf96303c-7b9c-4f27-933c-f27b6b568ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f38c6af6-a658-4ea6-a4b4-8c314ed28b0e" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_cf96303c-7b9c-4f27-933c-f27b6b568ab4" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_79a7460a-1754-4106-9002-00b45a78358d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f38c6af6-a658-4ea6-a4b4-8c314ed28b0e" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_79a7460a-1754-4106-9002-00b45a78358d" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_ddc3860d-3a05-469f-9bb1-ca85cdd67bbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f38c6af6-a658-4ea6-a4b4-8c314ed28b0e" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_ddc3860d-3a05-469f-9bb1-ca85cdd67bbc" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a336780e-9ac3-4670-88d9-1492158b315a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f38c6af6-a658-4ea6-a4b4-8c314ed28b0e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a336780e-9ac3-4670-88d9-1492158b315a" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8ca9aeff-c25d-4fbb-a735-3645eb70356d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8ca9aeff-c25d-4fbb-a735-3645eb70356d" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2952d66d-31e6-4e0b-beec-5860ef941b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2952d66d-31e6-4e0b-beec-5860ef941b82" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_2b70d535-5059-4cb8-8f71-c34e87bd8149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_2b70d535-5059-4cb8-8f71-c34e87bd8149" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_266a026a-fb60-424d-9f7b-9352a1022f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_266a026a-fb60-424d-9f7b-9352a1022f84" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b5c3af9a-d188-4840-b23a-68aad641a7e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b5c3af9a-d188-4840-b23a-68aad641a7e4" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_4a9e62d3-08b1-4437-bf2d-20733c1bd19b" xlink:href="rmti-20210630.xsd#rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:to="loc_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_4a9e62d3-08b1-4437-bf2d-20733c1bd19b" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c102cb77-98d2-4672-8a8e-d560e1eca398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c102cb77-98d2-4672-8a8e-d560e1eca398" xlink:type="arc" order="7"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fabb4421-81b5-4cf4-b4ba-3b0844355938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fabb4421-81b5-4cf4-b4ba-3b0844355938" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bcd94911-9d28-40aa-9d8f-4ed6951ccc93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bcd94911-9d28-40aa-9d8f-4ed6951ccc93" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e933a7c5-6ccd-476c-ad61-c196fe086065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5009fa77-59af-4fd9-baa2-12a472c42917" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5009fa77-59af-4fd9-baa2-12a472c42917" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_c2647606-2da6-4267-9727-5c9ddca8bf7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5009fa77-59af-4fd9-baa2-12a472c42917" xlink:to="loc_us-gaap_InterestPaidNet_c2647606-2da6-4267-9727-5c9ddca8bf7a" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_912ae4a7-dfb5-474f-abf1-057fd00371f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_912ae4a7-dfb5-474f-abf1-057fd00371f4" xlink:type="arc" order="7"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_a4c54787-68cb-4a3b-97aa-39d2ed6cda2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_912ae4a7-dfb5-474f-abf1-057fd00371f4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_a4c54787-68cb-4a3b-97aa-39d2ed6cda2c" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_6e4879c4-bbfb-48c9-92aa-1c9aeafc5b6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_912ae4a7-dfb5-474f-abf1-057fd00371f4" xlink:to="loc_us-gaap_StockIssued1_6e4879c4-bbfb-48c9-92aa-1c9aeafc5b6d" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d1929cda-b9c1-4734-83e5-140b829d4a89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:to="loc_us-gaap_StatementTable_d1929cda-b9c1-4734-83e5-140b829d4a89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_639abf3b-b73d-45fd-a104-d30ec488e714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d1929cda-b9c1-4734-83e5-140b829d4a89" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_639abf3b-b73d-45fd-a104-d30ec488e714" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_639abf3b-b73d-45fd-a104-d30ec488e714_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_639abf3b-b73d-45fd-a104-d30ec488e714" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_639abf3b-b73d-45fd-a104-d30ec488e714_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf857065-23b8-474b-930b-8f4880e4895c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_639abf3b-b73d-45fd-a104-d30ec488e714" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf857065-23b8-474b-930b-8f4880e4895c" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PublicOfferingMember_ab1af95f-46b5-4f8f-8d21-5b2bd4cd6a57" xlink:href="rmti-20210630.xsd#rmti_PublicOfferingMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf857065-23b8-474b-930b-8f4880e4895c" xlink:to="loc_rmti_PublicOfferingMember_ab1af95f-46b5-4f8f-8d21-5b2bd4cd6a57" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_AtthemarketOfferingMember_c85ac205-9508-47b4-b2ec-35de3411c703" xlink:href="rmti-20210630.xsd#rmti_AtthemarketOfferingMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf857065-23b8-474b-930b-8f4880e4895c" xlink:to="loc_rmti_AtthemarketOfferingMember_c85ac205-9508-47b4-b2ec-35de3411c703" xlink:type="arc" order="1"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails" xlink:type="extended" id="i9a0275184f144a9fa2d8d945046df3c8_BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_44f55a0d-18cd-4011-9ad3-31f4ac9e5aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1d57f633-e742-4482-a827-c6750c0ebf07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_44f55a0d-18cd-4011-9ad3-31f4ac9e5aa3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1d57f633-e742-4482-a827-c6750c0ebf07" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b579ac49-b679-4c96-b922-5bc68b022f10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_44f55a0d-18cd-4011-9ad3-31f4ac9e5aa3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b579ac49-b679-4c96-b922-5bc68b022f10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_56a4f7b1-e493-4377-847e-5831554d0afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b579ac49-b679-4c96-b922-5bc68b022f10" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_56a4f7b1-e493-4377-847e-5831554d0afe" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_56a4f7b1-e493-4377-847e-5831554d0afe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_56a4f7b1-e493-4377-847e-5831554d0afe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_56a4f7b1-e493-4377-847e-5831554d0afe_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85192a08-4a10-4e58-9ba8-55eeb24b2fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_56a4f7b1-e493-4377-847e-5831554d0afe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85192a08-4a10-4e58-9ba8-55eeb24b2fd6" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d59f9b91-0229-46c6-b5d5-c7b87e031f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85192a08-4a10-4e58-9ba8-55eeb24b2fd6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d59f9b91-0229-46c6-b5d5-c7b87e031f7d" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0768a771-f87b-4054-b176-a5fd792ec1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85192a08-4a10-4e58-9ba8-55eeb24b2fd6" xlink:to="loc_us-gaap_RestrictedStockMember_0768a771-f87b-4054-b176-a5fd792ec1d9" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_baffe867-6d28-4a0e-a5ed-5813433badad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85192a08-4a10-4e58-9ba8-55eeb24b2fd6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_baffe867-6d28-4a0e-a5ed-5813433badad" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_3c628738-bee7-40fa-9a94-1acbaf7eb333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85192a08-4a10-4e58-9ba8-55eeb24b2fd6" xlink:to="loc_us-gaap_WarrantMember_3c628738-bee7-40fa-9a94-1acbaf7eb333" xlink:type="arc" order="3"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended" id="ifd54fe02895e4d9f8af4a76f65200ea8_RevenueRecognitionDisaggregationofRevenueDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7c790e00-d366-49b2-8536-d47026a4462a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c9cfb9da-5bd6-42d8-931f-32b55d2216ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7c790e00-d366-49b2-8536-d47026a4462a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c9cfb9da-5bd6-42d8-931f-32b55d2216ab" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_22ae5c45-d46f-48e3-90b2-3fb9b518b6c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7c790e00-d366-49b2-8536-d47026a4462a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_22ae5c45-d46f-48e3-90b2-3fb9b518b6c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_78c3c1a4-ed5c-4011-aed7-dcb452a7263a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_22ae5c45-d46f-48e3-90b2-3fb9b518b6c1" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_78c3c1a4-ed5c-4011-aed7-dcb452a7263a" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_78c3c1a4-ed5c-4011-aed7-dcb452a7263a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_78c3c1a4-ed5c-4011-aed7-dcb452a7263a" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_78c3c1a4-ed5c-4011-aed7-dcb452a7263a_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_4a29c659-c52b-4949-aa29-371468469620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_78c3c1a4-ed5c-4011-aed7-dcb452a7263a" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_4a29c659-c52b-4949-aa29-371468469620" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_7e25329a-3f9e-4762-be81-a81b1be32dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredAtPointInTimeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_4a29c659-c52b-4949-aa29-371468469620" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_7e25329a-3f9e-4762-be81-a81b1be32dd4" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_b68def1d-647f-4905-a93a-f1c05391219f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_4a29c659-c52b-4949-aa29-371468469620" xlink:to="loc_us-gaap_TransferredOverTimeMember_b68def1d-647f-4905-a93a-f1c05391219f" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_46091c6e-ee58-488e-bb59-d9d84ec512a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_22ae5c45-d46f-48e3-90b2-3fb9b518b6c1" xlink:to="loc_srt_StatementGeographicalAxis_46091c6e-ee58-488e-bb59-d9d84ec512a6" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_46091c6e-ee58-488e-bb59-d9d84ec512a6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_46091c6e-ee58-488e-bb59-d9d84ec512a6" xlink:to="loc_srt_SegmentGeographicalDomain_46091c6e-ee58-488e-bb59-d9d84ec512a6_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1d46aa3b-ef40-449b-b190-12e21023848e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_46091c6e-ee58-488e-bb59-d9d84ec512a6" xlink:to="loc_srt_SegmentGeographicalDomain_1d46aa3b-ef40-449b-b190-12e21023848e" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_country_US_3bec35bd-851e-4e6b-98bb-23d050517400" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1d46aa3b-ef40-449b-b190-12e21023848e" xlink:to="loc_country_US_3bec35bd-851e-4e6b-98bb-23d050517400" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_b7747984-bbfb-4640-b5fa-8995ab183a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1d46aa3b-ef40-449b-b190-12e21023848e" xlink:to="loc_us-gaap_NonUsMember_b7747984-bbfb-4640-b5fa-8995ab183a7e" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2ff91489-ae6b-478a-86dd-2080033e2098" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_22ae5c45-d46f-48e3-90b2-3fb9b518b6c1" xlink:to="loc_srt_ProductOrServiceAxis_2ff91489-ae6b-478a-86dd-2080033e2098" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2ff91489-ae6b-478a-86dd-2080033e2098_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2ff91489-ae6b-478a-86dd-2080033e2098" xlink:to="loc_srt_ProductsAndServicesDomain_2ff91489-ae6b-478a-86dd-2080033e2098_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6f33e8d6-57ef-47dc-bc0a-27b69c0ee71d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2ff91489-ae6b-478a-86dd-2080033e2098" xlink:to="loc_srt_ProductsAndServicesDomain_6f33e8d6-57ef-47dc-bc0a-27b69c0ee71d" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DrugRevenueMember_a35f97b1-f90a-4a9b-b72b-7eec317aa6b1" xlink:href="rmti-20210630.xsd#rmti_DrugRevenueMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6f33e8d6-57ef-47dc-bc0a-27b69c0ee71d" xlink:to="loc_rmti_DrugRevenueMember_a35f97b1-f90a-4a9b-b72b-7eec317aa6b1" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DrugProductSalesMember_7d1d4ca1-e7c0-4150-baf7-305443bd7b96" xlink:href="rmti-20210630.xsd#rmti_DrugProductSalesMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_DrugRevenueMember_a35f97b1-f90a-4a9b-b72b-7eec317aa6b1" xlink:to="loc_rmti_DrugProductSalesMember_7d1d4ca1-e7c0-4150-baf7-305443bd7b96" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DrugLicenseFeeMember_232470a2-ff00-48b2-a391-ad3015099e11" xlink:href="rmti-20210630.xsd#rmti_DrugLicenseFeeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_DrugRevenueMember_a35f97b1-f90a-4a9b-b72b-7eec317aa6b1" xlink:to="loc_rmti_DrugLicenseFeeMember_232470a2-ff00-48b2-a391-ad3015099e11" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductsMember_217f4427-5933-43e4-9572-f4db572db207" xlink:href="rmti-20210630.xsd#rmti_ConcentrateProductsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6f33e8d6-57ef-47dc-bc0a-27b69c0ee71d" xlink:to="loc_rmti_ConcentrateProductsMember_217f4427-5933-43e4-9572-f4db572db207" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductSalesMember_4b5f185f-5479-40ac-96f7-8268fca43297" xlink:href="rmti-20210630.xsd#rmti_ConcentrateProductSalesMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ConcentrateProductsMember_217f4427-5933-43e4-9572-f4db572db207" xlink:to="loc_rmti_ConcentrateProductSalesMember_4b5f185f-5479-40ac-96f7-8268fca43297" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductLicenseFeeMember_4a61d5d6-ea5e-4433-bcfc-b89c91b688f4" xlink:href="rmti-20210630.xsd#rmti_ConcentrateProductLicenseFeeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ConcentrateProductsMember_217f4427-5933-43e4-9572-f4db572db207" xlink:to="loc_rmti_ConcentrateProductLicenseFeeMember_4a61d5d6-ea5e-4433-bcfc-b89c91b688f4" xlink:type="arc" order="2"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#RevenueRecognitionNarrativeDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended" id="i485bde3c2ceb440687b7d0adbea96aa9_RevenueRecognitionNarrativeDetails">
<link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionLineItems_6c0d0093-166c-47f7-8acb-9f42b77b6731" xlink:href="rmti-20210630.xsd#rmti_RevenueRecognitionLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCreditLossExpense_0fb44af7-3a4b-4400-9e5d-d30c4b7882f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetCreditLossExpense"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_RevenueRecognitionLineItems_6c0d0093-166c-47f7-8acb-9f42b77b6731" xlink:to="loc_us-gaap_ContractWithCustomerAssetCreditLossExpense_0fb44af7-3a4b-4400-9e5d-d30c4b7882f9" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_593f3ea0-ceb5-48ad-9269-346df26d035d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_RevenueRecognitionLineItems_6c0d0093-166c-47f7-8acb-9f42b77b6731" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_593f3ea0-ceb5-48ad-9269-346df26d035d" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability_010f1138-2a5e-4fd8-b8c1-cc8e4a04cdbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_RevenueRecognitionLineItems_6c0d0093-166c-47f7-8acb-9f42b77b6731" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiability_010f1138-2a5e-4fd8-b8c1-cc8e4a04cdbe" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_62474c4c-7f23-4d07-91ac-2419eb762df0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_RevenueRecognitionLineItems_6c0d0093-166c-47f7-8acb-9f42b77b6731" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_62474c4c-7f23-4d07-91ac-2419eb762df0" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionTable_dca8378a-2677-47f4-9d6b-708e989be28b" xlink:href="rmti-20210630.xsd#rmti_RevenueRecognitionTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rmti_RevenueRecognitionLineItems_6c0d0093-166c-47f7-8acb-9f42b77b6731" xlink:to="loc_rmti_RevenueRecognitionTable_dca8378a-2677-47f4-9d6b-708e989be28b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b16e2bdb-44bf-4c02-a5f9-42b127e6b9b9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmti_RevenueRecognitionTable_dca8378a-2677-47f4-9d6b-708e989be28b" xlink:to="loc_srt_ProductOrServiceAxis_b16e2bdb-44bf-4c02-a5f9-42b127e6b9b9" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b16e2bdb-44bf-4c02-a5f9-42b127e6b9b9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b16e2bdb-44bf-4c02-a5f9-42b127e6b9b9" xlink:to="loc_srt_ProductsAndServicesDomain_b16e2bdb-44bf-4c02-a5f9-42b127e6b9b9_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9082b3e2-a93d-4699-b6cc-a6c741e31725" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b16e2bdb-44bf-4c02-a5f9-42b127e6b9b9" xlink:to="loc_srt_ProductsAndServicesDomain_9082b3e2-a93d-4699-b6cc-a6c741e31725" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductsMember_4ad6548b-7989-41a8-94ed-7407d38873c8" xlink:href="rmti-20210630.xsd#rmti_ConcentrateProductsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9082b3e2-a93d-4699-b6cc-a6c741e31725" xlink:to="loc_rmti_ConcentrateProductsMember_4ad6548b-7989-41a8-94ed-7407d38873c8" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_26fc3034-6554-4244-946b-9f4674d175ac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmti_RevenueRecognitionTable_dca8378a-2677-47f4-9d6b-708e989be28b" xlink:to="loc_srt_CounterpartyNameAxis_26fc3034-6554-4244-946b-9f4674d175ac" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26fc3034-6554-4244-946b-9f4674d175ac_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_26fc3034-6554-4244-946b-9f4674d175ac" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26fc3034-6554-4244-946b-9f4674d175ac_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5175663-ef13-4bd6-8e88-1f6ae4954a12" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_26fc3034-6554-4244-946b-9f4674d175ac" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5175663-ef13-4bd6-8e88-1f6ae4954a12" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_BaxterHealthcareOrganizationMember_33cad2c9-06f3-410e-bdc3-ef85689b296e" xlink:href="rmti-20210630.xsd#rmti_BaxterHealthcareOrganizationMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5175663-ef13-4bd6-8e88-1f6ae4954a12" xlink:to="loc_rmti_BaxterHealthcareOrganizationMember_33cad2c9-06f3-410e-bdc3-ef85689b296e" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/InventoryDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#InventoryDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/InventoryDetails" xlink:type="extended" id="ia7c57ccfa6d0499793c06395b6e3df74_InventoryDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_d559d24d-c90d-4d9f-998a-af785a29ab5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_39022aa0-3bf2-44e8-9c7c-12eeea0fffb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_d559d24d-c90d-4d9f-998a-af785a29ab5b" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_39022aa0-3bf2-44e8-9c7c-12eeea0fffb9" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6c3950b7-768f-4a44-9b23-d1a359b9346d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_d559d24d-c90d-4d9f-998a-af785a29ab5b" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6c3950b7-768f-4a44-9b23-d1a359b9346d" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_756d1692-e630-4b2b-9283-074f3fc70b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_d559d24d-c90d-4d9f-998a-af785a29ab5b" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_756d1692-e630-4b2b-9283-074f3fc70b91" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_CurrentAndNonCurrentInventory_ac390209-8cdf-4306-87d6-04d91c16d863" xlink:href="rmti-20210630.xsd#rmti_CurrentAndNonCurrentInventory"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_d559d24d-c90d-4d9f-998a-af785a29ab5b" xlink:to="loc_rmti_CurrentAndNonCurrentInventory_ac390209-8cdf-4306-87d6-04d91c16d863" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_82b90c3a-a680-4585-ac9d-232cc80ea53c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_d559d24d-c90d-4d9f-998a-af785a29ab5b" xlink:to="loc_us-gaap_InventoryNoncurrent_82b90c3a-a680-4585-ac9d-232cc80ea53c" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c5524367-3424-451d-aa6d-a5d4cf53d8ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_d559d24d-c90d-4d9f-998a-af785a29ab5b" xlink:to="loc_us-gaap_InventoryNet_c5524367-3424-451d-aa6d-a5d4cf53d8ee" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_8d9233e8-74b4-4fa9-8d33-45a39747ebb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_d559d24d-c90d-4d9f-998a-af785a29ab5b" xlink:to="loc_us-gaap_InventoryCurrentTable_8d9233e8-74b4-4fa9-8d33-45a39747ebb7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_2f26002a-fd8d-4b55-a46a-0b0e78956ec4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_8d9233e8-74b4-4fa9-8d33-45a39747ebb7" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_2f26002a-fd8d-4b55-a46a-0b0e78956ec4" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_2f26002a-fd8d-4b55-a46a-0b0e78956ec4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_2f26002a-fd8d-4b55-a46a-0b0e78956ec4" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_2f26002a-fd8d-4b55-a46a-0b0e78956ec4_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_32244b62-4db5-46f9-b646-0d7ed375eb08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_2f26002a-fd8d-4b55-a46a-0b0e78956ec4" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_32244b62-4db5-46f9-b646-0d7ed375eb08" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericInventoryMember_5408b7f5-9dcf-4420-8f5f-eb005f4193bd" xlink:href="rmti-20210630.xsd#rmti_TrifericInventoryMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_32244b62-4db5-46f9-b646-0d7ed375eb08" xlink:to="loc_rmti_TrifericInventoryMember_5408b7f5-9dcf-4420-8f5f-eb005f4193bd" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericDialysateMember_b47fdf5d-6614-4814-a34e-be2c7be5a140" xlink:href="rmti-20210630.xsd#rmti_TrifericDialysateMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_TrifericInventoryMember_5408b7f5-9dcf-4420-8f5f-eb005f4193bd" xlink:to="loc_rmti_TrifericDialysateMember_b47fdf5d-6614-4814-a34e-be2c7be5a140" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericAPIMember_63b71b28-0677-48c4-a8de-70bdcbdb2137" xlink:href="rmti-20210630.xsd#rmti_TrifericAPIMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_TrifericInventoryMember_5408b7f5-9dcf-4420-8f5f-eb005f4193bd" xlink:to="loc_rmti_TrifericAPIMember_63b71b28-0677-48c4-a8de-70bdcbdb2137" xlink:type="arc" order="2"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#PropertyandEquipmentDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/PropertyandEquipmentDetails" xlink:type="extended" id="ib06cc746e69d48cfbf32ed4926ad5f10_PropertyandEquipmentDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7102d615-7897-4e1b-8e39-818acb4a3483" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4614f194-d097-4070-98f1-b2a694189ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7102d615-7897-4e1b-8e39-818acb4a3483" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4614f194-d097-4070-98f1-b2a694189ab5" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6e5fd10e-92d1-4c54-9549-776ecdc29b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7102d615-7897-4e1b-8e39-818acb4a3483" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6e5fd10e-92d1-4c54-9549-776ecdc29b03" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_397fe339-d9a7-454f-a1a0-fca99a009190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7102d615-7897-4e1b-8e39-818acb4a3483" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_397fe339-d9a7-454f-a1a0-fca99a009190" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1ddae384-a4fd-4a8a-b3d1-265c96342fc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7102d615-7897-4e1b-8e39-818acb4a3483" xlink:to="loc_us-gaap_Depreciation_1ddae384-a4fd-4a8a-b3d1-265c96342fc0" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_00d691d5-fffd-45ff-a448-90cdc133049a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7102d615-7897-4e1b-8e39-818acb4a3483" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_00d691d5-fffd-45ff-a448-90cdc133049a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87bc4957-f64c-45be-886c-7babd6e2cc12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_00d691d5-fffd-45ff-a448-90cdc133049a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87bc4957-f64c-45be-886c-7babd6e2cc12" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_87bc4957-f64c-45be-886c-7babd6e2cc12_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87bc4957-f64c-45be-886c-7babd6e2cc12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_87bc4957-f64c-45be-886c-7babd6e2cc12_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7071bfc-26a8-4c59-bcb6-c26991597054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87bc4957-f64c-45be-886c-7babd6e2cc12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7071bfc-26a8-4c59-bcb6-c26991597054" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7d8e83cc-0a27-4080-83ca-2960fc72c56d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7071bfc-26a8-4c59-bcb6-c26991597054" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7d8e83cc-0a27-4080-83ca-2960fc72c56d" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_6bab802c-e9bf-4127-9ddd-c13352ab398b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7071bfc-26a8-4c59-bcb6-c26991597054" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_6bab802c-e9bf-4127-9ddd-c13352ab398b" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_5f4630f9-0b72-4674-8ba3-a1eb615eeab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7071bfc-26a8-4c59-bcb6-c26991597054" xlink:to="loc_us-gaap_OfficeEquipmentMember_5f4630f9-0b72-4674-8ba3-a1eb615eeab4" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_a48c095b-7540-4872-8d8d-907f94670db5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7071bfc-26a8-4c59-bcb6-c26991597054" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_a48c095b-7540-4872-8d8d-907f94670db5" xlink:type="arc" order="3"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/DeferredRevenueDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#DeferredRevenueDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/DeferredRevenueDetails" xlink:type="extended" id="i87cce8adeb0042e0a1d834f5ebc7e47e_DeferredRevenueDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_7f544706-d31e-4873-aee7-95702f0415b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionReceived_7be583a8-868e-419f-ab19-5b27b1220d6e" xlink:href="rmti-20210630.xsd#rmti_RevenueRecognitionReceived"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_7f544706-d31e-4873-aee7-95702f0415b6" xlink:to="loc_rmti_RevenueRecognitionReceived_7be583a8-868e-419f-ab19-5b27b1220d6e" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_21d1a43f-c420-4aac-8afa-0450d71fcc3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_7f544706-d31e-4873-aee7-95702f0415b6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_21d1a43f-c420-4aac-8afa-0450d71fcc3f" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_077ac896-2bc6-4629-803a-b166d4da2432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_7f544706-d31e-4873-aee7-95702f0415b6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_077ac896-2bc6-4629-803a-b166d4da2432" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee_8192e14b-6dc1-4377-8ff1-66596acb3bdf" xlink:href="rmti-20210630.xsd#rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_7f544706-d31e-4873-aee7-95702f0415b6" xlink:to="loc_rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee_8192e14b-6dc1-4377-8ff1-66596acb3bdf" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_91ba46e2-ef61-463a-9609-42b127e1f221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_7f544706-d31e-4873-aee7-95702f0415b6" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_91ba46e2-ef61-463a-9609-42b127e1f221" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_addf3a06-ad9f-4cde-aeb1-200c518384a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_91ba46e2-ef61-463a-9609-42b127e1f221" xlink:to="loc_srt_CounterpartyNameAxis_addf3a06-ad9f-4cde-aeb1-200c518384a5" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_addf3a06-ad9f-4cde-aeb1-200c518384a5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_addf3a06-ad9f-4cde-aeb1-200c518384a5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_addf3a06-ad9f-4cde-aeb1-200c518384a5_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d2bd514-4ad8-4510-a451-40d9384a0db2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_addf3a06-ad9f-4cde-aeb1-200c518384a5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d2bd514-4ad8-4510-a451-40d9384a0db2" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_BaxterHealthcareOrganizationMember_f3d915bd-f36b-4c56-b530-88910e0bf6ba" xlink:href="rmti-20210630.xsd#rmti_BaxterHealthcareOrganizationMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d2bd514-4ad8-4510-a451-40d9384a0db2" xlink:to="loc_rmti_BaxterHealthcareOrganizationMember_f3d915bd-f36b-4c56-b530-88910e0bf6ba" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_WanbangBiopharmaceuticalMember_e12e2187-d0af-4c5f-892c-6061aa238e20" xlink:href="rmti-20210630.xsd#rmti_WanbangBiopharmaceuticalMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d2bd514-4ad8-4510-a451-40d9384a0db2" xlink:to="loc_rmti_WanbangBiopharmaceuticalMember_e12e2187-d0af-4c5f-892c-6061aa238e20" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_SunPharmaAgreementsMember_4b181628-4f99-44af-8b3b-677218a4af7f" xlink:href="rmti-20210630.xsd#rmti_SunPharmaAgreementsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d2bd514-4ad8-4510-a451-40d9384a0db2" xlink:to="loc_rmti_SunPharmaAgreementsMember_4b181628-4f99-44af-8b3b-677218a4af7f" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_JeilPharmaAgreementsMember_c83b2540-58a5-4a6f-9e65-94475e57ff45" xlink:href="rmti-20210630.xsd#rmti_JeilPharmaAgreementsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d2bd514-4ad8-4510-a451-40d9384a0db2" xlink:to="loc_rmti_JeilPharmaAgreementsMember_c83b2540-58a5-4a6f-9e65-94475e57ff45" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DrogsanAgreementsMember_d4231ecc-34df-4897-9945-0ae2d7e3cf7e" xlink:href="rmti-20210630.xsd#rmti_DrogsanAgreementsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d2bd514-4ad8-4510-a451-40d9384a0db2" xlink:to="loc_rmti_DrogsanAgreementsMember_d4231ecc-34df-4897-9945-0ae2d7e3cf7e" xlink:type="arc" order="4"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockholdersEquityDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/StockholdersEquityDetails" xlink:type="extended" id="i151e4bc920a44d7486df232012ffa4bd_StockholdersEquityDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fe55b49d-0063-49cb-b7f5-dee83a91ae2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fe55b49d-0063-49cb-b7f5-dee83a91ae2c" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_98805acd-f723-4be0-a17d-958463232b51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_98805acd-f723-4be0-a17d-958463232b51" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_cc7f92f2-9d89-47ab-a662-57848a0b25dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_us-gaap_PreferredStockSharesIssued_cc7f92f2-9d89-47ab-a662-57848a0b25dc" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a187038e-fc64-41d8-abcc-812cbf21e848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a187038e-fc64-41d8-abcc-812cbf21e848" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e21d7c23-1df9-471a-8c12-3f2762ddd864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e21d7c23-1df9-471a-8c12-3f2762ddd864" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5b9036c8-ecf0-4877-ac64-8c01a85d05e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5b9036c8-ecf0-4877-ac64-8c01a85d05e4" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0fb24e7e-8f6d-438e-a006-ce46905ecf69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_us-gaap_CommonStockSharesIssued_0fb24e7e-8f6d-438e-a006-ce46905ecf69" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3fec9876-2005-4d16-8fe3-89783c680486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3fec9876-2005-4d16-8fe3-89783c680486" xlink:type="arc" order="7"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_SalesAgreementThresholdSaleOfShares_de317190-47c2-4499-8a4b-eab2c5257595" xlink:href="rmti-20210630.xsd#rmti_SalesAgreementThresholdSaleOfShares"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_rmti_SalesAgreementThresholdSaleOfShares_de317190-47c2-4499-8a4b-eab2c5257595" xlink:type="arc" order="8"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_SaleofStockRemainingSalesAmount_57cb7cca-03bc-4c54-bd72-db2f9ea5a9df" xlink:href="rmti-20210630.xsd#rmti_SaleofStockRemainingSalesAmount"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_rmti_SaleofStockRemainingSalesAmount_57cb7cca-03bc-4c54-bd72-db2f9ea5a9df" xlink:type="arc" order="9"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_63917ec3-9003-4664-b1cb-2ed924943b09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_63917ec3-9003-4664-b1cb-2ed924943b09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ba54da14-3165-457f-91c3-6c20590d9d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_63917ec3-9003-4664-b1cb-2ed924943b09" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ba54da14-3165-457f-91c3-6c20590d9d14" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ba54da14-3165-457f-91c3-6c20590d9d14_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ba54da14-3165-457f-91c3-6c20590d9d14" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ba54da14-3165-457f-91c3-6c20590d9d14_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41425e7c-83a7-4a36-b768-071bbbe74de1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ba54da14-3165-457f-91c3-6c20590d9d14" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41425e7c-83a7-4a36-b768-071bbbe74de1" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_AtthemarketOfferingMember_9bd62bbe-59a3-47e6-8b3a-f0d054e6966e" xlink:href="rmti-20210630.xsd#rmti_AtthemarketOfferingMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41425e7c-83a7-4a36-b768-071bbbe74de1" xlink:to="loc_rmti_AtthemarketOfferingMember_9bd62bbe-59a3-47e6-8b3a-f0d054e6966e" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f7634fac-b9a5-4a9f-bf56-612502a298e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_63917ec3-9003-4664-b1cb-2ed924943b09" xlink:to="loc_srt_RangeAxis_f7634fac-b9a5-4a9f-bf56-612502a298e1" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f7634fac-b9a5-4a9f-bf56-612502a298e1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f7634fac-b9a5-4a9f-bf56-612502a298e1" xlink:to="loc_srt_RangeMember_f7634fac-b9a5-4a9f-bf56-612502a298e1_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_01324e36-07af-49b5-b4a0-4ba8352b6794" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f7634fac-b9a5-4a9f-bf56-612502a298e1" xlink:to="loc_srt_RangeMember_01324e36-07af-49b5-b4a0-4ba8352b6794" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0b18a0c9-c081-489b-8e35-72b8ba28c0d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_01324e36-07af-49b5-b4a0-4ba8352b6794" xlink:to="loc_srt_MaximumMember_0b18a0c9-c081-489b-8e35-72b8ba28c0d9" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockBasedCompensationTables"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationTables" xlink:type="extended" id="i19585e849c70460a88d62a0569a9f0d6_StockBasedCompensationTables">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ddcdb3f4-b25c-4b01-be00-c84ead88a040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e5fd0f36-8190-47e2-b005-56edd9dd44a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ddcdb3f4-b25c-4b01-be00-c84ead88a040" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e5fd0f36-8190-47e2-b005-56edd9dd44a5" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_582712a7-eacc-45bb-ae86-b51cf1cb19a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ddcdb3f4-b25c-4b01-be00-c84ead88a040" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_582712a7-eacc-45bb-ae86-b51cf1cb19a6" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5e088315-b29d-4df7-a37c-6603210acc91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ddcdb3f4-b25c-4b01-be00-c84ead88a040" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5e088315-b29d-4df7-a37c-6603210acc91" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_92f994c5-f7e4-45c3-926b-d76e60ff1130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ddcdb3f4-b25c-4b01-be00-c84ead88a040" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_92f994c5-f7e4-45c3-926b-d76e60ff1130" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_167ee61a-769e-4f39-b53b-c2e4e68618b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ddcdb3f4-b25c-4b01-be00-c84ead88a040" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_167ee61a-769e-4f39-b53b-c2e4e68618b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_45d7d7c4-e66e-4448-88b5-6ecf8e5f7188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_167ee61a-769e-4f39-b53b-c2e4e68618b9" xlink:to="loc_us-gaap_AwardTypeAxis_45d7d7c4-e66e-4448-88b5-6ecf8e5f7188" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45d7d7c4-e66e-4448-88b5-6ecf8e5f7188_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_45d7d7c4-e66e-4448-88b5-6ecf8e5f7188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45d7d7c4-e66e-4448-88b5-6ecf8e5f7188_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e98cf41b-5679-4e7a-9cd1-b77a2c58220d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_45d7d7c4-e66e-4448-88b5-6ecf8e5f7188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e98cf41b-5679-4e7a-9cd1-b77a2c58220d" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_edce009f-2a80-4c01-adec-0b1ade76ff65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e98cf41b-5679-4e7a-9cd1-b77a2c58220d" xlink:to="loc_us-gaap_RestrictedStockMember_edce009f-2a80-4c01-adec-0b1ade76ff65" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedRestrictedStockUnitsMember_b9a6c59d-a502-4f3f-ac89-55a93f1f77ed" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedRestrictedStockUnitsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e98cf41b-5679-4e7a-9cd1-b77a2c58220d" xlink:to="loc_rmti_ServiceBasedRestrictedStockUnitsMember_b9a6c59d-a502-4f3f-ac89-55a93f1f77ed" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_70d879e8-4f22-4547-87de-1df942e4e1e2" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedRestrictedStockUnitsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e98cf41b-5679-4e7a-9cd1-b77a2c58220d" xlink:to="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_70d879e8-4f22-4547-87de-1df942e4e1e2" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_fe2de48a-8a5f-42fa-a86f-d51f58d6ee7a" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e98cf41b-5679-4e7a-9cd1-b77a2c58220d" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_fe2de48a-8a5f-42fa-a86f-d51f58d6ee7a" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedStockOptionAwardsMember_c542ae1e-90ff-4d03-b903-c89f53472a3d" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedStockOptionAwardsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e98cf41b-5679-4e7a-9cd1-b77a2c58220d" xlink:to="loc_rmti_PerformanceBasedStockOptionAwardsMember_c542ae1e-90ff-4d03-b903-c89f53472a3d" xlink:type="arc" order="4"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockBasedCompensationSharebasedcompensationexpenseDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="extended" id="if014b66ecee84f36ba81f50d7ad92d87_StockBasedCompensationSharebasedcompensationexpenseDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa04f988-2852-437a-93e7-d8782c808e53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_549c999a-4831-484f-94b1-0a7d3839b3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa04f988-2852-437a-93e7-d8782c808e53" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_549c999a-4831-484f-94b1-0a7d3839b3de" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76dc8096-b51b-49bd-a582-7d5b33ead255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa04f988-2852-437a-93e7-d8782c808e53" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76dc8096-b51b-49bd-a582-7d5b33ead255" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e00e41f9-3460-4cb4-b883-914e1d3ef256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76dc8096-b51b-49bd-a582-7d5b33ead255" xlink:to="loc_us-gaap_AwardTypeAxis_e00e41f9-3460-4cb4-b883-914e1d3ef256" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e00e41f9-3460-4cb4-b883-914e1d3ef256_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e00e41f9-3460-4cb4-b883-914e1d3ef256" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e00e41f9-3460-4cb4-b883-914e1d3ef256_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_025ed155-1318-4399-8fcf-f68dbdb62512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e00e41f9-3460-4cb4-b883-914e1d3ef256" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_025ed155-1318-4399-8fcf-f68dbdb62512" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedAwardsMember_484a3095-11f2-4935-b0ff-93c903178688" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedAwardsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_025ed155-1318-4399-8fcf-f68dbdb62512" xlink:to="loc_rmti_ServiceBasedAwardsMember_484a3095-11f2-4935-b0ff-93c903178688" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedRestrictedStockUnitsMember_5051e5b8-238a-4b0e-beea-a27f2b6ec86b" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedRestrictedStockUnitsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ServiceBasedAwardsMember_484a3095-11f2-4935-b0ff-93c903178688" xlink:to="loc_rmti_ServiceBasedRestrictedStockUnitsMember_5051e5b8-238a-4b0e-beea-a27f2b6ec86b" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_4d67ef58-83cb-4187-8a8c-608007a01a14" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ServiceBasedAwardsMember_484a3095-11f2-4935-b0ff-93c903178688" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_4d67ef58-83cb-4187-8a8c-608007a01a14" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedAwardsMember_f6725477-b109-43bf-b411-ba62e5245384" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedAwardsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_025ed155-1318-4399-8fcf-f68dbdb62512" xlink:to="loc_rmti_PerformanceBasedAwardsMember_f6725477-b109-43bf-b411-ba62e5245384" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockAwardsMember_025657ce-0401-4179-9310-fa820a29c571" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedRestrictedStockAwardsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_PerformanceBasedAwardsMember_f6725477-b109-43bf-b411-ba62e5245384" xlink:to="loc_rmti_PerformanceBasedRestrictedStockAwardsMember_025657ce-0401-4179-9310-fa820a29c571" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_d677b5dc-694f-4cfc-927b-82322d075b18" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedRestrictedStockUnitsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_PerformanceBasedAwardsMember_f6725477-b109-43bf-b411-ba62e5245384" xlink:to="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_d677b5dc-694f-4cfc-927b-82322d075b18" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedStockOptionAwardsMember_211a01ce-fecc-465b-a5f3-fcd1bcbeebdb" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedStockOptionAwardsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_PerformanceBasedAwardsMember_f6725477-b109-43bf-b411-ba62e5245384" xlink:to="loc_rmti_PerformanceBasedStockOptionAwardsMember_211a01ce-fecc-465b-a5f3-fcd1bcbeebdb" xlink:type="arc" order="3"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockBasedCompensationRestrictedStockAwardsDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails" xlink:type="extended" id="i0ae1caab585a40c2ae0c6341de29438a_StockBasedCompensationRestrictedStockAwardsDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062b7c2-5abb-43c2-800b-79299acd8056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3d48d2db-895a-4d6c-816e-20bcbd15e74e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062b7c2-5abb-43c2-800b-79299acd8056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3d48d2db-895a-4d6c-816e-20bcbd15e74e" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1a709d27-60a2-46e0-bb4f-4dd2384eada2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3d48d2db-895a-4d6c-816e-20bcbd15e74e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1a709d27-60a2-46e0-bb4f-4dd2384eada2" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9b543172-1251-4962-8c7a-dbd9af4daf44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3d48d2db-895a-4d6c-816e-20bcbd15e74e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9b543172-1251-4962-8c7a-dbd9af4daf44" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ed19c03-ec19-40d1-876b-d474a673fd96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a37b9b7f-01a7-49e3-a40c-aeb143af5d55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062b7c2-5abb-43c2-800b-79299acd8056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a37b9b7f-01a7-49e3-a40c-aeb143af5d55" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5ecfff22-843e-44e5-8bf7-e60830e2895e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a37b9b7f-01a7-49e3-a40c-aeb143af5d55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5ecfff22-843e-44e5-8bf7-e60830e2895e" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8f9c42c4-1177-4a76-8ed5-9ed3b54341ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a37b9b7f-01a7-49e3-a40c-aeb143af5d55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8f9c42c4-1177-4a76-8ed5-9ed3b54341ac" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d9e45889-179b-4b35-8c90-da09c702b8c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3a19b6ef-60a6-4541-a493-6aff678d2017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062b7c2-5abb-43c2-800b-79299acd8056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3a19b6ef-60a6-4541-a493-6aff678d2017" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e6776a87-de60-4989-bfd5-257a71798678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ab09c98c-76b3-476a-a4c6-849f9480be97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d3dd5b0c-83bc-42a0-b7e2-cf2c8aee61ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062b7c2-5abb-43c2-800b-79299acd8056" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d3dd5b0c-83bc-42a0-b7e2-cf2c8aee61ed" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cf20e9f9-01a4-4b8e-a720-0377828d0fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062b7c2-5abb-43c2-800b-79299acd8056" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cf20e9f9-01a4-4b8e-a720-0377828d0fb8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9608b52b-d391-409d-af9c-3cef92425d63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cf20e9f9-01a4-4b8e-a720-0377828d0fb8" xlink:to="loc_us-gaap_AwardTypeAxis_9608b52b-d391-409d-af9c-3cef92425d63" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9608b52b-d391-409d-af9c-3cef92425d63_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9608b52b-d391-409d-af9c-3cef92425d63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9608b52b-d391-409d-af9c-3cef92425d63_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5f1254d-5815-49f2-a562-327969a516ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9608b52b-d391-409d-af9c-3cef92425d63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5f1254d-5815-49f2-a562-327969a516ee" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_a5d559c0-0b00-4e06-9774-7c1aba4ac6b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5f1254d-5815-49f2-a562-327969a516ee" xlink:to="loc_us-gaap_RestrictedStockMember_a5d559c0-0b00-4e06-9774-7c1aba4ac6b9" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockAwardsMember_88857869-df30-4652-9c13-91e4bf81b283" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedRestrictedStockAwardsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5f1254d-5815-49f2-a562-327969a516ee" xlink:to="loc_rmti_PerformanceBasedRestrictedStockAwardsMember_88857869-df30-4652-9c13-91e4bf81b283" xlink:type="arc" order="1"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails" xlink:type="extended" id="i1f5f72ff3d934398a146287457b30642_StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_44ed2713-8003-493f-8d3e-1efdace9fe46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_44ed2713-8003-493f-8d3e-1efdace9fe46" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07662673-f221-4997-ba57-4b1e7a575c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_44ed2713-8003-493f-8d3e-1efdace9fe46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07662673-f221-4997-ba57-4b1e7a575c7a" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4020d232-ed46-4953-af40-3a2ee7a49273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_44ed2713-8003-493f-8d3e-1efdace9fe46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4020d232-ed46-4953-af40-3a2ee7a49273" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_70545580-9ec3-4cfc-845e-a39ad0a89a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_44ed2713-8003-493f-8d3e-1efdace9fe46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_70545580-9ec3-4cfc-845e-a39ad0a89a32" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_15930875-d805-4f3e-b0d5-e3147afd0d75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_44ed2713-8003-493f-8d3e-1efdace9fe46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_15930875-d805-4f3e-b0d5-e3147afd0d75" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07f68937-b4bd-4f07-82f2-ac9783a8da7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c257c85f-4674-49fb-96e8-dc7e0ada7d30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c257c85f-4674-49fb-96e8-dc7e0ada7d30" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_82f38998-4d53-4909-81a0-282eda67c373" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c257c85f-4674-49fb-96e8-dc7e0ada7d30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_82f38998-4d53-4909-81a0-282eda67c373" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9bb3d749-51d0-4ef1-99b4-39b96a33258a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c257c85f-4674-49fb-96e8-dc7e0ada7d30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9bb3d749-51d0-4ef1-99b4-39b96a33258a" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_192a0924-e52a-4952-aba4-b76555d511f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c257c85f-4674-49fb-96e8-dc7e0ada7d30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_192a0924-e52a-4952-aba4-b76555d511f2" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9f18fb1b-4f54-4a79-b7e8-e25da4b81626" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c257c85f-4674-49fb-96e8-dc7e0ada7d30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9f18fb1b-4f54-4a79-b7e8-e25da4b81626" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_710e89b7-fecb-4b3f-b215-ee5d1e4db7a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_235664e6-c402-4d00-818e-5e28c341c9db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_235664e6-c402-4d00-818e-5e28c341c9db" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_38f4f150-1ee1-4dde-8b1f-d48ebbb96f62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_38f4f150-1ee1-4dde-8b1f-d48ebbb96f62" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_62a59fb0-51c3-4f3d-8d73-9fcf384ee686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_62a59fb0-51c3-4f3d-8d73-9fcf384ee686" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_291a1aba-1d9a-4a70-93fc-50b027486ecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_291a1aba-1d9a-4a70-93fc-50b027486ecb" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_00645af5-c623-4b11-928a-3e98e0399a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_00645af5-c623-4b11-928a-3e98e0399a3f" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c743e9-e06b-487f-ad4b-aa393e74256a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c743e9-e06b-487f-ad4b-aa393e74256a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_049c6a07-450d-403b-bffd-16421ada1c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c743e9-e06b-487f-ad4b-aa393e74256a" xlink:to="loc_us-gaap_AwardTypeAxis_049c6a07-450d-403b-bffd-16421ada1c24" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_049c6a07-450d-403b-bffd-16421ada1c24_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_049c6a07-450d-403b-bffd-16421ada1c24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_049c6a07-450d-403b-bffd-16421ada1c24_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ca23ef8-18d7-44cc-b146-9e7798844ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_049c6a07-450d-403b-bffd-16421ada1c24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ca23ef8-18d7-44cc-b146-9e7798844ec1" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedRestrictedStockUnitsMember_1da9b02b-3490-46cb-be7d-86b828bb39e5" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedRestrictedStockUnitsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ca23ef8-18d7-44cc-b146-9e7798844ec1" xlink:to="loc_rmti_ServiceBasedRestrictedStockUnitsMember_1da9b02b-3490-46cb-be7d-86b828bb39e5" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_7800fb70-238c-4d58-8bb1-e0a2d0bc3821" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedRestrictedStockUnitsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ca23ef8-18d7-44cc-b146-9e7798844ec1" xlink:to="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_7800fb70-238c-4d58-8bb1-e0a2d0bc3821" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c7f7f83e-f336-4bba-b9be-be2d73294ea2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c743e9-e06b-487f-ad4b-aa393e74256a" xlink:to="loc_srt_RangeAxis_c7f7f83e-f336-4bba-b9be-be2d73294ea2" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c7f7f83e-f336-4bba-b9be-be2d73294ea2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c7f7f83e-f336-4bba-b9be-be2d73294ea2" xlink:to="loc_srt_RangeMember_c7f7f83e-f336-4bba-b9be-be2d73294ea2_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0d0e1bd4-a1f2-4be5-8dc8-2d2dc6e2d69a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c7f7f83e-f336-4bba-b9be-be2d73294ea2" xlink:to="loc_srt_RangeMember_0d0e1bd4-a1f2-4be5-8dc8-2d2dc6e2d69a" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f6bbb54e-6c47-44be-bc57-f62f14716c54" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0d0e1bd4-a1f2-4be5-8dc8-2d2dc6e2d69a" xlink:to="loc_srt_MinimumMember_f6bbb54e-6c47-44be-bc57-f62f14716c54" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e879ea84-0d89-4c8b-ba04-a901694a97bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0d0e1bd4-a1f2-4be5-8dc8-2d2dc6e2d69a" xlink:to="loc_srt_MaximumMember_e879ea84-0d89-4c8b-ba04-a901694a97bf" xlink:type="arc" order="1"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" xlink:type="extended" id="i9af9513873e34d36897d1fd3145199f7_StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e52d2795-7136-4ef7-aeb5-b90c0d9ded4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_6bc00e0f-d5a3-408a-a730-32ff40e12a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e52d2795-7136-4ef7-aeb5-b90c0d9ded4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_6bc00e0f-d5a3-408a-a730-32ff40e12a8a" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_e64f3c75-e309-47b2-b7bd-0c7558cd2e37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e52d2795-7136-4ef7-aeb5-b90c0d9ded4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_e64f3c75-e309-47b2-b7bd-0c7558cd2e37" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_56cb1da7-7b4f-4205-9b22-58dbf9b0bf28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e52d2795-7136-4ef7-aeb5-b90c0d9ded4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_56cb1da7-7b4f-4205-9b22-58dbf9b0bf28" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6693c314-3a89-42bf-94f6-62da7805979e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e52d2795-7136-4ef7-aeb5-b90c0d9ded4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6693c314-3a89-42bf-94f6-62da7805979e" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a59a74d2-7369-4647-b232-20dd0298274f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e52d2795-7136-4ef7-aeb5-b90c0d9ded4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a59a74d2-7369-4647-b232-20dd0298274f" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f9476197-c573-41a1-b715-6b61c79cbb1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e52d2795-7136-4ef7-aeb5-b90c0d9ded4a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f9476197-c573-41a1-b715-6b61c79cbb1d" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebf51465-c9c9-49d1-afac-d6c8d36a3478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e52d2795-7136-4ef7-aeb5-b90c0d9ded4a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebf51465-c9c9-49d1-afac-d6c8d36a3478" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_45300136-3612-4103-a7ee-4f3a6f795101" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebf51465-c9c9-49d1-afac-d6c8d36a3478" xlink:to="loc_srt_RangeAxis_45300136-3612-4103-a7ee-4f3a6f795101" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45300136-3612-4103-a7ee-4f3a6f795101_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_45300136-3612-4103-a7ee-4f3a6f795101" xlink:to="loc_srt_RangeMember_45300136-3612-4103-a7ee-4f3a6f795101_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4baaa31b-8d80-4d56-87d6-c6add614d66a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_45300136-3612-4103-a7ee-4f3a6f795101" xlink:to="loc_srt_RangeMember_4baaa31b-8d80-4d56-87d6-c6add614d66a" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5d693cdb-17cf-4c41-9e86-63f2b3b96fc9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4baaa31b-8d80-4d56-87d6-c6add614d66a" xlink:to="loc_srt_MinimumMember_5d693cdb-17cf-4c41-9e86-63f2b3b96fc9" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6698e1c3-d48f-4de0-97bb-45e25070b102" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4baaa31b-8d80-4d56-87d6-c6add614d66a" xlink:to="loc_srt_MaximumMember_6698e1c3-d48f-4de0-97bb-45e25070b102" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b6b6a24c-b460-4290-91c0-a7ef712ed3ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebf51465-c9c9-49d1-afac-d6c8d36a3478" xlink:to="loc_us-gaap_AwardTypeAxis_b6b6a24c-b460-4290-91c0-a7ef712ed3ee" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6b6a24c-b460-4290-91c0-a7ef712ed3ee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b6b6a24c-b460-4290-91c0-a7ef712ed3ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6b6a24c-b460-4290-91c0-a7ef712ed3ee_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_432f81bd-4198-47f1-83ee-841254fb0c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b6b6a24c-b460-4290-91c0-a7ef712ed3ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_432f81bd-4198-47f1-83ee-841254fb0c54" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_ae7755b5-cdca-40a1-b96c-faa10fe8c78d" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_432f81bd-4198-47f1-83ee-841254fb0c54" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_ae7755b5-cdca-40a1-b96c-faa10fe8c78d" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockBasedCompensationServiceBasedStockOptionsDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" xlink:type="extended" id="ia7553902ae2040d28ba751cafff4d4b2_StockBasedCompensationServiceBasedStockOptionsDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47fbff20-f366-4ef6-8a7d-dd2f5c2a0642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d107b45d-92fe-4791-8f16-90657fcb969c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47fbff20-f366-4ef6-8a7d-dd2f5c2a0642" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d107b45d-92fe-4791-8f16-90657fcb969c" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_322bfcc9-1781-4387-9878-84a355152a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d107b45d-92fe-4791-8f16-90657fcb969c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_322bfcc9-1781-4387-9878-84a355152a5c" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e7178cfe-e89b-4bcb-8103-2257dc9858bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d107b45d-92fe-4791-8f16-90657fcb969c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e7178cfe-e89b-4bcb-8103-2257dc9858bf" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d7070df4-3130-4de8-8247-c7a4c1c68f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d107b45d-92fe-4791-8f16-90657fcb969c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d7070df4-3130-4de8-8247-c7a4c1c68f8d" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0538b26c-f0f5-444e-b56b-07cdc72f98f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d107b45d-92fe-4791-8f16-90657fcb969c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0538b26c-f0f5-444e-b56b-07cdc72f98f7" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ccf06f4b-c252-4065-8201-ce7f565329f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9604f2f5-73bd-4173-9785-a115b2c480fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d107b45d-92fe-4791-8f16-90657fcb969c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9604f2f5-73bd-4173-9785-a115b2c480fc" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2ce9994-d8eb-410c-a6f3-c1f342be6f30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47fbff20-f366-4ef6-8a7d-dd2f5c2a0642" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2ce9994-d8eb-410c-a6f3-c1f342be6f30" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9603aba8-3263-4352-9346-28cea1b4320e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2ce9994-d8eb-410c-a6f3-c1f342be6f30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9603aba8-3263-4352-9346-28cea1b4320e" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_822e67a8-e6ed-44ec-9b17-0ed05444cd8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2ce9994-d8eb-410c-a6f3-c1f342be6f30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_822e67a8-e6ed-44ec-9b17-0ed05444cd8e" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0160975c-564b-4846-8866-d959fa0cd771" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2ce9994-d8eb-410c-a6f3-c1f342be6f30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0160975c-564b-4846-8866-d959fa0cd771" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1c599cf4-80b4-4f59-af15-75f10e259e31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2ce9994-d8eb-410c-a6f3-c1f342be6f30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1c599cf4-80b4-4f59-af15-75f10e259e31" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_645edfd6-be73-4575-a4d4-40948e154f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_eb6d76bc-a979-4498-b25c-b69d2e6718e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2ce9994-d8eb-410c-a6f3-c1f342be6f30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_eb6d76bc-a979-4498-b25c-b69d2e6718e5" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_45315450-7e6d-47e9-9fdd-215918de5de2" xlink:href="rmti-20210630.xsd#rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47fbff20-f366-4ef6-8a7d-dd2f5c2a0642" xlink:to="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_45315450-7e6d-47e9-9fdd-215918de5de2" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4efe4c19-b1d9-4b81-9ef6-fb64fd51fa1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_45315450-7e6d-47e9-9fdd-215918de5de2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4efe4c19-b1d9-4b81-9ef6-fb64fd51fa1c" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_1eb2f758-5302-44b1-917f-1d0f7cdbdd65" xlink:href="rmti-20210630.xsd#rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_45315450-7e6d-47e9-9fdd-215918de5de2" xlink:to="loc_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_1eb2f758-5302-44b1-917f-1d0f7cdbdd65" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_67a03141-4396-4971-bc8a-f858234226a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_45315450-7e6d-47e9-9fdd-215918de5de2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_67a03141-4396-4971-bc8a-f858234226a9" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_aadfc09e-3ff0-4a10-affb-ba51c2b25657" xlink:href="rmti-20210630.xsd#rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47fbff20-f366-4ef6-8a7d-dd2f5c2a0642" xlink:to="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_aadfc09e-3ff0-4a10-affb-ba51c2b25657" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8d0dd5b8-b91f-4060-a50f-bd467c8e2da9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_aadfc09e-3ff0-4a10-affb-ba51c2b25657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8d0dd5b8-b91f-4060-a50f-bd467c8e2da9" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d999ed73-b76e-417a-9fa6-4b60da575ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_aadfc09e-3ff0-4a10-affb-ba51c2b25657" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d999ed73-b76e-417a-9fa6-4b60da575ae3" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_61c702df-b00e-4633-8efa-d9167465da6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47fbff20-f366-4ef6-8a7d-dd2f5c2a0642" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_61c702df-b00e-4633-8efa-d9167465da6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_16753971-f2f3-49a6-b934-ca40ab1699b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_61c702df-b00e-4633-8efa-d9167465da6a" xlink:to="loc_us-gaap_AwardTypeAxis_16753971-f2f3-49a6-b934-ca40ab1699b4" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16753971-f2f3-49a6-b934-ca40ab1699b4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_16753971-f2f3-49a6-b934-ca40ab1699b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16753971-f2f3-49a6-b934-ca40ab1699b4_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea689cf9-eafb-44e2-8c79-de2f609b90a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_16753971-f2f3-49a6-b934-ca40ab1699b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea689cf9-eafb-44e2-8c79-de2f609b90a2" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_4f7781d1-6bba-4255-a1a9-013cc8c2995b" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea689cf9-eafb-44e2-8c79-de2f609b90a2" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_4f7781d1-6bba-4255-a1a9-013cc8c2995b" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockBasedCompensationServiceBasedStockOptionsOthersDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" xlink:type="extended" id="i30f7679bd31a4253ae6cf35a7ab8c020_StockBasedCompensationServiceBasedStockOptionsOthersDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44543a1b-258b-4d3f-a241-1b9771f153d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_25cd2a1a-a93d-4149-818c-67642061cfec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44543a1b-258b-4d3f-a241-1b9771f153d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_25cd2a1a-a93d-4149-818c-67642061cfec" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0a7c48e1-e1ea-4ca6-b513-9eaf44b7a72a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44543a1b-258b-4d3f-a241-1b9771f153d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0a7c48e1-e1ea-4ca6-b513-9eaf44b7a72a" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b2a2dcd2-8690-444a-a8f6-cd97706213e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44543a1b-258b-4d3f-a241-1b9771f153d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b2a2dcd2-8690-444a-a8f6-cd97706213e4" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_584610ea-608b-4b83-a00f-988e108da5e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44543a1b-258b-4d3f-a241-1b9771f153d4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_584610ea-608b-4b83-a00f-988e108da5e8" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_63c137c9-a939-4261-b86d-9786870e9e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44543a1b-258b-4d3f-a241-1b9771f153d4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_63c137c9-a939-4261-b86d-9786870e9e4e" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9447902e-989e-478f-a498-1e93b1064323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44543a1b-258b-4d3f-a241-1b9771f153d4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9447902e-989e-478f-a498-1e93b1064323" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce312300-47d0-4644-a698-e82134907f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44543a1b-258b-4d3f-a241-1b9771f153d4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce312300-47d0-4644-a698-e82134907f8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_73dc7268-07a9-4606-aeed-2ad1e7d3bc63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce312300-47d0-4644-a698-e82134907f8e" xlink:to="loc_us-gaap_AwardTypeAxis_73dc7268-07a9-4606-aeed-2ad1e7d3bc63" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73dc7268-07a9-4606-aeed-2ad1e7d3bc63_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_73dc7268-07a9-4606-aeed-2ad1e7d3bc63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73dc7268-07a9-4606-aeed-2ad1e7d3bc63_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbb08cd0-28eb-43c4-b928-496d02bbf0d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_73dc7268-07a9-4606-aeed-2ad1e7d3bc63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbb08cd0-28eb-43c4-b928-496d02bbf0d2" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_92c359d8-d396-4163-b119-bc5df39e77fc" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbb08cd0-28eb-43c4-b928-496d02bbf0d2" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_92c359d8-d396-4163-b119-bc5df39e77fc" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockBasedCompensationPerformanceBasedStockOptionsDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails" xlink:type="extended" id="i98f960a2da904b169171495152cfb87b_StockBasedCompensationPerformanceBasedStockOptionsDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58c3cdc2-e6d8-4214-9ae4-d7f4d498f11c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e8b54a7-2d3f-43e9-9095-f2ac96ef8404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58c3cdc2-e6d8-4214-9ae4-d7f4d498f11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e8b54a7-2d3f-43e9-9095-f2ac96ef8404" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_05e87b6f-677f-4472-b421-00edd8d905a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e8b54a7-2d3f-43e9-9095-f2ac96ef8404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_05e87b6f-677f-4472-b421-00edd8d905a6" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bd9b162d-c0e8-41df-9fae-849b9113f4d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e8b54a7-2d3f-43e9-9095-f2ac96ef8404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bd9b162d-c0e8-41df-9fae-849b9113f4d3" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e5e35dba-b033-43e3-a46c-b8c7c24a1c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e8b54a7-2d3f-43e9-9095-f2ac96ef8404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e5e35dba-b033-43e3-a46c-b8c7c24a1c8f" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_283ca674-a6c3-4990-bcfa-9aefccfccb0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e8b54a7-2d3f-43e9-9095-f2ac96ef8404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_283ca674-a6c3-4990-bcfa-9aefccfccb0d" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6e472e68-7b7d-4fc1-932c-f3000d1ebf21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8e11969b-fd07-4a22-9341-a66b1e997acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e8b54a7-2d3f-43e9-9095-f2ac96ef8404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8e11969b-fd07-4a22-9341-a66b1e997acf" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f57cbb8-ea68-4032-90c6-b47d8398adbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58c3cdc2-e6d8-4214-9ae4-d7f4d498f11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f57cbb8-ea68-4032-90c6-b47d8398adbb" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96bbb65b-954d-480a-b8d9-636894d596b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f57cbb8-ea68-4032-90c6-b47d8398adbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96bbb65b-954d-480a-b8d9-636894d596b3" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d4fd7ed0-bbcc-46e3-9998-a54cf948c688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f57cbb8-ea68-4032-90c6-b47d8398adbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d4fd7ed0-bbcc-46e3-9998-a54cf948c688" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_54a4324b-3e3b-4374-8352-a736b08aa111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f57cbb8-ea68-4032-90c6-b47d8398adbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_54a4324b-3e3b-4374-8352-a736b08aa111" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ef3ac2d0-0314-47d7-a536-67614cbbb1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f57cbb8-ea68-4032-90c6-b47d8398adbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ef3ac2d0-0314-47d7-a536-67614cbbb1f5" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_822f5807-deb2-4791-bb0e-8fef96a7db37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9047bc8d-16f2-4080-8565-94d17f8d0db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f57cbb8-ea68-4032-90c6-b47d8398adbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9047bc8d-16f2-4080-8565-94d17f8d0db7" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_acda6700-ce6c-4547-bc8e-3dcebf1ebd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58c3cdc2-e6d8-4214-9ae4-d7f4d498f11c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_acda6700-ce6c-4547-bc8e-3dcebf1ebd8b" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2403973b-8502-49e5-af98-7556cb3e4aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58c3cdc2-e6d8-4214-9ae4-d7f4d498f11c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2403973b-8502-49e5-af98-7556cb3e4aa9" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e59a259-7109-4fad-b2d4-60eacbed3a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58c3cdc2-e6d8-4214-9ae4-d7f4d498f11c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e59a259-7109-4fad-b2d4-60eacbed3a62" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0273e18d-85fa-4a21-bd77-40ae4751c4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e59a259-7109-4fad-b2d4-60eacbed3a62" xlink:to="loc_us-gaap_AwardTypeAxis_0273e18d-85fa-4a21-bd77-40ae4751c4d1" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0273e18d-85fa-4a21-bd77-40ae4751c4d1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0273e18d-85fa-4a21-bd77-40ae4751c4d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0273e18d-85fa-4a21-bd77-40ae4751c4d1_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e2e12fe-72a3-4d0e-858f-f8bec40be3c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0273e18d-85fa-4a21-bd77-40ae4751c4d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e2e12fe-72a3-4d0e-858f-f8bec40be3c8" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedStockOptionAwardsMember_dc5080fe-caee-49fe-bbdd-58a0dc7fbcea" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedStockOptionAwardsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e2e12fe-72a3-4d0e-858f-f8bec40be3c8" xlink:to="loc_rmti_PerformanceBasedStockOptionAwardsMember_dc5080fe-caee-49fe-bbdd-58a0dc7fbcea" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LicensingAgreementsDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#LicensingAgreementsDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/LicensingAgreementsDetails" xlink:type="extended" id="ibf4f4a0ae1d849d2aa3a013964bced32_LicensingAgreementsDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fd9ddfc-5f3b-4dc6-b98b-9959082f7f38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_NumberOfAdditionalAgreements_eb6b5392-8952-4056-9959-b08e110c8e52" xlink:href="rmti-20210630.xsd#rmti_NumberOfAdditionalAgreements"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fd9ddfc-5f3b-4dc6-b98b-9959082f7f38" xlink:to="loc_rmti_NumberOfAdditionalAgreements_eb6b5392-8952-4056-9959-b08e110c8e52" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_cb9d5482-8a06-4324-9d35-17086da0a513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fd9ddfc-5f3b-4dc6-b98b-9959082f7f38" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_cb9d5482-8a06-4324-9d35-17086da0a513" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_CollaborativeArrangementNumberOfInstallmentPayments_099255b2-c400-4184-ae92-922137b8bc12" xlink:href="rmti-20210630.xsd#rmti_CollaborativeArrangementNumberOfInstallmentPayments"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fd9ddfc-5f3b-4dc6-b98b-9959082f7f38" xlink:to="loc_rmti_CollaborativeArrangementNumberOfInstallmentPayments_099255b2-c400-4184-ae92-922137b8bc12" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_InstallmentPaymentToRelatedParties_b395f0b9-72e7-4dd1-ac31-7873a320aad5" xlink:href="rmti-20210630.xsd#rmti_InstallmentPaymentToRelatedParties"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fd9ddfc-5f3b-4dc6-b98b-9959082f7f38" xlink:to="loc_rmti_InstallmentPaymentToRelatedParties_b395f0b9-72e7-4dd1-ac31-7873a320aad5" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses_76a94e74-b00e-4745-b0a2-c2718f3e197d" xlink:href="rmti-20210630.xsd#rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fd9ddfc-5f3b-4dc6-b98b-9959082f7f38" xlink:to="loc_rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses_76a94e74-b00e-4745-b0a2-c2718f3e197d" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees_bb873d92-54bb-4d5c-a2a2-b2cde0184173" xlink:href="rmti-20210630.xsd#rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fd9ddfc-5f3b-4dc6-b98b-9959082f7f38" xlink:to="loc_rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees_bb873d92-54bb-4d5c-a2a2-b2cde0184173" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fb897b2-ae2d-4651-9807-d839c3ac5dc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fd9ddfc-5f3b-4dc6-b98b-9959082f7f38" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fb897b2-ae2d-4651-9807-d839c3ac5dc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_fb88b3a6-7ba2-4ef6-93b2-c7e9518e4343" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fb897b2-ae2d-4651-9807-d839c3ac5dc4" xlink:to="loc_srt_TitleOfIndividualAxis_fb88b3a6-7ba2-4ef6-93b2-c7e9518e4343" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fb88b3a6-7ba2-4ef6-93b2-c7e9518e4343_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_fb88b3a6-7ba2-4ef6-93b2-c7e9518e4343" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fb88b3a6-7ba2-4ef6-93b2-c7e9518e4343_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d668d39e-b48d-4adb-a829-9889655d0c19" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_fb88b3a6-7ba2-4ef6-93b2-c7e9518e4343" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d668d39e-b48d-4adb-a829-9889655d0c19" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember_19cb8d28-5ca4-4a98-bb28-7be19160c91c" xlink:href="rmti-20210630.xsd#rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d668d39e-b48d-4adb-a829-9889655d0c19" xlink:to="loc_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember_19cb8d28-5ca4-4a98-bb28-7be19160c91c" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#LeasesNarrativeDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i7bd456d0c0b54c9e8f45a2779977c96e_LeasesNarrativeDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb6f44b1-fff5-4e55-b969-d99e548a6404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1191159e-f2d9-4ed8-966d-f83025d56d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb6f44b1-fff5-4e55-b969-d99e548a6404" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1191159e-f2d9-4ed8-966d-f83025d56d4d" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_172278b3-bc51-4144-b3b8-fc34b16376f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb6f44b1-fff5-4e55-b969-d99e548a6404" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_172278b3-bc51-4144-b3b8-fc34b16376f9" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseAndFinanceLeaseLiability_817f806e-3028-4925-a9a7-ffeaa494b647" xlink:href="rmti-20210630.xsd#rmti_OperatingLeaseAndFinanceLeaseLiability"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb6f44b1-fff5-4e55-b969-d99e548a6404" xlink:to="loc_rmti_OperatingLeaseAndFinanceLeaseLiability_817f806e-3028-4925-a9a7-ffeaa494b647" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet_56cb866d-914e-4006-b00d-151ece75d545" xlink:href="rmti-20210630.xsd#rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb6f44b1-fff5-4e55-b969-d99e548a6404" xlink:to="loc_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet_56cb866d-914e-4006-b00d-151ece75d545" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c7125683-485b-42bc-b9e9-0783d7f41380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb6f44b1-fff5-4e55-b969-d99e548a6404" xlink:to="loc_us-gaap_OperatingLeaseLiability_c7125683-485b-42bc-b9e9-0783d7f41380" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f1f1e698-edd3-4577-8b8c-6d97a7b5c749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb6f44b1-fff5-4e55-b969-d99e548a6404" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f1f1e698-edd3-4577-8b8c-6d97a7b5c749" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_904d62ec-ef1a-40d5-bacd-45fb58019054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb6f44b1-fff5-4e55-b969-d99e548a6404" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_904d62ec-ef1a-40d5-bacd-45fb58019054" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e7fc44a1-31d1-435f-ad0b-5bcbc29c84d4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_904d62ec-ef1a-40d5-bacd-45fb58019054" xlink:to="loc_srt_RangeAxis_e7fc44a1-31d1-435f-ad0b-5bcbc29c84d4" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e7fc44a1-31d1-435f-ad0b-5bcbc29c84d4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e7fc44a1-31d1-435f-ad0b-5bcbc29c84d4" xlink:to="loc_srt_RangeMember_e7fc44a1-31d1-435f-ad0b-5bcbc29c84d4_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_42877b1c-c8e9-4778-9301-d1fdb0a6d430" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e7fc44a1-31d1-435f-ad0b-5bcbc29c84d4" xlink:to="loc_srt_RangeMember_42877b1c-c8e9-4778-9301-d1fdb0a6d430" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a9a8c6a0-aa02-4611-8537-15f0feb629aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_42877b1c-c8e9-4778-9301-d1fdb0a6d430" xlink:to="loc_srt_MaximumMember_a9a8c6a0-aa02-4611-8537-15f0feb629aa" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f5c3e6c2-c04d-4db3-9e43-e24dcaa956a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_904d62ec-ef1a-40d5-bacd-45fb58019054" xlink:to="loc_srt_StatementGeographicalAxis_f5c3e6c2-c04d-4db3-9e43-e24dcaa956a6" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f5c3e6c2-c04d-4db3-9e43-e24dcaa956a6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f5c3e6c2-c04d-4db3-9e43-e24dcaa956a6" xlink:to="loc_srt_SegmentGeographicalDomain_f5c3e6c2-c04d-4db3-9e43-e24dcaa956a6_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_65f74734-a791-4d32-b0d8-2a37f31b528c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f5c3e6c2-c04d-4db3-9e43-e24dcaa956a6" xlink:to="loc_srt_SegmentGeographicalDomain_65f74734-a791-4d32-b0d8-2a37f31b528c" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_stpr_MI_fc25e5e1-96e2-4da6-904e-d4d4301a19ec" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MI"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_65f74734-a791-4d32-b0d8-2a37f31b528c" xlink:to="loc_stpr_MI_fc25e5e1-96e2-4da6-904e-d4d4301a19ec" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_stpr_TX_d0c8846a-2b31-4a5b-81a7-f1a24802c55f" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TX"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_65f74734-a791-4d32-b0d8-2a37f31b528c" xlink:to="loc_stpr_TX_d0c8846a-2b31-4a5b-81a7-f1a24802c55f" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_stpr_SC_734952dc-0eb4-427e-942c-d3c1d29dd8dc" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_65f74734-a791-4d32-b0d8-2a37f31b528c" xlink:to="loc_stpr_SC_734952dc-0eb4-427e-942c-d3c1d29dd8dc" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_799b91b4-f157-418c-aedd-4818648edb1c" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_65f74734-a791-4d32-b0d8-2a37f31b528c" xlink:to="loc_stpr_NJ_799b91b4-f157-418c-aedd-4818648edb1c" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1c1313eb-b34a-47bd-9ef8-4ca738282f14" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_904d62ec-ef1a-40d5-bacd-45fb58019054" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1c1313eb-b34a-47bd-9ef8-4ca738282f14" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1c1313eb-b34a-47bd-9ef8-4ca738282f14_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1c1313eb-b34a-47bd-9ef8-4ca738282f14" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1c1313eb-b34a-47bd-9ef8-4ca738282f14_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7a761efc-34df-4cfb-8c71-83b09cfc540b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1c1313eb-b34a-47bd-9ef8-4ca738282f14" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7a761efc-34df-4cfb-8c71-83b09cfc540b" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_WixomMichiganPropertyOneMember_f45e1c30-a0bb-495a-9eac-e24171f97493" xlink:href="rmti-20210630.xsd#rmti_WixomMichiganPropertyOneMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7a761efc-34df-4cfb-8c71-83b09cfc540b" xlink:to="loc_rmti_WixomMichiganPropertyOneMember_f45e1c30-a0bb-495a-9eac-e24171f97493" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_WixomMichiganPropertyTwoMember_15f4f1cd-bf3a-49d3-9c7e-f22844b1262a" xlink:href="rmti-20210630.xsd#rmti_WixomMichiganPropertyTwoMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7a761efc-34df-4cfb-8c71-83b09cfc540b" xlink:to="loc_rmti_WixomMichiganPropertyTwoMember_15f4f1cd-bf3a-49d3-9c7e-f22844b1262a" xlink:type="arc" order="1"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#LoansandSecurityAgreementNarrativeDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" xlink:type="extended" id="i993e031dc48941b4b8d3f7501a02347c_LoansandSecurityAgreementNarrativeDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_31c6c5b3-d0a3-474c-9b55-2b36c97a773d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_31c6c5b3-d0a3-474c-9b55-2b36c97a773d" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_cbbbba95-55f0-4504-8f50-9559df3eec44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_cbbbba95-55f0-4504-8f50-9559df3eec44" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_f865dfca-6ccc-4914-88b5-95443fb43447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_f865dfca-6ccc-4914-88b5-95443fb43447" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DebtInstrumentPeriodOfInterestOnlyPayments_bfacd212-72f6-4bda-88b5-ff57952ab3ff" xlink:href="rmti-20210630.xsd#rmti_DebtInstrumentPeriodOfInterestOnlyPayments"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_rmti_DebtInstrumentPeriodOfInterestOnlyPayments_bfacd212-72f6-4bda-88b5-ff57952ab3ff" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ddf6e8a8-b2fc-4fac-8e40-cd95526bc668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ddf6e8a8-b2fc-4fac-8e40-cd95526bc668" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_93e9ee73-c27a-4388-9970-f8eacf9d0022" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_93e9ee73-c27a-4388-9970-f8eacf9d0022" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_881a6e6f-8981-4c4e-868b-a2188c167db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_881a6e6f-8981-4c4e-868b-a2188c167db2" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0ecd36ad-3793-47f1-aba4-dec61a37cff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0ecd36ad-3793-47f1-aba4-dec61a37cff3" xlink:type="arc" order="7"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage_23629201-198e-4afc-88e7-4735218480ff" xlink:href="rmti-20210630.xsd#rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage_23629201-198e-4afc-88e7-4735218480ff" xlink:type="arc" order="8"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_1e617440-12ce-4d32-8926-c256b4545bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_InterestExpenseDebt_1e617440-12ce-4d32-8926-c256b4545bfa" xlink:type="arc" order="9"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded_d65c49dc-7faf-430c-bcd2-1326e7cac450" xlink:href="rmti-20210630.xsd#rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded_d65c49dc-7faf-430c-bcd2-1326e7cac450" xlink:type="arc" order="10"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays_65588532-683d-4005-9e9c-2344eff93e77" xlink:href="rmti-20210630.xsd#rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays_65588532-683d-4005-9e9c-2344eff93e77" xlink:type="arc" order="11"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e0b0a774-2e82-4020-b9b6-c76bac32f9ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e0b0a774-2e82-4020-b9b6-c76bac32f9ee" xlink:type="arc" order="12"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays_798f37e3-9be0-4010-99c8-cf17219fd5c0" xlink:href="rmti-20210630.xsd#rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays_798f37e3-9be0-4010-99c8-cf17219fd5c0" xlink:type="arc" order="13"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a6e90bfd-e0ca-4211-9a3b-05e0a12c8f00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a6e90bfd-e0ca-4211-9a3b-05e0a12c8f00" xlink:type="arc" order="14"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7903b99a-c3bd-4a3f-bc0f-88c5287bb549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7903b99a-c3bd-4a3f-bc0f-88c5287bb549" xlink:type="arc" order="15"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1088663d-3c29-4485-b1ae-6a597a0b2c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_LongTermDebt_1088663d-3c29-4485-b1ae-6a597a0b2c4e" xlink:type="arc" order="16"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_33145733-3655-4274-b22d-1d29c4738bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_33145733-3655-4274-b22d-1d29c4738bcf" xlink:type="arc" order="17"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ab48a38f-2a96-46fc-83e5-a6da86f16c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_DebtInstrumentTable_ab48a38f-2a96-46fc-83e5-a6da86f16c29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a8518050-a44b-4774-b8d7-fd9081b12f2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ab48a38f-2a96-46fc-83e5-a6da86f16c29" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a8518050-a44b-4774-b8d7-fd9081b12f2b" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a8518050-a44b-4774-b8d7-fd9081b12f2b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a8518050-a44b-4774-b8d7-fd9081b12f2b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a8518050-a44b-4774-b8d7-fd9081b12f2b_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_53dc9953-352d-40ea-9284-7f0c149b6a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a8518050-a44b-4774-b8d7-fd9081b12f2b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_53dc9953-352d-40ea-9284-7f0c149b6a27" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_7b12ca24-29e2-4759-a07a-8ccc0c38afca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MediumTermNotesMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_53dc9953-352d-40ea-9284-7f0c149b6a27" xlink:to="loc_us-gaap_MediumTermNotesMember_7b12ca24-29e2-4759-a07a-8ccc0c38afca" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2ecc04bf-1edd-4b08-b5a3-142b283d430b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ab48a38f-2a96-46fc-83e5-a6da86f16c29" xlink:to="loc_us-gaap_DebtInstrumentAxis_2ecc04bf-1edd-4b08-b5a3-142b283d430b" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2ecc04bf-1edd-4b08-b5a3-142b283d430b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2ecc04bf-1edd-4b08-b5a3-142b283d430b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2ecc04bf-1edd-4b08-b5a3-142b283d430b_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_62de41a3-181f-44a4-adc0-38b90771e34a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2ecc04bf-1edd-4b08-b5a3-142b283d430b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_62de41a3-181f-44a4-adc0-38b90771e34a" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanMember_df3f92ed-2321-402e-974d-7365700441ec" xlink:href="rmti-20210630.xsd#rmti_TermLoanMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_62de41a3-181f-44a4-adc0-38b90771e34a" xlink:to="loc_rmti_TermLoanMember_df3f92ed-2321-402e-974d-7365700441ec" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheOneMember_fed471a7-72df-45d1-8ad7-1dd3c82e251a" xlink:href="rmti-20210630.xsd#rmti_TermLoanTrancheOneMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_TermLoanMember_df3f92ed-2321-402e-974d-7365700441ec" xlink:to="loc_rmti_TermLoanTrancheOneMember_fed471a7-72df-45d1-8ad7-1dd3c82e251a" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember_d0633e78-4b1d-43a7-b938-f39504b9771d" xlink:href="rmti-20210630.xsd#rmti_TermLoanTrancheTwoAndTrancheThreeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_TermLoanMember_df3f92ed-2321-402e-974d-7365700441ec" xlink:to="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember_d0633e78-4b1d-43a7-b938-f39504b9771d" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheTwoMember_37666adc-b536-4a92-99bf-aae198573864" xlink:href="rmti-20210630.xsd#rmti_TermLoanTrancheTwoMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember_d0633e78-4b1d-43a7-b938-f39504b9771d" xlink:to="loc_rmti_TermLoanTrancheTwoMember_37666adc-b536-4a92-99bf-aae198573864" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheThreeMember_91846c09-3bc9-45df-9f24-1c37c383e881" xlink:href="rmti-20210630.xsd#rmti_TermLoanTrancheThreeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember_d0633e78-4b1d-43a7-b938-f39504b9771d" xlink:to="loc_rmti_TermLoanTrancheThreeMember_91846c09-3bc9-45df-9f24-1c37c383e881" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f18e5a51-84fa-4d48-ae64-789a463dbcd2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ab48a38f-2a96-46fc-83e5-a6da86f16c29" xlink:to="loc_srt_RangeAxis_f18e5a51-84fa-4d48-ae64-789a463dbcd2" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f18e5a51-84fa-4d48-ae64-789a463dbcd2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f18e5a51-84fa-4d48-ae64-789a463dbcd2" xlink:to="loc_srt_RangeMember_f18e5a51-84fa-4d48-ae64-789a463dbcd2_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_60ce89c9-1788-4b46-936b-a98957dd91b4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f18e5a51-84fa-4d48-ae64-789a463dbcd2" xlink:to="loc_srt_RangeMember_60ce89c9-1788-4b46-936b-a98957dd91b4" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f50bd10b-d7ad-4297-a0c0-78d80998006e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_60ce89c9-1788-4b46-936b-a98957dd91b4" xlink:to="loc_srt_MinimumMember_f50bd10b-d7ad-4297-a0c0-78d80998006e" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_143837e0-d675-482a-8c11-57eb6058d0da" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_60ce89c9-1788-4b46-936b-a98957dd91b4" xlink:to="loc_srt_MaximumMember_143837e0-d675-482a-8c11-57eb6058d0da" xlink:type="arc" order="1"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" xlink:type="extended" id="ic9d35468adb64b45b3b747fc74cad8b0_LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5945e707-be01-466b-bdee-349ea8b018ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_ed0462c9-e621-4e98-b34b-dcac9691452c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5945e707-be01-466b-bdee-349ea8b018ed" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_ed0462c9-e621-4e98-b34b-dcac9691452c" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2b323c87-4463-49e8-a7d5-c01e5c319536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5945e707-be01-466b-bdee-349ea8b018ed" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2b323c87-4463-49e8-a7d5-c01e5c319536" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5af5dd90-4cb4-4193-90b1-cc038cc59550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5945e707-be01-466b-bdee-349ea8b018ed" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5af5dd90-4cb4-4193-90b1-cc038cc59550" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_fbca8774-a714-4ded-afcc-8727e8ac53d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5945e707-be01-466b-bdee-349ea8b018ed" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_fbca8774-a714-4ded-afcc-8727e8ac53d8" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_bd56d6cd-d9f2-495b-88a2-bd75e6494ffb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5945e707-be01-466b-bdee-349ea8b018ed" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_bd56d6cd-d9f2-495b-88a2-bd75e6494ffb" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5c64c459-78a4-4951-b477-6b59c8781291" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5945e707-be01-466b-bdee-349ea8b018ed" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5c64c459-78a4-4951-b477-6b59c8781291" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_95096dcb-93e1-4222-84ed-0d476b7ae957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5945e707-be01-466b-bdee-349ea8b018ed" xlink:to="loc_us-gaap_DebtInstrumentTable_95096dcb-93e1-4222-84ed-0d476b7ae957" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d30da7b6-eed3-4d7b-b218-19e0be1730f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_95096dcb-93e1-4222-84ed-0d476b7ae957" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d30da7b6-eed3-4d7b-b218-19e0be1730f9" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d30da7b6-eed3-4d7b-b218-19e0be1730f9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d30da7b6-eed3-4d7b-b218-19e0be1730f9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d30da7b6-eed3-4d7b-b218-19e0be1730f9_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c1d5893c-e4e4-43bf-8ed3-5e51d8096978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d30da7b6-eed3-4d7b-b218-19e0be1730f9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c1d5893c-e4e4-43bf-8ed3-5e51d8096978" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_265a4a2f-f695-46e1-837f-ece85eb050fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MediumTermNotesMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c1d5893c-e4e4-43bf-8ed3-5e51d8096978" xlink:to="loc_us-gaap_MediumTermNotesMember_265a4a2f-f695-46e1-837f-ece85eb050fc" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f5cc216b-c2dc-4a8b-875f-9d969dadcc75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_95096dcb-93e1-4222-84ed-0d476b7ae957" xlink:to="loc_us-gaap_DebtInstrumentAxis_f5cc216b-c2dc-4a8b-875f-9d969dadcc75" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f5cc216b-c2dc-4a8b-875f-9d969dadcc75_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f5cc216b-c2dc-4a8b-875f-9d969dadcc75" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f5cc216b-c2dc-4a8b-875f-9d969dadcc75_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4e8c4c1d-8343-4fad-a63b-d16482682e64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f5cc216b-c2dc-4a8b-875f-9d969dadcc75" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4e8c4c1d-8343-4fad-a63b-d16482682e64" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanMember_c31600e7-2451-4636-bef3-2ffc82c7b385" xlink:href="rmti-20210630.xsd#rmti_TermLoanMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4e8c4c1d-8343-4fad-a63b-d16482682e64" xlink:to="loc_rmti_TermLoanMember_c31600e7-2451-4636-bef3-2ffc82c7b385" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://rockwellmed.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#SubsequentEventsDetails"/>
<link:definitionLink xlink:role="http://rockwellmed.com/role/SubsequentEventsDetails" xlink:type="extended" id="if949fab952dd449bb1b802a7b5c8e7d5_SubsequentEventsDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_14983732-0496-44d8-9b65-057b46e27d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_63598685-7419-4d01-a446-8ad6151b6c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_14983732-0496-44d8-9b65-057b46e27d5a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_63598685-7419-4d01-a446-8ad6151b6c90" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ec33711c-6ad0-474b-8997-e57f2cc12625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_14983732-0496-44d8-9b65-057b46e27d5a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ec33711c-6ad0-474b-8997-e57f2cc12625" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_8695c2b6-71a7-4681-ab29-90b1b0ceb1e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_14983732-0496-44d8-9b65-057b46e27d5a" xlink:to="loc_us-gaap_DebtInstrumentTerm_8695c2b6-71a7-4681-ab29-90b1b0ceb1e5" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_9fe7e447-ab0e-4339-a6e4-51bdc2945303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_14983732-0496-44d8-9b65-057b46e27d5a" xlink:to="loc_us-gaap_SubsequentEventTable_9fe7e447-ab0e-4339-a6e4-51bdc2945303" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_937fa332-95ad-44c9-bb7b-a191996ee1d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9fe7e447-ab0e-4339-a6e4-51bdc2945303" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_937fa332-95ad-44c9-bb7b-a191996ee1d1" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_937fa332-95ad-44c9-bb7b-a191996ee1d1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_937fa332-95ad-44c9-bb7b-a191996ee1d1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_937fa332-95ad-44c9-bb7b-a191996ee1d1_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d5cb61f3-47f5-4c7e-8cb7-aae267d3b152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_937fa332-95ad-44c9-bb7b-a191996ee1d1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d5cb61f3-47f5-4c7e-8cb7-aae267d3b152" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ee553423-66f0-4153-8c5d-fd9d66db6296" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d5cb61f3-47f5-4c7e-8cb7-aae267d3b152" xlink:to="loc_us-gaap_SubsequentEventMember_ee553423-66f0-4153-8c5d-fd9d66db6296" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_16ad217a-bbbe-4d0b-937b-2e84558638ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9fe7e447-ab0e-4339-a6e4-51bdc2945303" xlink:to="loc_us-gaap_DebtInstrumentAxis_16ad217a-bbbe-4d0b-937b-2e84558638ad" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_16ad217a-bbbe-4d0b-937b-2e84558638ad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_16ad217a-bbbe-4d0b-937b-2e84558638ad" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_16ad217a-bbbe-4d0b-937b-2e84558638ad_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1e7d5e12-57d5-4c1d-a21a-c92b9ae4636e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_16ad217a-bbbe-4d0b-937b-2e84558638ad" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1e7d5e12-57d5-4c1d-a21a-c92b9ae4636e" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_A3925NotePayableMember_87acfd55-5cda-4be0-b421-d60d6a67ae35" xlink:href="rmti-20210630.xsd#rmti_A3925NotePayableMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1e7d5e12-57d5-4c1d-a21a-c92b9ae4636e" xlink:to="loc_rmti_A3925NotePayableMember_87acfd55-5cda-4be0-b421-d60d6a67ae35" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1b120620-ad0a-4990-a20b-7859553b5021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9fe7e447-ab0e-4339-a6e4-51bdc2945303" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1b120620-ad0a-4990-a20b-7859553b5021" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1b120620-ad0a-4990-a20b-7859553b5021_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1b120620-ad0a-4990-a20b-7859553b5021" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1b120620-ad0a-4990-a20b-7859553b5021_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_92702e46-6d93-49ba-82ab-2aabbecf51b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1b120620-ad0a-4990-a20b-7859553b5021" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_92702e46-6d93-49ba-82ab-2aabbecf51b2" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_ba03e86e-5962-4552-a228-288ff46b8ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_92702e46-6d93-49ba-82ab-2aabbecf51b2" xlink:to="loc_us-gaap_NotesPayableToBanksMember_ba03e86e-5962-4552-a228-288ff46b8ada" xlink:type="arc" order="0"/>
</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>rmti-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3c1f30ef-dd44-4e46-abb9-054971f79e00,g:61350dd9-1066-401d-a0af-504d0c113dc8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:label id="lab_us-gaap_AreaOfRealEstateProperty_9fd26b5d-f9be-4f89-995f-c337e1cb310a_verboseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility sqft.</link:label>
<link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2722b859-0871-44e1-8a00-f74e10ec7cda_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_e675910f-bd17-4b86-98ec-56a164158fbb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
<link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Machinery and Equipment [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:to="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_AtthemarketOfferingMember_275f3183-006d-4989-a9ad-0d43744baa08_terseLabel_en-US" xlink:label="lab_rmti_AtthemarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-Market Offering</link:label>
<link:label id="lab_rmti_AtthemarketOfferingMember_label_en-US" xlink:label="lab_rmti_AtthemarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market Offering [Member]</link:label>
<link:label id="lab_rmti_AtthemarketOfferingMember_documentation_en-US" xlink:label="lab_rmti_AtthemarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-market Offering [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_AtthemarketOfferingMember" xlink:href="rmti-20210630.xsd#rmti_AtthemarketOfferingMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_AtthemarketOfferingMember" xlink:to="lab_rmti_AtthemarketOfferingMember" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentType_1823f79e-ab17-4fcf-bcd1-b55cbdae4377_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
<link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
<link:label id="lab_stpr_SC_2a324f7c-0bd2-4171-a5bb-c0753e769ff7_terseLabel_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greer, South Carolina</link:label>
<link:label id="lab_stpr_SC_label_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOUTH CAROLINA</link:label>
<link:loc xlink:type="locator" xlink:label="loc_stpr_SC" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_SC" xlink:to="lab_stpr_SC" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cc6abe98-e6a2-4024-86b9-968496418d57_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_73abaecd-1150-4e0f-8b37-58a00a104208_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other Expense</link:label>
<link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1d6f47e1-32d2-40c5-9714-7c76540b185e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
<link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_640e57bd-8958-4539-b6fe-21aa01867c5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_bc301c67-996c-4eef-9d5b-eac04905a757_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
<link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_DrugProductSalesMember_bd75d012-080c-4a0b-926d-0686fae25564_terseLabel_en-US" xlink:label="lab_rmti_DrugProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug product sales</link:label>
<link:label id="lab_rmti_DrugProductSalesMember_label_en-US" xlink:label="lab_rmti_DrugProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Product Sales [Member]</link:label>
<link:label id="lab_rmti_DrugProductSalesMember_documentation_en-US" xlink:label="lab_rmti_DrugProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Product Sales [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DrugProductSalesMember" xlink:href="rmti-20210630.xsd#rmti_DrugProductSalesMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_DrugProductSalesMember" xlink:to="lab_rmti_DrugProductSalesMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_279e78c4-9526-438d-b157-5b9949c621d9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments - Available-for-Sale</link:label>
<link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_febe3388-952d-43bb-909f-1b545286b2aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_bc010ae8-75e1-4bad-90f9-14d254484a23_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
<link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_srt_RangeMember_2d352af8-3410-4014-88fb-fa1bf9b9dd57_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
<link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bac847a-df41-4fcb-bc8a-152024a7678f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS’ EQUITY</link:label>
<link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_acc350c8-003d-4062-8d44-6b3fd50f5c3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7e439c8-a005-4872-b351-b598a28ff7d1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option awards</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8837591a-bc7a-4cc8-9efc-cb1aaa39de0d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
<link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
<link:label id="lab_dei_SecurityExchangeName_564923b1-4401-45b2-83f3-835f0bda9abe_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
<link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_771fc623-81c8-45d8-8f35-a8c70f0f5d57_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Term Loan</link:label>
<link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingIncomeLoss_bc335854-bfda-455c-b6f7-c72905a6e7ce_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss</link:label>
<link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_ae6579b9-47ae-4687-9ffc-82b10c921a2a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs</link:label>
<link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LiabilitiesCurrent_9ea83e09-caa1-4467-bb39-37fffcab7ac1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current Liabilities</link:label>
<link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_fac4aa98-9dbf-4008-9ef6-a278f7f863fd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Balances</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_TransferredOverTimeMember_85e47e40-7dde-4ae7-8704-b9bb97a3e24d_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee – Over time</link:label>
<link:label id="lab_us-gaap_TransferredOverTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred over Time [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8382b813-09e7-4de6-89b0-c4137216c389_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and Other Current Assets</link:label>
<link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2b48ca0f-86fa-486c-9049-4caf2941522f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at beginning of period (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ca4ebc4e-226c-447f-bba5-379cd8d80fc6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at end of period (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_AveragePaymentTermOfCustomers_5587e532-0771-4757-a9ea-1a6e97c67b88_terseLabel_en-US" xlink:label="lab_rmti_AveragePaymentTermOfCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers average payment term</link:label>
<link:label id="lab_rmti_AveragePaymentTermOfCustomers_label_en-US" xlink:label="lab_rmti_AveragePaymentTermOfCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Payment Term of Customers</link:label>
<link:label id="lab_rmti_AveragePaymentTermOfCustomers_documentation_en-US" xlink:label="lab_rmti_AveragePaymentTermOfCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the average payment term of customers.</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_AveragePaymentTermOfCustomers" xlink:href="rmti-20210630.xsd#rmti_AveragePaymentTermOfCustomers"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_AveragePaymentTermOfCustomers" xlink:to="lab_rmti_AveragePaymentTermOfCustomers" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommitmentsAndContingencies_186869dc-3810-4b82-b722-9aef1edc74d6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (See Note 14)</link:label>
<link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_35472b09-1e6f-4112-91c8-f772d2b82522_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_8dd13b0f-3a8a-4e35-b389-fb0fed7037f6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of Restricted Stock Units Issued, net of taxes withheld</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AssetsAbstract_9f8b58d8-8b45-4351-bb58-a1d5a6135472_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
<link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86201b0f-477e-4aa2-b5ae-ed817869bb58_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_da3a17da-e4fc-48c3-9821-b10f22aa9fe3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccountingPoliciesAbstract_324f2429-7aad-42fc-a75e-6f2bbd579a5c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
<link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityAddressStateOrProvince_9f9a5ae5-130c-42ce-a9f3-ebc6f51e1a80_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
<link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_17742fca-3e04-4d0b-b2d3-b11b061f3665_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7400ec51-75ae-4472-8273-279b37a52295_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_f541bf36-41f1-45b5-b09b-9df24b50185a_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liability - Related Party</link:label>
<link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeasePayments_c3d3c513-43f8-4cb4-9df5-083314e07148_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
<link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccountsPayableCurrent_8890dacc-89ec-4e6f-9383-3f7f282e2107_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
<link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_b604138c-9bc2-46c0-b203-aafad4a05bb0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_62763f37-5773-437f-824c-9980f9c93054_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
<link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_e87acc21-1843-4ca4-aa2f-50664732c087_terseLabel_en-US" xlink:label="lab_rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining future payments</link:label>
<link:label id="lab_rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
<link:label id="lab_rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="rmti-20210630.xsd#rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4e27eb69-b184-45ee-b22c-67335e6d50f2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
<link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_ce1e0fdb-4e25-4bc2-ab74-496d8dfa5c73_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, right of use assets</link:label>
<link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_ccdc8768-2ecf-461e-8c7d-4b8c921fb4c1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional debt discount recognized</link:label>
<link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_6ce3fe2f-9308-48c9-935d-91c8e4c76f37_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
<link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ed5522fe-7435-4875-bb28-48cbf6677b9f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2022</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_f5902f05-0a70-4e89-96ce-1bc59b8b3a79_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2022</link:label>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d1994fd2-5920-49c0-b160-a6a1746f3d68_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_464f6025-aa1a-4e05-9f4e-4c55a84e5a26_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f221ed41-740e-4ace-b4e9-8dde634dfac6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2025</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent_1c97c8cc-f06c-465b-973b-2705476e47a6_terseLabel_en-US" xlink:label="lab_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research & Development Expense</link:label>
<link:label id="lab_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Related Liabilities, Current</link:label>
<link:label id="lab_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:href="rmti-20210630.xsd#rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:to="lab_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays_f8f9ec86-4192-4ba7-ae32-bc480b4fb7a3_terseLabel_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price calculation, period immediately preceding relevant funding, number of trading days</link:label>
<link:label id="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays_label_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Relevant Funding, Trading Days</link:label>
<link:label id="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays_documentation_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Relevant Funding, Trading Days</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" xlink:href="rmti-20210630.xsd#rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" xlink:to="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_WanbangBiopharmaceuticalMember_6ec5a9fe-f0d4-40bb-af4f-6ebf09bfe261_terseLabel_en-US" xlink:label="lab_rmti_WanbangBiopharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wanbang Biopharmaceutical</link:label>
<link:label id="lab_rmti_WanbangBiopharmaceuticalMember_label_en-US" xlink:label="lab_rmti_WanbangBiopharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wanbang Biopharmaceutical [Member]</link:label>
<link:label id="lab_rmti_WanbangBiopharmaceuticalMember_documentation_en-US" xlink:label="lab_rmti_WanbangBiopharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents exclusive licensing and manufacturing supply agreements with Wanbang Biopharmaceutical Co., Ltd. (“Wanbang”) for the rights to commercialize the Triferic and Calcitriol drugs.</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_WanbangBiopharmaceuticalMember" xlink:href="rmti-20210630.xsd#rmti_WanbangBiopharmaceuticalMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_WanbangBiopharmaceuticalMember" xlink:to="lab_rmti_WanbangBiopharmaceuticalMember" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_PerformanceBasedRestrictedStockUnitsMember_9f9bfd10-e69b-43b7-8055-686d59bb96e9_terseLabel_en-US" xlink:label="lab_rmti_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units - performance based awards</link:label>
<link:label id="lab_rmti_PerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_rmti_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Units [Member]</link:label>
<link:label id="lab_rmti_PerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_rmti_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Units [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockUnitsMember" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedRestrictedStockUnitsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_rmti_PerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_CurrentAndNonCurrentInventory_9b2077b8-3443-4a0a-accd-d80cf4449698_totalLabel_en-US" xlink:label="lab_rmti_CurrentAndNonCurrentInventory" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
<link:label id="lab_rmti_CurrentAndNonCurrentInventory_label_en-US" xlink:label="lab_rmti_CurrentAndNonCurrentInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current And Non Current Inventory</link:label>
<link:label id="lab_rmti_CurrentAndNonCurrentInventory_documentation_en-US" xlink:label="lab_rmti_CurrentAndNonCurrentInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of current and non-current inventory.</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_CurrentAndNonCurrentInventory" xlink:href="rmti-20210630.xsd#rmti_CurrentAndNonCurrentInventory"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_CurrentAndNonCurrentInventory" xlink:to="lab_rmti_CurrentAndNonCurrentInventory" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LeaseCost_37958c50-5e1b-45fb-a09e-72f0d30c4741_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total rent expense</link:label>
<link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent_581f187b-339f-4e91-ab75-4868fea7f254_terseLabel_en-US" xlink:label="lab_rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability - Current</link:label>
<link:label id="lab_rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease And Finance Lease, Liability, Current</link:label>
<link:label id="lab_rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease And Finance Lease, Liability, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent" xlink:href="rmti-20210630.xsd#rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent" xlink:to="lab_rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8e379f43-0637-4d5e-a6b6-5bb239ca3117_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_c6f1523b-eedf-4383-81d2-84de0407b576_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, par value (in dollars per share)</link:label>
<link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PaymentsOfFinancingCosts_6a281085-fed9-4709-809d-6386212e3a91_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing costs</link:label>
<link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_PerformanceBasedAwardsMember_47e22bbc-3add-43c7-b238-dcfadcf9b73f_terseLabel_en-US" xlink:label="lab_rmti_PerformanceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance based awards</link:label>
<link:label id="lab_rmti_PerformanceBasedAwardsMember_label_en-US" xlink:label="lab_rmti_PerformanceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Awards [Member]</link:label>
<link:label id="lab_rmti_PerformanceBasedAwardsMember_documentation_en-US" xlink:label="lab_rmti_PerformanceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to performance based awards.</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedAwardsMember" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedAwardsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_PerformanceBasedAwardsMember" xlink:to="lab_rmti_PerformanceBasedAwardsMember" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_TrifericInventoryMember_d6aa81c8-dbef-477e-bf07-08d67b74264e_terseLabel_en-US" xlink:label="lab_rmti_TrifericInventoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic Inventory</link:label>
<link:label id="lab_rmti_TrifericInventoryMember_label_en-US" xlink:label="lab_rmti_TrifericInventoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic Inventory [Member]</link:label>
<link:label id="lab_rmti_TrifericInventoryMember_documentation_en-US" xlink:label="lab_rmti_TrifericInventoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic Inventory [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericInventoryMember" xlink:href="rmti-20210630.xsd#rmti_TrifericInventoryMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_TrifericInventoryMember" xlink:to="lab_rmti_TrifericInventoryMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_1888c87c-b03a-4b87-855c-fa42da815879_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from finance leases</link:label>
<link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_0304ae70-4e37-4c55-b178-e0ae5c4cb36b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in Process</link:label>
<link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_AveragePaymentTermOfDistributors_a51e3540-8d3d-47ae-bfa7-640263595218_terseLabel_en-US" xlink:label="lab_rmti_AveragePaymentTermOfDistributors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributors average payment term</link:label>
<link:label id="lab_rmti_AveragePaymentTermOfDistributors_label_en-US" xlink:label="lab_rmti_AveragePaymentTermOfDistributors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Payment Term of Distributors</link:label>
<link:label id="lab_rmti_AveragePaymentTermOfDistributors_documentation_en-US" xlink:label="lab_rmti_AveragePaymentTermOfDistributors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the average payment term of distributors.</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_AveragePaymentTermOfDistributors" xlink:href="rmti-20210630.xsd#rmti_AveragePaymentTermOfDistributors"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_AveragePaymentTermOfDistributors" xlink:to="lab_rmti_AveragePaymentTermOfDistributors" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InventoryNet_dcc1bfe1-613f-423a-a12b-4df05c94cd4b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
<link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InventoryLineItems_88c9ab84-4560-48db-a1c1-99e6c7248d67_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
<link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_BaxterHealthcareOrganizationMember_4fd97b3d-a35f-425e-a50a-d711fca48403_terseLabel_en-US" xlink:label="lab_rmti_BaxterHealthcareOrganizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxter Healthcare Organization</link:label>
<link:label id="lab_rmti_BaxterHealthcareOrganizationMember_label_en-US" xlink:label="lab_rmti_BaxterHealthcareOrganizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxter Healthcare Organization [Member]</link:label>
<link:label id="lab_rmti_BaxterHealthcareOrganizationMember_documentation_en-US" xlink:label="lab_rmti_BaxterHealthcareOrganizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxter Healthcare Organization [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_BaxterHealthcareOrganizationMember" xlink:href="rmti-20210630.xsd#rmti_BaxterHealthcareOrganizationMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_BaxterHealthcareOrganizationMember" xlink:to="lab_rmti_BaxterHealthcareOrganizationMember" xlink:type="arc" order="1"/>
<link:label id="lab_srt_SegmentGeographicalDomain_5178f4a7-1216-4651-bec0-0f50c54b3d99_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
<link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_ce515198-ac06-4e29-be6c-34483315f5f5_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
<link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementLineItems_1dd2d449-5de7-430f-912d-9b8a8cc79c17_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
<link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ce76f6e5-6bfa-4adc-8c1d-e7669ad7868b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Potentially Dilutive Securities</link:label>
<link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentTerm_6b47d342-02e1-436d-9884-2e3d6ca21da2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period (in months)</link:label>
<link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f22603f-76f3-4ccc-b674-c06f79a28b4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementTable_d4430559-51c9-427e-9bc1-6c18f06fdfd3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
<link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
<link:label id="lab_srt_RangeAxis_92443d05-62aa-4a75-a6b0-d78753afe059_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
<link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_IncreaseDecreaseInOperatingLeaseLiability_bfb8afaf-52dd-4781-a6b0-873a77a96bd0_terseLabel_en-US" xlink:label="lab_rmti_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Lease Liability</link:label>
<link:label id="lab_rmti_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_rmti_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
<link:label id="lab_rmti_IncreaseDecreaseInOperatingLeaseLiability_documentation_en-US" xlink:label="lab_rmti_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="rmti-20210630.xsd#rmti_IncreaseDecreaseInOperatingLeaseLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_rmti_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_ec1ec4ac-d1bf-4166-93ad-4e8a362e05c5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Right of Use Asset</link:label>
<link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_DebtInstrumentPeriodOfInterestOnlyPayments_053979f9-439b-4932-b641-633349d124c5_terseLabel_en-US" xlink:label="lab_rmti_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for which company is entitled to make interest-only payments</link:label>
<link:label id="lab_rmti_DebtInstrumentPeriodOfInterestOnlyPayments_label_en-US" xlink:label="lab_rmti_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Period Of Interest-Only Payments</link:label>
<link:label id="lab_rmti_DebtInstrumentPeriodOfInterestOnlyPayments_documentation_en-US" xlink:label="lab_rmti_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Period Of Interest-Only Payments</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:href="rmti-20210630.xsd#rmti_DebtInstrumentPeriodOfInterestOnlyPayments"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:to="lab_rmti_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PreferredStockSharesIssued_ac748553-800f-451b-bb18-124b9555948e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, shares issued (in shares)</link:label>
<link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8bd402b2-ba08-4d44-be6c-3bd7190708cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility, minimum</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9db84292-2b72-4f44-a30e-f449d6ce8123_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrant (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntitySmallBusiness_ae809447-6ffa-4aae-8eda-0f70d32a2bef_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
<link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_289b7c29-e4a7-4c21-b396-0fd60a6f942d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating</link:label>
<link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_224b2358-d418-44d0-a917-83b0166a5d04_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtDisclosureTextBlock_0270b7ce-9f17-4f57-8e65-760b87ad603c_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans and Security Agreement</link:label>
<link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5bfbe68b-7871-47b8-b401-7ca3dc781b0f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of the period</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_77711aab-0c9d-4d8b-bd65-aa78d8011f38_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the Issuance of Common Stock</link:label>
<link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet_9a4ceb93-57ac-4867-ab54-7eec23d67504_terseLabel_en-US" xlink:label="lab_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Use Assets, net</link:label>
<link:label id="lab_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet_71e9ff02-17a5-4da8-8751-eaa8db8b13db_verboseLabel_en-US" xlink:label="lab_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease and finance lease, right of use assets, net</link:label>
<link:label id="lab_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet_label_en-US" xlink:label="lab_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease And Finance Lease, Right of Use Assets, Net</link:label>
<link:label id="lab_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet_documentation_en-US" xlink:label="lab_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease And Finance Lease, Right of Use Assets, Net</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet" xlink:href="rmti-20210630.xsd#rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet" xlink:to="lab_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet" xlink:type="arc" order="1"/>
<link:label id="lab_dei_AmendmentFlag_e96cffd4-8bcc-4882-8f99-29ec887ea075_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
<link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_SaleofStockRemainingSalesAmount_78b8f7d2-e057-4224-9bab-c9c836eeb508_terseLabel_en-US" xlink:label="lab_rmti_SaleofStockRemainingSalesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amount available for sale</link:label>
<link:label id="lab_rmti_SaleofStockRemainingSalesAmount_label_en-US" xlink:label="lab_rmti_SaleofStockRemainingSalesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Remaining Sales Amount</link:label>
<link:label id="lab_rmti_SaleofStockRemainingSalesAmount_documentation_en-US" xlink:label="lab_rmti_SaleofStockRemainingSalesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Remaining Sales Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_SaleofStockRemainingSalesAmount" xlink:href="rmti-20210630.xsd#rmti_SaleofStockRemainingSalesAmount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_SaleofStockRemainingSalesAmount" xlink:to="lab_rmti_SaleofStockRemainingSalesAmount" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded_389ede28-41ff-4e6a-b0a3-c8ac136cb4ba_terseLabel_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calculation for number of shares of common stock able to be purchased by warrant, percentage of principal amount of relevant term loan funded funded</link:label>
<link:label id="lab_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded_label_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Calculation For Number Of Securities Called By Warrants Or Right, Numerator, Percentage Of Principal Amount Of Debt Instrument Funded</link:label>
<link:label id="lab_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded_documentation_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Calculation For Number Of Securities Called By Warrants Or Right, Numerator, Percentage Of Principal Amount Of Debt Instrument Funded</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" xlink:href="rmti-20210630.xsd#rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" xlink:to="lab_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_c95333b6-0a6b-4f39-9981-a6972f72094a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
<link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_d5bfe280-ce06-426d-ad3f-7240c24bc993_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities</link:label>
<link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_stpr_TX_36dbde94-150c-4047-b44c-98250ed7bea3_terseLabel_en-US" xlink:label="lab_stpr_TX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grapevine, Texas</link:label>
<link:label id="lab_stpr_TX_label_en-US" xlink:label="lab_stpr_TX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TEXAS</link:label>
<link:loc xlink:type="locator" xlink:label="loc_stpr_TX" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TX"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TX" xlink:to="lab_stpr_TX" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b10182f0-8be5-43d3-90fd-010e28fbe5b0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Used In Operating Activities</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_77a6e822-aea6-4b49-935f-7071defe24df_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityCentralIndexKey_ce2a36a8-5077-4d2c-a0eb-d4e386cfaac8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
<link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4c43a785-d188-4c80-9383-c4911f315190_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Available-for-Sale</link:label>
<link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_45c57d8d-3d57-4912-a937-cbe28e71ba79_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
<link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent_e22687a2-ac15-41b1-9a46-54f99ca6228d_terseLabel_en-US" xlink:label="lab_rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability - Long-Term</link:label>
<link:label id="lab_rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease And Finance Lease, Liability, Noncurrent</link:label>
<link:label id="lab_rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent_documentation_en-US" xlink:label="lab_rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease And Finance Lease, Liability, Noncurrent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent" xlink:href="rmti-20210630.xsd#rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent" xlink:to="lab_rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_aa4f3b1c-6ae0-41e4-ba9c-77880eb225f4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Deposits</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Refund Liability, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_WixomMichiganPropertyOneMember_3c037356-9811-48a6-abc3-8a738b35c98c_terseLabel_en-US" xlink:label="lab_rmti_WixomMichiganPropertyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wixom, Michigan Property One</link:label>
<link:label id="lab_rmti_WixomMichiganPropertyOneMember_label_en-US" xlink:label="lab_rmti_WixomMichiganPropertyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wixom, Michigan Property One [Member]</link:label>
<link:label id="lab_rmti_WixomMichiganPropertyOneMember_documentation_en-US" xlink:label="lab_rmti_WixomMichiganPropertyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wixom, Michigan Property One [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_WixomMichiganPropertyOneMember" xlink:href="rmti-20210630.xsd#rmti_WixomMichiganPropertyOneMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_WixomMichiganPropertyOneMember" xlink:to="lab_rmti_WixomMichiganPropertyOneMember" xlink:type="arc" order="1"/>
<link:label id="lab_srt_StatementGeographicalAxis_921ee81c-66ea-4962-80a4-349c1b4344dc_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
<link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SubsequentEventsTextBlock_42aa1643-ff35-4efa-980e-a5054c03db44_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
<link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_8ad52dc8-6586-40dd-8aad-c988768fbc9e_terseLabel_en-US" xlink:label="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
<link:label id="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
<link:label id="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NA</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="rmti-20210630.xsd#rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_TermLoanTrancheThreeMember_f07225e5-7b85-49d6-b4fb-f0f615ddf698_terseLabel_en-US" xlink:label="lab_rmti_TermLoanTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, third tranche</link:label>
<link:label id="lab_rmti_TermLoanTrancheThreeMember_label_en-US" xlink:label="lab_rmti_TermLoanTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche Three [Member]</link:label>
<link:label id="lab_rmti_TermLoanTrancheThreeMember_documentation_en-US" xlink:label="lab_rmti_TermLoanTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche Three [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheThreeMember" xlink:href="rmti-20210630.xsd#rmti_TermLoanTrancheThreeMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_TermLoanTrancheThreeMember" xlink:to="lab_rmti_TermLoanTrancheThreeMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_ceaf0394-5dfb-419f-adb8-ac6ab9a4e7c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Modification Expense</link:label>
<link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_9c0e2ec3-a446-418f-ad9a-2a1083352855_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Modification Expense</link:label>
<link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2c0061ec-9318-4e38-a3ab-2f2642f7d2e7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expenses</link:label>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_44f90d19-c0bf-4294-9627-b564098bee0c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain</link:label>
<link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_dc5dc948-8f27-40fd-94b3-d3867ca36587_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
<link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_d2216e6d-44e1-412a-9975-cd14d6cd2880_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_cc0be799-9a9f-45a9-a3f8-5bfdd2162e49_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net draw down proceeds</link:label>
<link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_RevenueRecognitionReceived_474bc287-4c82-4692-9207-baeb2eba5b0b_terseLabel_en-US" xlink:label="lab_rmti_RevenueRecognitionReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
<link:label id="lab_rmti_RevenueRecognitionReceived_label_en-US" xlink:label="lab_rmti_RevenueRecognitionReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Received</link:label>
<link:label id="lab_rmti_RevenueRecognitionReceived_documentation_en-US" xlink:label="lab_rmti_RevenueRecognitionReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of consideration received during the period for the milestone.</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionReceived" xlink:href="rmti-20210630.xsd#rmti_RevenueRecognitionReceived"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_RevenueRecognitionReceived" xlink:to="lab_rmti_RevenueRecognitionReceived" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7c33c72d-bdea-48cc-b86f-e485f3d7f095_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses_0c8b1885-914c-444d-b5a9-2935acc08558_terseLabel_en-US" xlink:label="lab_rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, accrued reimbursement of legal expenses</link:label>
<link:label id="lab_rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses_label_en-US" xlink:label="lab_rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accrued Reimbursement of Legal Expenses</link:label>
<link:label id="lab_rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses_documentation_en-US" xlink:label="lab_rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of related party transactions accrued reimbursement of legal expenses.</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses" xlink:href="rmti-20210630.xsd#rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses" xlink:to="lab_rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_YearsOfService_0c222b11-b5d2-4483-815c-13dcabb1e411_terseLabel_en-US" xlink:label="lab_rmti_YearsOfService" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Years of service</link:label>
<link:label id="lab_rmti_YearsOfService_label_en-US" xlink:label="lab_rmti_YearsOfService" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Years Of Service</link:label>
<link:label id="lab_rmti_YearsOfService_documentation_en-US" xlink:label="lab_rmti_YearsOfService" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Years Of Service</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_YearsOfService" xlink:href="rmti-20210630.xsd#rmti_YearsOfService"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_YearsOfService" xlink:to="lab_rmti_YearsOfService" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityCommonStockSharesOutstanding_3bbcce26-7c1c-4e22-b11f-b2733783295c_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
<link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_f7d7f6eb-f8ff-4396-b88a-6c8e34bc2fd4_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation expense</link:label>
<link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5e72302c-611f-4537-8613-d3700fb3f559_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2023</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e5135dc5-6b50-4bc3-b46a-e667e8945bac_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_BoughtDealMember_8129c03f-c83c-49a6-8e8f-f9b6e65dc70f_terseLabel_en-US" xlink:label="lab_rmti_BoughtDealMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bought Deal</link:label>
<link:label id="lab_rmti_BoughtDealMember_label_en-US" xlink:label="lab_rmti_BoughtDealMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bought Deal [Member]</link:label>
<link:label id="lab_rmti_BoughtDealMember_documentation_en-US" xlink:label="lab_rmti_BoughtDealMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bought Deal</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_BoughtDealMember" xlink:href="rmti-20210630.xsd#rmti_BoughtDealMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_BoughtDealMember" xlink:to="lab_rmti_BoughtDealMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LeaseCostTableTextBlock_ac2a8dba-1d0e-4ea5-9036-77cff52a71a2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Costs</link:label>
<link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4102fb8c-9855-4de3-8018-1981cd9625de_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2024</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherAssetsNoncurrent_0a1fb1cd-e891-429d-b657-49eff265909e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-Current Assets</link:label>
<link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_03a7b550-df22-42ae-967d-30f7a3a4b32b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2341e4b4-3ce9-4934-afac-e8cd9bf1b424_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of Restricted Stock Units Issued, net of taxes withheld (in shares)</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_TrifericAPIMember_fe6446bf-e388-4306-91fe-e196f9bf4fd5_terseLabel_en-US" xlink:label="lab_rmti_TrifericAPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic API</link:label>
<link:label id="lab_rmti_TrifericAPIMember_label_en-US" xlink:label="lab_rmti_TrifericAPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic API [Member]</link:label>
<link:label id="lab_rmti_TrifericAPIMember_documentation_en-US" xlink:label="lab_rmti_TrifericAPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic API [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericAPIMember" xlink:href="rmti-20210630.xsd#rmti_TrifericAPIMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_TrifericAPIMember" xlink:to="lab_rmti_TrifericAPIMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_a220cff2-d8f3-445f-81d1-6c9d26ce83df_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from finance leases</link:label>
<link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_Assets_0779b168-897a-4f91-9dd2-f5a74ebf5115_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
<link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InterestExpenseDebt_c1db2fc0-102b-46f8-b561-c559b1e355d4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
<link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_87a226c0-fac0-44fe-bafd-757d4eeeef12_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at beginning of period (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b5c95a7b-05fd-452e-aab1-22f869dda519_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at end of period (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5cf56d09-ceab-4867-9c4f-51b0b7a6560a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, number of shares (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
<link:label id="lab_dei_Security12bTitle_4d23ae69-8dd8-47f5-9583-68c6354b3594_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a78200dd-6675-49fa-8353-a8dd6283fc2b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
<link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_2c297351-69ef-4a6c-810e-f119f7b2a3d8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance</link:label>
<link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SubsequentEventTypeAxis_615cc1fa-7584-45eb-a7aa-088c780171dd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
<link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities_9a91d231-3e6b-4c5f-8e7c-6b06abf38a81_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Settlement Payable</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Insurance Liabilities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_169aa3b9-99eb-4088-9106-cb7f42454b68_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_465f0a23-0272-4ae1-8a80-97c0c3c1eae9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
<link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_8f1b1376-cc16-4ae2-8d6f-e8a6d797369b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Maturities</link:label>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InterestExpense_35fb6e04-d736-4846-9c29-265eb512f3aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
<link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_ServiceBasedStockOptionAwardsMember_50b065d9-c588-459c-be08-600c3e024559_terseLabel_en-US" xlink:label="lab_rmti_ServiceBasedStockOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option awards - service based awards</link:label>
<link:label id="lab_rmti_ServiceBasedStockOptionAwardsMember_label_en-US" xlink:label="lab_rmti_ServiceBasedStockOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Stock Option Awards [Member]</link:label>
<link:label id="lab_rmti_ServiceBasedStockOptionAwardsMember_documentation_en-US" xlink:label="lab_rmti_ServiceBasedStockOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">na</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ServiceBasedStockOptionAwardsMember" xlink:to="lab_rmti_ServiceBasedStockOptionAwardsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_a9feb817-29c5-423e-9e9f-59b786b1e23e_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization</link:label>
<link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
<link:label id="lab_srt_ProductOrServiceAxis_434238a5-71f9-4df7-8133-2fd350f006f6_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
<link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_Liabilities_8478c6e5-d86e-45aa-a3ee-2f3c98f11170_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
<link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_ConcentrateProductsMember_452a7832-3ebc-4e58-b4fa-899dfb388f5b_terseLabel_en-US" xlink:label="lab_rmti_ConcentrateProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate Products</link:label>
<link:label id="lab_rmti_ConcentrateProductsMember_label_en-US" xlink:label="lab_rmti_ConcentrateProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate Products [Member]</link:label>
<link:label id="lab_rmti_ConcentrateProductsMember_documentation_en-US" xlink:label="lab_rmti_ConcentrateProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate Products [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductsMember" xlink:href="rmti-20210630.xsd#rmti_ConcentrateProductsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ConcentrateProductsMember" xlink:to="lab_rmti_ConcentrateProductsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_TransferredAtPointInTimeMember_17372214-f4fa-4d34-babe-5b94341de99c_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales – Point-in-time</link:label>
<link:label id="lab_us-gaap_TransferredAtPointInTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred at Point in Time [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredAtPointInTimeMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredAtPointInTimeMember" xlink:to="lab_us-gaap_TransferredAtPointInTimeMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f37ee805-6d0f-4709-b9e2-59f6a380864b_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense, weighted average remaining term (in years) (less than)</link:label>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_90ba8af1-10af-49f5-9df4-65269624e0b5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense, weighted average remaining term (in years)</link:label>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d5e21f7b-8669-4084-9313-72b7233b8c37_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less present value discount</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NonUsMember_aec87b1a-5435-4e97-8006-5e82d90b1820_verboseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
<link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_a3c7dfb9-aaaa-40f9-b1a8-f657a0465c1e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_LiquidityAndFinancialConditionTextBlock_0b1b2648-967e-4a0a-8075-f0361ab75055_terseLabel_en-US" xlink:label="lab_rmti_LiquidityAndFinancialConditionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Capital Resources</link:label>
<link:label id="lab_rmti_LiquidityAndFinancialConditionTextBlock_label_en-US" xlink:label="lab_rmti_LiquidityAndFinancialConditionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity And Financial Condition [Text Block]</link:label>
<link:label id="lab_rmti_LiquidityAndFinancialConditionTextBlock_documentation_en-US" xlink:label="lab_rmti_LiquidityAndFinancialConditionTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure of liquidity position and financial conditions.</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_LiquidityAndFinancialConditionTextBlock" xlink:href="rmti-20210630.xsd#rmti_LiquidityAndFinancialConditionTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_LiquidityAndFinancialConditionTextBlock" xlink:to="lab_rmti_LiquidityAndFinancialConditionTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ba151ddc-a675-46bd-ba6f-9e06f1b86f3b_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized deferred revenue</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37b0b172-6909-456f-ac32-49faa658766f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
<link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseExpense_03641469-932e-4cf4-8119-a05de54f6de5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
<link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInInventories_3ba892fb-8ea6-4b87-8183-1de1a1aa6719_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Inventory</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_SunPharmaAgreementsMember_d16f4465-5b1c-41fe-84b1-5c0d98268a16_terseLabel_en-US" xlink:label="lab_rmti_SunPharmaAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sun Pharma Agreements</link:label>
<link:label id="lab_rmti_SunPharmaAgreementsMember_label_en-US" xlink:label="lab_rmti_SunPharmaAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sun Pharma Agreements [Member]</link:label>
<link:label id="lab_rmti_SunPharmaAgreementsMember_documentation_en-US" xlink:label="lab_rmti_SunPharmaAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sun Pharma Agreements [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_SunPharmaAgreementsMember" xlink:href="rmti-20210630.xsd#rmti_SunPharmaAgreementsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_SunPharmaAgreementsMember" xlink:to="lab_rmti_SunPharmaAgreementsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2af77190-83c0-410e-83b2-6db81a8cb641_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Accounts Payable</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_aa77fa30-dd0e-4321-bbf7-2d83e6795872_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_0b6d8797-7eab-43aa-a073-07526f0ddf15_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw Materials</link:label>
<link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_9ec026bf-37c9-41cc-a662-ad0c51d6ebfe_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
<link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentAxis_fe142c1e-0f26-46c0-badb-1384c765f07e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
<link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_91fa01b1-7fa4-48ad-8c81-e3b16468aa4c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADDITIONAL PAID-IN CAPITAL</link:label>
<link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a0d6b90e-8561-4dec-b16e-09452ba326a1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_03b78151-548a-45d0-a494-49f22be579df_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
<link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ClassOfStockLineItems_15498d81-4155-49d0-82df-cf973629ad30_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
<link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_NumberOfAdditionalAgreements_f7c5a14c-17e3-4603-9444-07c38d09297a_terseLabel_en-US" xlink:label="lab_rmti_NumberOfAdditionalAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional agreements</link:label>
<link:label id="lab_rmti_NumberOfAdditionalAgreements_label_en-US" xlink:label="lab_rmti_NumberOfAdditionalAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional agreements</link:label>
<link:label id="lab_rmti_NumberOfAdditionalAgreements_documentation_en-US" xlink:label="lab_rmti_NumberOfAdditionalAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of additional agreements.</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_NumberOfAdditionalAgreements" xlink:href="rmti-20210630.xsd#rmti_NumberOfAdditionalAgreements"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_NumberOfAdditionalAgreements" xlink:to="lab_rmti_NumberOfAdditionalAgreements" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_acf7edf4-16d5-48eb-ab4e-d9699e521eb7_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Assets and Liabilities</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_CollaborativeArrangementNumberOfInstallmentPayments_32a63f93-f011-472a-81b9-2ab996aacd84_terseLabel_en-US" xlink:label="lab_rmti_CollaborativeArrangementNumberOfInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of quarterly installment payments</link:label>
<link:label id="lab_rmti_CollaborativeArrangementNumberOfInstallmentPayments_label_en-US" xlink:label="lab_rmti_CollaborativeArrangementNumberOfInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Installment Payments</link:label>
<link:label id="lab_rmti_CollaborativeArrangementNumberOfInstallmentPayments_documentation_en-US" xlink:label="lab_rmti_CollaborativeArrangementNumberOfInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Installment Payments</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_CollaborativeArrangementNumberOfInstallmentPayments" xlink:href="rmti-20210630.xsd#rmti_CollaborativeArrangementNumberOfInstallmentPayments"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_CollaborativeArrangementNumberOfInstallmentPayments" xlink:to="lab_rmti_CollaborativeArrangementNumberOfInstallmentPayments" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b578442f-f471-4eb0-8f48-c7d1a66849eb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:</link:label>
<link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinanceLeaseInterestExpense_083506db-0e73-4306-831d-14b966615cf8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease obligations</link:label>
<link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_c304eb5e-d485-4abe-bfdc-78ceb832d6b6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_ServiceBasedRestrictedStockUnitsMember_6ef51925-e80a-4cb8-894d-9c91022bdae1_verboseLabel_en-US" xlink:label="lab_rmti_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units - service based awards</link:label>
<link:label id="lab_rmti_ServiceBasedRestrictedStockUnitsMember_6b06ee91-6114-4933-873d-d7fc935867c5_terseLabel_en-US" xlink:label="lab_rmti_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units - service based awards</link:label>
<link:label id="lab_rmti_ServiceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_rmti_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Restricted Stock Units [Member]</link:label>
<link:label id="lab_rmti_ServiceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_rmti_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">na</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedRestrictedStockUnitsMember" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedRestrictedStockUnitsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ServiceBasedRestrictedStockUnitsMember" xlink:to="lab_rmti_ServiceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_MachineryAndEquipmentMember_d24c47fa-d9d1-4b10-84f4-63df98607ae8_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment</link:label>
<link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherReceivables_16059ff8-1a80-4b9f-bda4-3c9389946f5e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, which are included in "Trade and other receivables"</link:label>
<link:label id="lab_us-gaap_OtherReceivables_label_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivables"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivables" xlink:to="lab_us-gaap_OtherReceivables" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockSharesOutstanding_9deab668-22e3-4193-be5c-c3390284e206_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, shares outstanding (in shares)</link:label>
<link:label id="lab_us-gaap_CommonStockSharesOutstanding_3142d289-5af9-454b-afbd-f9184a6fc455_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
<link:label id="lab_us-gaap_CommonStockSharesOutstanding_f1bab358-3315-4d77-a1ae-202a46c7dbde_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
<link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_VariableLeaseCost_abb2bc73-b76b-44ae-a1ed-c96382784d8f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
<link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_FinanceLeaseExpense_1047a6f8-5a2d-4ba6-88fc-81c5883c3922_totalLabel_en-US" xlink:label="lab_rmti_FinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease expense</link:label>
<link:label id="lab_rmti_FinanceLeaseExpense_label_en-US" xlink:label="lab_rmti_FinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Expense</link:label>
<link:label id="lab_rmti_FinanceLeaseExpense_documentation_en-US" xlink:label="lab_rmti_FinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_FinanceLeaseExpense" xlink:href="rmti-20210630.xsd#rmti_FinanceLeaseExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_FinanceLeaseExpense" xlink:to="lab_rmti_FinanceLeaseExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7dc38a91-73a5-4e93-af93-7fd66e740579_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Product Development</link:label>
<link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SubsequentEventMember_2fd1625d-0e3f-466a-8ee7-1b12532f6f16_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
<link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_251c65ca-2348-4fd1-85c1-a3c946459d24_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2b35176c-7e0e-41a7-a4b4-6e1128cafda6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NotesPayableToBanksMember_3e121000-1dcb-4c52-a3e5-72c9af6a902a_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable to Banks</link:label>
<link:label id="lab_us-gaap_NotesPayableToBanksMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable to Banks [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableToBanksMember" xlink:to="lab_us-gaap_NotesPayableToBanksMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockSharesAuthorized_62387c6b-c913-43ad-976f-2aaee7e6e72c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, shares authorized (in shares)</link:label>
<link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_22ddca89-72df-46d5-b295-111205bf250b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted stock award</link:label>
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_264b3d1e-0a54-420a-a6bd-5add87b8dd1f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross property and equipment</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ContractWithCustomerAssetCreditLossExpense_94ad99f2-863a-4371-9b66-ad1ad3fb7a1c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCreditLossExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment losses</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerAssetCreditLossExpense_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCreditLossExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Credit Loss Expense (Reversal)</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCreditLossExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetCreditLossExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetCreditLossExpense" xlink:to="lab_us-gaap_ContractWithCustomerAssetCreditLossExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_374def5e-dc23-43c2-9a8d-f7a0dd90286d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
<link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncomeStatementAbstract_52aca280-4c77-4bcc-a766-ea2b85c6bd48_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
<link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1961e4f8-9f89-4aab-9d4d-ecb0f4f8d8a0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE INCOME</link:label>
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_A3925NotePayableMember_725cd60e-eef5-43da-94b2-f6b3ea2f5c22_terseLabel_en-US" xlink:label="lab_rmti_A3925NotePayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.925% Note Payable</link:label>
<link:label id="lab_rmti_A3925NotePayableMember_label_en-US" xlink:label="lab_rmti_A3925NotePayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.925% Note Payable [Member]</link:label>
<link:label id="lab_rmti_A3925NotePayableMember_documentation_en-US" xlink:label="lab_rmti_A3925NotePayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.925% Note Payable</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_A3925NotePayableMember" xlink:href="rmti-20210630.xsd#rmti_A3925NotePayableMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_A3925NotePayableMember" xlink:to="lab_rmti_A3925NotePayableMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_9bb1b3c6-3b47-4e23-9798-ba4b2120e851_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Disposal of Assets</link:label>
<link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_13cec436-4a13-4141-af99-bd0d13cb3389_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (Increase) in Prepaid and Other Assets</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_a0506113-e2fb-4ad1-9da5-54c3d4295228_negatedTerseLabel_en-US" xlink:label="lab_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of Common Stock to Pay Employee Withholding Taxes</link:label>
<link:label id="lab_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_label_en-US" xlink:label="lab_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Of Common Shares To Pay Employee Withholding Taxes</link:label>
<link:label id="lab_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_documentation_en-US" xlink:label="lab_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares to pay employee withholding taxes.</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" xlink:href="rmti-20210630.xsd#rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" xlink:to="lab_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes" xlink:type="arc" order="1"/>
<link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2815b8a0-9495-4ec9-a197-4bafec0bf34e_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
<link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_00c4d8c0-f572-412f-baa3-5df709d81213_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized issuance costs and unaccreted discount</link:label>
<link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_UseOfEstimates_7ae7d8b5-9127-44d1-bab9-7072f09b3592_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
<link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
<link:label id="lab_stpr_NJ_caeba217-9dba-43ce-b9ba-7bf453123d33_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hackensack, New Jersey</link:label>
<link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
<link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InvestmentIncomeInterest_f7422dd7-db44-4429-aa77-447f12de1b51_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income</link:label>
<link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_b43ab312-4906-4e4f-a21c-21562d76c005_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
<link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_6a638d37-14d4-4c25-a13f-ed5b54c69fb8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2024</link:label>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_914a80f1-c5fc-4ffe-bab2-33746bc6c096_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, par value (in dollars per share)</link:label>
<link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b7ee2cfa-3078-45fd-b175-207831e9d434_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_PerformanceBasedRestrictedStockAwardsMember_6a62c6c2-1b85-4666-aeda-3469f75b5360_terseLabel_en-US" xlink:label="lab_rmti_PerformanceBasedRestrictedStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards - performance based awards</link:label>
<link:label id="lab_rmti_PerformanceBasedRestrictedStockAwardsMember_label_en-US" xlink:label="lab_rmti_PerformanceBasedRestrictedStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Awards [Member]</link:label>
<link:label id="lab_rmti_PerformanceBasedRestrictedStockAwardsMember_documentation_en-US" xlink:label="lab_rmti_PerformanceBasedRestrictedStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">na</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockAwardsMember" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedRestrictedStockAwardsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_PerformanceBasedRestrictedStockAwardsMember" xlink:to="lab_rmti_PerformanceBasedRestrictedStockAwardsMember" xlink:type="arc" order="1"/>
<link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_26d67b12-c8fc-4951-a765-4cc474afb242_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
<link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
<link:label id="lab_dei_CityAreaCode_5ec7566f-7f2e-40c4-b3b3-8f6209d7a7ef_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
<link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentPeriodEndDate_c1a7aa82-062d-421b-8305-45bf7b6ed40e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
<link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_WorkersCompensationLiabilityCurrent_251d32ab-6225-4e60-ad93-aa33da36f7f6_terseLabel_en-US" xlink:label="lab_us-gaap_WorkersCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Workers Compensation</link:label>
<link:label id="lab_us-gaap_WorkersCompensationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_WorkersCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers' Compensation Liability, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WorkersCompensationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="lab_us-gaap_WorkersCompensationLiabilityCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_stpr_MI_e9fc7710-386c-4eac-81b3-3e5123fa6ede_terseLabel_en-US" xlink:label="lab_stpr_MI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wixom, Michigan</link:label>
<link:label id="lab_stpr_MI_label_en-US" xlink:label="lab_stpr_MI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MICHIGAN</link:label>
<link:loc xlink:type="locator" xlink:label="loc_stpr_MI" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MI"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MI" xlink:to="lab_stpr_MI" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_3defc02e-aa90-4cf5-b6cf-83330501bef4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_e0b6d937-16b5-4665-ae15-1a06736943cb_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
<link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0a942ad2-11e1-4329-8747-4539fb619377_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DisaggregationOfRevenueTable_4b9178ea-3752-4540-a03e-858ccd32f6d7_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
<link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember_c624fe93-8589-4c90-a60e-9848ec07ed33_terseLabel_en-US" xlink:label="lab_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive vice president and chief scientific officer</link:label>
<link:label id="lab_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember_label_en-US" xlink:label="lab_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Vice President And Chief Scientific Officer [Member]</link:label>
<link:label id="lab_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember_documentation_en-US" xlink:label="lab_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to Executive Vice President and Chief Scientific Officer.</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember" xlink:href="rmti-20210630.xsd#rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember" xlink:to="lab_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_AccruedUnvoucheredReceiptsCurrent_54683265-9175-4a0f-b8df-bbb2f152fbc5_terseLabel_en-US" xlink:label="lab_rmti_AccruedUnvoucheredReceiptsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Unvouchered Receipts</link:label>
<link:label id="lab_rmti_AccruedUnvoucheredReceiptsCurrent_label_en-US" xlink:label="lab_rmti_AccruedUnvoucheredReceiptsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Unvouchered Receipts, Current</link:label>
<link:label id="lab_rmti_AccruedUnvoucheredReceiptsCurrent_documentation_en-US" xlink:label="lab_rmti_AccruedUnvoucheredReceiptsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Unvouchered Receipts, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_AccruedUnvoucheredReceiptsCurrent" xlink:href="rmti-20210630.xsd#rmti_AccruedUnvoucheredReceiptsCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_AccruedUnvoucheredReceiptsCurrent" xlink:to="lab_rmti_AccruedUnvoucheredReceiptsCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_caa69ccf-6671-4c3b-a79e-bdea212e03e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Components of Inventory</link:label>
<link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongtermDebtTypeDomain_f6b80552-c50e-4702-ab52-5848716a5649_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
<link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensation_17c03a1f-0ebe-4e17-a6bc-6448132b16af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_8ef9642b-3a7b-436c-9829-141361fa95ca_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InventoryNoncurrent_27123ba9-e8af-45c0-a058-de6ed73eed05_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Non-Current</link:label>
<link:label id="lab_us-gaap_InventoryNoncurrent_07230d45-ec1e-474a-b33f-39126592b9d9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, noncurrent</link:label>
<link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_dei_CoverAbstract_edc496e8-7752-4769-b188-90c4a1cb045b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
<link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0436d867-4b9b-47a0-93df-426089151ac8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments available for sale</link:label>
<link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebt_78d985e6-48f5-432e-a770-1d3cf4fbbeb4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, net of unamortized issuance costs and unaccreted discount</link:label>
<link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_fdd58f30-3253-4d29-935a-1eee37dd7bb9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
<link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6cb2422c-4fd1-4fae-a45b-80c6b8605428_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Deferred License Revenue</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_d768be7a-102a-4ba1-9305-34dd6279fce5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_SalesAgreementThresholdSaleOfShares_dfaf9bc3-1d91-493d-aeeb-67eafff01afb_terseLabel_en-US" xlink:label="lab_rmti_SalesAgreementThresholdSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales agreement, threshold sale of shares</link:label>
<link:label id="lab_rmti_SalesAgreementThresholdSaleOfShares_label_en-US" xlink:label="lab_rmti_SalesAgreementThresholdSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement, Threshold Sale Of Shares</link:label>
<link:label id="lab_rmti_SalesAgreementThresholdSaleOfShares_documentation_en-US" xlink:label="lab_rmti_SalesAgreementThresholdSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of threshold offering or sale of shares under the sales agreement.</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_SalesAgreementThresholdSaleOfShares" xlink:href="rmti-20210630.xsd#rmti_SalesAgreementThresholdSaleOfShares"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_SalesAgreementThresholdSaleOfShares" xlink:to="lab_rmti_SalesAgreementThresholdSaleOfShares" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_MediumTermNotesMember_d9ab21be-f425-4cfe-8b16-76156ceceae5_terseLabel_en-US" xlink:label="lab_us-gaap_MediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
<link:label id="lab_us-gaap_MediumTermNotesMember_label_en-US" xlink:label="lab_us-gaap_MediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medium-term Notes [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MediumTermNotesMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MediumTermNotesMember" xlink:to="lab_us-gaap_MediumTermNotesMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_891e3b1f-86b1-42d3-8dd1-c4a322f19614_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales</link:label>
<link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LeaseCostAbstract_f2d5c8df-0094-4c26-a7c6-6b30be5829c9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other information</link:label>
<link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_14fc9425-90d1-440d-8032-2cc9bd3f169c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_JeilPharmaAgreementsMember_896835f5-71c6-40e8-85d1-8b90f9e109bb_terseLabel_en-US" xlink:label="lab_rmti_JeilPharmaAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jeil Pharma Agreements</link:label>
<link:label id="lab_rmti_JeilPharmaAgreementsMember_label_en-US" xlink:label="lab_rmti_JeilPharmaAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jeil Pharma Agreements [Member]</link:label>
<link:label id="lab_rmti_JeilPharmaAgreementsMember_documentation_en-US" xlink:label="lab_rmti_JeilPharmaAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jeil Pharma Agreements</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_JeilPharmaAgreementsMember" xlink:href="rmti-20210630.xsd#rmti_JeilPharmaAgreementsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_JeilPharmaAgreementsMember" xlink:to="lab_rmti_JeilPharmaAgreementsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementEquityComponentsAxis_3f7da198-f44b-4eac-b754-f6ae6d8e6607_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
<link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RestrictedStockMember_44824853-8539-469b-b85b-9f1f831355ba_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock awards</link:label>
<link:label id="lab_us-gaap_RestrictedStockMember_37459b05-fe2a-42e3-8974-1204b72e4679_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
<link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_b57581c8-4e18-4a2a-acf0-a2350bd073ba_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished Goods</link:label>
<link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentNameDomain_a5285d86-dd88-4952-b3f8-8113ce7567f1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
<link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a392f950-7c3b-4498-bf04-31b18725c29a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
<link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_srt_MinimumMember_66c8dd18-4b61-4a3d-b291-b6917f9ad5ce_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
<link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RepaymentsOfNotesPayable_81df51ab-53b5-4e65-8e44-d473cabd5926_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on Short Term Note Payable</link:label>
<link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4bd0e6b7-b93e-4455-a051-e0b72d73f943_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_DrugRevenueMember_bac93047-4319-4286-ba5a-4b1d4d77396d_terseLabel_en-US" xlink:label="lab_rmti_DrugRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug products</link:label>
<link:label id="lab_rmti_DrugRevenueMember_label_en-US" xlink:label="lab_rmti_DrugRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Revenue [Member]</link:label>
<link:label id="lab_rmti_DrugRevenueMember_documentation_en-US" xlink:label="lab_rmti_DrugRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Revenue [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DrugRevenueMember" xlink:href="rmti-20210630.xsd#rmti_DrugRevenueMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_DrugRevenueMember" xlink:to="lab_rmti_DrugRevenueMember" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_ServiceBasedAwardsMember_b95be387-ecfb-4391-9740-18d54b2937eb_terseLabel_en-US" xlink:label="lab_rmti_ServiceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service based awards</link:label>
<link:label id="lab_rmti_ServiceBasedAwardsMember_label_en-US" xlink:label="lab_rmti_ServiceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Awards [Member]</link:label>
<link:label id="lab_rmti_ServiceBasedAwardsMember_documentation_en-US" xlink:label="lab_rmti_ServiceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to service based awards.</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedAwardsMember" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedAwardsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ServiceBasedAwardsMember" xlink:to="lab_rmti_ServiceBasedAwardsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_bf213284-9f5d-4953-a4e6-25afc892fadf_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets exchanged for finance lease liabilities</link:label>
<link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_7616fdc6-f4de-4181-af68-a1905d21bcbf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding performance-based restricted stock units (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_deed1864-77e1-4726-b03b-e10afe031e65_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_28a6c7e7-de88-47ec-8518-e2c1169750de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock option assumptions</link:label>
<link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityInteractiveDataCurrent_d98ee0dd-5eec-4c0f-a20b-c357bcbdebec_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
<link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_country_US_59e59a1f-62b9-49ac-93a6-2cec18ef40a4_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
<link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
<link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_65fea4b0-e57f-4a95-8a0d-7368b26cc683_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_455eb941-eeab-41f0-8321-043a1e83aee5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
<link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_902e77f4-f45e-4009-a683-2eab42c45b12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock options activity</link:label>
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ContractWithCustomerRefundLiability_1c5d42e1-af18-440a-b5cf-0b8306922be0_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for returns</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerRefundLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Refund Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiability" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment_2bf2b3b1-b32f-4741-a791-a007a1acdf76_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of Equipment</link:label>
<link:label id="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Machinery and Equipment</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityRegistrantName_fb0db5fe-f0ad-45e8-ba67-d05a335a5db7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
<link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SubsequentEventTypeDomain_eb438f0e-df2b-403a-9c7f-9074895ca219_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
<link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_bf99f994-711c-4a22-b406-871e0ee19d5d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
<link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_16dfa2b0-d741-429e-a12c-62e1b2936966_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate – operating leases</link:label>
<link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c5fae1b0-b0b3-4a29-a7c2-69e186f0f806_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Other Liabilities</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_WixomMichiganPropertyTwoMember_5718be6d-77ec-44c9-8848-1f76d3280dae_terseLabel_en-US" xlink:label="lab_rmti_WixomMichiganPropertyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wixom, Michigan Property Two</link:label>
<link:label id="lab_rmti_WixomMichiganPropertyTwoMember_label_en-US" xlink:label="lab_rmti_WixomMichiganPropertyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wixom, Michigan Property Two [Member]</link:label>
<link:label id="lab_rmti_WixomMichiganPropertyTwoMember_documentation_en-US" xlink:label="lab_rmti_WixomMichiganPropertyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wixom, Michigan Property Two [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_WixomMichiganPropertyTwoMember" xlink:href="rmti-20210630.xsd#rmti_WixomMichiganPropertyTwoMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_WixomMichiganPropertyTwoMember" xlink:to="lab_rmti_WixomMichiganPropertyTwoMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a58bc70-0445-4c13-8962-655e6af77346_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_c62d17c2-c867-4387-894e-70af32dd1978_terseLabel_en-US" xlink:label="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
<link:label id="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic Value</link:label>
<link:label id="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NA</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="rmti-20210630.xsd#rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_36cba081-25dd-41ad-97b8-a35f4f9a407a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Expense) Income</link:label>
<link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_b598586a-4dc4-4958-94a3-a902bc983baa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less present value discount</link:label>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_414e60e2-f541-4581-bd5f-47e4b268d41f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
<link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityIncorporationStateCountryCode_bd5638f7-e155-422a-a7fa-63e4d11eb475_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
<link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f43881d1-bc04-4c53-bbb5-c59529ede0ba_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, net</link:label>
<link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8d386492-b7fa-409e-9983-01f5d6d48d12_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_69b59e8a-d6dd-4a94-ad5e-e79ac767099d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6e65fa77-b495-405c-acea-c157510d29bc_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss</link:label>
<link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_5b69e987-8c6a-4177-a39e-128bf190c453_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
<link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityAddressPostalZipCode_5c06307c-a611-49d2-8431-d53fa34e9a38_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
<link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_ContractWithCustomerDeferredRevenueTextBlock_ab0fa880-2748-4e19-a162-b9001c1c39a6_terseLabel_en-US" xlink:label="lab_rmti_ContractWithCustomerDeferredRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
<link:label id="lab_rmti_ContractWithCustomerDeferredRevenueTextBlock_label_en-US" xlink:label="lab_rmti_ContractWithCustomerDeferredRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer Deferred Revenue [Text Block]</link:label>
<link:label id="lab_rmti_ContractWithCustomerDeferredRevenueTextBlock_documentation_en-US" xlink:label="lab_rmti_ContractWithCustomerDeferredRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer Deferred Revenue [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ContractWithCustomerDeferredRevenueTextBlock" xlink:href="rmti-20210630.xsd#rmti_ContractWithCustomerDeferredRevenueTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ContractWithCustomerDeferredRevenueTextBlock" xlink:to="lab_rmti_ContractWithCustomerDeferredRevenueTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_02327eca-8c19-41dd-8044-989c72e4294c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized (Loss) Gain on Investments</link:label>
<link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_8f700288-95b8-42ad-943d-5a3060467b33_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Loss (Gain) on Sale of Investments Available-for-Sale</link:label>
<link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain (Loss)</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_Goodwill_479a3b41-15f1-4a2d-962c-4d76438a6589_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
<link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentTransitionReport_336fb338-a8a2-4051-b57a-73c1dd6d0384_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
<link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
<link:label id="lab_srt_TitleOfIndividualAxis_05512263-bec2-4f80-affa-b6119846bfd1_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
<link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8a6b77fd-d1de-46e6-9b5d-40414d12a6c1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_WarrantMember_3284a0fe-407b-421c-a81e-ea468d80b9ff_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
<link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_104c5b03-bad1-4eeb-a7ce-2fe28e0f9bbc_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
<link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_NumberOfDistributionAndLicenseAgreements_fc2b6dee-e606-49aa-b0a2-eb037b5fe93d_terseLabel_en-US" xlink:label="lab_rmti_NumberOfDistributionAndLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distribution and license agreements</link:label>
<link:label id="lab_rmti_NumberOfDistributionAndLicenseAgreements_label_en-US" xlink:label="lab_rmti_NumberOfDistributionAndLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Distribution and License Agreements</link:label>
<link:label id="lab_rmti_NumberOfDistributionAndLicenseAgreements_documentation_en-US" xlink:label="lab_rmti_NumberOfDistributionAndLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of distribution and license agreements.</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_NumberOfDistributionAndLicenseAgreements" xlink:href="rmti-20210630.xsd#rmti_NumberOfDistributionAndLicenseAgreements"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_NumberOfDistributionAndLicenseAgreements" xlink:to="lab_rmti_NumberOfDistributionAndLicenseAgreements" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentFaceAmount_56cb4f2c-171b-4fc9-95a2-88986b46ebe3_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
<link:label id="lab_us-gaap_DebtInstrumentFaceAmount_b1ce7d1d-b60a-4312-adcf-fb9011de989b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term note payable</link:label>
<link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee_b4fbb072-71e4-4b41-ab34-2b1cf205def3_terseLabel_en-US" xlink:label="lab_rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refund percentage</link:label>
<link:label id="lab_rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee_label_en-US" xlink:label="lab_rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Repayment Percentage of Upfront Fee</link:label>
<link:label id="lab_rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee_documentation_en-US" xlink:label="lab_rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Repayment Percentage of Upfront Fee</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee" xlink:href="rmti-20210630.xsd#rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee" xlink:to="lab_rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentQuarterlyReport_26ad3728-ce49-4e51-b9f7-a74e3d8e0cea_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
<link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ce48de53-3bc0-4702-a53d-7b992d3f793b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_28086597-246e-47e8-8283-4d6968a7891c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_8efcc57d-f2ba-485a-afbf-46fc99c0eb3c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
<link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EquityAbstract_64399745-3b34-4cad-86a3-aca1271895f1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
<link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f81f6da9-0cdf-40bc-bfb3-c2ed9cea905e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_fa925cf2-ba3a-449f-9c34-87297c085c95_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred License Revenue - Current</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SubsequentEventLineItems_87463b8a-8284-404c-8d36-f52cce4ed3c9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
<link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_315fc8f5-e95c-4985-8309-5cb7dc2df2a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_79a277b6-b1c2-46cb-a68b-7a53068cd304_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted Weighted Average Shares Outstanding (in shares)</link:label>
<link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EarningsPerShareBasic_e6b71a06-6a32-4255-b0e3-f497278c339b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Net Loss per Share (in dollars per share)</link:label>
<link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_OperatingLeaseAndFinanceLeaseLiability_55317e61-364e-4ae9-a979-0f1e5c0ce5bd_terseLabel_en-US" xlink:label="lab_rmti_OperatingLeaseAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease and finance lease liabilities</link:label>
<link:label id="lab_rmti_OperatingLeaseAndFinanceLeaseLiability_label_en-US" xlink:label="lab_rmti_OperatingLeaseAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease And Finance Lease, Liability</link:label>
<link:label id="lab_rmti_OperatingLeaseAndFinanceLeaseLiability_documentation_en-US" xlink:label="lab_rmti_OperatingLeaseAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease And Finance Lease, Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseAndFinanceLeaseLiability" xlink:href="rmti-20210630.xsd#rmti_OperatingLeaseAndFinanceLeaseLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_OperatingLeaseAndFinanceLeaseLiability" xlink:to="lab_rmti_OperatingLeaseAndFinanceLeaseLiability" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_PerformanceBasedStockOptionAwardsMember_f4666e03-4cf6-477b-8574-b7904fcdff20_terseLabel_en-US" xlink:label="lab_rmti_PerformanceBasedStockOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option awards - performance based awards</link:label>
<link:label id="lab_rmti_PerformanceBasedStockOptionAwardsMember_label_en-US" xlink:label="lab_rmti_PerformanceBasedStockOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Stock Option Awards [Member]</link:label>
<link:label id="lab_rmti_PerformanceBasedStockOptionAwardsMember_documentation_en-US" xlink:label="lab_rmti_PerformanceBasedStockOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">na</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedStockOptionAwardsMember" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedStockOptionAwardsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_PerformanceBasedStockOptionAwardsMember" xlink:to="lab_rmti_PerformanceBasedStockOptionAwardsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8a99ae63-b66d-4a82-9056-9538234d28bf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term (years)</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityFileNumber_fa98557a-56df-4366-b6a5-a8ea3d35da88_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
<link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtDisclosureAbstract_32e9521f-bc1d-4339-89db-f69fe98c23a4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
<link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_12b9884f-31aa-4fbd-a5f0-ddc572236f87_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_fc2779d1-5c93-4c1d-bbd2-62fb9a035078_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expirations (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_80f951d4-85ee-4801-90f7-b0e2fd3643ca_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c54a3970-0add-48e3-8017-f238a75e63ee_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term – operating leases</link:label>
<link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InventoryCurrentTable_8b66091a-9521-4e03-b902-95818626b539_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
<link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SellingAndMarketingExpense_b5944a15-a8b2-4f87-92fa-7b83d4b74c69_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing</link:label>
<link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f091cc2b-b0ca-454e-8ced-f918d817680c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Financing Costs and Accretion of Debt Discount</link:label>
<link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockValueOutstanding_18492f70-951e-4f31-b43d-c41014bdc783_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, $0.0001 par value; 170,000,000 shares authorized; 93,811,381 and 93,573,165 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively</link:label>
<link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c44a940-080c-4643-831c-ddb21db2739e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash (Used In) Provided By Financing Activities</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShortTermDebtTypeAxis_34fa3d96-4b9a-4fee-9e0f-5021976fa58e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
<link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_0f5efeb2-be54-4326-b09c-f30c41b2fa93_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Warrants related to Debt Financing</link:label>
<link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_89377dbb-ccec-4f18-a1ea-35939cc990b2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue performance obligation</link:label>
<link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_750fefda-f20b-4f3d-ad3e-b7ac988079f9_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share based compensation expense</link:label>
<link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3c126ae6-2394-400d-a013-f4982defadb8_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation expenses</link:label>
<link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_72099133-6164-4f32-b82a-0b59b8aa1bdf_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales</link:label>
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_78a81106-a8cd-460b-8f2e-1d325aed39bb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenue</link:label>
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
<link:label id="lab_srt_CounterpartyNameAxis_694fda24-6230-4a2f-9800-417466caa63d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
<link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays_f21149c4-ac6a-45d3-bcb5-e0b11a1ca323_terseLabel_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price calculation, period immediately preceding execution of loan agreement, number of trading days</link:label>
<link:label id="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays_label_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Execution Of Agreement, Trading Days</link:label>
<link:label id="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays_documentation_en-US" xlink:label="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Execution Of Agreement, Trading Days</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" xlink:href="rmti-20210630.xsd#rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" xlink:to="lab_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentFiscalYearFocus_cd60a028-3cad-486e-9bb0-e4b50ebbe2a8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
<link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6076806b-562e-4cf0-805f-8b73ad4aeb75_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of the period</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebtCurrent_37052f48-a7de-445f-a472-af39070e1508_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan - Net of Issuance Costs</link:label>
<link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityCurrentReportingStatus_0a42f8b7-5ac3-4052-8434-6147a37f9fff_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
<link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_4c4f0d29-cd02-4156-bc87-f0d80623098d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2025</link:label>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_d511da31-b16b-4574-80e7-ca79b46766d2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial interest rate percentage</link:label>
<link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SubsequentEventTable_bcc50318-c550-4b2a-8705-7d28d8838eea_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
<link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5fd0f673-274a-466d-afb9-c20addbcd70b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of Investments Available-for-Sale</link:label>
<link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_f482d444-4d17-4ad7-a54a-d3d53d3d3a04_terseLabel_en-US" xlink:label="lab_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
<link:label id="lab_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term 2</link:label>
<link:label id="lab_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_documentation_en-US" xlink:label="lab_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term 2</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:href="rmti-20210630.xsd#rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:to="lab_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_79217121-4389-4a32-bba6-a8a7081b6c4c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Share</link:label>
<link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_572362ab-f2c2-4679-adf3-5ed79ae6702a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation expense (in shares)</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentTable_b9e08879-9a4d-4804-8e22-f88fff0df5ec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
<link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4207192b-c050-4a88-9dd1-4258aedd06ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InventoryDisclosureAbstract_3b872d32-43dd-4a11-9a64-f55273a7a6eb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
<link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_TermLoanTrancheOneMember_f0335313-a8a8-4d76-8929-f11ea42db135_terseLabel_en-US" xlink:label="lab_rmti_TermLoanTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, first tranche</link:label>
<link:label id="lab_rmti_TermLoanTrancheOneMember_label_en-US" xlink:label="lab_rmti_TermLoanTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche One [Member]</link:label>
<link:label id="lab_rmti_TermLoanTrancheOneMember_documentation_en-US" xlink:label="lab_rmti_TermLoanTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche One [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheOneMember" xlink:href="rmti-20210630.xsd#rmti_TermLoanTrancheOneMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_TermLoanTrancheOneMember" xlink:to="lab_rmti_TermLoanTrancheOneMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_be4535ac-25e3-428d-a378-f255b9095a75_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
<link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fdcf511e-7466-4adc-96e3-a69aa54f89fc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockSharesIssued_1e7d387c-8ba9-4b8e-bbee-17f241b6774e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, shares issued (in shares)</link:label>
<link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb92460a-a59a-486d-b7cb-ed24e799c943_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
<link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees_45d57ad0-9189-4327-943d-692cfa187591_terseLabel_en-US" xlink:label="lab_rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, accrued reimbursement of IP expenses and sublicense royalty fees</link:label>
<link:label id="lab_rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees_label_en-US" xlink:label="lab_rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accrued Reimbursement of IP Expenses And Sublicense Royalty Fees</link:label>
<link:label id="lab_rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees_documentation_en-US" xlink:label="lab_rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accrued Reimbursement of IP Expenses And Sublicense Royalty Fees</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" xlink:href="rmti-20210630.xsd#rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" xlink:to="lab_rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseLiability_3634a643-7e26-44c0-bcbb-4f551c9ed7f1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
<link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense_ddbdf80d-8d51-498d-aff4-7003396bf228_terseLabel_en-US" xlink:label="lab_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Modification Expense</link:label>
<link:label id="lab_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense_label_en-US" xlink:label="lab_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Modification Expense</link:label>
<link:label id="lab_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense_documentation_en-US" xlink:label="lab_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Modification Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" xlink:href="rmti-20210630.xsd#rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" xlink:to="lab_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebtNoncurrent_0ae2faa9-381b-4c56-af68-220d75af3fae_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Net of Issuance Costs</link:label>
<link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3fcefa5e-822c-4e09-9382-8bf938ea3bd9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) Decrease in Accounts Receivable, net</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentLineItems_e1439937-f41d-4386-8f6e-e896db2a133d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
<link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0608cbf0-7c7c-4857-bc7f-15457a21a278_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
<link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockholdersEquity_47d674f6-fbde-4ae3-9079-6e0441d83a1d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stockholders’ Equity</link:label>
<link:label id="lab_us-gaap_StockholdersEquity_86f32a4e-b101-4018-87d1-5e889eb847a6_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
<link:label id="lab_us-gaap_StockholdersEquity_618435a2-cbf7-4f3e-8515-8f895463a290_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
<link:label id="lab_us-gaap_StockholdersEquity_2d65c37a-2012-433b-b621-1f45c94f4dd3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
<link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_971c5812-a96d-4a3c-ad02-465f964faf45_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Costs from the Issuance of Common Stock</link:label>
<link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f88706d1-52a5-4a55-8df0-7fd4f45dd2aa_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders’ Equity</link:label>
<link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_030e39d4-3681-4cd2-8b0e-64d84a35ccb6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityAddressCityOrTown_2cec6bc8-2db3-4370-864f-e067d0720b86_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
<link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_77bb563a-eab8-4c78-9f77-c59cd482a29c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation and Benefits</link:label>
<link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_cfff2eaa-3831-42b4-b681-fb2784cf7eea_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
<link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseCost_e2f81976-f17a-4e81-97ef-a20156c67052_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
<link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_a936f581-b099-42e1-a1ab-3c272888c410_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative</link:label>
<link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_3df1752b-e520-4bfb-9866-538d4391cbce_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
<link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems" xlink:to="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0bf80ed1-3c5d-4dc2-8bb9-612da57fae5b_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities excluded from diluted loss per share calculation (in shares)</link:label>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_TrifericDialysateMember_d3ebb95f-09aa-43fb-9e1b-f9e15a77f8e2_terseLabel_en-US" xlink:label="lab_rmti_TrifericDialysateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic Dialysate</link:label>
<link:label id="lab_rmti_TrifericDialysateMember_label_en-US" xlink:label="lab_rmti_TrifericDialysateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic Dialysate [Member]</link:label>
<link:label id="lab_rmti_TrifericDialysateMember_documentation_en-US" xlink:label="lab_rmti_TrifericDialysateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triferic Dialysate [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericDialysateMember" xlink:href="rmti-20210630.xsd#rmti_TrifericDialysateMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_TrifericDialysateMember" xlink:to="lab_rmti_TrifericDialysateMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_74171dd5-0f94-47b4-95ca-0f44b5126cb1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term – finance leases</link:label>
<link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_ConcentrateProductSalesMember_a33db725-1580-4e83-adef-fc3aa8224df4_terseLabel_en-US" xlink:label="lab_rmti_ConcentrateProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate product sales</link:label>
<link:label id="lab_rmti_ConcentrateProductSalesMember_label_en-US" xlink:label="lab_rmti_ConcentrateProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate Product Sales [Member]</link:label>
<link:label id="lab_rmti_ConcentrateProductSalesMember_documentation_en-US" xlink:label="lab_rmti_ConcentrateProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate Product Sales [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductSalesMember" xlink:href="rmti-20210630.xsd#rmti_ConcentrateProductSalesMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ConcentrateProductSalesMember" xlink:to="lab_rmti_ConcentrateProductSalesMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShortTermLeaseCost_55649f78-b1ab-4f08-b0f8-6d7211d87484_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease rent expense</link:label>
<link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EquityComponentDomain_86fcd12d-efda-49a0-90a8-4c6084f6f414_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
<link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_687cb1f6-75bf-406a-b0fb-b916f72c5c27_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and investments available-for-sale</link:label>
<link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3175e6fc-50f6-4ee4-9eb0-7e3a0403ac80_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss on Available-for-Sale Debt Instrument Investments</link:label>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6bb76a65-1535-4755-898c-e490a0b19108_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss on Available-for-Sale Investments</link:label>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_GrossProfit_b3a16bb1-06cf-4b62-85a5-2104a5d8c2ec_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
<link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_01c50b00-e40c-4811-9819-dfa4ce97da1d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9069201f-ab3c-421e-a574-48b2ab26a0b4_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityTaxIdentificationNumber_5c126b56-6e4c-4143-afbf-d778199cb318_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
<link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_c6172817-6ae8-456a-a194-62bc88cf066a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
<link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c49d391a-783d-4f2d-9be5-6251b9ecbb96_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
<link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetIncomeLoss_7d8b2696-04f6-469a-8a5b-69d7b46ccde3_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss</link:label>
<link:label id="lab_us-gaap_NetIncomeLoss_67ebd098-c7ef-4ffa-86fb-6b1db0b901bc_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss</link:label>
<link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d917932b-4fde-4577-8f45-143a40b62eee_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Assets and Liabilities:</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cec41204-9f86-47db-ae98-4283e10fac0f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2021 (remaining)</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InventoryDisclosureTextBlock_35a12f3f-2154-4914-a67c-ea20ee5ce30b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
<link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LeasesAbstract_13fa42a9-17ab-44ca-a91f-e9a9b66c9267_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
<link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongtermDebtTypeAxis_d8896981-a642-449f-8325-b048496df873_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
<link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AssetsCurrent_e31fdd58-c528-4d54-aef5-dd768109dd66_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current Assets</link:label>
<link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_dei_CurrentFiscalYearEndDate_bc6263f2-a68e-4d3d-abf6-505d7c6afcce_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
<link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_PublicOfferingMember_157f85c9-d655-4520-adb1-379ba5ad2f92_terseLabel_en-US" xlink:label="lab_rmti_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
<link:label id="lab_rmti_PublicOfferingMember_label_en-US" xlink:label="lab_rmti_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
<link:label id="lab_rmti_PublicOfferingMember_documentation_en-US" xlink:label="lab_rmti_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PublicOfferingMember" xlink:href="rmti-20210630.xsd#rmti_PublicOfferingMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_PublicOfferingMember" xlink:to="lab_rmti_PublicOfferingMember" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_ConcentrateProductLicenseFeeMember_35e2b4ea-bca4-40be-a651-f7948ce6877e_terseLabel_en-US" xlink:label="lab_rmti_ConcentrateProductLicenseFeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate product license fee</link:label>
<link:label id="lab_rmti_ConcentrateProductLicenseFeeMember_label_en-US" xlink:label="lab_rmti_ConcentrateProductLicenseFeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate Product License Fee [Member]</link:label>
<link:label id="lab_rmti_ConcentrateProductLicenseFeeMember_documentation_en-US" xlink:label="lab_rmti_ConcentrateProductLicenseFeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrate Product License Fee [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductLicenseFeeMember" xlink:href="rmti-20210630.xsd#rmti_ConcentrateProductLicenseFeeMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_ConcentrateProductLicenseFeeMember" xlink:to="lab_rmti_ConcentrateProductLicenseFeeMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinanceLeaseLiability_4d977254-e7bb-43cb-ade8-9d9a482a1589_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
<link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_71389195-a1f3-45a6-8a4e-2cd97171bae4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Earnings per Share</link:label>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockholdersEquityAbstract_1bd6479b-bde1-4a5c-8205-4d8a43ab45ac_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders’ Equity:</link:label>
<link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_43c7a257-4afc-4a0b-b4e9-6f0501e08403_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock for which warrant is exercisable (in shares)</link:label>
<link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_76a5079b-17be-44b8-9006-474c285155e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Underlying Options</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_221cd0a6-17e4-4e39-8da8-17395eb217d4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentFiscalPeriodFocus_9650565e-4a2f-4c5b-829d-0b0de23e4706_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
<link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityNumberOfEmployees_60fa04c6-4c12-435a-8a1f-92ca26b46a9a_terseLabel_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
<link:label id="lab_dei_EntityNumberOfEmployees_label_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Number of Employees</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityNumberOfEmployees"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityNumberOfEmployees" xlink:to="lab_dei_EntityNumberOfEmployees" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_48c80464-27cd-4ff0-8184-a9bac7436a7e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred License Revenue - Long-Term</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_cc3cf866-9080-4fb1-836d-e5707ea88880_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure of Cash Flow Information:</link:label>
<link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityFilerCategory_006c380a-72e0-48e7-9b23-2a857142f405_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
<link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d6230f87-3c72-4a99-9c17-3a6c684b6301_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of total stock-based compensation expense</link:label>
<link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockMember_f4d6f54f-e540-42ed-bbd8-22835f0a30d4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMON STOCK</link:label>
<link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_fa1f4145-8472-4417-a248-7845076e2b1f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_srt_ProductsAndServicesDomain_cf7f92c0-cba7-41ef-877e-f6ca4b88311e_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
<link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_88a8e8c7-c270-4c8d-9492-02422951165a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_92fcdb18-1685-4b60-88b1-fb56a2344ed5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_LiquidityAndCapitalResourcesAbstract_4ec0154e-de86-4255-aa8f-22d5d1ca9ca2_terseLabel_en-US" xlink:label="lab_rmti_LiquidityAndCapitalResourcesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Capital Resources</link:label>
<link:label id="lab_rmti_LiquidityAndCapitalResourcesAbstract_label_en-US" xlink:label="lab_rmti_LiquidityAndCapitalResourcesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Capital Resources [Abstract]</link:label>
<link:label id="lab_rmti_LiquidityAndCapitalResourcesAbstract_documentation_en-US" xlink:label="lab_rmti_LiquidityAndCapitalResourcesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_LiquidityAndCapitalResourcesAbstract" xlink:href="rmti-20210630.xsd#rmti_LiquidityAndCapitalResourcesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_LiquidityAndCapitalResourcesAbstract" xlink:to="lab_rmti_LiquidityAndCapitalResourcesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_c73ae787-ab19-4eba-afa4-67fb25424972_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
<link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_efdffd77-ed3e-4862-bde7-76a939d74bed_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amount due</link:label>
<link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_41f84f64-5a9a-4a20-855c-c20055452950_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate – finance leases</link:label>
<link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_b21b5095-721a-450f-acbc-2d44c30fe3c9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Major Classes of Property and Equipment</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b75852a8-2acb-443e-9cd3-2921c33b40e1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LeaseholdImprovementsMember_0911b4f5-3d9d-4446-a323-40ca969385aa_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
<link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7b74a61d-0451-4092-8035-b306d3b006bd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, base percentage</link:label>
<link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1aadca73-0f1d-47be-9f7c-5ba63e882ff7_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
<link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_369185f5-bc38-4dad-9d64-419f39ef077e_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation</link:label>
<link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
<link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a24510fe-8d41-422f-abd1-9f0a1814b731_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
<link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PreferredStockValueOutstanding_bc17b6f5-966f-48f8-ae1d-f4efdb316f06_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at June 30, 2021 and December 31, 2020</link:label>
<link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0fb1b1ec-d212-4fb9-834a-b271927f8861_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure of Noncash Investing and Financing Activities:</link:label>
<link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1f0375db-3771-4601-b8f4-e691462e5966_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) Increase in Cash and Cash Equivalents</link:label>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_TermLoanMember_52698d7d-1091-4e8a-b362-6b2b3682f33c_terseLabel_en-US" xlink:label="lab_rmti_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
<link:label id="lab_rmti_TermLoanMember_label_en-US" xlink:label="lab_rmti_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
<link:label id="lab_rmti_TermLoanMember_documentation_en-US" xlink:label="lab_rmti_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanMember" xlink:href="rmti-20210630.xsd#rmti_TermLoanMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_TermLoanMember" xlink:to="lab_rmti_TermLoanMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_a78bf390-315e-4cff-9ab4-bf3d6e1a4362_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Loss on Marketable Securities Available-for-Sale</link:label>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a28b8a21-7d9d-461f-bed2-abfd586ab7ea_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Maturities</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeStockOptionMember_6293f62f-c15c-4a26-a7a1-fbf8a59e23bb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
<link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_38c02f35-7564-43f4-9c72-fdadf24ca520_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
<link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_e9ca841b-1696-4ec5-a01d-36e177e2f88b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
<link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockIssued1_5de5ab46-db3c-46b6-be67-1407bd414644_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Warrants issued related to Debt Financing</link:label>
<link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4fec9d23-5ebf-41b1-b11a-a3a7b5b3cc49_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Weighted Average Shares Outstanding (in shares)</link:label>
<link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d115d15b-e97d-42cb-b2fa-ff8dc0e6e394_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, additional percentage added to base percentage</link:label>
<link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SubsequentEventsAbstract_2ac63131-a159-4e2e-9214-c3f24fef0e5d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
<link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3d0158c4-566b-4924-8818-71a60b5c2d7f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3d4d75be-abea-4b02-8c75-bcb6b216f56b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_18576beb-88c8-482a-8dbc-6d48db127088_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
<link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_277dd071-d11c-47b1-914a-7d3f0a7ed1aa_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InterestPaidNet_c8841acb-b90b-427e-a6d8-4c607861213b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid for Interest</link:label>
<link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_DrugLicenseFeeMember_73464d42-2e1a-4a7f-a9c8-eff5de98a32e_terseLabel_en-US" xlink:label="lab_rmti_DrugLicenseFeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug license fee</link:label>
<link:label id="lab_rmti_DrugLicenseFeeMember_label_en-US" xlink:label="lab_rmti_DrugLicenseFeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug License Fee [Member]</link:label>
<link:label id="lab_rmti_DrugLicenseFeeMember_documentation_en-US" xlink:label="lab_rmti_DrugLicenseFeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug License Fee [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DrugLicenseFeeMember" xlink:href="rmti-20210630.xsd#rmti_DrugLicenseFeeMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_DrugLicenseFeeMember" xlink:to="lab_rmti_DrugLicenseFeeMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9b44d94d-ac46-491d-aec1-86668332a189_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility, maximum</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_72c75179-fdfd-490d-87f2-16d5850fa4a6_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets exchanged for operating lease liabilities</link:label>
<link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ee4a4e83-d62b-4f37-8efd-3cb618b3ab1f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
<link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_c5e8d9ec-fd2c-4e0f-a7cf-3e385e4167c6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2021 (remaining)</link:label>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AdditionalPaidInCapital_b47acbe0-cf90-49c6-96f5-e9403825246c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
<link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_021b9437-77eb-4812-97ad-3c8977873ce5_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
<link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f0b698b9-0b19-44fa-b9e0-5d529c7c97e7_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents at Beginning of Period</link:label>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_033379a0-18db-42e3-becf-5cad5aeee30b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents at End of Period</link:label>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_RevenueRecognitionTable_4774bf2d-f89c-40b0-90f3-f4d57f9b0c8c_terseLabel_en-US" xlink:label="lab_rmti_RevenueRecognitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Table]</link:label>
<link:label id="lab_rmti_RevenueRecognitionTable_label_en-US" xlink:label="lab_rmti_RevenueRecognitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Table]</link:label>
<link:label id="lab_rmti_RevenueRecognitionTable_documentation_en-US" xlink:label="lab_rmti_RevenueRecognitionTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionTable" xlink:href="rmti-20210630.xsd#rmti_RevenueRecognitionTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_RevenueRecognitionTable" xlink:to="lab_rmti_RevenueRecognitionTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ea06c687-936d-4617-a6a5-bca7e776c6f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Principal Payments on Term Loan</link:label>
<link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_24dab7ee-e2a9-4ca1-ae90-c11ceb2a55e9_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
<link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_baa0b498-9a0a-4758-bc7d-dcaab17f05c0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
<link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c6694604-87a0-4ba3-8b1a-e1804f6fa083_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Accrued Liabilities</link:label>
<link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EarningsPerShareDiluted_a875ccf2-13cc-40e3-a3a1-a59f8aa4a970_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted Net Loss per Share (in dollars per share)</link:label>
<link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_0463bbd7-44c3-440d-9973-5f6385859c12_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Investments Available-for-Sale</link:label>
<link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
<link:label id="lab_dei_LocalPhoneNumber_6239c9b7-06ef-42fe-9d7a-dbf20e15e27b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
<link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_TermLoanTrancheTwoMember_6cf064bb-4132-49b8-a6c4-b88b12428bf1_terseLabel_en-US" xlink:label="lab_rmti_TermLoanTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, second tranche</link:label>
<link:label id="lab_rmti_TermLoanTrancheTwoMember_label_en-US" xlink:label="lab_rmti_TermLoanTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche Two [Member]</link:label>
<link:label id="lab_rmti_TermLoanTrancheTwoMember_documentation_en-US" xlink:label="lab_rmti_TermLoanTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche Two [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheTwoMember" xlink:href="rmti-20210630.xsd#rmti_TermLoanTrancheTwoMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_TermLoanTrancheTwoMember" xlink:to="lab_rmti_TermLoanTrancheTwoMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfStockByClassTable_2dc9b044-48a3-4525-90fc-cca62381b48c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_bb308aa5-eee0-4bf0-af17-1382f18b9f12_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Payments</link:label>
<link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_Depreciation_7784fefb-21a4-4f63-a0e5-b59cb088e43f_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
<link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityAddressAddressLine1_76b606a5-2ee9-4952-84e7-b5cbad8fb7e2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
<link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ContractWithCustomerLiability_f606cd3d-1e48-4c76-8b1f-38970b86c2fb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerLiability_9663739c-7019-4544-9ac3-74026105754a_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityEmergingGrowthCompany_ee458d6e-1736-4bf1-8a05-f3a80cf6b0f4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
<link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage_5c0a52b7-37e1-413c-992c-c091b3f2edc8_terseLabel_en-US" xlink:label="lab_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to add interest rate amount to outstanding principal balance in lieu of paying such amount in cash, percentage</link:label>
<link:label id="lab_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage_label_en-US" xlink:label="lab_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Option To Add Interest Rate Amount To Outstanding Principal Balance In Lieu Of Payment, Percentage</link:label>
<link:label id="lab_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage_documentation_en-US" xlink:label="lab_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Option To Add Interest Rate Amount To Outstanding Principal Balance In Lieu Of Payment, Percentage</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" xlink:href="rmti-20210630.xsd#rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" xlink:to="lab_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_RevenueRecognitionLineItems_ca8fa952-a63d-4c22-8a23-33edf9004c43_terseLabel_en-US" xlink:label="lab_rmti_RevenueRecognitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Line Items]</link:label>
<link:label id="lab_rmti_RevenueRecognitionLineItems_label_en-US" xlink:label="lab_rmti_RevenueRecognitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Line Items]</link:label>
<link:label id="lab_rmti_RevenueRecognitionLineItems_documentation_en-US" xlink:label="lab_rmti_RevenueRecognitionLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionLineItems" xlink:href="rmti-20210630.xsd#rmti_RevenueRecognitionLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_RevenueRecognitionLineItems" xlink:to="lab_rmti_RevenueRecognitionLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AwardTypeAxis_6497bb39-5662-4039-8f82-e476ac3cc8f7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
<link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_399933b0-ab44-4369-a881-dd5566ae8b9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant-Date Fair Value</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
<link:label id="lab_srt_MaximumMember_fa865e72-e463-4c83-85f5-0876b35ea5ac_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
<link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PreferredStockSharesAuthorized_007730a6-8824-493a-bb86-7b21b36f4a4c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, shares authorized (in shares)</link:label>
<link:label id="lab_us-gaap_PreferredStockSharesAuthorized_6ffe9aa6-c4be-4819-8fcc-4262abec023e_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
<link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_TermLoanTrancheTwoAndTrancheThreeMember_1a19593f-83b3-46c5-bfc1-c3defe25349a_terseLabel_en-US" xlink:label="lab_rmti_TermLoanTrancheTwoAndTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, second and third tranches</link:label>
<link:label id="lab_rmti_TermLoanTrancheTwoAndTrancheThreeMember_label_en-US" xlink:label="lab_rmti_TermLoanTrancheTwoAndTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche Two And Tranche Three [Member]</link:label>
<link:label id="lab_rmti_TermLoanTrancheTwoAndTrancheThreeMember_documentation_en-US" xlink:label="lab_rmti_TermLoanTrancheTwoAndTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche Two And Tranche Three [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember" xlink:href="rmti-20210630.xsd#rmti_TermLoanTrancheTwoAndTrancheThreeMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember" xlink:to="lab_rmti_TermLoanTrancheTwoAndTrancheThreeMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RetainedEarningsMember_ec24c9e5-655f-49a7-a122-9aa8fc762f6a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED DEFICIT</link:label>
<link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PreferredStockSharesOutstanding_045be7f9-ff15-4c78-ba4f-44179d086851_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, shares outstanding (in shares)</link:label>
<link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShortTermDebtTypeDomain_80efbc62-058f-487a-8822-5778fd5dc88f_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
<link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_cc2e8b41-e0c0-4c79-85ba-0e600ea29484_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</link:label>
<link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_11ddfc55-4344-4894-bc68-e66f91be0421_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided By Investing Activities</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1d28427d-13d7-4097-9ecb-3d80a45f588d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9f0f0345-dcbd-4a0a-9d8f-756cca776b7b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_FinanceLeaseLiabilityToBePaidAfterYearFour_819cdf3c-c00e-48dc-bf0c-2803dcaa1691_terseLabel_en-US" xlink:label="lab_rmti_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining future payments</link:label>
<link:label id="lab_rmti_FinanceLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_rmti_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
<link:label id="lab_rmti_FinanceLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_rmti_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:href="rmti-20210630.xsd#rmti_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_rmti_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c499d769-4d56-4ea7-b2cc-9f63a12610ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_WorkingCapitalNet_7df3cb04-a677-4ff0-8970-a78c0d664eb7_terseLabel_en-US" xlink:label="lab_rmti_WorkingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
<link:label id="lab_rmti_WorkingCapitalNet_label_en-US" xlink:label="lab_rmti_WorkingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital Net</link:label>
<link:label id="lab_rmti_WorkingCapitalNet_documentation_en-US" xlink:label="lab_rmti_WorkingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the monetary amount of working capital, as of the indicated date.</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_WorkingCapitalNet" xlink:href="rmti-20210630.xsd#rmti_WorkingCapitalNet"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_WorkingCapitalNet" xlink:to="lab_rmti_WorkingCapitalNet" xlink:type="arc" order="1"/>
<link:label id="lab_dei_TradingSymbol_6c05f02f-f7c2-4c30-bfb6-58814fad5a38_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
<link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7fda0d20-618a-47fe-8f20-07f8b2c43804_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of the period (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4b2adfaa-72cb-44bd-b74c-2fcf02b50690_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ContractWithCustomerAssetNet_cf8da693-b2fc-45da-8250-185ec10ca19e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OfficeEquipmentMember_48a8eeb5-2176-48b8-b374-2bc154840e05_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information Technology & Office Equipment</link:label>
<link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_496543fa-9706-4f90-b1c1-c963708b7c5f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
<link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_0ff633ac-00c2-4431-adce-a4fc6709edfd_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Liability [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_DrogsanAgreementsMember_33948ccc-639e-4dc4-8a29-1c14e11d6e2a_terseLabel_en-US" xlink:label="lab_rmti_DrogsanAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drogsan Agreements</link:label>
<link:label id="lab_rmti_DrogsanAgreementsMember_label_en-US" xlink:label="lab_rmti_DrogsanAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drogsan Agreements [Member]</link:label>
<link:label id="lab_rmti_DrogsanAgreementsMember_documentation_en-US" xlink:label="lab_rmti_DrogsanAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drogsan Agreements</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DrogsanAgreementsMember" xlink:href="rmti-20210630.xsd#rmti_DrogsanAgreementsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_DrogsanAgreementsMember" xlink:to="lab_rmti_DrogsanAgreementsMember" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityShellCompany_c3af9642-a8a2-4dc6-9f9e-1a53aa640291_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
<link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent_23848776-a6ac-4602-86f0-de14032a7501_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest Income</link:label>
<link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_750335f4-df2b-4ed4-b5c1-d7a957461576_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2023</link:label>
<link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
<link:label id="lab_rmti_InstallmentPaymentToRelatedParties_d26e3fe9-f8cb-4064-97a7-a3ee3c4ab1ee_terseLabel_en-US" xlink:label="lab_rmti_InstallmentPaymentToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Installment paid</link:label>
<link:label id="lab_rmti_InstallmentPaymentToRelatedParties_label_en-US" xlink:label="lab_rmti_InstallmentPaymentToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Installment paid</link:label>
<link:label id="lab_rmti_InstallmentPaymentToRelatedParties_documentation_en-US" xlink:label="lab_rmti_InstallmentPaymentToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow associated with installment payment to related parties.</link:label>
<link:loc xlink:type="locator" xlink:label="loc_rmti_InstallmentPaymentToRelatedParties" xlink:href="rmti-20210630.xsd#rmti_InstallmentPaymentToRelatedParties"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmti_InstallmentPaymentToRelatedParties" xlink:to="lab_rmti_InstallmentPaymentToRelatedParties" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InventoryLIFOReservePeriodCharge_f64941cb-2a23-4b1b-8551-3a926bb895ce_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLIFOReservePeriodCharge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Inventory Reserves</link:label>
<link:label id="lab_us-gaap_InventoryLIFOReservePeriodCharge_label_en-US" xlink:label="lab_us-gaap_InventoryLIFOReservePeriodCharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, LIFO Reserve, Period Charge</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLIFOReservePeriodCharge" xlink:to="lab_us-gaap_InventoryLIFOReservePeriodCharge" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a74b9acf-a5e4-4a85-ae5e-fcd2f773efe3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in dollar per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5e935452-0817-464a-b1fe-995794f0da71_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of Recent Accounting Pronouncements</link:label>
<link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7fe66897-21e1-4de2-936b-a9fae6487f8a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
<link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>rmti-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3c1f30ef-dd44-4e46-abb9-054971f79e00,g:61350dd9-1066-401d-a0af-504d0c113dc8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://rockwellmed.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="rmti-20210630.xsd#DocumentandEntityInformation"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/DocumentandEntityInformation" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1dfc6e54-e533-4d24-a420-e7ba369ce31d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_DocumentType_1dfc6e54-e533-4d24-a420-e7ba369ce31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_f3edd0f4-b2a1-452e-b88b-c804705db126" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_DocumentQuarterlyReport_f3edd0f4-b2a1-452e-b88b-c804705db126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_18cb4e65-e1fd-4472-9d8b-0b297f8a383a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_DocumentPeriodEndDate_18cb4e65-e1fd-4472-9d8b-0b297f8a383a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_27ff7305-5cfa-4b5c-874f-7f187446a4e8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_DocumentTransitionReport_27ff7305-5cfa-4b5c-874f-7f187446a4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f0c1bf7b-c7f6-4807-abbc-3d97eace3318" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_EntityFileNumber_f0c1bf7b-c7f6-4807-abbc-3d97eace3318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3da1e668-662a-4aa3-a128-9fe5362fb065" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_EntityRegistrantName_3da1e668-662a-4aa3-a128-9fe5362fb065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bfac0f03-3b9b-437d-83c9-565240ed1f0c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bfac0f03-3b9b-437d-83c9-565240ed1f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_cb4b9aac-854b-4ec2-9ada-c5c5ad312630" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_EntityTaxIdentificationNumber_cb4b9aac-854b-4ec2-9ada-c5c5ad312630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3f488c5a-5b12-43b8-8c77-f0bf812aa1f1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_EntityAddressAddressLine1_3f488c5a-5b12-43b8-8c77-f0bf812aa1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_27894f35-ffc9-4c1d-a205-f818975fbda2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_EntityAddressCityOrTown_27894f35-ffc9-4c1d-a205-f818975fbda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d12de11e-988b-489a-bc58-bc5ef4764650" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
<link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_EntityAddressStateOrProvince_d12de11e-988b-489a-bc58-bc5ef4764650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_85538c78-3f9c-4538-a872-ac14529d0d07" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
<link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_EntityAddressPostalZipCode_85538c78-3f9c-4538-a872-ac14529d0d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_405a15dd-d994-4759-90fc-e48b2c751acb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
<link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_CityAreaCode_405a15dd-d994-4759-90fc-e48b2c751acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c5f1ccca-8bd4-4319-8927-1db93d8e3538" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
<link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_LocalPhoneNumber_c5f1ccca-8bd4-4319-8927-1db93d8e3538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7ac9a6f2-b33a-4695-b406-36dc562d2e9b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
<link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_EntityCurrentReportingStatus_7ac9a6f2-b33a-4695-b406-36dc562d2e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_9aa96d2d-86c4-47f0-a89d-2a6bed4e928c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
<link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_EntityInteractiveDataCurrent_9aa96d2d-86c4-47f0-a89d-2a6bed4e928c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e32d4f6a-0c38-423b-902b-c5543bfbe2fe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
<link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_EntityFilerCategory_e32d4f6a-0c38-423b-902b-c5543bfbe2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6850d3cc-ffd4-4e9f-8d96-72e28e3d5efc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
<link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_EntitySmallBusiness_6850d3cc-ffd4-4e9f-8d96-72e28e3d5efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_07832e30-5d6b-48d6-a0f0-f5a570dc77b0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
<link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_EntityEmergingGrowthCompany_07832e30-5d6b-48d6-a0f0-f5a570dc77b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_77ad833a-ca91-4b6e-867b-2e052bf12c69" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
<link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_EntityShellCompany_77ad833a-ca91-4b6e-867b-2e052bf12c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f44436e5-4fae-4cb6-9a7e-673cc6931463" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
<link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_Security12bTitle_f44436e5-4fae-4cb6-9a7e-673cc6931463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7d86e800-0fa9-43ce-bf84-f0cf12925f1d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
<link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_TradingSymbol_7d86e800-0fa9-43ce-bf84-f0cf12925f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4f2b2885-2669-4147-bda6-f6a4a3bdde2e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
<link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_SecurityExchangeName_4f2b2885-2669-4147-bda6-f6a4a3bdde2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_057d89a7-fa19-43f5-b69e-ff579e5cd4b3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
<link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_057d89a7-fa19-43f5-b69e-ff579e5cd4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f92d9278-1385-4fc7-ac83-e5dceb7a44e1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
<link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_EntityCentralIndexKey_f92d9278-1385-4fc7-ac83-e5dceb7a44e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_86c6b640-e3e9-456f-986a-76671ba256f5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
<link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_AmendmentFlag_86c6b640-e3e9-456f-986a-76671ba256f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2e1a2645-d47a-4fb9-bfb2-bd4bc1651d81" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
<link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_CurrentFiscalYearEndDate_2e1a2645-d47a-4fb9-bfb2-bd4bc1651d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d0b21766-cf61-4a39-a179-530996411c81" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
<link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_DocumentFiscalYearFocus_d0b21766-cf61-4a39-a179-530996411c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f7c4d20f-fd1e-423a-9d6a-e21295e9f88e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
<link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7cb6215f-fd68-4c34-af33-86619cb0edc8" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f7c4d20f-fd1e-423a-9d6a-e21295e9f88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="rmti-20210630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f6b68f47-2f6b-4f16-bf7e-baf72749a550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_95269c42-fcf2-41b3-a8b0-811c7aa38fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f6b68f47-2f6b-4f16-bf7e-baf72749a550" xlink:to="loc_us-gaap_AssetsAbstract_95269c42-fcf2-41b3-a8b0-811c7aa38fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f43533ad-8cd1-41c6-8c7e-cdc31898fbd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95269c42-fcf2-41b3-a8b0-811c7aa38fc5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f43533ad-8cd1-41c6-8c7e-cdc31898fbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_371c5d05-37da-4d7b-aba8-226c396691c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95269c42-fcf2-41b3-a8b0-811c7aa38fc5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_371c5d05-37da-4d7b-aba8-226c396691c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_98f83e6f-4b6e-4fc1-a97a-d1ef73f3786a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95269c42-fcf2-41b3-a8b0-811c7aa38fc5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_98f83e6f-4b6e-4fc1-a97a-d1ef73f3786a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c34c5348-be50-4a19-9058-28657e61233b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95269c42-fcf2-41b3-a8b0-811c7aa38fc5" xlink:to="loc_us-gaap_InventoryNet_c34c5348-be50-4a19-9058-28657e61233b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_391534af-4f49-4142-9312-3f94d190d2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95269c42-fcf2-41b3-a8b0-811c7aa38fc5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_391534af-4f49-4142-9312-3f94d190d2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_df437593-269f-468a-b26f-765c93ef09fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95269c42-fcf2-41b3-a8b0-811c7aa38fc5" xlink:to="loc_us-gaap_AssetsCurrent_df437593-269f-468a-b26f-765c93ef09fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9d63e4a7-786b-498f-a618-b83e575adade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95269c42-fcf2-41b3-a8b0-811c7aa38fc5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9d63e4a7-786b-498f-a618-b83e575adade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_bb86135b-1949-46d0-8177-a45cb85b1b55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95269c42-fcf2-41b3-a8b0-811c7aa38fc5" xlink:to="loc_us-gaap_InventoryNoncurrent_bb86135b-1949-46d0-8177-a45cb85b1b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet_fa8369a5-60c3-4c4e-b345-dbb2c24acb4b" xlink:href="rmti-20210630.xsd#rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95269c42-fcf2-41b3-a8b0-811c7aa38fc5" xlink:to="loc_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet_fa8369a5-60c3-4c4e-b345-dbb2c24acb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_85dd2527-4467-4201-b0b7-01e92855dd1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95269c42-fcf2-41b3-a8b0-811c7aa38fc5" xlink:to="loc_us-gaap_Goodwill_85dd2527-4467-4201-b0b7-01e92855dd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_db6e784e-0c72-4dd6-b82f-b9c15aff4368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
<link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95269c42-fcf2-41b3-a8b0-811c7aa38fc5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_db6e784e-0c72-4dd6-b82f-b9c15aff4368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_05780d7d-a337-476d-b0d9-1179518585da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
<link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_95269c42-fcf2-41b3-a8b0-811c7aa38fc5" xlink:to="loc_us-gaap_Assets_05780d7d-a337-476d-b0d9-1179518585da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f05e3b6-e185-47ce-a02c-cf66ad5f3f8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f6b68f47-2f6b-4f16-bf7e-baf72749a550" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f05e3b6-e185-47ce-a02c-cf66ad5f3f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f0ad4fe5-c90d-47dc-955c-0ec165063104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f05e3b6-e185-47ce-a02c-cf66ad5f3f8c" xlink:to="loc_us-gaap_AccountsPayableCurrent_f0ad4fe5-c90d-47dc-955c-0ec165063104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f235d404-158d-41cc-96c7-2e1400f299a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f05e3b6-e185-47ce-a02c-cf66ad5f3f8c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f235d404-158d-41cc-96c7-2e1400f299a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent_abd5d3a9-43f9-455f-ad84-0d47f83986e3" xlink:href="rmti-20210630.xsd#rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f05e3b6-e185-47ce-a02c-cf66ad5f3f8c" xlink:to="loc_rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent_abd5d3a9-43f9-455f-ad84-0d47f83986e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a92c6619-28e7-4f21-b0be-975d324b5b51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f05e3b6-e185-47ce-a02c-cf66ad5f3f8c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a92c6619-28e7-4f21-b0be-975d324b5b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_de5cad16-951d-4e1f-abef-3b8b3b431487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f05e3b6-e185-47ce-a02c-cf66ad5f3f8c" xlink:to="loc_us-gaap_LongTermDebtCurrent_de5cad16-951d-4e1f-abef-3b8b3b431487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_408f35fd-e825-4f3c-a252-ab0e1434107a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f05e3b6-e185-47ce-a02c-cf66ad5f3f8c" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_408f35fd-e825-4f3c-a252-ab0e1434107a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_1e35ef02-5fea-4f4b-a6ed-6906fa7961b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f05e3b6-e185-47ce-a02c-cf66ad5f3f8c" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_1e35ef02-5fea-4f4b-a6ed-6906fa7961b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4e1f0c88-dc97-4aea-b819-5a0c8dbdf9a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f05e3b6-e185-47ce-a02c-cf66ad5f3f8c" xlink:to="loc_us-gaap_LiabilitiesCurrent_4e1f0c88-dc97-4aea-b819-5a0c8dbdf9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent_9693ebcc-9fbf-4c04-b5a2-b82257c2ee66" xlink:href="rmti-20210630.xsd#rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f05e3b6-e185-47ce-a02c-cf66ad5f3f8c" xlink:to="loc_rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent_9693ebcc-9fbf-4c04-b5a2-b82257c2ee66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_03a1b354-6d5f-4d49-92c7-b27f8746eb00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f05e3b6-e185-47ce-a02c-cf66ad5f3f8c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_03a1b354-6d5f-4d49-92c7-b27f8746eb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2375ca39-8331-46f9-9353-c51d2fafed97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
<link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f05e3b6-e185-47ce-a02c-cf66ad5f3f8c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2375ca39-8331-46f9-9353-c51d2fafed97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7202a117-099a-433a-a424-82278a75a850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
<link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f05e3b6-e185-47ce-a02c-cf66ad5f3f8c" xlink:to="loc_us-gaap_Liabilities_7202a117-099a-433a-a424-82278a75a850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_12b7fd60-a8a0-4fbf-a994-0b33d323d2c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
<link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f05e3b6-e185-47ce-a02c-cf66ad5f3f8c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_12b7fd60-a8a0-4fbf-a994-0b33d323d2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4a965939-f3d6-4ef2-9e21-7684d774daa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
<link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f05e3b6-e185-47ce-a02c-cf66ad5f3f8c" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4a965939-f3d6-4ef2-9e21-7684d774daa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_f095823c-7eeb-409a-a1a7-1249d17e89c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4a965939-f3d6-4ef2-9e21-7684d774daa6" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_f095823c-7eeb-409a-a1a7-1249d17e89c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_d43379ae-5abc-44c2-934f-08e4fe6c98d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4a965939-f3d6-4ef2-9e21-7684d774daa6" xlink:to="loc_us-gaap_CommonStockValueOutstanding_d43379ae-5abc-44c2-934f-08e4fe6c98d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_bc24ffcb-7316-46e2-9d77-246e09c775ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4a965939-f3d6-4ef2-9e21-7684d774daa6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_bc24ffcb-7316-46e2-9d77-246e09c775ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4ad75a99-0b23-43c8-8d0e-9662eb5cfa91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4a965939-f3d6-4ef2-9e21-7684d774daa6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4ad75a99-0b23-43c8-8d0e-9662eb5cfa91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bef54f32-908c-45ac-b08a-cfdff0ebcf1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4a965939-f3d6-4ef2-9e21-7684d774daa6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bef54f32-908c-45ac-b08a-cfdff0ebcf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a9bdfc0c-0b9c-4b4a-93cb-4c6af772aa09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4a965939-f3d6-4ef2-9e21-7684d774daa6" xlink:to="loc_us-gaap_StockholdersEquity_a9bdfc0c-0b9c-4b4a-93cb-4c6af772aa09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_16ac86ff-a870-415a-b321-100105305dfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
<link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f05e3b6-e185-47ce-a02c-cf66ad5f3f8c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_16ac86ff-a870-415a-b321-100105305dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="rmti-20210630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b1736a63-b60a-4566-9c56-a67c0a4146a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ee1b84b5-0129-4975-a621-de0e7547d2c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1736a63-b60a-4566-9c56-a67c0a4146a7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ee1b84b5-0129-4975-a621-de0e7547d2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4af09d7c-e25f-41c5-9b44-12d201306def" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1736a63-b60a-4566-9c56-a67c0a4146a7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4af09d7c-e25f-41c5-9b44-12d201306def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5094020f-d3ed-44ac-9fa0-cbe491ccc45c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1736a63-b60a-4566-9c56-a67c0a4146a7" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5094020f-d3ed-44ac-9fa0-cbe491ccc45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_083745d5-1091-436e-bd18-6ce414ea4591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1736a63-b60a-4566-9c56-a67c0a4146a7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_083745d5-1091-436e-bd18-6ce414ea4591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6df19873-fe37-4bc2-9de9-d9676431dfd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1736a63-b60a-4566-9c56-a67c0a4146a7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6df19873-fe37-4bc2-9de9-d9676431dfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_bb451db7-8230-4756-a916-d1e37ce44002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1736a63-b60a-4566-9c56-a67c0a4146a7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_bb451db7-8230-4756-a916-d1e37ce44002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8774d3f8-55ec-47f5-ac43-b62b56929fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1736a63-b60a-4566-9c56-a67c0a4146a7" xlink:to="loc_us-gaap_CommonStockSharesIssued_8774d3f8-55ec-47f5-ac43-b62b56929fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b8f8f160-fb6e-4ce3-b7ce-47fc06726e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1736a63-b60a-4566-9c56-a67c0a4146a7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b8f8f160-fb6e-4ce3-b7ce-47fc06726e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="rmti-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_945cbc4b-2c27-4d5f-8811-09a64333ca9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ea48e635-e1fb-4ee6-abb2-41cd201dec77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_945cbc4b-2c27-4d5f-8811-09a64333ca9c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ea48e635-e1fb-4ee6-abb2-41cd201dec77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_625a2312-7caf-47e2-ba6f-7cd352d3b39f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_945cbc4b-2c27-4d5f-8811-09a64333ca9c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_625a2312-7caf-47e2-ba6f-7cd352d3b39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_ae71026d-74d0-4029-994a-a19238a85408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_945cbc4b-2c27-4d5f-8811-09a64333ca9c" xlink:to="loc_us-gaap_GrossProfit_ae71026d-74d0-4029-994a-a19238a85408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3d6f0b07-be88-4ca1-8b0f-7d83f4c52c5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_945cbc4b-2c27-4d5f-8811-09a64333ca9c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3d6f0b07-be88-4ca1-8b0f-7d83f4c52c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_e49968dc-b13d-42b2-8d9c-69ac8ca27240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_945cbc4b-2c27-4d5f-8811-09a64333ca9c" xlink:to="loc_us-gaap_SellingAndMarketingExpense_e49968dc-b13d-42b2-8d9c-69ac8ca27240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4c8c9de6-1dde-4858-a3c1-a46e45739922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_945cbc4b-2c27-4d5f-8811-09a64333ca9c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4c8c9de6-1dde-4858-a3c1-a46e45739922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5a393542-5e61-450e-9c1b-665b6f837fc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_945cbc4b-2c27-4d5f-8811-09a64333ca9c" xlink:to="loc_us-gaap_OperatingIncomeLoss_5a393542-5e61-450e-9c1b-665b6f837fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_afa48924-df3e-4e8e-9920-0125da96c907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_945cbc4b-2c27-4d5f-8811-09a64333ca9c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_afa48924-df3e-4e8e-9920-0125da96c907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_f99bf43a-418b-4b64-9a7a-adca3f8b2f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_afa48924-df3e-4e8e-9920-0125da96c907" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_f99bf43a-418b-4b64-9a7a-adca3f8b2f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_07e6f898-e396-4a31-9679-3c42fdfd77b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_afa48924-df3e-4e8e-9920-0125da96c907" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_07e6f898-e396-4a31-9679-3c42fdfd77b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_209fc823-cf7f-40e9-88b7-fab7c3fa7f87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_afa48924-df3e-4e8e-9920-0125da96c907" xlink:to="loc_us-gaap_InterestExpense_209fc823-cf7f-40e9-88b7-fab7c3fa7f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_68e7c21b-99bc-4b6f-baa3-547634fafece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_afa48924-df3e-4e8e-9920-0125da96c907" xlink:to="loc_us-gaap_InvestmentIncomeInterest_68e7c21b-99bc-4b6f-baa3-547634fafece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_082360b9-acab-4e4f-afdf-368c27f7043b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_afa48924-df3e-4e8e-9920-0125da96c907" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_082360b9-acab-4e4f-afdf-368c27f7043b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_99c4b367-63e1-48d4-b27e-62f04a3cfae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_945cbc4b-2c27-4d5f-8811-09a64333ca9c" xlink:to="loc_us-gaap_NetIncomeLoss_99c4b367-63e1-48d4-b27e-62f04a3cfae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f0eaf621-dbe9-46cc-8b27-20bf73727a64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_945cbc4b-2c27-4d5f-8811-09a64333ca9c" xlink:to="loc_us-gaap_EarningsPerShareBasic_f0eaf621-dbe9-46cc-8b27-20bf73727a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7fa58206-ea1e-4326-9f6b-c125dd4daff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
<link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_945cbc4b-2c27-4d5f-8811-09a64333ca9c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7fa58206-ea1e-4326-9f6b-c125dd4daff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fed57056-f3e0-436a-9f04-cbac2f73436f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_945cbc4b-2c27-4d5f-8811-09a64333ca9c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fed57056-f3e0-436a-9f04-cbac2f73436f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b26dcf7d-4733-4ddd-a422-3225827bb1e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_945cbc4b-2c27-4d5f-8811-09a64333ca9c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b26dcf7d-4733-4ddd-a422-3225827bb1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="rmti-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_62fa8769-0940-4e1a-ac6c-1d38aa497a15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4e386d95-cde2-4f30-be23-30f062f6a045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_62fa8769-0940-4e1a-ac6c-1d38aa497a15" xlink:to="loc_us-gaap_NetIncomeLoss_4e386d95-cde2-4f30-be23-30f062f6a045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_cebf6e98-3797-4fb1-b814-701e94e99130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_62fa8769-0940-4e1a-ac6c-1d38aa497a15" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_cebf6e98-3797-4fb1-b814-701e94e99130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3471f967-05c4-49b9-b3df-ecd0bdd00c68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_62fa8769-0940-4e1a-ac6c-1d38aa497a15" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3471f967-05c4-49b9-b3df-ecd0bdd00c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c2f1c69e-5d30-47dc-93a7-3d846f0a5369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_62fa8769-0940-4e1a-ac6c-1d38aa497a15" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c2f1c69e-5d30-47dc-93a7-3d846f0a5369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="rmti-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_bf7b0460-d356-4f30-a317-1e663b0129e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c8b2df87-c271-48a1-8881-b9e9e52d47a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_bf7b0460-d356-4f30-a317-1e663b0129e9" xlink:to="loc_us-gaap_StatementTable_c8b2df87-c271-48a1-8881-b9e9e52d47a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_501cd21c-d7af-4bba-8e89-55b86f57273d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c8b2df87-c271-48a1-8881-b9e9e52d47a4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_501cd21c-d7af-4bba-8e89-55b86f57273d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5227b286-e034-46ab-a851-c4d671a2e4d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_501cd21c-d7af-4bba-8e89-55b86f57273d" xlink:to="loc_us-gaap_EquityComponentDomain_5227b286-e034-46ab-a851-c4d671a2e4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7fa94261-1c13-417a-9915-4c9f82a9346f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5227b286-e034-46ab-a851-c4d671a2e4d6" xlink:to="loc_us-gaap_CommonStockMember_7fa94261-1c13-417a-9915-4c9f82a9346f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2ae763d1-0096-49ea-800e-311706377269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5227b286-e034-46ab-a851-c4d671a2e4d6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2ae763d1-0096-49ea-800e-311706377269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d56ad182-014b-4b4c-9752-7259d3b2622c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5227b286-e034-46ab-a851-c4d671a2e4d6" xlink:to="loc_us-gaap_RetainedEarningsMember_d56ad182-014b-4b4c-9752-7259d3b2622c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6cc9f9e-e4f0-4e5e-bb59-f885caf8ec5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5227b286-e034-46ab-a851-c4d671a2e4d6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6cc9f9e-e4f0-4e5e-bb59-f885caf8ec5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_83848190-b92a-4f35-b05d-9e21f7d417ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c8b2df87-c271-48a1-8881-b9e9e52d47a4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_83848190-b92a-4f35-b05d-9e21f7d417ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5db25f01-4fde-4e16-9140-25c149a2df8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_83848190-b92a-4f35-b05d-9e21f7d417ad" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5db25f01-4fde-4e16-9140-25c149a2df8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_BoughtDealMember_5f9c59a7-c06a-476e-86c6-395d136835ac" xlink:href="rmti-20210630.xsd#rmti_BoughtDealMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5db25f01-4fde-4e16-9140-25c149a2df8d" xlink:to="loc_rmti_BoughtDealMember_5f9c59a7-c06a-476e-86c6-395d136835ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PublicOfferingMember_82aea572-7420-4bb8-b689-d40ac6b83aac" xlink:href="rmti-20210630.xsd#rmti_PublicOfferingMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5db25f01-4fde-4e16-9140-25c149a2df8d" xlink:to="loc_rmti_PublicOfferingMember_82aea572-7420-4bb8-b689-d40ac6b83aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_859aa6a4-efc4-4a07-8380-205c91f2dcdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c8b2df87-c271-48a1-8881-b9e9e52d47a4" xlink:to="loc_us-gaap_StatementLineItems_859aa6a4-efc4-4a07-8380-205c91f2dcdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_859aa6a4-efc4-4a07-8380-205c91f2dcdb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c9f3a91a-42f4-4b40-ae56-88a58a7ad611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c9f3a91a-42f4-4b40-ae56-88a58a7ad611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a0017236-be67-45cd-8e7c-f92f485cf04e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_StockholdersEquity_a0017236-be67-45cd-8e7c-f92f485cf04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f711cf73-89da-4ec9-a9e9-a2aa5ef3bf89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_NetIncomeLoss_f711cf73-89da-4ec9-a9e9-a2aa5ef3bf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7a9cd190-4271-44f9-b940-d8eb559c0772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7a9cd190-4271-44f9-b940-d8eb559c0772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8b7dc506-88ce-429d-9ae1-78f285950551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8b7dc506-88ce-429d-9ae1-78f285950551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_be67ce1f-7764-4f4a-bf4a-9222e09f3c35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_be67ce1f-7764-4f4a-bf4a-9222e09f3c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2b457619-0aa4-4e7f-94a1-6c528e567311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2b457619-0aa4-4e7f-94a1-6c528e567311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f4fb38d3-6fe9-4cc6-9581-f4bdc1f1d8b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f4fb38d3-6fe9-4cc6-9581-f4bdc1f1d8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a50c8863-3797-4ccd-9ffb-517fec4d901b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a50c8863-3797-4ccd-9ffb-517fec4d901b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense_7f935825-3101-4884-bd12-f082de81e177" xlink:href="rmti-20210630.xsd#rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense_7f935825-3101-4884-bd12-f082de81e177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_3f9ad7ca-4bcb-4be5-811b-2bbbfa7b910c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
<link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_3f9ad7ca-4bcb-4be5-811b-2bbbfa7b910c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a68c26cf-4cb1-483f-a2a1-859cd0f91686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
<link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a68c26cf-4cb1-483f-a2a1-859cd0f91686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1ea40219-331c-431c-aa14-666c5f473be1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
<link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1ea40219-331c-431c-aa14-666c5f473be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a3f0c25a-a54b-4e9b-b274-5f3aa827d653" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
<link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a3f0c25a-a54b-4e9b-b274-5f3aa827d653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0d5e1e26-4e03-42a6-8483-f756bab923dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
<link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1eb241c-879a-4bb5-89e5-19bd016e0809" xlink:to="loc_us-gaap_StockholdersEquity_0d5e1e26-4e03-42a6-8483-f756bab923dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="rmti-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9fcb3a59-6858-4d97-9662-0209e1513529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d1929cda-b9c1-4734-83e5-140b829d4a89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9fcb3a59-6858-4d97-9662-0209e1513529" xlink:to="loc_us-gaap_StatementTable_d1929cda-b9c1-4734-83e5-140b829d4a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_639abf3b-b73d-45fd-a104-d30ec488e714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d1929cda-b9c1-4734-83e5-140b829d4a89" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_639abf3b-b73d-45fd-a104-d30ec488e714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf857065-23b8-474b-930b-8f4880e4895c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_639abf3b-b73d-45fd-a104-d30ec488e714" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf857065-23b8-474b-930b-8f4880e4895c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PublicOfferingMember_ab1af95f-46b5-4f8f-8d21-5b2bd4cd6a57" xlink:href="rmti-20210630.xsd#rmti_PublicOfferingMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf857065-23b8-474b-930b-8f4880e4895c" xlink:to="loc_rmti_PublicOfferingMember_ab1af95f-46b5-4f8f-8d21-5b2bd4cd6a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_AtthemarketOfferingMember_c85ac205-9508-47b4-b2ec-35de3411c703" xlink:href="rmti-20210630.xsd#rmti_AtthemarketOfferingMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf857065-23b8-474b-930b-8f4880e4895c" xlink:to="loc_rmti_AtthemarketOfferingMember_c85ac205-9508-47b4-b2ec-35de3411c703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d1929cda-b9c1-4734-83e5-140b829d4a89" xlink:to="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_31d6483c-319d-4774-81ed-a53a94c0ba45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_31d6483c-319d-4774-81ed-a53a94c0ba45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b75ed7db-0e60-4372-9247-77224ae13f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_31d6483c-319d-4774-81ed-a53a94c0ba45" xlink:to="loc_us-gaap_NetIncomeLoss_b75ed7db-0e60-4372-9247-77224ae13f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_31d6483c-319d-4774-81ed-a53a94c0ba45" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_bf3c5f23-fc15-4a34-8b6c-88ce16805c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_bf3c5f23-fc15-4a34-8b6c-88ce16805c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0527e997-7335-4cc5-ba21-3675c14ad1cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_ShareBasedCompensation_0527e997-7335-4cc5-ba21-3675c14ad1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_b8b2c381-770a-442b-9225-31343a547e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_b8b2c381-770a-442b-9225-31343a547e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReservePeriodCharge_c3769e55-066c-4a2f-bc7a-3ed35ca08a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_InventoryLIFOReservePeriodCharge_c3769e55-066c-4a2f-bc7a-3ed35ca08a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_45e2fdb1-87bf-4cdb-8820-25bbe1d2e0d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_45e2fdb1-87bf-4cdb-8820-25bbe1d2e0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_87c2d7f2-72bb-428b-ad9a-57138c54712e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_87c2d7f2-72bb-428b-ad9a-57138c54712e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_4dc41c47-aad9-4836-93bc-ad8026295fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_4dc41c47-aad9-4836-93bc-ad8026295fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_fcffb9aa-1af1-441e-8c2d-994a969f65bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_fcffb9aa-1af1-441e-8c2d-994a969f65bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0e1fa9e5-de30-4be6-a653-25db6bd3fc46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0e1fa9e5-de30-4be6-a653-25db6bd3fc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684535d3-9b2b-42b9-932b-c1d1c0be4ae0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_88cb60d7-87a1-45f8-801f-cb94d2ab9950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_88cb60d7-87a1-45f8-801f-cb94d2ab9950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_299f2784-2a2e-4702-b99c-1f3ab5046a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_299f2784-2a2e-4702-b99c-1f3ab5046a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_87070fa3-d785-4958-8390-a841dc9ace15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_87070fa3-d785-4958-8390-a841dc9ace15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b655e20a-3fa3-45df-9c4e-588385875548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b655e20a-3fa3-45df-9c4e-588385875548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_fcbe5332-96f5-43bc-9a47-3b5ff260cbd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_fcbe5332-96f5-43bc-9a47-3b5ff260cbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_IncreaseDecreaseInOperatingLeaseLiability_7fdcf459-dc2c-4b74-8c4d-313bdba90580" xlink:href="rmti-20210630.xsd#rmti_IncreaseDecreaseInOperatingLeaseLiability"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_rmti_IncreaseDecreaseInOperatingLeaseLiability_7fdcf459-dc2c-4b74-8c4d-313bdba90580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_406ec99c-21cf-4392-a4a8-684cfc018cc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_406ec99c-21cf-4392-a4a8-684cfc018cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_29c78191-9f6c-4024-b239-ba88b5e3c8a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_29c78191-9f6c-4024-b239-ba88b5e3c8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_ec886356-0297-4dfd-b5b9-8ca8c386bf10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2d275a6-6898-495d-a204-88cb62996ef7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_ec886356-0297-4dfd-b5b9-8ca8c386bf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_44a8da55-0edd-4b40-bb94-59984c3426b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_31d6483c-319d-4774-81ed-a53a94c0ba45" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_44a8da55-0edd-4b40-bb94-59984c3426b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f38c6af6-a658-4ea6-a4b4-8c314ed28b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f38c6af6-a658-4ea6-a4b4-8c314ed28b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_cf96303c-7b9c-4f27-933c-f27b6b568ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f38c6af6-a658-4ea6-a4b4-8c314ed28b0e" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_cf96303c-7b9c-4f27-933c-f27b6b568ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_79a7460a-1754-4106-9002-00b45a78358d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f38c6af6-a658-4ea6-a4b4-8c314ed28b0e" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_79a7460a-1754-4106-9002-00b45a78358d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_ddc3860d-3a05-469f-9bb1-ca85cdd67bbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f38c6af6-a658-4ea6-a4b4-8c314ed28b0e" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_ddc3860d-3a05-469f-9bb1-ca85cdd67bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a336780e-9ac3-4670-88d9-1492158b315a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f38c6af6-a658-4ea6-a4b4-8c314ed28b0e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a336780e-9ac3-4670-88d9-1492158b315a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8ca9aeff-c25d-4fbb-a735-3645eb70356d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8ca9aeff-c25d-4fbb-a735-3645eb70356d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2952d66d-31e6-4e0b-beec-5860ef941b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2952d66d-31e6-4e0b-beec-5860ef941b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_2b70d535-5059-4cb8-8f71-c34e87bd8149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_2b70d535-5059-4cb8-8f71-c34e87bd8149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_266a026a-fb60-424d-9f7b-9352a1022f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_266a026a-fb60-424d-9f7b-9352a1022f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b5c3af9a-d188-4840-b23a-68aad641a7e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b5c3af9a-d188-4840-b23a-68aad641a7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_4a9e62d3-08b1-4437-bf2d-20733c1bd19b" xlink:href="rmti-20210630.xsd#rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:to="loc_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes_4a9e62d3-08b1-4437-bf2d-20733c1bd19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c102cb77-98d2-4672-8a8e-d560e1eca398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6c99423-716a-426e-a4e2-f1f0dcce4ba5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c102cb77-98d2-4672-8a8e-d560e1eca398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fabb4421-81b5-4cf4-b4ba-3b0844355938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fabb4421-81b5-4cf4-b4ba-3b0844355938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bcd94911-9d28-40aa-9d8f-4ed6951ccc93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bcd94911-9d28-40aa-9d8f-4ed6951ccc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e933a7c5-6ccd-476c-ad61-c196fe086065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e933a7c5-6ccd-476c-ad61-c196fe086065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5009fa77-59af-4fd9-baa2-12a472c42917" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5009fa77-59af-4fd9-baa2-12a472c42917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_c2647606-2da6-4267-9727-5c9ddca8bf7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5009fa77-59af-4fd9-baa2-12a472c42917" xlink:to="loc_us-gaap_InterestPaidNet_c2647606-2da6-4267-9727-5c9ddca8bf7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_912ae4a7-dfb5-474f-abf1-057fd00371f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1f369b9-c642-4cce-a1a9-d05c48d4bb3d" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_912ae4a7-dfb5-474f-abf1-057fd00371f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_a4c54787-68cb-4a3b-97aa-39d2ed6cda2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_912ae4a7-dfb5-474f-abf1-057fd00371f4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_a4c54787-68cb-4a3b-97aa-39d2ed6cda2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_6e4879c4-bbfb-48c9-92aa-1c9aeafc5b6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_912ae4a7-dfb5-474f-abf1-057fd00371f4" xlink:to="loc_us-gaap_StockIssued1_6e4879c4-bbfb-48c9-92aa-1c9aeafc5b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="rmti-20210630.xsd#DescriptionofBusiness"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/DescriptionofBusiness" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6171c5b4-40cf-4062-ba71-3896ef9ed466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_264982ad-9e1a-4f6e-940b-4625a218ea81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6171c5b4-40cf-4062-ba71-3896ef9ed466" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_264982ad-9e1a-4f6e-940b-4625a218ea81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#DescriptionofBusinessDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/DescriptionofBusinessDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_816585d0-43c1-4e9f-8161-d0eba8e16d56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0eae1963-9c42-4b30-b5a3-fca83aa4e1bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_816585d0-43c1-4e9f-8161-d0eba8e16d56" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0eae1963-9c42-4b30-b5a3-fca83aa4e1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_YearsOfService_8d2f7964-6cbb-449e-af89-200402f9598e" xlink:href="rmti-20210630.xsd#rmti_YearsOfService"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_816585d0-43c1-4e9f-8161-d0eba8e16d56" xlink:to="loc_rmti_YearsOfService_8d2f7964-6cbb-449e-af89-200402f9598e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_76a9c13b-98ae-4659-bf25-575b3fa1d2c9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityNumberOfEmployees"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_816585d0-43c1-4e9f-8161-d0eba8e16d56" xlink:to="loc_dei_EntityNumberOfEmployees_76a9c13b-98ae-4659-bf25-575b3fa1d2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LiquidityandCapitalResources" xlink:type="simple" xlink:href="rmti-20210630.xsd#LiquidityandCapitalResources"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/LiquidityandCapitalResources" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_rmti_LiquidityAndCapitalResourcesAbstract_68c6c298-a386-4028-b0f3-784d05e9ec5e" xlink:href="rmti-20210630.xsd#rmti_LiquidityAndCapitalResourcesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_LiquidityAndFinancialConditionTextBlock_28e4ca5d-a2b5-479e-bd43-11bd2a7d4403" xlink:href="rmti-20210630.xsd#rmti_LiquidityAndFinancialConditionTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_LiquidityAndCapitalResourcesAbstract_68c6c298-a386-4028-b0f3-784d05e9ec5e" xlink:to="loc_rmti_LiquidityAndFinancialConditionTextBlock_28e4ca5d-a2b5-479e-bd43-11bd2a7d4403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#LiquidityandCapitalResourcesDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_rmti_LiquidityAndCapitalResourcesAbstract_c77c3c3a-4cbc-45c6-a75c-a82b253aaa67" xlink:href="rmti-20210630.xsd#rmti_LiquidityAndCapitalResourcesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_41dbd7f2-30eb-4064-8d13-538d9912fbbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_LiquidityAndCapitalResourcesAbstract_c77c3c3a-4cbc-45c6-a75c-a82b253aaa67" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_41dbd7f2-30eb-4064-8d13-538d9912fbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cc8b398d-60c9-4433-8ed7-cdcb6ad24411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_LiquidityAndCapitalResourcesAbstract_c77c3c3a-4cbc-45c6-a75c-a82b253aaa67" xlink:to="loc_us-gaap_StockholdersEquity_cc8b398d-60c9-4433-8ed7-cdcb6ad24411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_90df82f4-0683-4b51-b50f-a30bb4ccc44c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_LiquidityAndCapitalResourcesAbstract_c77c3c3a-4cbc-45c6-a75c-a82b253aaa67" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_90df82f4-0683-4b51-b50f-a30bb4ccc44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_WorkingCapitalNet_1083bc2b-6d1d-4df1-8b06-fb9149d90aaf" xlink:href="rmti-20210630.xsd#rmti_WorkingCapitalNet"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_LiquidityAndCapitalResourcesAbstract_c77c3c3a-4cbc-45c6-a75c-a82b253aaa67" xlink:to="loc_rmti_WorkingCapitalNet_1083bc2b-6d1d-4df1-8b06-fb9149d90aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce7679b2-1c8f-48a2-9ce8-516368ec83e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_LiquidityAndCapitalResourcesAbstract_c77c3c3a-4cbc-45c6-a75c-a82b253aaa67" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce7679b2-1c8f-48a2-9ce8-516368ec83e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements" xlink:type="simple" xlink:href="rmti-20210630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ff4eed43-0f4b-41bf-afb3-7ac54a658afa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_bf4e2ae5-2ea0-44b5-8d76-820fd8d08556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ff4eed43-0f4b-41bf-afb3-7ac54a658afa" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_bf4e2ae5-2ea0-44b5-8d76-820fd8d08556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies" xlink:type="simple" xlink:href="rmti-20210630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0f272055-fc1b-4181-8298-0cb0de0f727a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_06262604-7bf6-4698-8bd5-bc980ddd86f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f272055-fc1b-4181-8298-0cb0de0f727a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_06262604-7bf6-4698-8bd5-bc980ddd86f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_65a029a6-b622-4cc3-9f59-a4adc63ecac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f272055-fc1b-4181-8298-0cb0de0f727a" xlink:to="loc_us-gaap_UseOfEstimates_65a029a6-b622-4cc3-9f59-a4adc63ecac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_491eed48-484c-4fe9-92a6-2d0b8b311999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f272055-fc1b-4181-8298-0cb0de0f727a" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_491eed48-484c-4fe9-92a6-2d0b8b311999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_0e7cfc06-782b-46d5-a236-55c07212da39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f272055-fc1b-4181-8298-0cb0de0f727a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_0e7cfc06-782b-46d5-a236-55c07212da39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bb8fa90d-bb13-4a96-957d-9893f068402f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f272055-fc1b-4181-8298-0cb0de0f727a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bb8fa90d-bb13-4a96-957d-9893f068402f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables" xlink:type="simple" xlink:href="rmti-20210630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a204254e-9558-424b-89b8-305b74291dac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9da0376a-6465-4e17-9822-20bce2376b74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a204254e-9558-424b-89b8-305b74291dac" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9da0376a-6465-4e17-9822-20bce2376b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cec1e90a-2e92-444b-bffb-b8a3019ec6d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b579ac49-b679-4c96-b922-5bc68b022f10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cec1e90a-2e92-444b-bffb-b8a3019ec6d4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b579ac49-b679-4c96-b922-5bc68b022f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_56a4f7b1-e493-4377-847e-5831554d0afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b579ac49-b679-4c96-b922-5bc68b022f10" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_56a4f7b1-e493-4377-847e-5831554d0afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85192a08-4a10-4e58-9ba8-55eeb24b2fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_56a4f7b1-e493-4377-847e-5831554d0afe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85192a08-4a10-4e58-9ba8-55eeb24b2fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d59f9b91-0229-46c6-b5d5-c7b87e031f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85192a08-4a10-4e58-9ba8-55eeb24b2fd6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d59f9b91-0229-46c6-b5d5-c7b87e031f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0768a771-f87b-4054-b176-a5fd792ec1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85192a08-4a10-4e58-9ba8-55eeb24b2fd6" xlink:to="loc_us-gaap_RestrictedStockMember_0768a771-f87b-4054-b176-a5fd792ec1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_baffe867-6d28-4a0e-a5ed-5813433badad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85192a08-4a10-4e58-9ba8-55eeb24b2fd6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_baffe867-6d28-4a0e-a5ed-5813433badad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_3c628738-bee7-40fa-9a94-1acbaf7eb333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85192a08-4a10-4e58-9ba8-55eeb24b2fd6" xlink:to="loc_us-gaap_WarrantMember_3c628738-bee7-40fa-9a94-1acbaf7eb333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_44f55a0d-18cd-4011-9ad3-31f4ac9e5aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b579ac49-b679-4c96-b922-5bc68b022f10" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_44f55a0d-18cd-4011-9ad3-31f4ac9e5aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1d57f633-e742-4482-a827-c6750c0ebf07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_44f55a0d-18cd-4011-9ad3-31f4ac9e5aa3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1d57f633-e742-4482-a827-c6750c0ebf07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognition" xlink:type="simple" xlink:href="rmti-20210630.xsd#RevenueRecognition"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/RevenueRecognition" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f777a562-3c14-4f4e-abcc-4d9ceebc5174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_acc56645-15e6-402c-9ffc-e571e46b23c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f777a562-3c14-4f4e-abcc-4d9ceebc5174" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_acc56645-15e6-402c-9ffc-e571e46b23c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="rmti-20210630.xsd#RevenueRecognitionTables"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9ae32143-6f71-4a79-b7d1-a3896b7bda0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_3e2cc6cf-a190-4b9a-a035-10a4405680f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9ae32143-6f71-4a79-b7d1-a3896b7bda0f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_3e2cc6cf-a190-4b9a-a035-10a4405680f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_8e00fa1d-e5da-41b5-9a35-fcd27be880fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9ae32143-6f71-4a79-b7d1-a3896b7bda0f" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_8e00fa1d-e5da-41b5-9a35-fcd27be880fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#RevenueRecognitionNatureofGoodsandServicesDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6445a58d-4f36-4d26-aa25-83e83899d3d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_NumberOfDistributionAndLicenseAgreements_80725296-b8a1-4a3f-8e1a-195de963b317" xlink:href="rmti-20210630.xsd#rmti_NumberOfDistributionAndLicenseAgreements"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6445a58d-4f36-4d26-aa25-83e83899d3d9" xlink:to="loc_rmti_NumberOfDistributionAndLicenseAgreements_80725296-b8a1-4a3f-8e1a-195de963b317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_AveragePaymentTermOfCustomers_d862d2f2-aec2-4200-9cd2-9f1da53c91cd" xlink:href="rmti-20210630.xsd#rmti_AveragePaymentTermOfCustomers"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6445a58d-4f36-4d26-aa25-83e83899d3d9" xlink:to="loc_rmti_AveragePaymentTermOfCustomers_d862d2f2-aec2-4200-9cd2-9f1da53c91cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_AveragePaymentTermOfDistributors_b5be8c7d-5dad-450c-8970-3467f1dfe516" xlink:href="rmti-20210630.xsd#rmti_AveragePaymentTermOfDistributors"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6445a58d-4f36-4d26-aa25-83e83899d3d9" xlink:to="loc_rmti_AveragePaymentTermOfDistributors_b5be8c7d-5dad-450c-8970-3467f1dfe516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6410b6e-c331-40c5-8f35-dbdf5832687a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_22ae5c45-d46f-48e3-90b2-3fb9b518b6c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6410b6e-c331-40c5-8f35-dbdf5832687a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_22ae5c45-d46f-48e3-90b2-3fb9b518b6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_78c3c1a4-ed5c-4011-aed7-dcb452a7263a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_22ae5c45-d46f-48e3-90b2-3fb9b518b6c1" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_78c3c1a4-ed5c-4011-aed7-dcb452a7263a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_4a29c659-c52b-4949-aa29-371468469620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_78c3c1a4-ed5c-4011-aed7-dcb452a7263a" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_4a29c659-c52b-4949-aa29-371468469620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_7e25329a-3f9e-4762-be81-a81b1be32dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredAtPointInTimeMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_4a29c659-c52b-4949-aa29-371468469620" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_7e25329a-3f9e-4762-be81-a81b1be32dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_b68def1d-647f-4905-a93a-f1c05391219f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_4a29c659-c52b-4949-aa29-371468469620" xlink:to="loc_us-gaap_TransferredOverTimeMember_b68def1d-647f-4905-a93a-f1c05391219f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_46091c6e-ee58-488e-bb59-d9d84ec512a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_22ae5c45-d46f-48e3-90b2-3fb9b518b6c1" xlink:to="loc_srt_StatementGeographicalAxis_46091c6e-ee58-488e-bb59-d9d84ec512a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1d46aa3b-ef40-449b-b190-12e21023848e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_46091c6e-ee58-488e-bb59-d9d84ec512a6" xlink:to="loc_srt_SegmentGeographicalDomain_1d46aa3b-ef40-449b-b190-12e21023848e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_country_US_3bec35bd-851e-4e6b-98bb-23d050517400" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1d46aa3b-ef40-449b-b190-12e21023848e" xlink:to="loc_country_US_3bec35bd-851e-4e6b-98bb-23d050517400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_b7747984-bbfb-4640-b5fa-8995ab183a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1d46aa3b-ef40-449b-b190-12e21023848e" xlink:to="loc_us-gaap_NonUsMember_b7747984-bbfb-4640-b5fa-8995ab183a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2ff91489-ae6b-478a-86dd-2080033e2098" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_22ae5c45-d46f-48e3-90b2-3fb9b518b6c1" xlink:to="loc_srt_ProductOrServiceAxis_2ff91489-ae6b-478a-86dd-2080033e2098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6f33e8d6-57ef-47dc-bc0a-27b69c0ee71d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2ff91489-ae6b-478a-86dd-2080033e2098" xlink:to="loc_srt_ProductsAndServicesDomain_6f33e8d6-57ef-47dc-bc0a-27b69c0ee71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DrugRevenueMember_a35f97b1-f90a-4a9b-b72b-7eec317aa6b1" xlink:href="rmti-20210630.xsd#rmti_DrugRevenueMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6f33e8d6-57ef-47dc-bc0a-27b69c0ee71d" xlink:to="loc_rmti_DrugRevenueMember_a35f97b1-f90a-4a9b-b72b-7eec317aa6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DrugProductSalesMember_7d1d4ca1-e7c0-4150-baf7-305443bd7b96" xlink:href="rmti-20210630.xsd#rmti_DrugProductSalesMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_DrugRevenueMember_a35f97b1-f90a-4a9b-b72b-7eec317aa6b1" xlink:to="loc_rmti_DrugProductSalesMember_7d1d4ca1-e7c0-4150-baf7-305443bd7b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DrugLicenseFeeMember_232470a2-ff00-48b2-a391-ad3015099e11" xlink:href="rmti-20210630.xsd#rmti_DrugLicenseFeeMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_DrugRevenueMember_a35f97b1-f90a-4a9b-b72b-7eec317aa6b1" xlink:to="loc_rmti_DrugLicenseFeeMember_232470a2-ff00-48b2-a391-ad3015099e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductsMember_217f4427-5933-43e4-9572-f4db572db207" xlink:href="rmti-20210630.xsd#rmti_ConcentrateProductsMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6f33e8d6-57ef-47dc-bc0a-27b69c0ee71d" xlink:to="loc_rmti_ConcentrateProductsMember_217f4427-5933-43e4-9572-f4db572db207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductSalesMember_4b5f185f-5479-40ac-96f7-8268fca43297" xlink:href="rmti-20210630.xsd#rmti_ConcentrateProductSalesMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ConcentrateProductsMember_217f4427-5933-43e4-9572-f4db572db207" xlink:to="loc_rmti_ConcentrateProductSalesMember_4b5f185f-5479-40ac-96f7-8268fca43297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductLicenseFeeMember_4a61d5d6-ea5e-4433-bcfc-b89c91b688f4" xlink:href="rmti-20210630.xsd#rmti_ConcentrateProductLicenseFeeMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ConcentrateProductsMember_217f4427-5933-43e4-9572-f4db572db207" xlink:to="loc_rmti_ConcentrateProductLicenseFeeMember_4a61d5d6-ea5e-4433-bcfc-b89c91b688f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7c790e00-d366-49b2-8536-d47026a4462a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_22ae5c45-d46f-48e3-90b2-3fb9b518b6c1" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_7c790e00-d366-49b2-8536-d47026a4462a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c9cfb9da-5bd6-42d8-931f-32b55d2216ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7c790e00-d366-49b2-8536-d47026a4462a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c9cfb9da-5bd6-42d8-931f-32b55d2216ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#RevenueRecognitionContractBalancesDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d436730b-24dc-434c-8422-665a92c7a31e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_1931e934-a23f-4d2c-b174-fc4a8709e8bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivables"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d436730b-24dc-434c-8422-665a92c7a31e" xlink:to="loc_us-gaap_OtherReceivables_1931e934-a23f-4d2c-b174-fc4a8709e8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_27b831e2-a816-4273-848f-a18b59f32e85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d436730b-24dc-434c-8422-665a92c7a31e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_27b831e2-a816-4273-848f-a18b59f32e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#RevenueRecognitionNarrativeDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_848cefde-9ee3-4073-b699-747af4730bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionTable_dca8378a-2677-47f4-9d6b-708e989be28b" xlink:href="rmti-20210630.xsd#rmti_RevenueRecognitionTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_848cefde-9ee3-4073-b699-747af4730bbb" xlink:to="loc_rmti_RevenueRecognitionTable_dca8378a-2677-47f4-9d6b-708e989be28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b16e2bdb-44bf-4c02-a5f9-42b127e6b9b9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_RevenueRecognitionTable_dca8378a-2677-47f4-9d6b-708e989be28b" xlink:to="loc_srt_ProductOrServiceAxis_b16e2bdb-44bf-4c02-a5f9-42b127e6b9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9082b3e2-a93d-4699-b6cc-a6c741e31725" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b16e2bdb-44bf-4c02-a5f9-42b127e6b9b9" xlink:to="loc_srt_ProductsAndServicesDomain_9082b3e2-a93d-4699-b6cc-a6c741e31725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ConcentrateProductsMember_4ad6548b-7989-41a8-94ed-7407d38873c8" xlink:href="rmti-20210630.xsd#rmti_ConcentrateProductsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9082b3e2-a93d-4699-b6cc-a6c741e31725" xlink:to="loc_rmti_ConcentrateProductsMember_4ad6548b-7989-41a8-94ed-7407d38873c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_26fc3034-6554-4244-946b-9f4674d175ac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_RevenueRecognitionTable_dca8378a-2677-47f4-9d6b-708e989be28b" xlink:to="loc_srt_CounterpartyNameAxis_26fc3034-6554-4244-946b-9f4674d175ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5175663-ef13-4bd6-8e88-1f6ae4954a12" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_26fc3034-6554-4244-946b-9f4674d175ac" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5175663-ef13-4bd6-8e88-1f6ae4954a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_BaxterHealthcareOrganizationMember_33cad2c9-06f3-410e-bdc3-ef85689b296e" xlink:href="rmti-20210630.xsd#rmti_BaxterHealthcareOrganizationMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5175663-ef13-4bd6-8e88-1f6ae4954a12" xlink:to="loc_rmti_BaxterHealthcareOrganizationMember_33cad2c9-06f3-410e-bdc3-ef85689b296e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionLineItems_6c0d0093-166c-47f7-8acb-9f42b77b6731" xlink:href="rmti-20210630.xsd#rmti_RevenueRecognitionLineItems"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_RevenueRecognitionTable_dca8378a-2677-47f4-9d6b-708e989be28b" xlink:to="loc_rmti_RevenueRecognitionLineItems_6c0d0093-166c-47f7-8acb-9f42b77b6731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCreditLossExpense_0fb44af7-3a4b-4400-9e5d-d30c4b7882f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetCreditLossExpense"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_RevenueRecognitionLineItems_6c0d0093-166c-47f7-8acb-9f42b77b6731" xlink:to="loc_us-gaap_ContractWithCustomerAssetCreditLossExpense_0fb44af7-3a4b-4400-9e5d-d30c4b7882f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_593f3ea0-ceb5-48ad-9269-346df26d035d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_RevenueRecognitionLineItems_6c0d0093-166c-47f7-8acb-9f42b77b6731" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_593f3ea0-ceb5-48ad-9269-346df26d035d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability_010f1138-2a5e-4fd8-b8c1-cc8e4a04cdbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_RevenueRecognitionLineItems_6c0d0093-166c-47f7-8acb-9f42b77b6731" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiability_010f1138-2a5e-4fd8-b8c1-cc8e4a04cdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_62474c4c-7f23-4d07-91ac-2419eb762df0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_RevenueRecognitionLineItems_6c0d0093-166c-47f7-8acb-9f42b77b6731" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_62474c4c-7f23-4d07-91ac-2419eb762df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSale" xlink:type="simple" xlink:href="rmti-20210630.xsd#InvestmentsAvailableforSale"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/InvestmentsAvailableforSale" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_66618128-95b7-4704-a047-a3cd68e8999f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_aac18277-20f3-4efd-8b25-4cc33ffb0bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_66618128-95b7-4704-a047-a3cd68e8999f" xlink:to="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_aac18277-20f3-4efd-8b25-4cc33ffb0bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSaleTables" xlink:type="simple" xlink:href="rmti-20210630.xsd#InvestmentsAvailableforSaleTables"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/InvestmentsAvailableforSaleTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ccc0b2fa-2d61-4ea0-9b5e-3e6627244bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_dee50922-571e-4233-b431-0fea1dd60b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ccc0b2fa-2d61-4ea0-9b5e-3e6627244bee" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_dee50922-571e-4233-b431-0fea1dd60b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#InvestmentsAvailableforSaleDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3cae8fca-403e-42a2-a441-55d8961b72ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_d03c455d-60ff-4d6a-aba0-f7ae020706a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3cae8fca-403e-42a2-a441-55d8961b72ed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_d03c455d-60ff-4d6a-aba0-f7ae020706a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_08c72575-82a8-43c2-bb98-fa77ed5f0379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3cae8fca-403e-42a2-a441-55d8961b72ed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_08c72575-82a8-43c2-bb98-fa77ed5f0379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f08ddf11-26bc-4437-8445-875b3b759b9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3cae8fca-403e-42a2-a441-55d8961b72ed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f08ddf11-26bc-4437-8445-875b3b759b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent_15a36796-2a94-4f58-b009-e5902bcd6f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3cae8fca-403e-42a2-a441-55d8961b72ed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent_15a36796-2a94-4f58-b009-e5902bcd6f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5cd0115c-ceac-4cfc-8871-c0f598e0ff3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3cae8fca-403e-42a2-a441-55d8961b72ed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5cd0115c-ceac-4cfc-8871-c0f598e0ff3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/Inventory" xlink:type="simple" xlink:href="rmti-20210630.xsd#Inventory"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/Inventory" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5a9c4a8f-e6e2-4d71-993d-19f740edae6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_da583aec-5f52-4fc9-ab5e-aabc1ae362ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5a9c4a8f-e6e2-4d71-993d-19f740edae6a" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_da583aec-5f52-4fc9-ab5e-aabc1ae362ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/InventoryTables" xlink:type="simple" xlink:href="rmti-20210630.xsd#InventoryTables"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/InventoryTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b7e7262f-6f57-4d03-a1e4-0b4f3fddaf99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_dcec8b37-b0cc-4031-a00b-19bae511edd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b7e7262f-6f57-4d03-a1e4-0b4f3fddaf99" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_dcec8b37-b0cc-4031-a00b-19bae511edd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/InventoryDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#InventoryDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/InventoryDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_46c025cf-582f-4bd1-bbd5-00c90f877068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_8d9233e8-74b4-4fa9-8d33-45a39747ebb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_46c025cf-582f-4bd1-bbd5-00c90f877068" xlink:to="loc_us-gaap_InventoryCurrentTable_8d9233e8-74b4-4fa9-8d33-45a39747ebb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_2f26002a-fd8d-4b55-a46a-0b0e78956ec4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_8d9233e8-74b4-4fa9-8d33-45a39747ebb7" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_2f26002a-fd8d-4b55-a46a-0b0e78956ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_32244b62-4db5-46f9-b646-0d7ed375eb08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_2f26002a-fd8d-4b55-a46a-0b0e78956ec4" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_32244b62-4db5-46f9-b646-0d7ed375eb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericInventoryMember_5408b7f5-9dcf-4420-8f5f-eb005f4193bd" xlink:href="rmti-20210630.xsd#rmti_TrifericInventoryMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_32244b62-4db5-46f9-b646-0d7ed375eb08" xlink:to="loc_rmti_TrifericInventoryMember_5408b7f5-9dcf-4420-8f5f-eb005f4193bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericDialysateMember_b47fdf5d-6614-4814-a34e-be2c7be5a140" xlink:href="rmti-20210630.xsd#rmti_TrifericDialysateMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_TrifericInventoryMember_5408b7f5-9dcf-4420-8f5f-eb005f4193bd" xlink:to="loc_rmti_TrifericDialysateMember_b47fdf5d-6614-4814-a34e-be2c7be5a140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TrifericAPIMember_63b71b28-0677-48c4-a8de-70bdcbdb2137" xlink:href="rmti-20210630.xsd#rmti_TrifericAPIMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_TrifericInventoryMember_5408b7f5-9dcf-4420-8f5f-eb005f4193bd" xlink:to="loc_rmti_TrifericAPIMember_63b71b28-0677-48c4-a8de-70bdcbdb2137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_d559d24d-c90d-4d9f-998a-af785a29ab5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_8d9233e8-74b4-4fa9-8d33-45a39747ebb7" xlink:to="loc_us-gaap_InventoryLineItems_d559d24d-c90d-4d9f-998a-af785a29ab5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_39022aa0-3bf2-44e8-9c7c-12eeea0fffb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_d559d24d-c90d-4d9f-998a-af785a29ab5b" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_39022aa0-3bf2-44e8-9c7c-12eeea0fffb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6c3950b7-768f-4a44-9b23-d1a359b9346d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_d559d24d-c90d-4d9f-998a-af785a29ab5b" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6c3950b7-768f-4a44-9b23-d1a359b9346d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_756d1692-e630-4b2b-9283-074f3fc70b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_d559d24d-c90d-4d9f-998a-af785a29ab5b" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_756d1692-e630-4b2b-9283-074f3fc70b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_CurrentAndNonCurrentInventory_ac390209-8cdf-4306-87d6-04d91c16d863" xlink:href="rmti-20210630.xsd#rmti_CurrentAndNonCurrentInventory"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_d559d24d-c90d-4d9f-998a-af785a29ab5b" xlink:to="loc_rmti_CurrentAndNonCurrentInventory_ac390209-8cdf-4306-87d6-04d91c16d863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_82b90c3a-a680-4585-ac9d-232cc80ea53c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_d559d24d-c90d-4d9f-998a-af785a29ab5b" xlink:to="loc_us-gaap_InventoryNoncurrent_82b90c3a-a680-4585-ac9d-232cc80ea53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c5524367-3424-451d-aa6d-a5d4cf53d8ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_d559d24d-c90d-4d9f-998a-af785a29ab5b" xlink:to="loc_us-gaap_InventoryNet_c5524367-3424-451d-aa6d-a5d4cf53d8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="rmti-20210630.xsd#PropertyandEquipment"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/PropertyandEquipment" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c91eea12-64a3-4192-8f6f-7070b6d8c3cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0a5bbff4-3728-49a7-9fbd-64c9953b283a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c91eea12-64a3-4192-8f6f-7070b6d8c3cc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0a5bbff4-3728-49a7-9fbd-64c9953b283a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="rmti-20210630.xsd#PropertyandEquipmentTables"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/PropertyandEquipmentTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0d7f3805-fa62-4388-a155-6e1b7071e90a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f5d15a18-6700-4497-b699-e949d2231d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0d7f3805-fa62-4388-a155-6e1b7071e90a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f5d15a18-6700-4497-b699-e949d2231d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#PropertyandEquipmentDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/PropertyandEquipmentDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cf222e8d-da19-42d6-8d96-e0f7ed4ecbbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_00d691d5-fffd-45ff-a448-90cdc133049a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cf222e8d-da19-42d6-8d96-e0f7ed4ecbbc" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_00d691d5-fffd-45ff-a448-90cdc133049a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87bc4957-f64c-45be-886c-7babd6e2cc12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_00d691d5-fffd-45ff-a448-90cdc133049a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87bc4957-f64c-45be-886c-7babd6e2cc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7071bfc-26a8-4c59-bcb6-c26991597054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87bc4957-f64c-45be-886c-7babd6e2cc12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7071bfc-26a8-4c59-bcb6-c26991597054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7d8e83cc-0a27-4080-83ca-2960fc72c56d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7071bfc-26a8-4c59-bcb6-c26991597054" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7d8e83cc-0a27-4080-83ca-2960fc72c56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_6bab802c-e9bf-4127-9ddd-c13352ab398b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7071bfc-26a8-4c59-bcb6-c26991597054" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_6bab802c-e9bf-4127-9ddd-c13352ab398b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_5f4630f9-0b72-4674-8ba3-a1eb615eeab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7071bfc-26a8-4c59-bcb6-c26991597054" xlink:to="loc_us-gaap_OfficeEquipmentMember_5f4630f9-0b72-4674-8ba3-a1eb615eeab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_a48c095b-7540-4872-8d8d-907f94670db5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7071bfc-26a8-4c59-bcb6-c26991597054" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_a48c095b-7540-4872-8d8d-907f94670db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7102d615-7897-4e1b-8e39-818acb4a3483" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_00d691d5-fffd-45ff-a448-90cdc133049a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7102d615-7897-4e1b-8e39-818acb4a3483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4614f194-d097-4070-98f1-b2a694189ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7102d615-7897-4e1b-8e39-818acb4a3483" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4614f194-d097-4070-98f1-b2a694189ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6e5fd10e-92d1-4c54-9549-776ecdc29b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7102d615-7897-4e1b-8e39-818acb4a3483" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6e5fd10e-92d1-4c54-9549-776ecdc29b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_397fe339-d9a7-454f-a1a0-fca99a009190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7102d615-7897-4e1b-8e39-818acb4a3483" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_397fe339-d9a7-454f-a1a0-fca99a009190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1ddae384-a4fd-4a8a-b3d1-265c96342fc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7102d615-7897-4e1b-8e39-818acb4a3483" xlink:to="loc_us-gaap_Depreciation_1ddae384-a4fd-4a8a-b3d1-265c96342fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="rmti-20210630.xsd#AccruedLiabilities"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/AccruedLiabilities" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_47b7d4e2-c892-40a3-bdf8-70aeb28355ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_9203c876-4ecd-46e9-8221-27d2a6796ccb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_47b7d4e2-c892-40a3-bdf8-70aeb28355ea" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_9203c876-4ecd-46e9-8221-27d2a6796ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="rmti-20210630.xsd#AccruedLiabilitiesTables"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/AccruedLiabilitiesTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_f53a44aa-eee5-4b67-817f-67f6e8224533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_bd908c33-9126-43aa-918b-601e8ce2498c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f53a44aa-eee5-4b67-817f-67f6e8224533" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_bd908c33-9126-43aa-918b-601e8ce2498c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#AccruedLiabilitiesDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_7e73c98c-b40f-49f0-9599-7e6c0b1bea56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent_c95ff6a0-d23d-4f31-8f31-9d835f512838" xlink:href="rmti-20210630.xsd#rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7e73c98c-b40f-49f0-9599-7e6c0b1bea56" xlink:to="loc_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent_c95ff6a0-d23d-4f31-8f31-9d835f512838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_db64e28b-e9bc-4fe0-98db-50247dfd632b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7e73c98c-b40f-49f0-9599-7e6c0b1bea56" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_db64e28b-e9bc-4fe0-98db-50247dfd632b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_AccruedUnvoucheredReceiptsCurrent_f106e08b-bfb9-4c83-9ff0-f99f7bce5b5a" xlink:href="rmti-20210630.xsd#rmti_AccruedUnvoucheredReceiptsCurrent"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7e73c98c-b40f-49f0-9599-7e6c0b1bea56" xlink:to="loc_rmti_AccruedUnvoucheredReceiptsCurrent_f106e08b-bfb9-4c83-9ff0-f99f7bce5b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WorkersCompensationLiabilityCurrent_181a9219-6493-42b9-8656-4ed62bd06dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7e73c98c-b40f-49f0-9599-7e6c0b1bea56" xlink:to="loc_us-gaap_WorkersCompensationLiabilityCurrent_181a9219-6493-42b9-8656-4ed62bd06dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6df014a5-3335-45f0-920d-9905f0638c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7e73c98c-b40f-49f0-9599-7e6c0b1bea56" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6df014a5-3335-45f0-920d-9905f0638c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9b1db7c2-77ae-4b04-ab6f-018bddff20e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7e73c98c-b40f-49f0-9599-7e6c0b1bea56" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9b1db7c2-77ae-4b04-ab6f-018bddff20e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/DeferredRevenue" xlink:type="simple" xlink:href="rmti-20210630.xsd#DeferredRevenue"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/DeferredRevenue" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5d08c151-8615-4c15-bf24-3234869ac016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ContractWithCustomerDeferredRevenueTextBlock_849b58d1-7e58-4f03-8746-18a443ab4dea" xlink:href="rmti-20210630.xsd#rmti_ContractWithCustomerDeferredRevenueTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5d08c151-8615-4c15-bf24-3234869ac016" xlink:to="loc_rmti_ContractWithCustomerDeferredRevenueTextBlock_849b58d1-7e58-4f03-8746-18a443ab4dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/DeferredRevenueDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#DeferredRevenueDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/DeferredRevenueDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2e205105-b4b9-4421-9d0d-7f5738199f14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_91ba46e2-ef61-463a-9609-42b127e1f221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2e205105-b4b9-4421-9d0d-7f5738199f14" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_91ba46e2-ef61-463a-9609-42b127e1f221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_addf3a06-ad9f-4cde-aeb1-200c518384a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_91ba46e2-ef61-463a-9609-42b127e1f221" xlink:to="loc_srt_CounterpartyNameAxis_addf3a06-ad9f-4cde-aeb1-200c518384a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d2bd514-4ad8-4510-a451-40d9384a0db2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_addf3a06-ad9f-4cde-aeb1-200c518384a5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d2bd514-4ad8-4510-a451-40d9384a0db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_BaxterHealthcareOrganizationMember_f3d915bd-f36b-4c56-b530-88910e0bf6ba" xlink:href="rmti-20210630.xsd#rmti_BaxterHealthcareOrganizationMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d2bd514-4ad8-4510-a451-40d9384a0db2" xlink:to="loc_rmti_BaxterHealthcareOrganizationMember_f3d915bd-f36b-4c56-b530-88910e0bf6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_WanbangBiopharmaceuticalMember_e12e2187-d0af-4c5f-892c-6061aa238e20" xlink:href="rmti-20210630.xsd#rmti_WanbangBiopharmaceuticalMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d2bd514-4ad8-4510-a451-40d9384a0db2" xlink:to="loc_rmti_WanbangBiopharmaceuticalMember_e12e2187-d0af-4c5f-892c-6061aa238e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_SunPharmaAgreementsMember_4b181628-4f99-44af-8b3b-677218a4af7f" xlink:href="rmti-20210630.xsd#rmti_SunPharmaAgreementsMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d2bd514-4ad8-4510-a451-40d9384a0db2" xlink:to="loc_rmti_SunPharmaAgreementsMember_4b181628-4f99-44af-8b3b-677218a4af7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_JeilPharmaAgreementsMember_c83b2540-58a5-4a6f-9e65-94475e57ff45" xlink:href="rmti-20210630.xsd#rmti_JeilPharmaAgreementsMember"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d2bd514-4ad8-4510-a451-40d9384a0db2" xlink:to="loc_rmti_JeilPharmaAgreementsMember_c83b2540-58a5-4a6f-9e65-94475e57ff45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DrogsanAgreementsMember_d4231ecc-34df-4897-9945-0ae2d7e3cf7e" xlink:href="rmti-20210630.xsd#rmti_DrogsanAgreementsMember"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d2bd514-4ad8-4510-a451-40d9384a0db2" xlink:to="loc_rmti_DrogsanAgreementsMember_d4231ecc-34df-4897-9945-0ae2d7e3cf7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_7f544706-d31e-4873-aee7-95702f0415b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_91ba46e2-ef61-463a-9609-42b127e1f221" xlink:to="loc_us-gaap_DeferredRevenueArrangementLineItems_7f544706-d31e-4873-aee7-95702f0415b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_RevenueRecognitionReceived_7be583a8-868e-419f-ab19-5b27b1220d6e" xlink:href="rmti-20210630.xsd#rmti_RevenueRecognitionReceived"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_7f544706-d31e-4873-aee7-95702f0415b6" xlink:to="loc_rmti_RevenueRecognitionReceived_7be583a8-868e-419f-ab19-5b27b1220d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_21d1a43f-c420-4aac-8afa-0450d71fcc3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_7f544706-d31e-4873-aee7-95702f0415b6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_21d1a43f-c420-4aac-8afa-0450d71fcc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_077ac896-2bc6-4629-803a-b166d4da2432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_7f544706-d31e-4873-aee7-95702f0415b6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_077ac896-2bc6-4629-803a-b166d4da2432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee_8192e14b-6dc1-4377-8ff1-66596acb3bdf" xlink:href="rmti-20210630.xsd#rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_7f544706-d31e-4873-aee7-95702f0415b6" xlink:to="loc_rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee_8192e14b-6dc1-4377-8ff1-66596acb3bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockholdersEquity" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockholdersEquity"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/StockholdersEquity" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5c7e782f-2f87-4601-9257-fb8b2ac3c65a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c1883d54-81f6-4c81-a64a-cc9391baa965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5c7e782f-2f87-4601-9257-fb8b2ac3c65a" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c1883d54-81f6-4c81-a64a-cc9391baa965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockholdersEquityDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/StockholdersEquityDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c33e00ea-425e-4b17-aa8a-416451a752ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_63917ec3-9003-4664-b1cb-2ed924943b09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c33e00ea-425e-4b17-aa8a-416451a752ab" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_63917ec3-9003-4664-b1cb-2ed924943b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ba54da14-3165-457f-91c3-6c20590d9d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_63917ec3-9003-4664-b1cb-2ed924943b09" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ba54da14-3165-457f-91c3-6c20590d9d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41425e7c-83a7-4a36-b768-071bbbe74de1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ba54da14-3165-457f-91c3-6c20590d9d14" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41425e7c-83a7-4a36-b768-071bbbe74de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_AtthemarketOfferingMember_9bd62bbe-59a3-47e6-8b3a-f0d054e6966e" xlink:href="rmti-20210630.xsd#rmti_AtthemarketOfferingMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41425e7c-83a7-4a36-b768-071bbbe74de1" xlink:to="loc_rmti_AtthemarketOfferingMember_9bd62bbe-59a3-47e6-8b3a-f0d054e6966e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f7634fac-b9a5-4a9f-bf56-612502a298e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_63917ec3-9003-4664-b1cb-2ed924943b09" xlink:to="loc_srt_RangeAxis_f7634fac-b9a5-4a9f-bf56-612502a298e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_01324e36-07af-49b5-b4a0-4ba8352b6794" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f7634fac-b9a5-4a9f-bf56-612502a298e1" xlink:to="loc_srt_RangeMember_01324e36-07af-49b5-b4a0-4ba8352b6794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0b18a0c9-c081-489b-8e35-72b8ba28c0d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_01324e36-07af-49b5-b4a0-4ba8352b6794" xlink:to="loc_srt_MaximumMember_0b18a0c9-c081-489b-8e35-72b8ba28c0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_63917ec3-9003-4664-b1cb-2ed924943b09" xlink:to="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fe55b49d-0063-49cb-b7f5-dee83a91ae2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fe55b49d-0063-49cb-b7f5-dee83a91ae2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_98805acd-f723-4be0-a17d-958463232b51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_98805acd-f723-4be0-a17d-958463232b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_cc7f92f2-9d89-47ab-a662-57848a0b25dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_us-gaap_PreferredStockSharesIssued_cc7f92f2-9d89-47ab-a662-57848a0b25dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a187038e-fc64-41d8-abcc-812cbf21e848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a187038e-fc64-41d8-abcc-812cbf21e848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e21d7c23-1df9-471a-8c12-3f2762ddd864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e21d7c23-1df9-471a-8c12-3f2762ddd864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5b9036c8-ecf0-4877-ac64-8c01a85d05e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5b9036c8-ecf0-4877-ac64-8c01a85d05e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0fb24e7e-8f6d-438e-a006-ce46905ecf69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_us-gaap_CommonStockSharesIssued_0fb24e7e-8f6d-438e-a006-ce46905ecf69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3fec9876-2005-4d16-8fe3-89783c680486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3fec9876-2005-4d16-8fe3-89783c680486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_SalesAgreementThresholdSaleOfShares_de317190-47c2-4499-8a4b-eab2c5257595" xlink:href="rmti-20210630.xsd#rmti_SalesAgreementThresholdSaleOfShares"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_rmti_SalesAgreementThresholdSaleOfShares_de317190-47c2-4499-8a4b-eab2c5257595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_SaleofStockRemainingSalesAmount_57cb7cca-03bc-4c54-bd72-db2f9ea5a9df" xlink:href="rmti-20210630.xsd#rmti_SaleofStockRemainingSalesAmount"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16ed785d-1a9c-4cb9-a28a-cb4093505639" xlink:to="loc_rmti_SaleofStockRemainingSalesAmount_57cb7cca-03bc-4c54-bd72-db2f9ea5a9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockBasedCompensation"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensation" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5eda9b7-9f1b-4495-b5f7-59ac08c2d8ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6854bb08-c183-49c5-8a7d-57bc9479439f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5eda9b7-9f1b-4495-b5f7-59ac08c2d8ab" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6854bb08-c183-49c5-8a7d-57bc9479439f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockBasedCompensationTables"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0400817f-684e-4076-9c77-a4b97d8db406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_167ee61a-769e-4f39-b53b-c2e4e68618b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0400817f-684e-4076-9c77-a4b97d8db406" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_167ee61a-769e-4f39-b53b-c2e4e68618b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_45d7d7c4-e66e-4448-88b5-6ecf8e5f7188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_167ee61a-769e-4f39-b53b-c2e4e68618b9" xlink:to="loc_us-gaap_AwardTypeAxis_45d7d7c4-e66e-4448-88b5-6ecf8e5f7188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e98cf41b-5679-4e7a-9cd1-b77a2c58220d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_45d7d7c4-e66e-4448-88b5-6ecf8e5f7188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e98cf41b-5679-4e7a-9cd1-b77a2c58220d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_edce009f-2a80-4c01-adec-0b1ade76ff65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e98cf41b-5679-4e7a-9cd1-b77a2c58220d" xlink:to="loc_us-gaap_RestrictedStockMember_edce009f-2a80-4c01-adec-0b1ade76ff65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedRestrictedStockUnitsMember_b9a6c59d-a502-4f3f-ac89-55a93f1f77ed" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedRestrictedStockUnitsMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e98cf41b-5679-4e7a-9cd1-b77a2c58220d" xlink:to="loc_rmti_ServiceBasedRestrictedStockUnitsMember_b9a6c59d-a502-4f3f-ac89-55a93f1f77ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_70d879e8-4f22-4547-87de-1df942e4e1e2" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedRestrictedStockUnitsMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e98cf41b-5679-4e7a-9cd1-b77a2c58220d" xlink:to="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_70d879e8-4f22-4547-87de-1df942e4e1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_fe2de48a-8a5f-42fa-a86f-d51f58d6ee7a" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e98cf41b-5679-4e7a-9cd1-b77a2c58220d" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_fe2de48a-8a5f-42fa-a86f-d51f58d6ee7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedStockOptionAwardsMember_c542ae1e-90ff-4d03-b903-c89f53472a3d" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedStockOptionAwardsMember"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e98cf41b-5679-4e7a-9cd1-b77a2c58220d" xlink:to="loc_rmti_PerformanceBasedStockOptionAwardsMember_c542ae1e-90ff-4d03-b903-c89f53472a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ddcdb3f4-b25c-4b01-be00-c84ead88a040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_167ee61a-769e-4f39-b53b-c2e4e68618b9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ddcdb3f4-b25c-4b01-be00-c84ead88a040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e5fd0f36-8190-47e2-b005-56edd9dd44a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ddcdb3f4-b25c-4b01-be00-c84ead88a040" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e5fd0f36-8190-47e2-b005-56edd9dd44a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_582712a7-eacc-45bb-ae86-b51cf1cb19a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ddcdb3f4-b25c-4b01-be00-c84ead88a040" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_582712a7-eacc-45bb-ae86-b51cf1cb19a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5e088315-b29d-4df7-a37c-6603210acc91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ddcdb3f4-b25c-4b01-be00-c84ead88a040" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5e088315-b29d-4df7-a37c-6603210acc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_92f994c5-f7e4-45c3-926b-d76e60ff1130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ddcdb3f4-b25c-4b01-be00-c84ead88a040" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_92f994c5-f7e4-45c3-926b-d76e60ff1130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockBasedCompensationSharebasedcompensationexpenseDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a289fc59-2bf2-47d6-bc19-8fea468da674" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76dc8096-b51b-49bd-a582-7d5b33ead255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a289fc59-2bf2-47d6-bc19-8fea468da674" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76dc8096-b51b-49bd-a582-7d5b33ead255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e00e41f9-3460-4cb4-b883-914e1d3ef256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76dc8096-b51b-49bd-a582-7d5b33ead255" xlink:to="loc_us-gaap_AwardTypeAxis_e00e41f9-3460-4cb4-b883-914e1d3ef256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_025ed155-1318-4399-8fcf-f68dbdb62512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e00e41f9-3460-4cb4-b883-914e1d3ef256" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_025ed155-1318-4399-8fcf-f68dbdb62512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedAwardsMember_484a3095-11f2-4935-b0ff-93c903178688" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedAwardsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_025ed155-1318-4399-8fcf-f68dbdb62512" xlink:to="loc_rmti_ServiceBasedAwardsMember_484a3095-11f2-4935-b0ff-93c903178688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedRestrictedStockUnitsMember_5051e5b8-238a-4b0e-beea-a27f2b6ec86b" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedRestrictedStockUnitsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ServiceBasedAwardsMember_484a3095-11f2-4935-b0ff-93c903178688" xlink:to="loc_rmti_ServiceBasedRestrictedStockUnitsMember_5051e5b8-238a-4b0e-beea-a27f2b6ec86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_4d67ef58-83cb-4187-8a8c-608007a01a14" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ServiceBasedAwardsMember_484a3095-11f2-4935-b0ff-93c903178688" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_4d67ef58-83cb-4187-8a8c-608007a01a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedAwardsMember_f6725477-b109-43bf-b411-ba62e5245384" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedAwardsMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_025ed155-1318-4399-8fcf-f68dbdb62512" xlink:to="loc_rmti_PerformanceBasedAwardsMember_f6725477-b109-43bf-b411-ba62e5245384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockAwardsMember_025657ce-0401-4179-9310-fa820a29c571" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedRestrictedStockAwardsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_PerformanceBasedAwardsMember_f6725477-b109-43bf-b411-ba62e5245384" xlink:to="loc_rmti_PerformanceBasedRestrictedStockAwardsMember_025657ce-0401-4179-9310-fa820a29c571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_d677b5dc-694f-4cfc-927b-82322d075b18" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedRestrictedStockUnitsMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_PerformanceBasedAwardsMember_f6725477-b109-43bf-b411-ba62e5245384" xlink:to="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_d677b5dc-694f-4cfc-927b-82322d075b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedStockOptionAwardsMember_211a01ce-fecc-465b-a5f3-fcd1bcbeebdb" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedStockOptionAwardsMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_PerformanceBasedAwardsMember_f6725477-b109-43bf-b411-ba62e5245384" xlink:to="loc_rmti_PerformanceBasedStockOptionAwardsMember_211a01ce-fecc-465b-a5f3-fcd1bcbeebdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa04f988-2852-437a-93e7-d8782c808e53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76dc8096-b51b-49bd-a582-7d5b33ead255" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa04f988-2852-437a-93e7-d8782c808e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_549c999a-4831-484f-94b1-0a7d3839b3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa04f988-2852-437a-93e7-d8782c808e53" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_549c999a-4831-484f-94b1-0a7d3839b3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockBasedCompensationRestrictedStockAwardsDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e1a298c4-48f9-4501-a954-05cf0a27180b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cf20e9f9-01a4-4b8e-a720-0377828d0fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e1a298c4-48f9-4501-a954-05cf0a27180b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cf20e9f9-01a4-4b8e-a720-0377828d0fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9608b52b-d391-409d-af9c-3cef92425d63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cf20e9f9-01a4-4b8e-a720-0377828d0fb8" xlink:to="loc_us-gaap_AwardTypeAxis_9608b52b-d391-409d-af9c-3cef92425d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5f1254d-5815-49f2-a562-327969a516ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9608b52b-d391-409d-af9c-3cef92425d63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5f1254d-5815-49f2-a562-327969a516ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_a5d559c0-0b00-4e06-9774-7c1aba4ac6b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5f1254d-5815-49f2-a562-327969a516ee" xlink:to="loc_us-gaap_RestrictedStockMember_a5d559c0-0b00-4e06-9774-7c1aba4ac6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockAwardsMember_88857869-df30-4652-9c13-91e4bf81b283" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedRestrictedStockAwardsMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5f1254d-5815-49f2-a562-327969a516ee" xlink:to="loc_rmti_PerformanceBasedRestrictedStockAwardsMember_88857869-df30-4652-9c13-91e4bf81b283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062b7c2-5abb-43c2-800b-79299acd8056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cf20e9f9-01a4-4b8e-a720-0377828d0fb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062b7c2-5abb-43c2-800b-79299acd8056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3d48d2db-895a-4d6c-816e-20bcbd15e74e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062b7c2-5abb-43c2-800b-79299acd8056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3d48d2db-895a-4d6c-816e-20bcbd15e74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1a709d27-60a2-46e0-bb4f-4dd2384eada2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3d48d2db-895a-4d6c-816e-20bcbd15e74e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1a709d27-60a2-46e0-bb4f-4dd2384eada2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9b543172-1251-4962-8c7a-dbd9af4daf44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3d48d2db-895a-4d6c-816e-20bcbd15e74e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9b543172-1251-4962-8c7a-dbd9af4daf44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ed19c03-ec19-40d1-876b-d474a673fd96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3d48d2db-895a-4d6c-816e-20bcbd15e74e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ed19c03-ec19-40d1-876b-d474a673fd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a37b9b7f-01a7-49e3-a40c-aeb143af5d55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062b7c2-5abb-43c2-800b-79299acd8056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a37b9b7f-01a7-49e3-a40c-aeb143af5d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5ecfff22-843e-44e5-8bf7-e60830e2895e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a37b9b7f-01a7-49e3-a40c-aeb143af5d55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5ecfff22-843e-44e5-8bf7-e60830e2895e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8f9c42c4-1177-4a76-8ed5-9ed3b54341ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a37b9b7f-01a7-49e3-a40c-aeb143af5d55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8f9c42c4-1177-4a76-8ed5-9ed3b54341ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d9e45889-179b-4b35-8c90-da09c702b8c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a37b9b7f-01a7-49e3-a40c-aeb143af5d55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d9e45889-179b-4b35-8c90-da09c702b8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3a19b6ef-60a6-4541-a493-6aff678d2017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062b7c2-5abb-43c2-800b-79299acd8056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3a19b6ef-60a6-4541-a493-6aff678d2017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e6776a87-de60-4989-bfd5-257a71798678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062b7c2-5abb-43c2-800b-79299acd8056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e6776a87-de60-4989-bfd5-257a71798678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ab09c98c-76b3-476a-a4c6-849f9480be97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062b7c2-5abb-43c2-800b-79299acd8056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ab09c98c-76b3-476a-a4c6-849f9480be97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d3dd5b0c-83bc-42a0-b7e2-cf2c8aee61ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062b7c2-5abb-43c2-800b-79299acd8056" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d3dd5b0c-83bc-42a0-b7e2-cf2c8aee61ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b5a7cec-6b64-4a53-a229-a0b8f31c2b53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c743e9-e06b-487f-ad4b-aa393e74256a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b5a7cec-6b64-4a53-a229-a0b8f31c2b53" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c743e9-e06b-487f-ad4b-aa393e74256a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_049c6a07-450d-403b-bffd-16421ada1c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c743e9-e06b-487f-ad4b-aa393e74256a" xlink:to="loc_us-gaap_AwardTypeAxis_049c6a07-450d-403b-bffd-16421ada1c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ca23ef8-18d7-44cc-b146-9e7798844ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_049c6a07-450d-403b-bffd-16421ada1c24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ca23ef8-18d7-44cc-b146-9e7798844ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedRestrictedStockUnitsMember_1da9b02b-3490-46cb-be7d-86b828bb39e5" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedRestrictedStockUnitsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ca23ef8-18d7-44cc-b146-9e7798844ec1" xlink:to="loc_rmti_ServiceBasedRestrictedStockUnitsMember_1da9b02b-3490-46cb-be7d-86b828bb39e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_7800fb70-238c-4d58-8bb1-e0a2d0bc3821" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedRestrictedStockUnitsMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ca23ef8-18d7-44cc-b146-9e7798844ec1" xlink:to="loc_rmti_PerformanceBasedRestrictedStockUnitsMember_7800fb70-238c-4d58-8bb1-e0a2d0bc3821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c7f7f83e-f336-4bba-b9be-be2d73294ea2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c743e9-e06b-487f-ad4b-aa393e74256a" xlink:to="loc_srt_RangeAxis_c7f7f83e-f336-4bba-b9be-be2d73294ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0d0e1bd4-a1f2-4be5-8dc8-2d2dc6e2d69a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c7f7f83e-f336-4bba-b9be-be2d73294ea2" xlink:to="loc_srt_RangeMember_0d0e1bd4-a1f2-4be5-8dc8-2d2dc6e2d69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f6bbb54e-6c47-44be-bc57-f62f14716c54" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0d0e1bd4-a1f2-4be5-8dc8-2d2dc6e2d69a" xlink:to="loc_srt_MinimumMember_f6bbb54e-6c47-44be-bc57-f62f14716c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e879ea84-0d89-4c8b-ba04-a901694a97bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0d0e1bd4-a1f2-4be5-8dc8-2d2dc6e2d69a" xlink:to="loc_srt_MaximumMember_e879ea84-0d89-4c8b-ba04-a901694a97bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c743e9-e06b-487f-ad4b-aa393e74256a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_44ed2713-8003-493f-8d3e-1efdace9fe46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_44ed2713-8003-493f-8d3e-1efdace9fe46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07662673-f221-4997-ba57-4b1e7a575c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_44ed2713-8003-493f-8d3e-1efdace9fe46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07662673-f221-4997-ba57-4b1e7a575c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4020d232-ed46-4953-af40-3a2ee7a49273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_44ed2713-8003-493f-8d3e-1efdace9fe46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4020d232-ed46-4953-af40-3a2ee7a49273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_70545580-9ec3-4cfc-845e-a39ad0a89a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_44ed2713-8003-493f-8d3e-1efdace9fe46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_70545580-9ec3-4cfc-845e-a39ad0a89a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_15930875-d805-4f3e-b0d5-e3147afd0d75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_44ed2713-8003-493f-8d3e-1efdace9fe46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_15930875-d805-4f3e-b0d5-e3147afd0d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07f68937-b4bd-4f07-82f2-ac9783a8da7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_44ed2713-8003-493f-8d3e-1efdace9fe46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07f68937-b4bd-4f07-82f2-ac9783a8da7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c257c85f-4674-49fb-96e8-dc7e0ada7d30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c257c85f-4674-49fb-96e8-dc7e0ada7d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_82f38998-4d53-4909-81a0-282eda67c373" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c257c85f-4674-49fb-96e8-dc7e0ada7d30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_82f38998-4d53-4909-81a0-282eda67c373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9bb3d749-51d0-4ef1-99b4-39b96a33258a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c257c85f-4674-49fb-96e8-dc7e0ada7d30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9bb3d749-51d0-4ef1-99b4-39b96a33258a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_192a0924-e52a-4952-aba4-b76555d511f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c257c85f-4674-49fb-96e8-dc7e0ada7d30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_192a0924-e52a-4952-aba4-b76555d511f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9f18fb1b-4f54-4a79-b7e8-e25da4b81626" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c257c85f-4674-49fb-96e8-dc7e0ada7d30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9f18fb1b-4f54-4a79-b7e8-e25da4b81626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_710e89b7-fecb-4b3f-b215-ee5d1e4db7a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c257c85f-4674-49fb-96e8-dc7e0ada7d30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_710e89b7-fecb-4b3f-b215-ee5d1e4db7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_235664e6-c402-4d00-818e-5e28c341c9db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_235664e6-c402-4d00-818e-5e28c341c9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_38f4f150-1ee1-4dde-8b1f-d48ebbb96f62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_38f4f150-1ee1-4dde-8b1f-d48ebbb96f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_62a59fb0-51c3-4f3d-8d73-9fcf384ee686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_62a59fb0-51c3-4f3d-8d73-9fcf384ee686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_291a1aba-1d9a-4a70-93fc-50b027486ecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_291a1aba-1d9a-4a70-93fc-50b027486ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_00645af5-c623-4b11-928a-3e98e0399a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91601b5e-f579-4099-8f47-f39465294004" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_00645af5-c623-4b11-928a-3e98e0399a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1f10a76-0057-46d5-852c-59e64dff9e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebf51465-c9c9-49d1-afac-d6c8d36a3478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1f10a76-0057-46d5-852c-59e64dff9e86" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebf51465-c9c9-49d1-afac-d6c8d36a3478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_45300136-3612-4103-a7ee-4f3a6f795101" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebf51465-c9c9-49d1-afac-d6c8d36a3478" xlink:to="loc_srt_RangeAxis_45300136-3612-4103-a7ee-4f3a6f795101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4baaa31b-8d80-4d56-87d6-c6add614d66a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_45300136-3612-4103-a7ee-4f3a6f795101" xlink:to="loc_srt_RangeMember_4baaa31b-8d80-4d56-87d6-c6add614d66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5d693cdb-17cf-4c41-9e86-63f2b3b96fc9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4baaa31b-8d80-4d56-87d6-c6add614d66a" xlink:to="loc_srt_MinimumMember_5d693cdb-17cf-4c41-9e86-63f2b3b96fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6698e1c3-d48f-4de0-97bb-45e25070b102" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4baaa31b-8d80-4d56-87d6-c6add614d66a" xlink:to="loc_srt_MaximumMember_6698e1c3-d48f-4de0-97bb-45e25070b102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b6b6a24c-b460-4290-91c0-a7ef712ed3ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebf51465-c9c9-49d1-afac-d6c8d36a3478" xlink:to="loc_us-gaap_AwardTypeAxis_b6b6a24c-b460-4290-91c0-a7ef712ed3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_432f81bd-4198-47f1-83ee-841254fb0c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b6b6a24c-b460-4290-91c0-a7ef712ed3ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_432f81bd-4198-47f1-83ee-841254fb0c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_ae7755b5-cdca-40a1-b96c-faa10fe8c78d" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_432f81bd-4198-47f1-83ee-841254fb0c54" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_ae7755b5-cdca-40a1-b96c-faa10fe8c78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e52d2795-7136-4ef7-aeb5-b90c0d9ded4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebf51465-c9c9-49d1-afac-d6c8d36a3478" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e52d2795-7136-4ef7-aeb5-b90c0d9ded4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_6bc00e0f-d5a3-408a-a730-32ff40e12a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e52d2795-7136-4ef7-aeb5-b90c0d9ded4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_6bc00e0f-d5a3-408a-a730-32ff40e12a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_e64f3c75-e309-47b2-b7bd-0c7558cd2e37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e52d2795-7136-4ef7-aeb5-b90c0d9ded4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_e64f3c75-e309-47b2-b7bd-0c7558cd2e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_56cb1da7-7b4f-4205-9b22-58dbf9b0bf28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e52d2795-7136-4ef7-aeb5-b90c0d9ded4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_56cb1da7-7b4f-4205-9b22-58dbf9b0bf28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6693c314-3a89-42bf-94f6-62da7805979e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e52d2795-7136-4ef7-aeb5-b90c0d9ded4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6693c314-3a89-42bf-94f6-62da7805979e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a59a74d2-7369-4647-b232-20dd0298274f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e52d2795-7136-4ef7-aeb5-b90c0d9ded4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a59a74d2-7369-4647-b232-20dd0298274f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f9476197-c573-41a1-b715-6b61c79cbb1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e52d2795-7136-4ef7-aeb5-b90c0d9ded4a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f9476197-c573-41a1-b715-6b61c79cbb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockBasedCompensationServiceBasedStockOptionsDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4cec2a5-c488-4ed3-a684-cf776a5104f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_61c702df-b00e-4633-8efa-d9167465da6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4cec2a5-c488-4ed3-a684-cf776a5104f5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_61c702df-b00e-4633-8efa-d9167465da6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_16753971-f2f3-49a6-b934-ca40ab1699b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_61c702df-b00e-4633-8efa-d9167465da6a" xlink:to="loc_us-gaap_AwardTypeAxis_16753971-f2f3-49a6-b934-ca40ab1699b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea689cf9-eafb-44e2-8c79-de2f609b90a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_16753971-f2f3-49a6-b934-ca40ab1699b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea689cf9-eafb-44e2-8c79-de2f609b90a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_4f7781d1-6bba-4255-a1a9-013cc8c2995b" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea689cf9-eafb-44e2-8c79-de2f609b90a2" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_4f7781d1-6bba-4255-a1a9-013cc8c2995b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47fbff20-f366-4ef6-8a7d-dd2f5c2a0642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_61c702df-b00e-4633-8efa-d9167465da6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47fbff20-f366-4ef6-8a7d-dd2f5c2a0642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d107b45d-92fe-4791-8f16-90657fcb969c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47fbff20-f366-4ef6-8a7d-dd2f5c2a0642" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d107b45d-92fe-4791-8f16-90657fcb969c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_322bfcc9-1781-4387-9878-84a355152a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d107b45d-92fe-4791-8f16-90657fcb969c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_322bfcc9-1781-4387-9878-84a355152a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e7178cfe-e89b-4bcb-8103-2257dc9858bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d107b45d-92fe-4791-8f16-90657fcb969c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e7178cfe-e89b-4bcb-8103-2257dc9858bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d7070df4-3130-4de8-8247-c7a4c1c68f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d107b45d-92fe-4791-8f16-90657fcb969c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d7070df4-3130-4de8-8247-c7a4c1c68f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0538b26c-f0f5-444e-b56b-07cdc72f98f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d107b45d-92fe-4791-8f16-90657fcb969c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0538b26c-f0f5-444e-b56b-07cdc72f98f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ccf06f4b-c252-4065-8201-ce7f565329f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d107b45d-92fe-4791-8f16-90657fcb969c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ccf06f4b-c252-4065-8201-ce7f565329f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9604f2f5-73bd-4173-9785-a115b2c480fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d107b45d-92fe-4791-8f16-90657fcb969c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9604f2f5-73bd-4173-9785-a115b2c480fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2ce9994-d8eb-410c-a6f3-c1f342be6f30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47fbff20-f366-4ef6-8a7d-dd2f5c2a0642" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2ce9994-d8eb-410c-a6f3-c1f342be6f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9603aba8-3263-4352-9346-28cea1b4320e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2ce9994-d8eb-410c-a6f3-c1f342be6f30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9603aba8-3263-4352-9346-28cea1b4320e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_822e67a8-e6ed-44ec-9b17-0ed05444cd8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2ce9994-d8eb-410c-a6f3-c1f342be6f30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_822e67a8-e6ed-44ec-9b17-0ed05444cd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0160975c-564b-4846-8866-d959fa0cd771" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2ce9994-d8eb-410c-a6f3-c1f342be6f30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0160975c-564b-4846-8866-d959fa0cd771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1c599cf4-80b4-4f59-af15-75f10e259e31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2ce9994-d8eb-410c-a6f3-c1f342be6f30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1c599cf4-80b4-4f59-af15-75f10e259e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_645edfd6-be73-4575-a4d4-40948e154f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2ce9994-d8eb-410c-a6f3-c1f342be6f30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_645edfd6-be73-4575-a4d4-40948e154f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_eb6d76bc-a979-4498-b25c-b69d2e6718e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2ce9994-d8eb-410c-a6f3-c1f342be6f30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_eb6d76bc-a979-4498-b25c-b69d2e6718e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_45315450-7e6d-47e9-9fdd-215918de5de2" xlink:href="rmti-20210630.xsd#rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47fbff20-f366-4ef6-8a7d-dd2f5c2a0642" xlink:to="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_45315450-7e6d-47e9-9fdd-215918de5de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4efe4c19-b1d9-4b81-9ef6-fb64fd51fa1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_45315450-7e6d-47e9-9fdd-215918de5de2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4efe4c19-b1d9-4b81-9ef6-fb64fd51fa1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_1eb2f758-5302-44b1-917f-1d0f7cdbdd65" xlink:href="rmti-20210630.xsd#rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_45315450-7e6d-47e9-9fdd-215918de5de2" xlink:to="loc_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_1eb2f758-5302-44b1-917f-1d0f7cdbdd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_67a03141-4396-4971-bc8a-f858234226a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_45315450-7e6d-47e9-9fdd-215918de5de2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_67a03141-4396-4971-bc8a-f858234226a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_aadfc09e-3ff0-4a10-affb-ba51c2b25657" xlink:href="rmti-20210630.xsd#rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47fbff20-f366-4ef6-8a7d-dd2f5c2a0642" xlink:to="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_aadfc09e-3ff0-4a10-affb-ba51c2b25657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8d0dd5b8-b91f-4060-a50f-bd467c8e2da9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_aadfc09e-3ff0-4a10-affb-ba51c2b25657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8d0dd5b8-b91f-4060-a50f-bd467c8e2da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d999ed73-b76e-417a-9fa6-4b60da575ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_aadfc09e-3ff0-4a10-affb-ba51c2b25657" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d999ed73-b76e-417a-9fa6-4b60da575ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockBasedCompensationServiceBasedStockOptionsOthersDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87bd7b3a-8ea9-460c-ad1a-faba45f2e9cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce312300-47d0-4644-a698-e82134907f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87bd7b3a-8ea9-460c-ad1a-faba45f2e9cd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce312300-47d0-4644-a698-e82134907f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_73dc7268-07a9-4606-aeed-2ad1e7d3bc63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce312300-47d0-4644-a698-e82134907f8e" xlink:to="loc_us-gaap_AwardTypeAxis_73dc7268-07a9-4606-aeed-2ad1e7d3bc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbb08cd0-28eb-43c4-b928-496d02bbf0d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_73dc7268-07a9-4606-aeed-2ad1e7d3bc63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbb08cd0-28eb-43c4-b928-496d02bbf0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ServiceBasedStockOptionAwardsMember_92c359d8-d396-4163-b119-bc5df39e77fc" xlink:href="rmti-20210630.xsd#rmti_ServiceBasedStockOptionAwardsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbb08cd0-28eb-43c4-b928-496d02bbf0d2" xlink:to="loc_rmti_ServiceBasedStockOptionAwardsMember_92c359d8-d396-4163-b119-bc5df39e77fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44543a1b-258b-4d3f-a241-1b9771f153d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce312300-47d0-4644-a698-e82134907f8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44543a1b-258b-4d3f-a241-1b9771f153d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_25cd2a1a-a93d-4149-818c-67642061cfec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44543a1b-258b-4d3f-a241-1b9771f153d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_25cd2a1a-a93d-4149-818c-67642061cfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0a7c48e1-e1ea-4ca6-b513-9eaf44b7a72a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44543a1b-258b-4d3f-a241-1b9771f153d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0a7c48e1-e1ea-4ca6-b513-9eaf44b7a72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b2a2dcd2-8690-444a-a8f6-cd97706213e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44543a1b-258b-4d3f-a241-1b9771f153d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b2a2dcd2-8690-444a-a8f6-cd97706213e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_584610ea-608b-4b83-a00f-988e108da5e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44543a1b-258b-4d3f-a241-1b9771f153d4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_584610ea-608b-4b83-a00f-988e108da5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_63c137c9-a939-4261-b86d-9786870e9e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44543a1b-258b-4d3f-a241-1b9771f153d4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_63c137c9-a939-4261-b86d-9786870e9e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9447902e-989e-478f-a498-1e93b1064323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44543a1b-258b-4d3f-a241-1b9771f153d4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9447902e-989e-478f-a498-1e93b1064323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#StockBasedCompensationPerformanceBasedStockOptionsDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54863b85-08c7-4738-a925-294f1d035386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e59a259-7109-4fad-b2d4-60eacbed3a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54863b85-08c7-4738-a925-294f1d035386" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e59a259-7109-4fad-b2d4-60eacbed3a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0273e18d-85fa-4a21-bd77-40ae4751c4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e59a259-7109-4fad-b2d4-60eacbed3a62" xlink:to="loc_us-gaap_AwardTypeAxis_0273e18d-85fa-4a21-bd77-40ae4751c4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e2e12fe-72a3-4d0e-858f-f8bec40be3c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0273e18d-85fa-4a21-bd77-40ae4751c4d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e2e12fe-72a3-4d0e-858f-f8bec40be3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_PerformanceBasedStockOptionAwardsMember_dc5080fe-caee-49fe-bbdd-58a0dc7fbcea" xlink:href="rmti-20210630.xsd#rmti_PerformanceBasedStockOptionAwardsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e2e12fe-72a3-4d0e-858f-f8bec40be3c8" xlink:to="loc_rmti_PerformanceBasedStockOptionAwardsMember_dc5080fe-caee-49fe-bbdd-58a0dc7fbcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58c3cdc2-e6d8-4214-9ae4-d7f4d498f11c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e59a259-7109-4fad-b2d4-60eacbed3a62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58c3cdc2-e6d8-4214-9ae4-d7f4d498f11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e8b54a7-2d3f-43e9-9095-f2ac96ef8404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58c3cdc2-e6d8-4214-9ae4-d7f4d498f11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e8b54a7-2d3f-43e9-9095-f2ac96ef8404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_05e87b6f-677f-4472-b421-00edd8d905a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e8b54a7-2d3f-43e9-9095-f2ac96ef8404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_05e87b6f-677f-4472-b421-00edd8d905a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bd9b162d-c0e8-41df-9fae-849b9113f4d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e8b54a7-2d3f-43e9-9095-f2ac96ef8404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bd9b162d-c0e8-41df-9fae-849b9113f4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e5e35dba-b033-43e3-a46c-b8c7c24a1c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e8b54a7-2d3f-43e9-9095-f2ac96ef8404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e5e35dba-b033-43e3-a46c-b8c7c24a1c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_283ca674-a6c3-4990-bcfa-9aefccfccb0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e8b54a7-2d3f-43e9-9095-f2ac96ef8404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_283ca674-a6c3-4990-bcfa-9aefccfccb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6e472e68-7b7d-4fc1-932c-f3000d1ebf21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e8b54a7-2d3f-43e9-9095-f2ac96ef8404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6e472e68-7b7d-4fc1-932c-f3000d1ebf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8e11969b-fd07-4a22-9341-a66b1e997acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e8b54a7-2d3f-43e9-9095-f2ac96ef8404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8e11969b-fd07-4a22-9341-a66b1e997acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f57cbb8-ea68-4032-90c6-b47d8398adbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58c3cdc2-e6d8-4214-9ae4-d7f4d498f11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f57cbb8-ea68-4032-90c6-b47d8398adbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96bbb65b-954d-480a-b8d9-636894d596b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f57cbb8-ea68-4032-90c6-b47d8398adbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96bbb65b-954d-480a-b8d9-636894d596b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d4fd7ed0-bbcc-46e3-9998-a54cf948c688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f57cbb8-ea68-4032-90c6-b47d8398adbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d4fd7ed0-bbcc-46e3-9998-a54cf948c688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_54a4324b-3e3b-4374-8352-a736b08aa111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f57cbb8-ea68-4032-90c6-b47d8398adbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_54a4324b-3e3b-4374-8352-a736b08aa111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ef3ac2d0-0314-47d7-a536-67614cbbb1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f57cbb8-ea68-4032-90c6-b47d8398adbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ef3ac2d0-0314-47d7-a536-67614cbbb1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_822f5807-deb2-4791-bb0e-8fef96a7db37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f57cbb8-ea68-4032-90c6-b47d8398adbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_822f5807-deb2-4791-bb0e-8fef96a7db37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9047bc8d-16f2-4080-8565-94d17f8d0db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f57cbb8-ea68-4032-90c6-b47d8398adbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9047bc8d-16f2-4080-8565-94d17f8d0db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_acda6700-ce6c-4547-bc8e-3dcebf1ebd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58c3cdc2-e6d8-4214-9ae4-d7f4d498f11c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_acda6700-ce6c-4547-bc8e-3dcebf1ebd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2403973b-8502-49e5-af98-7556cb3e4aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58c3cdc2-e6d8-4214-9ae4-d7f4d498f11c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2403973b-8502-49e5-af98-7556cb3e4aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LicensingAgreements" xlink:type="simple" xlink:href="rmti-20210630.xsd#LicensingAgreements"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/LicensingAgreements" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e6fa05c7-4b1b-4472-b4d9-67a98eb978ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_09e68e48-c24c-469b-9971-3bda8e2f9574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e6fa05c7-4b1b-4472-b4d9-67a98eb978ec" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_09e68e48-c24c-469b-9971-3bda8e2f9574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LicensingAgreementsDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#LicensingAgreementsDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/LicensingAgreementsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_19113280-7051-4376-903f-e93e27a3a5a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fb897b2-ae2d-4651-9807-d839c3ac5dc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_19113280-7051-4376-903f-e93e27a3a5a7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fb897b2-ae2d-4651-9807-d839c3ac5dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_fb88b3a6-7ba2-4ef6-93b2-c7e9518e4343" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fb897b2-ae2d-4651-9807-d839c3ac5dc4" xlink:to="loc_srt_TitleOfIndividualAxis_fb88b3a6-7ba2-4ef6-93b2-c7e9518e4343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d668d39e-b48d-4adb-a829-9889655d0c19" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_fb88b3a6-7ba2-4ef6-93b2-c7e9518e4343" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d668d39e-b48d-4adb-a829-9889655d0c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember_19cb8d28-5ca4-4a98-bb28-7be19160c91c" xlink:href="rmti-20210630.xsd#rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d668d39e-b48d-4adb-a829-9889655d0c19" xlink:to="loc_rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember_19cb8d28-5ca4-4a98-bb28-7be19160c91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fd9ddfc-5f3b-4dc6-b98b-9959082f7f38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2fb897b2-ae2d-4651-9807-d839c3ac5dc4" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fd9ddfc-5f3b-4dc6-b98b-9959082f7f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_NumberOfAdditionalAgreements_eb6b5392-8952-4056-9959-b08e110c8e52" xlink:href="rmti-20210630.xsd#rmti_NumberOfAdditionalAgreements"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fd9ddfc-5f3b-4dc6-b98b-9959082f7f38" xlink:to="loc_rmti_NumberOfAdditionalAgreements_eb6b5392-8952-4056-9959-b08e110c8e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_cb9d5482-8a06-4324-9d35-17086da0a513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fd9ddfc-5f3b-4dc6-b98b-9959082f7f38" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_cb9d5482-8a06-4324-9d35-17086da0a513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_CollaborativeArrangementNumberOfInstallmentPayments_099255b2-c400-4184-ae92-922137b8bc12" xlink:href="rmti-20210630.xsd#rmti_CollaborativeArrangementNumberOfInstallmentPayments"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fd9ddfc-5f3b-4dc6-b98b-9959082f7f38" xlink:to="loc_rmti_CollaborativeArrangementNumberOfInstallmentPayments_099255b2-c400-4184-ae92-922137b8bc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_InstallmentPaymentToRelatedParties_b395f0b9-72e7-4dd1-ac31-7873a320aad5" xlink:href="rmti-20210630.xsd#rmti_InstallmentPaymentToRelatedParties"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fd9ddfc-5f3b-4dc6-b98b-9959082f7f38" xlink:to="loc_rmti_InstallmentPaymentToRelatedParties_b395f0b9-72e7-4dd1-ac31-7873a320aad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses_76a94e74-b00e-4745-b0a2-c2718f3e197d" xlink:href="rmti-20210630.xsd#rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fd9ddfc-5f3b-4dc6-b98b-9959082f7f38" xlink:to="loc_rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses_76a94e74-b00e-4745-b0a2-c2718f3e197d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees_bb873d92-54bb-4d5c-a2a2-b2cde0184173" xlink:href="rmti-20210630.xsd#rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fd9ddfc-5f3b-4dc6-b98b-9959082f7f38" xlink:to="loc_rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees_bb873d92-54bb-4d5c-a2a2-b2cde0184173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/Leases" xlink:type="simple" xlink:href="rmti-20210630.xsd#Leases"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/Leases" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0e9f6f4d-ca25-402e-8bc7-22c0e82a5a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_b9ed3ca7-0dce-4918-9b2a-46af7c3247e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0e9f6f4d-ca25-402e-8bc7-22c0e82a5a3a" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_b9ed3ca7-0dce-4918-9b2a-46af7c3247e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_48e41fb0-06c9-4e67-b64b-7a40797eb943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0e9f6f4d-ca25-402e-8bc7-22c0e82a5a3a" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_48e41fb0-06c9-4e67-b64b-7a40797eb943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LeasesTables" xlink:type="simple" xlink:href="rmti-20210630.xsd#LeasesTables"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/LeasesTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c5ce2bd3-eef1-4118-93d4-613e5e62221f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_a7d71946-3f59-44e6-ac16-7a7fde667b7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5ce2bd3-eef1-4118-93d4-613e5e62221f" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_a7d71946-3f59-44e6-ac16-7a7fde667b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ea10c863-ae75-45a0-9212-b30d76f4afd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5ce2bd3-eef1-4118-93d4-613e5e62221f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ea10c863-ae75-45a0-9212-b30d76f4afd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_326168a1-5797-4665-b0f0-5934c7f63545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5ce2bd3-eef1-4118-93d4-613e5e62221f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_326168a1-5797-4665-b0f0-5934c7f63545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#LeasesNarrativeDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/LeasesNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_28104025-7af7-48b9-b0d2-9ca1e4997cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_904d62ec-ef1a-40d5-bacd-45fb58019054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_28104025-7af7-48b9-b0d2-9ca1e4997cb2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_904d62ec-ef1a-40d5-bacd-45fb58019054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e7fc44a1-31d1-435f-ad0b-5bcbc29c84d4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_904d62ec-ef1a-40d5-bacd-45fb58019054" xlink:to="loc_srt_RangeAxis_e7fc44a1-31d1-435f-ad0b-5bcbc29c84d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_42877b1c-c8e9-4778-9301-d1fdb0a6d430" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e7fc44a1-31d1-435f-ad0b-5bcbc29c84d4" xlink:to="loc_srt_RangeMember_42877b1c-c8e9-4778-9301-d1fdb0a6d430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a9a8c6a0-aa02-4611-8537-15f0feb629aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_42877b1c-c8e9-4778-9301-d1fdb0a6d430" xlink:to="loc_srt_MaximumMember_a9a8c6a0-aa02-4611-8537-15f0feb629aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f5c3e6c2-c04d-4db3-9e43-e24dcaa956a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_904d62ec-ef1a-40d5-bacd-45fb58019054" xlink:to="loc_srt_StatementGeographicalAxis_f5c3e6c2-c04d-4db3-9e43-e24dcaa956a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_65f74734-a791-4d32-b0d8-2a37f31b528c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f5c3e6c2-c04d-4db3-9e43-e24dcaa956a6" xlink:to="loc_srt_SegmentGeographicalDomain_65f74734-a791-4d32-b0d8-2a37f31b528c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_stpr_MI_fc25e5e1-96e2-4da6-904e-d4d4301a19ec" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MI"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_65f74734-a791-4d32-b0d8-2a37f31b528c" xlink:to="loc_stpr_MI_fc25e5e1-96e2-4da6-904e-d4d4301a19ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_stpr_TX_d0c8846a-2b31-4a5b-81a7-f1a24802c55f" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TX"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_65f74734-a791-4d32-b0d8-2a37f31b528c" xlink:to="loc_stpr_TX_d0c8846a-2b31-4a5b-81a7-f1a24802c55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_stpr_SC_734952dc-0eb4-427e-942c-d3c1d29dd8dc" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_65f74734-a791-4d32-b0d8-2a37f31b528c" xlink:to="loc_stpr_SC_734952dc-0eb4-427e-942c-d3c1d29dd8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_799b91b4-f157-418c-aedd-4818648edb1c" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_65f74734-a791-4d32-b0d8-2a37f31b528c" xlink:to="loc_stpr_NJ_799b91b4-f157-418c-aedd-4818648edb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1c1313eb-b34a-47bd-9ef8-4ca738282f14" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_904d62ec-ef1a-40d5-bacd-45fb58019054" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1c1313eb-b34a-47bd-9ef8-4ca738282f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7a761efc-34df-4cfb-8c71-83b09cfc540b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1c1313eb-b34a-47bd-9ef8-4ca738282f14" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7a761efc-34df-4cfb-8c71-83b09cfc540b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_WixomMichiganPropertyOneMember_f45e1c30-a0bb-495a-9eac-e24171f97493" xlink:href="rmti-20210630.xsd#rmti_WixomMichiganPropertyOneMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7a761efc-34df-4cfb-8c71-83b09cfc540b" xlink:to="loc_rmti_WixomMichiganPropertyOneMember_f45e1c30-a0bb-495a-9eac-e24171f97493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_WixomMichiganPropertyTwoMember_15f4f1cd-bf3a-49d3-9c7e-f22844b1262a" xlink:href="rmti-20210630.xsd#rmti_WixomMichiganPropertyTwoMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7a761efc-34df-4cfb-8c71-83b09cfc540b" xlink:to="loc_rmti_WixomMichiganPropertyTwoMember_15f4f1cd-bf3a-49d3-9c7e-f22844b1262a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb6f44b1-fff5-4e55-b969-d99e548a6404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_904d62ec-ef1a-40d5-bacd-45fb58019054" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb6f44b1-fff5-4e55-b969-d99e548a6404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1191159e-f2d9-4ed8-966d-f83025d56d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb6f44b1-fff5-4e55-b969-d99e548a6404" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1191159e-f2d9-4ed8-966d-f83025d56d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_172278b3-bc51-4144-b3b8-fc34b16376f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb6f44b1-fff5-4e55-b969-d99e548a6404" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_172278b3-bc51-4144-b3b8-fc34b16376f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseAndFinanceLeaseLiability_817f806e-3028-4925-a9a7-ffeaa494b647" xlink:href="rmti-20210630.xsd#rmti_OperatingLeaseAndFinanceLeaseLiability"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb6f44b1-fff5-4e55-b969-d99e548a6404" xlink:to="loc_rmti_OperatingLeaseAndFinanceLeaseLiability_817f806e-3028-4925-a9a7-ffeaa494b647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet_56cb866d-914e-4006-b00d-151ece75d545" xlink:href="rmti-20210630.xsd#rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb6f44b1-fff5-4e55-b969-d99e548a6404" xlink:to="loc_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet_56cb866d-914e-4006-b00d-151ece75d545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c7125683-485b-42bc-b9e9-0783d7f41380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb6f44b1-fff5-4e55-b969-d99e548a6404" xlink:to="loc_us-gaap_OperatingLeaseLiability_c7125683-485b-42bc-b9e9-0783d7f41380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f1f1e698-edd3-4577-8b8c-6d97a7b5c749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb6f44b1-fff5-4e55-b969-d99e548a6404" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f1f1e698-edd3-4577-8b8c-6d97a7b5c749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#LeasesSummaryofLeaseCostsDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_53030c3c-e0fb-452f-bcfb-5411b6838e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_1803d430-d8c2-4d06-87ea-e7a8d377ad3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53030c3c-e0fb-452f-bcfb-5411b6838e6a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_1803d430-d8c2-4d06-87ea-e7a8d377ad3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_6dcfeb73-d887-4103-b28f-b8083e0ddeba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_1803d430-d8c2-4d06-87ea-e7a8d377ad3a" xlink:to="loc_us-gaap_OperatingLeaseCost_6dcfeb73-d887-4103-b28f-b8083e0ddeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_f88248c1-cd46-43ef-9958-e03a2c6f0f63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_1803d430-d8c2-4d06-87ea-e7a8d377ad3a" xlink:to="loc_us-gaap_VariableLeaseCost_f88248c1-cd46-43ef-9958-e03a2c6f0f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_394e29ae-1115-43fb-aac0-468e682f04b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_1803d430-d8c2-4d06-87ea-e7a8d377ad3a" xlink:to="loc_us-gaap_OperatingLeaseExpense_394e29ae-1115-43fb-aac0-468e682f04b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract_968f5a29-dad6-4f19-88d7-ee5d9741621c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53030c3c-e0fb-452f-bcfb-5411b6838e6a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityAbstract_968f5a29-dad6-4f19-88d7-ee5d9741621c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_c1273c51-e2d9-49b1-a31a-495276f09ee8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_968f5a29-dad6-4f19-88d7-ee5d9741621c" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_c1273c51-e2d9-49b1-a31a-495276f09ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_2e5e4f73-06ec-4c03-ae02-2c0b4bddf487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_968f5a29-dad6-4f19-88d7-ee5d9741621c" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_2e5e4f73-06ec-4c03-ae02-2c0b4bddf487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_FinanceLeaseExpense_dfc47693-66a2-4726-ae02-4e7236db6383" xlink:href="rmti-20210630.xsd#rmti_FinanceLeaseExpense"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_968f5a29-dad6-4f19-88d7-ee5d9741621c" xlink:to="loc_rmti_FinanceLeaseExpense_dfc47693-66a2-4726-ae02-4e7236db6383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_7b09ddf9-e4d9-472e-b6b9-e7bc3f74be62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53030c3c-e0fb-452f-bcfb-5411b6838e6a" xlink:to="loc_us-gaap_ShortTermLeaseCost_7b09ddf9-e4d9-472e-b6b9-e7bc3f74be62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_e5bcc5e2-489e-49aa-bde0-66baa8159b36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53030c3c-e0fb-452f-bcfb-5411b6838e6a" xlink:to="loc_us-gaap_LeaseCost_e5bcc5e2-489e-49aa-bde0-66baa8159b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_4b2f6846-6d64-4cb5-8045-9d0cbc2a8524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53030c3c-e0fb-452f-bcfb-5411b6838e6a" xlink:to="loc_us-gaap_LeaseCostAbstract_4b2f6846-6d64-4cb5-8045-9d0cbc2a8524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_711b9252-fcd2-49ee-85a5-eaecc0dbc91f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_4b2f6846-6d64-4cb5-8045-9d0cbc2a8524" xlink:to="loc_us-gaap_OperatingLeasePayments_711b9252-fcd2-49ee-85a5-eaecc0dbc91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_a9d3c828-939c-44b3-8ab5-8c3c487d5182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_4b2f6846-6d64-4cb5-8045-9d0cbc2a8524" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_a9d3c828-939c-44b3-8ab5-8c3c487d5182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_b53fd936-7b63-4d77-b85b-9eab1c5b03a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_4b2f6846-6d64-4cb5-8045-9d0cbc2a8524" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_b53fd936-7b63-4d77-b85b-9eab1c5b03a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b2cf7b03-cbbe-4078-a0d5-ebf2584f650b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_4b2f6846-6d64-4cb5-8045-9d0cbc2a8524" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b2cf7b03-cbbe-4078-a0d5-ebf2584f650b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_9f994f7f-1ed3-427c-be20-ce1f0c6a8d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_4b2f6846-6d64-4cb5-8045-9d0cbc2a8524" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_9f994f7f-1ed3-427c-be20-ce1f0c6a8d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fa302bf5-8d7a-4c2b-834b-a5ba689aebca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_4b2f6846-6d64-4cb5-8045-9d0cbc2a8524" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fa302bf5-8d7a-4c2b-834b-a5ba689aebca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_78808459-eb17-4bcd-865c-1198a413a37d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_4b2f6846-6d64-4cb5-8045-9d0cbc2a8524" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_78808459-eb17-4bcd-865c-1198a413a37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e84fb67d-9052-4c18-ae85-e260bd0bbb9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_4b2f6846-6d64-4cb5-8045-9d0cbc2a8524" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e84fb67d-9052-4c18-ae85-e260bd0bbb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_1cc6ef06-8781-49a0-874a-364c043a367a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_4b2f6846-6d64-4cb5-8045-9d0cbc2a8524" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_1cc6ef06-8781-49a0-874a-364c043a367a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b9a1aabb-8ce9-4045-b89a-b95b5535fc49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_67d887e4-d7ae-4561-85a6-e73f58266051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b9a1aabb-8ce9-4045-b89a-b95b5535fc49" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_67d887e4-d7ae-4561-85a6-e73f58266051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fe4d7679-1bac-40fb-ae66-a5fa33b97c95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_67d887e4-d7ae-4561-85a6-e73f58266051" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fe4d7679-1bac-40fb-ae66-a5fa33b97c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3ad85ce7-8e9e-43cd-aa7d-5cbfa987dc03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_67d887e4-d7ae-4561-85a6-e73f58266051" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3ad85ce7-8e9e-43cd-aa7d-5cbfa987dc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_21a1ff51-425b-4085-bff8-6086711fdcb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_67d887e4-d7ae-4561-85a6-e73f58266051" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_21a1ff51-425b-4085-bff8-6086711fdcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d0f3ae14-ab91-456e-afb9-ba73a4220271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_67d887e4-d7ae-4561-85a6-e73f58266051" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d0f3ae14-ab91-456e-afb9-ba73a4220271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ac898658-1946-4331-a141-445bd7dfc1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_67d887e4-d7ae-4561-85a6-e73f58266051" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ac898658-1946-4331-a141-445bd7dfc1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_f25b57b4-a02f-432e-8654-2a43ebfa84d4" xlink:href="rmti-20210630.xsd#rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_67d887e4-d7ae-4561-85a6-e73f58266051" xlink:to="loc_rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_f25b57b4-a02f-432e-8654-2a43ebfa84d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0ea6e83f-870e-4df6-a306-94e9223c58df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_67d887e4-d7ae-4561-85a6-e73f58266051" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0ea6e83f-870e-4df6-a306-94e9223c58df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a6902266-24c6-45b5-b2a5-705d8d8d2712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_67d887e4-d7ae-4561-85a6-e73f58266051" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a6902266-24c6-45b5-b2a5-705d8d8d2712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2b6eed9b-ef7c-4318-9eac-65c3dac856e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_67d887e4-d7ae-4561-85a6-e73f58266051" xlink:to="loc_us-gaap_OperatingLeaseLiability_2b6eed9b-ef7c-4318-9eac-65c3dac856e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ec95fe0-31d0-422d-8dc8-750d8f529799" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b9a1aabb-8ce9-4045-b89a-b95b5535fc49" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ec95fe0-31d0-422d-8dc8-750d8f529799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_f51e90f2-ff6a-4790-9b07-c5d9c3d1da9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ec95fe0-31d0-422d-8dc8-750d8f529799" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_f51e90f2-ff6a-4790-9b07-c5d9c3d1da9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_e4309a10-36c5-4018-adbc-7d8d85dea208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ec95fe0-31d0-422d-8dc8-750d8f529799" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_e4309a10-36c5-4018-adbc-7d8d85dea208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_284c4554-83b7-4eac-9586-7d704fe936e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ec95fe0-31d0-422d-8dc8-750d8f529799" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_284c4554-83b7-4eac-9586-7d704fe936e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_123c5b24-0d96-4a34-93db-ad9618d04986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ec95fe0-31d0-422d-8dc8-750d8f529799" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_123c5b24-0d96-4a34-93db-ad9618d04986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_17b1344c-908a-4638-9812-46a9c15571d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ec95fe0-31d0-422d-8dc8-750d8f529799" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_17b1344c-908a-4638-9812-46a9c15571d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_FinanceLeaseLiabilityToBePaidAfterYearFour_4bd71070-2261-4b25-bcc5-23f6d9283fa9" xlink:href="rmti-20210630.xsd#rmti_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ec95fe0-31d0-422d-8dc8-750d8f529799" xlink:to="loc_rmti_FinanceLeaseLiabilityToBePaidAfterYearFour_4bd71070-2261-4b25-bcc5-23f6d9283fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_68cef710-e052-4cd4-a7ae-9b5fed89e67b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ec95fe0-31d0-422d-8dc8-750d8f529799" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_68cef710-e052-4cd4-a7ae-9b5fed89e67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_f405af7d-7060-48f9-b22d-99e021c99602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ec95fe0-31d0-422d-8dc8-750d8f529799" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_f405af7d-7060-48f9-b22d-99e021c99602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_024c79e9-6a6e-4127-a9d8-ec2dd20b5900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_0ec95fe0-31d0-422d-8dc8-750d8f529799" xlink:to="loc_us-gaap_FinanceLeaseLiability_024c79e9-6a6e-4127-a9d8-ec2dd20b5900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1" xlink:type="simple" xlink:href="rmti-20210630.xsd#LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1" xlink:type="extended"/>
<link:roleRef roleURI="http://rockwellmed.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="rmti-20210630.xsd#CommitmentsandContingencies"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/CommitmentsandContingencies" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bbc8e06d-cdcc-42f5-9fbf-80c34e438624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3e0f6c76-cbb6-4846-a038-9ee9c26646de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bbc8e06d-cdcc-42f5-9fbf-80c34e438624" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3e0f6c76-cbb6-4846-a038-9ee9c26646de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreement" xlink:type="simple" xlink:href="rmti-20210630.xsd#LoansandSecurityAgreement"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreement" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_def69af2-46eb-4333-91f9-6ceeeaf5a7f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_20b55b66-0ff8-4969-b253-2c2b26f770f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_def69af2-46eb-4333-91f9-6ceeeaf5a7f0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_20b55b66-0ff8-4969-b253-2c2b26f770f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementTables" xlink:type="simple" xlink:href="rmti-20210630.xsd#LoansandSecurityAgreementTables"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreementTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c8d598ae-f956-48cd-afb9-1246b4a90062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7ca3b95a-4302-4e98-b7d5-1f6cf3deb9d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c8d598ae-f956-48cd-afb9-1246b4a90062" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7ca3b95a-4302-4e98-b7d5-1f6cf3deb9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#LoansandSecurityAgreementNarrativeDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_436aba18-aca6-4f0e-8378-a7df5adf97b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ab48a38f-2a96-46fc-83e5-a6da86f16c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_436aba18-aca6-4f0e-8378-a7df5adf97b5" xlink:to="loc_us-gaap_DebtInstrumentTable_ab48a38f-2a96-46fc-83e5-a6da86f16c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a8518050-a44b-4774-b8d7-fd9081b12f2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ab48a38f-2a96-46fc-83e5-a6da86f16c29" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a8518050-a44b-4774-b8d7-fd9081b12f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_53dc9953-352d-40ea-9284-7f0c149b6a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a8518050-a44b-4774-b8d7-fd9081b12f2b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_53dc9953-352d-40ea-9284-7f0c149b6a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_7b12ca24-29e2-4759-a07a-8ccc0c38afca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MediumTermNotesMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_53dc9953-352d-40ea-9284-7f0c149b6a27" xlink:to="loc_us-gaap_MediumTermNotesMember_7b12ca24-29e2-4759-a07a-8ccc0c38afca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2ecc04bf-1edd-4b08-b5a3-142b283d430b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ab48a38f-2a96-46fc-83e5-a6da86f16c29" xlink:to="loc_us-gaap_DebtInstrumentAxis_2ecc04bf-1edd-4b08-b5a3-142b283d430b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_62de41a3-181f-44a4-adc0-38b90771e34a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2ecc04bf-1edd-4b08-b5a3-142b283d430b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_62de41a3-181f-44a4-adc0-38b90771e34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanMember_df3f92ed-2321-402e-974d-7365700441ec" xlink:href="rmti-20210630.xsd#rmti_TermLoanMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_62de41a3-181f-44a4-adc0-38b90771e34a" xlink:to="loc_rmti_TermLoanMember_df3f92ed-2321-402e-974d-7365700441ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheOneMember_fed471a7-72df-45d1-8ad7-1dd3c82e251a" xlink:href="rmti-20210630.xsd#rmti_TermLoanTrancheOneMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_TermLoanMember_df3f92ed-2321-402e-974d-7365700441ec" xlink:to="loc_rmti_TermLoanTrancheOneMember_fed471a7-72df-45d1-8ad7-1dd3c82e251a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember_d0633e78-4b1d-43a7-b938-f39504b9771d" xlink:href="rmti-20210630.xsd#rmti_TermLoanTrancheTwoAndTrancheThreeMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_TermLoanMember_df3f92ed-2321-402e-974d-7365700441ec" xlink:to="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember_d0633e78-4b1d-43a7-b938-f39504b9771d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheTwoMember_37666adc-b536-4a92-99bf-aae198573864" xlink:href="rmti-20210630.xsd#rmti_TermLoanTrancheTwoMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember_d0633e78-4b1d-43a7-b938-f39504b9771d" xlink:to="loc_rmti_TermLoanTrancheTwoMember_37666adc-b536-4a92-99bf-aae198573864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanTrancheThreeMember_91846c09-3bc9-45df-9f24-1c37c383e881" xlink:href="rmti-20210630.xsd#rmti_TermLoanTrancheThreeMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmti_TermLoanTrancheTwoAndTrancheThreeMember_d0633e78-4b1d-43a7-b938-f39504b9771d" xlink:to="loc_rmti_TermLoanTrancheThreeMember_91846c09-3bc9-45df-9f24-1c37c383e881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f18e5a51-84fa-4d48-ae64-789a463dbcd2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ab48a38f-2a96-46fc-83e5-a6da86f16c29" xlink:to="loc_srt_RangeAxis_f18e5a51-84fa-4d48-ae64-789a463dbcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_60ce89c9-1788-4b46-936b-a98957dd91b4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f18e5a51-84fa-4d48-ae64-789a463dbcd2" xlink:to="loc_srt_RangeMember_60ce89c9-1788-4b46-936b-a98957dd91b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f50bd10b-d7ad-4297-a0c0-78d80998006e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_60ce89c9-1788-4b46-936b-a98957dd91b4" xlink:to="loc_srt_MinimumMember_f50bd10b-d7ad-4297-a0c0-78d80998006e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_143837e0-d675-482a-8c11-57eb6058d0da" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_60ce89c9-1788-4b46-936b-a98957dd91b4" xlink:to="loc_srt_MaximumMember_143837e0-d675-482a-8c11-57eb6058d0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ab48a38f-2a96-46fc-83e5-a6da86f16c29" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_31c6c5b3-d0a3-474c-9b55-2b36c97a773d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_31c6c5b3-d0a3-474c-9b55-2b36c97a773d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_cbbbba95-55f0-4504-8f50-9559df3eec44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_cbbbba95-55f0-4504-8f50-9559df3eec44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_f865dfca-6ccc-4914-88b5-95443fb43447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_f865dfca-6ccc-4914-88b5-95443fb43447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DebtInstrumentPeriodOfInterestOnlyPayments_bfacd212-72f6-4bda-88b5-ff57952ab3ff" xlink:href="rmti-20210630.xsd#rmti_DebtInstrumentPeriodOfInterestOnlyPayments"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_rmti_DebtInstrumentPeriodOfInterestOnlyPayments_bfacd212-72f6-4bda-88b5-ff57952ab3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ddf6e8a8-b2fc-4fac-8e40-cd95526bc668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ddf6e8a8-b2fc-4fac-8e40-cd95526bc668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_93e9ee73-c27a-4388-9970-f8eacf9d0022" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_93e9ee73-c27a-4388-9970-f8eacf9d0022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_881a6e6f-8981-4c4e-868b-a2188c167db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_881a6e6f-8981-4c4e-868b-a2188c167db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0ecd36ad-3793-47f1-aba4-dec61a37cff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0ecd36ad-3793-47f1-aba4-dec61a37cff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage_23629201-198e-4afc-88e7-4735218480ff" xlink:href="rmti-20210630.xsd#rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage_23629201-198e-4afc-88e7-4735218480ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_1e617440-12ce-4d32-8926-c256b4545bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_InterestExpenseDebt_1e617440-12ce-4d32-8926-c256b4545bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded_d65c49dc-7faf-430c-bcd2-1326e7cac450" xlink:href="rmti-20210630.xsd#rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded"/>
<link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded_d65c49dc-7faf-430c-bcd2-1326e7cac450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays_65588532-683d-4005-9e9c-2344eff93e77" xlink:href="rmti-20210630.xsd#rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays"/>
<link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays_65588532-683d-4005-9e9c-2344eff93e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e0b0a774-2e82-4020-b9b6-c76bac32f9ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e0b0a774-2e82-4020-b9b6-c76bac32f9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays_798f37e3-9be0-4010-99c8-cf17219fd5c0" xlink:href="rmti-20210630.xsd#rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays"/>
<link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays_798f37e3-9be0-4010-99c8-cf17219fd5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a6e90bfd-e0ca-4211-9a3b-05e0a12c8f00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a6e90bfd-e0ca-4211-9a3b-05e0a12c8f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7903b99a-c3bd-4a3f-bc0f-88c5287bb549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
<link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7903b99a-c3bd-4a3f-bc0f-88c5287bb549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1088663d-3c29-4485-b1ae-6a597a0b2c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
<link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_LongTermDebt_1088663d-3c29-4485-b1ae-6a597a0b2c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_33145733-3655-4274-b22d-1d29c4738bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
<link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f79717ff-2ff6-4229-92d4-da62d29ce446" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_33145733-3655-4274-b22d-1d29c4738bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_119b4d1f-b9dc-46fc-98b9-20f69920b4f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_95096dcb-93e1-4222-84ed-0d476b7ae957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_119b4d1f-b9dc-46fc-98b9-20f69920b4f6" xlink:to="loc_us-gaap_DebtInstrumentTable_95096dcb-93e1-4222-84ed-0d476b7ae957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d30da7b6-eed3-4d7b-b218-19e0be1730f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_95096dcb-93e1-4222-84ed-0d476b7ae957" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d30da7b6-eed3-4d7b-b218-19e0be1730f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c1d5893c-e4e4-43bf-8ed3-5e51d8096978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d30da7b6-eed3-4d7b-b218-19e0be1730f9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c1d5893c-e4e4-43bf-8ed3-5e51d8096978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_265a4a2f-f695-46e1-837f-ece85eb050fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MediumTermNotesMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c1d5893c-e4e4-43bf-8ed3-5e51d8096978" xlink:to="loc_us-gaap_MediumTermNotesMember_265a4a2f-f695-46e1-837f-ece85eb050fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f5cc216b-c2dc-4a8b-875f-9d969dadcc75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_95096dcb-93e1-4222-84ed-0d476b7ae957" xlink:to="loc_us-gaap_DebtInstrumentAxis_f5cc216b-c2dc-4a8b-875f-9d969dadcc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4e8c4c1d-8343-4fad-a63b-d16482682e64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f5cc216b-c2dc-4a8b-875f-9d969dadcc75" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4e8c4c1d-8343-4fad-a63b-d16482682e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_TermLoanMember_c31600e7-2451-4636-bef3-2ffc82c7b385" xlink:href="rmti-20210630.xsd#rmti_TermLoanMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4e8c4c1d-8343-4fad-a63b-d16482682e64" xlink:to="loc_rmti_TermLoanMember_c31600e7-2451-4636-bef3-2ffc82c7b385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5945e707-be01-466b-bdee-349ea8b018ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_95096dcb-93e1-4222-84ed-0d476b7ae957" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5945e707-be01-466b-bdee-349ea8b018ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_ed0462c9-e621-4e98-b34b-dcac9691452c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5945e707-be01-466b-bdee-349ea8b018ed" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_ed0462c9-e621-4e98-b34b-dcac9691452c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2b323c87-4463-49e8-a7d5-c01e5c319536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5945e707-be01-466b-bdee-349ea8b018ed" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2b323c87-4463-49e8-a7d5-c01e5c319536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5af5dd90-4cb4-4193-90b1-cc038cc59550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5945e707-be01-466b-bdee-349ea8b018ed" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5af5dd90-4cb4-4193-90b1-cc038cc59550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_fbca8774-a714-4ded-afcc-8727e8ac53d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5945e707-be01-466b-bdee-349ea8b018ed" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_fbca8774-a714-4ded-afcc-8727e8ac53d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_bd56d6cd-d9f2-495b-88a2-bd75e6494ffb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5945e707-be01-466b-bdee-349ea8b018ed" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_bd56d6cd-d9f2-495b-88a2-bd75e6494ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5c64c459-78a4-4951-b477-6b59c8781291" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5945e707-be01-466b-bdee-349ea8b018ed" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5c64c459-78a4-4951-b477-6b59c8781291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/SubsequentEvents" xlink:type="simple" xlink:href="rmti-20210630.xsd#SubsequentEvents"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/SubsequentEvents" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_2e6c71d1-8d02-45fb-93f8-e4146fc621e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_793e48d6-8a02-4e52-b7fd-951016c28840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_2e6c71d1-8d02-45fb-93f8-e4146fc621e8" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_793e48d6-8a02-4e52-b7fd-951016c28840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://rockwellmed.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="rmti-20210630.xsd#SubsequentEventsDetails"/>
<link:presentationLink xlink:role="http://rockwellmed.com/role/SubsequentEventsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_23b5f3d4-84ac-4619-98a4-991eae2ff6e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_9fe7e447-ab0e-4339-a6e4-51bdc2945303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_23b5f3d4-84ac-4619-98a4-991eae2ff6e1" xlink:to="loc_us-gaap_SubsequentEventTable_9fe7e447-ab0e-4339-a6e4-51bdc2945303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_937fa332-95ad-44c9-bb7b-a191996ee1d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9fe7e447-ab0e-4339-a6e4-51bdc2945303" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_937fa332-95ad-44c9-bb7b-a191996ee1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d5cb61f3-47f5-4c7e-8cb7-aae267d3b152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_937fa332-95ad-44c9-bb7b-a191996ee1d1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d5cb61f3-47f5-4c7e-8cb7-aae267d3b152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ee553423-66f0-4153-8c5d-fd9d66db6296" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d5cb61f3-47f5-4c7e-8cb7-aae267d3b152" xlink:to="loc_us-gaap_SubsequentEventMember_ee553423-66f0-4153-8c5d-fd9d66db6296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_16ad217a-bbbe-4d0b-937b-2e84558638ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9fe7e447-ab0e-4339-a6e4-51bdc2945303" xlink:to="loc_us-gaap_DebtInstrumentAxis_16ad217a-bbbe-4d0b-937b-2e84558638ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1e7d5e12-57d5-4c1d-a21a-c92b9ae4636e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_16ad217a-bbbe-4d0b-937b-2e84558638ad" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1e7d5e12-57d5-4c1d-a21a-c92b9ae4636e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_rmti_A3925NotePayableMember_87acfd55-5cda-4be0-b421-d60d6a67ae35" xlink:href="rmti-20210630.xsd#rmti_A3925NotePayableMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1e7d5e12-57d5-4c1d-a21a-c92b9ae4636e" xlink:to="loc_rmti_A3925NotePayableMember_87acfd55-5cda-4be0-b421-d60d6a67ae35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1b120620-ad0a-4990-a20b-7859553b5021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9fe7e447-ab0e-4339-a6e4-51bdc2945303" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1b120620-ad0a-4990-a20b-7859553b5021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_92702e46-6d93-49ba-82ab-2aabbecf51b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1b120620-ad0a-4990-a20b-7859553b5021" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_92702e46-6d93-49ba-82ab-2aabbecf51b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_ba03e86e-5962-4552-a228-288ff46b8ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_92702e46-6d93-49ba-82ab-2aabbecf51b2" xlink:to="loc_us-gaap_NotesPayableToBanksMember_ba03e86e-5962-4552-a228-288ff46b8ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_14983732-0496-44d8-9b65-057b46e27d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9fe7e447-ab0e-4339-a6e4-51bdc2945303" xlink:to="loc_us-gaap_SubsequentEventLineItems_14983732-0496-44d8-9b65-057b46e27d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_63598685-7419-4d01-a446-8ad6151b6c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_14983732-0496-44d8-9b65-057b46e27d5a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_63598685-7419-4d01-a446-8ad6151b6c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ec33711c-6ad0-474b-8997-e57f2cc12625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_14983732-0496-44d8-9b65-057b46e27d5a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ec33711c-6ad0-474b-8997-e57f2cc12625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_8695c2b6-71a7-4681-ab29-90b1b0ceb1e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_14983732-0496-44d8-9b65-057b46e27d5a" xlink:to="loc_us-gaap_DebtInstrumentTerm_8695c2b6-71a7-4681-ab29-90b1b0ceb1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>rmti-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
xml:lang="en-US"
xmlns="http://www.xbrl.org/2003/instance"
xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
xmlns:link="http://www.xbrl.org/2003/linkbase"
xmlns:rmti="http://rockwellmed.com/20210630"
xmlns:srt="http://fasb.org/srt/2020-01-31"
xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
xmlns:utr="http://www.xbrl.org/2009/utr"
xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
xmlns:xlink="http://www.w3.org/1999/xlink"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<link:schemaRef xlink:href="rmti-20210630.xsd" xlink:type="simple"/>
<context id="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i179f99b00109446d8a4f4d374551db0b_I20210813">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
</entity>
<period>
<instant>2021-08-13</instant>
</period>
</context>
<context id="i55273b6777354d8bbb4e783f2786d443_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i544f39c3225445aa9a9903581a14c535_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="i736a800e19204a58b4825177573a05a2_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i3b07a43b8619400ca8c95f27f08d1ba5_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="i0ba271b9447b4d5f949594629592652a_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="i9807fc3339154e519ccef4517a1e8357_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="idf30cdc4b4b9449e8880eba00e1e682d_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="ibf754b423a114a0597693457a11d520c_D20210101-20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-03-31</endDate>
</period>
</context>
<context id="i73e508b6a03f4f7b8143e955a745dbfa_D20210101-20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-03-31</endDate>
</period>
</context>
<context id="idd51386c0f204b70ab961d89fac6b414_D20210101-20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-03-31</endDate>
</period>
</context>
<context id="iea063dee27124e3cb8e847225bc9a727_D20210101-20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-03-31</endDate>
</period>
</context>
<context id="i81559f9595424094af9504f5e9176fb6_D20210101-20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-03-31</endDate>
</period>
</context>
<context id="i2bbc1a5a98724c2f8dca606328b38948_I20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-03-31</instant>
</period>
</context>
<context id="i56d558368b464ba98704441dbcaaabf9_I20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-03-31</instant>
</period>
</context>
<context id="iabe3c25da72c456a845f39add7002756_I20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-03-31</instant>
</period>
</context>
<context id="i2fcb676677b441d99b1a3adf52053525_I20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-03-31</instant>
</period>
</context>
<context id="ic460d5f9387a4d06b4cc0bc019a1734f_I20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
</entity>
<period>
<instant>2021-03-31</instant>
</period>
</context>
<context id="i8dce86a076074a34ab97dd39cec92b15_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i9474a82666f14c4a96556216f214b159_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i09f5e26ca97b4ed5a7c42b24779e77dd_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ic407fb18061d4956b9355d05fc844063_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="idef3faf9cfc649c7b67efb0ea9882617_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i6b87d1b1f1f141b88fbbb40d8e3f5d32_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i974b2e044bfa4a0385fe4bbe668091b8_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i7b18e138a6594afba9bdaa869817c283_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="if1331b5ebfa64639a2e460e5675967a1_I20191231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="ib996a5fca98d4d6fa54ca00eb94caa3a_I20191231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="i569ca4d2801b45ef95abf90a705c76df_I20191231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="ib10111ed45264e43ba61d121ddd55efd_I20191231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="i43c45a3bec674ffb9577158bb599935f_I20191231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="ic19a9d3e1a27430b8e5242841760bea9_D20200101-20200331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-03-31</endDate>
</period>
</context>
<context id="i51f3e4812fbe47e5aa54eace8ed662e8_D20200101-20200331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-03-31</endDate>
</period>
</context>
<context id="ib7e74f88217d46d08457f4184133e631_D20200101-20200331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-03-31</endDate>
</period>
</context>
<context id="i3de306d20bfc41faa248fc7b78c41c67_D20200101-20200331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:BoughtDealMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-03-31</endDate>
</period>
</context>
<context id="i0115d005cfa0459aa5a4504336d80145_D20200101-20200331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:BoughtDealMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-03-31</endDate>
</period>
</context>
<context id="id97b06daeb6d4f0382282fc44378994f_D20200101-20200331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:BoughtDealMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-03-31</endDate>
</period>
</context>
<context id="i08bdbce20f8c405a928c41402ca43cde_D20200101-20200331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-03-31</endDate>
</period>
</context>
<context id="ifc8684882fbe48c186518ce3c43ea805_I20200331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-03-31</instant>
</period>
</context>
<context id="ifc14b52f677a45e8953c87dcfa86734e_I20200331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-03-31</instant>
</period>
</context>
<context id="ia7f30c59a79940599a681143825fab90_I20200331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-03-31</instant>
</period>
</context>
<context id="i0d6b6a4094954db59808d66f399716fc_I20200331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-03-31</instant>
</period>
</context>
<context id="i9a4f7793fa564ff88ca3fbead5bfdd86_I20200331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
</entity>
<period>
<instant>2020-03-31</instant>
</period>
</context>
<context id="i1859822b74774adfbfa6ba5fad1b506d_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i500b8c7b421a4b73a7804aa65a26c308_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i25489ab4a8544c46b57a6837b6d94fb4_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i5eed6445722d476897f396e3b650e2fc_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i9b404b31727244c9a3dafa0dfaa79147_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i8b376170a7a3481b9e8ceaf392294f49_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i6aa75d0adc8143288bf6adb66cdca8b3_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="id26df19b9a654c2c8b37f4d6700c1341_I20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-06-30</instant>
</period>
</context>
<context id="i27fe27368b2b463192fd03bba6ea7fb6_I20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-06-30</instant>
</period>
</context>
<context id="i07c59fcd42914f3b85721e88dd99ea93_I20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-06-30</instant>
</period>
</context>
<context id="i60accea2370749c788fcb682961480d2_I20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-06-30</instant>
</period>
</context>
<context id="i071f7359c8ca4332a2fa89ffb08ab774_I20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
</entity>
<period>
<instant>2020-06-30</instant>
</period>
</context>
<context id="ia37f306f86304d1db38e7502e2c78594_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i9f360d22e2b9419f8e68140a6ac31e88_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:PublicOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i362afd3374074c7cada0c9ce798f3143_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i7b04f90c66774760bcf6df9405476edc_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i60a1e178baa84a468624d0acac59ece5_D20200101-20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-12-31</endDate>
</period>
</context>
<context id="ib836387b9dbf4d2194d1f2d0760e18fb_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i4213fa50227d476f94ac06eb631a5c6f_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i3f359e12f74143a3aecd3e1aea69c9f6_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ib187f06d4c2b4b44a5076ea0d0b431b5_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i234e6a6e01d345a2a2a9ecbd74387219_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i4cb310df91c047af8dd3a11fd4886ab3_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="ied0dd598d05f4288a25014c07eebd870_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i22e74f63f96b4ccf89d59802612fc8c4_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="id817573b63f545c4b0779381d9eecaa4_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="id9a3833807ea4f74a7a1f27cf203fd5e_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="id4a5ecfa7b564990bee4389ba90e2ec4_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ieca9a4e9f9244e53bbff8d044bfaccc4_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="iafedcd0ea4794c7aaa56752656d24c74_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="id6cb7e08ae2d49e6a5b26d9d272b9f1d_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ie4ae2a5c5baf465e84899070e8d326d6_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="if096b68927464500b4e88829e37637c2_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i6f3b0b018abf4ad28e152dd527bf3362_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i06a344e202084e8db05b539ad000672f_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="if238d6f15fb74086ad99dba36761f71f_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i745d398121d3420c9e3c52c10191697f_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i0a076ec540424aaca3aa0743cc065e09_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i02702a823cf648519e82be8308bd7596_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ib6922c012b894f83b88c3ade46b3691c_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i3c130100b8bb44d2a7a09782e10841de_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="id3053c900b0b4cd6b2f2b892bea072a6_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i292ea93b319445a483177b398681ba09_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i6ce20ced6701401694822bf3176021b8_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i42661da0c9dd422d99f958a822e76c80_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ic569e934568a4510a8431b3e9b0cce78_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ib4ccc0ab30cf47169a22197ca958e494_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i1a7ed85229724ee2a7a0722168d880b7_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ib4f4a67681724daaa3e7eeed7f750918_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i923167f606cf40d7a53bb0e1fbf64893_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i5ddb390e46cf4c218e6473e46dfc5e7e_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i8be39cf73a5645cfa4869eccd7ffd140_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i499887d5bc04466a881225c24de111c9_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ic1b0c675ad3a4dc5a6cfbdb5e8eab0ba_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i72196e4fcc3d4c68b85555ee776e8323_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i7fc604f0bbfc49e0af5bd3f913f7bcac_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ie9afd3e3be09480b93f86d7baf05a03e_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i19717f382ea34d3a8d3ba919c064ab70_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i04631d2e7a6f46958f2abcf1c20c0165_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i46c0764450934a84aede084a08f162d3_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i453a3991692c48d196c8d65dfcef5486_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ib211340e5e4741839359edb488b6820a_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="if69d4f2ec51d4ebab66a7c6c0b08fd69_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="if84c75bc21bd454e9387eea17889b736_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ica982797685d4867885a3bbb4e1799f8_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i84f272a5e5e04e439fb8926e0ca1edf7_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="if4a510f683e7412cabff75b22f5281da_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i3f3b95dc158544189ce6a5d99f57cfed_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="if572cd5222f042df8163eeda30992465_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i3c202ad8a44b417c93e84a0b4edc89df_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i33e8984dceec4885937bef7aade6f1bf_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="id52be33547c9431b85a4342a2f2a4c9c_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i0da48e7639534786971c53ed0c8a8b79_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="if3579aee169c40d1b1ebf79b3f56a3a3_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i00411df7d3c04001838b0d136b05ff9c_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="ie1fce7f95ed24da2bedbd4e38c03b866_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i0315167a57d743cb8c4cccfeed4f43c9_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="id72af55606eb4c8eb7cfbe2a7544505e_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i40b91f57dc5345558f46f78c6e809cde_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="ie0480fc74d5745178e00498bd3c64905_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i5145ce2ef7ad4c80b3936b501436c3ca_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="id9090f1f2b024e1fa299abac8f5b8a94_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="iff460b44d83a459a91b73a4e4bf3b9a6_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:DrugRevenueMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="ib6593dca464b48b688b4062dcb38e469_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="ia3c726d6f00c48748ecb13e2df4349a0_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="if40ef0e6f3b34b859ff96c8f94e67052_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="iab0454faec22428e95ed05ab8e5b75e4_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i57d87eb7fbd94c44a05255171f31ec4f_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i855c474985a24e75a1db3f85ab19407d_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i8fd60db6aa864ebda72c4b973f6bb595_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i0c57eb7213114137a35dc2e9414b8ad7_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i2b9266a45b8644df99c3c3cc5a340793_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i7a6c6fed0fce4b14a3c5bd84ed2eb65a_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i9e0a6c01cca24e8fa233e43822d66e39_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i666be76116bd4dbba8fd86f8788fbd2e_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductLicenseFeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i87b28ce51d1b45beb18577ab76dfd443_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i5cc214e4793343a9a278e81b78adef30_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i8c637418d7d54d0eb1be550eeadc155a_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i333c560005714b44882c1307abb33985_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="if4800217e44243a0a6c3800959e5d3bf_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="ic6b367e5e5f34fc1abc31941f97868c3_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="iaeea20075b5643f2bc9e29ae4bc8bb9a_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i21c4c64e4427462690f1cc8ac29aba99_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="ib2537301a83f4c34b4d7b41169bbdc07_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="id5323b8c605048f9883ce2e0cf2efc2e_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i2221de36cdaa43edb16860bc141df763_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i531d67a3cb074164b661fe82095b4e11_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmti:ConcentrateProductsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="iffc4d933f9f0489188683fe4b938ade0_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i5da195dc185f4ad2823040c5515d8512_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">rmti:TrifericInventoryMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="ideb44eb229184ecda8a91c6139e0d759_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">rmti:TrifericDialysateMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i90a1bca35c1243f08d1d94a939cef6c4_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">rmti:TrifericAPIMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i2b0b6f74a05044e4873509f11c7db6af_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i9d0128a643514513b686ad5149092728_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="i465a7180dcdf4d2b801c1f4275cbdb15_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i2878341b4b7445749e3907105900094d_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="i16b1bae1038f45d8bacf79228eeb50a8_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i283693a6ea47413b8d27e797fcda6960_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="i2d2310b000e944b4a1bafa95387c732b_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i9904a6ff79bb4fc3884be08d20ddd455_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="ib41a5b0fba4342b8a42fbf0205323776_D20141001-20141031">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2014-10-01</startDate>
<endDate>2014-10-31</endDate>
</period>
</context>
<context id="i5a444cdf60204392ba5ee29a80d7a166_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i108ba00af91143ca9c3ed9b4e9bb5c39_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i2d78ddfa8815448196febe7de94d00ab_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="iaeff68f2861040f5976c97fb25345bac_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="ib11ae81bd8164d54aefe2b07a1acc333_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:BaxterHealthcareOrganizationMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="id44e4c40542f422392e127f7e00d1cef_D20160101-20161231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-01-01</startDate>
<endDate>2016-12-31</endDate>
</period>
</context>
<context id="ia6b9801f65854970b5da63868031cd71_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i97d0767332814c26b7040a7f42da83d7_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i29a9d581630545e5b9d979ee4a331a36_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="ib261789f13ed45118a64720f9ece6816_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="id1200549772a41baab582b78ceebca58_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="ia416a305cef740509c44aa63f6654918_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:WanbangBiopharmaceuticalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="i7cbe96745d4a4ee7949e736eff90fddd_D20200101-20200131">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-01-31</endDate>
</period>
</context>
<context id="id7f108a122f849b691d34141d686f377_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i1bbf0986a8a141be81ed18c1868716dc_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="idf5243f34d8c414c9014f13c02e11602_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i979ffd2d5930459a8fee1a724d668606_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="ic278353975334c0eb61849b38be42f55_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="id1509c49ed2945d6a5a0f7728fe181ec_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:SunPharmaAgreementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="i4698c56f368245e5b301c41e5ecebf1c_D20200901-20200930">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-09-01</startDate>
<endDate>2020-09-30</endDate>
</period>
</context>
<context id="i2deedffb02b34d8da21c7fab0fe0b691_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ie5a61d1ec2a6474a931f248906e77c43_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i765972d583d94402bc7862f121892b89_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i4081bbacdfc8425bbf6a232aeb6f1b27_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i3f97c0f7f55d43f9b70110bf979d68b5_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i91bb067c41004b14ad33a703a367c7da_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:JeilPharmaAgreementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="i2770d871f3fc4222a123073cfdeb613a_D20210601-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rmti:DrogsanAgreementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-06-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ia4046492d81c4dcfbc80f8128d23a0e8_D20190322-20190322">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-03-22</startDate>
<endDate>2019-03-22</endDate>
</period>
</context>
<context id="i54ebd73955be4ec087f2c3127f7aef9f_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rmti:AtthemarketOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i9c4394b8322844b885708d0a121c0250_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i328ca3ef8e144273a05211111c192e60_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="iacc309a401f7466cb3e18730470f3752_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="if90c1947aa9c420f9f93f64285facd2f_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i55e1c1131a084252abc713575b403ea8_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="if9f58870aefd4e5f887f2aa505cf9e96_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i4015b62fa1a0414b80069a233cc0d05e_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i812bfc33e296453fa2415e929c6925d0_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i3e0e7f5848454b9ba1e6e17804b0edc3_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i9e07dbab6dd248f6969e269920c504d6_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="if12de0f76e944b3bb7b40b44269dcce8_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i5595532179db49e29df13d2e4d7388be_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="ie9c93c9caba84edd95b2548a2b744445_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i6edb07a7cf7d4dfd9ea0c2aa04d300be_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="if6ebf042a7d748bc926786bbeaa6e5be_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ie8068b0b08b04c629bb3323c7e3c6b00_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i233d9a246600434d8e13d460c3115a63_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i18efd6bca7ec4a579e596234751a12c6_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="iee6f8140c1524d41888a692944254bf5_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ifeb306a8995c48b88ea62ab0a33622a3_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="ic3796b585b2249e4a838d2e201de472f_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i6f0a1cbef1614ce18f5c5d366eca4edd_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i08c773fc721845f790f8ef203229134d_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i6519cfa82a8542f3bb0c56cb262141f8_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i7b89ee6dba67472bb93b39369d3a62e5_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i9cc879ec3d384c4891fc21ec9fe0b853_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="ibf99680c33194615a4cde239ceeb4697_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i1222c7a7994947a5bec3e3f85f308708_I20191231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="i3a4f48e172c544ae980c5a5322bd7e1b_I20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-06-30</instant>
</period>
</context>
<context id="i23d7d82cf9a64899b7f1206eabcb09ba_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i1dc167d328cb46c68fb83fa95a614259_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="i59ed53d4977e452abe904ab6ebf547cb_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="iccc11aef27a949598168c7e139f011cf_I20191231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="i8e71868a215c4613b29c948c789638c1_I20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-06-30</instant>
</period>
</context>
<context id="id2bc1e2e4f8f4649bbe2dfd466d3ec82_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i6f366d79a6c6435a80da6fa75f516bb1_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i9d18ac7044704140bef4ab937ea9ab1d_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i3c44b152081048d6b3e5aa2d27e30992_I20191231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="icd51c0a0b5b34333bd95586be0b8d818_I20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-06-30</instant>
</period>
</context>
<context id="i377ec7f50aff44afbeea1a0fddf83054_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i4500479b46394800b4b9f21530bd9449_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i387b50c6a04b446ea4adc3f7f089a489_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ib0d53e2aa30e4cb2be00af8ad6ff6d23_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ie590926897c544debd71e35ba26b6cb4_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="i6070dee6d0e0457e9691825bf5ba3091_D20200101-20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-12-31</endDate>
</period>
</context>
<context id="i72d3d3d7938c411bb6ffd58511f24608_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="ic639b26ebf744397b60970c46c3ac479_I20191231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="i5c8dbaa25e2e4cac985ded30596cdaae_D20190101-20191231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="if7b50de406504a1199ae8a1f61a650ac_I20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:ServiceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-06-30</instant>
</period>
</context>
<context id="i12f2cce783ab4aa19f82d7776112d561_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="i218c5ca968e448d4951556a9ac1e5e79_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="if5a5a222803a4f01af33dfbbd4edd90e_I20191231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="icbc5ecc328954a549da54b7fbbe4c241_I20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmti:PerformanceBasedStockOptionAwardsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-06-30</instant>
</period>
</context>
<context id="i1ec99fab2f214abe99616df767617659_D20181007-20181007">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
</entity>
<period>
<startDate>2018-10-07</startDate>
<endDate>2018-10-07</endDate>
</period>
</context>
<context id="i460677d97abe4d1e8cb8e4f651ec0039_I20181007">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-10-07</instant>
</period>
</context>
<context id="i759627e2f50f423aafc0dfcca70bfd78_D20181007-20181007">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-10-07</startDate>
<endDate>2018-10-07</endDate>
</period>
</context>
<context id="i809ecae77c69447cbf9e47687819d366_I20190115">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-01-15</instant>
</period>
</context>
<context id="i97f806f584404ce2871df7a18de3ca11_I20190415">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-04-15</instant>
</period>
</context>
<context id="if0e0b072a5234c05bc5ad0336ebb3ec8_I20181015">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-10-15</instant>
</period>
</context>
<context id="ia12ceffd5d8641e892942dd059f10047_I20190715">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-07-15</instant>
</period>
</context>
<context id="ic3906b27be7c4423ae983ce14db75f27_D20190101-20191231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="ie29e7d1c982f494cba429b4a0196ff5b_I20191231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmti:ExecutiveVicePresidentAndChiefScientificOfficerMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="ic98fba3f2dc143ee8df5663a86c4661c_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="ic51c88898b0b42d4b034d35705eeaf8a_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">rmti:WixomMichiganPropertyOneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MI</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="if5db4542d469452c8d4313a5744d4574_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">rmti:WixomMichiganPropertyTwoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MI</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i91c605c7aa7a4caebb53cdfdd424223a_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="ia59cfceb831d4c4ba96a80f128ab4ead_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="if2aff2a50c9f45c59831b6c31dde2cc9_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="ibc87c3a83e2348a693051682f6add7a3_I20200331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-03-31</instant>
</period>
</context>
<context id="ia4304315a451412aa6227dd3d7825bbd_I20200316">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheOneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-03-16</instant>
</period>
</context>
<context id="i9fdc6c38a5ba44f4b1470b93d16d3808_I20200316">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheTwoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-03-16</instant>
</period>
</context>
<context id="i9301ccf847b14601a0409335c024832e_I20200316">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheThreeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-03-16</instant>
</period>
</context>
<context id="ib7283d6d91074cb3b430c6bac11ae64d_D20200316-20200316">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheOneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-03-16</startDate>
<endDate>2020-03-16</endDate>
</period>
</context>
<context id="i7fa07c9abdfb4de9a8f92bf2cb718792_D20200316-20200316">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-03-16</startDate>
<endDate>2020-03-16</endDate>
</period>
</context>
<context id="idf213bc00b65407ca919f5dd19c8467b_D20200316-20200316">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-03-16</startDate>
<endDate>2020-03-16</endDate>
</period>
</context>
<context id="iff0f4151e69d41f1a37b619b32340008_I20200316">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-03-16</instant>
</period>
</context>
<context id="i7fac8535567243c58d7ee0b17a853032_D20200316-20200316">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-03-16</startDate>
<endDate>2020-03-16</endDate>
</period>
</context>
<context id="i6cc94eef73f94e268d7a68b7dad267bd_D20200401-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="ie79abc16084e479aa59aa703cef935f0_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i718b2b1115aa4464937e15a664860aea_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="if0e9b928a38b40e7850ffdd7b26ec0dd_D20200101-20200630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-06-30</endDate>
</period>
</context>
<context id="i2ee87b88447b43f4bf5d2a2510a5ede7_I20200316">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheTwoAndTrancheThreeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-03-16</instant>
</period>
</context>
<context id="i58f2d0162acd40c0942ea5380b124712_D20200316-20200316">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanTrancheTwoAndTrancheThreeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-03-16</startDate>
<endDate>2020-03-16</endDate>
</period>
</context>
<context id="ia82218c7009949eebf722cc90aec1835_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:TermLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i909302a232e445a29fbed3c3520b5158_I20210703">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:A3925NotePayableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-07-03</instant>
</period>
</context>
<context id="i41920f2da0c24c9ea164cc61d469bc9b_D20210703-20210703">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rmti:A3925NotePayableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-07-03</startDate>
<endDate>2021-07-03</endDate>
</period>
</context>
<unit id="shares">
<measure>shares</measure>
</unit>
<unit id="usd">
<measure>iso4217:USD</measure>
</unit>
<unit id="usdPerShare">
<divide>
<unitNumerator>
<measure>iso4217:USD</measure>
</unitNumerator>
<unitDenominator>
<measure>shares</measure>
</unitDenominator>
</divide>
</unit>
<unit id="employee">
<measure>rmti:employee</measure>
</unit>
<unit id="agreement">
<measure>rmti:agreement</measure>
</unit>
<unit id="number">
<measure>pure</measure>
</unit>
<unit id="installment">
<measure>rmti:installment</measure>
</unit>
<unit id="sqft">
<measure>utr:sqft</measure>
</unit>
<dei:EntityCentralIndexKey
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80L2ZyYWc6M2U5OTdiMTU4MTQyNDdiZDk1YWM1ODJlZDI5MTE5ZGUvdGFibGU6NzkyZmU2YmJlN2NkNGY5MmE2ZGY1ZmFiZTdmNDVkMmYvdGFibGVyYW5nZTo3OTJmZTZiYmU3Y2Q0ZjkyYTZkZjVmYWJlN2Y0NWQyZl8zLTEtMS0xLTA_b372fc19-76bb-417b-8fc8-a4d7b561d798">0001041024</dei:EntityCentralIndexKey>
<dei:AmendmentFlag
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80L2ZyYWc6M2U5OTdiMTU4MTQyNDdiZDk1YWM1ODJlZDI5MTE5ZGUvdGFibGU6NzkyZmU2YmJlN2NkNGY5MmE2ZGY1ZmFiZTdmNDVkMmYvdGFibGVyYW5nZTo3OTJmZTZiYmU3Y2Q0ZjkyYTZkZjVmYWJlN2Y0NWQyZl80LTEtMS0xLTA_50b33b83-b6e3-4c71-b110-8c78362aa71f">false</dei:AmendmentFlag>
<dei:CurrentFiscalYearEndDate
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80L2ZyYWc6M2U5OTdiMTU4MTQyNDdiZDk1YWM1ODJlZDI5MTE5ZGUvdGFibGU6NzkyZmU2YmJlN2NkNGY5MmE2ZGY1ZmFiZTdmNDVkMmYvdGFibGVyYW5nZTo3OTJmZTZiYmU3Y2Q0ZjkyYTZkZjVmYWJlN2Y0NWQyZl81LTEtMS0xLTA_b5659930-9da6-4cc9-8a9a-53269aa5c928">--12-31</dei:CurrentFiscalYearEndDate>
<dei:DocumentFiscalYearFocus
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80L2ZyYWc6M2U5OTdiMTU4MTQyNDdiZDk1YWM1ODJlZDI5MTE5ZGUvdGFibGU6NzkyZmU2YmJlN2NkNGY5MmE2ZGY1ZmFiZTdmNDVkMmYvdGFibGVyYW5nZTo3OTJmZTZiYmU3Y2Q0ZjkyYTZkZjVmYWJlN2Y0NWQyZl82LTEtMS0xLTA_67bb139e-e206-4cba-962a-6228e726b7fd">2021</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80L2ZyYWc6M2U5OTdiMTU4MTQyNDdiZDk1YWM1ODJlZDI5MTE5ZGUvdGFibGU6NzkyZmU2YmJlN2NkNGY5MmE2ZGY1ZmFiZTdmNDVkMmYvdGFibGVyYW5nZTo3OTJmZTZiYmU3Y2Q0ZjkyYTZkZjVmYWJlN2Y0NWQyZl83LTEtMS0xLTA_a7d1abed-c406-44b7-9b06-45fc43d02e0f">Q2</dei:DocumentFiscalPeriodFocus>
<dei:DocumentType
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTA1_790650b5-69e5-47f2-85cd-a211c8cd89c6">10-Q</dei:DocumentType>
<dei:DocumentQuarterlyReport
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6MDY4ODI0Y2E4OGE2NDQ3M2I2YTJjY2Y5NDM1Y2ZlOTQvdGFibGVyYW5nZTowNjg4MjRjYTg4YTY0NDczYjZhMmNjZjk0MzVjZmU5NF8wLTAtMS0xLTA_b4e3ff48-01b0-44ec-8d8d-81513b222dd5">true</dei:DocumentQuarterlyReport>
<dei:DocumentPeriodEndDate
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8xODU_3837efad-7c8f-4411-a947-f2682e941a12">2021-06-30</dei:DocumentPeriodEndDate>
<dei:DocumentTransitionReport
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6ZTllZWY3YmJiOTAwNDhlYWJkYjFiM2EyYzc3MjQ2MDIvdGFibGVyYW5nZTplOWVlZjdiYmI5MDA0OGVhYmRiMWIzYTJjNzcyNDYwMl8wLTAtMS0xLTA_9c94251c-3a17-4553-b968-edd6995d94de">false</dei:DocumentTransitionReport>
<dei:EntityFileNumber
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTA2_b1b47560-8962-4b9e-ac67-712c1ba53c46">000-23661</dei:EntityFileNumber>
<dei:EntityRegistrantName
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTA3_a96506b3-43f9-4dfa-8c35-1dc08eb82fcf">ROCKWELL MEDICAL, INC.</dei:EntityRegistrantName>
<dei:EntityIncorporationStateCountryCode
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6ZjU1YzZkMDk2ODU0NDk2ZGE4ZjA3ODljMzQ2MGY0NmUvdGFibGVyYW5nZTpmNTVjNmQwOTY4NTQ0OTZkYThmMDc4OWMzNDYwZjQ2ZV8wLTAtMS0xLTA_2cbc9f22-8d1d-4f32-83e8-05c1111d3ca5">DE</dei:EntityIncorporationStateCountryCode>
<dei:EntityTaxIdentificationNumber
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6ZjU1YzZkMDk2ODU0NDk2ZGE4ZjA3ODljMzQ2MGY0NmUvdGFibGVyYW5nZTpmNTVjNmQwOTY4NTQ0OTZkYThmMDc4OWMzNDYwZjQ2ZV8wLTMtMS0xLTA_a10ac2a1-a91c-43c8-a2c0-e81df63b59fc">38-3317208</dei:EntityTaxIdentificationNumber>
<dei:EntityAddressAddressLine1
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6ZjU1YzZkMDk2ODU0NDk2ZGE4ZjA3ODljMzQ2MGY0NmUvdGFibGVyYW5nZTpmNTVjNmQwOTY4NTQ0OTZkYThmMDc4OWMzNDYwZjQ2ZV8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpmZDYwZTI5YTMwYzY0NGZkYWUxYjBiMmFkMzhmMzEyMV80_771714d7-586e-401f-8382-2b284af6aee7">30142 S. Wixom Road</dei:EntityAddressAddressLine1>
<dei:EntityAddressCityOrTown
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6ZjU1YzZkMDk2ODU0NDk2ZGE4ZjA3ODljMzQ2MGY0NmUvdGFibGVyYW5nZTpmNTVjNmQwOTY4NTQ0OTZkYThmMDc4OWMzNDYwZjQ2ZV8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpmZDYwZTI5YTMwYzY0NGZkYWUxYjBiMmFkMzhmMzEyMV84_ef00368c-c14a-42df-917e-696a1fe3084b">Wixom</dei:EntityAddressCityOrTown>
<dei:EntityAddressStateOrProvince
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6ZjU1YzZkMDk2ODU0NDk2ZGE4ZjA3ODljMzQ2MGY0NmUvdGFibGVyYW5nZTpmNTVjNmQwOTY4NTQ0OTZkYThmMDc4OWMzNDYwZjQ2ZV8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpmZDYwZTI5YTMwYzY0NGZkYWUxYjBiMmFkMzhmMzEyMV8xMg_704b2b7a-ae3b-4b37-80e8-af18afb02278">MI</dei:EntityAddressStateOrProvince>
<dei:EntityAddressPostalZipCode
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6ZjU1YzZkMDk2ODU0NDk2ZGE4ZjA3ODljMzQ2MGY0NmUvdGFibGVyYW5nZTpmNTVjNmQwOTY4NTQ0OTZkYThmMDc4OWMzNDYwZjQ2ZV8yLTMtMS0xLTA_ccf8cad6-674d-47d3-a869-afbf2c5c5713">48393</dei:EntityAddressPostalZipCode>
<dei:CityAreaCode
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTEw_d645d7e4-3e79-45ec-b383-b0bb00519ff3">248</dei:CityAreaCode>
<dei:LocalPhoneNumber
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTEx_3d139111-d99a-439f-a258-70f32486008a">960-9009</dei:LocalPhoneNumber>
<dei:EntityCurrentReportingStatus
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTA4_35787535-0a10-4a25-af7c-0f78f8025021">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityInteractiveDataCurrent
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTEy_15c0a9ad-be04-4f75-8a59-f60afd819c2f">Yes</dei:EntityInteractiveDataCurrent>
<dei:EntityFilerCategory
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6YzViZGMxMzM3NjBlNDllMjk5NTYyNmFjZGJhYjM2NGQvdGFibGVyYW5nZTpjNWJkYzEzMzc2MGU0OWUyOTk1NjI2YWNkYmFiMzY0ZF8xLTAtMS0xLTA_2ff59092-fa0b-410f-94ab-0511549dd9d3">Non-accelerated Filer</dei:EntityFilerCategory>
<dei:EntitySmallBusiness
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6YzViZGMxMzM3NjBlNDllMjk5NTYyNmFjZGJhYjM2NGQvdGFibGVyYW5nZTpjNWJkYzEzMzc2MGU0OWUyOTk1NjI2YWNkYmFiMzY0ZF8xLTMtMS0xLTA_0d76418b-099a-4f9e-b2b4-3b6fe9307726">true</dei:EntitySmallBusiness>
<dei:EntityEmergingGrowthCompany
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6YzViZGMxMzM3NjBlNDllMjk5NTYyNmFjZGJhYjM2NGQvdGFibGVyYW5nZTpjNWJkYzEzMzc2MGU0OWUyOTk1NjI2YWNkYmFiMzY0ZF8yLTMtMS0xLTA_0f50c057-9beb-45ea-8f33-8201777abf26">false</dei:EntityEmergingGrowthCompany>
<dei:EntityShellCompany
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTEz_9c542c34-65d6-4684-bbcc-44b08aa295e1">false</dei:EntityShellCompany>
<dei:Security12bTitle
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6NmYwZWE2MmFhMWE3NDJlMTg0YjA5Yzc0ZGM4MzQzMjEvdGFibGVyYW5nZTo2ZjBlYTYyYWExYTc0MmUxODRiMDljNzRkYzgzNDMyMV8xLTAtMS0xLTA_dfe1c0fd-1005-4109-b933-12cee601e8c9">Common Stock, par value $0.0001</dei:Security12bTitle>
<dei:TradingSymbol
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6NmYwZWE2MmFhMWE3NDJlMTg0YjA5Yzc0ZGM4MzQzMjEvdGFibGVyYW5nZTo2ZjBlYTYyYWExYTc0MmUxODRiMDljNzRkYzgzNDMyMV8xLTItMS0xLTA_f2996f45-fdf6-4080-bea4-f131a5507c66">RMTI</dei:TradingSymbol>
<dei:SecurityExchangeName
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGFibGU6NmYwZWE2MmFhMWE3NDJlMTg0YjA5Yzc0ZGM4MzQzMjEvdGFibGVyYW5nZTo2ZjBlYTYyYWExYTc0MmUxODRiMDljNzRkYzgzNDMyMV8xLTQtMS0xLTA_978ac096-94fd-4e09-9e75-0a70dcc3b57b">NASDAQ</dei:SecurityExchangeName>
<dei:EntityCommonStockSharesOutstanding
contextRef="i179f99b00109446d8a4f4d374551db0b_I20210813"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xL2ZyYWc6ZmUwYjAzOGM3MmU2NGI3MThjOTdlMzAxNTM5YWZhMmQvdGV4dHJlZ2lvbjpmZTBiMDM4YzcyZTY0YjcxOGM5N2UzMDE1MzlhZmEyZF8yMTAx_f9b9526d-73f6-4e79-a80c-dc3edcdc81ef"
unitRef="shares">93888881</dei:EntityCommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMy0xLTEtMS0w_8aef98d0-6bbf-41b1-981c-5a86ccab01a8"
unitRef="usd">32378000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMy0zLTEtMS0w_95a11550-11ce-4e80-96d7-a096f32c4a12"
unitRef="usd">48682000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNC0xLTEtMS0w_97bf2254-c2a9-4472-b711-b73b39f87ff1"
unitRef="usd">8574000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNC0zLTEtMS0w_2871dc25-a508-40af-9146-88d4edbddd0e"
unitRef="usd">9997000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
<us-gaap:AccountsReceivableNetCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNS0xLTEtMS0w_711662f3-0fc9-478d-895c-7014a6bf388d"
unitRef="usd">5357000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNS0zLTEtMS0w_c7ce00e8-c6d6-4dc6-aa28-a777a89dc595"
unitRef="usd">4171000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:InventoryNet
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNy0xLTEtMS0w_ea0a59a3-26e1-4ae5-9acc-e224d9074d83"
unitRef="usd">4677000</us-gaap:InventoryNet>
<us-gaap:InventoryNet
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNy0zLTEtMS0w_5580baf7-698e-4964-baba-cc06f3dcc89e"
unitRef="usd">3913000</us-gaap:InventoryNet>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfOC0xLTEtMS0w_1000b112-fc4d-4055-a8ef-5350097943a7"
unitRef="usd">1413000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfOC0zLTEtMS0w_59cc201c-f3cc-49bd-882b-ac8a771da952"
unitRef="usd">2706000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfOS0xLTEtMS0w_4a42267f-c5db-44b0-b768-87f8ed65b735"
unitRef="usd">52399000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfOS0zLTEtMS0w_88ef6cf8-cd29-41c0-9c80-a0b1b21133c8"
unitRef="usd">69469000</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTAtMS0xLTEtMA_67ddbec7-3d5b-4760-90bb-02b6d00032db"
unitRef="usd">2529000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTAtMy0xLTEtMA_978cc32d-ef78-42d2-a0a1-8fa755e0104e"
unitRef="usd">2642000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:InventoryNoncurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTEtMS0xLTEtMA_45dc4deb-f96c-4b5c-978f-ad5bf2000792"
unitRef="usd">1122000</us-gaap:InventoryNoncurrent>
<us-gaap:InventoryNoncurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTEtMy0xLTEtMA_4cb9729a-eee1-4fe1-a147-c4c8d3c3483a"
unitRef="usd">1176000</us-gaap:InventoryNoncurrent>
<rmti:OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTItMS0xLTEtMA_9ecbd122-9f11-4a9d-90a0-5e4fcca03a3f"
unitRef="usd">6085000</rmti:OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet>
<rmti:OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTItMy0xLTEtMA_8914f530-2f05-425a-8b4b-e8700f00c92b"
unitRef="usd">2911000</rmti:OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet>
<us-gaap:Goodwill
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTMtMS0xLTEtMA_4ac5661f-5dc3-4d14-9386-579ad00dab9a"
unitRef="usd">921000</us-gaap:Goodwill>
<us-gaap:Goodwill
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTMtMy0xLTEtMA_ecffaff3-b8f5-4591-9f50-9b5e4b40a5b7"
unitRef="usd">921000</us-gaap:Goodwill>
<us-gaap:OtherAssetsNoncurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTQtMS0xLTEtMA_3d1421c9-84a0-46ee-ab41-43f7930689fd"
unitRef="usd">628000</us-gaap:OtherAssetsNoncurrent>
<us-gaap:OtherAssetsNoncurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTQtMy0xLTEtMA_f5a809ba-4b4c-4923-bc01-ff4dca213f70"
unitRef="usd">629000</us-gaap:OtherAssetsNoncurrent>
<us-gaap:Assets
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTUtMS0xLTEtMA_2cd4422a-068e-4108-ac75-6924dc899da1"
unitRef="usd">63684000</us-gaap:Assets>
<us-gaap:Assets
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTUtMy0xLTEtMA_a05332b5-03f7-4ed3-b5f0-4b6b63f564d8"
unitRef="usd">77748000</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTctMS0xLTEtMA_22a26562-3a88-4c7f-a7a5-ae9aaeaf18a8"
unitRef="usd">4932000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTctMy0xLTEtMA_22e5321d-3037-45de-8ea9-dcd23fee5e9e"
unitRef="usd">4155000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTgtMS0xLTEtMA_9ab5656e-4988-4e07-805d-6b46bba87ab2"
unitRef="usd">3993000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMTgtMy0xLTEtMA_c4cb5871-b3f8-40ea-867b-e99806924e7e"
unitRef="usd">5013000</us-gaap:AccruedLiabilitiesCurrent>
<rmti:OperatingLeaseAndFinanceLeaseLiabilityCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjAtMS0xLTEtMA_7b09337a-5bad-4747-b68c-91004cca454c"
unitRef="usd">1674000</rmti:OperatingLeaseAndFinanceLeaseLiabilityCurrent>
<rmti:OperatingLeaseAndFinanceLeaseLiabilityCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjAtMy0xLTEtMA_f7b30fbb-728c-48aa-9374-04c8b7a94ddd"
unitRef="usd">1167000</rmti:OperatingLeaseAndFinanceLeaseLiabilityCurrent>
<us-gaap:ContractWithCustomerLiabilityCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjEtMS0xLTEtMA_6753c184-401b-4ee3-acc9-9968fec6310b"
unitRef="usd">2166000</us-gaap:ContractWithCustomerLiabilityCurrent>
<us-gaap:ContractWithCustomerLiabilityCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjEtMy0xLTEtMA_5714cecc-0498-4a77-aaec-08ff74ceafb8"
unitRef="usd">2175000</us-gaap:ContractWithCustomerLiabilityCurrent>
<us-gaap:LongTermDebtCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjItMS0xLTEtMTU4OA_03707826-461a-4bbd-8f90-d23bbcd629d3"
unitRef="usd">21133000</us-gaap:LongTermDebtCurrent>
<us-gaap:LongTermDebtCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjItMy0xLTEtMTU4OA_7f0dea5d-f27b-4f45-af9a-3dd4a8d16aa3"
unitRef="usd">0</us-gaap:LongTermDebtCurrent>
<us-gaap:ContractWithCustomerRefundLiabilityCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjMtMS0xLTEtMA_152733de-fe26-4b5d-8975-0ee6ed5c9257"
unitRef="usd">140000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
<us-gaap:ContractWithCustomerRefundLiabilityCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjMtMy0xLTEtMA_0f87763e-7869-4fd7-8784-00abbea56bb2"
unitRef="usd">152000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
<us-gaap:DueToRelatedPartiesCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjQtMS0xLTEtMA_72ae555c-152d-46f2-b30a-a5eed8f9cd1e"
unitRef="usd">0</us-gaap:DueToRelatedPartiesCurrent>
<us-gaap:DueToRelatedPartiesCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjQtMy0xLTEtMA_17336d47-9227-4106-84a4-66b66062b028"
unitRef="usd">131000</us-gaap:DueToRelatedPartiesCurrent>
<us-gaap:LiabilitiesCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjUtMS0xLTEtMA_8b1f2875-4f6d-4d01-ae5d-947ebac67138"
unitRef="usd">34038000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjUtMy0xLTEtMA_c2d9dde4-89d8-4f91-ad31-43fd7655d2f4"
unitRef="usd">12793000</us-gaap:LiabilitiesCurrent>
<rmti:OperatingLeaseAndFinanceLeaseLiabilityNoncurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjctMS0xLTEtMA_51c63fd2-bf17-4fa8-9ab6-766630acfded"
unitRef="usd">4506000</rmti:OperatingLeaseAndFinanceLeaseLiabilityNoncurrent>
<rmti:OperatingLeaseAndFinanceLeaseLiabilityNoncurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjctMy0xLTEtMA_374fb97c-f12e-4f74-847d-ba536bbfdee3"
unitRef="usd">1821000</rmti:OperatingLeaseAndFinanceLeaseLiabilityNoncurrent>
<us-gaap:LongTermDebtNoncurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjgtMS0xLTEtMA_39cc2de6-7a42-4b81-aab8-15c534c3aab3"
unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
<us-gaap:LongTermDebtNoncurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjgtMy0xLTEtMA_b523531d-2930-4d47-b569-6d5116ecceca"
unitRef="usd">20949000</us-gaap:LongTermDebtNoncurrent>
<us-gaap:ContractWithCustomerLiabilityNoncurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjktMS0xLTEtMA_93f5b4cc-0562-46fc-aa95-d68cec6a824a"
unitRef="usd">6937000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<us-gaap:ContractWithCustomerLiabilityNoncurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMjktMy0xLTEtMA_4cfae6d9-04a0-418f-b78b-467a786a1ed8"
unitRef="usd">8015000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<us-gaap:Liabilities
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzAtMS0xLTEtMA_5c62f7f8-1e9a-4d0b-b1e0-14a455482405"
unitRef="usd">45481000</us-gaap:Liabilities>
<us-gaap:Liabilities
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzAtMy0xLTEtMA_62242f38-b9f3-488c-ac39-da2a8e40889e"
unitRef="usd">43578000</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzItMS0xLTEtMA_177c71a6-078c-4033-92b5-caaf0589195e"
unitRef="usd"
xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzItMy0xLTEtMA_ed3471fe-3854-4ba3-b0a7-4a2e6ea8cd4f"
unitRef="usd"
xsi:nil="true"/>
<us-gaap:PreferredStockParOrStatedValuePerShare
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjAzYWMzODlmZDAzNjQzMDliMTllYzlmNTZiNjYyYTVlXzIx_add399db-bb82-4458-977d-81ddbfa02e77"
unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjAzYWMzODlmZDAzNjQzMDliMTllYzlmNTZiNjYyYTVlXzIx_fb83f3fa-d2c4-4c0d-8fe3-0bb6a014916f"
unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjAzYWMzODlmZDAzNjQzMDliMTllYzlmNTZiNjYyYTVlXzM1_13880135-d9f4-4e5f-812a-6af9b81661b5"
unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjAzYWMzODlmZDAzNjQzMDliMTllYzlmNTZiNjYyYTVlXzM1_6ae34b84-014a-43e9-9520-f9050a50f08a"
unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesOutstanding
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjAzYWMzODlmZDAzNjQzMDliMTllYzlmNTZiNjYyYTVlXzU3_41fe5f61-9330-4162-ad86-50e1cb4bdfdf"
unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesIssued
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjAzYWMzODlmZDAzNjQzMDliMTllYzlmNTZiNjYyYTVlXzU3_61569094-4e18-43cf-b3f5-af2110ca9d9c"
unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjAzYWMzODlmZDAzNjQzMDliMTllYzlmNTZiNjYyYTVlXzU3_cfbaee82-fe5e-41ad-9f0d-1e1a5abc2fc8"
unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesIssued
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjAzYWMzODlmZDAzNjQzMDliMTllYzlmNTZiNjYyYTVlXzU3_d135d0a9-4dc1-4ed6-83bd-1fb52c0eab2e"
unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockValueOutstanding
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMS0xLTEtMA_2693684c-1627-4c7c-8276-b037c979d6be"
unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
<us-gaap:PreferredStockValueOutstanding
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzUtMy0xLTEtMA_fc02d642-7ccb-4529-9876-c5c53c665978"
unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFkY2VhODk3M2M4YzRiOTVhMDcwMzg3NGUxMDVjN2VhXzE4_76d37be6-11eb-4c50-bf2a-e40fd65e7606"
unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFkY2VhODk3M2M4YzRiOTVhMDcwMzg3NGUxMDVjN2VhXzE4_a250472a-e858-478e-a44f-2c989c7cbfa2"
unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFkY2VhODk3M2M4YzRiOTVhMDcwMzg3NGUxMDVjN2VhXzMy_20a9d7c4-165c-4d41-9255-61ba68148793"
unitRef="shares">170000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFkY2VhODk3M2M4YzRiOTVhMDcwMzg3NGUxMDVjN2VhXzMy_61e4c894-acf5-4279-9c3f-07ffde12daab"
unitRef="shares">170000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFkY2VhODk3M2M4YzRiOTVhMDcwMzg3NGUxMDVjN2VhXzU0_28c638ee-e217-431c-845a-3cc23b9354ee"
unitRef="shares">93811381</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFkY2VhODk3M2M4YzRiOTVhMDcwMzg3NGUxMDVjN2VhXzU0_c372b1bf-8188-40b4-9882-6b8ae1d909a2"
unitRef="shares">93811381</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFkY2VhODk3M2M4YzRiOTVhMDcwMzg3NGUxMDVjN2VhXzYx_8c9343c9-c4ce-49dc-b55b-05d5940cc1e7"
unitRef="shares">93573165</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesIssued
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjFkY2VhODk3M2M4YzRiOTVhMDcwMzg3NGUxMDVjN2VhXzYx_de8897fb-cd63-4883-8e4b-759d04ee2172"
unitRef="shares">93573165</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockValueOutstanding
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMS0xLTEtMA_d192f36c-bd58-445c-9982-3edf467ac39f"
unitRef="usd">9000</us-gaap:CommonStockValueOutstanding>
<us-gaap:CommonStockValueOutstanding
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzYtMy0xLTEtMA_da7a7209-b8bc-48ae-b8c7-37048d75b1c0"
unitRef="usd">9000</us-gaap:CommonStockValueOutstanding>
<us-gaap:AdditionalPaidInCapital
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzctMS0xLTEtMA_0d9f36d1-eedb-4397-9502-4f03fa6baa17"
unitRef="usd">371700000</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzctMy0xLTEtMA_a50a3fc0-78bc-4e87-9a07-ad235480263e"
unitRef="usd">371510000</us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzgtMS0xLTEtMA_42deb260-ccd4-4b29-8b9e-360f906cd260"
unitRef="usd">-353558000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzgtMy0xLTEtMA_d28ebf8a-0251-425f-80db-937129c1d0f4"
unitRef="usd">-337406000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzktMS0xLTEtMA_cc728859-8f19-499b-bf21-cee2ebda4c6a"
unitRef="usd">52000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfMzktMy0xLTEtMA_30d2bfa9-03f7-4eeb-80c3-487c16362290"
unitRef="usd">57000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:StockholdersEquity
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNDAtMS0xLTEtMA_17aabf73-67f8-42aa-9a78-0d4f7c24d9d1"
unitRef="usd">18203000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNDAtMy0xLTEtMA_701569c8-dd01-4851-95f5-51e1427cec7a"
unitRef="usd">34170000</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNDEtMS0xLTEtMA_b7b48893-db48-4ad9-bad4-8248e8560adf"
unitRef="usd">63684000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xNi9mcmFnOmE1NjdhMWU1YjRkMTRhNTFiYjdmZjQxMTZmMjAxZTQ3L3RhYmxlOjA1ZDBhYmRmNGU3YjRhOThiZWViNGRlNTIwNzYwMjQ4L3RhYmxlcmFuZ2U6MDVkMGFiZGY0ZTdiNGE5OGJlZWI0ZGU1MjA3NjAyNDhfNDEtMy0xLTEtMA_f7cdf411-26cb-404f-83a9-8de01d43c630"
unitRef="usd">77748000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMi0xLTEtMS0w_0e6a05a6-6038-4178-a6cb-697236a32e99"
unitRef="usd">15137000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMi0zLTEtMS0w_acb0c615-d741-4e81-9de9-2dfa270ecf22"
unitRef="usd">15896000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMi01LTEtMS0w_723bcbb4-5236-4ec3-9db3-9c4c64b0825a"
unitRef="usd">30611000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMi03LTEtMS0w_41afce49-b13a-4089-9397-562ae6caf20f"
unitRef="usd">31753000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:CostOfGoodsAndServicesSold
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMy0xLTEtMS0w_285881a9-b280-4b15-a4d7-f9cf31dab77d"
unitRef="usd">15399000</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMy0zLTEtMS0w_d091ade4-2343-49a2-9a7d-b177f2c706f1"
unitRef="usd">15015000</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMy01LTEtMS0w_bc554b2e-134e-4323-91fa-474f290f2897"
unitRef="usd">30471000</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMy03LTEtMS0w_7b9d345d-d9aa-43a9-90d4-e55d6664831e"
unitRef="usd">29759000</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:GrossProfit
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNC0xLTEtMS0w_78b0a1f7-4707-4033-aee5-835b1f29549a"
unitRef="usd">-262000</us-gaap:GrossProfit>
<us-gaap:GrossProfit
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNC0zLTEtMS0w_233ee0bf-37ab-4c84-9db4-449860ac66eb"
unitRef="usd">881000</us-gaap:GrossProfit>
<us-gaap:GrossProfit
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNC01LTEtMS0w_21d8ab45-c43d-4ee4-8c6b-46f7647bbf8d"
unitRef="usd">140000</us-gaap:GrossProfit>
<us-gaap:GrossProfit
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNC03LTEtMS0w_368a303d-7760-4c72-97cf-1ae7c0a52311"
unitRef="usd">1994000</us-gaap:GrossProfit>
<us-gaap:ResearchAndDevelopmentExpense
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNS0xLTEtMS0w_9925b325-0257-41ae-a9f1-916cad4c2371"
unitRef="usd">2416000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNS0zLTEtMS0w_196778c2-ae74-49f9-82a8-40cb9b23f9b1"
unitRef="usd">1616000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNS01LTEtMS0w_f4d36f0f-c2a5-46cb-965e-d7d318b6fd14"
unitRef="usd">4224000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNS03LTEtMS0w_4fc1e3f9-b2af-45bd-a587-1b66e6502766"
unitRef="usd">3438000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:SellingAndMarketingExpense
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNi0xLTEtMS0w_bc78781b-3ba1-4179-8567-f3a2b3bc09a2"
unitRef="usd">1468000</us-gaap:SellingAndMarketingExpense>
<us-gaap:SellingAndMarketingExpense
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNi0zLTEtMS0w_3c32d1ac-ca92-4cb9-a87e-e55ebf8390fc"
unitRef="usd">1997000</us-gaap:SellingAndMarketingExpense>
<us-gaap:SellingAndMarketingExpense
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNi01LTEtMS0w_956f7627-e4d5-421d-9ded-7332e5e23cb3"
unitRef="usd">3319000</us-gaap:SellingAndMarketingExpense>
<us-gaap:SellingAndMarketingExpense
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNi03LTEtMS0w_9176264e-a6b3-4055-8623-2905cac8f90c"
unitRef="usd">4069000</us-gaap:SellingAndMarketingExpense>
<us-gaap:GeneralAndAdministrativeExpense
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNy0xLTEtMS0w_59c17b2c-f793-4672-9594-ff3347fa9d1a"
unitRef="usd">3677000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNy0zLTEtMS0w_2240d8ef-6bed-4706-862e-d9dd1233dbaf"
unitRef="usd">2871000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNy01LTEtMS0w_575abd00-2869-4a34-a5a0-52c99db93e95"
unitRef="usd">7602000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfNy03LTEtMS0w_65941157-6757-4dd2-abd1-ff0cb62df9ec"
unitRef="usd">8145000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingIncomeLoss
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfOS0xLTEtMS0w_bbc107da-e1c9-4569-a05c-05b201a6bcc5"
unitRef="usd">-7823000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfOS0zLTEtMS0w_c17d6639-6b1d-451f-bc1d-42b3681e125c"
unitRef="usd">-5603000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfOS01LTEtMS0w_d281c70b-c462-4a13-9e0c-8937adc7b8db"
unitRef="usd">-15005000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfOS03LTEtMS0w_0cf77902-843d-4eec-baec-e1e22db46739"
unitRef="usd">-13658000</us-gaap:OperatingIncomeLoss>
<us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTItMS0xLTEtMA_4564c216-7649-462b-b1be-39ae3649c380"
unitRef="usd">-1000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
<us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTItMy0xLTEtMA_131dcaff-7390-44f8-beed-afde7d1c76dc"
unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
<us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTItNS0xLTEtMA_1ed726ba-c263-4615-9c9b-b15f75bf8103"
unitRef="usd">-1000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
<us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTItNy0xLTEtMA_17a5a348-4586-4d5a-ac92-3dfc9ff156de"
unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
<us-gaap:FairValueAdjustmentOfWarrants
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTMtMS0xLTEtMA_bb558222-60e3-4d57-84c8-8125e17acd71"
unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTMtMy0xLTEtMA_b62266a2-0ed3-4bf2-b0a9-c4f5e872e20e"
unitRef="usd">837000</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTMtNS0xLTEtMA_aa511b59-ded2-4ca3-b243-61eed1292034"
unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTMtNy0xLTEtMA_df7e5c25-ad86-4ea6-bac0-411b41e76437"
unitRef="usd">837000</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:InterestExpense
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTQtMS0xLTEtMA_738ee7e4-0e82-4882-8cad-3b35493e3f1a"
unitRef="usd">583000</us-gaap:InterestExpense>
<us-gaap:InterestExpense
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTQtMy0xLTEtMA_af9192ff-854e-4d1d-91b2-c414388caa32"
unitRef="usd">521000</us-gaap:InterestExpense>
<us-gaap:InterestExpense
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTQtNS0xLTEtMA_5b05b094-4b93-4e1a-9d28-b8daae645573"
unitRef="usd">1164000</us-gaap:InterestExpense>
<us-gaap:InterestExpense
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTQtNy0xLTEtMA_d80c9ad6-7dbb-4415-9fbf-72b7515af9ed"
unitRef="usd">623000</us-gaap:InterestExpense>
<us-gaap:InvestmentIncomeInterest
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTUtMS0xLTEtMA_3da0de97-b5a1-44f1-a1df-e8dae5d7635a"
unitRef="usd">7000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTUtMy0xLTEtMA_3c18f389-dcb0-4db5-9376-e1da5e806f8c"
unitRef="usd">67000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTUtNS0xLTEtMA_53e3dec4-62d2-4f90-9a29-e272e249d32b"
unitRef="usd">18000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTUtNy0xLTEtMA_4b7a71c7-563d-4519-ac49-992cd89fe046"
unitRef="usd">238000</us-gaap:InvestmentIncomeInterest>
<us-gaap:OtherNonoperatingIncomeExpense
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTYtMS0xLTEtMA_1625ddc1-fc4d-46fc-be9d-3c911c0e59a8"
unitRef="usd">-577000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTYtMy0xLTEtMA_26927ac8-e176-47ab-bef0-61b006a6b87c"
unitRef="usd">-1289000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTYtNS0xLTEtMA_dd519299-c7be-4867-a599-1ba47065ce52"
unitRef="usd">-1147000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTYtNy0xLTEtMA_e444850f-d2cf-47bc-ae0e-c14a63539859"
unitRef="usd">-1218000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:NetIncomeLoss
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTgtMS0xLTEtMA_7ee192d5-0b84-4a80-b961-9f5e7412b66e"
unitRef="usd">-8400000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTgtMy0xLTEtMA_23a30af1-16d1-43d3-b824-688031ec1f25"
unitRef="usd">-6892000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTgtNS0xLTEtMA_21a7b3f8-bc27-42d7-b2a5-83fdd13972aa"
unitRef="usd">-16152000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMTgtNy0xLTEtMA_fcd2a68c-f2d8-44d6-8804-07dbede5bcea"
unitRef="usd">-14876000</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareDiluted
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjAtMS0xLTEtMA_81ef95eb-4198-4a42-a26c-99085d166317"
unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjAtMS0xLTEtMA_af5735a2-5efe-4978-b11e-b01c08de8b82"
unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjAtMy0xLTEtMA_155cfecb-b85d-4ba9-948a-16b32bc38e8f"
unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjAtMy0xLTEtMA_863f016c-376a-48b7-b8fb-5ec0c722b993"
unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjAtNS0xLTEtMA_6b432fba-cc89-4840-9d3c-84d6b1292352"
unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjAtNS0xLTEtMA_bb629987-68f0-47d7-9b3e-cc880d992823"
unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjAtNy0xLTEtMA_174c0a10-1b67-4a8d-987e-5e2ff4820fbf"
unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjAtNy0xLTEtMA_261d7516-9f25-4239-8288-170a54e43c1d"
unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjEtMS0xLTEtMA_dff1628a-f4ca-4ee5-b838-392bd9081616"
unitRef="shares">93703492</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjEtMS0xLTEtMA_ee5feb45-84dc-4801-9c49-d900fde0f740"
unitRef="shares">93703492</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjEtMy0xLTEtMA_1cf8b857-d1d2-4618-95e9-4b51da526727"
unitRef="shares">69428574</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjEtMy0xLTEtMA_846c314c-be9d-4c0c-b275-ef2b29ca62ce"
unitRef="shares">69428574</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjEtNS0xLTEtMA_68a59e2a-b15a-47ba-b4d9-8ef337c83f78"
unitRef="shares">93647583</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjEtNS0xLTEtMA_818a8b37-daaa-41d9-8c28-43fc150929ac"
unitRef="shares">93647583</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjEtNy0xLTEtMA_211b9b7b-08c0-4cc4-8bfd-fa9ed31c3204"
unitRef="shares">68473407</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xOS9mcmFnOmY3YzhkMGZhOTM5NzRjN2VhMzdmNDJkZjQ2NGQyNzg3L3RhYmxlOjZmMjE3OTgxMmUxYzQyMmJiM2YzZDI0NTg1YzMxZDZiL3RhYmxlcmFuZ2U6NmYyMTc5ODEyZTFjNDIyYmIzZjNkMjQ1ODVjMzFkNmJfMjEtNy0xLTEtMA_8ef289af-fdf9-4fea-985f-45721009077d"
unitRef="shares">68473407</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:NetIncomeLoss
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfMi0xLTEtMS0w_0889a067-c7cf-4921-bc85-fe3828ca57b4"
unitRef="usd">-8400000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfMi0zLTEtMS0w_fc7c577b-7e30-401b-a649-f35f1d427be3"
unitRef="usd">-6892000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfMi01LTEtMS0w_caa825e8-def2-45e6-8d2e-04fca3e1dead"
unitRef="usd">-16152000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfMi03LTEtMS0w_fe1ddaac-431f-4692-92c4-cd01e055a48e"
unitRef="usd">-14876000</us-gaap:NetIncomeLoss>
<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfMy0xLTEtMS0w_8b450d4e-d0d8-459b-ab9a-a5565ed0674f"
unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfMy0zLTEtMS0w_22333dbe-1ef5-4653-bddc-2a3e0243a188"
unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfMy01LTEtMS0w_bede23e9-f08d-4fda-905e-de15283c6d99"
unitRef="usd">-8000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfMy03LTEtMS0w_7f2a20a5-529c-48cf-b839-f71356617389"
unitRef="usd">-13000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfNC0xLTEtMS0w_4032d4ac-3208-434f-be56-815bbc485093"
unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfNC0zLTEtMS0w_136f8b39-bddc-4cb4-b82c-6e4f84627168"
unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfNC01LTEtMS0w_1264dacb-ebc9-4a0d-a7b0-516d73bb0890"
unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfNC03LTEtMS0w_2ace87e3-25a1-457b-aef9-c172b7dd608e"
unitRef="usd">7000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfNS0xLTEtMS0w_32b0f472-2f17-401c-aa6c-e17b6eb3acf6"
unitRef="usd">-8401000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfNS0zLTEtMS0w_32bc428c-5cb9-4102-bf9a-a6ef9e5296e7"
unitRef="usd">-6897000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfNS01LTEtMS0w_72b2314b-889a-4b2b-86d4-4850143d79b8"
unitRef="usd">-16157000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yMi9mcmFnOjRhMmU2MmZiN2U4ZTQ4YTg5YzFmODA2MGVjNTk4MTg4L3RhYmxlOmU4ODNjNWViNTllMTRmZDc4MDQxZjFhZmI4Mzk5NGZjL3RhYmxlcmFuZ2U6ZTg4M2M1ZWI1OWUxNGZkNzgwNDFmMWFmYjgzOTk0ZmNfNS03LTEtMS0w_a3277203-fe26-44bc-8229-193944022c0d"
unitRef="usd">-14882000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:CommonStockSharesOutstanding
contextRef="i3b07a43b8619400ca8c95f27f08d1ba5_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMi0xLTEtMS0w_5b9fbc37-a5d9-45d8-88eb-c9301b94bcaa"
unitRef="shares">93573165</us-gaap:CommonStockSharesOutstanding>
<us-gaap:StockholdersEquity
contextRef="i3b07a43b8619400ca8c95f27f08d1ba5_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMi0zLTEtMS0w_a1a97c00-9854-4ffd-a47a-bc4f3c3db671"
unitRef="usd">9000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i0ba271b9447b4d5f949594629592652a_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMi01LTEtMS0w_58d080cb-777c-4d24-a3b3-da9c04220805"
unitRef="usd">371510000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i9807fc3339154e519ccef4517a1e8357_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMi03LTEtMS0w_e6810945-1599-4fd3-844e-18517179522b"
unitRef="usd">-337406000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="idf30cdc4b4b9449e8880eba00e1e682d_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMi05LTEtMS0w_175841c3-59a7-41f3-8755-d39f230cbf16"
unitRef="usd">57000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMi0xMS0xLTEtMA_7ffba2da-8d2a-4913-b83d-6d288f1dbc8c"
unitRef="usd">34170000</us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss
contextRef="ibf754b423a114a0597693457a11d520c_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMy03LTEtMS0w_d80d9946-eb9b-4bd0-ae84-8042eea22062"
unitRef="usd">-7752000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="i73e508b6a03f4f7b8143e955a745dbfa_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMy0xMS0xLTEtMA_2cb1eb87-ad93-44fa-a2d0-0b838556d4f1"
unitRef="usd">-7752000</us-gaap:NetIncomeLoss>
<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
contextRef="idd51386c0f204b70ab961d89fac6b414_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfNC05LTEtMS0w_e8ca996f-8c43-44e9-8583-78bef887ac39"
unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
contextRef="i73e508b6a03f4f7b8143e955a745dbfa_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfNC0xMS0xLTEtMA_f269107d-e4a7-4033-9c28-1ea166600c0d"
unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
contextRef="idd51386c0f204b70ab961d89fac6b414_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfNS05LTEtMS0w_75f5ea86-4975-4cc4-902d-01c81be3f402"
unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
contextRef="i73e508b6a03f4f7b8143e955a745dbfa_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfNS0xMS0xLTEtMA_935b9080-c103-4cb2-9edc-91315872cabc"
unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
contextRef="iea063dee27124e3cb8e847225bc9a727_D20210101-20210331"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOC0xLTEtMS0w_f1534f74-8172-4157-ae8e-124f39a34ce4"
unitRef="shares">26354</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
contextRef="i81559f9595424094af9504f5e9176fb6_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOC01LTEtMS0w_66e50118-8620-4294-914c-e43daa389567"
unitRef="usd">-236000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
contextRef="i73e508b6a03f4f7b8143e955a745dbfa_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOC0xMS0xLTEtMA_4a13da0c-2824-4ce7-8e95-735b01acd260"
unitRef="usd">-236000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:CommonStockSharesOutstanding
contextRef="i2bbc1a5a98724c2f8dca606328b38948_I20210331"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOS0xLTEtMS0w_789fdd86-ad49-4868-a767-32e6d69e653d"
unitRef="shares">93599519</us-gaap:CommonStockSharesOutstanding>
<us-gaap:StockholdersEquity
contextRef="i2bbc1a5a98724c2f8dca606328b38948_I20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOS0zLTEtMS0w_b81c1e38-83aa-4f51-97a3-86b0a4f710d9"
unitRef="usd">9000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i56d558368b464ba98704441dbcaaabf9_I20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOS01LTEtMS0w_0661a420-1b14-4d51-9107-da09c13c0c5a"
unitRef="usd">371274000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="iabe3c25da72c456a845f39add7002756_I20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOS03LTEtMS0w_4fa161bb-4607-4347-8e08-7d44a9040566"
unitRef="usd">-345158000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i2fcb676677b441d99b1a3adf52053525_I20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOS05LTEtMS0w_fb88af31-2346-4f62-a0cc-24a132dd4981"
unitRef="usd">53000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="ic460d5f9387a4d06b4cc0bc019a1734f_I20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfOS0xMS0xLTEtMA_23546d95-d23f-4403-9e8b-34a65bd349d3"
unitRef="usd">26178000</us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss
contextRef="i8dce86a076074a34ab97dd39cec92b15_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTAtNy0xLTEtMA_598a7fd2-a2ce-472c-8ff5-9da72f6937dd"
unitRef="usd">-8400000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTAtMTEtMS0xLTA_efd6984d-1901-48d3-b19e-fd2b8a918ebe"
unitRef="usd">-8400000</us-gaap:NetIncomeLoss>
<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
contextRef="i9474a82666f14c4a96556216f214b159_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTEtOS0xLTEtMA_ddec8497-96b3-4772-9cf4-1935e6806dc2"
unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTEtMTEtMS0xLTA_6cd86713-7162-476c-ba07-eec61e6f3e13"
unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
contextRef="i09f5e26ca97b4ed5a7c42b24779e77dd_D20210401-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTQtMS0xLTEtMA_b011f6ce-18f1-4003-bdf3-5c28ac8a9db2"
unitRef="shares">211862</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
contextRef="ic407fb18061d4956b9355d05fc844063_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTQtNS0xLTEtMA_c8b5f83c-c241-4601-b616-ab5644579e01"
unitRef="usd">-7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTQtMTEtMS0xLTA_652bcf6f-185a-4cf0-baff-0470fba2a367"
unitRef="usd">-7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
contextRef="ic407fb18061d4956b9355d05fc844063_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTYtNS0xLTEtMA_1ae09864-a0a6-4123-9b25-66e6d397bbb6"
unitRef="usd">433000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTYtMTEtMS0xLTA_bce46f2e-39f4-4afa-a862-29afc7b2747a"
unitRef="usd">433000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:CommonStockSharesOutstanding
contextRef="idef3faf9cfc649c7b67efb0ea9882617_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTctMS0xLTEtMA_9c26c191-f38e-4331-a73a-e775ce82994b"
unitRef="shares">93811381</us-gaap:CommonStockSharesOutstanding>
<us-gaap:StockholdersEquity
contextRef="idef3faf9cfc649c7b67efb0ea9882617_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTctMy0xLTEtMA_d6567b02-947b-45f9-962b-7a0c502f320a"
unitRef="usd">9000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i6b87d1b1f1f141b88fbbb40d8e3f5d32_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTctNS0xLTEtMA_9304227e-d19b-4808-96b4-9e7416e716b8"
unitRef="usd">371700000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i974b2e044bfa4a0385fe4bbe668091b8_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTctNy0xLTEtMA_07ff12b2-781f-4843-9ce3-ef576f991cbf"
unitRef="usd">-353558000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i7b18e138a6594afba9bdaa869817c283_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTctOS0xLTEtMA_ca0b664f-9f0c-425e-81a8-d1f09628de81"
unitRef="usd">52000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOmNhZmY4ODVjZDY0NDQ4MGVhZWIzY2M3ZjAzYTYzMzNiL3RhYmxlcmFuZ2U6Y2FmZjg4NWNkNjQ0NDgwZWFlYjNjYzdmMDNhNjMzM2JfMTctMTEtMS0xLTA_812844b2-a4a2-454f-9320-12d1fa813f52"
unitRef="usd">18203000</us-gaap:StockholdersEquity>
<us-gaap:CommonStockSharesOutstanding
contextRef="if1331b5ebfa64639a2e460e5675967a1_I20191231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMi0xLTEtMS0w_498df6a0-53e3-4b79-970d-f5cc7c58948b"
unitRef="shares">65378890</us-gaap:CommonStockSharesOutstanding>
<us-gaap:StockholdersEquity
contextRef="if1331b5ebfa64639a2e460e5675967a1_I20191231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMi0zLTEtMS0w_f8f2140f-58cc-4b92-9221-d687246f546f"
unitRef="usd">7000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="ib996a5fca98d4d6fa54ca00eb94caa3a_I20191231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMi01LTEtMS0w_50dfb0c6-8801-4f6f-b76d-84d3964ca428"
unitRef="usd">326777000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i569ca4d2801b45ef95abf90a705c76df_I20191231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMi03LTEtMS0w_00eb001f-3302-484f-b1db-f656134772be"
unitRef="usd">-306516000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="ib10111ed45264e43ba61d121ddd55efd_I20191231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMi05LTEtMS0w_14c62219-0076-4577-bd42-fc2ed5618217"
unitRef="usd">52000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i43c45a3bec674ffb9577158bb599935f_I20191231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMi0xMS0xLTEtMA_48678a61-cf89-4ee8-83bd-1cf3f59c3864"
unitRef="usd">20320000</us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss
contextRef="ic19a9d3e1a27430b8e5242841760bea9_D20200101-20200331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMy03LTEtMS0w_99d2f459-9b24-47c3-946d-8d4367c470c6"
unitRef="usd">-7984000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="i51f3e4812fbe47e5aa54eace8ed662e8_D20200101-20200331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMy0xMS0xLTEtMA_cb229ae8-558a-40c3-8eba-304b5f39e515"
unitRef="usd">-7984000</us-gaap:NetIncomeLoss>
<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
contextRef="ib7e74f88217d46d08457f4184133e631_D20200101-20200331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNC05LTEtMS0w_bb7c9541-2535-484a-be22-c3c7f70ae1d3"
unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
contextRef="i51f3e4812fbe47e5aa54eace8ed662e8_D20200101-20200331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNC0xMS0xLTEtMA_4ab3694e-1b3d-4ed5-8412-f49be7cefea1"
unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
contextRef="ib7e74f88217d46d08457f4184133e631_D20200101-20200331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNS05LTEtMS0w_895b1327-6e43-453d-9e79-758d34032f50"
unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
contextRef="i51f3e4812fbe47e5aa54eace8ed662e8_D20200101-20200331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNS0xMS0xLTEtMA_5c9a8b4b-0d77-4e8d-93af-75b9ba78de6b"
unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues
contextRef="i3de306d20bfc41faa248fc7b78c41c67_D20200101-20200331"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNi0xLTEtMS0w_8eecddec-4bd3-40aa-853a-32680e86d6df"
unitRef="shares">3670212</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="i0115d005cfa0459aa5a4504336d80145_D20200101-20200331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNi01LTEtMS0w_0bd0674d-0834-49f3-95ba-ccc96f0467f5"
unitRef="usd">8003000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="id97b06daeb6d4f0382282fc44378994f_D20200101-20200331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNi0xMS0xLTEtMA_00986a3c-cf90-48a8-827b-f573ec5d2403"
unitRef="usd">8003000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
contextRef="i08bdbce20f8c405a928c41402ca43cde_D20200101-20200331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNy01LTEtMS0w_dc0c412e-c053-404a-bb4a-8a277b8d9906"
unitRef="usd">501000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
contextRef="i51f3e4812fbe47e5aa54eace8ed662e8_D20200101-20200331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfNy0xMS0xLTEtMA_4f217f7a-4a9c-48e7-9b4b-62c7f97b0eac"
unitRef="usd">501000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
contextRef="i08bdbce20f8c405a928c41402ca43cde_D20200101-20200331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfOC01LTEtMS0w_e68032d8-591a-44e6-8dc3-4fd7a21cf490"
unitRef="usd">935000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
contextRef="i51f3e4812fbe47e5aa54eace8ed662e8_D20200101-20200331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfOC0xMS0xLTEtMA_dcbb5c9e-9b77-499c-99fa-b6f4bd5f1ae0"
unitRef="usd">935000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:CommonStockSharesOutstanding
contextRef="ifc8684882fbe48c186518ce3c43ea805_I20200331"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfOS0xLTEtMS0w_eb3a0376-52ed-45d7-a03b-b4483381f1f6"
unitRef="shares">69049102</us-gaap:CommonStockSharesOutstanding>
<us-gaap:StockholdersEquity
contextRef="ifc8684882fbe48c186518ce3c43ea805_I20200331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfOS0zLTEtMS0w_f817e316-5b53-46c4-8fac-d598f976e90d"
unitRef="usd">7000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="ifc14b52f677a45e8953c87dcfa86734e_I20200331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfOS01LTEtMS0w_7cb729ca-819e-47de-a1fd-4912b5d0832e"
unitRef="usd">336216000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="ia7f30c59a79940599a681143825fab90_I20200331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfOS03LTEtMS0w_e70c2a4e-574a-49bf-be99-2311ee2c18de"
unitRef="usd">-314500000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i0d6b6a4094954db59808d66f399716fc_I20200331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfOS05LTEtMS0w_933c1145-6293-4348-9170-09aedfce0f23"
unitRef="usd">51000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i9a4f7793fa564ff88ca3fbead5bfdd86_I20200331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfOS0xMS0xLTEtMA_07fa45db-10e9-4f07-a938-acc4f08392b5"
unitRef="usd">21774000</us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss
contextRef="i1859822b74774adfbfa6ba5fad1b506d_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTAtNy0xLTEtMA_779b4ac4-501f-4142-9c82-413c74751622"
unitRef="usd">-6892000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTAtMTEtMS0xLTA_c834e046-c7a4-4495-87cd-4a313463d9ca"
unitRef="usd">-6892000</us-gaap:NetIncomeLoss>
<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
contextRef="i500b8c7b421a4b73a7804aa65a26c308_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTEtOS0xLTEtMA_2b20f4d4-c81f-44ea-b6fe-fa2ebd29ac63"
unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTEtMTEtMS0xLTA_72f11256-aeb5-4cef-86a0-b8ffa456e0f2"
unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
contextRef="i500b8c7b421a4b73a7804aa65a26c308_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTItOS0xLTEtMA_516ff471-55b6-4ad8-8057-b11f4bf9f9d0"
unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTItMTEtMS0xLTA_141f21dd-7c32-43ae-a926-e33dfdf2ecb0"
unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues
contextRef="i25489ab4a8544c46b57a6837b6d94fb4_D20200401-20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTMtMS0xLTEtMA_415eb207-faab-4662-99bf-2bd4b5556fb1"
unitRef="shares">987716</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="i5eed6445722d476897f396e3b650e2fc_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTMtNS0xLTEtMA_98078af6-b7b3-4c9a-aa24-545a7c64884a"
unitRef="usd">1978000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="i9b404b31727244c9a3dafa0dfaa79147_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTMtMTEtMS0xLTA_6a1f4b52-a098-4f0f-b0e1-2e9c8be33110"
unitRef="usd">1978000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
contextRef="i8b376170a7a3481b9e8ceaf392294f49_D20200401-20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTQtMS0xLTEtMA_b45869fd-95e7-4efe-b30f-d1dfd179ba39"
unitRef="shares">120104</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
contextRef="i6aa75d0adc8143288bf6adb66cdca8b3_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTQtNS0xLTEtMA_0f80f922-570b-4c33-abbb-fe529c7a1383"
unitRef="usd">-19000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTQtMTEtMS0xLTA_3e7a7925-0786-4f61-8ea8-a6d814d32667"
unitRef="usd">-19000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<rmti:AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense
contextRef="i6aa75d0adc8143288bf6adb66cdca8b3_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTUtNS0xLTEtNjY_415084d5-99bc-4ea9-8b20-4d48898473a9"
unitRef="usd">837000</rmti:AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense>
<rmti:AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTUtMTEtMS0xLTc1_7979616f-ff34-4a7c-9eef-bc5ca3839822"
unitRef="usd">837000</rmti:AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
contextRef="i6aa75d0adc8143288bf6adb66cdca8b3_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTUtNS0xLTEtMA_fc47044d-ef26-4024-9eeb-7a97f0c4653e"
unitRef="usd">-1461000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTUtMTEtMS0xLTA_ee2681ab-68b0-453e-a94b-cc5085eacfa2"
unitRef="usd">-1461000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:CommonStockSharesOutstanding
contextRef="id26df19b9a654c2c8b37f4d6700c1341_I20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTYtMS0xLTEtMA_a67f23eb-ae81-47b1-bc1b-e4f4475b63e7"
unitRef="shares">70156922</us-gaap:CommonStockSharesOutstanding>
<us-gaap:StockholdersEquity
contextRef="id26df19b9a654c2c8b37f4d6700c1341_I20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTYtMy0xLTEtMA_063b72d9-7524-439e-9672-5896442a24bb"
unitRef="usd">7000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i27fe27368b2b463192fd03bba6ea7fb6_I20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTYtNS0xLTEtMA_721c086a-04ba-4ecb-933b-5c15ab8c3243"
unitRef="usd">337551000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i07c59fcd42914f3b85721e88dd99ea93_I20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTYtNy0xLTEtMA_e80269fc-a813-4be3-886c-c5d6dc824eae"
unitRef="usd">-321392000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i60accea2370749c788fcb682961480d2_I20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTYtOS0xLTEtMA_1f814b63-2906-4119-9a58-e3b89ee474e7"
unitRef="usd">46000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yNS9mcmFnOjM0ZTU3NmIxNjMwMTQxMGI5OTZlZjMwNGY4MTY4ZTBjL3RhYmxlOjI5NWMzNWJkMzk4YTQ3OWRiZGUzYWVmOTRjNDk1Yzg2L3RhYmxlcmFuZ2U6Mjk1YzM1YmQzOThhNDc5ZGJkZTNhZWY5NGM0OTVjODZfMTYtMTEtMS0xLTA_600a4cdd-f813-4c6f-8842-679df6c2e04f"
unitRef="usd">16212000</us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMy0xLTEtMS0w_80c394de-d564-4003-aba2-9189873fdb1f"
unitRef="usd">-16152000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMy0zLTEtMS0w_a7f2bab0-005e-4102-9466-6816bdd9c2f4"
unitRef="usd">-14876000</us-gaap:NetIncomeLoss>
<us-gaap:DepreciationDepletionAndAmortization
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNS0xLTEtMS0w_82c3315f-d0e5-4a45-8052-1b89cbfda44a"
unitRef="usd">385000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNS0zLTEtMS0w_774683f4-d4f0-4962-a822-ec46e9905e3e"
unitRef="usd">408000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:ShareBasedCompensation
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNi0xLTEtMS0w_ddf5f5fc-c4d3-48ab-a556-bbc2149cd75f"
unitRef="usd">197000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNi0zLTEtMS0w_669fc3f6-eb42-4a2f-95f5-78755e160687"
unitRef="usd">-526000</us-gaap:ShareBasedCompensation>
<us-gaap:FairValueAdjustmentOfWarrants
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNy0xLTEtMS0w_4c440928-ec16-4922-8389-d3db7b6a60f5"
unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNy0zLTEtMS0w_db84fa6c-6641-4090-98e3-889d8ac51dcd"
unitRef="usd">837000</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:InventoryLIFOReservePeriodCharge
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfOC0xLTEtMS0w_8bb8b882-0602-4c9a-bbc8-6ea48172dcb9"
unitRef="usd">89000</us-gaap:InventoryLIFOReservePeriodCharge>
<us-gaap:InventoryLIFOReservePeriodCharge
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfOC0zLTEtMS0w_8cbc322d-7057-435d-9731-3cc53cb936f1"
unitRef="usd">12000</us-gaap:InventoryLIFOReservePeriodCharge>
<us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfOS0xLTEtMS0w_a6fb5469-a7d5-4764-8462-125707672cf2"
unitRef="usd">857000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
<us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfOS0zLTEtMS0w_45fe040b-d9cf-4d77-a3c8-3dc819368da0"
unitRef="usd">748000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
<us-gaap:AmortizationOfFinancingCostsAndDiscounts
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTAtMS0xLTEtMA_5d298b53-b4c8-40d7-8d8f-65d45799cc29"
unitRef="usd">184000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
<us-gaap:AmortizationOfFinancingCostsAndDiscounts
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTAtMy0xLTEtMA_2581884d-9d77-45a5-b7f1-e773f523f9bc"
unitRef="usd">108000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
<us-gaap:GainLossOnDispositionOfAssets1
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTEtMS0xLTEtMA_f6161ac9-893e-482b-98da-3671f63f87ae"
unitRef="usd">-8000</us-gaap:GainLossOnDispositionOfAssets1>
<us-gaap:GainLossOnDispositionOfAssets1
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTEtMy0xLTEtMA_e76a690e-9962-4d81-acc0-4f8d7c79d32e"
unitRef="usd">-6000</us-gaap:GainLossOnDispositionOfAssets1>
<us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTItMS0xLTEtMA_d85bc737-2a8f-46ee-81f2-c5442858b5ac"
unitRef="usd">-1000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
<us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTItMy0xLTEtMA_8f49b86c-35a2-48bf-b010-b5a4d6411917"
unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTMtMS0xLTEtMA_5db5f8fa-1562-4cd9-be9a-388884b17c2a"
unitRef="usd">-3000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTMtMy0xLTEtMA_ce6dde98-7a8d-4e52-a56e-ec256acb44cf"
unitRef="usd">-6000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:IncreaseDecreaseInAccountsReceivable
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTUtMS0xLTEtMA_adbfd084-b137-4d24-b0f1-f1a0feec0857"
unitRef="usd">1186000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTUtMy0xLTEtMA_26f32889-5c7d-45cd-8fe2-9a6166715406"
unitRef="usd">-637000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInInventories
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTctMS0xLTEtMA_1ac921d4-8707-406c-a8ea-954e03b9142b"
unitRef="usd">799000</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTctMy0xLTEtMA_42956bc6-5a00-4797-abe8-c4e54d019f56"
unitRef="usd">1302000</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTgtMS0xLTEtMA_375d07da-c1c7-467a-825a-2e0bc621c35a"
unitRef="usd">-1293000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTgtMy0xLTEtMA_77aa7679-e7cc-45b2-a4ff-d4b35623cb6c"
unitRef="usd">608000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayable
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTktMS0xLTEtMA_0e64dbc8-229c-4bed-92b7-ab54679167e3"
unitRef="usd">777000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMTktMy0xLTEtMA_2c4c585d-4f15-49d7-827a-11911bcd92bd"
unitRef="usd">295000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInInsuranceLiabilities
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjAtMS0xLTEtMA_56a1a95e-83ef-4b11-888e-3ca118b9fee0"
unitRef="usd">0</us-gaap:IncreaseDecreaseInInsuranceLiabilities>
<us-gaap:IncreaseDecreaseInInsuranceLiabilities
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjAtMy0xLTEtMA_672e306e-9357-4d0f-81a8-64b7d068eb9d"
unitRef="usd">-104000</us-gaap:IncreaseDecreaseInInsuranceLiabilities>
<rmti:IncreaseDecreaseInOperatingLeaseLiability
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjEtMS0xLTEtMA_32535d52-2c0c-44ea-bec0-791792e11c9a"
unitRef="usd">-839000</rmti:IncreaseDecreaseInOperatingLeaseLiability>
<rmti:IncreaseDecreaseInOperatingLeaseLiability
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjEtMy0xLTEtMA_ffbc3b94-b3a2-49af-bed7-55aa937ff50b"
unitRef="usd">-703000</rmti:IncreaseDecreaseInOperatingLeaseLiability>
<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjItMS0xLTEtMA_2b2def1f-e1dc-43d5-bccc-c34a9dd08f9e"
unitRef="usd">-1163000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjItMy0xLTEtMA_f06266e3-c666-49b6-a54c-d0bd8427be47"
unitRef="usd">-96000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjMtMS0xLTEtMA_1b23e862-ac6c-4078-b831-f0204490f524"
unitRef="usd">-1088000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjMtMy0xLTEtMA_c80f8747-ba91-4e1a-a83c-19d84265c6f9"
unitRef="usd">-992000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<us-gaap:IncreaseDecreaseInOperatingCapital
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjQtMS0xLTEtMA_4f3cf5cf-efd8-4d22-b06a-cb228c52a2db"
unitRef="usd">3005000</us-gaap:IncreaseDecreaseInOperatingCapital>
<us-gaap:IncreaseDecreaseInOperatingCapital
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjQtMy0xLTEtMA_2500d6f5-07d2-4ba9-9752-6510719db8fd"
unitRef="usd">2873000</us-gaap:IncreaseDecreaseInOperatingCapital>
<us-gaap:NetCashProvidedByUsedInOperatingActivities
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjUtMS0xLTEtMA_a3f28297-0b29-45ee-a440-9ecac6001c2a"
unitRef="usd">-17433000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjUtMy0xLTEtMA_b5202e5a-a377-4155-a150-2889e2f08249"
unitRef="usd">-16154000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjctMS0xLTEtMA_ff2e5b45-87cc-4d7e-a0c0-6070a4bd50f0"
unitRef="usd">13765000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjctMy0xLTEtMA_6453ed3d-fd8c-47a3-81a3-0563baf17384"
unitRef="usd">16514000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
<us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjgtMS0xLTEtMA_6f2d3002-a5f7-4ed7-adb0-7b78354d31ff"
unitRef="usd">15181000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
<us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjgtMy0xLTEtMA_4749e678-b4da-4157-a138-2a54eafee679"
unitRef="usd">17497000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
<us-gaap:PaymentsToAcquireMachineryAndEquipment
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjktMS0xLTEtMA_246257b0-1cca-48f3-b0a0-cbf26c580846"
unitRef="usd">281000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
<us-gaap:PaymentsToAcquireMachineryAndEquipment
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMjktMy0xLTEtMA_95573c7c-b5da-4e2e-b783-457ffa7a6fa0"
unitRef="usd">283000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzEtMS0xLTEtMA_677528b0-d9b9-48bb-9424-4d91b562b432"
unitRef="usd">1135000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzEtMy0xLTEtMA_d9c9dfe2-5a30-488f-b1a9-da830e71cb1e"
unitRef="usd">700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromIssuanceOfLongTermDebt
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzMtMS0xLTEtMA_10d2dbf8-ff19-49dd-8ea3-99326475a771"
unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
<us-gaap:ProceedsFromIssuanceOfLongTermDebt
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzMtMy0xLTEtMA_ecc06a6f-8482-4bfb-b6d6-b2ae05789cf0"
unitRef="usd">22500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
<us-gaap:PaymentsOfDebtIssuanceCosts
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzQtMS0xLTEtMA_dbf8e2bb-adaf-4bfd-b910-d82f7e3956a0"
unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
<us-gaap:PaymentsOfDebtIssuanceCosts
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzQtMy0xLTEtMA_5e409802-581b-4171-8074-aac5503286ac"
unitRef="usd">1343000</us-gaap:PaymentsOfDebtIssuanceCosts>
<us-gaap:RepaymentsOfNotesPayable
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzUtMS0xLTEtMA_8fe744a6-4d4d-4f53-81c9-5527fecf9d11"
unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:RepaymentsOfNotesPayable
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzUtMy0xLTEtMA_b2c7a15c-519e-4a4a-a7f7-54b98e78ccf1"
unitRef="usd">763000</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:ProceedsFromIssuanceOfCommonStock
contextRef="ia37f306f86304d1db38e7502e2c78594_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzYtMS0xLTEtMA_f445a591-6843-43ad-8444-a8425a8fc703"
unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock
contextRef="i9f360d22e2b9419f8e68140a6ac31e88_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzYtMy0xLTEtMA_4af69281-3d46-4a10-9641-a407ec225c38"
unitRef="usd">8148000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:PaymentsOfStockIssuanceCosts
contextRef="ia37f306f86304d1db38e7502e2c78594_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzctMS0xLTEtMA_7408d153-a2e0-49d3-af9e-ea28f71efe22"
unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:PaymentsOfStockIssuanceCosts
contextRef="i9f360d22e2b9419f8e68140a6ac31e88_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzctMy0xLTEtMA_1b5c1090-ca28-4684-a1c9-b43815906fb1"
unitRef="usd">144000</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:ProceedsFromIssuanceOfCommonStock
contextRef="i362afd3374074c7cada0c9ce798f3143_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzgtMS0xLTEtMA_e29fa80e-448b-49c9-bfb9-1923de19d6e4"
unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock
contextRef="i7b04f90c66774760bcf6df9405476edc_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzgtMy0xLTEtMA_4f118137-954a-4a53-a9d7-802eb6960ceb"
unitRef="usd">2034000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:PaymentsOfStockIssuanceCosts
contextRef="i362afd3374074c7cada0c9ce798f3143_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzktMS0xLTEtMA_1426c4a6-84e5-41eb-88ba-705ee549294c"
unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:PaymentsOfStockIssuanceCosts
contextRef="i7b04f90c66774760bcf6df9405476edc_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfMzktMy0xLTEtMA_729879b1-ffc1-40b3-a01c-155414c92eb5"
unitRef="usd">56000</us-gaap:PaymentsOfStockIssuanceCosts>
<rmti:RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDEtMS0xLTEtMA_89c9d409-4ad0-4998-8ff6-202f096255ba"
unitRef="usd">6000</rmti:RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes>
<rmti:RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDEtMy0xLTEtMA_f059de88-920d-47b9-87fe-3b48dcf86b29"
unitRef="usd">19000</rmti:RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes>
<us-gaap:NetCashProvidedByUsedInFinancingActivities
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDItMS0xLTEtMA_31d777a6-e9b8-4d05-8fc6-a9239541e873"
unitRef="usd">-6000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDItMy0xLTEtMA_857c56be-194e-4d2b-942a-6e8c9021fb39"
unitRef="usd">30357000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDQtMS0xLTEtMA_264a00c2-7a68-467d-8a4e-753a5e59845a"
unitRef="usd">-16304000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDQtMy0xLTEtMA_f18275e0-3351-40ba-bc00-96570348c78e"
unitRef="usd">14903000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDUtMS0xLTEtMA_f1496fad-dcb5-4cd8-b982-6e05920683ca"
unitRef="usd">48682000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="i43c45a3bec674ffb9577158bb599935f_I20191231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDUtMy0xLTEtMA_14156592-a680-40ed-bb9d-7b7e6b1d4b57"
unitRef="usd">11794000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDYtMS0xLTEtMA_58765488-5900-49c0-abcd-452d4606edbc"
unitRef="usd">32378000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDYtMy0xLTEtMA_a8fd9381-9020-4bf3-862a-ebc12c339a0e"
unitRef="usd">26697000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:InterestPaidNet
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDktMS0xLTEtMA_7a4e0e96-67fc-4bd5-94c6-63c3906b5d15"
unitRef="usd">982000</us-gaap:InterestPaidNet>
<us-gaap:InterestPaidNet
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNDktMy0xLTEtMA_51aa0f84-8851-45ba-9b46-ddcb626e122b"
unitRef="usd">410000</us-gaap:InterestPaidNet>
<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNTEtMS0xLTEtMA_0ba5edcb-e18d-472e-b86f-d0dc97387902"
unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNTEtMy0xLTEtMA_9f6b3c66-5286-46c5-ad7f-c8e502c3c084"
unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
<us-gaap:StockIssued1
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNTUtMS0xLTEtMA_67845dc0-cf9f-4ef3-bfd0-06ee5b7581bd"
unitRef="usd">0</us-gaap:StockIssued1>
<us-gaap:StockIssued1
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8yOC9mcmFnOjE1ODIwNTQzZWJlYjRlYzdiNzZjZWI1ZjdlYTc3ODczL3RhYmxlOjVlZTFiYmQ4NDM1MTQwZmM5OGFjODc2MjQzODQ5ZTZmL3RhYmxlcmFuZ2U6NWVlMWJiZDg0MzUxNDBmYzk4YWM4NzYyNDM4NDllNmZfNTUtMy0xLTEtMA_482c7593-0a35-4368-9c81-3368ea23b42c"
unitRef="usd">501000</us-gaap:StockIssued1>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNC9mcmFnOmRiZWExN2IyNWExNjRmNWQ5YzM4MDFhYmQzNThmMDg4L3RleHRyZWdpb246ZGJlYTE3YjI1YTE2NGY1ZDljMzgwMWFiZDM1OGYwODhfMTczOA_bf4656b0-0c1f-4c38-9a5f-0b6093b3587b">Description of Business<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rockwell Medical, Inc. ("Rockwell Medical," "Rockwell" or the "Company") is a commercial-stage, biopharmaceutical company developing and commercializing our next-generation parenteral iron technology platform, ferric pyrophosphate citrate (“FPC”), which we believe has the potential to lead to transformative treatments for iron deficiency in multiple disease states, that we believe could reduce healthcare costs and improve patients’ lives. We are also one of the two major suppliers of life saving hemodialysis concentrate products to kidney dialysis clinics in the United States.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two novel, FDA approved therapies, Triferic and Triferic AVNU, which are the first two products developed from our FPC platform. We are marketing both products to kidney dialysis centers for their patients receiving dialysis. In 2021, we intend to advance our FPC platform strategy outside of dialysis by starting a Phase II trial for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving long-term and or chronic intravenous medications for various therapeutic needs in the home infusion setting. In our R&amp;D pipeline, we are also exploring FPC’s impact in the treatment of hospitalized patients with acute heart failure, with the potential to begin another Phase 2 trial in these patients in 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the second largest supplier of hemodialysis concentrates in the United States generating approximately $60 million in annual revenue. The Company's reputation for excellent service, quality, and reliability is based on over 25 years of service to kidney dialysis centers. Our approximately 300 dedicated employees, as well as a management team with experience in manufacturing, logistics, pharmaceutical development and commercialization gives us a solid foundation upon which to grow.</span></div></us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i60a1e178baa84a468624d0acac59ece5_D20200101-20201231"
decimals="-6"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNC9mcmFnOmRiZWExN2IyNWExNjRmNWQ5YzM4MDFhYmQzNThmMDg4L3RleHRyZWdpb246ZGJlYTE3YjI1YTE2NGY1ZDljMzgwMWFiZDM1OGYwODhfMTM4Nw_f5b1f8ec-dad6-44c3-89a7-c828d389ff51"
unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<rmti:YearsOfService
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNC9mcmFnOmRiZWExN2IyNWExNjRmNWQ5YzM4MDFhYmQzNThmMDg4L3RleHRyZWdpb246ZGJlYTE3YjI1YTE2NGY1ZDljMzgwMWFiZDM1OGYwODhfMTQ5OQ_14ea2527-082c-430d-aaab-6ae84d141dbc">P25Y</rmti:YearsOfService>
<dei:EntityNumberOfEmployees
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNC9mcmFnOmRiZWExN2IyNWExNjRmNWQ5YzM4MDFhYmQzNThmMDg4L3RleHRyZWdpb246ZGJlYTE3YjI1YTE2NGY1ZDljMzgwMWFiZDM1OGYwODhfMTU0NQ_0a7df9a1-828c-4274-ad11-0535093089b4"
unitRef="employee">300</dei:EntityNumberOfEmployees>
<rmti:LiquidityAndFinancialConditionTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNy9mcmFnOjUxZDQ5ZTNjNTEyNjQ4YWY5NzQwZTIxNWFlNzA2MmQzL3RleHRyZWdpb246NTFkNDllM2M1MTI2NDhhZjk3NDBlMjE1YWU3MDYyZDNfMzQwNA_a26fb119-472f-4877-8d75-73253851deeb">Liquidity and Capital Resources<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, Rockwell has incurred significant net losses and has funded its operations primarily through revenue from commercial products, proceeds from the issuance of debt and equity securities and payments from partnerships. At June 30, 2021, Rockwell had an accumulated deficit of approximately $353.6 million and stockholders' equity of $18.2 million. As of June 30, 2021, Rockwell had approximately $41.0 million of cash, cash equivalents and investments available-for-sale, and working capital of $18.4 million. Net cash used in operating activities for the six months ended June 30, 2021 was approximately $17.4 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is subject to certain covenants and cure provisions under its Loan Agreement with Innovatus. As of the date of this report, the Company is in compliance with all covenants. As a result of the ongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company may not be able to satisfy such covenants over the next 12 months. However, based on the foregoing, the Company has classified amounts payable under the Loan Agreement as a current liability. If and when the Company reaches an agreement with Innovatus to avoid an event of default, the amounts payable under the Loan Agreement will be reclassified. The financial statements for June 30, 2021, have been prepared with the assumption that the Company will be able to agree to an appropriate remedy during the applicable cure period for any future breaches of operating covenants. If the Company is unable to comply with the covenants under the Loan Agreement, it would pursue all available cure options in order to regain compliance (See Note 15 for further detail).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company expects it will require additional capital to sustain its operations and make the investments it needs to execute its strategic plan, including the commercialization of Triferic (dialysate) and Triferic AVNU in dialysis, generating additional data for Triferic in dialysis, developing FPC for iron deficiency anemia in patients undergoing home infusion and for progressing our pipeline development program of new indications for its FPC platform. If the Company is unable to generate sufficient revenue from sales of its commercial products and from partnerships, the Company will need to obtain additional equity or debt financing. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the currently available working capital and managements assumption that the Company will be able to agree to an appropriate remedy, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic and resulting domestic and global disruptions have adversely affected Rockwell's business and operations, including, but not limited to, our sales and marketing efforts, research and development activities, and the operations of third parties upon whom the Company relies. Quarantines, shelter-in-place, executive and similar government orders and the recent surge in infections domestically may continue to negatively impact Rockwell's sales and marketing activities, particularly if its sales representatives are unable to interact with current and potential customers to the same extent as before onset of the COVID-19 pandemic. The Company's international business development activities may also continue to be negatively impacted by COVID-19, especially with the recent surge in infections internationally, ongoing international travel restrictions and quarantines or shelter-in-place orders. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic, the domestic and international surge in infections and resulting global disruptions have caused significant volatility in financial and credit markets. Rockwell has utilized a range of financing methods to fund its operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding, refinancing or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect the Company's liquidity and capital resources in the future.</span></div></rmti:LiquidityAndFinancialConditionTextBlock>
<us-gaap:RetainedEarningsAccumulatedDeficit
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNy9mcmFnOjUxZDQ5ZTNjNTEyNjQ4YWY5NzQwZTIxNWFlNzA2MmQzL3RleHRyZWdpb246NTFkNDllM2M1MTI2NDhhZjk3NDBlMjE1YWU3MDYyZDNfMzM0_8725fb9e-8732-4c1d-a5f4-d7677aabe687"
unitRef="usd">-353600000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNy9mcmFnOjUxZDQ5ZTNjNTEyNjQ4YWY5NzQwZTIxNWFlNzA2MmQzL3RleHRyZWdpb246NTFkNDllM2M1MTI2NDhhZjk3NDBlMjE1YWU3MDYyZDNfMzY1_94562339-a800-4b32-a569-30af3e949dea"
unitRef="usd">18200000</us-gaap:StockholdersEquity>
<us-gaap:CashCashEquivalentsAndShortTermInvestments
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNy9mcmFnOjUxZDQ5ZTNjNTEyNjQ4YWY5NzQwZTIxNWFlNzA2MmQzL3RleHRyZWdpb246NTFkNDllM2M1MTI2NDhhZjk3NDBlMjE1YWU3MDYyZDNfNDA2_c30ef263-9111-45e8-a20d-233837a00fe2"
unitRef="usd">41000000.0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
<rmti:WorkingCapitalNet
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNy9mcmFnOjUxZDQ5ZTNjNTEyNjQ4YWY5NzQwZTIxNWFlNzA2MmQzL3RleHRyZWdpb246NTFkNDllM2M1MTI2NDhhZjk3NDBlMjE1YWU3MDYyZDNfNDk0_4fc4238d-9b16-47fc-8177-810173ec0e98"
unitRef="usd">18400000</rmti:WorkingCapitalNet>
<us-gaap:NetCashProvidedByUsedInOperatingActivities
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8zNy9mcmFnOjUxZDQ5ZTNjNTEyNjQ4YWY5NzQwZTIxNWFlNzA2MmQzL3RleHRyZWdpb246NTFkNDllM2M1MTI2NDhhZjk3NDBlMjE1YWU3MDYyZDNfNTgx_a0269c16-1ae9-4a2f-8d42-38407d6aaf9e"
unitRef="usd">-17400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:SignificantAccountingPoliciesTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RleHRyZWdpb246MTI1MzFmMTZlZjg0NGQxYzhhOGM1Y2VkODMwZWM5Y2FfNTgzMg_35030dd6-0ea8-4548-8f3f-4e4357bdcac0">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U. S. Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet at June 30, 2021, condensed consolidated statements of operations for the three and six months ended June 30, 2021 and 2020, condensed consolidated statements of comprehensive loss for the three and six months ended June 30, 2021 and 2020, condensed consolidated statement of changes in stockholders' equity for the three and six months ended June 30, 2021 and 2020, and condensed consolidated statements of cash flows for the six months ended June 30, 2021 and 2020 are unaudited, but include all adjustments, consisting of normal recurring adjustments, that the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and six months ended June 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021 or for any future interim period. The condensed consolidated balance sheet at December 31, 2020 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020 and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 as filed with the SEC on March 31, 2021. The Company’s consolidated subsidiaries consisted of its wholly-owned subsidiaries, Rockwell Transportation, Inc. and Rockwell Medical India Private Limited.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock excludes dilution and is computed by dividing the net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. The Company has only incurred losses, therefore, basic and diluted net loss per share is the same. Securities that could potentially dilute net income per share in the future that were not included in the computation of diluted loss per share were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,070,801 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,225,562 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">342,604 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">503,395 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,426,863 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,248,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,918,568 </span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,123,811 </span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually assesses new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Financial Accounting Standards Board ("FASB") recently issued Accounting Standards Update ("ASU") 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements.</span></div></us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RleHRyZWdpb246MTI1MzFmMTZlZjg0NGQxYzhhOGM1Y2VkODMwZWM5Y2FfNTgzMw_64b5deef-8160-4967-bf44-08a4c77cc596">The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:UseOfEstimates
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RleHRyZWdpb246MTI1MzFmMTZlZjg0NGQxYzhhOGM1Y2VkODMwZWM5Y2FfNTgzNA_61dc653d-63ac-4544-9adf-b223c257f7a2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></div></us-gaap:UseOfEstimates>
<us-gaap:LesseeLeasesPolicyTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RleHRyZWdpb246MTI1MzFmMTZlZjg0NGQxYzhhOGM1Y2VkODMwZWM5Y2FfNTgzNQ_bb5b8550-199e-40d0-900c-88a81f8f2154"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.</span></div>In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.</us-gaap:LesseeLeasesPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RleHRyZWdpb246MTI1MzFmMTZlZjg0NGQxYzhhOGM1Y2VkODMwZWM5Y2FfNTgzNw_aebf203d-3f74-4fa3-a0e3-629b977cad81"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.</span></div>Basic net loss per share of common stock excludes dilution and is computed by dividing the net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. The Company has only incurred losses, therefore, basic and diluted net loss per share is the same.</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RleHRyZWdpb246MTI1MzFmMTZlZjg0NGQxYzhhOGM1Y2VkODMwZWM5Y2FfNTgzOA_bbb973cd-68cb-4887-8913-33f3d61285f8">Securities that could potentially dilute net income per share in the future that were not included in the computation of diluted loss per share were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,070,801 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,225,562 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">342,604 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">503,395 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,426,863 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,248,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,918,568 </span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,123,811 </span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="ib836387b9dbf4d2194d1f2d0760e18fb_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfMi0xLTEtMS0w_4f02b5df-8f2c-417d-9868-9aa471058791"
unitRef="shares">6070801</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="i4213fa50227d476f94ac06eb631a5c6f_D20200101-20200630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfMi0zLTEtMS0w_02e7ea30-6e88-4f2c-a9d7-d1297e290cb9"
unitRef="shares">6225562</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="i3f359e12f74143a3aecd3e1aea69c9f6_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfMy0xLTEtMS0w_2fd434cb-8610-4561-a863-4024092bc75b"
unitRef="shares">78300</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="ib187f06d4c2b4b44a5076ea0d0b431b5_D20200101-20200630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfMy0zLTEtMS0w_f32ca3de-8bf4-47fa-8fc8-a5cc26450c7a"
unitRef="shares">146800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="i234e6a6e01d345a2a2a9ecbd74387219_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfNC0xLTEtMS0w_56a3c414-ae82-4447-bc2e-635ad816ce19"
unitRef="shares">342604</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="i4cb310df91c047af8dd3a11fd4886ab3_D20200101-20200630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfNC0zLTEtMS0w_3223324a-92ed-4e0d-bef6-fa07013ba86a"
unitRef="shares">503395</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="ied0dd598d05f4288a25014c07eebd870_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfNS0xLTEtMS0w_bc5ee3e7-04da-4b56-b689-43d47a6cc5d6"
unitRef="shares">26426863</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="i22e74f63f96b4ccf89d59802612fc8c4_D20200101-20200630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfNS0zLTEtMS0w_cbad3949-3e20-4eb4-8a5c-a9bb7fc79a06"
unitRef="shares">3248054</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfNi0xLTEtMS0w_d6277d5e-1c05-4ff6-bce1-ff01c8801ea7"
unitRef="shares">32918568</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RhYmxlOjYxMmRlMWFiYmUzMTQzYzhiZjUyZjcwNjEwNTA0NWVkL3RhYmxlcmFuZ2U6NjEyZGUxYWJiZTMxNDNjOGJmNTJmNzA2MTA1MDQ1ZWRfNi0zLTEtMS0w_3c700875-7ea1-4e74-8467-2c4e1a65118d"
unitRef="shares">10123811</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80MC9mcmFnOjEyNTMxZjE2ZWY4NDRkMWM4YThjNWNlZDgzMGVjOWNhL3RleHRyZWdpb246MTI1MzFmMTZlZjg0NGQxYzhhOGM1Y2VkODMwZWM5Y2FfNTgzMQ_6e279ab3-8f90-4337-96fc-2b95c36d0325"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually assesses new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Financial Accounting Standards Board ("FASB") recently issued Accounting Standards Update ("ASU") 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements.</span></div></us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:RevenueFromContractWithCustomerTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNjczMw_2a3c2323-b103-40d0-b752-662e267c3ad8">Revenue Recognition<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 1: Identify the contract with the customer</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 2: Identify the performance obligations in the contract</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 3: Determine the transaction price</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 4: Allocate the transaction price to the performance obligations in the contract</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 5: Recognize revenue when the company satisfies a performance obligation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Nature of goods and services</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of principal activities from which the Company generates its revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales –</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug and dialysis concentrate products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales.  For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales.  In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude that regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time that control of the product transfers to the customer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received upfront fees under five distribution and license agreements that have been deferred as a contract liability.  The amounts received from Wanbang Biopharmaceuticals Co., Ltd. (“Wanbang”), Sun Pharmaceutical Industries Ltd. ("Sun Pharma"), Jeil Pharmaceutical Co., Ltd. ("Jeil Pharma") and Drogsan Pharmaceuticals ("Drogsan Pharma") are recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China, India and South Korea, respectively, to determine that regulatory approval was probable as of the execution of the agreement.  The amounts received from Baxter Healthcare Corporation (“Baxter”) are recognized as revenue at the point in time that the estimated product sales under the agreement occur. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the business under the Company’s Distribution Agreement with Baxter (the “Baxter Agreement”), and for the majority of the Company’s international customers, the Company recognizes revenue at the shipping point, which is generally the Company’s plant or warehouse. For other business, the Company recognizes revenue based on when the customer takes control or receipt of the product. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers. There were no such adjustments for the periods reported. Customers typically pay for the product based on customary business practices with payment terms averaging 30 days, while distributor payment terms average 45 days.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Disaggregation of revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.901%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($) </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">273 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">556 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrate Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,379 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,026 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,353 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,084 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,227 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,857 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,864 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,511 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,353 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,055 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,198 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,857 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,137 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,726 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,411 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,611 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,637 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,974 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrate Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,849 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,454 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,658 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,809 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,849 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,806 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,896 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,991 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,905 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,753 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,187 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,566 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Contract balances</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, which are included in "Trade and other receivables"</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material losses recognized related to any receivables arising from the Company’s contracts with customers for the three and six months ended June 30, 2021 and 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021 and June 30, 2020, the Company did not recognize any material bad-debt expense. There were no material contract assets recorded on the condensed consolidated balance sheet as of June 30, 2021 and December 31, 2020.  The Company does not generally accept returns of its concentrate products and no material reserve for returns of concentrate products was established as of June 30, 2021 or December 31, 2020. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract liabilities primarily relate to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Transaction price allocated to remaining performance obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, revenue recognized from performance obligations related to prior periods was not material.</span></div>Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, totaled $9.1 million as of June 30, 2021. The amount relates primarily to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The Baxter Agreement includes minimum commitments of product sales over the duration of the agreement. Unfulfilled minimum commitments related to the Baxter Agreement are product sales of $6.2 million as of June 30, 2021, which is amortized ratably through expiration of the Baxter Agreement on October 2, 2024.</us-gaap:RevenueFromContractWithCustomerTextBlock>
<rmti:NumberOfDistributionAndLicenseAgreements
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfMjk1NQ_7738948c-0192-45e8-be2e-418436dc1027"
unitRef="agreement">5</rmti:NumberOfDistributionAndLicenseAgreements>
<rmti:AveragePaymentTermOfCustomers
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNDQ0Mw_223d9cfb-6e5e-4543-a145-81be8393c589">P30D</rmti:AveragePaymentTermOfCustomers>
<rmti:AveragePaymentTermOfDistributors
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNDQ4Nw_2abd4625-91cd-45e4-a920-7ea1b5989780">P45D</rmti:AveragePaymentTermOfDistributors>
<us-gaap:DisaggregationOfRevenueTableTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNjczNA_c1a9e04e-ddc4-41c3-823a-0489d3828917">Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.<div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.901%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($) </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">273 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">556 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrate Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,379 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,026 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,353 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,084 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,227 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,857 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,864 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,511 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,353 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,055 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,198 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,857 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,137 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,726 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,411 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,611 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,637 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,974 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrate Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,849 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,454 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,658 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,809 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,849 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,806 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,896 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,991 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,905 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,753 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,187 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,566 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:DisaggregationOfRevenueTableTextBlock>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="id817573b63f545c4b0779381d9eecaa4_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMy0xLTEtMS0w_a443c75c-f008-4633-bd27-32f64b4c0734"
unitRef="usd">215000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="id9a3833807ea4f74a7a1f27cf203fd5e_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMy0zLTEtMS0w_6d0344f7-d08e-421d-a775-b92703c46422"
unitRef="usd">215000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="id4a5ecfa7b564990bee4389ba90e2ec4_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMy01LTEtMS0w_272556b7-a2be-456e-83e8-7447bb5bc54f"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="ieca9a4e9f9244e53bbff8d044bfaccc4_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMy03LTEtMS0w_3217775b-9b58-4145-9af1-0e7be8f1fa9f"
unitRef="usd">439000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="iafedcd0ea4794c7aaa56752656d24c74_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMy05LTEtMS0w_fbb2f16f-0d22-4107-9df3-dad79558374d"
unitRef="usd">439000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="id6cb7e08ae2d49e6a5b26d9d272b9f1d_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMy0xMS0xLTEtMA_33363a92-6640-4c20-8d1b-9185782da3d2"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="ie4ae2a5c5baf465e84899070e8d326d6_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNC0xLTEtMS0w_0b8b2377-10ae-41e9-a41b-55487f49a8ce"
unitRef="usd">58000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="if096b68927464500b4e88829e37637c2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNC0zLTEtMS0w_9ae018bb-16b8-41c9-97c4-c198c9efda34"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i6f3b0b018abf4ad28e152dd527bf3362_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNC01LTEtMS0w_28a6e6f2-f6dc-40ce-89cb-bed331ea7712"
unitRef="usd">58000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i06a344e202084e8db05b539ad000672f_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNC03LTEtMS0w_1c4ae436-49fb-46d3-8930-fb0209de5621"
unitRef="usd">117000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="if238d6f15fb74086ad99dba36761f71f_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNC05LTEtMS0w_8fe4bb5e-306a-40f6-9cb3-d9f2f4fe0420"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i745d398121d3420c9e3c52c10191697f_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNC0xMS0xLTEtMA_d26a5c3a-54bd-4840-959b-3f8daa1a0842"
unitRef="usd">117000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i0a076ec540424aaca3aa0743cc065e09_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNS0xLTEtMS0w_45e84179-d39d-4171-b67c-539364dbcfbe"
unitRef="usd">273000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i02702a823cf648519e82be8308bd7596_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNS0zLTEtMS0w_c98280c3-0262-4b4b-ac09-dc2193896be1"
unitRef="usd">215000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="ib6922c012b894f83b88c3ade46b3691c_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNS01LTEtMS0w_34cb8637-58f6-4199-85cb-d4f0d371d50a"
unitRef="usd">58000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i3c130100b8bb44d2a7a09782e10841de_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNS03LTEtMS0w_5a891314-639c-42e8-9325-1ba1b61d3cbb"
unitRef="usd">556000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="id3053c900b0b4cd6b2f2b892bea072a6_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNS05LTEtMS0w_37932e32-2dd8-4af5-9eea-9e1159dedca6"
unitRef="usd">439000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i292ea93b319445a483177b398681ba09_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNS0xMS0xLTEtMA_025ea6d2-d144-42b8-9220-e3bfbf290f25"
unitRef="usd">117000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i6ce20ced6701401694822bf3176021b8_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNy0xLTEtMS0w_a8d4a726-fe10-456e-a72c-7df26ce902f6"
unitRef="usd">14379000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i42661da0c9dd422d99f958a822e76c80_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNy0zLTEtMS0w_1a3d8ac8-49b1-4499-a457-19f2b3a2166a"
unitRef="usd">13026000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="ic569e934568a4510a8431b3e9b0cce78_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNy01LTEtMS0w_c0c57c4c-b859-4ed4-9a9c-5a9e896680da"
unitRef="usd">1353000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="ib4ccc0ab30cf47169a22197ca958e494_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNy03LTEtMS0w_08fc822d-da7c-4476-a575-ad6ecfa76d37"
unitRef="usd">29084000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i1a7ed85229724ee2a7a0722168d880b7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNy05LTEtMS0w_3aea65d8-8231-4700-86de-b4757fa24359"
unitRef="usd">26227000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="ib4f4a67681724daaa3e7eeed7f750918_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfNy0xMS0xLTEtMA_c74b9ec3-30d1-4e03-a136-a3f7128e0c81"
unitRef="usd">2857000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i923167f606cf40d7a53bb0e1fbf64893_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOC0xLTEtMS0w_52d6ef00-f2df-47b5-9c6c-ecf8a195970b"
unitRef="usd">485000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i5ddb390e46cf4c218e6473e46dfc5e7e_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOC0zLTEtMS0w_41bb955f-26f1-4f61-af42-cf5f97e424ee"
unitRef="usd">485000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i8be39cf73a5645cfa4869eccd7ffd140_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOC01LTEtMS0w_f5613591-5d1d-4040-9e99-e10dcb85aec4"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i499887d5bc04466a881225c24de111c9_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOC03LTEtMS0w_bf9db88b-c681-45be-8e3a-54b3a67480f2"
unitRef="usd">971000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="ic1b0c675ad3a4dc5a6cfbdb5e8eab0ba_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOC05LTEtMS0w_7984daed-efc7-4a39-a814-467ac38d6dcd"
unitRef="usd">971000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i72196e4fcc3d4c68b85555ee776e8323_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOC0xMS0xLTEtMA_6591b40e-4740-4720-b747-7c71cb0dedef"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i7fc604f0bbfc49e0af5bd3f913f7bcac_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOS0xLTEtMS0w_70ea1f71-067b-42bf-ae06-32b1bac30786"
unitRef="usd">14864000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="ie9afd3e3be09480b93f86d7baf05a03e_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOS0zLTEtMS0w_0114f80b-bcc9-436d-a4c0-6208bb2cee3b"
unitRef="usd">13511000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i19717f382ea34d3a8d3ba919c064ab70_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOS01LTEtMS0w_6986d41a-36c9-4fce-9cd4-4a314397e134"
unitRef="usd">1353000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i04631d2e7a6f46958f2abcf1c20c0165_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOS03LTEtMS0w_2b2c0f66-bd74-4ce6-befa-3a2a2488a24d"
unitRef="usd">30055000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i46c0764450934a84aede084a08f162d3_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOS05LTEtMS0w_930d4c1d-afa0-4d2f-81ba-72f967c04583"
unitRef="usd">27198000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i453a3991692c48d196c8d65dfcef5486_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfOS0xMS0xLTEtMA_f17b104c-7820-4c61-8c6e-f1101a693ece"
unitRef="usd">2857000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMTAtMS0xLTEtMA_79ae2d72-0b44-423a-8941-7d7d6aadb162"
unitRef="usd">15137000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="ib211340e5e4741839359edb488b6820a_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMTAtMy0xLTEtMA_a6e92871-d190-42e2-bfe7-62fe9c2d6bd9"
unitRef="usd">13726000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="if69d4f2ec51d4ebab66a7c6c0b08fd69_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMTAtNS0xLTEtMA_67f02e11-3185-43c3-8a37-bf30ae7a0651"
unitRef="usd">1411000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMTAtNy0xLTEtMA_be08ce60-08f8-4203-a24a-aea399d96a8b"
unitRef="usd">30611000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="if84c75bc21bd454e9387eea17889b736_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMTAtOS0xLTEtMA_27f76021-fe78-42d2-a2b2-fa5a6ac269d2"
unitRef="usd">27637000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="ica982797685d4867885a3bbb4e1799f8_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmRiNDk1MGE1ZjlhNzRhMjBhY2VmMTZjYTYxZmJmZTc5L3RhYmxlcmFuZ2U6ZGI0OTUwYTVmOWE3NGEyMGFjZWYxNmNhNjFmYmZlNzlfMTAtMTEtMS0xLTA_3c7cc6fc-681f-41bd-9956-c4d7ec1fb664"
unitRef="usd">2974000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i84f272a5e5e04e439fb8926e0ca1edf7_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMy0xLTEtMS0w_d938308b-b805-404b-81e3-6c3c4ee2c09d"
unitRef="usd">182000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="if4a510f683e7412cabff75b22f5281da_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMy0zLTEtMS0w_a8f6aa83-c0ba-428f-9693-3d79c4775288"
unitRef="usd">182000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i3f3b95dc158544189ce6a5d99f57cfed_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMy01LTEtMS0w_ba95362f-63e9-4285-b6e7-8493e3f0e78f"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="if572cd5222f042df8163eeda30992465_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMy03LTEtMS0w_d6867c41-24fa-424b-8e62-2a3a5b8b10df"
unitRef="usd">381000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i3c202ad8a44b417c93e84a0b4edc89df_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMy05LTEtMS0w_5021b509-5e8f-4193-97cb-1a223bd1c5e9"
unitRef="usd">381000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i33e8984dceec4885937bef7aade6f1bf_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMy0xMS0xLTEtMA_e2cd3b7f-8841-49ea-9aec-f05ce53b7c53"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="id52be33547c9431b85a4342a2f2a4c9c_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNC0xLTEtMS0w_90768a9e-205d-4af8-b1c3-7088812d73d6"
unitRef="usd">56000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i0da48e7639534786971c53ed0c8a8b79_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNC0zLTEtMS0w_56092e0e-ba88-49b3-a9d0-55a6eb232ef5"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="if3579aee169c40d1b1ebf79b3f56a3a3_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNC01LTEtMS0w_9817e582-e1cf-4e6d-aaf7-4d2d5bf92ef4"
unitRef="usd">56000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i00411df7d3c04001838b0d136b05ff9c_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNC03LTEtMS0w_7e7904ec-0b7d-46b6-ad2e-adf86f2ba632"
unitRef="usd">112000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="ie1fce7f95ed24da2bedbd4e38c03b866_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNC05LTEtMS0w_2a4c79f3-90b1-4acf-9f2c-ec9167e66ff5"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i0315167a57d743cb8c4cccfeed4f43c9_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNC0xMS0xLTEtMA_13e7bcc0-97be-4c3a-b6ac-922d0c110634"
unitRef="usd">112000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="id72af55606eb4c8eb7cfbe2a7544505e_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNS0xLTEtMS0w_40f9f0b0-5f72-4586-93fc-c1d4ca0c7d21"
unitRef="usd">238000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i40b91f57dc5345558f46f78c6e809cde_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNS0zLTEtMS0w_13327416-8234-4d4e-9c00-81483f220f88"
unitRef="usd">182000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="ie0480fc74d5745178e00498bd3c64905_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNS01LTEtMS0w_538690b7-2550-4f04-bb8b-3167302ad89f"
unitRef="usd">56000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i5145ce2ef7ad4c80b3936b501436c3ca_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNS03LTEtMS0w_7615483c-9f85-4d05-a9c1-6286f53e0a53"
unitRef="usd">493000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="id9090f1f2b024e1fa299abac8f5b8a94_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNS05LTEtMS0w_74e00632-6fe5-4970-8e75-134bab85f0b6"
unitRef="usd">381000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="iff460b44d83a459a91b73a4e4bf3b9a6_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNS0xMS0xLTEtMA_6a2fdfbd-7bb1-40e7-ab44-7aee060c0d69"
unitRef="usd">112000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="ib6593dca464b48b688b4062dcb38e469_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNy0xLTEtMS0w_0d5660c9-73e6-42dd-81ef-d4239c65fb38"
unitRef="usd">15168000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="ia3c726d6f00c48748ecb13e2df4349a0_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNy0zLTEtMS0w_7f2bb593-7ecc-40a1-95a1-cf95b66ed58d"
unitRef="usd">13319000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="if40ef0e6f3b34b859ff96c8f94e67052_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNy01LTEtMS0w_68db800c-a7b2-469f-862f-19e4fd5f4649"
unitRef="usd">1849000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="iab0454faec22428e95ed05ab8e5b75e4_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNy03LTEtMS0w_94929163-8fe9-411b-bd63-d3f6ee91c630"
unitRef="usd">30280000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i57d87eb7fbd94c44a05255171f31ec4f_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNy05LTEtMS0w_0e511037-ad7f-4552-8051-ab62240721b3"
unitRef="usd">26826000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i855c474985a24e75a1db3f85ab19407d_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfNy0xMS0xLTEtMA_74c9b646-4c5e-437b-a8d7-00c5e3693cf2"
unitRef="usd">3454000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i8fd60db6aa864ebda72c4b973f6bb595_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOC0xLTEtMS0w_6229e380-4628-4de9-9b10-4e0cb0d8f6f3"
unitRef="usd">490000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i0c57eb7213114137a35dc2e9414b8ad7_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOC0zLTEtMS0w_c7f7427c-51cd-4722-b85d-6394c5409995"
unitRef="usd">490000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i2b9266a45b8644df99c3c3cc5a340793_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOC01LTEtMS0w_7c3d3bb1-77ce-458d-b662-4d97dba9562c"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i7a6c6fed0fce4b14a3c5bd84ed2eb65a_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOC03LTEtMS0w_142f40fe-60cf-4e6e-9b80-572c9753215e"
unitRef="usd">980000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i9e0a6c01cca24e8fa233e43822d66e39_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOC05LTEtMS0w_b88903c0-101b-4ffe-ba47-39646af95697"
unitRef="usd">980000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i666be76116bd4dbba8fd86f8788fbd2e_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOC0xMS0xLTEtMA_34d24120-b23c-4a48-8394-f4812dbcb402"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i87b28ce51d1b45beb18577ab76dfd443_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOS0xLTEtMS0w_4c183430-c631-4959-bc81-906fb0149133"
unitRef="usd">15658000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i5cc214e4793343a9a278e81b78adef30_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOS0zLTEtMS0w_b98e58f8-0d83-4db4-8446-e5b630e2ee19"
unitRef="usd">13809000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i8c637418d7d54d0eb1be550eeadc155a_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOS01LTEtMS0w_105c8951-a7c9-4dfb-b3cb-85a445d81df7"
unitRef="usd">1849000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i333c560005714b44882c1307abb33985_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOS03LTEtMS0w_b0e69f24-1ce7-425a-8568-6c018efb8089"
unitRef="usd">31260000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="if4800217e44243a0a6c3800959e5d3bf_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOS05LTEtMS0w_e8f31f29-8c6f-4d5e-a889-4b78b6040f1f"
unitRef="usd">27806000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="ic6b367e5e5f34fc1abc31941f97868c3_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfOS0xMS0xLTEtMA_c739e984-1d8c-4353-a32a-38ba748262bf"
unitRef="usd">3454000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMTAtMS0xLTEtMA_6e35121a-0c39-4a16-a1be-94c7c962c680"
unitRef="usd">15896000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="iaeea20075b5643f2bc9e29ae4bc8bb9a_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMTAtMy0xLTEtMA_fe5a4ccb-2057-41a4-ac39-51c73d4696e3"
unitRef="usd">13991000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i21c4c64e4427462690f1cc8ac29aba99_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMTAtNS0xLTEtMA_67932275-cfc9-4cf5-994c-6cd1ab35291c"
unitRef="usd">1905000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMTAtNy0xLTEtMA_cb5d419e-5d6a-4f0c-b6d3-cc3c37210aac"
unitRef="usd">31753000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="ib2537301a83f4c34b4d7b41169bbdc07_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMTAtOS0xLTEtMA_334ae7cd-18fa-45ab-96fd-cee32f0a5aed"
unitRef="usd">28187000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
contextRef="id5323b8c605048f9883ce2e0cf2efc2e_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOjMxZmRhMjVmZmFiNzQwODA4YWZkM2JhMzlhNGI0NWE5L3RhYmxlcmFuZ2U6MzFmZGEyNWZmYWI3NDA4MDhhZmQzYmEzOWE0YjQ1YTlfMTAtMTEtMS0xLTA_e991bf54-830c-466e-b118-197e4637ff95"
unitRef="usd">3566000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNjczNQ_3ced42ad-a0c1-4764-a7c0-6cc2b9328d2a"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, which are included in "Trade and other receivables"</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
<us-gaap:OtherReceivables
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmE0OWVmZjdlYjExOTRiNjQ4OWVkNjFjZjc0ODI0MjA0L3RhYmxlcmFuZ2U6YTQ5ZWZmN2ViMTE5NGI2NDg5ZWQ2MWNmNzQ4MjQyMDRfMS0xLTEtMS0w_31ca032f-ade6-4f61-89d3-783309e3d62d"
unitRef="usd">5357000</us-gaap:OtherReceivables>
<us-gaap:OtherReceivables
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmE0OWVmZjdlYjExOTRiNjQ4OWVkNjFjZjc0ODI0MjA0L3RhYmxlcmFuZ2U6YTQ5ZWZmN2ViMTE5NGI2NDg5ZWQ2MWNmNzQ4MjQyMDRfMS0zLTEtMS0w_e9f12fdb-a867-471c-859d-27840290655e"
unitRef="usd">4171000</us-gaap:OtherReceivables>
<us-gaap:ContractWithCustomerLiability
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmE0OWVmZjdlYjExOTRiNjQ4OWVkNjFjZjc0ODI0MjA0L3RhYmxlcmFuZ2U6YTQ5ZWZmN2ViMTE5NGI2NDg5ZWQ2MWNmNzQ4MjQyMDRfMi0xLTEtMS0w_2ae1f2ac-f44a-49e2-97d5-6b91a80c8c4b"
unitRef="usd">9103000</us-gaap:ContractWithCustomerLiability>
<us-gaap:ContractWithCustomerLiability
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RhYmxlOmE0OWVmZjdlYjExOTRiNjQ4OWVkNjFjZjc0ODI0MjA0L3RhYmxlcmFuZ2U6YTQ5ZWZmN2ViMTE5NGI2NDg5ZWQ2MWNmNzQ4MjQyMDRfMi0zLTEtMS0w_3365f89d-63a6-4f09-831f-3a14168ebb5c"
unitRef="usd">10190000</us-gaap:ContractWithCustomerLiability>
<us-gaap:ContractWithCustomerAssetCreditLossExpense
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNDc5Nw_560120a7-5dfa-44f0-9d59-5213517b9683"
unitRef="usd">0</us-gaap:ContractWithCustomerAssetCreditLossExpense>
<us-gaap:ContractWithCustomerAssetCreditLossExpense
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNDc5Nw_bed2159f-f358-478d-b03b-43f45038781a"
unitRef="usd">0</us-gaap:ContractWithCustomerAssetCreditLossExpense>
<us-gaap:ContractWithCustomerAssetCreditLossExpense
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNDc5Nw_bff59780-48d7-4f88-b1f4-3d81dc9e2b1f"
unitRef="usd">0</us-gaap:ContractWithCustomerAssetCreditLossExpense>
<us-gaap:ContractWithCustomerAssetCreditLossExpense
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNDc5Nw_d2d0b65a-31cf-4b67-912c-59f8ee7ecc83"
unitRef="usd">0</us-gaap:ContractWithCustomerAssetCreditLossExpense>
<us-gaap:ContractWithCustomerAssetNet
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNTA0OA_198694bb-dd29-4a7b-8e96-455e06f52c78"
unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
<us-gaap:ContractWithCustomerAssetNet
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNTA0OA_2ef7fbb7-79b2-4c68-b314-3c0923444123"
unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
<us-gaap:ContractWithCustomerRefundLiability
contextRef="i2221de36cdaa43edb16860bc141df763_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNTIyNQ_63df5140-327a-48e5-a53d-425860ef623d"
unitRef="usd">0</us-gaap:ContractWithCustomerRefundLiability>
<us-gaap:ContractWithCustomerRefundLiability
contextRef="i531d67a3cb074164b661fe82095b4e11_I20201231"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNTIyNQ_c916d351-2c90-4305-b975-c3240d8e00c2"
unitRef="usd">0</us-gaap:ContractWithCustomerRefundLiability>
<us-gaap:RevenueRemainingPerformanceObligation
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNjAzOA_0dd8cb6c-864a-4881-b0a9-6e4cd1f9e6e6"
unitRef="usd">9100000</us-gaap:RevenueRemainingPerformanceObligation>
<us-gaap:RevenueRemainingPerformanceObligation
contextRef="iffc4d933f9f0489188683fe4b938ade0_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80My9mcmFnOjU1YzgwYWE5NGU5ZTQzYWJiMDQxOWJkY2Q0Mzk2ODBiL3RleHRyZWdpb246NTVjODBhYTk0ZTllNDNhYmIwNDE5YmRjZDQzOTY4MGJfNjYyMA_cef79bc0-48a1-45ec-889a-d34a0f7d833e"
unitRef="usd">6200000</us-gaap:RevenueRemainingPerformanceObligation>
<us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RleHRyZWdpb246NWU1ZDYyMTMyNWMwNDFmMmIwMWFkZTc4OWI4YTExY2FfNTI5_7724449c-72d4-4025-9138-5906c5b34dd5">Investments - Available-for-Sale<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available-for-sale consisted of the following as of June 30, 2021 and December 31, 2020 (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,558 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,574 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,987 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,997 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of investments available-for-sale are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as a Level 1 measurement under ASC 820 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, the amortized cost and estimated fair value of our available-for-sale securities were due within one year.</span></div></us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
<us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RleHRyZWdpb246NWU1ZDYyMTMyNWMwNDFmMmIwMWFkZTc4OWI4YTExY2FfNTMw_893cdf02-1d32-484a-bb13-936dff78ccd1"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available-for-sale consisted of the following as of June 30, 2021 and December 31, 2020 (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,558 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,574 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,987 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,997 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
<us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmUxMjU3MjE2NjJiZDQzZGRhNDhmNDQxMzZlOWRiMWY0L3RhYmxlcmFuZ2U6ZTEyNTcyMTY2MmJkNDNkZGE0OGY0NDEzNmU5ZGIxZjRfMy0xLTEtMS0w_53128432-da1a-4124-9421-fe331d30cdfa"
unitRef="usd">8558000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmUxMjU3MjE2NjJiZDQzZGRhNDhmNDQxMzZlOWRiMWY0L3RhYmxlcmFuZ2U6ZTEyNTcyMTY2MmJkNDNkZGE0OGY0NDEzNmU5ZGIxZjRfMy0zLTEtMS0w_6b60f970-5947-43f0-ab13-4b4d41e21f1b"
unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmUxMjU3MjE2NjJiZDQzZGRhNDhmNDQxMzZlOWRiMWY0L3RhYmxlcmFuZ2U6ZTEyNTcyMTY2MmJkNDNkZGE0OGY0NDEzNmU5ZGIxZjRfMy01LTEtMS0w_94f34428-c736-4985-af85-ac13f064664b"
unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
<us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmUxMjU3MjE2NjJiZDQzZGRhNDhmNDQxMzZlOWRiMWY0L3RhYmxlcmFuZ2U6ZTEyNTcyMTY2MmJkNDNkZGE0OGY0NDEzNmU5ZGIxZjRfMy03LTEtMS0w_8bec3560-de32-4f67-b749-2f9147a1dc86"
unitRef="usd">15000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent>
<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmUxMjU3MjE2NjJiZDQzZGRhNDhmNDQxMzZlOWRiMWY0L3RhYmxlcmFuZ2U6ZTEyNTcyMTY2MmJkNDNkZGE0OGY0NDEzNmU5ZGIxZjRfMy05LTEtMS0w_9f314933-7904-4906-8359-f8f93bb9abcd"
unitRef="usd">8574000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
<us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmU3NDRlMDhhZDYwNzQ0ODNhYjE5Y2M0ZGZlYjg4YjJjL3RhYmxlcmFuZ2U6ZTc0NGUwOGFkNjA3NDQ4M2FiMTljYzRkZmViODhiMmNfMy0xLTEtMS0w_228e358d-c609-4a14-83f1-6990c3be4311"
unitRef="usd">9987000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmU3NDRlMDhhZDYwNzQ0ODNhYjE5Y2M0ZGZlYjg4YjJjL3RhYmxlcmFuZ2U6ZTc0NGUwOGFkNjA3NDQ4M2FiMTljYzRkZmViODhiMmNfMy0zLTEtMS0w_78ef3231-60bb-4d98-a562-acf794de6eaa"
unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmU3NDRlMDhhZDYwNzQ0ODNhYjE5Y2M0ZGZlYjg4YjJjL3RhYmxlcmFuZ2U6ZTc0NGUwOGFkNjA3NDQ4M2FiMTljYzRkZmViODhiMmNfMy01LTEtMS0w_d7125643-c6de-4fd8-b92c-13687bb8e9b4"
unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
<us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmU3NDRlMDhhZDYwNzQ0ODNhYjE5Y2M0ZGZlYjg4YjJjL3RhYmxlcmFuZ2U6ZTc0NGUwOGFkNjA3NDQ4M2FiMTljYzRkZmViODhiMmNfMy03LTEtMS0w_b39dd637-a693-4e5d-81a9-05df76eee88d"
unitRef="usd">7000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent>
<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80Ni9mcmFnOjVlNWQ2MjEzMjVjMDQxZjJiMDFhZGU3ODliOGExMWNhL3RhYmxlOmU3NDRlMDhhZDYwNzQ0ODNhYjE5Y2M0ZGZlYjg4YjJjL3RhYmxlcmFuZ2U6ZTc0NGUwOGFkNjA3NDQ4M2FiMTljYzRkZmViODhiMmNfMy05LTEtMS0w_4525a6a6-151e-4548-85ae-0bb94a2f7afa"
unitRef="usd">9997000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
<us-gaap:InventoryDisclosureTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RleHRyZWdpb246NTAwYWVjYjNlZmQxNDlhMjkyNDhhNmVhNDEzMzEyYzFfNzE0_ec84cb6d-df20-41cf-a1a5-532d2c55640d">Inventory<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of inventory, net of reserves, as of June 30, 2021 and December 31, 2020 are as follows (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:74.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw Materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,598 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in Process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished Goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,805 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,799 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,089 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, the Company classified $1.1 million of inventory as non-current, all of which was related to Triferic or the active pharmaceutical ingredient and raw materials for Triferic. As of June 30, 2021, the total Triferic inventory net of reserve was $1.7 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $1.7 million net value of Triferic inventory consisted of $0.3 million of Triferic (dialysate) finished goods with expiration dates ranging from September 2021 to December 2023, $0.5 million of Triferic API with estimated remaining shelf life extending beyond 2021, and $0.9 million of raw materials for Triferic with estimated remaining shelf life extending beyond 2025.</span></div></us-gaap:InventoryDisclosureTextBlock>
<us-gaap:ScheduleOfInventoryCurrentTableTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RleHRyZWdpb246NTAwYWVjYjNlZmQxNDlhMjkyNDhhNmVhNDEzMzEyYzFfNzE1_68ca10d4-5e3b-4237-95ce-64b6785436a9"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of inventory, net of reserves, as of June 30, 2021 and December 31, 2020 are as follows (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:74.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw Materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,598 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in Process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished Goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,805 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,799 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,089 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
<us-gaap:InventoryRawMaterialsNetOfReserves
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RhYmxlOjY2ZDJkN2YxN2U0YTQ3NzdiODdlZWUxYjQxZjNlNzMzL3RhYmxlcmFuZ2U6NjZkMmQ3ZjE3ZTRhNDc3N2I4N2VlZTFiNDFmM2U3MzNfMS0xLTEtMS0w_9dd26984-3550-4e56-9e62-5d9517b6454a"
unitRef="usd">3598000</us-gaap:InventoryRawMaterialsNetOfReserves>
<us-gaap:InventoryRawMaterialsNetOfReserves
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RhYmxlOjY2ZDJkN2YxN2U0YTQ3NzdiODdlZWUxYjQxZjNlNzMzL3RhYmxlcmFuZ2U6NjZkMmQ3ZjE3ZTRhNDc3N2I4N2VlZTFiNDFmM2U3MzNfMS0zLTEtMS0w_06b0b534-82d6-413f-8eda-6a1664daf56e"
unitRef="usd">3112000</us-gaap:InventoryRawMaterialsNetOfReserves>
<us-gaap:InventoryWorkInProcessNetOfReserves
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RhYmxlOjY2ZDJkN2YxN2U0YTQ3NzdiODdlZWUxYjQxZjNlNzMzL3RhYmxlcmFuZ2U6NjZkMmQ3ZjE3ZTRhNDc3N2I4N2VlZTFiNDFmM2U3MzNfMi0xLTEtMS0w_e69782ef-f027-4d72-afd0-b09b2aa05b69"
unitRef="usd">265000</us-gaap:InventoryWorkInProcessNetOfReserves>
<us-gaap:InventoryWorkInProcessNetOfReserves
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RhYmxlOjY2ZDJkN2YxN2U0YTQ3NzdiODdlZWUxYjQxZjNlNzMzL3RhYmxlcmFuZ2U6NjZkMmQ3ZjE3ZTRhNDc3N2I4N2VlZTFiNDFmM2U3MzNfMi0zLTEtMS0w_dc3a87a0-9cd1-4e17-af31-aad75d9eed88"
unitRef="usd">172000</us-gaap:InventoryWorkInProcessNetOfReserves>
<us-gaap:InventoryFinishedGoodsNetOfReserves
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RhYmxlOjY2ZDJkN2YxN2U0YTQ3NzdiODdlZWUxYjQxZjNlNzMzL3RhYmxlcmFuZ2U6NjZkMmQ3ZjE3ZTRhNDc3N2I4N2VlZTFiNDFmM2U3MzNfMy0xLTEtMS0w_7d654f67-888e-41b5-8bc5-58d8195dba27"
unitRef="usd">1936000</us-gaap:InventoryFinishedGoodsNetOfReserves>
<us-gaap:InventoryFinishedGoodsNetOfReserves
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RhYmxlOjY2ZDJkN2YxN2U0YTQ3NzdiODdlZWUxYjQxZjNlNzMzL3RhYmxlcmFuZ2U6NjZkMmQ3ZjE3ZTRhNDc3N2I4N2VlZTFiNDFmM2U3MzNfMy0zLTEtMS0w_9c2ec06b-7475-4b27-a698-8f58459e22c3"
unitRef="usd">1805000</us-gaap:InventoryFinishedGoodsNetOfReserves>
<rmti:CurrentAndNonCurrentInventory
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RhYmxlOjY2ZDJkN2YxN2U0YTQ3NzdiODdlZWUxYjQxZjNlNzMzL3RhYmxlcmFuZ2U6NjZkMmQ3ZjE3ZTRhNDc3N2I4N2VlZTFiNDFmM2U3MzNfNC0xLTEtMS0w_d19ab0db-3047-4466-9f20-1fe06aa9aaea"
unitRef="usd">5799000</rmti:CurrentAndNonCurrentInventory>
<rmti:CurrentAndNonCurrentInventory
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RhYmxlOjY2ZDJkN2YxN2U0YTQ3NzdiODdlZWUxYjQxZjNlNzMzL3RhYmxlcmFuZ2U6NjZkMmQ3ZjE3ZTRhNDc3N2I4N2VlZTFiNDFmM2U3MzNfNC0zLTEtMS0w_47c7ea11-7d97-423f-95a5-7c3d927532c1"
unitRef="usd">5089000</rmti:CurrentAndNonCurrentInventory>
<us-gaap:InventoryNoncurrent
contextRef="i5da195dc185f4ad2823040c5515d8512_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RleHRyZWdpb246NTAwYWVjYjNlZmQxNDlhMjkyNDhhNmVhNDEzMzEyYzFfMTQ5_35187fa1-a0c4-4efd-95d8-0f085f89511e"
unitRef="usd">1100000</us-gaap:InventoryNoncurrent>
<us-gaap:InventoryNet
contextRef="i5da195dc185f4ad2823040c5515d8512_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RleHRyZWdpb246NTAwYWVjYjNlZmQxNDlhMjkyNDhhNmVhNDEzMzEyYzFfMTA5OTUxMTYyODU4NA_b5a599da-e71f-441a-bf33-24ce68a94d1e"
unitRef="usd">1700000</us-gaap:InventoryNet>
<us-gaap:InventoryNet
contextRef="i5da195dc185f4ad2823040c5515d8512_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RleHRyZWdpb246NTAwYWVjYjNlZmQxNDlhMjkyNDhhNmVhNDEzMzEyYzFfMzg0_b5a599da-e71f-441a-bf33-24ce68a94d1e"
unitRef="usd">1700000</us-gaap:InventoryNet>
<us-gaap:InventoryFinishedGoodsNetOfReserves
contextRef="ideb44eb229184ecda8a91c6139e0d759_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RleHRyZWdpb246NTAwYWVjYjNlZmQxNDlhMjkyNDhhNmVhNDEzMzEyYzFfNDMy_6e3766b1-eae3-4c37-a0b3-10420eba094c"
unitRef="usd">300000</us-gaap:InventoryFinishedGoodsNetOfReserves>
<us-gaap:InventoryNet
contextRef="i90a1bca35c1243f08d1d94a939cef6c4_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RleHRyZWdpb246NTAwYWVjYjNlZmQxNDlhMjkyNDhhNmVhNDEzMzEyYzFfNTQy_9ba8c503-3b39-41e0-a21d-af88190b84e4"
unitRef="usd">500000</us-gaap:InventoryNet>
<us-gaap:InventoryRawMaterialsNetOfReserves
contextRef="i5da195dc185f4ad2823040c5515d8512_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV80OS9mcmFnOjUwMGFlY2IzZWZkMTQ5YTI5MjQ4YTZlYTQxMzMxMmMxL3RleHRyZWdpb246NTAwYWVjYjNlZmQxNDlhMjkyNDhhNmVhNDEzMzEyYzFfNjI0_c7f7f19e-fd33-4546-9d70-5daacc8c1885"
unitRef="usd">900000</us-gaap:InventoryRawMaterialsNetOfReserves>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RleHRyZWdpb246NWFmMDEwYTc1OWQ1NDliMThkMmFlOGI0MDFjMDk2OGRfMjA2_1620e5f4-2192-4638-b848-40800ee7ca85">Property and Equipment<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, the Company’s property and equipment consisted of the following (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold Improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,684 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,475 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information Technology &amp; Office Equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,403 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated Depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,874)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,536)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,529 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,642 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation expense for each of the three and six months ended June 30, 2021 and 2020 totaled $0.2 million and $0.4 million.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RleHRyZWdpb246NWFmMDEwYTc1OWQ1NDliMThkMmFlOGI0MDFjMDk2OGRfMjA3_85261ab7-eda9-4370-a2ef-9424f3441362"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, the Company’s property and equipment consisted of the following (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold Improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,684 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,475 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information Technology &amp; Office Equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,403 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated Depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,874)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,536)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,529 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,642 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i2b0b6f74a05044e4873509f11c7db6af_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfMS0xLTEtMS0w_811abbca-e661-4052-b777-13222caa3090"
unitRef="usd">1196000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i9d0128a643514513b686ad5149092728_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfMS0zLTEtMS0w_3295aae8-cd72-46d6-9351-3f67c4734d0c"
unitRef="usd">1196000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i465a7180dcdf4d2b801c1f4275cbdb15_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfMi0xLTEtMS0w_834f0789-ba73-4da6-bcf5-660fef558c6e"
unitRef="usd">5684000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i2878341b4b7445749e3907105900094d_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfMi0zLTEtMS0w_5395191f-3d3f-425e-a4aa-510692f2197a"
unitRef="usd">5475000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i16b1bae1038f45d8bacf79228eeb50a8_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfMy0xLTEtMS0w_df6dd156-b362-46a3-8efd-2d46d9fce2a0"
unitRef="usd">1847000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i283693a6ea47413b8d27e797fcda6960_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfMy0zLTEtMS0w_da18636a-86ae-4080-8cc2-606e6b0449cc"
unitRef="usd">1831000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i2d2310b000e944b4a1bafa95387c732b_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfNC0xLTEtMS0w_29f715fd-810d-45f5-a8b8-724397f336cb"
unitRef="usd">676000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i9904a6ff79bb4fc3884be08d20ddd455_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfNC0zLTEtMS0w_c70d495e-7823-4049-af8c-df1caa5e9a29"
unitRef="usd">676000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfNS0xLTEtMS0w_24b031c3-7770-4e77-bf18-a359bf5bc7d4"
unitRef="usd">9403000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfNS0zLTEtMS0w_a4d598a8-9f08-4c52-8872-db6fb52a7740"
unitRef="usd">9178000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfNi0xLTEtMS0w_e2838d74-bd80-4bd0-8773-a4b053253c78"
unitRef="usd">6874000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfNi0zLTEtMS0w_450a4583-821e-45af-af35-86391a9d4104"
unitRef="usd">6536000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:PropertyPlantAndEquipmentNet
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfNy0xLTEtMS0w_48c6b941-0ac1-443a-9662-d180613fcd2c"
unitRef="usd">2529000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RhYmxlOjdhYjQ4YzZmOGEyZTQ2OTViYmRkY2MxZjI1MzI0MmY3L3RhYmxlcmFuZ2U6N2FiNDhjNmY4YTJlNDY5NWJiZGRjYzFmMjUzMjQyZjdfNy0zLTEtMS0w_c3e4ea8b-4cc2-408a-b264-def6a4aca35b"
unitRef="usd">2642000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Depreciation
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RleHRyZWdpb246NWFmMDEwYTc1OWQ1NDliMThkMmFlOGI0MDFjMDk2OGRfMjAz_19d0c4bb-c338-4faa-a7cc-5cd2ee258d32"
unitRef="usd">200000</us-gaap:Depreciation>
<us-gaap:Depreciation
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RleHRyZWdpb246NWFmMDEwYTc1OWQ1NDliMThkMmFlOGI0MDFjMDk2OGRfMjAz_6b4eb4ae-2dad-4023-9bb6-c49858c044cc"
unitRef="usd">200000</us-gaap:Depreciation>
<us-gaap:Depreciation
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RleHRyZWdpb246NWFmMDEwYTc1OWQ1NDliMThkMmFlOGI0MDFjMDk2OGRfMTA5OTUxMTYyODAwMQ_20504ef2-c897-4b03-8f5f-75de9ca76d3a"
unitRef="usd">400000</us-gaap:Depreciation>
<us-gaap:Depreciation
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81Mi9mcmFnOjVhZjAxMGE3NTlkNTQ5YjE4ZDJhZThiNDAxYzA5NjhkL3RleHRyZWdpb246NWFmMDEwYTc1OWQ1NDliMThkMmFlOGI0MDFjMDk2OGRfMTA5OTUxMTYyODAwMQ_4bd33deb-d12c-429c-b50f-e6eb181211d0"
unitRef="usd">400000</us-gaap:Depreciation>
<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RleHRyZWdpb246Y2U2NWNjZWFiZDFhNDAwZWE4ODIyNDhkZjgzYWZhYjVfMTE1_baad0018-c781-4bfd-a0b4-0f94a9663498">Accrued Liabilities<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of June 30, 2021 and December 31, 2020 consisted of the following (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Research &amp; Development Expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Compensation and Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Unvouchered Receipts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Workers Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Accrued Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Accrued Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,993 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,013 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RleHRyZWdpb246Y2U2NWNjZWFiZDFhNDAwZWE4ODIyNDhkZjgzYWZhYjVfMTE2_a00b06e5-049c-427e-ad15-ee3463d298c2"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of June 30, 2021 and December 31, 2020 consisted of the following (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Research &amp; Development Expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Compensation and Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Unvouchered Receipts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Workers Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Accrued Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Accrued Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,993 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,013 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
<rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfMS0xLTEtMS0w_0d92c9e0-ac9e-406a-8e7f-d77ea6dc7e67"
unitRef="usd">315000</rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent>
<rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfMS0zLTEtMS0w_38406710-bf0e-439d-b7f2-df6f6ad747d0"
unitRef="usd">232000</rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent>
<us-gaap:EmployeeRelatedLiabilitiesCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfMi0xLTEtMS0w_c205f2fa-0119-4bc3-bc4a-1e8c2bfa9bd9"
unitRef="usd">1420000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
<us-gaap:EmployeeRelatedLiabilitiesCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfMi0zLTEtMS0w_41f97a60-40ac-4396-ba89-813ecdff7f41"
unitRef="usd">2500000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
<rmti:AccruedUnvoucheredReceiptsCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfMy0xLTEtMS0w_cbce7549-d733-4c0b-a7f6-1be076e3d43c"
unitRef="usd">647000</rmti:AccruedUnvoucheredReceiptsCurrent>
<rmti:AccruedUnvoucheredReceiptsCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfMy0zLTEtMS0w_f5a88b76-2c3a-4242-96d1-c675f833bc6b"
unitRef="usd">755000</rmti:AccruedUnvoucheredReceiptsCurrent>
<us-gaap:WorkersCompensationLiabilityCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfNC0xLTEtMS0w_db37188e-3371-4439-959c-f048781d7218"
unitRef="usd">531000</us-gaap:WorkersCompensationLiabilityCurrent>
<us-gaap:WorkersCompensationLiabilityCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfNC0zLTEtMS0w_fc9ef734-9b28-42c3-a759-e782ad0c5764"
unitRef="usd">395000</us-gaap:WorkersCompensationLiabilityCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfNS0xLTEtMS0w_db6e5b04-5d0e-4e5a-90da-0a760fa0b5b9"
unitRef="usd">1080000</us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfNS0zLTEtMS0w_6c5d13a6-7daf-447e-a390-ff8ef61931c3"
unitRef="usd">1131000</us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfNi0xLTEtMS0w_805ed2c4-21da-4e55-85d0-1f7d57ce655d"
unitRef="usd">3993000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81NS9mcmFnOmNlNjVjY2VhYmQxYTQwMGVhODgyMjQ4ZGY4M2FmYWI1L3RhYmxlOmE2ZWIxZjNjZWU0MzQxYWFiNzNkNGM5ZDBhNDJhZDNjL3RhYmxlcmFuZ2U6YTZlYjFmM2NlZTQzNDFhYWI3M2Q0YzlkMGE0MmFkM2NfNi0zLTEtMS0w_10324681-b325-44dc-8c44-fa77d32dc2fc"
unitRef="usd">5013000</us-gaap:AccruedLiabilitiesCurrent>
<rmti:ContractWithCustomerDeferredRevenueTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMzUxMw_66754270-c53d-4247-9ff2-cdaa56c21865">Deferred Revenue<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, the Company entered into the Baxter Agreement with Baxter and received an upfront fee of $20 million. The upfront fee was recorded as deferred revenue and is being recognized based on the proportion of product shipments to Baxter in each period, compared with total expected sales volume over the term of the Baxter Agreement, which expires in October 2024. The Company recognized revenue of approximately $0.5 million and $1.0 million for each of the three and six months ended June 30, 2021 and 2020. Deferred revenue related to the Baxter Agreement totaled $6.2 million as of June 30, 2021 and $7.2 million as of December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a “Refund Trigger Event” occurs under the Baxter Agreement prior to December 31, 2021, Rockwell would be obligated to repay 25% of the upfront fee.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into a distribution and license agreement with Wanbang (the "Wanbang Agreement") and received an upfront fee of $4.0 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized approximately $53,000 and $0.1 million revenue for each of the three and six months ended June 30, 2021 and 2020. Deferred revenue related to the Wanbang Agreement totaled $2.6 million as of June 30, 2021 and $2.7 million as of December 31, 2020.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company entered into license and supply agreements with Sun Pharma (the "Sun Pharma Agreements"), for the rights to commercialize Triferic (dialysate) (ferric pyrophosphate citrate) in India. Under the terms of the Sun Pharma Agreements, Sun Pharma will be the exclusive development and commercialization partner for Triferic (dialysate) in India, and the Company will supply the product to Sun Pharma. In consideration for the license, the Company received an upfront fee of $0.1 million, and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Sun Pharma, will guide the development and execution for Triferic (dialysate) in </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">India. Sun Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $2,500 and $5,000 for each of the three and six months ended June 30, 2021 and 2020. Deferred revenue related to the Sun Pharma Agreement totaled $85,000 and $90,000 as of June 30, 2021 and December 31, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into a license and supply agreements with Jeil Pharma (the "Jeil Pharma Agreements"), for the rights to commercialize Triferic (dialysate) (ferric pyrophosphate citrate) in South Korea. Under the terms of the Jeil Pharma Agreements, Jeil Pharma will be the exclusive development and commercialization partner for Triferic (dialysate) in South Korea, and the Company will supply the product to Jeil Pharma. In consideration for the license, the Company received an upfront fee of $0.2 million, and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Jeil Pharma, will guide the development and execution for Triferic (dialysate) in South Korea. Jeil Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of $2,500 and nil for the three months ended June 30, 2021 and 2020, respectively, and $5,000 and nil for the six months ended June 30, 2021 and 2020, respectively. Deferred revenue related to the Jeil Pharma Agreement totaled approximately $0.2 million as of June 30, 2021 and December 31, 2020.</span></div>In June 2021, the Company entered into license and supply agreements with Drogsan Pharma (the "Drogsan Agreements"), for the rights to commercialize Triferic (dialysate) and Triferic AVNU in Turkey. Under the terms of the Drogsan Agreements, Drogsan Pharma will be the exclusive commercialization partner for Triferic (dialysate) and Triferic AVNU in Turkey. In consideration for the license, the Company is due to receive an upfront fee of $0.2 million, and will be eligible for milestone payment and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Drogsan Pharma, will guide the execution for Triferic (dialysate) and Triferic AVNU in Turkey. Drogsan Pharma will be responsible for all regulatory approval and commercialization activities, and the Company will supply the product to Drogsan Pharma for Turkey. The upfront fee will be recorded as deferred revenue and will be recognized as revenue based on the agreement term.</rmti:ContractWithCustomerDeferredRevenueTextBlock>
<rmti:RevenueRecognitionReceived
contextRef="ib41a5b0fba4342b8a42fbf0205323776_D20141001-20141031"
decimals="-6"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTMy_4bc7bbb1-287e-443a-9c94-3818080bac73"
unitRef="usd">20000000</rmti:RevenueRecognitionReceived>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="i5a444cdf60204392ba5ee29a80d7a166_D20210401-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfNDQw_4e315e1e-523c-48e8-9f71-16846914aabc"
unitRef="usd">500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="i108ba00af91143ca9c3ed9b4e9bb5c39_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfNDQw_fbea279c-fddd-4be1-91db-24103e3ed93e"
unitRef="usd">500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="i2d78ddfa8815448196febe7de94d00ab_D20200101-20200630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTU3OA_7c0f9145-9cf9-43b0-91db-85a5ae693047"
unitRef="usd">1000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="iaeff68f2861040f5976c97fb25345bac_D20200401-20200630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTU3OA_88524e65-8868-41a7-b72e-e9b593b6bf83"
unitRef="usd">1000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiability
contextRef="iffc4d933f9f0489188683fe4b938ade0_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfNTQz_6ee70b74-92e8-404d-818c-8bf44d82cd3e"
unitRef="usd">6200000</us-gaap:ContractWithCustomerLiability>
<us-gaap:ContractWithCustomerLiability
contextRef="ib11ae81bd8164d54aefe2b07a1acc333_I20201231"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfNTU5_1ba4e6b5-e433-4297-8775-8ec9aea993de"
unitRef="usd">7200000</us-gaap:ContractWithCustomerLiability>
<rmti:ContractWithCustomerRepaymentPercentageOfUpfrontFee
contextRef="i108ba00af91143ca9c3ed9b4e9bb5c39_D20210101-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfNjk5_2e8ddfbe-3b34-4cb4-8fe1-bb6bb305b558"
unitRef="number">0.25</rmti:ContractWithCustomerRepaymentPercentageOfUpfrontFee>
<rmti:RevenueRecognitionReceived
contextRef="id44e4c40542f422392e127f7e00d1cef_D20160101-20161231"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfODYx_d267946e-e71b-45c2-8bbb-4152f4889de4"
unitRef="usd">4000000.0</rmti:RevenueRecognitionReceived>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="ia6b9801f65854970b5da63868031cd71_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTAxNg_7fec9268-3505-4d51-8c9e-f0098df71db3"
unitRef="usd">53000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="i97d0767332814c26b7040a7f42da83d7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTAxNg_d435bcb9-9f0f-4f80-93ed-d63bfc9ebffe"
unitRef="usd">53000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="i29a9d581630545e5b9d979ee4a331a36_D20200401-20200630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTMxMg_9c4de17c-5fca-46e7-a5d2-0d6ae88bf522"
unitRef="usd">100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="ib261789f13ed45118a64720f9ece6816_D20200101-20200630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTMxMg_e89191b3-414c-4673-b59e-d99dba9d9b45"
unitRef="usd">100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiability
contextRef="id1200549772a41baab582b78ceebca58_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTE0NA_36dc71fd-5add-4ae9-a410-c691f66e258f"
unitRef="usd">2600000</us-gaap:ContractWithCustomerLiability>
<us-gaap:ContractWithCustomerLiability
contextRef="ia416a305cef740509c44aa63f6654918_I20201231"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTU4NQ_68d66757-1da4-4e81-b31d-9147fc9cb64b"
unitRef="usd">2700000</us-gaap:ContractWithCustomerLiability>
<rmti:RevenueRecognitionReceived
contextRef="i7cbe96745d4a4ee7949e736eff90fddd_D20200101-20200131"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTY2Mg_de336da3-51c5-4ff3-a17c-13888fa009a1"
unitRef="usd">100000</rmti:RevenueRecognitionReceived>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="id7f108a122f849b691d34141d686f377_D20210401-20210630"
decimals="-2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMjE3MQ_7d2e66cb-4717-49ed-817b-f8e3e0cfd63f"
unitRef="usd">2500</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="i1bbf0986a8a141be81ed18c1868716dc_D20210101-20210630"
decimals="-2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMjE3MQ_8ef95ff9-a9a9-4fd3-a3ac-7e1def4220dd"
unitRef="usd">2500</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="idf5243f34d8c414c9014f13c02e11602_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTM2Mg_096c3771-41e1-48c0-90e3-0834d9a72a96"
unitRef="usd">5000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="i979ffd2d5930459a8fee1a724d668606_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTM2Mg_70e38c7a-05d6-4570-b2c9-d8e8f10b1d51"
unitRef="usd">5000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiability
contextRef="ic278353975334c0eb61849b38be42f55_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMjI3OA_b6d53acb-00b6-4725-948c-9c0fce71a999"
unitRef="usd">85000</us-gaap:ContractWithCustomerLiability>
<us-gaap:ContractWithCustomerLiability
contextRef="id1509c49ed2945d6a5a0f7728fe181ec_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMjI4NQ_34a2b2cb-206b-4ea1-ab33-b8ef3830a690"
unitRef="usd">90000</us-gaap:ContractWithCustomerLiability>
<rmti:RevenueRecognitionReceived
contextRef="i4698c56f368245e5b301c41e5ecebf1c_D20200901-20200930"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMjg1MA_456c3f16-8311-4d60-8d3b-6cc7abf90593"
unitRef="usd">200000</rmti:RevenueRecognitionReceived>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="i2deedffb02b34d8da21c7fab0fe0b691_D20210401-20210630"
decimals="-2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMzM1NA_cb1a188f-c26a-40d1-b6e5-547c93df386a"
unitRef="usd">2500</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="ie5a61d1ec2a6474a931f248906e77c43_D20200401-20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTU1Ng_2004a21c-8691-4be6-b145-0f22853cb7f2"
unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="i765972d583d94402bc7862f121892b89_D20210101-20210630"
decimals="-2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTQyOA_a38a4cb4-b792-40f3-97b9-1a93bd365080"
unitRef="usd">5000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="i4081bbacdfc8425bbf6a232aeb6f1b27_D20200101-20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMTU1OQ_2be743e9-5129-4c52-8ffd-b09df1b57d6e"
unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiability
contextRef="i3f97c0f7f55d43f9b70110bf979d68b5_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMzQ4Mw_9e6a8bf2-8a45-404d-95f6-fcc572dc7a1b"
unitRef="usd">200000</us-gaap:ContractWithCustomerLiability>
<us-gaap:ContractWithCustomerLiability
contextRef="i91bb067c41004b14ad33a703a367c7da_I20201231"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMzQ4Mw_d2807d70-407d-4cbb-8ae9-75c5f5538129"
unitRef="usd">200000</us-gaap:ContractWithCustomerLiability>
<rmti:RevenueRecognitionReceived
contextRef="i2770d871f3fc4222a123073cfdeb613a_D20210601-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV81OC9mcmFnOjI0ZmE1NTRjYWM0NTRkY2I4MjJjMGFkNDYxOGVmNzQxL3RleHRyZWdpb246MjRmYTU1NGNhYzQ1NGRjYjgyMmMwYWQ0NjE4ZWY3NDFfMTA5OTUxMTYzMzQ2NA_730cd1c5-436a-481b-83d5-24ae98ddf6ad"
unitRef="usd">200000</rmti:RevenueRecognitionReceived>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMjE4MA_b7b28c74-4c75-40cc-869a-ab463993475f">Stockholders’ Equity<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, there were 2,000,000 shares of preferred stock, $0.0001 par value per share, authorized and no shares of preferred stock issued or outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, there were 170,000,000 shares of common stock, $0.0001 par value per share, authorized and 93,811,381 and 93,573,165 shares issued and outstanding, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controlled Equity Offering (or "At the Market" Offering)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2019, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald &amp; Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time shares of the Company’s common stock through the Agent. The offering and sale of up to $40.0 million of the shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company’s registration statement on Form S-3 (File No. 333-227363), which was originally filed with the SEC on September 14, 2018 and declared effective by the SEC on October 1, 2018, the base prospectus contained within the registration statement, and a prospectus supplement that was filed with the SEC on March 22, 2019.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the shares, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an “at the market" offering as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Global Market or on any other existing trading market for the Company’s common stock. The Company intends to use the proceeds from the offering for working capital and other general corporate purposes. The Company may suspend or terminate the Sales Agreement at any time.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2021, the Company has not sold shares of its common stock pursuant to the Sales Agreement. Approximately $32.3 million remains available for sale under this facility.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not required to sell any shares at any time during the term of the facility. The Company's ability to sell common stock under the facility may be limited by several factors including, among other things, the trading volume of its common stock and certain black-out periods that the Company may impose upon the facility, among other things.</span></div></us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:PreferredStockSharesAuthorized
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfNzY_62bc4355-2069-4196-b18b-a48e01a8c0e0"
unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfNzY_e8f4baee-e419-4865-a366-176ce0976d05"
unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockParOrStatedValuePerShare
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMTA2_48110758-36a3-4fba-b07f-3dc34cc45266"
unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMTA2_7cd423d9-a265-421d-bdb2-b06c9c8575a8"
unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesOutstanding
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMTQ1_167f4111-d041-479a-8417-b6d878e85463"
unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesIssued
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMTQ1_71a51862-6047-4184-ab6a-bee6169432d9"
unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMTQ1_8075f323-d42b-4342-80e3-438304f35cc0"
unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMTQ1_97307b7e-3203-4773-b578-76c08a616b0a"
unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockSharesAuthorized
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMjM4_152e80ea-29d8-4be9-abb1-f34ed283aa45"
unitRef="shares">170000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMjM4_f50127f8-a56d-4f9b-b05d-aa6ceae50a09"
unitRef="shares">170000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockParOrStatedValuePerShare
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMjY1_486ad204-3a20-4e90-8741-da31ed26743a"
unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMjY1_ad7ba2ce-a140-4fa9-af13-4487b9c9d936"
unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesIssued
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMzA0_3a4e793a-7e20-4e0f-858a-bcff302ca30a"
unitRef="shares">93811381</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMzA0_d76d7821-aa36-4a28-9a0f-7a34bcde8250"
unitRef="shares">93811381</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesIssued
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMzEx_4cba5123-e5ae-4fb0-ba08-7e0740f0d09a"
unitRef="shares">93573165</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMzEx_5435f4b6-1e05-4ac9-8d0e-d045da6198e3"
unitRef="shares">93573165</us-gaap:CommonStockSharesOutstanding>
<rmti:SalesAgreementThresholdSaleOfShares
contextRef="ia4046492d81c4dcfbc80f8128d23a0e8_D20190322-20190322"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfNzAw_888ec7b7-9e7c-4b9e-a579-65ae590bf6f8"
unitRef="usd">40000000.0</rmti:SalesAgreementThresholdSaleOfShares>
<rmti:SaleofStockRemainingSalesAmount
contextRef="i54ebd73955be4ec087f2c3127f7aef9f_D20210401-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMTc3NA_24374772-0c4a-407c-9158-3eb1b72acc7b"
unitRef="usd">32300000</rmti:SaleofStockRemainingSalesAmount>
<rmti:SaleofStockRemainingSalesAmount
contextRef="i362afd3374074c7cada0c9ce798f3143_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82MS9mcmFnOmMyZTRiMmJmZmM3OTRjMjg5YmNmOTg1N2E4MTA2YTM5L3RleHRyZWdpb246YzJlNGIyYmZmYzc5NGMyODliY2Y5ODU3YTgxMDZhMzlfMTc3NA_dc2a5750-936c-4035-85ba-712c812e8753"
unitRef="usd">32300000</rmti:SaleofStockRemainingSalesAmount>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzg3MQ_3a5d2fd7-d22b-47df-9f8c-335423512e5b">Stock-Based Compensation<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized total stock-based compensation expense during the three and six months ended June 30, 2021 and 2020 as follows (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Service-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">422 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">332 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">917 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,010 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Performance-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(596)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,793)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(720)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,536)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">433 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,461)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">197 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(526)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s restricted stock awards during the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average <br/>Grant-Date <br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.70 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s restricted stock awards during the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,800 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of 20 months. As of June 30, 2021, unvested restricted stock awards of 78,300 were related to performance-based awards. The forfeited performance-based restricted stock awards of 68,500 was due to the termination of the Company's former Chief Science Officer on January 19, 2021. These forfeited awards reduced stock-based compensation expense by $0.4 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service-Based Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">265,494 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">310,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,474)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">342,604 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.17 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">463,786 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188,904 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(128,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">420,062 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.27 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of service based restricted stock units are measured based on their fair value on the date of grant and amortized over the vesting period. The vesting periods range from 1 to 3 years. Stock-based compensation expense of $0.1 million and $0.2 million was recognized for the three and six months ended June 30, 2021, respectively. Stock-based compensation expense of nil and $0.2 million was recognized for the three and six months ended June 30, 2020, respectively. As of June 30, 2021, the unrecognized stock-based compensation expense was $0.3 million, which is expected to be recognized over an estimated weighted average remaining term of less than 1 year. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, there were no outstanding performance-based restricted stock units.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s performance-based restricted stock units during the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:74.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.683%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988,958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(905,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,333 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service-Based Stock Options</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the service-based stock options granted for the six months ended June 30, 2021 were based on the following assumptions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.766%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.90 - $0.94</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.8% - 77.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.47% - 1.06%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 - 6</span></div></td></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based stock option activity for the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,717,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,266,553)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,695,801 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387,440 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based stock option activity for the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,210,024 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.06 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211,471)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,983,335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625,562 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809,954 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.09 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the table above is calculated as the difference between the closing price of the Company's common stock and the exercise price of the stock options that had strike prices below the closing price.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, the Company granted stock options to purchase up to 1,522,162 shares of common stock to certain employees. During the six months ended June 30, 2021, 277,764 shares were forfeited and 1,266,553 shares expired. Forfeitures are recorded in the period of occurrence; compensation expense is adjusted accordingly.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for service-based stock options was $0.3 million and $0.7 million for the three and six months ended June 30, 2021, respectively. Stock-based compensation expense recognized for service-based stock options was $0.3 million and $0.8 million for the three and six months ended June 30, 2020, respectively. As of June 30, 2021, total stock-based compensation expense related to unvested options not yet recognized totaled approximately $2.0 million, which is expected to be recognized over an estimated weighted average remaining term of 3.0 years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Stock Options</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the performance-based stock options for the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">750,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the performance-based stock options for the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">388,125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388,125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">600,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.45 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for performance-based stock options was nil and $(0.3) million for the three and six months ended June 30, 2021, respectively. Stock-based compensation expense recognized for performance-based stock options was $(0.6) million and $(0.5) million for the three and six months ended June 30, 2020, respectively. The reduction in stock-based compensation expense was due to the performance criteria of certain performance-based options granted to officers of the Company becoming non-probable as of March 31, 2021. The Company will continue to assess the probability of the performance criteria until such time the criteria becomes probable and the performance-based stock option vests or continues to be non-probable and the performance-based stock option expires. As of June 30, 2021, there was no unrecognized stock-based compensation expense related to unvested performance-based stock options.</span></div></us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzg3Mw_5da085d4-c263-448f-a7f5-156e10e4a0f5"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized total stock-based compensation expense during the three and six months ended June 30, 2021 and 2020 as follows (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Service-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">422 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">332 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">917 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,010 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Performance-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(596)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,793)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(720)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,536)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">433 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,461)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">197 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(526)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i9c4394b8322844b885708d0a121c0250_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNC0xLTEtMS0w_6a35791b-a99e-4038-9375-96aac301d4ce"
unitRef="usd">78000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i328ca3ef8e144273a05211111c192e60_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNC0zLTEtMS0w_876a058a-129a-4298-8cc2-5d5a58158f60"
unitRef="usd">-4000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNC01LTEtMS0w_b825fdce-c978-4d56-bbf4-26efb87d66a9"
unitRef="usd">182000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNC03LTEtMS0w_0f2a060a-4ea2-4cfc-9d56-51a9be35b627"
unitRef="usd">234000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="iacc309a401f7466cb3e18730470f3752_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNS0xLTEtMS0w_30924f9d-1566-4181-bdc3-7ad10b41e398"
unitRef="usd">344000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="if90c1947aa9c420f9f93f64285facd2f_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNS0zLTEtMS0w_afc8c84b-f8d2-4485-936b-63fbfd8fbfb8"
unitRef="usd">336000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNS01LTEtMS0w_389d9080-18e2-4b4d-b377-d7ef1946e588"
unitRef="usd">735000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNS03LTEtMS0w_f54167da-d042-4395-b9c1-73d3393ee3ea"
unitRef="usd">776000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i55e1c1131a084252abc713575b403ea8_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNi0xLTEtMS0w_cb6334ce-e7b7-4d7d-864d-76f5f97fd57d"
unitRef="usd">422000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="if9f58870aefd4e5f887f2aa505cf9e96_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNi0zLTEtMS0w_4b6eb81c-b509-45f1-9907-873df44daf9f"
unitRef="usd">332000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i4015b62fa1a0414b80069a233cc0d05e_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNi01LTEtMS0w_77844300-008f-4e41-913b-c4ca078b972b"
unitRef="usd">917000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i812bfc33e296453fa2415e929c6925d0_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfNi03LTEtMS0w_c5b95562-b297-447b-bb35-79c44cfcd512"
unitRef="usd">1010000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i3e0e7f5848454b9ba1e6e17804b0edc3_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfOC0xLTEtMS0w_505eaade-6c90-4226-8162-c65ebdd2def4"
unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i9e07dbab6dd248f6969e269920c504d6_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfOC0zLTEtMS0w_35a9864c-952c-44fd-9933-6e808cca1e85"
unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="if12de0f76e944b3bb7b40b44269dcce8_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfOC01LTEtMS00NTA_92483f92-ec84-485c-b171-3b95417a69d7"
unitRef="usd">-390000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i5595532179db49e29df13d2e4d7388be_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfOC03LTEtMS00NTM_849eb903-9ac3-421b-b7a1-51f133536d95"
unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="ie9c93c9caba84edd95b2548a2b744445_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfOS0xLTEtMS0w_c70e18ca-ed66-431d-868b-201228799c2e"
unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i6edb07a7cf7d4dfd9ea0c2aa04d300be_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfOS0zLTEtMS0w_813508f7-4d6f-4ca9-9ad0-a06cdbf4e780"
unitRef="usd">-1197000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="if6ebf042a7d748bc926786bbeaa6e5be_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfOS01LTEtMS0w_9a26fa64-acde-4271-93e6-0c65f224e486"
unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="ie8068b0b08b04c629bb3323c7e3c6b00_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfOS03LTEtMS0w_efdf7f6c-fcbd-4c05-ae68-d87c46d5e231"
unitRef="usd">-1025000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i233d9a246600434d8e13d460c3115a63_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTAtMS0xLTEtMA_ab68650f-2b49-45b5-b048-29d8e31f0d3a"
unitRef="usd">11000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i18efd6bca7ec4a579e596234751a12c6_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTAtMy0xLTEtMA_10cd5503-0675-426c-bb3d-b4d5e29b57f1"
unitRef="usd">-596000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="iee6f8140c1524d41888a692944254bf5_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTAtNS0xLTEtMA_03a58d4f-a790-4e90-84c2-ca8d9084fc52"
unitRef="usd">-330000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="ifeb306a8995c48b88ea62ab0a33622a3_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTAtNy0xLTEtMA_8ac6609d-860f-4006-b099-ca7d55c84c24"
unitRef="usd">-511000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="ic3796b585b2249e4a838d2e201de472f_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTEtMS0xLTEtMA_51a1ed15-a9ca-483c-9605-e7ce3d681fe5"
unitRef="usd">11000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i6f0a1cbef1614ce18f5c5d366eca4edd_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTEtMy0xLTEtMA_fc8c84c9-670a-4dc4-8eb5-bc38d39c0007"
unitRef="usd">-1793000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i08c773fc721845f790f8ef203229134d_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTEtNS0xLTEtMA_bf5e042c-83bc-49f7-a0e5-a0a2a3e9ac86"
unitRef="usd">-720000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i6519cfa82a8542f3bb0c56cb262141f8_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTEtNy0xLTEtMA_2da5bd81-22b2-4e92-baf2-d1178ce6451f"
unitRef="usd">-1536000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTItMS0xLTEtMA_aca56d81-eb8c-46e5-b827-1a66d305cc96"
unitRef="usd">433000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTItMy0xLTEtMA_9df336bf-6685-4c79-ae64-996a5d00f734"
unitRef="usd">-1461000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTItNS0xLTEtMA_48091452-789c-461f-ab5e-e959303206b0"
unitRef="usd">197000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjFhNDExNjk3NmE3YjQwNDZiNjUzZWQyNTJjZTkzYTM1L3RhYmxlcmFuZ2U6MWE0MTE2OTc2YTdiNDA0NmI2NTNlZDI1MmNlOTNhMzVfMTItNy0xLTEtMA_6526a754-1feb-4d06-b9b9-dc143608a02b"
unitRef="usd">-526000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
contextRef="i7b89ee6dba67472bb93b39369d3a62e5_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzg3NQ_61986f8a-fb4e-4de7-8a45-5cab03a232e6"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s restricted stock awards during the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average <br/>Grant-Date <br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.70 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s restricted stock awards during the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,800 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
contextRef="i9cc879ec3d384c4891fc21ec9fe0b853_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjdiYTk2NTJhMDg1MDQxZTViNmIyYTBlNDYxYzU5MDhjL3RhYmxlcmFuZ2U6N2JhOTY1MmEwODUwNDFlNWI2YjJhMGU0NjFjNTkwOGNfMS0xLTEtMS0w_b107ad9a-77f3-49fd-92d5-f3ced8949397"
unitRef="shares">146800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
contextRef="i9cc879ec3d384c4891fc21ec9fe0b853_I20201231"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjdiYTk2NTJhMDg1MDQxZTViNmIyYTBlNDYxYzU5MDhjL3RhYmxlcmFuZ2U6N2JhOTY1MmEwODUwNDFlNWI2YjJhMGU0NjFjNTkwOGNfMS0zLTEtMS0w_6c28dc03-1e9f-4c10-976a-545a0e13d4dc"
unitRef="usdPerShare">5.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
contextRef="i7b89ee6dba67472bb93b39369d3a62e5_D20210101-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjdiYTk2NTJhMDg1MDQxZTViNmIyYTBlNDYxYzU5MDhjL3RhYmxlcmFuZ2U6N2JhOTY1MmEwODUwNDFlNWI2YjJhMGU0NjFjNTkwOGNfMi0xLTEtMS0w_273a084f-8dca-4b8b-b4f0-d37f16f76d17"
unitRef="shares">68500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
contextRef="i7b89ee6dba67472bb93b39369d3a62e5_D20210101-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjdiYTk2NTJhMDg1MDQxZTViNmIyYTBlNDYxYzU5MDhjL3RhYmxlcmFuZ2U6N2JhOTY1MmEwODUwNDFlNWI2YjJhMGU0NjFjNTkwOGNfMi0zLTEtMS0w_190c347b-30e1-4f0f-bd81-38664f226fbb"
unitRef="usdPerShare">5.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
contextRef="ibf99680c33194615a4cde239ceeb4697_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjdiYTk2NTJhMDg1MDQxZTViNmIyYTBlNDYxYzU5MDhjL3RhYmxlcmFuZ2U6N2JhOTY1MmEwODUwNDFlNWI2YjJhMGU0NjFjNTkwOGNfMy0xLTEtMS0w_0808a52a-0ab7-4fb6-9a3a-e778c521a1b7"
unitRef="shares">78300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
contextRef="ibf99680c33194615a4cde239ceeb4697_I20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjdiYTk2NTJhMDg1MDQxZTViNmIyYTBlNDYxYzU5MDhjL3RhYmxlcmFuZ2U6N2JhOTY1MmEwODUwNDFlNWI2YjJhMGU0NjFjNTkwOGNfMy0zLTEtMS0w_4923da84-5a7f-4fa9-9afc-b9d2b83194f2"
unitRef="usdPerShare">5.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
contextRef="i1222c7a7994947a5bec3e3f85f308708_I20191231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmEwYjBjMDYzYmU4NjQ2NGViYzNmMDliYzk1NzE2NGI2L3RhYmxlcmFuZ2U6YTBiMGMwNjNiZTg2NDY0ZWJjM2YwOWJjOTU3MTY0YjZfMS0xLTEtMS0w_6c14b041-b620-4d03-b55b-d2aba8fcb3b3"
unitRef="shares">146800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
contextRef="i1222c7a7994947a5bec3e3f85f308708_I20191231"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmEwYjBjMDYzYmU4NjQ2NGViYzNmMDliYzk1NzE2NGI2L3RhYmxlcmFuZ2U6YTBiMGMwNjNiZTg2NDY0ZWJjM2YwOWJjOTU3MTY0YjZfMS0zLTEtMS0w_5e91d110-4f15-4a7a-8522-c0709adb183d"
unitRef="usdPerShare">5.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
contextRef="i3a4f48e172c544ae980c5a5322bd7e1b_I20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmEwYjBjMDYzYmU4NjQ2NGViYzNmMDliYzk1NzE2NGI2L3RhYmxlcmFuZ2U6YTBiMGMwNjNiZTg2NDY0ZWJjM2YwOWJjOTU3MTY0YjZfMi0xLTEtMS0w_8a27c1ca-5c4a-4141-9fba-54f22fc48ad6"
unitRef="shares">146800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
contextRef="i3a4f48e172c544ae980c5a5322bd7e1b_I20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmEwYjBjMDYzYmU4NjQ2NGViYzNmMDliYzk1NzE2NGI2L3RhYmxlcmFuZ2U6YTBiMGMwNjNiZTg2NDY0ZWJjM2YwOWJjOTU3MTY0YjZfMi0zLTEtMS0w_88d1c15c-a0d6-4d6d-b37f-37c96321e3ea"
unitRef="usdPerShare">5.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
contextRef="i7b89ee6dba67472bb93b39369d3a62e5_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfNTI1_884864ad-a075-46f4-a931-0bd9a525c077">P20M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
contextRef="i23d7d82cf9a64899b7f1206eabcb09ba_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfNTc1_c51633a5-5144-4d84-84e3-ddf6da2e1778"
unitRef="shares">78300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
contextRef="if12de0f76e944b3bb7b40b44269dcce8_D20210101-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfNjc5_a735fbac-ef4b-40ef-9011-ac4e58597ead"
unitRef="shares">68500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="if12de0f76e944b3bb7b40b44269dcce8_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfODQy_47fd8410-7beb-42e8-907f-eeb3d6500ffb"
unitRef="usd">-400000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzg3Nw_fb23aa0e-70fd-4de9-910f-e73528b62342"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">265,494 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">310,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,474)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">342,604 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.17 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">463,786 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188,904 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(128,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">420,062 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.27 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
contextRef="i1dc167d328cb46c68fb83fa95a614259_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfMS0xLTEtMS0w_f0764a00-55be-415e-8585-0b09785c4bd4"
unitRef="shares">265494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
contextRef="i1dc167d328cb46c68fb83fa95a614259_I20201231"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfMS0zLTEtMS0w_653f3942-2134-4281-8a89-56cfa45e5b07"
unitRef="usdPerShare">2.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfMi0xLTEtMS0w_d06ea749-728b-41e1-8a74-804748c9eb97"
unitRef="shares">310050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfMi0zLTEtMS0w_e14c3b85-848b-4f2e-905c-c9ee0a4c5193"
unitRef="usdPerShare">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfMy0xLTEtMS0w_d9a5357f-30d7-43a4-93b7-915b20809ecb"
unitRef="shares">221474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfMy0zLTEtMS0w_4fa6cc92-6319-4179-9ac3-90a3c0c61473"
unitRef="usdPerShare">2.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfNC0xLTEtMS0w_e36ebadb-47f4-4649-be91-d6cfe0314c48"
unitRef="shares">11466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfNC0zLTEtMS0w_3df7b176-ff46-4fec-b7e7-541a608991c4"
unitRef="usdPerShare">4.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
contextRef="i59ed53d4977e452abe904ab6ebf547cb_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfNS0xLTEtMS0w_d2e45a96-28ce-4515-9573-8593db34f2ce"
unitRef="shares">342604</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
contextRef="i59ed53d4977e452abe904ab6ebf547cb_I20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRjMTZhZTQ1MWQ3MTQ0YzI4NmM4NmY3NzgyM2E5N2Y5L3RhYmxlcmFuZ2U6NGMxNmFlNDUxZDcxNDRjMjg2Yzg2Zjc3ODIzYTk3ZjlfNS0zLTEtMS0w_a5789090-14d2-4b97-b9bf-922d9ded04d9"
unitRef="usdPerShare">1.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
contextRef="iccc11aef27a949598168c7e139f011cf_I20191231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfMS0xLTEtMS0w_543922af-314c-4a5b-a02a-2a7a35efef7a"
unitRef="shares">463786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
contextRef="iccc11aef27a949598168c7e139f011cf_I20191231"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfMS0zLTEtMS0w_234e3206-b027-430c-bd88-150d16e854b3"
unitRef="usdPerShare">4.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
contextRef="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfMi0xLTEtMS0w_3b9ec95e-0d3e-4ec5-a1e6-1b9eba39f27c"
unitRef="shares">188904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
contextRef="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfMi0zLTEtMS0w_4913ba05-4dc7-4a4b-a639-d687162fa572"
unitRef="usdPerShare">2.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
contextRef="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfMy0xLTEtMS0xMjg5_f15c0f94-51ef-41d4-b96b-af90178edced"
unitRef="shares">104168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
contextRef="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfMy0zLTEtMS0xMjkx_bdfbb436-c7ce-4926-a17e-6b36a9688f9d"
unitRef="usdPerShare">4.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
contextRef="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfMy0xLTEtMS0w_8f46d13c-7f62-48e7-8614-11d0a2600cdf"
unitRef="shares">128460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
contextRef="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfMy0zLTEtMS0w_2e782ee8-482e-439c-90e7-156a2bb84229"
unitRef="usdPerShare">4.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
contextRef="i8e71868a215c4613b29c948c789638c1_I20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfNS0xLTEtMS0w_9ab87971-624f-4442-a0f8-f163f5c32d36"
unitRef="shares">420062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
contextRef="i8e71868a215c4613b29c948c789638c1_I20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk1YmY0NWU4ZWU1ZTRjMjJhNWQ2ZjAyZTQyNTI0Y2ZlL3RhYmxlcmFuZ2U6OTViZjQ1ZThlZTVlNGMyMmE1ZDZmMDJlNDI1MjRjZmVfNS0zLTEtMS0w_13da3fcc-9770-4501-b37a-a22774ced044"
unitRef="usdPerShare">3.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
contextRef="id2bc1e2e4f8f4649bbe2dfd466d3ec82_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTI5MQ_95dc62bf-d737-4dd2-a0ca-e9f0d204e4bb">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
contextRef="i6f366d79a6c6435a80da6fa75f516bb1_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTI5Nw_389fb1e6-9c33-43b2-be8e-75a5072e6a98">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i9c4394b8322844b885708d0a121c0250_D20210401-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTMzNw_f71d4aa2-32f5-4328-b1d8-c1ded2dc1ca7"
unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjc2NQ_fcb7ff8b-04e1-4727-896a-d03c5a3d0b1b"
unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i328ca3ef8e144273a05211111c192e60_D20200401-20200630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjc0Nw_29e4d686-0e03-4aff-8ae9-c3f828437070"
unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="iecce8b7afa4e4660bf912cdfe6c6cd9a_D20200101-20200630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjc2Mg_54872d54-6694-4b0e-9c70-90b4614edba7"
unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
contextRef="i59ed53d4977e452abe904ab6ebf547cb_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTQ3OA_2c174135-6fa1-47af-83ac-a0edac010157"
unitRef="usd">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
contextRef="ie24ebd13cffd43289817d870b633a38b_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTU4MA_72baed2e-4a37-4595-97ca-e5d3d6e2d30a">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
contextRef="i9d18ac7044704140bef4ab937ea9ab1d_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTY1OQ_96c8ad52-b259-4220-8049-482a6b37feb6"
unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
contextRef="if6ebf042a7d748bc926786bbeaa6e5be_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzg3OA_68f2179d-8fc2-4c8d-ad15-466520e5389a"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s performance-based restricted stock units during the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:74.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.683%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988,958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(905,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,333 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
contextRef="i3c44b152081048d6b3e5aa2d27e30992_I20191231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjQzMjRjODM4NGVjMzRmNTlhNDM4MzEzNjMxMTVmYWRhL3RhYmxlcmFuZ2U6NDMyNGM4Mzg0ZWMzNGY1OWE0MzgzMTM2MzExNWZhZGFfMS0xLTEtMS0w_f2b31ea8-f346-47ad-81e6-7c0c51cb4061"
unitRef="shares">988958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
contextRef="i3c44b152081048d6b3e5aa2d27e30992_I20191231"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjQzMjRjODM4NGVjMzRmNTlhNDM4MzEzNjMxMTVmYWRhL3RhYmxlcmFuZ2U6NDMyNGM4Mzg0ZWMzNGY1OWE0MzgzMTM2MzExNWZhZGFfMS0zLTEtMS0w_929fe22e-b19b-46f4-a513-2bbf5a2ce904"
unitRef="usdPerShare">4.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
contextRef="ie8068b0b08b04c629bb3323c7e3c6b00_D20200101-20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjQzMjRjODM4NGVjMzRmNTlhNDM4MzEzNjMxMTVmYWRhL3RhYmxlcmFuZ2U6NDMyNGM4Mzg0ZWMzNGY1OWE0MzgzMTM2MzExNWZhZGFfMi0xLTEtMS0zOTY_49450206-e6be-44d2-96b4-631e4941e92f"
unitRef="shares">905625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
contextRef="ie8068b0b08b04c629bb3323c7e3c6b00_D20200101-20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjQzMjRjODM4NGVjMzRmNTlhNDM4MzEzNjMxMTVmYWRhL3RhYmxlcmFuZ2U6NDMyNGM4Mzg0ZWMzNGY1OWE0MzgzMTM2MzExNWZhZGFfMi0zLTEtMS0zOTI_316ce931-cf13-4e55-ae3e-cf3dd3f9ffcb"
unitRef="usdPerShare">4.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
contextRef="icd51c0a0b5b34333bd95586be0b8d818_I20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjQzMjRjODM4NGVjMzRmNTlhNDM4MzEzNjMxMTVmYWRhL3RhYmxlcmFuZ2U6NDMyNGM4Mzg0ZWMzNGY1OWE0MzgzMTM2MzExNWZhZGFfMi0xLTEtMS0w_1de5d4e8-095a-46f4-b399-d55d31cbde62"
unitRef="shares">83333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
contextRef="icd51c0a0b5b34333bd95586be0b8d818_I20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjQzMjRjODM4NGVjMzRmNTlhNDM4MzEzNjMxMTVmYWRhL3RhYmxlcmFuZ2U6NDMyNGM4Mzg0ZWMzNGY1OWE0MzgzMTM2MzExNWZhZGFfMi0zLTEtMS0w_b85a8bb7-ce3c-41d2-a1ef-1f6f02c8d344"
unitRef="usdPerShare">3.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzg3OQ_4af89ee6-f909-42b4-8537-7c37ad13e331"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the service-based stock options granted for the six months ended June 30, 2021 were based on the following assumptions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.766%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.90 - $0.94</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.8% - 77.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.47% - 1.06%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 - 6</span></div></td></tr></table></div></us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
contextRef="i377ec7f50aff44afbeea1a0fddf83054_I20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmU3N2ZlZmExMDU3NDQ1NzZhMWMwZWZjMjM5OTUwMDk2L3RhYmxlcmFuZ2U6ZTc3ZmVmYTEwNTc0NDU3NmExYzBlZmMyMzk5NTAwOTZfMS0xLTEtMS0wL3RleHRyZWdpb246MDViYzk3NGIyMjBmNGQ5Njk3NGQ3ZjAxYzdlYzEyMGNfNA_eece4baa-547a-4048-8faa-2e368eab27c8"
unitRef="usdPerShare">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
contextRef="i4500479b46394800b4b9f21530bd9449_I20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmU3N2ZlZmExMDU3NDQ1NzZhMWMwZWZjMjM5OTUwMDk2L3RhYmxlcmFuZ2U6ZTc3ZmVmYTEwNTc0NDU3NmExYzBlZmMyMzk5NTAwOTZfMS0xLTEtMS0wL3RleHRyZWdpb246MDViYzk3NGIyMjBmNGQ5Njk3NGQ3ZjAxYzdlYzEyMGNfOQ_cdd98a64-d464-4c9f-a124-195eb5c822aa"
unitRef="usdPerShare">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmU3N2ZlZmExMDU3NDQ1NzZhMWMwZWZjMjM5OTUwMDk2L3RhYmxlcmFuZ2U6ZTc3ZmVmYTEwNTc0NDU3NmExYzBlZmMyMzk5NTAwOTZfMi0xLTEtMS0wL3RleHRyZWdpb246Y2NmYzNhZjE5MTI3NGI2ZjhhOWY4ZDEyODhhZGIwMWNfNA_b3c7343a-8ff5-4666-ac2e-a189076f90ed"
unitRef="number">0.758</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmU3N2ZlZmExMDU3NDQ1NzZhMWMwZWZjMjM5OTUwMDk2L3RhYmxlcmFuZ2U6ZTc3ZmVmYTEwNTc0NDU3NmExYzBlZmMyMzk5NTAwOTZfMi0xLTEtMS0wL3RleHRyZWdpb246Y2NmYzNhZjE5MTI3NGI2ZjhhOWY4ZDEyODhhZGIwMWNfOQ_622054ec-b591-47f7-a889-c64d3e65d0ff"
unitRef="number">0.777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
decimals="4"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmU3N2ZlZmExMDU3NDQ1NzZhMWMwZWZjMjM5OTUwMDk2L3RhYmxlcmFuZ2U6ZTc3ZmVmYTEwNTc0NDU3NmExYzBlZmMyMzk5NTAwOTZfMy0xLTEtMS0wL3RleHRyZWdpb246ODIyZjdiMjRlMTU5NGUzNmFkOTA0ZWMxNWUyYTI5OTJfNA_2dd4eca2-bc76-497a-9440-3eb4dbaee573"
unitRef="number">0.0047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
decimals="4"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmU3N2ZlZmExMDU3NDQ1NzZhMWMwZWZjMjM5OTUwMDk2L3RhYmxlcmFuZ2U6ZTc3ZmVmYTEwNTc0NDU3NmExYzBlZmMyMzk5NTAwOTZfMy0xLTEtMS0wL3RleHRyZWdpb246ODIyZjdiMjRlMTU5NGUzNmFkOTA0ZWMxNWUyYTI5OTJfOQ_bba957b5-d899-4e6a-bb57-273caec01a08"
unitRef="number">0.0106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
contextRef="i387b50c6a04b446ea4adc3f7f089a489_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmU3N2ZlZmExMDU3NDQ1NzZhMWMwZWZjMjM5OTUwMDk2L3RhYmxlcmFuZ2U6ZTc3ZmVmYTEwNTc0NDU3NmExYzBlZmMyMzk5NTAwOTZfNC0xLTEtMS0wL3RleHRyZWdpb246NjU2ZDRkNTNlYzNjNDc4ZmJjNDgwMGExNWMxN2IwM2ZfMTA5OTUxMTYyNzgxMg_b84156de-8903-43dd-b5fe-4576d078c220">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
contextRef="ib0d53e2aa30e4cb2be00af8ad6ff6d23_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmU3N2ZlZmExMDU3NDQ1NzZhMWMwZWZjMjM5OTUwMDk2L3RhYmxlcmFuZ2U6ZTc3ZmVmYTEwNTc0NDU3NmExYzBlZmMyMzk5NTAwOTZfNC0xLTEtMS0wL3RleHRyZWdpb246NjU2ZDRkNTNlYzNjNDc4ZmJjNDgwMGExNWMxN2IwM2ZfMTA5OTUxMTYyNzgwOA_f9ce8cdf-6623-49b4-8654-2dd48cda2342">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzg2OQ_dfe4b8e5-9337-40e9-bf4e-e88c1d30ea21"><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based stock option activity for the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,717,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,266,553)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,695,801 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387,440 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based stock option activity for the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,210,024 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.06 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211,471)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,983,335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625,562 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809,954 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.09 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
contextRef="ie590926897c544debd71e35ba26b6cb4_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfMS0xLTEtMS0w_371e000a-c4c7-4d1b-b921-1cd2674c3d45"
unitRef="shares">5717956</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
contextRef="ie590926897c544debd71e35ba26b6cb4_I20201231"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfMS0zLTEtMS0w_fbfae166-54ae-4b37-b2f9-e51a46b3c071"
unitRef="usdPerShare">4.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
contextRef="i6070dee6d0e0457e9691825bf5ba3091_D20200101-20201231"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfMS01LTEtMS0w_7e98bcaf-c9df-4fa9-9bf6-56572be088c2">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
contextRef="ie590926897c544debd71e35ba26b6cb4_I20201231"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfMS03LTEtMS0w_3727571f-a5e1-4cd2-8d2d-b75978d1fe25"
unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfMi0xLTEtMS0w_021db2ae-5b21-4836-82f5-5aab4cf48f4f"
unitRef="shares">1522162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfMi0zLTEtMS0w_661cf7a7-1246-4f42-9aa7-6e9e7ff518ce"
unitRef="usdPerShare">0.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<rmti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfMi01LTEtMS0w_df986edd-c382-4505-a0a1-88eff66874c5">P6Y</rmti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfNC0xLTEtMS0w_44627861-a2ca-4b4a-ae9e-e10c56f45de0"
unitRef="shares">277764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfNC0zLTEtMS0w_89a397d9-e8b1-4e51-85f1-aa9785c6930e"
unitRef="usdPerShare">2.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfNS0xLTEtMS0w_0465d5b5-249a-49a8-9d42-40b978f797dc"
unitRef="shares">1266553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfNS0zLTEtMS0w_3f21ff73-b334-4646-b4cd-70ed83f26a16"
unitRef="usdPerShare">7.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
contextRef="i72d3d3d7938c411bb6ffd58511f24608_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfNi0xLTEtMS0w_5171e05f-6b57-40d7-bd40-3e7b954bb2d1"
unitRef="shares">5695801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
contextRef="i72d3d3d7938c411bb6ffd58511f24608_I20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfNi0zLTEtMS0w_e35a51c8-de51-4e7e-9ad4-7019b6d4f8cb"
unitRef="usdPerShare">3.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfNi01LTEtMS0w_ed5a06c9-9566-46b8-9664-ae008fb7fdf9">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
contextRef="i72d3d3d7938c411bb6ffd58511f24608_I20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfNi03LTEtMS0w_ed1b6416-3ad9-4a66-92ba-fc35be4151be"
unitRef="usd">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
contextRef="i72d3d3d7938c411bb6ffd58511f24608_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfOC0xLTEtMS0w_abad6964-0ce0-4c93-ab49-6cb05337456c"
unitRef="shares">2387440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
contextRef="i72d3d3d7938c411bb6ffd58511f24608_I20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfOC0zLTEtMS0w_158e19cf-b496-4fea-8129-e29e130746ff"
unitRef="usdPerShare">5.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfOC01LTEtMS0w_0c921ccc-2bc5-40e9-9631-f962d45af39b">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
contextRef="i72d3d3d7938c411bb6ffd58511f24608_I20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmIxNzNkOTBjMWMyZTQ4YzA4ZDc2YzBhOGYwMzk2ZWJmL3RhYmxlcmFuZ2U6YjE3M2Q5MGMxYzJlNDhjMDhkNzZjMGE4ZjAzOTZlYmZfOC03LTEtMS0w_361ed554-3593-4a54-a46a-f8ab6d6e1a39"
unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
contextRef="ic639b26ebf744397b60970c46c3ac479_I20191231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMS0xLTEtMS0w_e99e5729-1a03-43b9-baf3-f72281dafd1a"
unitRef="shares">8210024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
contextRef="ic639b26ebf744397b60970c46c3ac479_I20191231"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMS0zLTEtMS0w_10041f8f-a72d-4c1d-a0ce-daab712c5dae"
unitRef="usdPerShare">7.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
contextRef="i5c8dbaa25e2e4cac985ded30596cdaae_D20190101-20191231"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMS01LTEtMS0w_6d10a215-ab96-4565-91f3-b16bd62f55d7">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
contextRef="ic639b26ebf744397b60970c46c3ac479_I20191231"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMS03LTEtMS0w_93f85c2a-4336-4da6-93bb-3df2d0f3312e"
unitRef="usd">107000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMi0xLTEtMS0w_836c1881-24e1-4613-be9e-603fc9274951"
unitRef="shares">1610344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMi0zLTEtMS0w_8b8d9f66-311f-4a08-84fd-f754577c082f"
unitRef="usdPerShare">2.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<rmti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2
contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMi01LTEtMS0w_d4f6cdeb-0668-495f-9ada-0779ca2a219d">P5Y10M24D</rmti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMy0xLTEtMS0w_9ab6ac57-babd-4db5-b715-13ddc9aa6179"
unitRef="shares">211471</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfMy0zLTEtMS0w_26879a60-806b-410d-b777-761dd9fdfe19"
unitRef="usdPerShare">4.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNC0xLTEtMS0w_b56d98aa-f009-45b5-9fa0-73da7d9ce0fe"
unitRef="shares">3983335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNC0zLTEtMS0w_e91bc0dd-07ab-4e89-8982-a1910a4b321d"
unitRef="usdPerShare">8.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
contextRef="if7b50de406504a1199ae8a1f61a650ac_I20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNS0xLTEtMS0w_3caef057-42f1-4427-8083-9a9217dd9a1d"
unitRef="shares">5625562</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
contextRef="if7b50de406504a1199ae8a1f61a650ac_I20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNS0zLTEtMS0w_a69a3055-7a90-4e25-8b99-005edfca8208"
unitRef="usdPerShare">4.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNS01LTEtMS0w_35d1128f-f13a-457e-b480-6e995bb1bcc7">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
contextRef="if7b50de406504a1199ae8a1f61a650ac_I20200630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNS03LTEtMS0w_fd3dc108-8f81-4d84-92ed-e9b7b4f988d0"
unitRef="usd">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
contextRef="if7b50de406504a1199ae8a1f61a650ac_I20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNy0xLTEtMS0w_cdeba98f-2a89-4c58-8369-67667f65355b"
unitRef="shares">2809954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
contextRef="if7b50de406504a1199ae8a1f61a650ac_I20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNy0zLTEtMS0w_1c0b515d-c6b4-4728-b52a-6c9cd5736c99"
unitRef="usdPerShare">7.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNy01LTEtMS0w_1d9fa65c-a2fa-48c4-835a-a213ad7051fa">P4Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
contextRef="if7b50de406504a1199ae8a1f61a650ac_I20200630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOmQ4Njc5MjVjYTgwNTQ0Y2FiNDRkMjFlNzkwMDFlMzE5L3RhYmxlcmFuZ2U6ZDg2NzkyNWNhODA1NDRjYWI0NGQyMWU3OTAwMWUzMTlfNy03LTEtMS0w_39f85771-1df9-4478-8dc4-c3f0f496c52f"
unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMjQwMA_b5fb59e1-e8ca-4950-98d0-210b82c84260"
unitRef="shares">1522162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMjQ3OQ_45dc030b-14da-4ad7-8132-6bfefc2d9eef"
unitRef="shares">277764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMTk4MQ_9fe566cc-63fc-4ef1-b78a-9aac1b8b776c"
unitRef="shares">1266553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="iacc309a401f7466cb3e18730470f3752_D20210401-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMjY4NQ_3bf9518e-0817-4466-b2cb-065c946a3b4b"
unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjE5NA_625497e7-b1d0-46cb-9ac0-5444c0870590"
unitRef="usd">700000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="if90c1947aa9c420f9f93f64285facd2f_D20200401-20200630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjE3Nw_eb1e7513-8473-4929-9882-26872020edb3"
unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="ib0f20bc9b3004af0b9a6c438a6880e8f_D20200101-20200630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjE4MQ_7f33b720-ac37-4040-a0ee-39bdf2e540da"
unitRef="usd">800000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
contextRef="i72d3d3d7938c411bb6ffd58511f24608_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMjg1MA_9b6ffc53-b659-4015-948a-61ba1d3e5128"
unitRef="usd">2000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
contextRef="ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMjk0Mg_c69c5d1d-552f-4ceb-953c-5528e9c524c0">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
contextRef="iee6f8140c1524d41888a692944254bf5_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzg3MA_52d467ec-9eeb-42f0-85b5-de1d76d2aa6b"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the performance-based stock options for the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">750,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the performance-based stock options for the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">388,125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388,125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">600,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.45 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
contextRef="i12f2cce783ab4aa19f82d7776112d561_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRkYmY1ODhlMmU0ZjRhOTFiMjFjNjFjNjQxM2ZlMzBjL3RhYmxlcmFuZ2U6NGRiZjU4OGUyZTRmNGE5MWIyMWM2MWM2NDEzZmUzMGNfMS0xLTEtMS0w_3c813b48-c172-4c77-a4fa-8f94139b418e"
unitRef="shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
contextRef="i12f2cce783ab4aa19f82d7776112d561_I20201231"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRkYmY1ODhlMmU0ZjRhOTFiMjFjNjFjNjQxM2ZlMzBjL3RhYmxlcmFuZ2U6NGRiZjU4OGUyZTRmNGE5MWIyMWM2MWM2NDEzZmUzMGNfMS0zLTEtMS0w_2ad77d51-83b3-4188-acc6-e12c51c3dd7f"
unitRef="usdPerShare">2.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
contextRef="iee6f8140c1524d41888a692944254bf5_D20210101-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRkYmY1ODhlMmU0ZjRhOTFiMjFjNjFjNjQxM2ZlMzBjL3RhYmxlcmFuZ2U6NGRiZjU4OGUyZTRmNGE5MWIyMWM2MWM2NDEzZmUzMGNfMy0xLTEtMS0w_78d29313-92d0-48c8-b45c-37466e7f9f27"
unitRef="shares">375000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
contextRef="iee6f8140c1524d41888a692944254bf5_D20210101-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRkYmY1ODhlMmU0ZjRhOTFiMjFjNjFjNjQxM2ZlMzBjL3RhYmxlcmFuZ2U6NGRiZjU4OGUyZTRmNGE5MWIyMWM2MWM2NDEzZmUzMGNfMy0zLTEtMS0w_21e9640f-1d1f-45fc-b879-ec487393d30f"
unitRef="usdPerShare">2.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
contextRef="i218c5ca968e448d4951556a9ac1e5e79_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRkYmY1ODhlMmU0ZjRhOTFiMjFjNjFjNjQxM2ZlMzBjL3RhYmxlcmFuZ2U6NGRiZjU4OGUyZTRmNGE5MWIyMWM2MWM2NDEzZmUzMGNfNC0xLTEtMS0w_230d6850-02bf-4d34-9224-445ceba70642"
unitRef="shares">375000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
contextRef="i218c5ca968e448d4951556a9ac1e5e79_I20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRkYmY1ODhlMmU0ZjRhOTFiMjFjNjFjNjQxM2ZlMzBjL3RhYmxlcmFuZ2U6NGRiZjU4OGUyZTRmNGE5MWIyMWM2MWM2NDEzZmUzMGNfNC0zLTEtMS0w_0afb7cb6-3e08-4f97-b8df-04a233be9989"
unitRef="usdPerShare">2.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
contextRef="i218c5ca968e448d4951556a9ac1e5e79_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRkYmY1ODhlMmU0ZjRhOTFiMjFjNjFjNjQxM2ZlMzBjL3RhYmxlcmFuZ2U6NGRiZjU4OGUyZTRmNGE5MWIyMWM2MWM2NDEzZmUzMGNfNi0xLTEtMS0w_be313203-4127-4557-be57-7dd799a11d9c"
unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
contextRef="i218c5ca968e448d4951556a9ac1e5e79_I20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjRkYmY1ODhlMmU0ZjRhOTFiMjFjNjFjNjQxM2ZlMzBjL3RhYmxlcmFuZ2U6NGRiZjU4OGUyZTRmNGE5MWIyMWM2MWM2NDEzZmUzMGNfNi0zLTEtMS0w_3eed733f-b0fb-402c-87df-3a56bc8e4380"
unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
contextRef="if5a5a222803a4f01af33dfbbd4edd90e_I20191231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfMS0xLTEtMS0w_e4c05daa-9d05-4c93-8cb6-2104e30b4ff8"
unitRef="shares">388125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
contextRef="if5a5a222803a4f01af33dfbbd4edd90e_I20191231"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfMS0zLTEtMS0w_94c83234-f461-4f2f-ace6-ab29168ae3e4"
unitRef="usdPerShare">4.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
contextRef="ifeb306a8995c48b88ea62ab0a33622a3_D20200101-20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfMi0xLTEtMS0xOTc_875383f9-f87c-44d7-b5ad-a326b0818432"
unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
contextRef="ifeb306a8995c48b88ea62ab0a33622a3_D20200101-20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfMi0zLTEtMS0yMDM_c568b736-eddd-4d4f-b923-85e024732361"
unitRef="usdPerShare">2.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
contextRef="ifeb306a8995c48b88ea62ab0a33622a3_D20200101-20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfMy0xLTEtMS0yMDA_df607c12-6f1e-4883-a3a7-65bd59d37f32"
unitRef="shares">388125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
contextRef="ifeb306a8995c48b88ea62ab0a33622a3_D20200101-20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfMy0zLTEtMS0yMDY_760d569c-ea69-4b7f-8c2f-f3f04ac77ded"
unitRef="usdPerShare">4.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
contextRef="icbc5ecc328954a549da54b7fbbe4c241_I20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfMi0xLTEtMS0w_ed08f69e-8df5-488f-9597-29371cfbfa4c"
unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
contextRef="icbc5ecc328954a549da54b7fbbe4c241_I20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfMi0zLTEtMS0w_676215b0-5aaa-45c9-8040-07db5e529cb4"
unitRef="usdPerShare">2.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
contextRef="icbc5ecc328954a549da54b7fbbe4c241_I20200630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfNC0xLTEtMS0w_e55934ec-8671-447f-a9de-47714cf99c01"
unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
contextRef="icbc5ecc328954a549da54b7fbbe4c241_I20200630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RhYmxlOjk3YWJiYmVjODFjMjRiMTk4Y2M4ZWQyYjAwNTM1MjZkL3RhYmxlcmFuZ2U6OTdhYmJiZWM4MWMyNGIxOThjYzhlZDJiMDA1MzUyNmRfNC0zLTEtMS0w_ddd02e81-6cd9-4bf7-8c98-f76b25fe8540"
unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i233d9a246600434d8e13d460c3115a63_D20210401-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzI0OA_0fa36eb2-3583-4c98-803a-60d3e17ba0d0"
unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="iee6f8140c1524d41888a692944254bf5_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjM3Mg_bad4c733-e399-4d46-bb48-263f28cdb622"
unitRef="usd">-300000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i18efd6bca7ec4a579e596234751a12c6_D20200401-20200630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjM2Mg_1dfada43-fe7e-4d49-96aa-2707719c0929"
unitRef="usd">-600000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="ifeb306a8995c48b88ea62ab0a33622a3_D20200101-20200630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMTA5OTUxMTYzMjM2Ng_13643632-10c4-49c8-9df6-f9c5af995376"
unitRef="usd">-500000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
contextRef="i218c5ca968e448d4951556a9ac1e5e79_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82NC9mcmFnOmEwZjJjOTVlZTBiYjQ4MzI4NDI4YjFjMmEzNjY3NzZkL3RleHRyZWdpb246YTBmMmM5NWVlMGJiNDgzMjg0MjhiMWMyYTM2Njc3NmRfMzc2OA_0fe8c554-3ac5-44d4-ba93-844100d56338"
unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:CollaborativeArrangementDisclosureTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfNTM1NQ_957437c0-5327-465b-b720-592341f32d25">Licensing Agreements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product License Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to a Licensing Agreement with Charak, LLC ("Charak") dated January 7, 2002 (the "2002 Agreement") that grants the Company exclusive worldwide rights to certain patents and information related to our Triferic® product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the “Charak MSA”) with Charak and Dr. Ajay Gupta, a former Officer of the Company. Pursuant to the MSA, the parties entered into three additional agreements described below related to the license of certain soluble ferric pyrophosphate (“SFP”) intellectual property owned by Charak. The Charak MSA provided for a payment of $1.0 million to Dr. Gupta, payable in four quarterly installments of $250,000 each on October 15, 2018, January 15, 2019, April 15, 2019 and July 15, 2019, and reimbursement for certain legal fees incurred in connection with the Charak MSA. The Company paid all four of the quarterly installments totaling $1.0 million and accrued $0.1 million for the reimbursement of certain legal expenses during the year ended December 31, 2019. As of December 31, 2020, the Company had fulfilled its reimbursement obligation of certain legal expenses. As of June 30, 2021, the Company accrued $0.2 million relating to certain IP reimbursement expenses and certain sublicense royalty fees within accrued liabilities on the condensed consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Charak MSA, the aforementioned parties entered into an Amendment, dated as of October 7, 2018 (the “Charak Amendment”), to the 2002 Agreement, under which Charak granted the Company an exclusive, worldwide, non-transferable license to commercialize SFP for the treatment of patients with renal failure. The Charak Amendment amends the royalty payments due to Charak under the 2002 Agreement such that the Company is liable to pay Charak royalties on net sales </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by the Company of products developed under the license, which includes the Company’s Triferic® product, at a specified rate until December 31, 2021 and thereafter at a reduced rate from January 1, 2022 until February 1, 2034. Additionally, the Company shall pay Charak a percentage of any sublicense income during the term of the agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and be no less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Charak MSA, the Company and Charak entered into a Commercialization and Technology License Agreement I.V. Triferic® (now Triferic AVNU), dated as of October 7, 2018 (the “IV Agreement”), under which Charak granted the Company an exclusive, sub-licensable, royalty-bearing license to SFP for the purpose of commercializing certain intravenous-delivered products incorporating SFP for the treatment of iron disorders worldwide for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. The Company is liable to pay Charak royalties on net sales by the Company of products developed under the license at a specified rate until December 31, 2021. From January 1, 2022 until February 1, 2034, the Company is liable to pay Charak a base royalty at a reduced rate on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the IV Agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Charak MSA, the Company and Charak entered into a Technology License Agreement TPN Triferic®, dated as of October 7, 2018 (the “TPN Agreement”), pursuant to which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing worldwide certain parenteral nutritional ("TPN”) products incorporating SFP. The license grant under the TPN Agreement continues for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. During the term of the TPN Agreement, the Company is liable to pay Charak a base royalty on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the TPN Agreement, which amount shall not be less than a minimum royalty on net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div></us-gaap:CollaborativeArrangementDisclosureTextBlock>
<rmti:NumberOfAdditionalAgreements
contextRef="i1ec99fab2f214abe99616df767617659_D20181007-20181007"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfNTE1_990083ea-f17b-4f40-9cd1-5895e5a71ded"
unitRef="agreement">3</rmti:NumberOfAdditionalAgreements>
<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
contextRef="i460677d97abe4d1e8cb8e4f651ec0039_I20181007"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfNzA3_989ad485-195a-4c71-b94c-30dde438995d"
unitRef="usd">1000000.0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
<rmti:CollaborativeArrangementNumberOfInstallmentPayments
contextRef="i759627e2f50f423aafc0dfcca70bfd78_D20181007-20181007"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfNzM1_2b905823-5c90-46e9-af66-665017a94890"
unitRef="installment">4</rmti:CollaborativeArrangementNumberOfInstallmentPayments>
<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
contextRef="i809ecae77c69447cbf9e47687819d366_I20190115"
decimals="-4"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfNzY0_21ce538d-87ea-4f3f-bfea-c3132b180d10"
unitRef="usd">250000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
contextRef="i97f806f584404ce2871df7a18de3ca11_I20190415"
decimals="-4"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfNzY0_484fcbd0-b5e0-4647-8327-ae3553087cf4"
unitRef="usd">250000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
contextRef="if0e0b072a5234c05bc5ad0336ebb3ec8_I20181015"
decimals="-4"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfNzY0_d6134730-96d3-462d-be80-c0aaaa61afa9"
unitRef="usd">250000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
contextRef="ia12ceffd5d8641e892942dd059f10047_I20190715"
decimals="-4"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfNzY0_fa62df1a-9151-4faa-afb8-c46546c4cd8a"
unitRef="usd">250000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
<rmti:InstallmentPaymentToRelatedParties
contextRef="ic3906b27be7c4423ae983ce14db75f27_D20190101-20191231"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfOTk1_febc098f-fcfc-4749-9048-a55f15c6b548"
unitRef="usd">1000000.0</rmti:InstallmentPaymentToRelatedParties>
<rmti:CollaborativeArrangementAccruedReimbursementOfLegalExpenses
contextRef="ie29e7d1c982f494cba429b4a0196ff5b_I20191231"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfMTAxMA_40540873-6ee9-4285-833d-c4c4a4fe56e9"
unitRef="usd">100000</rmti:CollaborativeArrangementAccruedReimbursementOfLegalExpenses>
<rmti:CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV82Ny9mcmFnOjJlNjIxMTU0ODY5NjQ2YThhYTI1YWNlYjE2NDEyNTg3L3RleHRyZWdpb246MmU2MjExNTQ4Njk2NDZhOGFhMjVhY2ViMTY0MTI1ODdfMTIwOQ_d57577bb-696d-4eaa-82f5-6348ac41ef3e"
unitRef="usd">200000</rmti:CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees>
<us-gaap:LesseeOperatingLeasesTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMTMzMw_06e02ea6-71ba-49d7-b237-d8d272fb3446">Leases<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its production facilities and administrative offices as well as certain equipment used in our operations including leases on transportation equipment used in the delivery of its products. The lease terms range from monthly to five years. The Company occupies a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2024. The Company also occupies two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2025, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2023. In addition, the Company occupies 4,100 square feet of office space in Hackensack, New Jersey under a lease expiring on July 1, 2024. This lease is currently being offered for sublease.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2021, the Company had operating and finance lease liabilities of $6.2 million and right-of-use assets of $6.1 million, which are included in the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, the Company had operating lease liabilities of $3.0 million and right-of-use assets of $2.9 million, which are included in the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes quantitative information about the Company’s operating leases (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">522 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">526 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,043 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term lease rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total rent expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">613 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">530 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,196 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for finance lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating lease agreements are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"/><td style="width:71.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2021 (remaining)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">865 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining future payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,726 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:LesseeOperatingLeasesTextBlock>
<us-gaap:LesseeFinanceLeasesTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMTMzMw_1703753e-a687-4bfa-844e-4bc8f4b31861">Leases<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its production facilities and administrative offices as well as certain equipment used in our operations including leases on transportation equipment used in the delivery of its products. The lease terms range from monthly to five years. The Company occupies a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2024. The Company also occupies two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2025, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2023. In addition, the Company occupies 4,100 square feet of office space in Hackensack, New Jersey under a lease expiring on July 1, 2024. This lease is currently being offered for sublease.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2021, the Company had operating and finance lease liabilities of $6.2 million and right-of-use assets of $6.1 million, which are included in the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, the Company had operating lease liabilities of $3.0 million and right-of-use assets of $2.9 million, which are included in the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes quantitative information about the Company’s operating leases (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">522 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">526 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,043 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term lease rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total rent expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">613 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">530 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,196 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for finance lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating lease agreements are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"/><td style="width:71.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2021 (remaining)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">865 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining future payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,726 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:LesseeFinanceLeasesTextBlock>
<us-gaap:LesseeOperatingLeaseTermOfContract
contextRef="ic98fba3f2dc143ee8df5663a86c4661c_I20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMjYy_be484078-e9ef-40db-90d3-2d3294be7797">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
<us-gaap:AreaOfRealEstateProperty
contextRef="ic51c88898b0b42d4b034d35705eeaf8a_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMjg5_89b4d52a-0499-473e-910f-cb561d878599"
unitRef="sqft">51000</us-gaap:AreaOfRealEstateProperty>
<us-gaap:AreaOfRealEstateProperty
contextRef="if5db4542d469452c8d4313a5744d4574_I20210630"
decimals="-2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMzE5_417aa7e6-f728-4ade-9f83-2b2c4a8f4976"
unitRef="sqft">17500</us-gaap:AreaOfRealEstateProperty>
<us-gaap:AreaOfRealEstateProperty
contextRef="i91c605c7aa7a4caebb53cdfdd424223a_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfNDY1_3ce97fb7-7d75-4844-9793-e22593997db1"
unitRef="sqft">51000</us-gaap:AreaOfRealEstateProperty>
<us-gaap:AreaOfRealEstateProperty
contextRef="ia59cfceb831d4c4ba96a80f128ab4ead_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfNTU2_99493431-fd5f-459b-91a8-8088c75439a8"
unitRef="sqft">57000</us-gaap:AreaOfRealEstateProperty>
<us-gaap:AreaOfRealEstateProperty
contextRef="if2aff2a50c9f45c59831b6c31dde2cc9_I20210630"
decimals="-2"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfNjc3_37a06254-740d-465b-9e86-ee17f22b6fa1"
unitRef="sqft">4100</us-gaap:AreaOfRealEstateProperty>
<rmti:OperatingLeaseAndFinanceLeaseLiability
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfODky_5b860a2b-470c-44f9-a371-c7e51aa5bf2d"
unitRef="usd">6200000</rmti:OperatingLeaseAndFinanceLeaseLiability>
<rmti:OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfOTIy_0dc2efe2-4162-435c-8e5f-c74b51e07138"
unitRef="usd">6100000</rmti:OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet>
<us-gaap:OperatingLeaseLiability
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMTAzNA_6df7bb6d-c286-47fa-8c47-738ac87d8d54"
unitRef="usd">3000000.0</us-gaap:OperatingLeaseLiability>
<us-gaap:OperatingLeaseRightOfUseAsset
contextRef="i544f39c3225445aa9a9903581a14c535_I20201231"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMTA2NA_4608688f-7e6f-4803-8e25-35b93f18f889"
unitRef="usd">2900000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:LeaseCostTableTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMTMyOQ_e5346430-887a-4650-8c7e-7365cbfbcf6f">The following summarizes quantitative information about the Company’s operating leases (table in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">522 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">526 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,043 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term lease rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total rent expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">613 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">530 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,196 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for finance lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></us-gaap:LeaseCostTableTextBlock>
<us-gaap:OperatingLeaseCost
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMi0xLTEtMS0w_2e85bcce-87e2-4656-979f-d1b7eaa84c32"
unitRef="usd">432000</us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMi0zLTEtMS0w_e6f572e1-c7f9-4835-8300-e7e5d8ed13db"
unitRef="usd">403000</us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMi01LTEtMS0w_16f9813c-91ae-4a6b-9ce2-aeb22c4410fa"
unitRef="usd">851000</us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMi03LTEtMS0w_5cb5aa2e-3b4b-410e-ab5c-1b979d0efea2"
unitRef="usd">846000</us-gaap:OperatingLeaseCost>
<us-gaap:VariableLeaseCost
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMy0xLTEtMS0w_1374a097-0147-4911-82cb-5e09c1cd5d0d"
unitRef="usd">90000</us-gaap:VariableLeaseCost>
<us-gaap:VariableLeaseCost
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMy0zLTEtMS0w_180a12b8-1f93-4ef7-ba3b-a607b9314081"
unitRef="usd">123000</us-gaap:VariableLeaseCost>
<us-gaap:VariableLeaseCost
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMy01LTEtMS0w_f045be07-ef16-4ac0-80e8-9eb4af7a0a07"
unitRef="usd">192000</us-gaap:VariableLeaseCost>
<us-gaap:VariableLeaseCost
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMy03LTEtMS0w_dc48eda1-78ef-48af-95d3-bf67847ca6d5"
unitRef="usd">312000</us-gaap:VariableLeaseCost>
<us-gaap:OperatingLeaseExpense
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNC0xLTEtMS0w_331b49e8-c606-4053-a989-9a24792b9061"
unitRef="usd">522000</us-gaap:OperatingLeaseExpense>
<us-gaap:OperatingLeaseExpense
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNC0zLTEtMS0w_8d34b4e5-db6c-4eaf-afbd-c92a9fbf8f5d"
unitRef="usd">526000</us-gaap:OperatingLeaseExpense>
<us-gaap:OperatingLeaseExpense
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNC01LTEtMS0w_cf361805-7475-43cc-a5a3-9381568de1fe"
unitRef="usd">1043000</us-gaap:OperatingLeaseExpense>
<us-gaap:OperatingLeaseExpense
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNC03LTEtMS0w_0908ffc3-d76f-4f32-909f-0946c8f2b638"
unitRef="usd">1158000</us-gaap:OperatingLeaseExpense>
<us-gaap:FinanceLeaseRightOfUseAssetAmortization
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNi0xLTEtMS0w_00780186-52f3-4cf5-8b69-b8dd6db7e167"
unitRef="usd">67000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
<us-gaap:FinanceLeaseRightOfUseAssetAmortization
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNi0zLTEtMS0w_33014532-4d73-4451-9e4f-37cc78cb569f"
unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
<us-gaap:FinanceLeaseRightOfUseAssetAmortization
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNi01LTEtMS0xMTM_8131d83f-fab6-46a6-a34a-418c102f1965"
unitRef="usd">112000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
<us-gaap:FinanceLeaseRightOfUseAssetAmortization
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNi03LTEtMS0xMTY_c21f133c-979d-4300-9b61-14a4a781f8cf"
unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
<us-gaap:FinanceLeaseInterestExpense
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNy0xLTEtMS0w_fd5d6c4f-641b-4960-8c56-1c678ed075ca"
unitRef="usd">20000</us-gaap:FinanceLeaseInterestExpense>
<us-gaap:FinanceLeaseInterestExpense
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNy0zLTEtMS0w_6123adbb-ea05-4f96-9016-6d26a08e78c3"
unitRef="usd">0</us-gaap:FinanceLeaseInterestExpense>
<us-gaap:FinanceLeaseInterestExpense
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNy01LTEtMS0xMTM_6d71c632-cc6b-4067-ba9a-e7c2c7023247"
unitRef="usd">33000</us-gaap:FinanceLeaseInterestExpense>
<us-gaap:FinanceLeaseInterestExpense
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfNy03LTEtMS0xMTY_36403b60-d196-4e85-8ae6-46fd5047e6a3"
unitRef="usd">0</us-gaap:FinanceLeaseInterestExpense>
<rmti:FinanceLeaseExpense
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfOC0xLTEtMS0w_8d8808f0-868a-4176-b680-f2310d34df07"
unitRef="usd">87000</rmti:FinanceLeaseExpense>
<rmti:FinanceLeaseExpense
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfOC0zLTEtMS0w_95a15b11-f3b5-4ac5-b466-e02494a6bb61"
unitRef="usd">0</rmti:FinanceLeaseExpense>
<rmti:FinanceLeaseExpense
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfOC01LTEtMS0xMTM_2065cddd-f0fb-4837-9abb-a77877075ca1"
unitRef="usd">145000</rmti:FinanceLeaseExpense>
<rmti:FinanceLeaseExpense
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfOC03LTEtMS0xMTY_ed0290b7-9578-4b45-b0aa-867dd83c981c"
unitRef="usd">0</rmti:FinanceLeaseExpense>
<us-gaap:ShortTermLeaseCost
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfOS0xLTEtMS0w_d2bad35d-36f7-43cc-8d5a-45c184042a01"
unitRef="usd">4000</us-gaap:ShortTermLeaseCost>
<us-gaap:ShortTermLeaseCost
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfOS0zLTEtMS0w_c5795d15-52d1-47db-9c6e-6af961168be0"
unitRef="usd">4000</us-gaap:ShortTermLeaseCost>
<us-gaap:ShortTermLeaseCost
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfOS01LTEtMS0w_9f5b0b71-8fa2-4541-b598-bbb9043da49a"
unitRef="usd">8000</us-gaap:ShortTermLeaseCost>
<us-gaap:ShortTermLeaseCost
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfOS03LTEtMS0w_3001e290-78d4-44e9-86ab-aab3e1cb06f9"
unitRef="usd">8000</us-gaap:ShortTermLeaseCost>
<us-gaap:LeaseCost
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTAtMS0xLTEtMA_85d8f73b-fef2-4f37-b187-35c1fe04274a"
unitRef="usd">613000</us-gaap:LeaseCost>
<us-gaap:LeaseCost
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTAtMy0xLTEtMA_95e2e75c-5772-427a-9d88-204adc8cec43"
unitRef="usd">530000</us-gaap:LeaseCost>
<us-gaap:LeaseCost
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTAtNS0xLTEtMA_d4a3fcd3-97de-4bfc-b9b9-90eaab2c0c56"
unitRef="usd">1196000</us-gaap:LeaseCost>
<us-gaap:LeaseCost
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTAtNy0xLTEtMA_57df3509-3d20-422e-a942-1fecd8cda315"
unitRef="usd">1166000</us-gaap:LeaseCost>
<us-gaap:OperatingLeasePayments
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTMtMS0xLTEtMA_940a00f1-b8fa-47ce-86e2-b25363ef355d"
unitRef="usd">428000</us-gaap:OperatingLeasePayments>
<us-gaap:OperatingLeasePayments
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTMtMy0xLTEtMA_c4ed7539-5c6a-43df-b2de-4f00208594eb"
unitRef="usd">410000</us-gaap:OperatingLeasePayments>
<us-gaap:OperatingLeasePayments
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTMtNS0xLTEtMA_c2693fc0-6de5-442f-87d3-95ca1ca8687f"
unitRef="usd">853000</us-gaap:OperatingLeasePayments>
<us-gaap:OperatingLeasePayments
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTMtNy0xLTEtMA_d0db351c-0d83-415a-a198-9d57c22f2a14"
unitRef="usd">855000</us-gaap:OperatingLeasePayments>
<us-gaap:FinanceLeaseInterestPaymentOnLiability
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTQtMS0xLTEtMA_a2f8b2cb-5e9c-4694-92fb-9ab00e2c12c6"
unitRef="usd">21000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
<us-gaap:FinanceLeaseInterestPaymentOnLiability
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTQtMy0xLTEtMA_3c46dd3f-4a56-4edb-aa18-b8b7923b6d99"
unitRef="usd">0</us-gaap:FinanceLeaseInterestPaymentOnLiability>
<us-gaap:FinanceLeaseInterestPaymentOnLiability
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTQtNS0xLTEtMTIx_aada86f3-ebe7-4e43-be5b-0a3a5185e548"
unitRef="usd">34000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
<us-gaap:FinanceLeaseInterestPaymentOnLiability
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTQtNy0xLTEtMTI0_418df902-13da-4ed7-8fa7-e0f6789e1ec2"
unitRef="usd">0</us-gaap:FinanceLeaseInterestPaymentOnLiability>
<us-gaap:FinanceLeasePrincipalPayments
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTUtMS0xLTEtMA_3093615a-6231-41f3-82ff-b4c2d22d7867"
unitRef="usd">56000</us-gaap:FinanceLeasePrincipalPayments>
<us-gaap:FinanceLeasePrincipalPayments
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTUtMy0xLTEtMA_bf12bce5-981f-4bd7-ac2c-b96a1456e53d"
unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
<us-gaap:FinanceLeasePrincipalPayments
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTUtNS0xLTEtMTIx_856bc10e-f380-461f-af81-751e1b4f7f65"
unitRef="usd">93000</us-gaap:FinanceLeasePrincipalPayments>
<us-gaap:FinanceLeasePrincipalPayments
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTUtNy0xLTEtMTI0_c998f3e7-536b-4983-b268-36607e43affa"
unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTYtMS0xLTEtMA_145605fd-4872-4dc7-9e43-36487f801fcc"
unitRef="usd">1476000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTYtMy0xLTEtMA_e7f5caf8-c6e0-4d90-bf85-5807ced3d4d1"
unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTYtNS0xLTEtMA_733c4208-a3c8-4cc7-906a-ce6ec764f3a6"
unitRef="usd">3371000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTYtNy0xLTEtMA_50f1b52e-220f-42a5-bdd6-649f1446e237"
unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
<us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
contextRef="i736a800e19204a58b4825177573a05a2_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTctMS0xLTEtMA_18810722-c665-4b27-9193-e189375f6995"
unitRef="usd">316000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
<us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
contextRef="i76f6ba574f934e6fa928b039ddbdb309_D20200401-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTctMy0xLTEtMA_68a30183-3511-4115-96a9-3ff5239f1c0b"
unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
<us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTctNS0xLTEtMTYw_fa23435b-5276-4162-b603-c15eb90b71e6"
unitRef="usd">777000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
<us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
contextRef="i2c93832fa4304f4bbcfd44fa17ea7727_D20200101-20200630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTctNy0xLTEtMTY0_3e006540-6152-4da1-87b6-afd503910679"
unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTgtMS0xLTEtMA_57550dfb-9b8a-4d50-90e7-3d3ec5ad5db6">P3Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTgtMy0xLTEtMA_5de0e29f-70e9-4081-8aed-ff9efd55cf01">P2Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTgtNS0xLTEtMA_935ab327-9f15-4b19-bdc6-b66058fe32c5">P3Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTgtNy0xLTEtMA_76660362-18e5-41eb-b3b2-cbea892a7d74">P2Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
<us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTktMS0xLTEtMA_52db5839-8d27-45f4-8d42-127d1a5f4dbd">P5Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
<us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTktMy0xLTEtMA_bbd5fb46-890e-4134-81c9-404191f2b0d1">P0Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
<us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTktNS0xLTEtMTI3_16996486-cd8f-4823-9d70-a2d4f196bee6">P5Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
<us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMTktNy0xLTEtMTMx_316af1a6-2c19-44e3-99ee-c7e53898f6c1">P0Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMjAtMS0xLTEtMA_9fdf3e4a-bee9-40b1-836f-d1c29318972d"
unitRef="number">0.062</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMjAtMy0xLTEtMA_03047a5b-cb61-4693-baaa-6d97dd201411"
unitRef="number">0.068</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMjAtNS0xLTEtMA_2a9ef39f-ad1f-4c32-ba67-758ac3e37df4"
unitRef="number">0.062</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMjAtNy0xLTEtMA_a095fc93-6af2-43e8-9485-6d49c4be57ed"
unitRef="number">0.068</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
<us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMjEtMS0xLTEtMA_968556c3-2b49-46d4-917c-c0c7b7240edf"
unitRef="number">0.055</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
<us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMjEtMy0xLTEtMA_1dccfc18-c8a3-4026-822f-17cdefb25e4e"
unitRef="number">0</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
<us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMjEtNS0xLTEtMTM1_705f705d-6868-4cd7-9404-4b9254c9c8a0"
unitRef="number">0.055</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
<us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
contextRef="i071f7359c8ca4332a2fa89ffb08ab774_I20200630"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmU2YmU1YjY5MzcwMTQ0ZDI4MGNjNDMyZjg4ZTNkMjFiL3RhYmxlcmFuZ2U6ZTZiZTViNjkzNzAxNDRkMjgwY2M0MzJmODhlM2QyMWJfMjEtNy0xLTEtMTM4_4d25cdaa-c595-4e36-8cad-79ccb8a85dbc"
unitRef="number">0</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
<us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMTMzMQ_61f18f3f-9a37-463b-a23d-d5b6bd583509"><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating lease agreements are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"/><td style="width:71.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2021 (remaining)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">865 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining future payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,726 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RleHRyZWdpb246YzAwNjM5ZDY0ZWNkNDBkZjkxYTMxZTk1NGZhYTBjMWZfMTMzMQ_ca503818-8e15-47c3-a4aa-c456e161509d"><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating lease agreements are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"/><td style="width:71.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2021 (remaining)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">865 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining future payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,726 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfMS0xLTEtMS0w_fdf33160-a1e5-4c58-a65d-11c8721ff21f"
unitRef="usd">865000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
<us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfMS0zLTEtMS0w_fc76902c-ac8e-4eda-8479-cb6091baf65d"
unitRef="usd">148000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfMi0xLTEtMS0w_03bff1e8-b8db-4dcf-b97f-89afed0b574a"
unitRef="usd">1603000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
<us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfMi0zLTEtMS0w_24430f1c-5b19-48d1-b1e5-e627b7ac128a"
unitRef="usd">300000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfMy0xLTEtMS0w_0647f299-29ba-4a43-9d1c-9dba5a55b73f"
unitRef="usd">1285000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
<us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfMy0zLTEtMS0w_ee5abe6b-43aa-4790-9003-18f4189fc152"
unitRef="usd">305000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfNC0xLTEtMS0w_518c10d3-2b0e-4998-9a66-2884019b4d92"
unitRef="usd">930000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
<us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfNC0zLTEtMS0w_6f21f4ba-38da-4aeb-98b5-727f63d4fadb"
unitRef="usd">305000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfNS0xLTEtMS0w_ec919e80-4e2c-47d8-baf6-fc68c187f91e"
unitRef="usd">468000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
<us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfNS0zLTEtMS0w_3f870bd9-39f3-4432-8112-3a95331364e0"
unitRef="usd">305000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
<rmti:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfNi0xLTEtMS0w_dad314b8-f427-4086-a6f4-faf0fcbe1c69"
unitRef="usd">97000</rmti:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
<rmti:FinanceLeaseLiabilityToBePaidAfterYearFour
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfNi0zLTEtMS0w_f2b339b5-aeed-4421-b6c4-5cea441528ca"
unitRef="usd">319000</rmti:FinanceLeaseLiabilityToBePaidAfterYearFour>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfNy0xLTEtMS0w_269739c8-66c4-444f-8f9e-ba7110362164"
unitRef="usd">5248000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
<us-gaap:FinanceLeaseLiabilityPaymentsDue
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfNy0zLTEtMS0w_490f5093-6cc1-4a0b-8293-7b0739938d0e"
unitRef="usd">1682000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfOC0xLTEtMS0w_c601ebdf-498e-48b7-892b-dbee76998a44"
unitRef="usd">522000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
<us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfOC0zLTEtMS0w_5706b9a3-ef8f-4768-b273-6a4bf0f978f1"
unitRef="usd">228000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
<us-gaap:OperatingLeaseLiability
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfOS0xLTEtMS0w_3716f3fc-3ff6-4617-8e20-59a576c4d238"
unitRef="usd">4726000</us-gaap:OperatingLeaseLiability>
<us-gaap:FinanceLeaseLiability
contextRef="i55273b6777354d8bbb4e783f2786d443_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83MC9mcmFnOmMwMDYzOWQ2NGVjZDQwZGY5MWEzMWU5NTRmYWEwYzFmL3RhYmxlOmIwYmM4YTQ2ZjU0OTQ3Y2E4MDkyMTAyOTA1MmEwNTY0L3RhYmxlcmFuZ2U6YjBiYzhhNDZmNTQ5NDdjYTgwOTIxMDI5MDUyYTA1NjRfOS0zLTEtMS0w_532e6fdc-9d16-47ee-bc28-cf0442c3c673"
unitRef="usd">1454000</us-gaap:FinanceLeaseLiability>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83My9mcmFnOjIyZGY4N2M4ZmM4ZDQ5ODU4NTlkZjBlMGUyNzU0ZTM3L3RleHRyZWdpb246MjJkZjg3YzhmYzhkNDk4NTg1OWRmMGUwZTI3NTRlMzdfNzc5_dadec3ce-0519-4cbb-a208-4abd4365d360">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SEC Investigation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a follow up to certain prior inquiries, the Company received a subpoena from the SEC during the Company’s quarter ended September 30, 2018 requesting, among other things, certain information and documents relating to the status of the Company’s request to the Centers for Medicare &amp; Medicaid Services (the "CMS") for separate reimbursement </span></div>status for Triferic (dialysate), the Company’s reserving methodology for expiring Triferic inventory, and the basis for the Board’s termination of the former Chief Executive Officer, Robert Chioini, and former Chief Financial Officer, Thomas Klema, in 2018. The Company is cooperating with the SEC and is responding to the SEC’s requests for documents and information.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:DebtDisclosureTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDk2OA_8b6694f6-06dc-4de6-b89c-ac1356a77b05">Loan and Security Agreement<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Rockwell Medical, Inc. and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the "Term Loans"). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company is no longer eligible to draw on a second tranche of $5.0 million, which was tied to the achievement of certain milestones by a specific date. The Company may be eligible to draw on a third tranche of $7.5 million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds. Net draw down proceeds were $21.2 million with closing costs of $1.3 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to make interest-only payments for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75%, plus 4.00% with an initial interest rate of 8.75% per annum and an effective interest rate of 10.9%. The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For each of the three months ended June 30, 2021 interest expense amounted to $0.6 million. For the six months ended June 30, 2021 and 2020, interest expense amounted to $1.2 million and $0.6 million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds are being used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of Triferic, with the latter beginning with the period ending December 31, 2020. The Company cannot assure you that we can maintain compliance with the covenants under our Loan Agreement, which may result in an event of default. The Company's ability to comply with these covenants may be adversely affected by events beyond its control. For example, the Loan Agreement contains certain financial covenants relating to sales and, as a result of the ongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company may not be able to satisfy such covenants in the future. If the Company is unable to comply with the covenants under the Loan Agreement, it would pursue all available cure options in order to regain compliance. The Company previously failed to satisfy a revenue covenant for the period ended December 31, 2020 and then subsequently agreed to an appropriate remedy during the applicable cure period. However, the Company may not be able to mutually agree with Innovatus on appropriate remedies to cure a future breach of a covenant, which could give rise to an event of default. If the Company is unable to avoid an event of default, any required repayments could have an adverse effect on its liquidity. As of June 30, 2021, the Company is in compliance with all the reporting and financial covenants. The financial statements for June 30, 2021 have been prepared with the assumption that the Company will be able to agree to an appropriate remedy during the applicable cure period for any future breaches of operating covenants. Based on the foregoing, the Company has classified amounts payable under the Loan Agreement as a current liability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If and when the Company reaches an agreement with Innovatus to avoid an event of default, the amounts payable under the Loan Agreement will be reevaluated for its classification and presentation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the “Warrants”) to purchase a number of shares of the Company’s common stock equal to 3.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $1.65 per share or (ii) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of 477,273 shares of the Company’s common stock at an exercise price of $1.65 per share. The Company evaluated the warrant under ASC 470, Debt, and recognized an additional debt discount of approximately $0.5 million based on the relative fair value of the base instruments and warrants. The Company calculated the fair value of the warrant using the Black-Scholes model. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, the outstanding balance of the Term Loan was $21.1 million, net of unamortized issuance costs and unaccreted discount of $1.4 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the schedule of principal payments on the Term Loan as of June 30, 2021 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.385%"><tr><td style="width:1.0%"/><td style="width:47.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000 </span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:DebtDisclosureTextBlock>
<us-gaap:DebtInstrumentFaceAmount
contextRef="ibc87c3a83e2348a693051682f6add7a3_I20200331"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDM5_f895bf87-2d53-4ab6-8f33-00fe15bd1d47"
unitRef="usd">35000000.0</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentFaceAmount
contextRef="ia4304315a451412aa6227dd3d7825bbd_I20200316"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDgz_b16c0453-d644-483c-9a02-bf468ad7cdeb"
unitRef="usd">22500000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentFaceAmount
contextRef="i9fdc6c38a5ba44f4b1470b93d16d3808_I20200316"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNTky_79ce1af1-6ac7-44fd-83b5-e103e87ef4fa"
unitRef="usd">5000000.0</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentFaceAmount
contextRef="i9301ccf847b14601a0409335c024832e_I20200316"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNzMw_0b613688-5549-4909-ae45-38df548adbea"
unitRef="usd">7500000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:ProceedsFromDebtNetOfIssuanceCosts
contextRef="ib7283d6d91074cb3b430c6bac11ae64d_D20200316-20200316"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfODgw_bb5c6a05-54e9-4a59-9ec0-9aed8d14a077"
unitRef="usd">21200000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
<us-gaap:PaymentsOfFinancingCosts
contextRef="ib7283d6d91074cb3b430c6bac11ae64d_D20200316-20200316"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfOTA1_c737b6ec-6754-4c4c-8f97-2c3deb779ccf"
unitRef="usd">1300000</us-gaap:PaymentsOfFinancingCosts>
<rmti:DebtInstrumentPeriodOfInterestOnlyPayments
contextRef="i7fa07c9abdfb4de9a8f92bf2cb718792_D20200316-20200316"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfOTcw_8f1734c8-cea4-4359-b21e-6a6a65a7f5f0">P30M</rmti:DebtInstrumentPeriodOfInterestOnlyPayments>
<rmti:DebtInstrumentPeriodOfInterestOnlyPayments
contextRef="idf213bc00b65407ca919f5dd19c8467b_D20200316-20200316"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfOTgz_ae14c457-93a9-4c29-99c0-8e7315609181">P36M</rmti:DebtInstrumentPeriodOfInterestOnlyPayments>
<us-gaap:DebtInstrumentInterestRateStatedPercentage
contextRef="iff0f4151e69d41f1a37b619b32340008_I20200316"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTE2Mw_700973a1-ffd2-4038-be50-909f39682d84"
unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
contextRef="i7fac8535567243c58d7ee0b17a853032_D20200316-20200316"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTE3Mg_24699a1b-ba33-4250-b5ea-2a6b2b6e7868"
unitRef="number">0.0400</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
<us-gaap:DebtInstrumentInterestRateDuringPeriod
contextRef="i7fac8535567243c58d7ee0b17a853032_D20200316-20200316"
decimals="4"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTIwOA_169c423b-8a91-42dc-a750-e8bb4e66d355"
unitRef="number">0.0875</us-gaap:DebtInstrumentInterestRateDuringPeriod>
<us-gaap:DebtInstrumentInterestRateEffectivePercentage
contextRef="iff0f4151e69d41f1a37b619b32340008_I20200316"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTI1NQ_317e016f-3a6a-49cf-b30a-4cfdafa16148"
unitRef="number">0.109</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
<rmti:DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage
contextRef="iff0f4151e69d41f1a37b619b32340008_I20200316"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTMyMw_304d4de8-94ff-4d65-9a63-8cba2a3f7c9d"
unitRef="number">0.0100</rmti:DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage>
<us-gaap:InterestExpenseDebt
contextRef="i6cc94eef73f94e268d7a68b7dad267bd_D20200401-20200630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTUwNQ_5dc964ed-dca7-4f29-aa52-33b293a22edd"
unitRef="usd">600000</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt
contextRef="ie79abc16084e479aa59aa703cef935f0_D20210401-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTUwNQ_6da2b79d-e47b-47fd-b669-a2d9a8b89d7c"
unitRef="usd">600000</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt
contextRef="i718b2b1115aa4464937e15a664860aea_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTA5OTUxMTYzMjkxMA_7e7e0933-600c-4528-a144-cae2cee9a538"
unitRef="usd">1200000</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt
contextRef="if0e9b928a38b40e7850ffdd7b26ec0dd_D20200101-20200630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMTA5OTUxMTYzMjkxOA_ba2ca52f-e8b7-4631-a304-4db67fc63943"
unitRef="usd">600000</us-gaap:InterestExpenseDebt>
<rmti:ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded
contextRef="i7fac8535567243c58d7ee0b17a853032_D20200316-20200316"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMzIzMQ_0deb3e7a-b3f0-4bac-8485-4af941d823c4"
unitRef="number">0.035</rmti:ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded>
<rmti:ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays
contextRef="i7fac8535567243c58d7ee0b17a853032_D20200316-20200316"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMzQzNQ_bdcf0947-6f5a-48ad-9acd-c7c2aef4151c">P5D</rmti:ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
contextRef="i2ee87b88447b43f4bf5d2a2510a5ede7_I20200316"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMzcxNw_358126fb-a7a9-41a4-b246-6a9d14980950"
unitRef="usdPerShare">1.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<rmti:ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays
contextRef="i58f2d0162acd40c0942ea5380b124712_D20200316-20200316"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfMzgxMQ_5106f7b2-2c6a-4dfe-945e-9b25887833e5">P5D</rmti:ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
contextRef="ia4304315a451412aa6227dd3d7825bbd_I20200316"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDM4Mw_41148c22-dd33-4af2-84b8-26e4f6e324ca"
unitRef="shares">477273</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
contextRef="ia4304315a451412aa6227dd3d7825bbd_I20200316"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDQ0Nw_4336b2d8-28e7-41ea-9b29-764b97743113"
unitRef="usdPerShare">1.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:DebtInstrumentUnamortizedDiscount
contextRef="ia4304315a451412aa6227dd3d7825bbd_I20200316"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDU3Ng_1f6e5501-5ce1-48e8-bf2f-065208e4a834"
unitRef="usd">500000</us-gaap:DebtInstrumentUnamortizedDiscount>
<us-gaap:LongTermDebt
contextRef="ia82218c7009949eebf722cc90aec1835_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDc5MQ_bcd864cf-06b9-40ca-9124-478bd43f9f1d"
unitRef="usd">21100000</us-gaap:LongTermDebt>
<us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
contextRef="ia82218c7009949eebf722cc90aec1835_I20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDg1Ng_060a0b3a-e093-424d-8afe-a30bde10a574"
unitRef="usd">1400000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RleHRyZWdpb246MGJiMDc2MDdhZDA5NDFlYWFkMjg1MmQ5OWY4ODI0MDBfNDk3MA_42580795-a371-40e6-a3ae-48a27a802940"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the schedule of principal payments on the Term Loan as of June 30, 2021 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.385%"><tr><td style="width:1.0%"/><td style="width:47.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000 </span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
contextRef="ia82218c7009949eebf722cc90aec1835_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RhYmxlOmIyODI0OGUxYzkwZDQ0N2JhMzU3ZmEyYTY3YmNhMjY2L3RhYmxlcmFuZ2U6YjI4MjQ4ZTFjOTBkNDQ3YmEzNTdmYTJhNjdiY2EyNjZfMi0xLTEtMS0w_e3f79436-61ee-4ca2-b1d0-b40523e0afeb"
unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
contextRef="ia82218c7009949eebf722cc90aec1835_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RhYmxlOmIyODI0OGUxYzkwZDQ0N2JhMzU3ZmEyYTY3YmNhMjY2L3RhYmxlcmFuZ2U6YjI4MjQ4ZTFjOTBkNDQ3YmEzNTdmYTJhNjdiY2EyNjZfMy0xLTEtMS0w_e7d5b6b4-07dc-4b90-a8df-828f0ecd8281"
unitRef="usd">2250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
contextRef="ia82218c7009949eebf722cc90aec1835_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RhYmxlOmIyODI0OGUxYzkwZDQ0N2JhMzU3ZmEyYTY3YmNhMjY2L3RhYmxlcmFuZ2U6YjI4MjQ4ZTFjOTBkNDQ3YmEzNTdmYTJhNjdiY2EyNjZfNC0xLTEtMS0w_645e72cb-2c36-4ed7-8cb0-eddb9c909a32"
unitRef="usd">9000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
contextRef="ia82218c7009949eebf722cc90aec1835_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RhYmxlOmIyODI0OGUxYzkwZDQ0N2JhMzU3ZmEyYTY3YmNhMjY2L3RhYmxlcmFuZ2U6YjI4MjQ4ZTFjOTBkNDQ3YmEzNTdmYTJhNjdiY2EyNjZfNS0xLTEtMS0w_146a54aa-cd06-4ee9-abdd-91b41d99dbbb"
unitRef="usd">9000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
contextRef="ia82218c7009949eebf722cc90aec1835_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RhYmxlOmIyODI0OGUxYzkwZDQ0N2JhMzU3ZmEyYTY3YmNhMjY2L3RhYmxlcmFuZ2U6YjI4MjQ4ZTFjOTBkNDQ3YmEzNTdmYTJhNjdiY2EyNjZfNi0xLTEtMS0w_a56b5fc7-4e7c-4708-9c1f-ee1994239712"
unitRef="usd">2250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
<us-gaap:DebtInstrumentCarryingAmount
contextRef="ia82218c7009949eebf722cc90aec1835_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV83Ni9mcmFnOjBiYjA3NjA3YWQwOTQxZWFhZDI4NTJkOTlmODgyNDAwL3RhYmxlOmIyODI0OGUxYzkwZDQ0N2JhMzU3ZmEyYTY3YmNhMjY2L3RhYmxlcmFuZ2U6YjI4MjQ4ZTFjOTBkNDQ3YmEzNTdmYTJhNjdiY2EyNjZfNy0xLTEtMS0w_75bc2850-8bc4-4597-9b01-9efded9702a7"
unitRef="usd">22500000</us-gaap:DebtInstrumentCarryingAmount>
<us-gaap:SubsequentEventsTextBlock
contextRef="i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xMTE0L2ZyYWc6NDEwMjQ2OWI2NzNiNGY5MTg1NjVkODU4OWU2MTc3ZGMvdGV4dHJlZ2lvbjo0MTAyNDY5YjY3M2I0ZjkxODU2NWQ4NTg5ZTYxNzdkY18yMTk5MDIzMjU2Njc0_087f8704-590b-4130-9e3c-202ce71d850d">Subsequent EventsOn July 3, 2021, the Company entered into a short-term note payable for $2.0 million, bearing interest at 3.925% per annum to finance various insurance policies. Principal and interest payments related to this note will begin on July 3, 2021 and are paid on a straight-line amortization over a 9-month period with the final payment due on March 3, 2022.</us-gaap:SubsequentEventsTextBlock>
<us-gaap:DebtInstrumentFaceAmount
contextRef="i909302a232e445a29fbed3c3520b5158_I20210703"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xMTE0L2ZyYWc6NDEwMjQ2OWI2NzNiNGY5MTg1NjVkODU4OWU2MTc3ZGMvdGV4dHJlZ2lvbjo0MTAyNDY5YjY3M2I0ZjkxODU2NWQ4NTg5ZTYxNzdkY18yMTk5MDIzMjU2Njc2_fdafa733-d7cb-451b-a974-9135ae118d7a"
unitRef="usd">2000000.0</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentInterestRateStatedPercentage
contextRef="i909302a232e445a29fbed3c3520b5158_I20210703"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xMTE0L2ZyYWc6NDEwMjQ2OWI2NzNiNGY5MTg1NjVkODU4OWU2MTc3ZGMvdGV4dHJlZ2lvbjo0MTAyNDY5YjY3M2I0ZjkxODU2NWQ4NTg5ZTYxNzdkY18yMTk5MDIzMjU2Njkw_980f4dc5-b905-4ee6-b021-22a6a11274f9"
unitRef="number">0.03925</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentTerm
contextRef="i41920f2da0c24c9ea164cc61d469bc9b_D20210703-20210703"
id="id3VybDovL2RvY3MudjEvZG9jOjFkNjJiNGFkZmQ5YjRmNGQ4NThjOWE5Y2E3OWUzZTQ5L3NlYzoxZDYyYjRhZGZkOWI0ZjRkODU4YzlhOWNhNzllM2U0OV8xMTE0L2ZyYWc6NDEwMjQ2OWI2NzNiNGY5MTg1NjVkODU4OWU2MTc3ZGMvdGV4dHJlZ2lvbjo0MTAyNDY5YjY3M2I0ZjkxODU2NWQ4NTg5ZTYxNzdkY18yMTk5MDIzMjU2NzA0_4cffae6b-9d2f-40b2-87d0-0888cc091198">P9M</us-gaap:DebtInstrumentTerm>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347805243048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 13, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30, 2021<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-23661<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ROCKWELL MEDICAL, INC.<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-3317208<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">30142 S. Wixom Road<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wixom<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MI<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">48393<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">248<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">960-9009<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RMTI<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">93,888,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001041024<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347797065576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 32,378<span></span>
</td>
<td class="nump">$ 48,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments Available-for-Sale</a></td>
<td class="nump">8,574<span></span>
</td>
<td class="nump">9,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts Receivable, net</a></td>
<td class="nump">5,357<span></span>
</td>
<td class="nump">4,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">4,677<span></span>
</td>
<td class="nump">3,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and Other Current Assets</a></td>
<td class="nump">1,413<span></span>
</td>
<td class="nump">2,706<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">52,399<span></span>
</td>
<td class="nump">69,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, net</a></td>
<td class="nump">2,529<span></span>
</td>
<td class="nump">2,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Non-Current</a></td>
<td class="nump">1,122<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet', window );">Right of Use Assets, net</a></td>
<td class="nump">6,085<span></span>
</td>
<td class="nump">2,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">921<span></span>
</td>
<td class="nump">921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other Non-Current Assets</a></td>
<td class="nump">628<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="nump">77,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS’ EQUITY</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable</a></td>
<td class="nump">4,932<span></span>
</td>
<td class="nump">4,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities</a></td>
<td class="nump">3,993<span></span>
</td>
<td class="nump">5,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent', window );">Lease Liability - Current</a></td>
<td class="nump">1,674<span></span>
</td>
<td class="nump">1,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred License Revenue - Current</a></td>
<td class="nump">2,166<span></span>
</td>
<td class="nump">2,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Term Loan - Net of Issuance Costs</a></td>
<td class="nump">21,133<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Customer Deposits</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Other Current Liability - Related Party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">34,038<span></span>
</td>
<td class="nump">12,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent', window );">Lease Liability - Long-Term</a></td>
<td class="nump">4,506<span></span>
</td>
<td class="nump">1,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term Loan, Net of Issuance Costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred License Revenue - Long-Term</a></td>
<td class="nump">6,937<span></span>
</td>
<td class="nump">8,015<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">45,481<span></span>
</td>
<td class="nump">43,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (See Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders’ Equity:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at June 30, 2021 and December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common Stock, $0.0001 par value; 170,000,000 shares authorized; 93,811,381 and 93,573,165 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-in Capital</a></td>
<td class="nump">371,700<span></span>
</td>
<td class="nump">371,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="num">(353,558)<span></span>
</td>
<td class="num">(337,406)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders’ Equity</a></td>
<td class="nump">18,203<span></span>
</td>
<td class="nump">34,170<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders’ Equity</a></td>
<td class="nump">$ 63,684<span></span>
</td>
<td class="nump">$ 77,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease And Finance Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease And Finance Lease, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease And Finance Lease, Right of Use Assets, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&oid=121551570&loc=SL49130611-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347801359496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, shares authorized (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="nump">170,000,000<span></span>
</td>
<td class="nump">170,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="nump">93,811,381<span></span>
</td>
<td class="nump">93,573,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="nump">93,811,381<span></span>
</td>
<td class="nump">93,573,165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347801514952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Sales</a></td>
<td class="nump">$ 15,137<span></span>
</td>
<td class="nump">$ 15,896<span></span>
</td>
<td class="nump">$ 30,611<span></span>
</td>
<td class="nump">$ 31,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="nump">15,399<span></span>
</td>
<td class="nump">15,015<span></span>
</td>
<td class="nump">30,471<span></span>
</td>
<td class="nump">29,759<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="num">(262)<span></span>
</td>
<td class="nump">881<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">1,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Product Development</a></td>
<td class="nump">2,416<span></span>
</td>
<td class="nump">1,616<span></span>
</td>
<td class="nump">4,224<span></span>
</td>
<td class="nump">3,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and Marketing</a></td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
<td class="nump">3,319<span></span>
</td>
<td class="nump">4,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative</a></td>
<td class="nump">3,677<span></span>
</td>
<td class="nump">2,871<span></span>
</td>
<td class="nump">7,602<span></span>
</td>
<td class="nump">8,145<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Loss</a></td>
<td class="num">(7,823)<span></span>
</td>
<td class="num">(5,603)<span></span>
</td>
<td class="num">(15,005)<span></span>
</td>
<td class="num">(13,658)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other (Expense) Income</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized (Loss) Gain on Investments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant Modification Expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(837)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(837)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="num">(583)<span></span>
</td>
<td class="num">(521)<span></span>
</td>
<td class="num">(1,164)<span></span>
</td>
<td class="num">(623)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest Income</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total Other Expense</a></td>
<td class="num">(577)<span></span>
</td>
<td class="num">(1,289)<span></span>
</td>
<td class="num">(1,147)<span></span>
</td>
<td class="num">(1,218)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (8,400)<span></span>
</td>
<td class="num">$ (6,892)<span></span>
</td>
<td class="num">$ (16,152)<span></span>
</td>
<td class="num">$ (14,876)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic Net Loss per Share (in dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted Net Loss per Share (in dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic Weighted Average Shares Outstanding (in shares)</a></td>
<td class="nump">93,703,492<span></span>
</td>
<td class="nump">69,428,574<span></span>
</td>
<td class="nump">93,647,583<span></span>
</td>
<td class="nump">68,473,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted Weighted Average Shares Outstanding (in shares)</a></td>
<td class="nump">93,703,492<span></span>
</td>
<td class="nump">69,428,574<span></span>
</td>
<td class="nump">93,647,583<span></span>
</td>
<td class="nump">68,473,407<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347805446232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (8,400)<span></span>
</td>
<td class="num">$ (6,892)<span></span>
</td>
<td class="num">$ (16,152)<span></span>
</td>
<td class="num">$ (14,876)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Loss on Available-for-Sale Debt Instrument Investments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss</a></td>
<td class="num">$ (8,401)<span></span>
</td>
<td class="num">$ (6,897)<span></span>
</td>
<td class="num">$ (16,157)<span></span>
</td>
<td class="num">$ (14,882)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347802073384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Bought Deal</div></th>
<th class="th"><div>Public Offering</div></th>
<th class="th"><div>COMMON STOCK</div></th>
<th class="th">
<div>COMMON STOCK </div>
<div>Bought Deal</div>
</th>
<th class="th">
<div>COMMON STOCK </div>
<div>Public Offering</div>
</th>
<th class="th"><div>ADDITIONAL PAID-IN CAPITAL</div></th>
<th class="th">
<div>ADDITIONAL PAID-IN CAPITAL </div>
<div>Bought Deal</div>
</th>
<th class="th">
<div>ADDITIONAL PAID-IN CAPITAL </div>
<div>Public Offering</div>
</th>
<th class="th"><div>ACCUMULATED DEFICIT</div></th>
<th class="th"><div>ACCUMULATED OTHER COMPREHENSIVE INCOME</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">65,378,890<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 20,320<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 326,777<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (306,516)<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(7,984)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,984)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Loss on Available-for-Sale Investments</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="nump">6<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,670,212<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,003<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,003<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of Warrants related to Debt Financing</a></td>
<td class="nump">501<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based Compensation expense</a></td>
<td class="nump">935<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">935<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">69,049,102<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">21,774<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">336,216<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(314,500)<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">65,378,890<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">20,320<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">326,777<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(306,516)<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(14,876)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Loss on Available-for-Sale Investments</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="nump">7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">70,156,922<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">16,212<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">337,551<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(321,392)<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">69,049,102<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">21,774<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">336,216<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(314,500)<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(6,892)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,892)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Loss on Available-for-Sale Investments</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">987,716<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,978<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,978<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of Restricted Stock Units Issued, net of taxes withheld (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">120,104<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of Restricted Stock Units Issued, net of taxes withheld</a></td>
<td class="num">(19)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense', window );">Warrant Modification Expense</a></td>
<td class="nump">837<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">837<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based Compensation expense</a></td>
<td class="num">(1,461)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,461)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">70,156,922<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">$ 16,212<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">337,551<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(321,392)<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">93,573,165<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">93,573,165<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 34,170<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">371,510<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(337,406)<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(7,752)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,752)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Loss on Available-for-Sale Investments</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based Compensation expense (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,354<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based Compensation expense</a></td>
<td class="num">(236)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(236)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">93,599,519<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 26,178<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">371,274<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(345,158)<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">93,573,165<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">93,573,165<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 34,170<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">371,510<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(337,406)<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(16,152)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Loss on Available-for-Sale Investments</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="nump">93,811,381<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">93,811,381<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 18,203<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">371,700<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(353,558)<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">93,599,519<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">26,178<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">371,274<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(345,158)<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(8,400)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,400)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Loss on Available-for-Sale Investments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of Restricted Stock Units Issued, net of taxes withheld (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">211,862<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of Restricted Stock Units Issued, net of taxes withheld</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based Compensation expense</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">433<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="nump">93,811,381<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">93,811,381<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 18,203<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 371,700<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (353,558)<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Warrant Modification Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347792941064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (16,152)<span></span>
</td>
<td class="num">$ (14,876)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based Compensation</a></td>
<td class="nump">197<span></span>
</td>
<td class="num">(526)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant Modification Expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLIFOReservePeriodCharge', window );">Increase in Inventory Reserves</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of Right of Use Asset</a></td>
<td class="nump">857<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of Debt Financing Costs and Accretion of Debt Discount</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on Disposal of Assets</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized Loss (Gain) on Sale of Investments Available-for-Sale</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in Assets and Liabilities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) Decrease in Accounts Receivable, net</a></td>
<td class="num">(1,186)<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in Inventory</a></td>
<td class="num">(799)<span></span>
</td>
<td class="num">(1,302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease (Increase) in Prepaid and Other Assets</a></td>
<td class="nump">1,293<span></span>
</td>
<td class="num">(608)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase in Accounts Payable</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInsuranceLiabilities', window );">Decrease in Settlement Payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_IncreaseDecreaseInOperatingLeaseLiability', window );">Decrease in Lease Liability</a></td>
<td class="num">(839)<span></span>
</td>
<td class="num">(703)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Decrease in Other Liabilities</a></td>
<td class="num">(1,163)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in Deferred License Revenue</a></td>
<td class="num">(1,088)<span></span>
</td>
<td class="num">(992)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapital', window );">Changes in Assets and Liabilities</a></td>
<td class="num">(3,005)<span></span>
</td>
<td class="num">(2,873)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash Used In Operating Activities</a></td>
<td class="num">(17,433)<span></span>
</td>
<td class="num">(16,154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of Investments Available-for-Sale</a></td>
<td class="num">(13,765)<span></span>
</td>
<td class="num">(16,514)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sale of Investments Available-for-Sale</a></td>
<td class="nump">15,181<span></span>
</td>
<td class="nump">17,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Purchase of Equipment</a></td>
<td class="num">(281)<span></span>
</td>
<td class="num">(283)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash Provided By Investing Activities</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Term Loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt Issuance Costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,343)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on Short Term Note Payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes', window );">Repurchase of Common Stock to Pay Employee Withholding Taxes</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash (Used In) Provided By Financing Activities</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">30,357<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease) Increase in Cash and Cash Equivalents</a></td>
<td class="num">(16,304)<span></span>
</td>
<td class="nump">14,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="nump">48,682<span></span>
</td>
<td class="nump">11,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents at End of Period</a></td>
<td class="nump">32,378<span></span>
</td>
<td class="nump">26,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Cash Flow Information:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash Paid for Interest</a></td>
<td class="nump">982<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Noncash Investing and Financing Activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Change in Unrealized Loss on Marketable Securities Available-for-Sale</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Fair Value of Warrants issued related to Debt Financing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the Issuance of Common Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering Costs from the Issuance of Common Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_AtthemarketOfferingMember', window );">At-the-Market Offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the Issuance of Common Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering Costs from the Issuance of Common Stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (56)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repurchase of common shares to pay employee withholding taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInsuranceLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in insurance liability balances during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInsuranceLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReservePeriodCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6b)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6c)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6a)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.L)<br> -URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e99989-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReservePeriodCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rmti_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_AtthemarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rmti_AtthemarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347796096376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rockwell Medical, Inc. ("Rockwell Medical," "Rockwell" or the "Company") is a commercial-stage, biopharmaceutical company developing and commercializing our next-generation parenteral iron technology platform, ferric pyrophosphate citrate (“FPC”), which we believe has the potential to lead to transformative treatments for iron deficiency in multiple disease states, that we believe could reduce healthcare costs and improve patients’ lives. We are also one of the two major suppliers of life saving hemodialysis concentrate products to kidney dialysis clinics in the United States.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two novel, FDA approved therapies, Triferic and Triferic AVNU, which are the first two products developed from our FPC platform. We are marketing both products to kidney dialysis centers for their patients receiving dialysis. In 2021, we intend to advance our FPC platform strategy outside of dialysis by starting a Phase II trial for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving long-term and or chronic intravenous medications for various therapeutic needs in the home infusion setting. In our R&D pipeline, we are also exploring FPC’s impact in the treatment of hospitalized patients with acute heart failure, with the potential to begin another Phase 2 trial in these patients in 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the second largest supplier of hemodialysis concentrates in the United States generating approximately $60 million in annual revenue. The Company's reputation for excellent service, quality, and reliability is based on over 25 years of service to kidney dialysis centers. Our approximately 300 dedicated employees, as well as a management team with experience in manufacturing, logistics, pharmaceutical development and commercialization gives us a solid foundation upon which to grow.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347794589592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Capital Resources<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_LiquidityAndCapitalResourcesAbstract', window );"><strong>Liquidity and Capital Resources [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_LiquidityAndFinancialConditionTextBlock', window );">Liquidity and Capital Resources</a></td>
<td class="text">Liquidity and Capital Resources<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, Rockwell has incurred significant net losses and has funded its operations primarily through revenue from commercial products, proceeds from the issuance of debt and equity securities and payments from partnerships. At June 30, 2021, Rockwell had an accumulated deficit of approximately $353.6 million and stockholders' equity of $18.2 million. As of June 30, 2021, Rockwell had approximately $41.0 million of cash, cash equivalents and investments available-for-sale, and working capital of $18.4 million. Net cash used in operating activities for the six months ended June 30, 2021 was approximately $17.4 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is subject to certain covenants and cure provisions under its Loan Agreement with Innovatus. As of the date of this report, the Company is in compliance with all covenants. As a result of the ongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company may not be able to satisfy such covenants over the next 12 months. However, based on the foregoing, the Company has classified amounts payable under the Loan Agreement as a current liability. If and when the Company reaches an agreement with Innovatus to avoid an event of default, the amounts payable under the Loan Agreement will be reclassified. The financial statements for June 30, 2021, have been prepared with the assumption that the Company will be able to agree to an appropriate remedy during the applicable cure period for any future breaches of operating covenants. If the Company is unable to comply with the covenants under the Loan Agreement, it would pursue all available cure options in order to regain compliance (See Note 15 for further detail).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company expects it will require additional capital to sustain its operations and make the investments it needs to execute its strategic plan, including the commercialization of Triferic (dialysate) and Triferic AVNU in dialysis, generating additional data for Triferic in dialysis, developing FPC for iron deficiency anemia in patients undergoing home infusion and for progressing our pipeline development program of new indications for its FPC platform. If the Company is unable to generate sufficient revenue from sales of its commercial products and from partnerships, the Company will need to obtain additional equity or debt financing. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the currently available working capital and managements assumption that the Company will be able to agree to an appropriate remedy, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic and resulting domestic and global disruptions have adversely affected Rockwell's business and operations, including, but not limited to, our sales and marketing efforts, research and development activities, and the operations of third parties upon whom the Company relies. Quarantines, shelter-in-place, executive and similar government orders and the recent surge in infections domestically may continue to negatively impact Rockwell's sales and marketing activities, particularly if its sales representatives are unable to interact with current and potential customers to the same extent as before onset of the COVID-19 pandemic. The Company's international business development activities may also continue to be negatively impacted by COVID-19, especially with the recent surge in infections internationally, ongoing international travel restrictions and quarantines or shelter-in-place orders. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic, the domestic and international surge in infections and resulting global disruptions have caused significant volatility in financial and credit markets. Rockwell has utilized a range of financing methods to fund its operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding, refinancing or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect the Company's liquidity and capital resources in the future.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_LiquidityAndCapitalResourcesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_LiquidityAndCapitalResourcesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_LiquidityAndFinancialConditionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of liquidity position and financial conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_LiquidityAndFinancialConditionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347796649224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</a></td>
<td class="text">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U. S. Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet at June 30, 2021, condensed consolidated statements of operations for the three and six months ended June 30, 2021 and 2020, condensed consolidated statements of comprehensive loss for the three and six months ended June 30, 2021 and 2020, condensed consolidated statement of changes in stockholders' equity for the three and six months ended June 30, 2021 and 2020, and condensed consolidated statements of cash flows for the six months ended June 30, 2021 and 2020 are unaudited, but include all adjustments, consisting of normal recurring adjustments, that the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and six months ended June 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021 or for any future interim period. The condensed consolidated balance sheet at December 31, 2020 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020 and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 as filed with the SEC on March 31, 2021. The Company’s consolidated subsidiaries consisted of its wholly-owned subsidiaries, Rockwell Transportation, Inc. and Rockwell Medical India Private Limited.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock excludes dilution and is computed by dividing the net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. The Company has only incurred losses, therefore, basic and diluted net loss per share is the same. Securities that could potentially dilute net income per share in the future that were not included in the computation of diluted loss per share were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,070,801 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,225,562 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">342,604 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">503,395 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,426,863 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,248,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,918,568 </span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,123,811 </span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually assesses new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Financial Accounting Standards Board ("FASB") recently issued Accounting Standards Update ("ASU") 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347796067192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 1: Identify the contract with the customer</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 2: Identify the performance obligations in the contract</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 3: Determine the transaction price</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 4: Allocate the transaction price to the performance obligations in the contract</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Step 5: Recognize revenue when the company satisfies a performance obligation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Nature of goods and services</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of principal activities from which the Company generates its revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales –</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug and dialysis concentrate products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales.  For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales.  In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude that regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time that control of the product transfers to the customer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received upfront fees under five distribution and license agreements that have been deferred as a contract liability.  The amounts received from Wanbang Biopharmaceuticals Co., Ltd. (“Wanbang”), Sun Pharmaceutical Industries Ltd. ("Sun Pharma"), Jeil Pharmaceutical Co., Ltd. ("Jeil Pharma") and Drogsan Pharmaceuticals ("Drogsan Pharma") are recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China, India and South Korea, respectively, to determine that regulatory approval was probable as of the execution of the agreement.  The amounts received from Baxter Healthcare Corporation (“Baxter”) are recognized as revenue at the point in time that the estimated product sales under the agreement occur. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the business under the Company’s Distribution Agreement with Baxter (the “Baxter Agreement”), and for the majority of the Company’s international customers, the Company recognizes revenue at the shipping point, which is generally the Company’s plant or warehouse. For other business, the Company recognizes revenue based on when the customer takes control or receipt of the product. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers. There were no such adjustments for the periods reported. Customers typically pay for the product based on customary business practices with payment terms averaging 30 days, while distributor payment terms average 45 days.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Disaggregation of revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.901%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($) </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">273 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">556 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrate Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,379 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,026 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,353 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,084 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,227 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,857 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,864 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,511 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,353 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,055 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,198 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,857 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,137 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,726 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,411 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,611 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,637 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,974 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrate Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,849 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,454 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,658 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,809 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,849 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,806 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,896 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,991 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,905 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,753 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,187 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,566 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Contract balances</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, which are included in "Trade and other receivables"</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material losses recognized related to any receivables arising from the Company’s contracts with customers for the three and six months ended June 30, 2021 and 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021 and June 30, 2020, the Company did not recognize any material bad-debt expense. There were no material contract assets recorded on the condensed consolidated balance sheet as of June 30, 2021 and December 31, 2020.  The Company does not generally accept returns of its concentrate products and no material reserve for returns of concentrate products was established as of June 30, 2021 or December 31, 2020. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract liabilities primarily relate to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Transaction price allocated to remaining performance obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, revenue recognized from performance obligations related to prior periods was not material.</span></div>Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, totaled $9.1 million as of June 30, 2021. The amount relates primarily to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The Baxter Agreement includes minimum commitments of product sales over the duration of the agreement. Unfulfilled minimum commitments related to the Baxter Agreement are product sales of $6.2 million as of June 30, 2021, which is amortized ratably through expiration of the Baxter Agreement on October 2, 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347796058728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Available-for-Sale<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">Investments - Available-for-Sale</a></td>
<td class="text">Investments - Available-for-Sale<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available-for-sale consisted of the following as of June 30, 2021 and December 31, 2020 (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,558 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,574 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,987 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,997 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of investments available-for-sale are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as a Level 1 measurement under ASC 820 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, the amortized cost and estimated fair value of our available-for-sale securities were due within one year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347796171960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of inventory, net of reserves, as of June 30, 2021 and December 31, 2020 are as follows (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:74.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw Materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,598 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in Process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished Goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,805 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,799 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,089 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, the Company classified $1.1 million of inventory as non-current, all of which was related to Triferic or the active pharmaceutical ingredient and raw materials for Triferic. As of June 30, 2021, the total Triferic inventory net of reserve was $1.7 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $1.7 million net value of Triferic inventory consisted of $0.3 million of Triferic (dialysate) finished goods with expiration dates ranging from September 2021 to December 2023, $0.5 million of Triferic API with estimated remaining shelf life extending beyond 2021, and $0.9 million of raw materials for Triferic with estimated remaining shelf life extending beyond 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347794271304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, the Company’s property and equipment consisted of the following (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold Improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,684 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,475 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information Technology & Office Equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,403 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated Depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,874)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,536)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,529 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,642 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation expense for each of the three and six months ended June 30, 2021 and 2020 totaled $0.2 million and $0.4 million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347794614584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">Accrued Liabilities<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of June 30, 2021 and December 31, 2020 consisted of the following (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Research & Development Expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Compensation and Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Unvouchered Receipts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Workers Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Accrued Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Accrued Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,993 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,013 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347794481064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ContractWithCustomerDeferredRevenueTextBlock', window );">Deferred Revenue</a></td>
<td class="text">Deferred Revenue<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, the Company entered into the Baxter Agreement with Baxter and received an upfront fee of $20 million. The upfront fee was recorded as deferred revenue and is being recognized based on the proportion of product shipments to Baxter in each period, compared with total expected sales volume over the term of the Baxter Agreement, which expires in October 2024. The Company recognized revenue of approximately $0.5 million and $1.0 million for each of the three and six months ended June 30, 2021 and 2020. Deferred revenue related to the Baxter Agreement totaled $6.2 million as of June 30, 2021 and $7.2 million as of December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a “Refund Trigger Event” occurs under the Baxter Agreement prior to December 31, 2021, Rockwell would be obligated to repay 25% of the upfront fee.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into a distribution and license agreement with Wanbang (the "Wanbang Agreement") and received an upfront fee of $4.0 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized approximately $53,000 and $0.1 million revenue for each of the three and six months ended June 30, 2021 and 2020. Deferred revenue related to the Wanbang Agreement totaled $2.6 million as of June 30, 2021 and $2.7 million as of December 31, 2020.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company entered into license and supply agreements with Sun Pharma (the "Sun Pharma Agreements"), for the rights to commercialize Triferic (dialysate) (ferric pyrophosphate citrate) in India. Under the terms of the Sun Pharma Agreements, Sun Pharma will be the exclusive development and commercialization partner for Triferic (dialysate) in India, and the Company will supply the product to Sun Pharma. In consideration for the license, the Company received an upfront fee of $0.1 million, and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Sun Pharma, will guide the development and execution for Triferic (dialysate) in </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">India. Sun Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $2,500 and $5,000 for each of the three and six months ended June 30, 2021 and 2020. Deferred revenue related to the Sun Pharma Agreement totaled $85,000 and $90,000 as of June 30, 2021 and December 31, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into a license and supply agreements with Jeil Pharma (the "Jeil Pharma Agreements"), for the rights to commercialize Triferic (dialysate) (ferric pyrophosphate citrate) in South Korea. Under the terms of the Jeil Pharma Agreements, Jeil Pharma will be the exclusive development and commercialization partner for Triferic (dialysate) in South Korea, and the Company will supply the product to Jeil Pharma. In consideration for the license, the Company received an upfront fee of $0.2 million, and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Jeil Pharma, will guide the development and execution for Triferic (dialysate) in South Korea. Jeil Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of $2,500 and nil for the three months ended June 30, 2021 and 2020, respectively, and $5,000 and nil for the six months ended June 30, 2021 and 2020, respectively. Deferred revenue related to the Jeil Pharma Agreement totaled approximately $0.2 million as of June 30, 2021 and December 31, 2020.</span></div>In June 2021, the Company entered into license and supply agreements with Drogsan Pharma (the "Drogsan Agreements"), for the rights to commercialize Triferic (dialysate) and Triferic AVNU in Turkey. Under the terms of the Drogsan Agreements, Drogsan Pharma will be the exclusive commercialization partner for Triferic (dialysate) and Triferic AVNU in Turkey. In consideration for the license, the Company is due to receive an upfront fee of $0.2 million, and will be eligible for milestone payment and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Drogsan Pharma, will guide the execution for Triferic (dialysate) and Triferic AVNU in Turkey. Drogsan Pharma will be responsible for all regulatory approval and commercialization activities, and the Company will supply the product to Drogsan Pharma for Turkey. The upfront fee will be recorded as deferred revenue and will be recognized as revenue based on the agreement term.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ContractWithCustomerDeferredRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer Deferred Revenue [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ContractWithCustomerDeferredRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347810438200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders’ Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders’ Equity<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, there were 2,000,000 shares of preferred stock, $0.0001 par value per share, authorized and no shares of preferred stock issued or outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, there were 170,000,000 shares of common stock, $0.0001 par value per share, authorized and 93,811,381 and 93,573,165 shares issued and outstanding, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controlled Equity Offering (or "At the Market" Offering)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2019, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time shares of the Company’s common stock through the Agent. The offering and sale of up to $40.0 million of the shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company’s registration statement on Form S-3 (File No. 333-227363), which was originally filed with the SEC on September 14, 2018 and declared effective by the SEC on October 1, 2018, the base prospectus contained within the registration statement, and a prospectus supplement that was filed with the SEC on March 22, 2019.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the shares, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an “at the market" offering as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Global Market or on any other existing trading market for the Company’s common stock. The Company intends to use the proceeds from the offering for working capital and other general corporate purposes. The Company may suspend or terminate the Sales Agreement at any time.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2021, the Company has not sold shares of its common stock pursuant to the Sales Agreement. Approximately $32.3 million remains available for sale under this facility.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not required to sell any shares at any time during the term of the facility. The Company's ability to sell common stock under the facility may be limited by several factors including, among other things, the trading volume of its common stock and certain black-out periods that the Company may impose upon the facility, among other things.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347794254040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized total stock-based compensation expense during the three and six months ended June 30, 2021 and 2020 as follows (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Service-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">422 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">332 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">917 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,010 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Performance-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(596)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,793)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(720)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,536)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">433 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,461)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">197 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(526)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s restricted stock awards during the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average <br/>Grant-Date <br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.70 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s restricted stock awards during the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,800 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of 20 months. As of June 30, 2021, unvested restricted stock awards of 78,300 were related to performance-based awards. The forfeited performance-based restricted stock awards of 68,500 was due to the termination of the Company's former Chief Science Officer on January 19, 2021. These forfeited awards reduced stock-based compensation expense by $0.4 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service-Based Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">265,494 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">310,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,474)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">342,604 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.17 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">463,786 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188,904 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(128,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">420,062 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.27 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of service based restricted stock units are measured based on their fair value on the date of grant and amortized over the vesting period. The vesting periods range from 1 to 3 years. Stock-based compensation expense of $0.1 million and $0.2 million was recognized for the three and six months ended June 30, 2021, respectively. Stock-based compensation expense of nil and $0.2 million was recognized for the three and six months ended June 30, 2020, respectively. As of June 30, 2021, the unrecognized stock-based compensation expense was $0.3 million, which is expected to be recognized over an estimated weighted average remaining term of less than 1 year. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, there were no outstanding performance-based restricted stock units.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s performance-based restricted stock units during the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:74.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.683%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988,958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(905,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,333 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service-Based Stock Options</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the service-based stock options granted for the six months ended June 30, 2021 were based on the following assumptions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.766%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.90 - $0.94</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.8% - 77.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.47% - 1.06%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 - 6</span></div></td></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based stock option activity for the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,717,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,266,553)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,695,801 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387,440 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based stock option activity for the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,210,024 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.06 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211,471)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,983,335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625,562 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809,954 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.09 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the table above is calculated as the difference between the closing price of the Company's common stock and the exercise price of the stock options that had strike prices below the closing price.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, the Company granted stock options to purchase up to 1,522,162 shares of common stock to certain employees. During the six months ended June 30, 2021, 277,764 shares were forfeited and 1,266,553 shares expired. Forfeitures are recorded in the period of occurrence; compensation expense is adjusted accordingly.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for service-based stock options was $0.3 million and $0.7 million for the three and six months ended June 30, 2021, respectively. Stock-based compensation expense recognized for service-based stock options was $0.3 million and $0.8 million for the three and six months ended June 30, 2020, respectively. As of June 30, 2021, total stock-based compensation expense related to unvested options not yet recognized totaled approximately $2.0 million, which is expected to be recognized over an estimated weighted average remaining term of 3.0 years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Stock Options</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the performance-based stock options for the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">750,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the performance-based stock options for the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">388,125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388,125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">600,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.45 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for performance-based stock options was nil and $(0.3) million for the three and six months ended June 30, 2021, respectively. Stock-based compensation expense recognized for performance-based stock options was $(0.6) million and $(0.5) million for the three and six months ended June 30, 2020, respectively. The reduction in stock-based compensation expense was due to the performance criteria of certain performance-based options granted to officers of the Company becoming non-probable as of March 31, 2021. The Company will continue to assess the probability of the performance criteria until such time the criteria becomes probable and the performance-based stock option vests or continues to be non-probable and the performance-based stock option expires. As of June 30, 2021, there was no unrecognized stock-based compensation expense related to unvested performance-based stock options.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347795841960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Licensing Agreements</a></td>
<td class="text">Licensing Agreements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product License Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to a Licensing Agreement with Charak, LLC ("Charak") dated January 7, 2002 (the "2002 Agreement") that grants the Company exclusive worldwide rights to certain patents and information related to our Triferic® product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the “Charak MSA”) with Charak and Dr. Ajay Gupta, a former Officer of the Company. Pursuant to the MSA, the parties entered into three additional agreements described below related to the license of certain soluble ferric pyrophosphate (“SFP”) intellectual property owned by Charak. The Charak MSA provided for a payment of $1.0 million to Dr. Gupta, payable in four quarterly installments of $250,000 each on October 15, 2018, January 15, 2019, April 15, 2019 and July 15, 2019, and reimbursement for certain legal fees incurred in connection with the Charak MSA. The Company paid all four of the quarterly installments totaling $1.0 million and accrued $0.1 million for the reimbursement of certain legal expenses during the year ended December 31, 2019. As of December 31, 2020, the Company had fulfilled its reimbursement obligation of certain legal expenses. As of June 30, 2021, the Company accrued $0.2 million relating to certain IP reimbursement expenses and certain sublicense royalty fees within accrued liabilities on the condensed consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Charak MSA, the aforementioned parties entered into an Amendment, dated as of October 7, 2018 (the “Charak Amendment”), to the 2002 Agreement, under which Charak granted the Company an exclusive, worldwide, non-transferable license to commercialize SFP for the treatment of patients with renal failure. The Charak Amendment amends the royalty payments due to Charak under the 2002 Agreement such that the Company is liable to pay Charak royalties on net sales </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by the Company of products developed under the license, which includes the Company’s Triferic® product, at a specified rate until December 31, 2021 and thereafter at a reduced rate from January 1, 2022 until February 1, 2034. Additionally, the Company shall pay Charak a percentage of any sublicense income during the term of the agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and be no less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Charak MSA, the Company and Charak entered into a Commercialization and Technology License Agreement I.V. Triferic® (now Triferic AVNU), dated as of October 7, 2018 (the “IV Agreement”), under which Charak granted the Company an exclusive, sub-licensable, royalty-bearing license to SFP for the purpose of commercializing certain intravenous-delivered products incorporating SFP for the treatment of iron disorders worldwide for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. The Company is liable to pay Charak royalties on net sales by the Company of products developed under the license at a specified rate until December 31, 2021. From January 1, 2022 until February 1, 2034, the Company is liable to pay Charak a base royalty at a reduced rate on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the IV Agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Charak MSA, the Company and Charak entered into a Technology License Agreement TPN Triferic®, dated as of October 7, 2018 (the “TPN Agreement”), pursuant to which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing worldwide certain parenteral nutritional ("TPN”) products incorporating SFP. The license grant under the TPN Agreement continues for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. During the term of the TPN Agreement, the Company is liable to pay Charak a base royalty on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the TPN Agreement, which amount shall not be less than a minimum royalty on net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347794534264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its production facilities and administrative offices as well as certain equipment used in our operations including leases on transportation equipment used in the delivery of its products. The lease terms range from monthly to five years. The Company occupies a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2024. The Company also occupies two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2025, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2023. In addition, the Company occupies 4,100 square feet of office space in Hackensack, New Jersey under a lease expiring on July 1, 2024. This lease is currently being offered for sublease.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2021, the Company had operating and finance lease liabilities of $6.2 million and right-of-use assets of $6.1 million, which are included in the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, the Company had operating lease liabilities of $3.0 million and right-of-use assets of $2.9 million, which are included in the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes quantitative information about the Company’s operating leases (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">522 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">526 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,043 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term lease rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total rent expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">613 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">530 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,196 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for finance lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating lease agreements are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"/><td style="width:71.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2021 (remaining)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">865 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining future payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,726 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its production facilities and administrative offices as well as certain equipment used in our operations including leases on transportation equipment used in the delivery of its products. The lease terms range from monthly to five years. The Company occupies a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2024. The Company also occupies two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2025, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2023. In addition, the Company occupies 4,100 square feet of office space in Hackensack, New Jersey under a lease expiring on July 1, 2024. This lease is currently being offered for sublease.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2021, the Company had operating and finance lease liabilities of $6.2 million and right-of-use assets of $6.1 million, which are included in the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, the Company had operating lease liabilities of $3.0 million and right-of-use assets of $2.9 million, which are included in the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes quantitative information about the Company’s operating leases (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">522 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">526 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,043 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term lease rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total rent expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">613 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">530 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,196 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for finance lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating lease agreements are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"/><td style="width:71.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2021 (remaining)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">865 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining future payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,726 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347794516824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SEC Investigation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a follow up to certain prior inquiries, the Company received a subpoena from the SEC during the Company’s quarter ended September 30, 2018 requesting, among other things, certain information and documents relating to the status of the Company’s request to the Centers for Medicare & Medicaid Services (the "CMS") for separate reimbursement </span></div>status for Triferic (dialysate), the Company’s reserving methodology for expiring Triferic inventory, and the basis for the Board’s termination of the former Chief Executive Officer, Robert Chioini, and former Chief Financial Officer, Thomas Klema, in 2018. The Company is cooperating with the SEC and is responding to the SEC’s requests for documents and information.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347796535192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans and Security Agreement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Loans and Security Agreement</a></td>
<td class="text">Loan and Security Agreement<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Rockwell Medical, Inc. and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the "Term Loans"). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company is no longer eligible to draw on a second tranche of $5.0 million, which was tied to the achievement of certain milestones by a specific date. The Company may be eligible to draw on a third tranche of $7.5 million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds. Net draw down proceeds were $21.2 million with closing costs of $1.3 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to make interest-only payments for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75%, plus 4.00% with an initial interest rate of 8.75% per annum and an effective interest rate of 10.9%. The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For each of the three months ended June 30, 2021 interest expense amounted to $0.6 million. For the six months ended June 30, 2021 and 2020, interest expense amounted to $1.2 million and $0.6 million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds are being used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of Triferic, with the latter beginning with the period ending December 31, 2020. The Company cannot assure you that we can maintain compliance with the covenants under our Loan Agreement, which may result in an event of default. The Company's ability to comply with these covenants may be adversely affected by events beyond its control. For example, the Loan Agreement contains certain financial covenants relating to sales and, as a result of the ongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company may not be able to satisfy such covenants in the future. If the Company is unable to comply with the covenants under the Loan Agreement, it would pursue all available cure options in order to regain compliance. The Company previously failed to satisfy a revenue covenant for the period ended December 31, 2020 and then subsequently agreed to an appropriate remedy during the applicable cure period. However, the Company may not be able to mutually agree with Innovatus on appropriate remedies to cure a future breach of a covenant, which could give rise to an event of default. If the Company is unable to avoid an event of default, any required repayments could have an adverse effect on its liquidity. As of June 30, 2021, the Company is in compliance with all the reporting and financial covenants. The financial statements for June 30, 2021 have been prepared with the assumption that the Company will be able to agree to an appropriate remedy during the applicable cure period for any future breaches of operating covenants. Based on the foregoing, the Company has classified amounts payable under the Loan Agreement as a current liability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If and when the Company reaches an agreement with Innovatus to avoid an event of default, the amounts payable under the Loan Agreement will be reevaluated for its classification and presentation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the “Warrants”) to purchase a number of shares of the Company’s common stock equal to 3.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $1.65 per share or (ii) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of 477,273 shares of the Company’s common stock at an exercise price of $1.65 per share. The Company evaluated the warrant under ASC 470, Debt, and recognized an additional debt discount of approximately $0.5 million based on the relative fair value of the base instruments and warrants. The Company calculated the fair value of the warrant using the Black-Scholes model. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, the outstanding balance of the Term Loan was $21.1 million, net of unamortized issuance costs and unaccreted discount of $1.4 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the schedule of principal payments on the Term Loan as of June 30, 2021 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.385%"><tr><td style="width:1.0%"/><td style="width:47.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000 </span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347830810312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsOn July 3, 2021, the Company entered into a short-term note payable for $2.0 million, bearing interest at 3.925% per annum to finance various insurance policies. Principal and interest payments related to this note will begin on July 3, 2021 and are paid on a straight-line amortization over a 9-month period with the final payment due on March 3, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347799410248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.</span></div>In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.</span></div>Basic net loss per share of common stock excludes dilution and is computed by dividing the net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. The Company has only incurred losses, therefore, basic and diluted net loss per share is the same.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually assesses new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Financial Accounting Standards Board ("FASB") recently issued Accounting Standards Update ("ASU") 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347796027848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Potentially Dilutive Securities</a></td>
<td class="text">Securities that could potentially dilute net income per share in the future that were not included in the computation of diluted loss per share were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,070,801 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,225,562 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">342,604 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">503,395 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,426,863 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,248,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,918,568 </span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,123,811 </span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347794600792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text">Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.<div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.901%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($) </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">273 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">556 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrate Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,379 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,026 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,353 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,084 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,227 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,857 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,864 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,511 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,353 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,055 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,198 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,857 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,137 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,726 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,411 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,611 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,637 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,974 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products By Geographic Area</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rest of World</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Drug Products</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrate Products</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Sales – Point-in-time</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,849 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,454 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Fee – Over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Concentrate Products</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,658 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,809 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,849 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,806 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,896 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,991 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,905 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,753 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,187 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,566 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract Balances</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In thousands of U.S. dollars ($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, which are included in "Trade and other receivables"</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347794516824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Available-for-Sale (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Investments available for sale</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available-for-sale consisted of the following as of June 30, 2021 and December 31, 2020 (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,558 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,574 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Available-for-Sale Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,987 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,997 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347796035080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule Components of Inventory</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of inventory, net of reserves, as of June 30, 2021 and December 31, 2020 are as follows (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:74.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw Materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,598 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in Process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished Goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,805 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,799 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,089 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347796640744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Major Classes of Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, the Company’s property and equipment consisted of the following (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold Improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,684 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,475 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information Technology & Office Equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,403 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated Depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,874)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,536)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,529 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,642 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347794569592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of June 30, 2021 and December 31, 2020 consisted of the following (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Research & Development Expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Compensation and Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Unvouchered Receipts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Workers Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Accrued Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Accrued Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,993 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,013 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347801615912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of total stock-based compensation expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized total stock-based compensation expense during the three and six months ended June 30, 2021 and 2020 as follows (table in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Service-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">422 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">332 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">917 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,010 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Performance-based awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(596)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,793)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(720)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,536)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">433 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,461)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">197 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(526)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted stock award</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s restricted stock awards during the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average <br/>Grant-Date <br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.70 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s restricted stock awards during the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,800 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember', window );">Restricted stock units - service based awards</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted stock award</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">265,494 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">310,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,474)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">342,604 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.17 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">463,786 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188,904 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(128,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">420,062 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.27 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember', window );">Restricted stock units - performance based awards</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted stock award</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s performance-based restricted stock units during the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:74.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.683%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988,958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(905,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,333 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember', window );">Stock option awards - service based awards</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of stock option assumptions</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the service-based stock options granted for the six months ended June 30, 2021 were based on the following assumptions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.766%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.90 - $0.94</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.8% - 77.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.47% - 1.06%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 - 6</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock options activity</a></td>
<td class="text"><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based stock option activity for the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,717,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,266,553)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,695,801 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387,440 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s service-based stock option activity for the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,210,024 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.06 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211,471)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,983,335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625,562 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809,954 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.09 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember', window );">Stock option awards - performance based awards</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock options activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the performance-based stock options for the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">750,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the performance-based stock options for the six months ended June 30, 2020 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:74.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.666%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">388,125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388,125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">600,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.45 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347798421336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Costs</a></td>
<td class="text">The following summarizes quantitative information about the Company’s operating leases (table in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">522 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">526 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,043 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term lease rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total rent expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">613 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">530 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,196 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets exchanged for finance lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term – finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate – finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease Maturities</a></td>
<td class="text"><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating lease agreements are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"/><td style="width:71.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2021 (remaining)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">865 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining future payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,726 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Finance Lease Maturities</a></td>
<td class="text"><div style="margin-top:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating lease agreements are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"/><td style="width:71.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2021 (remaining)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">865 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining future payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,726 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347796189352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans and Security Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Principal Payments on Term Loan</a></td>
<td class="text"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the schedule of principal payments on the Term Loan as of June 30, 2021 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.385%"><tr><td style="width:1.0%"/><td style="width:47.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000 </span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ccffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ccffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347808552328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue | $</a></td>
<td class="nump">$ 15,137<span></span>
</td>
<td class="nump">$ 15,896<span></span>
</td>
<td class="nump">$ 30,611<span></span>
</td>
<td class="nump">$ 31,753<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_YearsOfService', window );">Years of service</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityNumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="nump">300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of persons employed by the Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_YearsOfService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Years Of Service</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_YearsOfService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347809019496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Capital Resources (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_LiquidityAndCapitalResourcesAbstract', window );"><strong>Liquidity and Capital Resources [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="num">$ (353,558)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (337,406)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="nump">18,203<span></span>
</td>
<td class="nump">$ 16,212<span></span>
</td>
<td class="nump">$ 26,178<span></span>
</td>
<td class="nump">$ 34,170<span></span>
</td>
<td class="nump">$ 21,774<span></span>
</td>
<td class="nump">$ 20,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and investments available-for-sale</a></td>
<td class="nump">41,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_WorkingCapitalNet', window );">Working capital</a></td>
<td class="nump">18,400<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">$ (17,433)<span></span>
</td>
<td class="num">$ (16,154)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_LiquidityAndCapitalResourcesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_LiquidityAndCapitalResourcesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_WorkingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the monetary amount of working capital, as of the indicated date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_WorkingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347801396504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Summary of Potentially Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Earnings per Share</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from diluted loss per share calculation (in shares)</a></td>
<td class="nump">32,918,568<span></span>
</td>
<td class="nump">10,123,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Earnings per Share</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from diluted loss per share calculation (in shares)</a></td>
<td class="nump">6,070,801<span></span>
</td>
<td class="nump">6,225,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Earnings per Share</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from diluted loss per share calculation (in shares)</a></td>
<td class="nump">78,300<span></span>
</td>
<td class="nump">146,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Earnings per Share</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from diluted loss per share calculation (in shares)</a></td>
<td class="nump">342,604<span></span>
</td>
<td class="nump">503,395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Earnings per Share</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from diluted loss per share calculation (in shares)</a></td>
<td class="nump">26,426,863<span></span>
</td>
<td class="nump">3,248,054<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347796054200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Nature of Goods and Services (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>agreement</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_NumberOfDistributionAndLicenseAgreements', window );">Number of distribution and license agreements</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_AveragePaymentTermOfCustomers', window );">Customers average payment term</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_AveragePaymentTermOfDistributors', window );">Distributors average payment term</a></td>
<td class="text">45 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_AveragePaymentTermOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the average payment term of customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_AveragePaymentTermOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_AveragePaymentTermOfDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the average payment term of distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_AveragePaymentTermOfDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_NumberOfDistributionAndLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of distribution and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_NumberOfDistributionAndLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347801116024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">$ 15,137<span></span>
</td>
<td class="nump">$ 15,896<span></span>
</td>
<td class="nump">$ 30,611<span></span>
</td>
<td class="nump">$ 31,753<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rmti_DrugRevenueMember', window );">Drug products</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="nump">493<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rmti_ConcentrateProductsMember', window );">Concentrate Products</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">14,864<span></span>
</td>
<td class="nump">15,658<span></span>
</td>
<td class="nump">30,055<span></span>
</td>
<td class="nump">31,260<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">13,726<span></span>
</td>
<td class="nump">13,991<span></span>
</td>
<td class="nump">27,637<span></span>
</td>
<td class="nump">28,187<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Drug products</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Concentrate Products</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">13,511<span></span>
</td>
<td class="nump">13,809<span></span>
</td>
<td class="nump">27,198<span></span>
</td>
<td class="nump">27,806<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">1,411<span></span>
</td>
<td class="nump">1,905<span></span>
</td>
<td class="nump">2,974<span></span>
</td>
<td class="nump">3,566<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | Drug products</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | Concentrate Products</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">1,353<span></span>
</td>
<td class="nump">1,849<span></span>
</td>
<td class="nump">2,857<span></span>
</td>
<td class="nump">3,454<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Product Sales – Point-in-time | Drug product sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Product Sales – Point-in-time | Concentrate product sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">14,379<span></span>
</td>
<td class="nump">15,168<span></span>
</td>
<td class="nump">29,084<span></span>
</td>
<td class="nump">30,280<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Product Sales – Point-in-time | U.S. | Drug product sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Product Sales – Point-in-time | U.S. | Concentrate product sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">13,026<span></span>
</td>
<td class="nump">13,319<span></span>
</td>
<td class="nump">26,227<span></span>
</td>
<td class="nump">26,826<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Product Sales – Point-in-time | Rest of World | Drug product sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Product Sales – Point-in-time | Rest of World | Concentrate product sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">1,353<span></span>
</td>
<td class="nump">1,849<span></span>
</td>
<td class="nump">2,857<span></span>
</td>
<td class="nump">3,454<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">License Fee – Over time | Drug license fee</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">License Fee – Over time | Concentrate product license fee</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">485<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="nump">971<span></span>
</td>
<td class="nump">980<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">License Fee – Over time | U.S. | Drug license fee</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">License Fee – Over time | U.S. | Concentrate product license fee</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">485<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="nump">971<span></span>
</td>
<td class="nump">980<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">License Fee – Over time | Rest of World | Drug license fee</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">License Fee – Over time | Rest of World | Concentrate product license fee</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmti_DrugRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmti_DrugRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmti_ConcentrateProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmti_ConcentrateProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmti_DrugProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmti_DrugProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmti_ConcentrateProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmti_ConcentrateProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmti_DrugLicenseFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmti_DrugLicenseFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmti_ConcentrateProductLicenseFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmti_ConcentrateProductLicenseFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347796463640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Contract Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Receivables, which are included in "Trade and other receivables"</a></td>
<td class="nump">$ 5,357<span></span>
</td>
<td class="nump">$ 4,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 9,103<span></span>
</td>
<td class="nump">$ 10,190<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347886416216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetCreditLossExpense', window );">Impairment losses</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue performance obligation</a></td>
<td class="nump">9.1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9.1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rmti_BaxterHealthcareOrganizationMember', window );">Baxter Healthcare Organization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue performance obligation</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rmti_ConcentrateProductsMember', window );">Concentrate Products</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiability', window );">Reserve for returns</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_RevenueRecognitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_RevenueRecognitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetCreditLossExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetCreditLossExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&oid=121551570&loc=SL49130611-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rmti_BaxterHealthcareOrganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rmti_BaxterHealthcareOrganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmti_ConcentrateProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmti_ConcentrateProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347794510136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Available-for-Sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">$ 8,558<span></span>
</td>
<td class="nump">$ 9,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent', window );">Accrued Interest Income</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">$ 8,574<span></span>
</td>
<td class="nump">$ 9,997<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&oid=121645371&loc=SL121698322-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&oid=121582814&loc=SL120267853-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347797128232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw Materials</a></td>
<td class="nump">$ 3,598<span></span>
</td>
<td class="nump">$ 3,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in Process</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished Goods</a></td>
<td class="nump">1,936<span></span>
</td>
<td class="nump">1,805<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_CurrentAndNonCurrentInventory', window );">Total</a></td>
<td class="nump">5,799<span></span>
</td>
<td class="nump">5,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, noncurrent</a></td>
<td class="nump">1,122<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">4,677<span></span>
</td>
<td class="nump">$ 3,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericInventoryMember', window );">Triferic Inventory</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw Materials</a></td>
<td class="nump">900<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, noncurrent</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericDialysateMember', window );">Triferic Dialysate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished Goods</a></td>
<td class="nump">300<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericAPIMember', window );">Triferic API</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_CurrentAndNonCurrentInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of current and non-current inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_CurrentAndNonCurrentInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericInventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericInventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericDialysateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericDialysateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericAPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=rmti_TrifericAPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347805122664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 9,403<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,403<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="num">(6,874)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,874)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,536)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, net</a></td>
<td class="nump">2,529<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,529<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">1,196<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,196<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">5,684<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,684<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Information Technology & Office Equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">1,847<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,847<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 676<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 676<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347797113416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent', window );">Accrued Research & Development Expense</a></td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued Compensation and Benefits</a></td>
<td class="nump">1,420<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_AccruedUnvoucheredReceiptsCurrent', window );">Accrued Unvouchered Receipts</a></td>
<td class="nump">647<span></span>
</td>
<td class="nump">755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued Workers Compensation</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other Accrued Liabilities</a></td>
<td class="nump">1,080<span></span>
</td>
<td class="nump">1,131<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total Accrued Liabilities</a></td>
<td class="nump">$ 3,993<span></span>
</td>
<td class="nump">$ 5,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_AccruedUnvoucheredReceiptsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Unvouchered Receipts, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_AccruedUnvoucheredReceiptsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347801760808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 9,103,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,103,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,103,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10,190,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rmti_BaxterHealthcareOrganizationMember', window );">Baxter Healthcare Organization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RevenueRecognitionReceived', window );">Upfront payment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized deferred revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee', window );">Refund percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rmti_WanbangBiopharmaceuticalMember', window );">Wanbang Biopharmaceutical</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RevenueRecognitionReceived', window );">Upfront payment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized deferred revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 53,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rmti_SunPharmaAgreementsMember', window );">Sun Pharma Agreements</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RevenueRecognitionReceived', window );">Upfront payment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized deferred revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rmti_JeilPharmaAgreementsMember', window );">Jeil Pharma Agreements</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RevenueRecognitionReceived', window );">Upfront payment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized deferred revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rmti_DrogsanAgreementsMember', window );">Drogsan Agreements</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_RevenueRecognitionReceived', window );">Upfront payment</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Repayment Percentage of Upfront Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_RevenueRecognitionReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration received during the period for the milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_RevenueRecognitionReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rmti_BaxterHealthcareOrganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rmti_BaxterHealthcareOrganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rmti_WanbangBiopharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rmti_WanbangBiopharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rmti_SunPharmaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rmti_SunPharmaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rmti_JeilPharmaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rmti_JeilPharmaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rmti_DrogsanAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rmti_DrogsanAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347797096376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders’ Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 22, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, shares issued (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares, shares outstanding (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">170,000,000<span></span>
</td>
<td class="nump">170,000,000<span></span>
</td>
<td class="nump">170,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">93,811,381<span></span>
</td>
<td class="nump">93,811,381<span></span>
</td>
<td class="nump">93,573,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">93,811,381<span></span>
</td>
<td class="nump">93,811,381<span></span>
</td>
<td class="nump">93,573,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_AtthemarketOfferingMember', window );">At-the-Market Offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_SaleofStockRemainingSalesAmount', window );">Remaining amount available for sale</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 32,300,000<span></span>
</td>
<td class="nump">$ 32,300,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_AtthemarketOfferingMember', window );">At-the-Market Offering | Maximum</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_SalesAgreementThresholdSaleOfShares', window );">Sales agreement, threshold sale of shares</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_SaleofStockRemainingSalesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Remaining Sales Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_SaleofStockRemainingSalesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_SalesAgreementThresholdSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of threshold offering or sale of shares under the sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_SalesAgreementThresholdSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rmti_AtthemarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rmti_AtthemarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347801914168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Share-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="num">$ (1,461)<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="num">$ (526)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedAwardsMember', window );">Service based awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">332<span></span>
</td>
<td class="nump">917<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember', window );">Restricted stock units - service based awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="nump">78<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember', window );">Stock option awards - service based awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="nump">735<span></span>
</td>
<td class="nump">776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedAwardsMember', window );">Performance based awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="nump">11<span></span>
</td>
<td class="num">(1,793)<span></span>
</td>
<td class="num">(720)<span></span>
</td>
<td class="num">(1,536)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockAwardsMember', window );">Restricted stock awards - performance based awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(390)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember', window );">Restricted stock units - performance based awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,197)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,025)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember', window );">Stock option awards - performance based awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="num">$ (596)<span></span>
</td>
<td class="num">$ (330)<span></span>
</td>
<td class="num">$ (511)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_PerformanceBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347797918024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Awards (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant-Date Fair Value</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expenses</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="num">$ (1,461)<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="num">$ (526)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">146,800<span></span>
</td>
<td class="nump">146,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(68,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period (in shares)</a></td>
<td class="nump">78,300<span></span>
</td>
<td class="nump">146,800<span></span>
</td>
<td class="nump">78,300<span></span>
</td>
<td class="nump">146,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant-Date Fair Value</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of period (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5.70<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of period (in dollars per share)</a></td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">20 months<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, number of shares (in shares)</a></td>
<td class="nump">78,300<span></span>
</td>
<td class="nump">146,800<span></span>
</td>
<td class="nump">78,300<span></span>
</td>
<td class="nump">146,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(68,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockAwardsMember', window );">Restricted stock awards - performance based awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(68,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period (in shares)</a></td>
<td class="nump">78,300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">78,300<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant-Date Fair Value</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, number of shares (in shares)</a></td>
<td class="nump">78,300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">78,300<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(68,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (390)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347801401880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Service Based and Performance Based Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant-Date Fair Value</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expenses</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="num">$ (1,461)<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="num">$ (526)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember', window );">Restricted stock units - service based awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">265,494<span></span>
</td>
<td class="nump">463,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">310,050<span></span>
</td>
<td class="nump">188,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(221,474)<span></span>
</td>
<td class="num">(104,168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,466)<span></span>
</td>
<td class="num">(128,460)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period (in shares)</a></td>
<td class="nump">342,604<span></span>
</td>
<td class="nump">420,062<span></span>
</td>
<td class="nump">342,604<span></span>
</td>
<td class="nump">420,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant-Date Fair Value</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of period (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.60<span></span>
</td>
<td class="nump">$ 4.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0.90<span></span>
</td>
<td class="nump">2.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2.38<span></span>
</td>
<td class="nump">4.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4.81<span></span>
</td>
<td class="nump">4.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of period (in dollars per share)</a></td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expenses</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="nump">300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense, weighted average remaining term (in years) (less than)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember', window );">Restricted stock units - service based awards | Minimum</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant-Date Fair Value</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember', window );">Restricted stock units - service based awards | Maximum</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant-Date Fair Value</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember', window );">Restricted stock units - performance based awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">988,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(905,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">83,333<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">83,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant-Date Fair Value</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of period (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of period (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,197)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,025)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding performance-based restricted stock units (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347801338824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Service Based Stock Options - Fair value assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember', window );">Stock option awards - service based awards</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, minimum</a></td>
<td class="nump">75.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum</a></td>
<td class="nump">77.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.47%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.06%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Stock option awards - service based awards</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Stock option awards - service based awards</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347798706456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Service Based Stock Options (Details) - Stock option awards - service based awards - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Underlying Options</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">5,717,956<span></span>
</td>
<td class="nump">8,210,024<span></span>
</td>
<td class="nump">8,210,024<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,522,162<span></span>
</td>
<td class="nump">1,610,344<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(277,764)<span></span>
</td>
<td class="num">(211,471)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(1,266,553)<span></span>
</td>
<td class="num">(3,983,335)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">5,695,801<span></span>
</td>
<td class="nump">5,625,562<span></span>
</td>
<td class="nump">5,717,956<span></span>
</td>
<td class="nump">8,210,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">2,387,440<span></span>
</td>
<td class="nump">2,809,954<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 4.55<span></span>
</td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0.96<span></span>
</td>
<td class="nump">2.24<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">2.52<span></span>
</td>
<td class="nump">4.41<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollar per share)</a></td>
<td class="nump">7.35<span></span>
</td>
<td class="nump">8.30<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">3.07<span></span>
</td>
<td class="nump">4.90<span></span>
</td>
<td class="nump">$ 4.55<span></span>
</td>
<td class="nump">$ 7.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of the period (in dollars per share)</a></td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 7.09<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2', window );">Granted</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of the period</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 107,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at end of the period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>NA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>NA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term 2</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347801474216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Service Based Stock Options - Others (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expenses</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="num">$ (1,461)<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="num">$ (526)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember', window );">Stock option awards - service based awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,522,162<span></span>
</td>
<td class="nump">1,610,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">277,764<span></span>
</td>
<td class="nump">211,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expirations (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,266,553<span></span>
</td>
<td class="nump">3,983,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expenses</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">$ 336<span></span>
</td>
<td class="nump">$ 735<span></span>
</td>
<td class="nump">$ 776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expenses</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense, weighted average remaining term (in years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_ServiceBasedStockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347797212984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Performance Based Stock Options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expenses</a></td>
<td class="nump">$ 433,000<span></span>
</td>
<td class="num">$ (1,461,000)<span></span>
</td>
<td class="nump">$ 197,000<span></span>
</td>
<td class="num">$ (526,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember', window );">Stock option awards - performance based awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">388,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(388,125)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(375,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">375,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.20<span></span>
</td>
<td class="nump">$ 4.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollar per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2.20<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 2.20<span></span>
</td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="nump">2.20<span></span>
</td>
<td class="nump">2.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of the period (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expenses</a></td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="num">$ (596,000)<span></span>
</td>
<td class="num">$ (330,000)<span></span>
</td>
<td class="num">$ (511,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmti_PerformanceBasedStockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347796728520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing Agreements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 07, 2018 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>installment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 15, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 15, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 15, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 15, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_NumberOfAdditionalAgreements', window );">Number of additional agreements | agreement</a></td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees', window );">Collaborative arrangement, accrued reimbursement of IP expenses and sublicense royalty fees</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember', window );">Executive vice president and chief scientific officer</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Total amount due</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_CollaborativeArrangementNumberOfInstallmentPayments', window );">Number of quarterly installment payments | installment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_InstallmentPaymentToRelatedParties', window );">Installment paid</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses', window );">Collaborative arrangement, accrued reimbursement of legal expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Accrued Reimbursement of IP Expenses And Sublicense Royalty Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of related party transactions accrued reimbursement of legal expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_CollaborativeArrangementNumberOfInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Installment Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_CollaborativeArrangementNumberOfInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_InstallmentPaymentToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with installment payment to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_InstallmentPaymentToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_NumberOfAdditionalAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of additional agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_NumberOfAdditionalAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347797355768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>ft²</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_OperatingLeaseAndFinanceLeaseLiability', window );">Operating lease and finance lease liabilities | $</a></td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet', window );">Operating lease and finance lease, right of use assets, net | $</a></td>
<td class="nump">6,085<span></span>
</td>
<td class="nump">$ 2,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities | $</a></td>
<td class="nump">$ 4,726<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right of use assets | $</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MI', window );">Wixom, Michigan | Wixom, Michigan Property One</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Facility sqft.</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MI', window );">Wixom, Michigan | Wixom, Michigan Property Two</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Facility sqft.</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_TX', window );">Grapevine, Texas</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Facility sqft.</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">Greer, South Carolina</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Facility sqft.</a></td>
<td class="nump">57,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NJ', window );">Hackensack, New Jersey</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Facility sqft.</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_OperatingLeaseAndFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease And Finance Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_OperatingLeaseAndFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease And Finance Lease, Right of Use Assets, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=rmti_WixomMichiganPropertyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=rmti_WixomMichiganPropertyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=rmti_WixomMichiganPropertyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=rmti_WixomMichiganPropertyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_TX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_TX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_SC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_SC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347797195688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 432<span></span>
</td>
<td class="nump">$ 403<span></span>
</td>
<td class="nump">$ 851<span></span>
</td>
<td class="nump">$ 846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">522<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="nump">1,043<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Finance leases</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease obligations</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_FinanceLeaseExpense', window );">Finance lease expense</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease rent expense</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total rent expense</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="nump">1,196<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Other information</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">428<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="nump">853<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets exchanged for operating lease liabilities</a></td>
<td class="nump">1,476<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,371<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right of use assets exchanged for finance lease liabilities</a></td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 777<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term – operating leases</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term – finance leases</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate – operating leases</a></td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate – finance leases</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_FinanceLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_FinanceLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347805032808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Finance Lease and Operating Lease Maturities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Year ending December 31, 2021 (remaining)</a></td>
<td class="nump">$ 865<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year ending December 31, 2022</a></td>
<td class="nump">1,603<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year ending December 31, 2023</a></td>
<td class="nump">1,285<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Year ending December 31, 2024</a></td>
<td class="nump">930<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Year ending December 31, 2025</a></td>
<td class="nump">468<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Remaining future payments</a></td>
<td class="nump">97<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">5,248<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less present value discount</a></td>
<td class="num">(522)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">4,726<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Year ending December 31, 2021 (remaining)</a></td>
<td class="nump">148<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year ending December 31, 2022</a></td>
<td class="nump">300<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">Year ending December 31, 2023</a></td>
<td class="nump">305<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">Year ending December 31, 2024</a></td>
<td class="nump">305<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">Year ending December 31, 2025</a></td>
<td class="nump">305<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_FinanceLeaseLiabilityToBePaidAfterYearFour', window );">Remaining future payments</a></td>
<td class="nump">319<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">1,682<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less present value discount</a></td>
<td class="num">(228)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liabilities</a></td>
<td class="nump">$ 1,454<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_FinanceLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_FinanceLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347805307144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans and Security Agreement - Narrative (Details) - Term loan - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 16, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Term loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, base percentage</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate, additional percentage added to base percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Initial interest rate percentage</a></td>
<td class="nump">8.75%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">10.90%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage', window );">Option to add interest rate amount to outstanding principal balance in lieu of paying such amount in cash, percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded', window );">Calculation for number of shares of common stock able to be purchased by warrant, percentage of principal amount of relevant term loan funded funded</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays', window );">Warrant exercise price calculation, period immediately preceding execution of loan agreement, number of trading days</a></td>
<td class="text">5 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding balance, net of unamortized issuance costs and unaccreted discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21,100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">21,100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized issuance costs and unaccreted discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Term loan | Minimum</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_DebtInstrumentPeriodOfInterestOnlyPayments', window );">Period for which company is entitled to make interest-only payments</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Term loan | Maximum</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_DebtInstrumentPeriodOfInterestOnlyPayments', window );">Period for which company is entitled to make interest-only payments</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Term loan, first tranche</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net draw down proceeds</a></td>
<td class="nump">21,200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Closing costs</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock for which warrant is exercisable (in shares)</a></td>
<td class="nump">477,273<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Additional debt discount recognized</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Term loan, second and third tranches</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays', window );">Warrant exercise price calculation, period immediately preceding relevant funding, number of trading days</a></td>
<td class="text">5 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Term loan, second and third tranches | Maximum</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Term loan, second tranche</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Term loan, third tranche</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Calculation For Number Of Securities Called By Warrants Or Right, Numerator, Percentage Of Principal Amount Of Debt Instrument Funded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Execution Of Agreement, Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Relevant Funding, Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Option To Add Interest Rate Amount To Outstanding Principal Balance In Lieu Of Payment, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmti_DebtInstrumentPeriodOfInterestOnlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Period Of Interest-Only Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmti_DebtInstrumentPeriodOfInterestOnlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rmti_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rmti_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rmti_TermLoanTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rmti_TermLoanTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rmti_TermLoanTrancheTwoAndTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rmti_TermLoanTrancheTwoAndTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rmti_TermLoanTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rmti_TermLoanTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rmti_TermLoanTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rmti_TermLoanTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347800875880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details) - Term loan - Term loan<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Payments</a></td>
<td class="nump">$ 22,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rmti_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rmti_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140347799505192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent event - 3.925% Note Payable - Notes Payable to Banks<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jul. 03, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Short-term note payable</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">3.925%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Amortization period (in months)</a></td>
<td class="text">9 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rmti_A3925NotePayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rmti_A3925NotePayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0 ( +&)$%,'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M " "QB1!3W%[LWNX K @ $0 &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>*$Z@;";UI:.G#@8K;.QF;+4UBQUC:R1]^SE9FS*V!]C1TN]/
MGT"M#D+W$9]C'S"2Q70WNLXGH<.:G8B" $CZA$ZE,B=\;A[ZZ!3E9SQ"4/I#
M'1'JJEJ!0U)&D8()6(2%R&1KM- 1%?7Q@C=ZP8?/V,TPHP$[=.@I 2\Y,#E-
M#.>Q:^$&F&"$T:7O IJ%.%?_Q,X=8)?DF.R2&H:A')HYEW?@\/:T>YG7+:Q/
MI+S&_"M90>> :W:=_-IL'O=;)NNJYD5U7_#5ON:"-X(_O$^N/_QNPJXW]F#_
ML?%54+;PZR[D%U!+ P04 " "QB1!3F5R<(Q & "<)P $P 'AL+W1H
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M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 (
M +&)$%,JRG"G1@4 'T5 8 >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
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M['T.Q;ZD_E):PV9?.;5?,6<P+X.^US-_,(@O90P+ Z#U# D58$W3: L?R7?
M>/ETJRP.7*?C.K2#Y:XP (K+]1 *J, 64=<16Y7RP0&JEJ17*+Z'*_7!'J_#
MQ!CX=PY+"2LW*^":39<V/?2XH9!Z#Y?HO-)\R^T:'I;J?058U2%(H?<>+L\?
M6>U+]..\<+@'6L:J_>: RQB+/?=+B&\*LNRL*W^:GRT.[8E:NVB>'4S>,N-+
M"8GX$D*=UADL-96=]64W6F[L<=E":BUC>[GF+.#*-(#W2RGUX<9\(#]Q'?P'
M4$L#!!0 ( +&)$%-]YC7BNP8 ! ; 8 >&PO=V]R:W-H965T<R]S
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MY88SD%X:P.^/ EA9WY0?19J/8)?_ U!+ P04 " "QB1!373^P7N8" #1
M"0 & 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;*5676_:,!3]*U:TAU;J
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MB3G5JUM<_R]02P,$% @ L8D04\H69P.!!0 AA8 !@ !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6RM6%USXC84_2L:9A^2F298\G>&,$.P=TMG$S(A
MZ3YT^N!@$3QK+"J)9-M?7\DFADC73J;;%[#%N5<Z1]+50:,7QK^+-:42_=B4
ME;@<K*7<7@R'8KFFFTR<LRVMU"\KQC>95*_\:2BVG&9Y';0IA\1Q@N$F*ZK!
M>%2WW?+QB.UD653TEB.QVVPR_O<5+=G+Y0 /7AONBJ>UU W#\6B;/=$%E0_;
M6Z[>AFV6O-C02A2L0IRN+@<3?)&2.J!&_%[0%W'TC#251\:^ZY=9?CEP](AH
M29=2I\C4US.=TK+4F=0X_MHG';1]ZL#CY]?LGVORBLQC)NB4E=^*7*XO!]$
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M Q.4V""/$,^@;8-<SXU@VE%+.^JEO5#'>%$]U:RO,_Z=2O4&<8V >0DB@RL
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MDFWK6[U')B7;U(]KFN64:X#Z?<68?'W1';17S^-_ 5!+ P04 " "QB1!3
MQ@F!DCH# "J"0 & 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;*56T6[:
M,!3]%2O:PR:M34A"8!4@49)I3"VM&N@>ICT88DC6Q&:V ]N^?M=.FD%J4+6]
M$-LYY]Y[3LRU!WO>1*B$0_BYR*H95*N;VR;;%*28'%)=L2"F_6C!=8PI1O
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MFC'Y/%$)FNO9Z ]02P,$% @ L8D04[K8>P &"0 ##8 !@ !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6S%FVMSXC@6AO^*BYJJG:X:&NOFRU22*@*D
M0X>$;" ]M1\=<(*WC9VQ3=(]OWYE<!"6CF1".MD/T^'R'OG5]3F2AJ/G-/N>
M+\*PL'XLXR0_;BV*XO'/3B>?+<)ED'].'\.$?W.?9LN@X&^SAT[^F(7!?!VT
MC#O8MIW.,HB2ULG1^K/K[.0H715QE(37F96OELL@^WD:QNGS<0NU7CZXB1X6
M1?E!Y^3H,7@()V%Q^WB=\7>=;2GS:!DF>90F5A;>'[>ZZ,^10\N M>);%#[G
M.Z^MLBIW:?J]?#.<'[?LTE$8A[.B+"+@?Y["7AC'94G<Q]]5H:WM,\O W=<O
MI9^M*\\K<Q?D82^-_XKFQ>*XY;6L>7@?K.+B)GT^#ZL*L;*\61KGZW^MYTIK
MMZS9*B_2917,'2RC9/,W^%$UQ$X (IH 7 7@?0-(%4#D $<30*L NN\36!7
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ML\;W]V$6)0] 0-S ;WQY>6X:AH@^FS_:',]ONQ?4'.=SLV%=?M\? S'5]V1
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MI(_KGW_<I461+M<O%V' 25,*^/?W:5J\O"E_4;+] =C)_P!02P,$% @
ML8D04[@:"V93" 9B0 !@ !X;"]W;W)K<VAE971S+W-H965T-RYX;6RM
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MOO*BIFG?P($@@PU4C7*VA"F]+Q'XLVI?:FF_"+YNW@MYXD+PHCE<L3AEE32
M_R\Y="&[+_("AU>+SOX'4$L#!!0 ( +&)$%/]X!!4:P4 ,X+ 8
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M!]F [PL/0?<O$F"XPA__ U!+ P04 " "QB1!3F>6XAYD( "H%0 &
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;*U8;6_<QA'^*XM# "? Z4XZR8Z;
M2@(DN4%4)*YK)^Z'HA_VR"6YU7*7WEW>Z?+K^\PL7\^24+3Y(AW)G9EGWIX9
M\G+O_$.HE(KBL38V7"VJ&)L?UNN05:J68>4:9?&D<+Z6$9>^7(?&*YFS4&W6
MF]/3-^M::KNXON1['_SUI6NCT59]\"*T=2W]X589M[]:G"WZ&Q]U646ZL;Z^
M;&2I/JGX6_/!XVH]:,EUK6S0S@JOBJO%S=D/MQ=TG@]\UFH?)K\%>;)U[H$N
M[O.KQ2D!4D9ED31(_-NI.V4,*0*,+YW.Q6"2!*>_>^T_LN_P92N#NG/F'SJ/
MU=7B[4+DJI"MB1_=_B?5^?.:]&7.!/XK]NGLQ?E"9&V(KNZ$@:#6-OV7CUT<
M)@)O3Y\1V'0"&\:=##'*=S+*ZTOO]L+3:6BC'^PJ2P.<MI243]'CJ89<O/Y9
M?VEUKN-!2)N+.]GH*(WXJ()K?:;"Y3K""!U=9YW"VZ1P\XS"-^(79V,5Q%]L
MKO*Y_!K@!H2;'N'MYD6%?VWM2IR?+L7F='/V@K[SP>-SUG?^OWDL_GFS#=&C
M6O[U@K&+P=@%&[OXX\+[?RD4G[3-E* _#57]4GQTV<,>12\J&>A^Z[W*1="E
MU87.I(W"HO6-"P'2I)/.%2TE3^@8!-K?2U(51.,U&E>;@XB5=VU9H2MWRK9*
M%-[5(G-UK7RF@:?Q+F^S&);T*U,J#^E(K( MA%822%>@?;:1C2IX!9^" CX=
M=0>ED0?T?^R$&^FC53Y4N@DK<1,%*D,-E3'S-(<X&CYKZ];("$_0ISK3D6S*
M!I@>X4E4\.2;\]?GJS?H+&.8)& 5/9<]5,[DL/6J1P;!;\[>KC;]20 (=/-%
M#'-+%V>KT\$01#,9JB7_92,[:=A7@J#M3H68?)<[J8W<&G4""CX).+7D,\1V
MVI90D&J@0W@Q(GR/Q++Z-E R;9]+"#$9ID!#*^<EZ$=1I]95G/V9:V*/LCAR
MZ.S[J;5?H>/.U8VT!^08++_]-YA71"<RY2/& PH$U2)['Y%I1>6QTX&KBTK.
M<\G][)"]F](K11$ (<9*W%OK=C*VH0\\0<X!)/V&0:\:Y^.2'TQPL-VZ,9IK
MCG5)Y&? POHDI -XO%?L;.DH3'=_^WS_[N3L3Z@]H*MUEK(#C*HHR#MD<F+O
M%=Q&?L(DO,@5@EH*AV->%'C@?)B#K.5!6!?%5@E*,T4L($NA0#^T634)&WZD
M7%GU&,79ILO72OSD]NA$O^0!E?>HD%G%?LSM48-G1H8 L!AX&M).9J-S:<\
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M<A$"O#=+-#A*LUN1MHK6+K1I4,,Z^579S>;>JY ,6]DQS%!"3V>98R5-<+.
M;=77,4-I;0^#=20O8,!JCO>P#[R0H!DJ@Z;OU^(Y7,Q/V*3ZC!A@XQ3^,E82
M\>5Q+765\DQC)C:=]>/<ZE. Y\W\7/]FDM^'IJ_ .X<IQNLL:1SW17Y/P1Z(
MW2%5&N#.7JA;DOJ=MF@!7TOFH)'B:Q4KE]B.:.]X5=&)RAL0W)\QJ;L5OB\[
M)#?-G.'@2[BX*)A/TF*9AD)RB3#!/%./5R,\FN(6:C!7NETGQ,GAE7B72HO+
M!#,E1]THA&I'PD@$[X&IPKM8!QU;F;X[ C(EUBN<=@TN@YK"'26,'8]@[O[
M2F=<C4%-W<YX!SVFVZ,7+C/[(-*//C]\$.ECQZOTZJE/.NO)US,T=LG?"-FZ
MC>E#VG!W^ QYD[Z^C<?3-\Q?I"\UD!M50/1T]?WKA?#INV"ZB*[A;W%;%\$B
M_+-2$GU !_"\<"":[H(,#!]GK_\#4$L#!!0 ( +&)$%.<F-[-;@L *<@
M 9 >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;-U::V\;N17]*X0*M D@
MRWK8CC<O0$Z<;=H$=:UD4Z#H!VJ&LKB9(;4DQ[+WU_?<2W)F9"M>IT6!13]L
M+,V0E_=Y[KG4OMQ:]]6OE0KBIJZ,?S58A[!Y?GCHB[6JI1_9C3)XL[*NE@%?
MW=6AWS@E2]Y45X?3\?CDL);:#%Z_Y&<7[O5+VX1*&W7AA&_J6KK;,U79[:O!
M9) ?7.JK=: 'AZ]?;N256JCP>7/A\.VPE5+J6AFOK1%.K5X-YI/G9T>TGA?\
MI-76]SX+LF1I[5?Z\KY\-1B30JI212 )$G^NU1M5520(:OR29 [:(VEC_W.6
M_HYMARU+Z=4;6WW195B_&IP.1*E6LJG"I=W^625[CDE>82O/_XIM6CL>B*+Q
MP=9I,S2HM8E_Y4WRPV,V3-.&*>L=#V(MW\H@7[]T=BL<K88T^L"F\FXHIPT%
M91$<WFKL"Z_/I-=>V)6X<,HK$R3Y:B@6,4;T8J&OC%[I0IH@YD5A&Q.TN1(7
MMM*%5EY(4XI+5:@[KYTU^%PH!##XEX<!NM*)AT72ZRSJ-?V&7B?BHS5A[<6Y
M*56YN_\0-K:&3K.A9],'!?ZE,2,Q&P_%=#R=/"!OUCINQO)FWY"WSQ7_G"]]
M<$BT?SUPP%%[P!$?</2[B\SO02_Q::U0LH6M-]+<TOO"(A.,5R5]\I!5RH O
M*VVD*;2LA(<J:?-:7BNQ5,H((-5&.JS3AL6Y$JL5BBRL14A') 4V3D/0IH*&
M5\HH)ZOJEMZK38C[:?UGH^G;@LYB+\QKY6"J>/+'/YQ.I^,7GT>+D?AQ/K_@
M[Y,73P60$[L#EM4];;6)B,K0!(=L&N<;\EBP?) V2*6&H<O3,\(@,1D?_#VZ
MKZD4?1M/2(=+==544=3BX!_TA%4=":BR4$7C=,A^/[\IUM)<*?'&UK7VC*U9
M]<7YFU9I6FNCR5[6BI /49>>G[R)4<G.]4('DFX:V"6;DCWTFT$:<8B_$=6E
MK#A.L3')(%"^JBW?X;>V]5( 3D#G<C(ZD&) FH>U4XJ-\_I&U!%B%$',[@F\
M!!_&CSR*\M2I-34K9%YE_?_T2#Z1P^@I+]$DBJ]K6Y7*^3\)]4NCP^U_<SQ]
M>IS5TJ_%"GV]L_:1APBDC6A,2I:A6#8!EA154T+7"EE4_HS>QP>Q.Y!\7*,X
MU%#95" $R&M'SW;6AC62I9^CO)D\(PP@QWO"*%)6BI74CE*X!;%<.%VV;JS7
M$=Y2+N$X;$#'C]6TQP%8IVWILV!5QCS/N[X_+'"4L:'57@.4M"D!.41G2.4L
M&B"Q5$+=;$!XJ.;22;=*.I),NK^%D'JIG)A-DG@L8F_ 4ZLF-$ZU4!4-^;XJ
MO2M_#"3V$8@1 N@+M9RM6Y#8APM#L;9;=:W<$+ B2HL<)_O[V9'B=!="L0R+
M'14 (?[R5K1@S$92D58JJ ?@Z#_N.'YMFZJD ! UIJK$GI_1SEB[KMT\8/B]
MB&'=?8=VAF*I4PAZ\DS;HE+F$Y1/GKWP8AZ!^5)MK L$ZKF5_+4]<:5]@24/
M'PP%=857K3'H%R3NHW3%NLVHZ,>[.NR"2+-$26KDLO*YN/$84:4^L@625;<'
M=FON+!V*2^#<%@1>?'+2>#(GD8_WIAC%OIA7?%14(A7>8#>XA;[&T>*#KG5;
MDH^)]?V^W8M73LD>C_ Y-S/\D%)D5=^0D9A#0R0N1#,3P(>D2BZI""^!S)2)
M W2<1E4PPR3]>OIBV4A\]@P*Y\#+FCD*F1H;]0[(?4]RQU.HV*BS</R[RDKU
MYF&0P1C'_0E96<NO *-6"S)'>HQ^F\1H"*=K"0>M5L K5LEQAD()6;>^Q!Z5
MP+;2<JFKCLJ42%IT6L(L[L#,XNCT;^V)IY"=]Y&^9RWMVZ<*(2L<YD79<-_I
M5&;VF.!R7H2&VU,$Y8)AH=2PTD7L"VOK>YX9B0]*^A2G-FMR-C%WQ-\JKFD0
M,]<GS>"AII0._>:-+9ESASZCFR\Z1G=Z-!WFLY F+"FL0>JN&LVD&(W?.2(5
MT0TU,#V;B3%7&YW31T9UN#45%;R-@\E5OM<EJ:]$Y^)+TIYSP)'3B(>KEF ^
MU%/0/2S230I'X_6!71TT=#)%. :8-<EAO@59D%5!9#@V ,J1[*N5OE%YPT;>
M)A9SK2($QN>HQ#HGBJ-$T6@9F%I"!M>X+,'F790#(#CV'A)@:1T&/B8,D).B
MO)N/W&RQ0_JH+ ,!$B-E8-D4\7FKK)( VIAHD:6QFO<=0TR]IKS\E9Q\W\(1
MM8!>L&)\AIT"MF]LZ]SVR"1\!T_VJ!%K(#)4)_D]#9-XCB)-U;1?O9^ DW)9
MY8>Y\J#ABJC*<#>-MN#=Y$GP0<+V]Z9-@K9,'YD\?>3FBR-F5<#F)>F=LIX;
ML#F(WPBWK>D(1+O[AGL#$P,7#CBO4AD R$DO+B@D"KUB?)E,,P]$<#"%^HP7
M((!JVY8IU80T.X,K#=9)X<R%R#F8PG]E0M1W-U[?"4<<[?;&X0,-,A=XL5B3
MQP$G8GH"9GHNG<')_7?#KA&4!(!WB36=4B3<KAHJ3Y6%( _A)A*2<>O\8I%Q
M:QC[C62+ ">(5C_M3%-3%C.%A6AE++=&2N^X()X+@1RJ)BF4ANS?W)UUO;-_
M),Y:L6VD>2V_?-O;Y=0J)1+U81 WPU'/BV,CC%W"%DAA2G'?S>RD"A$][F]T
MM<09B<&]X=Q#PL3Q3VQ1N= %3$(3G##=-8AI8C%V=S5>Q^KL:"/)Y/R*XVRW
MEC6DZ 2J,PI43%_>U08Q.8S,"[?9/P:%QL-P%^*[TN^Y+U(FG]R=8?Q:E[F8
M6Z%X0=^W?/-*#0CF@H%05(FYXB0^$KHUP5.C) F]YIU;=@[7([3]/XEF&\EN
MP_Y @G$P$C'5]:GN?(,VE%R[S6./Q/J#Z(=KM8N%- -:PW-KQ&CVLN)I'7:"
MXX![W,>'/>'0OKV1VKG9ZKF]#4IUFR2Q(!QM:]47%<U.0R\+8*?W9LW6-WWD
M@/U9P3O*\7::DC"_V*U_+N;LS-UQGD>IOVW::[U-@^$I-9(N2"?#\;/Q\'0\
MP:?I]'AX?#(%8[M6/"=1AW:ZB-<QM%INF0$^.QW.QF,Q.3K!SO$#ZQM#E'(&
M/G@R/A+'X]EP]L.Q^,+L+SR@U?1D>(3_3D]F8C:<'IT.Q\='XI,EMC.;#G^8
MG$+/4PR6P\ET-CR=3,2\M)OLM$==^/8N;;"DB3>PE"K4-ZD)[ES7[FR'UJ6B
MKD4M#4'3P/0-<;?4W$?B"],$9D?MRC*AVX/"TXRR<_?9<KYNA&AG@5T>P9P]
M8!KRW,2NZ9>JN\HR!4;[5#SZY0DM7M020 3_B"DMCU@N%P17%R.W;U8KNGLW
M(2*/K7BHVU2RX .D+TA';>[=G^V?X/>>#Y^A&!"Q!)(](YB4S3=.5^G^EEZ]
M:X7L'6C.+/Z()X-W\\79X"FU?YQ"($)H6>[?\WG#T]V3P7SQ&7OHK .D..,E
MQJ/;=NBKHL>-;X@?@5;'/D.OST$)KDCL>SH(>2G]5^++\-23\_>?WCTE#K6V
M6R)AK(O+ES\I?WAHJWOC&(W&)?LYWLT>](:F+1 ,@$6,M1(VX<(3"IQ<(4'(
MEXHADZ.$#-K&,MVIT@SXRO7"U17NTPC'+8%,J 8?=9RM$\'<",=35?2MX,G/
M[#,A:T2IT][7%;))FO4T7BI&X99Q'^R.CR0^_SZ1BL""NG.\LI1X=TOEFIZ0
M<;TI-E8]=::UXE9+4G;LP.+XTTKCVF/14$R9KR[X?I99>;X)US$N2:>L"FGB
M12SC'5)Z3^E(:;J.?,^ #BZ@G;J65=,-+QA!P12B[+ZA9$H$AL=>Y(SV_2QY
MV/OQF%*??R+GBPL3XN_([=/V5_AY_/&Y6QY_PO\HJ7+HMF*%K>/1L^-!'+WR
MEV W_%,T9OI@:_ZX5J@-1POP?F71O=,7.J#]?Q->_QM02P,$% @ L8D0
M4[Y>(1_3"P ?"$ !D !X;"]W;W)K<VAE971S+W-H965T,3$N>&ULS5I;
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M2CM52A*3[X5F)^S9;YEV'KIZ\5(/U3"A9S)RZ-07LK++(:2WEJN\KMJ *,J
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MU&'@5Y3P?D'^""5V*[@=9H9D^-15*PPTAZ>&@\]68C]**L9SJ(9F ?-40K(
M4;-DC$IR?<R*%^(B&8_(K>,12L7HH,73F&DU0IP;.O_M#B2=(]%V#\>BH:=V
M?*(?-_R'@]?),]0X#WBN)'R8A9*Q"R5#'6EDM(3<U8ZXOXNT5W^2H_N2]M4+
MW6T<LI+9ZTRMPCZEH,GQA.<.$,7\;-8]/H-N!8T]=!1H<IV%R2*@6807R&%_
M\EC_1[#I;ZR;HX]V#I9IJDK?C(K@2D>:QX_EBJQG"799RMZ%TXP._5%:VEWU
M#F6.& V)_0_FG!AT*(SU0 ]0EX\,*@G.Q?3M?/FJK]1:Z'6.:FM%]#19787
M#F?6_3D>L:MVX7U![Z C)D%C]^='[W#:4UOH:Q6]SN>=RHEW.K\7QLFQS0*;
M>DI")W&A(8VG];@>M^HQX,-CKVO/.F_$X9D-O_<G &'/$%Z.-W>;?RVX"F_4
MV^7A_Q)^Y.-BA[W+&J2CX?E\(&QXUQ^^>%/R^_65\0@#7VX5*IZE!7B^-L;'
M+R2@^8>+]_\#4$L#!!0 ( +&)$%-BS=#-30, /8' 9 >&PO=V]R
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M$;Q>DW(OX/5^GW(+3G#I0.@,7E]5TMW M/*2B>1X.ML2<[RM?GV2-!^$[0?
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M]YW@ S1/_?0'4$L#!!0 ( +&)$%,@Z))38P, +\' 9 >&PO=V]R
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M?;$R5M-A^/%&A),^PHF/</(_U?M'*%RJJE:2)@94 7QO'X"D.TD6C0;U!LT
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MN>@F5M6^1:^4I8;O?TMZ85$[!UHOE++[B0O0O]GSWU!+ P04 " "QB1!3
MXY3G)\\" A!@ &0 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6RE56U/
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M " "QB1!3I@!IA;(" #T!0 &0 'AL+W=O<FMS:&5E=',O<VAE970Q
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M_+&BL8S:.=![J93=75R ?M!/_P%02P,$% @ L8D04__<"Q^V!0 K!,
M !D !X;"]W;W)K<VAE971S+W-H965T,38N>&ULY5A;;]LV%/XKA)<-#6#(
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M /]"@!XH6[*],!@WT?.QV!L&;3@9*+1RIX9C4^#P:D8L6%YU$;DN8N@!:GO
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M"70B)EE5V] @W 505."5*L6^K=629U;@; $B3NR/V0"=LYN%*J$G<,NE[%'
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MS$J]^H[UCNN9D(9E-,72,#@:]RIF; 96%?Y[S$19JW+_F!)'\SL%S$^5LLW
M;=!^H#O[%U!+ P04 " "QB1!31=O@(YP% !X#0 &0 'AL+W=O<FMS
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M#7!-98K68@%!"&8.S!*(&MQ2 T(7\!9SK!9H(4O"6]KS)5J$-?]+AY/)A/_
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M]K-B%F_3]^+QFX2Z=,4)5[@DU<GH^' -M[SX\*;.MRM%\;333T\EO1IA)8%
M:']IC.\6;&#[L77Q#U!+ P04 " "QB1!3#S/>K#() #X( &0 'AL
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M[4AZ0><GB9/$IOA'_MX(!P[)I2EICA_'3A3!=)6X,#/N$NZ*/+ A/4T@J;;
MLS&; N,_\BAT#HV 6&&YKV=OA.DB1.&MEWW(_A)>ZK^>6[< X'_UXV0QHZ/
MW9B/C5,"H0JZH8$\FAB[;-T8 QG.Z[X+M)$[/>A&[-42#[$C](Z[,7"F!CT
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M0:YM96H:J-->->^20'K9":<: !\J^#AFMLDX]L*\>>> 2^>^*+E4.$Z$Z[N
MH2^ED][7Z)++I?GFCITGV-9^F.Y6N\_Z-_9K]I;<_D\ >'L)O3$I^ *V0C\2
MC8BTW]GMC19K\VU[)K06I;E<<3;G$@G@^4((W=[@ =T_.US_#U!+ P04
M" "QB1!32$]J980' ,&@ &0 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
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MCP?QBVE]XTT1OO<OC/<F#Y>9X! #6H#W2V-\?4,;-'\ .OX=4$L#!!0 (
M +&)$%/):(]5008 *,< 9 >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM
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MA#>R581ZMJRR@:(FK]I"-/-.,[1!;J.7$A*<\MLR# 7O()NM8;V;;1ZZ,QQ
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MZ8ZA9M(86;O'!6=()TN [W8MV0VL@OY<\NQ?4$L#!!0 ( +&)$%/>M3@-
MQP( "4& 9 >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;*U546O;0 S^
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M%+A0=<D/;O,)M_6<!;[<E3[^PJ:)/<L2R&O/SFS!HL!HVSS5\[8/>X!^YPU
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M7147P=RQK)5X7,D>1PH!\G[A'.^,D*#]9QC] E!+ P04 " "QB1!3\>'F
M/*D* !$' &0 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6S-6=MR&[D1
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M8V<JB G;!6]$70>B/R#GJ49ZXV>UJ]0;Z:R>S&O^P]U"P0:(S;5 I7W)A)W
MG+Q[-OT)D5\@'#0*F*!YUVAU7;VQ"\ET@^D!4!22:2. CG6@DZD==4CM'2/
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M5%GCQU-9C6>N+J>[3";?7SXD:T.GA]RD*CLR5W5O-NK[C'T$\ TBW9)-VSN
M0H5+T@*=!$"DP!$R>'^X-2.G\#I)+-]V=F.(S%WT;].6)@.1L0L,':N6])M/
MN-BA7['2*F/#VA;6C)@QX*VY\JFSH$%:A:,#S')G;^F.*\JYK^7PNA-NRM/9
M.WJ<B=EP-I_0QW/Q9CB9\,>+]N,\+C@1L]EPCN\._0(Q[ORRDRN[XM^O>#(N
M?/B1I_FV^8GL-OPRU"X/OZ]]D79%)]-,+;%U,KJ<#S#-\V]6X<&;DG\G6ACO
M3<X?UTH"]+0 [Y?&^/J!%#0_'-[\&U!+ P04 " "QB1!3O[P-R:4" "V
M!0 &0 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6REE&U/VS 0Q[_**7MX
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M8+HIT6V<KD-GYMI1GX=E18,5C7>@\Y6F>O4;?\$PJN>_ 5!+ P04 " "Q
MB1!3L8'36Y4' !L% &0 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6RM
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M"*/CA?4^[9YUVCW;J[U9;NLVTM^;Q'<I^__SOM71XF A9=KK@[T3QB\I\F-
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M'Q@O_P-02P,$% @ L8D04ZMQ[.X) P ;P8 !D !X;"]W;W)K<VAE
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M.%(.QM. BF)+?P2T08'.&T/-<EX$ ],_9OT?4$L#!!0 ( +&)$%.*1<E$
MD00 .T+ 9 >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;,U6;6_;-A#^
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M3"/[].BSA-BGGW>1G 2) -(X- B0O8 ,-->%&&L+LG2/8!?L?KT3+X $KDD
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M!/,KN^:RFVBQM@W=4FC<2CNLL!]GT@C@_Y40NI\8!T.'/_L;4$L#!!0 (
M +&)$%,Y#TNVN@( %,& 9 >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM
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M,3;$0RAL9SSUT7H#/I\80VO!!ZB^(X.?4$L#!!0 ( +&)$%-2B99\B (
M %T% 9 >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;(5474_;,!3]*U?1
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M7(+^1<W^ 5!+ P04 " "QB1!3JV\\'>H" P!@ &0 'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6R%56U/VS 0_BNG#"&0(M*D:5I*6ZF\3&,"K0*V
M?9CVP4TN389C!]NA\.]W=DHH$W0?ZM=[GN?NXKM.UE+=ZP+1P%/%A9YZA3'U
M. AT6F#%])&L4=!-+E7%#&W5*M"U0I8Y4,6#J-=+@HJ5PIM-W-E"S2:R,;P4
MN%"@FZIBZOD4N5Q/O=![.;@I5X6Q!\%L4K,5WJ+Y7B\4[8*.)2LK%+J4 A3F
M4V\>CD]C:^\,?I2XUEMKL)$LI;RWF\MLZO6L0\@Q-9:!T?2(9\BY)2(W'C:<
M7B=I@=OK%_;/+G:*9<DTGDG^L\Q,,?5&'F28LX:;&[G^@IMX!I8OE5R[$=:M
M[2#R(&VTD=4&3!Y4I6AG]K3)PQ9@U/L $&T D?.[%7)>GC/#9A,EUZ"L-;'9
MA0O5H<FY4MB/<FL4W9:$,[.%HN^KS#,PD<'%0U/6E'$#!W=LR5$?3@)#(M8T
M2#>$IRUA] %A M=2F$+#A<@P>XL/R+G.P^C%P]-H)^'71AQ!O^=#U(O"'7S]
M+N*^X^O_)V(?%IQ1J&\#_S5?:J/HK?S>(15W4K&3BC^0NJ42RAJ.('.X9G^D
M@C/.M$9M#][/_'L)WREBJW:L:Y;BU*.RU*@>T9O-G02E#KO4.9US3+%:HH)^
MZ$[ISA0(9[*JF7C>_S2*PN&)AGK;-^R2DTHJ1FTPL^06ETM.55V*%1P8^V"@
M%'0N&TTX?3A^=>"-[A52&1629W!9D=(C6G(->Q#ZX7'2S=<L+2A6]>_;'/C)
M**8Q'@[@4K1]R1;X'::%D%RNGF&?5?4)?,OS,L4M9.B/XJ$=^R%<L:54S$BB
M?S5(AHG['?MQKT]C.!S!/$V;JN',AGV.E.*T;/4.$G\TC _M/.@GAQ]\4!\$
MM=8]B/Q!=.SF)([@O<<5;%5QA6KE>I6FI#?"M 7=G7;M<-YV@5?SMI=>,[4J
MA0:..4%[1\.!!ZKM3^W&R-KUA*4TU&'<LJ"6CLH:T'TNI7G96('N3V+V%U!+
M P04 " "QB1!3VE&0W< " #U!0 &0 'AL+W=O<FMS:&5E=',O<VAE
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MG5UD >AVR+0'JVK?V'-E:4SX;4ES&;5SH/N%4G9[< &Z23_^#U!+ P04
M" "QB1!3S18BN/0& !<' &0 'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6S-66USX[81_BL[REU&FJ$I "0!TK$]8U^N;3)-ZSD[R8=./M 2)'&.+RH
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M7\"C M9BA!K@UNT^,-)J[\PZF+.>L%HLZ(7/)ZQZ86+71WNBXUQY\*GD&KN
MKK4T3&Q@U7<_S6QS=7997QBUY/6]VR^IFF>H^5S.<"GQ!9:[JK[*J@>F6KKK
MH[O*F*IPKPN93J6R!/A]5E5F,[ ;-!>*%_\%4$L#!!0 ( +&)$%-*9G,6
MGP0 )$. 9 >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;.U7;6_;-A#^
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MGD)G_P-02P,$% @ L8D04\TA<A]X @ 3 4 !D !X;"]W;W)K<VAE
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M]-RA\0#:+[1V>\<?T#^@Z3]02P,$% @ L8D04ZUN^:7V @ ]0@ !D
M !X;"]W;W)K<VAE971S+W-H965T,S0N>&ULK5;?;]HP$/Y7K*@/K30UOTC:
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M&:;JNP2X!JCW*\;D;J(=-%\ZH[]02P,$% @ L8D04Z=415 _ P \0D
M !D !X;"]W;W)K<VAE971S+W-H965T,S4N>&ULG59;3]LP%/XK5C1I( UR
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M FV7-_X+4$L#!!0 ( +&)$%-E:$&J; , !4, 9 >&PO=V]R:W-H
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MEY7N9M!N8U43QK@'9=U0&):5F]N9]@;N?JO<6-5O?(#AG\#R)U!+ P04
M" "QB1!3+3]H26$" #(!0 &0 'AL+W=O<FMS:&5E=',O<VAE970S-RYX
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MW89>W6I'VH=E0Z,6C7>@\TIK=S1\@F%XY\]02P,$% @ L8D04_"R<WFE
M!@ RBH !D !X;"]W;W)K<VAE971S+W-H965T,S@N>&ULM5I=;]LV%/TK
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MLLMB 64Q0"JO2QFVH"8VX ^1@5?N4374C8D__XH,[1?$,<UZ%Y*5W*U(["!
M6SY,*S[KU?)A=O?%>BF%,-9/2D!/R'HI!4$M+Z5<&PUW&TT7@]"2/(Y0K@V
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MIDJEF^KC6H9+F96 XOO[-%7/!^4$S?;5B_\!4$L#!!0 ( +&)$%-,;^,+
M50( %<% 9 >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;(U476_:,!3]
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M<$UJIA>B^8R=GJ'-EPNFW!>:-G8T]""OE195!S855)2W?_+<^7 "),3@*@#
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MOZ797U!+ P04 " "QB1!3>-S5>R,# !'"P &0 'AL+W=O<FMS:&5E
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M,0)%[]S[ U!+ P04 " "QB1!3-SQ'/)4" #B!@ &0 'AL+W=O<FMS
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MR::T[:)Q6F@C\TJ,!#D3Y9N^5G78$K0Z!P1A)0@_*VA7@K9+M"1S:4VHH<E
MR0U1UAJ]V8&KC5-C-DS84YP:A;L,=2:Y%6O0!H_%:')!1FO*.)UQN,#[<3&E
M',CI! PNZC/<?IQ.R.G)&3DA3)"?2UEH*C(]\ V"6'=^6@6]+H.&!X+>%>*2
MM(-S$@9AJT$^/BZ?0(KREI,''^4^IE_7(*QK$#I_[?_7X)Q,8&8(ID6^O!3,
MO)$II(5BAH$FOT<S;11>O#]'@K;KH&T7M',@Z"B7RK"_D)&QU*:IAJ6^Z_3V
M8UPGO2CJ#?SU=J7VC?K]7EP;?4#KU&B=HVB/ OL!=VQ?L0\TL94.HJVPK1VP
M?8MV,U544T6?I?HN=>.MB_9B!CM4QRP^4'5KJN[Q8TQ352#2K3"@\!;A()4Y
M--%U]VL6[>#MFQPXRKC&BX_BW5"FR!/E12-1W'##XLX.T[Y1O]_?Q?*W.I#M
M_C^H6C"A"8<YRH++&'-294<M)T:N7%.:28,MS@V7^!,"90UP?RZE>9_8/E?_
MUI)_4$L#!!0 ( +&)$%. 6*<[(P, +\+ 9 >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;*U676_:,!3]*U:TAU;JFC@A7Q4@M:!NG58)]6-]F/;@
M!@-6$YO9!MI_/SND3B FK31>P([O.3[W^OK(_0WC+V*!L02O14[%P%E(N;QP
M79$M<('$.5MBJE9FC!=(JBF?NV+),9J6H")W?<^+W (1Z@S[Y;<)'_;92N:$
MX@D'8E44B+]=X9QM!@YTWC_<D?E"Z@_NL+]$<WR/Y>-RPM7,-2Q34F J"*.
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MSKS9A_\ 4$L#!!0 ( +&)$%,%'O:RL0, ),/ 9 >&PO=V]R:W-H
M965T<R]S:&5E=#0S+GAM;*U7:V^;,!3]*Q:;IDW:"N:9=$FD-@E;IU6KUCT^
MN^ $-+"9;9KVW\\& H00QK1\2<"<<ZZ/K[GFSG:4_>(1Q@(\I0GA<RT2(KO4
M=1Y$.$7\@F:8R"<;RE(DY"W;ZCQC&(4%*4UTTS!</44QT1:S8NR.+68T%TE,
M\!T#/$]3Q)ZO<4)W<PUJ^X&O\382:D!?S#*TQ?=8?,_NF+S3:Y4P3C'A,26
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M&3,%D,\WE(K]C0I0]^&+/U!+ P04 " "QB1!3RA#C;\4" #(!P &0
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M)@"_SX70[Q-SFM>7]_ ?4$L#!!0 ( +&)$%/1I*@*L00 &L8 9
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MU "21PT@!8"\!?1. +H%H&L*Z!6 GBF@7P#ZIC$X!< Q]3 H -3#\,",#3U
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M,7%HI [*WQ<F_P%02P,$% @ L8D04_?4J\:B P D0X !D !X;"]W
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M#-4I=/H#4$L#!!0 ( +&)$%/U3/" +@0 -P4 9 >&PO=V]R:W-H
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MH#S0'/\/4$L#!!0 ( +&)$%-1'FLP1@0 #T3 9 >&PO=V]R:W-H
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M/ W7V[!%^ "L<&<"!!1\$(C*>[4HKK^=\-V M-0#%VI\M51W666VR3-#5W)
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MD6QK#B,63$J6F,L-P2'AVD ]7S$FCS<Z0'YB-OX?4$L#!!0 ( +&)$%/
M@T%VT@4 /X; 9 >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;+U9VV[;
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M4$L#!!0 ( +&)$%.HIORG8@, $4- 9 >&PO=V]R:W-H965T<R]S
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MW>/2O.>@M!O,^EP(?3^P#NHWI\D/4$L#!!0 ( +&)$%,Q6E6K @4 )<5
M 9 >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;*U877.;.!3]*QK//G1G
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M)7Y#?DU0!0V5;Z5Z[7JW7T'0NFKO=CM.=T12\$&MT:P4V09\)?G1MAM"W:X
MV7<%$VNT08>7]4KUFEZ],EC!@=7*8-4S61N)HDNJUVYV>PEDWTO\5/[X4WJ7
M5I-:JGMQT%10OJM.^ 38L&,IZ[."=K0]1;RKSLYZX_?P9@D-XRMXLZ[/"#OZ
M^LCR(^%J7RM 3K=J*L^)5'OD]2E@?2/9H3KF>F)2LJ*ZW%.24JX-U/,M8_)\
MHR=HSV(7_P)02P,$% @ L8D04WMDVTBB P >0P !D !X;"]W;W)K
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MF/P'4$L#!!0 ( +&)$%/_),B+5@0 (82 9 >&PO=V]R:W-H965T
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M P04 " "QB1!3F!7@;F<# "%"P &0 'AL+W=O<FMS:&5E=',O<VAE
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M:+R/V&&"]V20Q@#_QT+HW<1<2JJ;]_0O4$L#!!0 ( +&)$%.U"X29F@,
M "$. 9 >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;+5778^;.!3]*Q8=
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M)L/ZM5Z"[6;RCD9W>B>KKR[ZI'>J'T!(.-CV(JU=$/_$ I+6)PA^HH U0%?
M _I1SH[+KMI7-(]R[:9K8C6!LCHU(*U[D#L^Z0R!U(@LEZQ[,$A.@ 5O3;E
M=?;OYO!T2<6&Y5+O"F(-Y9]/] 2(ZCQ2-10ORBW]+5?Z@% ^)OH,!\(,T.]C
MSM5#PYP2FE/AXB=02P,$% @ L8D04PNU<R@C!0 BA@ !D !X;"]W
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MC$!*5GB7BR]T_Y$T@J**;TESKOZ"?8V-QR.PW'%!BR98CJ#(ROH3/S1&' 3
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M'?!T):$VVM]^21"$?YRV8+H3!N"18,9!# KU&FU[X1V@0 U%V% %((4/]JH
MYJ\?S>)_&4W_9*#KZI"[JWO>XQE>T0;212<\G $*OZ:P'D2\.OGB)<G[UG=]
M)G+WF8;U:<:7="<;,3D%R+.FQ$"F^!SYOUJM'HI+K''S%^9;/#]?W]NNJT7N
MKO9$;T^H9W>>Z#PZXJP[SC_WCSC[LGR+Y^>KG?4.SE8+PM;J4)L#Y55]J-;>
M;0_.WZOC8NW^%;RXAI;[<WBQJ(_%._KZE/XS9NNLY-+\E4SEGX_E/LSJ@^_Z
M0M"M.MF]HT+00GW=$)P25@'D[RM*Q=-%E:#]]\/L/U!+ P04 " "QB1!3
M56'+3%H# "*#0 &0 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6RUEUMO
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M2P,$% @ L8D04WH*8XL,!@ 31L !D !X;"]W;W)K<VAE971S+W-H
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MCFV>3(B,0U-D&4T8-$2Z@U4TIJ8-P# N3#XA5!,<V0\Z9XWT*D',\H3L9&O
M;IA1B^%AQ%9(?>SN]$8/5YT+0*DI59%#V81B_T)QF)2%:>N82U7.<O XC@55
M\#1A,CXBC_,*0-0XO8'OMS9$CY6'85I!]]V*_N7'A/)<ZOVP-9+NA8>!V)G
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M+P8-KI" !1>J[Q:,Y'L:<-%2M@2*_9.P1O8LAYVL]YW3Z3UO*W':[CQDC&T
M UOG&(HM_^*>/PXY"M9+=''C)Z23_(:$+=-B-]/^"*:IMNC'--CR+^XY1=;I
M[A93;"D6GV26Q)8HL9LH7R:FE;/G+'.$9K"E/=QS'CP[/*JN("V'X9,,A:'E
MKM ]GKTLB^'S'R$FK60]:KPGT"^:/A*Q8KE$*5V"I3><P-$4Y;N;\H/B&_/J
M8,&5XIFY7%.24*$7P/,EYVK_0;^-J-^@S?X'4$L#!!0 ( +&)$%-JZI(V
M6P( #(& 9 >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;)6576_:,!2&
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MFL/$-IKV,Y'\!5!+ P04 " "QB1!3=PP_"CX" O!0 &0 'AL+W=O
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MK1&FK'LCQW\!4$L#!!0 ( +&)$%,N6:.)'P, ! 2 - >&PO<W1Y
M;&5S+GAM;-U8;6O;,!#^*T8=HX51)W'CQFL2V *%P38*[8=]*THL)P)9\F2E
M2_KKIY,<YZ6ZTO7#ULPAM72/[KE'=^?*9%B;M6"W"\9,M"J%K$=D84SU,8[K
MV8*5M#Y7%9,6*90NJ;%3/8_K2C.:U^!4BKC7Z:1Q2;DDXZ%<EM>EJ:.96DHS
M(A>M*?*W+_F(=-,+$GFZB<K9B-R?OO^Y5.;J7>3O)Q].3CKW9U>']E,'G)$X
M2-I_ >EYQUXHLT,Q^O1E],^18]27^]3-<LNT\72.<9/;\;!0<IOBA'B#9:8E
MBQZH&)$)%7RJ.7@5M.1B[<T],,R44#HRMK8V5!<L]:.'NWX&96]X2BZ5=K%]
M!/]WVBP_ #8S$,B%: 7VB#>,AQ4UAFEY;2=NL3,^@:)F?+>NK,*YINMNKT^V
M#NYF@TR5SIENPW3)QC0>"E: ',WG"[@;5<4 &J-*.\@YG2M)G8:-1S.PM#,F
MQ"T\$S^*/>Y5L5.S#E1,MD,KJ!EZ&C\!_ETVS[U+^SK>J.(/RGQ>VNU(-X<N
M8S>:%7SEYJNB%8"Q=W%V6E5B_4GPN2R9W_R+ XZ'=.,7+93FCS8:M,K,&I@F
MT0/3AL]V+;\TK>[8RFS::57@FGM'J/GOYGG.)--4[(JVO?^6L_QJQ<GEOY+L
M_JL<"@YJ; ZZMRZR?PPBTV,0>00]F61O4F/<'(T[Y^_>Z=M:(WC+&9'O\+XD
MMD&CZ9(+PV4S6_ \9_+)(6SI#9W:U]T]?KL^9P5="G/7@B.R'7]C.5^66;OJ
M!A+1K-J.O\+VNFG[BF5C<9FS%<LGS53/IVX8V8&-VES@<(A<NRN,8#X>"R.
M87$P!9B/]\+B_$_[&:#[\1BF;1!$!JC/ /7Q7B%DXCY8G+!/9J_P3K,L2=(4
MR^AD$E0PP?*6IO -LV':P .+ Y'^+-=XM?$.>;X/L)H^UR'83O%.Q':*YQJ0
M<-[ (\O"U<;B@ =6!:QW('XX#O14V"=)H*J8-NP)QI$LPQ#HQ7"/IBF2G10^
MX?I@3TF29%D8 2RL($DP!)Y&',$4@ 8,21)W#AZ<1_'FG(JWOP&-?P-02P,$
M% @ L8D04Y>*NQS $P( L !?<F5L<R\N<F5L<YV2N6[#, Q
M?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2V
MBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=S
MI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YV
MX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)
M#^Q^ %!+ P04 " "QB1!3_C9UEML$ #3)P #P 'AL+W=O<FMB;V]K
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M\CR]-:SZ:/:UXZ3:H=J6>3Z%MAL%@<K.[Z2=WZ?[_"]02P,$% @ L8D0
M4Y@;6I[[ 0 RR, !H !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W:
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MOV@O."?X=^?Q+U!+ P04 " "QB1!3=-+&8MX! !:(P $P %M#;VYT
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M A0#% @ L8D04P=!36*! L0 ! ( ! &1O
M8U!R;W!S+V%P<"YX;6Q02P$"% ,4 " "QB1!3W%[LWNX K @ $0
M @ &O 9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 " "Q
MB1!3F5R<(Q & "<)P $P @ ', 0 >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0 ( +&)$%,JRG"G1@4 'T5 8
M " @0T( !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4 " "Q
MB1!3?>8UXKL& 0&P & @(&)#0 >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#% @ L8D04UT_L%[F @ T0D !@
M ("!>A0 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M ( +&)$%/*%F<#@04 (86 8 " @987 !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4 " "QB1!3Q@F!DCH# "J"0
M& @(%-'0 >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#% @ L8D04[K8>P &"0 ##8 !@ ("!O2 'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0 ( +&)$%.X&@MF4P@
M &8D 8 " @?DI !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4 " "QB1!3_> 05&L% #."P & @(&"
M,@ >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#% @ L8D04YGE
MN(>9" J!4 !@ ("!(S@ 'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0 ( +&)$%.<F-[-;@L *<@ 9
M " @?) !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#% @
ML8D04[Y>(1_3"P ?"$ !D ("!ETP 'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4 " "QB1!38LW0S4T# #V!P &0
M @(&A6 >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0 ( +&)$%,@Z))38P, +\' 9 " @25< !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#% @ L8D04^.4YR?/ @
M(08 !D ("!OU\ 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4 " "QB1!3I@!IA;(" #T!0 &0 @('%
M8@ >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0 ( +&)$%/_
MW L?M@4 *P3 9 " @:YE !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#% @ L8D04T7;X".<!0 > T !D
M ("!FVL 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M" "QB1!3#S/>K#() #X( &0 @(%N<0 >&PO=V]R:W-H
M965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0 ( +&)$%-(3VIEA < P: 9
M " @==Z !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L!
M A0#% @ L8D04\EHCU5!!@ HQP !D ("!DH( 'AL
M+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4 " "QB1!3WK4X#<<"
M E!@ &0 @($*B0 >&PO=V]R:W-H965T<R]S:&5E=#(Q
M+GAM;%!+ 0(4 Q0 ( +&)$%/QX>8\J0H $0< 9 "
M@0B, !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#% @ L8D0
M4[^\#<FE @ M@4 !D ("!Z)8 'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4 " "QB1!3L8'36Y4' !L% &0
M @('$F0 >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M ( +&)$%.K<>SN"0, &\& 9 " @9"A !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#% @ L8D04XI%R421! [0L
M !D ("!T*0 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4 " "QB1!3.0]+MKH" !3!@ &0 @(&8J0
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0 ( +&)$%-2B99\
MB ( %T% 9 " @8FL !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#% @ L8D04ZMO/!WJ @ , 8 !D
M ("!2*\ 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4 " "Q
MB1!3VE&0W< " #U!0 &0 @(%IL@ >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0 ( +&)$%/-%B*X] 8 %P< 9
M " @6"U !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#
M% @ L8D04TIF<Q:?! D0X !D ("!B[P 'AL+W=O
M<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4 " "QB1!3S2%R'W@" !,
M!0 &0 @(%AP0 >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM
M;%!+ 0(4 Q0 ( +&)$%.M;OFE]@( /4( 9 " @1#$
M !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#% @ L8D04Z=4
M15 _ P \0D !D ("!/<< 'AL+W=O<FMS:&5E=',O<VAE
M970S-2YX;6Q02P$"% ,4 " "QB1!396A!JFP# 5# &0
M @(&SR@ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0 (
M +&)$%,M/VA)80( ,@% 9 " @5;. !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#% @ L8D04_"R<WFE!@ RBH !D
M ("![M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4 " "QB1!33&_C"U4" !7!0 &0 @('*UP >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0 ( +&)$%-XW-5[(P,
M $<+ 9 " @5;: !X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#% @ L8D04S<\1SR5 @ X@8 !D ("!
ML-T 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4 " "QB1!3
M@%BG.R,# "_"P &0 @(%\X >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0 ( +&)$%,%'O:RL0, ),/ 9
M " @=;C !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M @ L8D04\H0XV_% @ R < !D ("!ON< 'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4 " "QB1!3T:2H"K$$ !K&
M&0 @(&ZZ@ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0 ( +&)$%/WU*O&H@, )$. 9 " @:+O !X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#% @ L8D04_5,\( N
M! W!0 !D ("!>_, 'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4 " "QB1!341YK,$8$ ]$P &0
M@('@]P >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0 ( +&)
M$%/ @T%VT@4 /X; 9 " @5W\ !X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#% @ L8D04ZBF_*=B P 10T !D
M ("!9@(! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
M " "QB1!3,5I5JP(% "7%0 &0 @('_!0$ >&PO=V]R
M:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0 ( +&)$%-[9-M(H@, 'D,
M 9 " @3@+ 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL
M4$L! A0#% @ L8D04_\DR(M6! AA( !D ("!$0\!
M 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4 " "QB1!3F!7@
M;F<# "%"P &0 @(&>$P$ >&PO=V]R:W-H965T<R]S:&5E
M=#4T+GAM;%!+ 0(4 Q0 ( +&)$%.U"X29F@, "$. 9
M " @3P7 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#% @
ML8D04PNU<R@C!0 BA@ !D ("!#1L! 'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"% ,4 " "QB1!356'+3%H# "*#0 &0
M @(%G( $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4
M Q0 ( +&)$%-Z"F.+# 8 $T; 9 " @?@C 0!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#% @ L8D04VKJDC9; @
M,@8 !D ("!.RH! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6Q02P$"% ,4 " "QB1!3=PP_"CX" O!0 &0 @('-
M+ $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0 ( +&)$%,N
M6:.)'P, ! 2 - " 4(O 0!X;"]S='EL97,N>&UL4$L!
M A0#% @ L8D04Y>*NQS $P( L ( !C#(! %]R
M96QS+RYR96QS4$L! A0#% @ L8D04_XV=9;;! TR< \
M ( !=3,! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0 ( +&)$%.8&UJ>
M^P$ ,LC : " 7TX 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0 ( +&)$%-TTL9BW@$ %HC 3
M " ; Z 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@ !$ $0 DQ( +\\
$ 0 $!
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
..report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
..report table.authRefData a {
display: block;
font-weight: bold;
}
..report table.authRefData p {
margin-top: 0px;
}
..report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
..report table.authRefData .hide a:hover {
background-color: #2F4497;
}
..report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
..report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
..pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
..report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
..report hr {
border: 1px solid #acf;
}
/* Top labels */
..report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
..report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
..report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
..report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
..report td.pl div.a {
width: 200px;
}
..report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
..report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
..report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
..report .re, .report .reu {
background-color: #def;
}
..report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
..report .ro, .report .rou {
background-color: white;
}
..report .rou td {
border-bottom: 1px solid black;
}
..report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
..report .fn {
white-space: nowrap;
}
/* styles for numeric types */
..report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
..report .nump {
padding-left: 2em;
}
..report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
..report .text {
text-align: left;
white-space: normal;
}
..report .text .big {
margin-bottom: 1em;
width: 17em;
}
..report .text .more {
display: none;
}
..report .text .note {
font-style: italic;
font-weight: bold;
}
..report .text .small {
width: 10em;
}
..report sup {
font-style: italic;
}
..report .outerFootnotes {
font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
<Version>3.21.2</Version>
<ProcessingTime/>
<ReportFormat>html</ReportFormat>
<ContextCount>285</ContextCount>
<ElementCount>374</ElementCount>
<EntityCount>1</EntityCount>
<FootnotesReported>false</FootnotesReported>
<SegmentCount>59</SegmentCount>
<ScenarioCount>0</ScenarioCount>
<TuplesReported>false</TuplesReported>
<UnitCount>8</UnitCount>
<MyReports>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R1.htm</HtmlFileName>
<LongName>0001001 - Document - Document and Entity Information</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/DocumentandEntityInformation</Role>
<ShortName>Document and Entity Information</ShortName>
<MenuCategory>Cover</MenuCategory>
<Position>1</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R2.htm</HtmlFileName>
<LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
<ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>2</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R3.htm</HtmlFileName>
<LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
<ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>3</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R4.htm</HtmlFileName>
<LongName>1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
<ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>4</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R5.htm</HtmlFileName>
<LongName>1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
<ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>5</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R6.htm</HtmlFileName>
<LongName>1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
<ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>6</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R7.htm</HtmlFileName>
<LongName>1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
<ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>7</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R8.htm</HtmlFileName>
<LongName>2101101 - Disclosure - Description of Business</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/DescriptionofBusiness</Role>
<ShortName>Description of Business</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>8</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R9.htm</HtmlFileName>
<LongName>2103102 - Disclosure - Liquidity and Capital Resources</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/LiquidityandCapitalResources</Role>
<ShortName>Liquidity and Capital Resources</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>9</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R10.htm</HtmlFileName>
<LongName>2105103 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements</Role>
<ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>10</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R11.htm</HtmlFileName>
<LongName>2109104 - Disclosure - Revenue Recognition</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/RevenueRecognition</Role>
<ShortName>Revenue Recognition</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>11</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R12.htm</HtmlFileName>
<LongName>2115105 - Disclosure - Investments - Available-for-Sale</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/InvestmentsAvailableforSale</Role>
<ShortName>Investments - Available-for-Sale</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>12</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R13.htm</HtmlFileName>
<LongName>2118106 - Disclosure - Inventory</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/Inventory</Role>
<ShortName>Inventory</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>13</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R14.htm</HtmlFileName>
<LongName>2121107 - Disclosure - Property and Equipment</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/PropertyandEquipment</Role>
<ShortName>Property and Equipment</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>14</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R15.htm</HtmlFileName>
<LongName>2124108 - Disclosure - Accrued Liabilities</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/AccruedLiabilities</Role>
<ShortName>Accrued Liabilities</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>15</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R16.htm</HtmlFileName>
<LongName>2127109 - Disclosure - Deferred Revenue</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/DeferredRevenue</Role>
<ShortName>Deferred Revenue</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>16</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R17.htm</HtmlFileName>
<LongName>2129110 - Disclosure - Stockholders??? Equity</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/StockholdersEquity</Role>
<ShortName>Stockholders??? Equity</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>17</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R18.htm</HtmlFileName>
<LongName>2131111 - Disclosure - Stock-Based Compensation</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/StockBasedCompensation</Role>
<ShortName>Stock-Based Compensation</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>18</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R19.htm</HtmlFileName>
<LongName>2140112 - Disclosure - Licensing Agreements</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/LicensingAgreements</Role>
<ShortName>Licensing Agreements</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>19</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R20.htm</HtmlFileName>
<LongName>2142113 - Disclosure - Leases</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/Leases</Role>
<ShortName>Leases</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>20</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R21.htm</HtmlFileName>
<LongName>2147114 - Disclosure - Commitments and Contingencies</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/CommitmentsandContingencies</Role>
<ShortName>Commitments and Contingencies</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>21</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R22.htm</HtmlFileName>
<LongName>2148115 - Disclosure - Loans and Security Agreement</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/LoansandSecurityAgreement</Role>
<ShortName>Loans and Security Agreement</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>22</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R23.htm</HtmlFileName>
<LongName>2152116 - Disclosure - Subsequent Events</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/SubsequentEvents</Role>
<ShortName>Subsequent Events</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>23</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R24.htm</HtmlFileName>
<LongName>2206201 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies</Role>
<ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</ShortName>
<MenuCategory>Policies</MenuCategory>
<ParentRole>http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements</ParentRole>
<Position>24</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R25.htm</HtmlFileName>
<LongName>2307301 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables</Role>
<ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements</ParentRole>
<Position>25</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R26.htm</HtmlFileName>
<LongName>2310302 - Disclosure - Revenue Recognition (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/RevenueRecognitionTables</Role>
<ShortName>Revenue Recognition (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://rockwellmed.com/role/RevenueRecognition</ParentRole>
<Position>26</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R27.htm</HtmlFileName>
<LongName>2316303 - Disclosure - Investments - Available-for-Sale (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/InvestmentsAvailableforSaleTables</Role>
<ShortName>Investments - Available-for-Sale (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://rockwellmed.com/role/InvestmentsAvailableforSale</ParentRole>
<Position>27</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R28.htm</HtmlFileName>
<LongName>2319304 - Disclosure - Inventory (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/InventoryTables</Role>
<ShortName>Inventory (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://rockwellmed.com/role/Inventory</ParentRole>
<Position>28</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R29.htm</HtmlFileName>
<LongName>2322305 - Disclosure - Property and Equipment (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/PropertyandEquipmentTables</Role>
<ShortName>Property and Equipment (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://rockwellmed.com/role/PropertyandEquipment</ParentRole>
<Position>29</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R30.htm</HtmlFileName>
<LongName>2325306 - Disclosure - Accrued Liabilities (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/AccruedLiabilitiesTables</Role>
<ShortName>Accrued Liabilities (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://rockwellmed.com/role/AccruedLiabilities</ParentRole>
<Position>30</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R31.htm</HtmlFileName>
<LongName>2332307 - Disclosure - Stock-Based Compensation (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/StockBasedCompensationTables</Role>
<ShortName>Stock-Based Compensation (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://rockwellmed.com/role/StockBasedCompensation</ParentRole>
<Position>31</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R32.htm</HtmlFileName>
<LongName>2343308 - Disclosure - Leases (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/LeasesTables</Role>
<ShortName>Leases (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://rockwellmed.com/role/Leases</ParentRole>
<Position>32</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R33.htm</HtmlFileName>
<LongName>2349309 - Disclosure - Loans and Security Agreement (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/LoansandSecurityAgreementTables</Role>
<ShortName>Loans and Security Agreement (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://rockwellmed.com/role/LoansandSecurityAgreement</ParentRole>
<Position>33</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R34.htm</HtmlFileName>
<LongName>2402401 - Disclosure - Description of Business (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/DescriptionofBusinessDetails</Role>
<ShortName>Description of Business (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://rockwellmed.com/role/DescriptionofBusiness</ParentRole>
<Position>34</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R35.htm</HtmlFileName>
<LongName>2404402 - Disclosure - Liquidity and Capital Resources (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails</Role>
<ShortName>Liquidity and Capital Resources (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://rockwellmed.com/role/LiquidityandCapitalResources</ParentRole>
<Position>35</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R36.htm</HtmlFileName>
<LongName>2408403 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Summary of Potentially Dilutive Securities (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails</Role>
<ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Summary of Potentially Dilutive Securities (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>36</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R37.htm</HtmlFileName>
<LongName>2411404 - Disclosure - Revenue Recognition - Nature of Goods and Services (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails</Role>
<ShortName>Revenue Recognition - Nature of Goods and Services (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>37</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R38.htm</HtmlFileName>
<LongName>2412405 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails</Role>
<ShortName>Revenue Recognition - Disaggregation of Revenue (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>38</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R39.htm</HtmlFileName>
<LongName>2413406 - Disclosure - Revenue Recognition - Contract Balances (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails</Role>
<ShortName>Revenue Recognition - Contract Balances (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>39</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R40.htm</HtmlFileName>
<LongName>2414407 - Disclosure - Revenue Recognition - Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails</Role>
<ShortName>Revenue Recognition - Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>40</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R41.htm</HtmlFileName>
<LongName>2417408 - Disclosure - Investments - Available-for-Sale (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails</Role>
<ShortName>Investments - Available-for-Sale (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://rockwellmed.com/role/InvestmentsAvailableforSaleTables</ParentRole>
<Position>41</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R42.htm</HtmlFileName>
<LongName>2420409 - Disclosure - Inventory (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/InventoryDetails</Role>
<ShortName>Inventory (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://rockwellmed.com/role/InventoryTables</ParentRole>
<Position>42</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R43.htm</HtmlFileName>
<LongName>2423410 - Disclosure - Property and Equipment (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/PropertyandEquipmentDetails</Role>
<ShortName>Property and Equipment (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://rockwellmed.com/role/PropertyandEquipmentTables</ParentRole>
<Position>43</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R44.htm</HtmlFileName>
<LongName>2426411 - Disclosure - Accrued Liabilities (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/AccruedLiabilitiesDetails</Role>
<ShortName>Accrued Liabilities (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://rockwellmed.com/role/AccruedLiabilitiesTables</ParentRole>
<Position>44</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R45.htm</HtmlFileName>
<LongName>2428412 - Disclosure - Deferred Revenue (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/DeferredRevenueDetails</Role>
<ShortName>Deferred Revenue (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://rockwellmed.com/role/DeferredRevenue</ParentRole>
<Position>45</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R46.htm</HtmlFileName>
<LongName>2430413 - Disclosure - Stockholders??? Equity (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/StockholdersEquityDetails</Role>
<ShortName>Stockholders??? Equity (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://rockwellmed.com/role/StockholdersEquity</ParentRole>
<Position>46</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R47.htm</HtmlFileName>
<LongName>2433414 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails</Role>
<ShortName>Stock-Based Compensation - Share-based compensation expense (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>47</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R48.htm</HtmlFileName>
<LongName>2434415 - Disclosure - Stock-Based Compensation - Restricted Stock Awards (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails</Role>
<ShortName>Stock-Based Compensation - Restricted Stock Awards (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>48</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R49.htm</HtmlFileName>
<LongName>2435416 - Disclosure - Stock-Based Compensation - Service Based and Performance Based Restricted Stock Units (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails</Role>
<ShortName>Stock-Based Compensation - Service Based and Performance Based Restricted Stock Units (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>49</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R50.htm</HtmlFileName>
<LongName>2436417 - Disclosure - Stock-Based Compensation - Service Based Stock Options - Fair value assumptions (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails</Role>
<ShortName>Stock-Based Compensation - Service Based Stock Options - Fair value assumptions (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>50</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R51.htm</HtmlFileName>
<LongName>2437418 - Disclosure - Stock-Based Compensation - Service Based Stock Options (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails</Role>
<ShortName>Stock-Based Compensation - Service Based Stock Options (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>51</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R52.htm</HtmlFileName>
<LongName>2438419 - Disclosure - Stock-Based Compensation - Service Based Stock Options - Others (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails</Role>
<ShortName>Stock-Based Compensation - Service Based Stock Options - Others (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>52</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R53.htm</HtmlFileName>
<LongName>2439420 - Disclosure - Stock-Based Compensation - Performance Based Stock Options (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails</Role>
<ShortName>Stock-Based Compensation - Performance Based Stock Options (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>53</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R54.htm</HtmlFileName>
<LongName>2441421 - Disclosure - Licensing Agreements (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/LicensingAgreementsDetails</Role>
<ShortName>Licensing Agreements (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://rockwellmed.com/role/LicensingAgreements</ParentRole>
<Position>54</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R55.htm</HtmlFileName>
<LongName>2444422 - Disclosure - Leases - Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/LeasesNarrativeDetails</Role>
<ShortName>Leases - Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>55</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R56.htm</HtmlFileName>
<LongName>2445423 - Disclosure - Leases - Summary of Lease Costs (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails</Role>
<ShortName>Leases - Summary of Lease Costs (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>56</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R57.htm</HtmlFileName>
<LongName>2446424 - Disclosure - Leases - Finance Lease and Operating Lease Maturities (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails</Role>
<ShortName>Leases - Finance Lease and Operating Lease Maturities (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>57</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R58.htm</HtmlFileName>
<LongName>2450425 - Disclosure - Loans and Security Agreement - Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails</Role>
<ShortName>Loans and Security Agreement - Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>58</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R59.htm</HtmlFileName>
<LongName>2451426 - Disclosure - Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails</Role>
<ShortName>Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>59</Position>
</Report>
<Report instance="rmti-20210630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R60.htm</HtmlFileName>
<LongName>2453427 - Disclosure - Subsequent Events (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://rockwellmed.com/role/SubsequentEventsDetails</Role>
<ShortName>Subsequent Events (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://rockwellmed.com/role/SubsequentEvents</ParentRole>
<Position>60</Position>
</Report>
<Report>
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<LongName>All Reports</LongName>
<ReportType>Book</ReportType>
<ShortName>All Reports</ShortName>
</Report>
</MyReports>
<InputFiles>
<File doctype="10-Q" original="rmti-20210630.htm">rmti-20210630.htm</File>
<File>rmti-20210630.xsd</File>
<File>rmti-20210630_cal.xml</File>
<File>rmti-20210630_def.xml</File>
<File>rmti-20210630_lab.xml</File>
<File>rmti-20210630_pre.xml</File>
<File>rmti-20210630x10qex311.htm</File>
<File>rmti-20210630x10qex312.htm</File>
<File>rmti-20210630x10qex321.htm</File>
</InputFiles>
<SupplementalFiles/>
<BaseTaxonomies>
<BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
<BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
<BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
<BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
<BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
</BaseTaxonomies>
<HasPresentationLinkbase>true</HasPresentationLinkbase>
<HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
"instance": {
"rmti-20210630.htm": {
"axisCustom": 0,
"axisStandard": 17,
"contextCount": 285,
"dts": {
"calculationLink": {
"local": [
"rmti-20210630_cal.xml"
]
},
"definitionLink": {
"local": [
"rmti-20210630_def.xml"
],
"remote": [
"http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
"http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
]
},
"inline": {
"local": [
"rmti-20210630.htm"
]
},
"labelLink": {
"local": [
"rmti-20210630_lab.xml"
],
"remote": [
"http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
"https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
]
},
"presentationLink": {
"local": [
"rmti-20210630_pre.xml"
]
},
"referenceLink": {
"remote": [
"https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
"http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
]
},
"schema": {
"local": [
"rmti-20210630.xsd"
],
"remote": [
"http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
"http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
"http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
"http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
"http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
"https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
"http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
"https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
"https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
]
}
},
"elementCount": 470,
"entityCount": 1,
"hidden": {
"http://xbrl.sec.gov/dei/2020-01-31": 5,
"total": 5
},
"keyCustom": 35,
"keyStandard": 339,
"memberCustom": 33,
"memberStandard": 25,
"nsprefix": "rmti",
"nsuri": "http://rockwellmed.com/20210630",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "0001001 - Document - Document and Entity Information",
"role": "http://rockwellmed.com/role/DocumentandEntityInformation",
"shortName": "Document and Entity Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R10": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2105103 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements",
"role": "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements",
"shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R11": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2109104 - Disclosure - Revenue Recognition",
"role": "http://rockwellmed.com/role/RevenueRecognition",
"shortName": "Revenue Recognition",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R12": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2115105 - Disclosure - Investments - Available-for-Sale",
"role": "http://rockwellmed.com/role/InvestmentsAvailableforSale",
"shortName": "Investments - Available-for-Sale",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R13": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:InventoryDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2118106 - Disclosure - Inventory",
"role": "http://rockwellmed.com/role/Inventory",
"shortName": "Inventory",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:InventoryDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R14": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2121107 - Disclosure - Property and Equipment",
"role": "http://rockwellmed.com/role/PropertyandEquipment",
"shortName": "Property and Equipment",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R15": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2124108 - Disclosure - Accrued Liabilities",
"role": "http://rockwellmed.com/role/AccruedLiabilities",
"shortName": "Accrued Liabilities",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R16": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "rmti:ContractWithCustomerDeferredRevenueTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2127109 - Disclosure - Deferred Revenue",
"role": "http://rockwellmed.com/role/DeferredRevenue",
"shortName": "Deferred Revenue",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "rmti:ContractWithCustomerDeferredRevenueTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R17": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2129110 - Disclosure - Stockholders\u2019 Equity",
"role": "http://rockwellmed.com/role/StockholdersEquity",
"shortName": "Stockholders\u2019 Equity",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R18": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2131111 - Disclosure - Stock-Based Compensation",
"role": "http://rockwellmed.com/role/StockBasedCompensation",
"shortName": "Stock-Based Compensation",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R19": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2140112 - Disclosure - Licensing Agreements",
"role": "http://rockwellmed.com/role/LicensingAgreements",
"shortName": "Licensing Agreements",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R2": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
"role": "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R20": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LesseeOperatingLeasesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2142113 - Disclosure - Leases",
"role": "http://rockwellmed.com/role/Leases",
"shortName": "Leases",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LesseeOperatingLeasesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R21": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2147114 - Disclosure - Commitments and Contingencies",
"role": "http://rockwellmed.com/role/CommitmentsandContingencies",
"shortName": "Commitments and Contingencies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R22": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2148115 - Disclosure - Loans and Security Agreement",
"role": "http://rockwellmed.com/role/LoansandSecurityAgreement",
"shortName": "Loans and Security Agreement",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R23": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SubsequentEventsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2152116 - Disclosure - Subsequent Events",
"role": "http://rockwellmed.com/role/SubsequentEvents",
"shortName": "Subsequent Events",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SubsequentEventsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R24": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2206201 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)",
"role": "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies",
"shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)",
"subGroupType": "policies",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R25": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2307301 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)",
"role": "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables",
"shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R26": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2310302 - Disclosure - Revenue Recognition (Tables)",
"role": "http://rockwellmed.com/role/RevenueRecognitionTables",
"shortName": "Revenue Recognition (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R27": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2316303 - Disclosure - Investments - Available-for-Sale (Tables)",
"role": "http://rockwellmed.com/role/InvestmentsAvailableforSaleTables",
"shortName": "Investments - Available-for-Sale (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R28": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2319304 - Disclosure - Inventory (Tables)",
"role": "http://rockwellmed.com/role/InventoryTables",
"shortName": "Inventory (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R29": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2322305 - Disclosure - Property and Equipment (Tables)",
"role": "http://rockwellmed.com/role/PropertyandEquipmentTables",
"shortName": "Property and Equipment (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R3": {
"firstAnchor": {
"ancestors": [
"us-gaap:PreferredStockParOrStatedValuePerShare",
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:PreferredStockParOrStatedValuePerShare",
"reportCount": 1,
"unitRef": "usdPerShare",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
"role": "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
"subGroupType": "parenthetical",
"uniqueAnchor": null
},
"R30": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2325306 - Disclosure - Accrued Liabilities (Tables)",
"role": "http://rockwellmed.com/role/AccruedLiabilitiesTables",
"shortName": "Accrued Liabilities (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R31": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2332307 - Disclosure - Stock-Based Compensation (Tables)",
"role": "http://rockwellmed.com/role/StockBasedCompensationTables",
"shortName": "Stock-Based Compensation (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R32": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LeaseCostTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2343308 - Disclosure - Leases (Tables)",
"role": "http://rockwellmed.com/role/LeasesTables",
"shortName": "Leases (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LeaseCostTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R33": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2349309 - Disclosure - Loans and Security Agreement (Tables)",
"role": "http://rockwellmed.com/role/LoansandSecurityAgreementTables",
"shortName": "Loans and Security Agreement (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R34": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i736a800e19204a58b4825177573a05a2_D20210401-20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2402401 - Disclosure - Description of Business (Details)",
"role": "http://rockwellmed.com/role/DescriptionofBusinessDetails",
"shortName": "Description of Business (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"lang": "en-US",
"name": "rmti:YearsOfService",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R35": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:RetainedEarningsAccumulatedDeficit",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2404402 - Disclosure - Liquidity and Capital Resources (Details)",
"role": "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails",
"shortName": "Liquidity and Capital Resources (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R36": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2408403 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Summary of Potentially Dilutive Securities (Details)",
"role": "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails",
"shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Summary of Potentially Dilutive Securities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R37": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "rmti:NumberOfDistributionAndLicenseAgreements",
"reportCount": 1,
"unique": true,
"unitRef": "agreement",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2411404 - Disclosure - Revenue Recognition - Nature of Goods and Services (Details)",
"role": "http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails",
"shortName": "Revenue Recognition - Nature of Goods and Services (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "rmti:NumberOfDistributionAndLicenseAgreements",
"reportCount": 1,
"unique": true,
"unitRef": "agreement",
"xsiNil": "false"
}
},
"R38": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i736a800e19204a58b4825177573a05a2_D20210401-20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2412405 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)",
"role": "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
"shortName": "Revenue Recognition - Disaggregation of Revenue (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i0a076ec540424aaca3aa0743cc065e09_D20210401-20210630",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R39": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherReceivables",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2413406 - Disclosure - Revenue Recognition - Contract Balances (Details)",
"role": "http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails",
"shortName": "Revenue Recognition - Contract Balances (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherReceivables",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R4": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i736a800e19204a58b4825177573a05a2_D20210401-20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
"role": "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i736a800e19204a58b4825177573a05a2_D20210401-20210630",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:CostOfGoodsAndServicesSold",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R40": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i736a800e19204a58b4825177573a05a2_D20210401-20210630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:ContractWithCustomerAssetCreditLossExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2414407 - Disclosure - Revenue Recognition - Narrative (Details)",
"role": "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails",
"shortName": "Revenue Recognition - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i736a800e19204a58b4825177573a05a2_D20210401-20210630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:ContractWithCustomerAssetCreditLossExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R41": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2417408 - Disclosure - Investments - Available-for-Sale (Details)",
"role": "http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails",
"shortName": "Investments - Available-for-Sale (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R42": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:InventoryRawMaterialsNetOfReserves",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2420409 - Disclosure - Inventory (Details)",
"role": "http://rockwellmed.com/role/InventoryDetails",
"shortName": "Inventory (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:InventoryRawMaterialsNetOfReserves",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R43": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:PropertyPlantAndEquipmentTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:PropertyPlantAndEquipmentGross",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2423410 - Disclosure - Property and Equipment (Details)",
"role": "http://rockwellmed.com/role/PropertyandEquipmentDetails",
"shortName": "Property and Equipment (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:PropertyPlantAndEquipmentTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i544f39c3225445aa9a9903581a14c535_I20201231",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:PropertyPlantAndEquipmentGross",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R44": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2426411 - Disclosure - Accrued Liabilities (Details)",
"role": "http://rockwellmed.com/role/AccruedLiabilitiesDetails",
"shortName": "Accrued Liabilities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R45": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:ContractWithCustomerLiability",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2428412 - Disclosure - Deferred Revenue (Details)",
"role": "http://rockwellmed.com/role/DeferredRevenueDetails",
"shortName": "Deferred Revenue (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "ib41a5b0fba4342b8a42fbf0205323776_D20141001-20141031",
"decimals": "-6",
"lang": "en-US",
"name": "rmti:RevenueRecognitionReceived",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R46": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:PreferredStockSharesAuthorized",
"reportCount": 1,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2430413 - Disclosure - Stockholders\u2019 Equity (Details)",
"role": "http://rockwellmed.com/role/StockholdersEquityDetails",
"shortName": "Stockholders\u2019 Equity (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i54ebd73955be4ec087f2c3127f7aef9f_D20210401-20210630",
"decimals": "-5",
"lang": "en-US",
"name": "rmti:SaleofStockRemainingSalesAmount",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R47": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i736a800e19204a58b4825177573a05a2_D20210401-20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2433414 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)",
"role": "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
"shortName": "Stock-Based Compensation - Share-based compensation expense (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55e1c1131a084252abc713575b403ea8_D20210401-20210630",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R48": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i736a800e19204a58b4825177573a05a2_D20210401-20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2434415 - Disclosure - Stock-Based Compensation - Restricted Stock Awards (Details)",
"role": "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
"shortName": "Stock-Based Compensation - Restricted Stock Awards (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i9cc879ec3d384c4891fc21ec9fe0b853_I20201231",
"decimals": "INF",
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R49": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i736a800e19204a58b4825177573a05a2_D20210401-20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2435416 - Disclosure - Stock-Based Compensation - Service Based and Performance Based Restricted Stock Units (Details)",
"role": "http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails",
"shortName": "Stock-Based Compensation - Service Based and Performance Based Restricted Stock Units (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i1dc167d328cb46c68fb83fa95a614259_I20201231",
"decimals": "INF",
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R5": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i736a800e19204a58b4825177573a05a2_D20210401-20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
"role": "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
"shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i736a800e19204a58b4825177573a05a2_D20210401-20210630",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:ComprehensiveIncomeNetOfTax",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R50": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630",
"decimals": "3",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
"reportCount": 1,
"unique": true,
"unitRef": "number",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2436417 - Disclosure - Stock-Based Compensation - Service Based Stock Options - Fair value assumptions (Details)",
"role": "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
"shortName": "Stock-Based Compensation - Service Based Stock Options - Fair value assumptions (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630",
"decimals": "3",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
"reportCount": 1,
"unique": true,
"unitRef": "number",
"xsiNil": "false"
}
},
"R51": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "ie590926897c544debd71e35ba26b6cb4_I20201231",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"reportCount": 1,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2437418 - Disclosure - Stock-Based Compensation - Service Based Stock Options (Details)",
"role": "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
"shortName": "Stock-Based Compensation - Service Based Stock Options (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i72d3d3d7938c411bb6ffd58511f24608_I20210630",
"decimals": "INF",
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R52": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i736a800e19204a58b4825177573a05a2_D20210401-20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2438419 - Disclosure - Stock-Based Compensation - Service Based Stock Options - Others (Details)",
"role": "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails",
"shortName": "Stock-Based Compensation - Service Based Stock Options - Others (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "ie6e6070b3d7646a281c7f2a52c65fbfc_D20210101-20210630",
"decimals": null,
"lang": "en-US",
"name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R53": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i736a800e19204a58b4825177573a05a2_D20210401-20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2439420 - Disclosure - Stock-Based Compensation - Performance Based Stock Options (Details)",
"role": "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"shortName": "Stock-Based Compensation - Performance Based Stock Options (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i12f2cce783ab4aa19f82d7776112d561_I20201231",
"decimals": "INF",
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R54": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i1ec99fab2f214abe99616df767617659_D20181007-20181007",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "rmti:NumberOfAdditionalAgreements",
"reportCount": 1,
"unique": true,
"unitRef": "agreement",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2441421 - Disclosure - Licensing Agreements (Details)",
"role": "http://rockwellmed.com/role/LicensingAgreementsDetails",
"shortName": "Licensing Agreements (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i1ec99fab2f214abe99616df767617659_D20181007-20181007",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "rmti:NumberOfAdditionalAgreements",
"reportCount": 1,
"unique": true,
"unitRef": "agreement",
"xsiNil": "false"
}
},
"R55": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "rmti:OperatingLeaseAndFinanceLeaseLiability",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2444422 - Disclosure - Leases - Narrative (Details)",
"role": "http://rockwellmed.com/role/LeasesNarrativeDetails",
"shortName": "Leases - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "rmti:OperatingLeaseAndFinanceLeaseLiability",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R56": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i736a800e19204a58b4825177573a05a2_D20210401-20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:OperatingLeaseCost",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2445423 - Disclosure - Leases - Summary of Lease Costs (Details)",
"role": "http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails",
"shortName": "Leases - Summary of Lease Costs (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i736a800e19204a58b4825177573a05a2_D20210401-20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:OperatingLeaseCost",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R57": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2446424 - Disclosure - Leases - Finance Lease and Operating Lease Maturities (Details)",
"role": "http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails",
"shortName": "Leases - Finance Lease and Operating Lease Maturities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i55273b6777354d8bbb4e783f2786d443_I20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R58": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "ibc87c3a83e2348a693051682f6add7a3_I20200331",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtInstrumentFaceAmount",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2450425 - Disclosure - Loans and Security Agreement - Narrative (Details)",
"role": "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
"shortName": "Loans and Security Agreement - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "ibc87c3a83e2348a693051682f6add7a3_I20200331",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtInstrumentFaceAmount",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R59": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "ia82218c7009949eebf722cc90aec1835_I20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2451426 - Disclosure - Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details)",
"role": "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails",
"shortName": "Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "ia82218c7009949eebf722cc90aec1835_I20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R6": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "if1331b5ebfa64639a2e460e5675967a1_I20191231",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:CommonStockSharesOutstanding",
"reportCount": 1,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
"role": "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
"shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "ic19a9d3e1a27430b8e5242841760bea9_D20200101-20200331",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R60": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i909302a232e445a29fbed3c3520b5158_I20210703",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtInstrumentFaceAmount",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2453427 - Disclosure - Subsequent Events (Details)",
"role": "http://rockwellmed.com/role/SubsequentEventsDetails",
"shortName": "Subsequent Events (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i909302a232e445a29fbed3c3520b5158_I20210703",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtInstrumentFaceAmount",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R7": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
"role": "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:DepreciationDepletionAndAmortization",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R8": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2101101 - Disclosure - Description of Business",
"role": "http://rockwellmed.com/role/DescriptionofBusiness",
"shortName": "Description of Business",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R9": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "rmti:LiquidityAndFinancialConditionTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2103102 - Disclosure - Liquidity and Capital Resources",
"role": "http://rockwellmed.com/role/LiquidityandCapitalResources",
"shortName": "Liquidity and Capital Resources",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "rmti-20210630.htm",
"contextRef": "i3e1bd365c21f4442837676bd9a195cd7_D20210101-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "rmti:LiquidityAndFinancialConditionTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 59,
"tag": {
"country_US": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "UNITED STATES",
"verboseLabel": "U.S."
}
}
},
"localname": "US",
"nsuri": "http://xbrl.sec.gov/country/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"dei_AmendmentFlag": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag",
"terseLabel": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code",
"terseLabel": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CoverAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Cover page.",
"label": "Cover [Abstract]",
"terseLabel": "Cover [Abstract]"
}
}
},
"localname": "CoverAbstract",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"xbrltype": "stringItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date",
"terseLabel": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus",
"terseLabel": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus",
"terseLabel": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date",
"terseLabel": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "dateItemType"
},
"dei_DocumentQuarterlyReport": {
"auth_ref": [
"r401"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an quarterly report.",
"label": "Document Quarterly Report",
"terseLabel": "Document Quarterly Report"
}
}
},
"localname": "DocumentQuarterlyReport",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentTransitionReport": {
"auth_ref": [
"r402"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a transition report.",
"label": "Document Transition Report",
"terseLabel": "Document Transition Report"
}
}
},
"localname": "DocumentTransitionReport",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentType": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type",
"terseLabel": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address, Address Line One",
"terseLabel": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address, City or Town",
"terseLabel": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address, Postal Zip Code",
"terseLabel": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address, State or Province",
"terseLabel": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key",
"terseLabel": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityCommonStockSharesOutstanding": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
"label": "Entity Common Stock, Shares Outstanding",
"terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
}
}
},
"localname": "EntityCommonStockSharesOutstanding",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "sharesItemType"
},
"dei_EntityCurrentReportingStatus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Current Reporting Status",
"terseLabel": "Entity Current Reporting Status"
}
}
},
"localname": "EntityCurrentReportingStatus",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company",
"terseLabel": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number",
"terseLabel": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category",
"terseLabel": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation, State or Country Code",
"terseLabel": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityInteractiveDataCurrent": {
"auth_ref": [
"r404"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
"label": "Entity Interactive Data Current",
"terseLabel": "Entity Interactive Data Current"
}
}
},
"localname": "EntityInteractiveDataCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityNumberOfEmployees": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Number of persons employed by the Entity",
"label": "Entity Number of Employees",
"terseLabel": "Number of employees"
}
}
},
"localname": "EntityNumberOfEmployees",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DescriptionofBusinessDetails"
],
"xbrltype": "decimalItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name",
"terseLabel": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityShellCompany": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
"label": "Entity Shell Company",
"terseLabel": "Entity Shell Company"
}
}
},
"localname": "EntityShellCompany",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business",
"terseLabel": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number",
"terseLabel": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "employerIdItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number",
"terseLabel": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r399"
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Title of 12(b) Security",
"terseLabel": "Title of 12(b) Security"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "securityTitleItemType"
},
"dei_SecurityExchangeName": {
"auth_ref": [
"r400"
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the Exchange on which a security is registered.",
"label": "Security Exchange Name",
"terseLabel": "Security Exchange Name"
}
}
},
"localname": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "edgarExchangeCodeItemType"
},
"dei_TradingSymbol": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol",
"terseLabel": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DocumentandEntityInformation"
],
"xbrltype": "tradingSymbolItemType"
},
"rmti_A3925NotePayableMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "3.925% Note Payable",
"label": "3.925% Note Payable [Member]",
"terseLabel": "3.925% Note Payable"
}
}
},
"localname": "A3925NotePayableMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/SubsequentEventsDetails"
],
"xbrltype": "domainItemType"
},
"rmti_AccruedUnvoucheredReceiptsCurrent": {
"auth_ref": [],
"calculation": {
"http://rockwellmed.com/role/AccruedLiabilitiesDetails": {
"order": 4.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accrued Unvouchered Receipts, Current",
"label": "Accrued Unvouchered Receipts, Current",
"terseLabel": "Accrued Unvouchered Receipts"
}
}
},
"localname": "AccruedUnvoucheredReceiptsCurrent",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/AccruedLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Adjustments to Additional Paid in Capital, Warrant Modification Expense",
"label": "Adjustments to Additional Paid in Capital, Warrant Modification Expense",
"terseLabel": "Warrant Modification Expense"
}
}
},
"localname": "AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "monetaryItemType"
},
"rmti_AtthemarketOfferingMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "At-The-market Offering [Member]",
"label": "At-the-market Offering [Member]",
"terseLabel": "At-the-Market Offering"
}
}
},
"localname": "AtthemarketOfferingMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/StockholdersEquityDetails",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "domainItemType"
},
"rmti_AveragePaymentTermOfCustomers": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the average payment term of customers.",
"label": "Average Payment Term of Customers",
"terseLabel": "Customers average payment term"
}
}
},
"localname": "AveragePaymentTermOfCustomers",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails"
],
"xbrltype": "durationItemType"
},
"rmti_AveragePaymentTermOfDistributors": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the average payment term of distributors.",
"label": "Average Payment Term of Distributors",
"terseLabel": "Distributors average payment term"
}
}
},
"localname": "AveragePaymentTermOfDistributors",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails"
],
"xbrltype": "durationItemType"
},
"rmti_BaxterHealthcareOrganizationMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Baxter Healthcare Organization [Member]",
"label": "Baxter Healthcare Organization [Member]",
"terseLabel": "Baxter Healthcare Organization"
}
}
},
"localname": "BaxterHealthcareOrganizationMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/DeferredRevenueDetails",
"http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"rmti_BoughtDealMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Bought Deal",
"label": "Bought Deal [Member]",
"terseLabel": "Bought Deal"
}
}
},
"localname": "BoughtDealMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "domainItemType"
},
"rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Class Of Warrant Or Right, Calculation For Number Of Securities Called By Warrants Or Right, Numerator, Percentage Of Principal Amount Of Debt Instrument Funded",
"label": "Class Of Warrant Or Right, Calculation For Number Of Securities Called By Warrants Or Right, Numerator, Percentage Of Principal Amount Of Debt Instrument Funded",
"terseLabel": "Calculation for number of shares of common stock able to be purchased by warrant, percentage of principal amount of relevant term loan funded funded"
}
}
},
"localname": "ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Execution Of Agreement, Trading Days",
"label": "Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Execution Of Agreement, Trading Days",
"terseLabel": "Warrant exercise price calculation, period immediately preceding execution of loan agreement, number of trading days"
}
}
},
"localname": "ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Relevant Funding, Trading Days",
"label": "Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Relevant Funding, Trading Days",
"terseLabel": "Warrant exercise price calculation, period immediately preceding relevant funding, number of trading days"
}
}
},
"localname": "ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"rmti_CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Collaborative Arrangement, Accrued Reimbursement of IP Expenses And Sublicense Royalty Fees",
"label": "Collaborative Arrangement, Accrued Reimbursement of IP Expenses And Sublicense Royalty Fees",
"terseLabel": "Collaborative arrangement, accrued reimbursement of IP expenses and sublicense royalty fees"
}
}
},
"localname": "CollaborativeArrangementAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LicensingAgreementsDetails"
],
"xbrltype": "monetaryItemType"
},
"rmti_CollaborativeArrangementAccruedReimbursementOfLegalExpenses": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the amount of related party transactions accrued reimbursement of legal expenses.",
"label": "Collaborative Arrangement, Accrued Reimbursement of Legal Expenses",
"terseLabel": "Collaborative arrangement, accrued reimbursement of legal expenses"
}
}
},
"localname": "CollaborativeArrangementAccruedReimbursementOfLegalExpenses",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LicensingAgreementsDetails"
],
"xbrltype": "monetaryItemType"
},
"rmti_CollaborativeArrangementNumberOfInstallmentPayments": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Collaborative Arrangement, Number Of Installment Payments",
"label": "Collaborative Arrangement, Number Of Installment Payments",
"terseLabel": "Number of quarterly installment payments"
}
}
},
"localname": "CollaborativeArrangementNumberOfInstallmentPayments",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LicensingAgreementsDetails"
],
"xbrltype": "integerItemType"
},
"rmti_ConcentrateProductLicenseFeeMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Concentrate Product License Fee [Member]",
"label": "Concentrate Product License Fee [Member]",
"terseLabel": "Concentrate product license fee"
}
}
},
"localname": "ConcentrateProductLicenseFeeMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"rmti_ConcentrateProductSalesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Concentrate Product Sales [Member]",
"label": "Concentrate Product Sales [Member]",
"terseLabel": "Concentrate product sales"
}
}
},
"localname": "ConcentrateProductSalesMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"rmti_ConcentrateProductsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Concentrate Products [Member]",
"label": "Concentrate Products [Member]",
"terseLabel": "Concentrate Products"
}
}
},
"localname": "ConcentrateProductsMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
"http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"rmti_ContractWithCustomerDeferredRevenueTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Contract with Customer Deferred Revenue [Text Block]",
"label": "Contract with Customer Deferred Revenue [Text Block]",
"terseLabel": "Deferred Revenue"
}
}
},
"localname": "ContractWithCustomerDeferredRevenueTextBlock",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/DeferredRevenue"
],
"xbrltype": "textBlockItemType"
},
"rmti_ContractWithCustomerRepaymentPercentageOfUpfrontFee": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Contract with Customer, Repayment Percentage of Upfront Fee",
"label": "Contract with Customer, Repayment Percentage of Upfront Fee",
"terseLabel": "Refund percentage"
}
}
},
"localname": "ContractWithCustomerRepaymentPercentageOfUpfrontFee",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/DeferredRevenueDetails"
],
"xbrltype": "percentItemType"
},
"rmti_CurrentAndNonCurrentInventory": {
"auth_ref": [],
"calculation": {
"http://rockwellmed.com/role/InventoryDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the amount of current and non-current inventory.",
"label": "Current And Non Current Inventory",
"totalLabel": "Total"
}
}
},
"localname": "CurrentAndNonCurrentInventory",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/InventoryDetails"
],
"xbrltype": "monetaryItemType"
},
"rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Option To Add Interest Rate Amount To Outstanding Principal Balance In Lieu Of Payment, Percentage",
"label": "Debt Instrument, Option To Add Interest Rate Amount To Outstanding Principal Balance In Lieu Of Payment, Percentage",
"terseLabel": "Option to add interest rate amount to outstanding principal balance in lieu of paying such amount in cash, percentage"
}
}
},
"localname": "DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"rmti_DebtInstrumentPeriodOfInterestOnlyPayments": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Period Of Interest-Only Payments",
"label": "Debt Instrument, Period Of Interest-Only Payments",
"terseLabel": "Period for which company is entitled to make interest-only payments"
}
}
},
"localname": "DebtInstrumentPeriodOfInterestOnlyPayments",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"rmti_DrogsanAgreementsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Drogsan Agreements",
"label": "Drogsan Agreements [Member]",
"terseLabel": "Drogsan Agreements"
}
}
},
"localname": "DrogsanAgreementsMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/DeferredRevenueDetails"
],
"xbrltype": "domainItemType"
},
"rmti_DrugLicenseFeeMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Drug License Fee [Member]",
"label": "Drug License Fee [Member]",
"terseLabel": "Drug license fee"
}
}
},
"localname": "DrugLicenseFeeMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"rmti_DrugProductSalesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Drug Product Sales [Member]",
"label": "Drug Product Sales [Member]",
"terseLabel": "Drug product sales"
}
}
},
"localname": "DrugProductSalesMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"rmti_DrugRevenueMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Drug Revenue [Member]",
"label": "Drug Revenue [Member]",
"terseLabel": "Drug products"
}
}
},
"localname": "DrugRevenueMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the information pertaining to Executive Vice President and Chief Scientific Officer.",
"label": "Executive Vice President And Chief Scientific Officer [Member]",
"terseLabel": "Executive vice president and chief scientific officer"
}
}
},
"localname": "ExecutiveVicePresidentAndChiefScientificOfficerMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LicensingAgreementsDetails"
],
"xbrltype": "domainItemType"
},
"rmti_FinanceLeaseExpense": {
"auth_ref": [],
"calculation": {
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails": {
"order": 2.0,
"parentTag": "us-gaap_LeaseCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Finance Lease, Expense",
"label": "Finance Lease, Expense",
"totalLabel": "Finance lease expense"
}
}
},
"localname": "FinanceLeaseExpense",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"rmti_FinanceLeaseLiabilityToBePaidAfterYearFour": {
"auth_ref": [],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1": {
"order": 5.0,
"parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Finance Lease, Liability, To Be Paid, After Year Four",
"label": "Finance Lease, Liability, To Be Paid, After Year Four",
"terseLabel": "Remaining future payments"
}
}
},
"localname": "FinanceLeaseLiabilityToBePaidAfterYearFour",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"rmti_IncreaseDecreaseInOperatingLeaseLiability": {
"auth_ref": [],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 2.0,
"parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Increase (Decrease) in Operating Lease Liability",
"label": "Increase (Decrease) in Operating Lease Liability",
"terseLabel": "Decrease in Lease Liability"
}
}
},
"localname": "IncreaseDecreaseInOperatingLeaseLiability",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"rmti_InstallmentPaymentToRelatedParties": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow associated with installment payment to related parties.",
"label": "Installment paid",
"terseLabel": "Installment paid"
}
}
},
"localname": "InstallmentPaymentToRelatedParties",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LicensingAgreementsDetails"
],
"xbrltype": "monetaryItemType"
},
"rmti_JeilPharmaAgreementsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Jeil Pharma Agreements",
"label": "Jeil Pharma Agreements [Member]",
"terseLabel": "Jeil Pharma Agreements"
}
}
},
"localname": "JeilPharmaAgreementsMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/DeferredRevenueDetails"
],
"xbrltype": "domainItemType"
},
"rmti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
"auth_ref": [],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1": {
"order": 2.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
"label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
"terseLabel": "Remaining future payments"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"rmti_LiquidityAndCapitalResourcesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "No definition available.",
"label": "Liquidity and Capital Resources [Abstract]",
"terseLabel": "Liquidity and Capital Resources"
}
}
},
"localname": "LiquidityAndCapitalResourcesAbstract",
"nsuri": "http://rockwellmed.com/20210630",
"xbrltype": "stringItemType"
},
"rmti_LiquidityAndFinancialConditionTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure of liquidity position and financial conditions.",
"label": "Liquidity And Financial Condition [Text Block]",
"terseLabel": "Liquidity and Capital Resources"
}
}
},
"localname": "LiquidityAndFinancialConditionTextBlock",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LiquidityandCapitalResources"
],
"xbrltype": "textBlockItemType"
},
"rmti_NumberOfAdditionalAgreements": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the number of additional agreements.",
"label": "Number of additional agreements",
"terseLabel": "Number of additional agreements"
}
}
},
"localname": "NumberOfAdditionalAgreements",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LicensingAgreementsDetails"
],
"xbrltype": "integerItemType"
},
"rmti_NumberOfDistributionAndLicenseAgreements": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the number of distribution and license agreements.",
"label": "Number of Distribution and License Agreements",
"terseLabel": "Number of distribution and license agreements"
}
}
},
"localname": "NumberOfDistributionAndLicenseAgreements",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails"
],
"xbrltype": "integerItemType"
},
"rmti_OperatingLeaseAndFinanceLeaseLiability": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Operating Lease And Finance Lease, Liability",
"label": "Operating Lease And Finance Lease, Liability",
"terseLabel": "Operating lease and finance lease liabilities"
}
}
},
"localname": "OperatingLeaseAndFinanceLeaseLiability",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"rmti_OperatingLeaseAndFinanceLeaseLiabilityCurrent": {
"auth_ref": [],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 7.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Operating Lease And Finance Lease, Liability, Current",
"label": "Operating Lease And Finance Lease, Liability, Current",
"terseLabel": "Lease Liability - Current"
}
}
},
"localname": "OperatingLeaseAndFinanceLeaseLiabilityCurrent",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"rmti_OperatingLeaseAndFinanceLeaseLiabilityNoncurrent": {
"auth_ref": [],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 1.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Operating Lease And Finance Lease, Liability, Noncurrent",
"label": "Operating Lease And Finance Lease, Liability, Noncurrent",
"terseLabel": "Lease Liability - Long-Term"
}
}
},
"localname": "OperatingLeaseAndFinanceLeaseLiabilityNoncurrent",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"rmti_OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet": {
"auth_ref": [],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 3.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Operating Lease And Finance Lease, Right of Use Assets, Net",
"label": "Operating Lease And Finance Lease, Right of Use Assets, Net",
"terseLabel": "Right of Use Assets, net",
"verboseLabel": "Operating lease and finance lease, right of use assets, net"
}
}
},
"localname": "OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://rockwellmed.com/role/LeasesNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"rmti_PerformanceBasedAwardsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to performance based awards.",
"label": "Performance Based Awards [Member]",
"terseLabel": "Performance based awards"
}
}
},
"localname": "PerformanceBasedAwardsMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails"
],
"xbrltype": "domainItemType"
},
"rmti_PerformanceBasedRestrictedStockAwardsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "na",
"label": "Performance Based Restricted Stock Awards [Member]",
"terseLabel": "Restricted stock awards - performance based awards"
}
}
},
"localname": "PerformanceBasedRestrictedStockAwardsMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
"http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails"
],
"xbrltype": "domainItemType"
},
"rmti_PerformanceBasedRestrictedStockUnitsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Performance Based Restricted Stock Units [Member]",
"label": "Performance Based Restricted Stock Units [Member]",
"terseLabel": "Restricted stock units - performance based awards"
}
}
},
"localname": "PerformanceBasedRestrictedStockUnitsMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails",
"http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
"http://rockwellmed.com/role/StockBasedCompensationTables"
],
"xbrltype": "domainItemType"
},
"rmti_PerformanceBasedStockOptionAwardsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "na",
"label": "Performance Based Stock Option Awards [Member]",
"terseLabel": "Stock option awards - performance based awards"
}
}
},
"localname": "PerformanceBasedStockOptionAwardsMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
"http://rockwellmed.com/role/StockBasedCompensationTables"
],
"xbrltype": "domainItemType"
},
"rmti_PublicOfferingMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Public Offering [Member]",
"label": "Public Offering [Member]",
"terseLabel": "Public Offering"
}
}
},
"localname": "PublicOfferingMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "domainItemType"
},
"rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes": {
"auth_ref": [],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Repurchase of common shares to pay employee withholding taxes.",
"label": "Repurchase Of Common Shares To Pay Employee Withholding Taxes",
"negatedTerseLabel": "Repurchase of Common Stock to Pay Employee Withholding Taxes"
}
}
},
"localname": "RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent": {
"auth_ref": [],
"calculation": {
"http://rockwellmed.com/role/AccruedLiabilitiesDetails": {
"order": 2.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Research and Development Related Liabilities, Current",
"terseLabel": "Accrued Research\u00a0& Development Expense"
}
}
},
"localname": "ResearchAndDevelopmentRelatedLiabilitiesCurrent",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/AccruedLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"rmti_RevenueRecognitionLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Revenue Recognition [Line Items]",
"label": "Revenue Recognition [Line Items]",
"terseLabel": "Revenue Recognition [Line Items]"
}
}
},
"localname": "RevenueRecognitionLineItems",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"rmti_RevenueRecognitionReceived": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of consideration received during the period for the milestone.",
"label": "Revenue Recognition Received",
"terseLabel": "Upfront payment"
}
}
},
"localname": "RevenueRecognitionReceived",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/DeferredRevenueDetails"
],
"xbrltype": "monetaryItemType"
},
"rmti_RevenueRecognitionTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Revenue Recognition [Table]",
"label": "Revenue Recognition [Table]",
"terseLabel": "Revenue Recognition [Table]"
}
}
},
"localname": "RevenueRecognitionTable",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"rmti_SaleofStockRemainingSalesAmount": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sale of Stock, Remaining Sales Amount",
"label": "Sale of Stock, Remaining Sales Amount",
"terseLabel": "Remaining amount available for sale"
}
}
},
"localname": "SaleofStockRemainingSalesAmount",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/StockholdersEquityDetails"
],
"xbrltype": "monetaryItemType"
},
"rmti_SalesAgreementThresholdSaleOfShares": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of threshold offering or sale of shares under the sales agreement.",
"label": "Sales Agreement, Threshold Sale Of Shares",
"terseLabel": "Sales agreement, threshold sale of shares"
}
}
},
"localname": "SalesAgreementThresholdSaleOfShares",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/StockholdersEquityDetails"
],
"xbrltype": "monetaryItemType"
},
"rmti_ServiceBasedAwardsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to service based awards.",
"label": "Service Based Awards [Member]",
"terseLabel": "Service based awards"
}
}
},
"localname": "ServiceBasedAwardsMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails"
],
"xbrltype": "domainItemType"
},
"rmti_ServiceBasedRestrictedStockUnitsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "na",
"label": "Service Based Restricted Stock Units [Member]",
"terseLabel": "Restricted stock units - service based awards",
"verboseLabel": "Restricted stock units - service based awards"
}
}
},
"localname": "ServiceBasedRestrictedStockUnitsMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails",
"http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
"http://rockwellmed.com/role/StockBasedCompensationTables"
],
"xbrltype": "domainItemType"
},
"rmti_ServiceBasedStockOptionAwardsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "na",
"label": "Service Based Stock Option Awards [Member]",
"terseLabel": "Stock option awards - service based awards"
}
}
},
"localname": "ServiceBasedStockOptionAwardsMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails",
"http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
"http://rockwellmed.com/role/StockBasedCompensationTables"
],
"xbrltype": "domainItemType"
},
"rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "NA",
"label": "Aggregate intrinsic Value",
"terseLabel": "Aggregate Intrinsic Value"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
],
"xbrltype": "stringItemType"
},
"rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "NA",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
"terseLabel": "Weighted Average Remaining Contractual Term"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
],
"xbrltype": "stringItemType"
},
"rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term 2",
"label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term 2",
"terseLabel": "Granted"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
],
"xbrltype": "durationItemType"
},
"rmti_SunPharmaAgreementsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Sun Pharma Agreements [Member]",
"label": "Sun Pharma Agreements [Member]",
"terseLabel": "Sun Pharma Agreements"
}
}
},
"localname": "SunPharmaAgreementsMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/DeferredRevenueDetails"
],
"xbrltype": "domainItemType"
},
"rmti_TermLoanMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Term Loan [Member]",
"label": "Term Loan [Member]",
"terseLabel": "Term loan"
}
}
},
"localname": "TermLoanMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
],
"xbrltype": "domainItemType"
},
"rmti_TermLoanTrancheOneMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Term Loan, Tranche One [Member]",
"label": "Term Loan, Tranche One [Member]",
"terseLabel": "Term loan, first tranche"
}
}
},
"localname": "TermLoanTrancheOneMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"rmti_TermLoanTrancheThreeMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Term Loan, Tranche Three [Member]",
"label": "Term Loan, Tranche Three [Member]",
"terseLabel": "Term loan, third tranche"
}
}
},
"localname": "TermLoanTrancheThreeMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"rmti_TermLoanTrancheTwoAndTrancheThreeMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Term Loan, Tranche Two And Tranche Three [Member]",
"label": "Term Loan, Tranche Two And Tranche Three [Member]",
"terseLabel": "Term loan, second and third tranches"
}
}
},
"localname": "TermLoanTrancheTwoAndTrancheThreeMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"rmti_TermLoanTrancheTwoMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Term Loan, Tranche Two [Member]",
"label": "Term Loan, Tranche Two [Member]",
"terseLabel": "Term loan, second tranche"
}
}
},
"localname": "TermLoanTrancheTwoMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"rmti_TrifericAPIMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Triferic API [Member]",
"label": "Triferic API [Member]",
"terseLabel": "Triferic API"
}
}
},
"localname": "TrifericAPIMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/InventoryDetails"
],
"xbrltype": "domainItemType"
},
"rmti_TrifericDialysateMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Triferic Dialysate [Member]",
"label": "Triferic Dialysate [Member]",
"terseLabel": "Triferic Dialysate"
}
}
},
"localname": "TrifericDialysateMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/InventoryDetails"
],
"xbrltype": "domainItemType"
},
"rmti_TrifericInventoryMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Triferic Inventory [Member]",
"label": "Triferic Inventory [Member]",
"terseLabel": "Triferic Inventory"
}
}
},
"localname": "TrifericInventoryMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/InventoryDetails"
],
"xbrltype": "domainItemType"
},
"rmti_WanbangBiopharmaceuticalMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Represents exclusive licensing and manufacturing supply agreements with Wanbang Biopharmaceutical Co., Ltd. (\u201cWanbang\u201d) for the rights to commercialize the Triferic and Calcitriol drugs.",
"label": "Wanbang Biopharmaceutical [Member]",
"terseLabel": "Wanbang Biopharmaceutical"
}
}
},
"localname": "WanbangBiopharmaceuticalMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/DeferredRevenueDetails"
],
"xbrltype": "domainItemType"
},
"rmti_WixomMichiganPropertyOneMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Wixom, Michigan Property One [Member]",
"label": "Wixom, Michigan Property One [Member]",
"terseLabel": "Wixom, Michigan Property One"
}
}
},
"localname": "WixomMichiganPropertyOneMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"rmti_WixomMichiganPropertyTwoMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Wixom, Michigan Property Two [Member]",
"label": "Wixom, Michigan Property Two [Member]",
"terseLabel": "Wixom, Michigan Property Two"
}
}
},
"localname": "WixomMichiganPropertyTwoMember",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"rmti_WorkingCapitalNet": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the monetary amount of working capital, as of the indicated date.",
"label": "Working Capital Net",
"terseLabel": "Working capital"
}
}
},
"localname": "WorkingCapitalNet",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails"
],
"xbrltype": "monetaryItemType"
},
"rmti_YearsOfService": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Years Of Service",
"label": "Years Of Service",
"terseLabel": "Years of service"
}
}
},
"localname": "YearsOfService",
"nsuri": "http://rockwellmed.com/20210630",
"presentation": [
"http://rockwellmed.com/role/DescriptionofBusinessDetails"
],
"xbrltype": "durationItemType"
},
"srt_CounterpartyNameAxis": {
"auth_ref": [
"r57",
"r107"
],
"lang": {
"en-us": {
"role": {
"label": "Counterparty Name [Axis]",
"terseLabel": "Counterparty Name [Axis]"
}
}
},
"localname": "CounterpartyNameAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DeferredRevenueDetails",
"http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"srt_MaximumMember": {
"auth_ref": [
"r249",
"r250",
"r342",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r375",
"r378"
],
"lang": {
"en-us": {
"role": {
"label": "Maximum [Member]",
"terseLabel": "Maximum"
}
}
},
"localname": "MaximumMember",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails",
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails",
"http://rockwellmed.com/role/StockholdersEquityDetails"
],
"xbrltype": "domainItemType"
},
"srt_MinimumMember": {
"auth_ref": [
"r249",
"r250",
"r342",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r375",
"r378"
],
"lang": {
"en-us": {
"role": {
"label": "Minimum [Member]",
"terseLabel": "Minimum"
}
}
},
"localname": "MinimumMember",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"
],
"xbrltype": "domainItemType"
},
"srt_ProductOrServiceAxis": {
"auth_ref": [
"r162",
"r235",
"r240",
"r349",
"r374",
"r376"
],
"lang": {
"en-us": {
"role": {
"label": "Product and Service [Axis]",
"terseLabel": "Product and Service [Axis]"
}
}
},
"localname": "ProductOrServiceAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
"http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"srt_ProductsAndServicesDomain": {
"auth_ref": [
"r162",
"r235",
"r240",
"r349",
"r374",
"r376"
],
"lang": {
"en-us": {
"role": {
"label": "Product and Service [Domain]",
"terseLabel": "Product and Service [Domain]"
}
}
},
"localname": "ProductsAndServicesDomain",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
"http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"srt_RangeAxis": {
"auth_ref": [
"r248",
"r249",
"r250",
"r342",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r375",
"r378"
],
"lang": {
"en-us": {
"role": {
"label": "Statistical Measurement [Axis]",
"terseLabel": "Statistical Measurement [Axis]"
}
}
},
"localname": "RangeAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails",
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails",
"http://rockwellmed.com/role/StockholdersEquityDetails"
],
"xbrltype": "stringItemType"
},
"srt_RangeMember": {
"auth_ref": [
"r248",
"r249",
"r250",
"r342",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r375",
"r378"
],
"lang": {
"en-us": {
"role": {
"label": "Statistical Measurement [Domain]",
"terseLabel": "Range [Domain]"
}
}
},
"localname": "RangeMember",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails",
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails",
"http://rockwellmed.com/role/StockholdersEquityDetails"
],
"xbrltype": "domainItemType"
},
"srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
"auth_ref": [
"r389",
"r390",
"r391",
"r392",
"r393",
"r394",
"r395",
"r396"
],
"lang": {
"en-us": {
"role": {
"label": "Name of Property [Axis]",
"terseLabel": "Name of Property [Axis]"
}
}
},
"localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
"auth_ref": [
"r389",
"r390",
"r391",
"r392",
"r393",
"r394",
"r395",
"r396"
],
"lang": {
"en-us": {
"role": {
"label": "Name of Property [Domain]",
"terseLabel": "Name of Property [Domain]"
}
}
},
"localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"srt_RepurchaseAgreementCounterpartyNameDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Counterparty Name [Domain]",
"terseLabel": "Counterparty Name [Domain]"
}
}
},
"localname": "RepurchaseAgreementCounterpartyNameDomain",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DeferredRevenueDetails",
"http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"srt_SegmentGeographicalDomain": {
"auth_ref": [
"r163",
"r164",
"r235",
"r241",
"r377",
"r389",
"r390",
"r391",
"r392",
"r393",
"r394",
"r395",
"r396"
],
"lang": {
"en-us": {
"role": {
"label": "Geographical [Domain]",
"terseLabel": "Geographical [Domain]"
}
}
},
"localname": "SegmentGeographicalDomain",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails",
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"srt_StatementGeographicalAxis": {
"auth_ref": [
"r163",
"r164",
"r235",
"r241",
"r377",
"r385",
"r389",
"r390",
"r391",
"r392",
"r393",
"r394",
"r395",
"r396",
"r397"
],
"lang": {
"en-us": {
"role": {
"label": "Geographical [Axis]",
"terseLabel": "Geographical [Axis]"
}
}
},
"localname": "StatementGeographicalAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails",
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
],
"xbrltype": "stringItemType"
},
"srt_TitleOfIndividualAxis": {
"auth_ref": [
"r166",
"r338"
],
"lang": {
"en-us": {
"role": {
"label": "Title of Individual [Axis]",
"terseLabel": "Title of Individual [Axis]"
}
}
},
"localname": "TitleOfIndividualAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LicensingAgreementsDetails"
],
"xbrltype": "stringItemType"
},
"srt_TitleOfIndividualWithRelationshipToEntityDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Title of Individual [Domain]",
"terseLabel": "Title of Individual [Domain]"
}
}
},
"localname": "TitleOfIndividualWithRelationshipToEntityDomain",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LicensingAgreementsDetails"
],
"xbrltype": "domainItemType"
},
"stpr_MI": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "MICHIGAN",
"terseLabel": "Wixom, Michigan"
}
}
},
"localname": "MI",
"nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"stpr_NJ": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "NEW JERSEY",
"terseLabel": "Hackensack, New Jersey"
}
}
},
"localname": "NJ",
"nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"stpr_SC": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "SOUTH CAROLINA",
"terseLabel": "Greer, South Carolina"
}
}
},
"localname": "SC",
"nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"stpr_TX": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "TEXAS",
"terseLabel": "Grapevine, Texas"
}
}
},
"localname": "TX",
"nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccountingPoliciesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Accounting Policies [Abstract]",
"terseLabel": "Accounting Policies [Abstract]"
}
}
},
"localname": "AccountingPoliciesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
"auth_ref": [
"r39"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
"label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
"terseLabel": "Accrued Liabilities"
}
}
},
"localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/AccruedLiabilities"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_AccountsPayableCurrent": {
"auth_ref": [
"r38"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accounts Payable, Current",
"terseLabel": "Accounts Payable"
}
}
},
"localname": "AccountsPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsReceivableNetCurrent": {
"auth_ref": [
"r4",
"r19",
"r167",
"r168"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 2.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
"label": "Accounts Receivable, after Allowance for Credit Loss, Current",
"verboseLabel": "Accounts Receivable, net"
}
}
},
"localname": "AccountsReceivableNetCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedLiabilitiesCurrent": {
"auth_ref": [
"r43"
],
"calculation": {
"http://rockwellmed.com/role/AccruedLiabilitiesDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 6.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accrued Liabilities, Current",
"terseLabel": "Accrued Liabilities",
"totalLabel": "Total Accrued Liabilities"
}
}
},
"localname": "AccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/AccruedLiabilitiesDetails",
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
"auth_ref": [
"r36",
"r190"
],
"calculation": {
"http://rockwellmed.com/role/PropertyandEquipmentDetails": {
"order": 1.0,
"parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
"label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
"negatedLabel": "Accumulated Depreciation"
}
}
},
"localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/PropertyandEquipmentDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
"auth_ref": [
"r22",
"r62",
"r63",
"r64",
"r365",
"r383",
"r384"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 3.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
"label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
"terseLabel": "Accumulated Other Comprehensive Income"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
"auth_ref": [
"r61",
"r64",
"r65",
"r112",
"r113",
"r114",
"r293",
"r379",
"r380"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
"label": "AOCI Attributable to Parent [Member]",
"terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdditionalPaidInCapital": {
"auth_ref": [
"r20",
"r280"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 5.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
"label": "Additional Paid in Capital",
"terseLabel": "Additional Paid-in Capital"
}
}
},
"localname": "AdditionalPaidInCapital",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapitalMember": {
"auth_ref": [
"r112",
"r113",
"r114",
"r277",
"r278",
"r279"
],
"lang": {
"en-us": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
"label": "Additional Paid-in Capital [Member]",
"terseLabel": "ADDITIONAL PAID-IN CAPITAL"
}
}
},
"localname": "AdditionalPaidInCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
"label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition",
"verboseLabel": "Stock-based Compensation expense"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
"auth_ref": [
"r200",
"r211",
"r218"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
"label": "Adjustments to Additional Paid in Capital, Warrant Issued",
"terseLabel": "Issuance of Warrants related to Debt Financing"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:"
}
}
},
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "stringItemType"
},
"us-gaap_AllocatedShareBasedCompensationExpense": {
"auth_ref": [
"r252",
"r274",
"r282"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
"label": "Share-based Payment Arrangement, Expense",
"terseLabel": "Stock based compensation expenses",
"verboseLabel": "Total share based compensation expense"
}
}
},
"localname": "AllocatedShareBasedCompensationExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails",
"http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
"auth_ref": [
"r95",
"r313"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 9.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
"label": "Amortization of Debt Issuance Costs and Discounts",
"terseLabel": "Amortization of Debt Financing Costs and Accretion of Debt Discount"
}
}
},
"localname": "AmortizationOfFinancingCostsAndDiscounts",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"auth_ref": [
"r132"
],
"lang": {
"en-us": {
"role": {
"documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
"verboseLabel": "Securities excluded from diluted loss per share calculation (in shares)"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
"auth_ref": [
"r132"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of antidilutive security.",
"label": "Antidilutive Securities [Axis]",
"terseLabel": "Antidilutive Securities [Axis]"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
"terseLabel": "Net Earnings per Share"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesNameDomain": {
"auth_ref": [
"r132"
],
"lang": {
"en-us": {
"role": {
"documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
"label": "Antidilutive Securities, Name [Domain]",
"terseLabel": "Antidilutive Securities, Name [Domain]"
}
}
},
"localname": "AntidilutiveSecuritiesNameDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AreaOfRealEstateProperty": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Area of a real estate property.",
"label": "Area of Real Estate Property",
"verboseLabel": "Facility sqft."
}
}
},
"localname": "AreaOfRealEstateProperty",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails"
],
"xbrltype": "areaItemType"
},
"us-gaap_Assets": {
"auth_ref": [
"r106",
"r151",
"r154",
"r160",
"r178",
"r291",
"r294",
"r297",
"r351",
"r363"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets",
"totalLabel": "Total Assets"
}
}
},
"localname": "Assets",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Assets [Abstract]",
"terseLabel": "ASSETS"
}
}
},
"localname": "AssetsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsCurrent": {
"auth_ref": [
"r5",
"r6",
"r56",
"r106",
"r178",
"r291",
"r294",
"r297"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 6.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets, Current",
"totalLabel": "Total Current Assets"
}
}
},
"localname": "AssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
"auth_ref": [
"r172"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
"terseLabel": "Unrealized Gain"
}
}
},
"localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
"auth_ref": [
"r173"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
"negatedLabel": "Unrealized Loss"
}
}
},
"localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
"auth_ref": [
"r171",
"r181"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 1.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
"label": "Debt Securities, Available-for-sale, Current",
"terseLabel": "Investments Available-for-Sale",
"verboseLabel": "Fair Value"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AwardTypeAxis": {
"auth_ref": [
"r253",
"r276"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of award under share-based payment arrangement.",
"label": "Award Type [Axis]",
"terseLabel": "Award Type [Axis]"
}
}
},
"localname": "AwardTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails",
"http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
"http://rockwellmed.com/role/StockBasedCompensationTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
"label": "Basis of Accounting, Policy [Policy Text Block]",
"terseLabel": "Basis of Presentation"
}
}
},
"localname": "BasisOfAccountingPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"auth_ref": [
"r2",
"r34",
"r97"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 5.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash and Cash Equivalents, at Carrying Value",
"terseLabel": "Cash and Cash Equivalents"
}
}
},
"localname": "CashAndCashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsAndShortTermInvestments": {
"auth_ref": [
"r34"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
"label": "Cash, Cash Equivalents, and Short-term Investments",
"terseLabel": "Cash, cash equivalents and investments available-for-sale"
}
}
},
"localname": "CashCashEquivalentsAndShortTermInvestments",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"auth_ref": [
"r91",
"r97",
"r102"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
"periodEndLabel": "Cash and Cash Equivalents at End of Period",
"periodStartLabel": "Cash and Cash Equivalents at Beginning of Period"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
"auth_ref": [
"r91",
"r302"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
"totalLabel": "(Decrease) Increase in Cash and Cash Equivalents"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ClassOfStockLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Class of Stock [Line Items]",
"terseLabel": "Class of Stock [Line Items]"
}
}
},
"localname": "ClassOfStockLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockholdersEquityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
"auth_ref": [
"r212"
],
"lang": {
"en-us": {
"role": {
"documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
"label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
"terseLabel": "Exercise price of warrant (in dollars per share)"
}
}
},
"localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
"auth_ref": [
"r212"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
"label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
"terseLabel": "Number of shares of common stock for which warrant is exercisable (in shares)"
}
}
},
"localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CollaborativeArrangementDisclosureTextBlock": {
"auth_ref": [
"r287",
"r288",
"r290"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
"label": "Collaborative Arrangement Disclosure [Text Block]",
"terseLabel": "Licensing Agreements"
}
}
},
"localname": "CollaborativeArrangementDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LicensingAgreements"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
"terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
}
}
},
"localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LicensingAgreementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CommitmentsAndContingencies": {
"auth_ref": [
"r47",
"r196",
"r356",
"r369"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
"label": "Commitments and Contingencies",
"terseLabel": "Commitments and Contingencies (See Note 14)"
}
}
},
"localname": "CommitmentsAndContingencies",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Commitments and Contingencies Disclosure [Abstract]",
"terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
"auth_ref": [
"r193",
"r194",
"r195",
"r197"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for commitments and contingencies.",
"label": "Commitments and Contingencies Disclosure [Text Block]",
"terseLabel": "Commitments and Contingencies"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CommitmentsandContingencies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CommonStockMember": {
"auth_ref": [
"r112",
"r113"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock that is subordinate to all other stock of the issuer.",
"label": "Common Stock [Member]",
"terseLabel": "COMMON STOCK"
}
}
},
"localname": "CommonStockMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"auth_ref": [
"r18"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of common stock.",
"label": "Common Stock, Par or Stated Value Per Share",
"terseLabel": "Common shares, par value (in dollars per share)"
}
}
},
"localname": "CommonStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://rockwellmed.com/role/StockholdersEquityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockSharesAuthorized": {
"auth_ref": [
"r18"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
"label": "Common Stock, Shares Authorized",
"terseLabel": "Common shares, shares authorized (in shares)"
}
}
},
"localname": "CommonStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://rockwellmed.com/role/StockholdersEquityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesIssued": {
"auth_ref": [
"r18"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
"label": "Common Stock, Shares, Issued",
"terseLabel": "Common shares, shares issued (in shares)"
}
}
},
"localname": "CommonStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://rockwellmed.com/role/StockholdersEquityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesOutstanding": {
"auth_ref": [
"r18",
"r211"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
"label": "Common Stock, Shares, Outstanding",
"periodEndLabel": "Ending balance (in shares)",
"periodStartLabel": "Beginning balance (in shares)",
"terseLabel": "Common shares, shares outstanding (in shares)"
}
}
},
"localname": "CommonStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://rockwellmed.com/role/StockholdersEquityDetails",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockValueOutstanding": {
"auth_ref": [
"r18"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 1.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
"label": "Common Stock, Value, Outstanding",
"verboseLabel": "Common Stock, $0.0001 par value; 170,000,000 shares authorized; 93,811,381 and 93,573,165 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively"
}
}
},
"localname": "CommonStockValueOutstanding",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTax": {
"auth_ref": [
"r67",
"r69",
"r70",
"r73",
"r358",
"r372"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
"totalLabel": "Comprehensive Loss"
}
}
},
"localname": "ComprehensiveIncomeNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
"auth_ref": [
"r224"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
"label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
"terseLabel": "Contract Balances"
}
}
},
"localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ContractWithCustomerAssetCreditLossExpense": {
"auth_ref": [
"r180",
"r223",
"r234"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense (reversal of expense) for expected credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
"label": "Contract with Customer, Asset, Credit Loss Expense (Reversal)",
"terseLabel": "Impairment losses"
}
}
},
"localname": "ContractWithCustomerAssetCreditLossExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerAssetNet": {
"auth_ref": [
"r220",
"r222",
"r236"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
"label": "Contract with Customer, Asset, after Allowance for Credit Loss",
"terseLabel": "Contract assets"
}
}
},
"localname": "ContractWithCustomerAssetNet",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiability": {
"auth_ref": [
"r220",
"r221",
"r236"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
"label": "Contract with Customer, Liability",
"terseLabel": "Contract liabilities",
"verboseLabel": "Deferred revenue"
}
}
},
"localname": "ContractWithCustomerLiability",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DeferredRevenueDetails",
"http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiabilityCurrent": {
"auth_ref": [
"r220",
"r221",
"r236"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
"label": "Contract with Customer, Liability, Current",
"terseLabel": "Deferred License Revenue - Current"
}
}
},
"localname": "ContractWithCustomerLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiabilityNoncurrent": {
"auth_ref": [
"r220",
"r221",
"r236"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 2.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
"label": "Contract with Customer, Liability, Noncurrent",
"terseLabel": "Deferred License Revenue - Long-Term"
}
}
},
"localname": "ContractWithCustomerLiabilityNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
"auth_ref": [
"r237"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
"label": "Contract with Customer, Liability, Revenue Recognized",
"verboseLabel": "Recognized deferred revenue"
}
}
},
"localname": "ContractWithCustomerLiabilityRevenueRecognized",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DeferredRevenueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerRefundLiability": {
"auth_ref": [
"r239"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.",
"label": "Contract with Customer, Refund Liability",
"verboseLabel": "Reserve for returns"
}
}
},
"localname": "ContractWithCustomerRefundLiability",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
"auth_ref": [
"r239"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.",
"label": "Contract with Customer, Refund Liability, Current",
"terseLabel": "Customer Deposits"
}
}
},
"localname": "ContractWithCustomerRefundLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CostOfGoodsAndServicesSold": {
"auth_ref": [
"r76",
"r349"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 2.0,
"parentTag": "us-gaap_GrossProfit",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
"label": "Cost of Goods and Services Sold",
"terseLabel": "Cost of Sales"
}
}
},
"localname": "CostOfGoodsAndServicesSold",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtDisclosureAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Debt Disclosure [Abstract]",
"terseLabel": "Debt Disclosure [Abstract]"
}
}
},
"localname": "DebtDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_DebtDisclosureTextBlock": {
"auth_ref": [
"r206"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
"label": "Debt Disclosure [Text Block]",
"verboseLabel": "Loans and Security Agreement"
}
}
},
"localname": "DebtDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreement"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DebtInstrumentAxis": {
"auth_ref": [
"r14",
"r15",
"r16",
"r352",
"r353",
"r362"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
"label": "Debt Instrument [Axis]",
"terseLabel": "Debt Instrument [Axis]"
}
}
},
"localname": "DebtInstrumentAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails",
"http://rockwellmed.com/role/SubsequentEventsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
"label": "Debt Instrument, Basis Spread on Variable Rate",
"terseLabel": "Interest rate, additional percentage added to base percentage"
}
}
},
"localname": "DebtInstrumentBasisSpreadOnVariableRate1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentCarryingAmount": {
"auth_ref": [
"r16",
"r201",
"r353",
"r362"
],
"calculation": {
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
"label": "Long-term Debt, Gross",
"totalLabel": "Principal Payments"
}
}
},
"localname": "DebtInstrumentCarryingAmount",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentFaceAmount": {
"auth_ref": [
"r312",
"r314"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Face (par) amount of debt instrument at time of issuance.",
"label": "Debt Instrument, Face Amount",
"terseLabel": "Short-term note payable",
"verboseLabel": "Aggregate principal amount"
}
}
},
"localname": "DebtInstrumentFaceAmount",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
"http://rockwellmed.com/role/SubsequentEventsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentInterestRateDuringPeriod": {
"auth_ref": [
"r45",
"r312"
],
"lang": {
"en-us": {
"role": {
"documentation": "The average effective interest rate during the reporting period.",
"label": "Debt Instrument, Interest Rate During Period",
"terseLabel": "Initial interest rate percentage"
}
}
},
"localname": "DebtInstrumentInterestRateDuringPeriod",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
"auth_ref": [
"r45",
"r204",
"r312"
],
"lang": {
"en-us": {
"role": {
"documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
"label": "Debt Instrument, Interest Rate, Effective Percentage",
"verboseLabel": "Effective interest rate"
}
}
},
"localname": "DebtInstrumentInterestRateEffectivePercentage",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentInterestRateStatedPercentage": {
"auth_ref": [
"r45"
],
"lang": {
"en-us": {
"role": {
"documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
"label": "Debt Instrument, Interest Rate, Stated Percentage",
"terseLabel": "Interest rate, base percentage",
"verboseLabel": "Interest rate"
}
}
},
"localname": "DebtInstrumentInterestRateStatedPercentage",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
"http://rockwellmed.com/role/SubsequentEventsDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Debt Instrument [Line Items]",
"terseLabel": "Debt Instrument [Line Items]"
}
}
},
"localname": "DebtInstrumentLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentNameDomain": {
"auth_ref": [
"r46"
],
"lang": {
"en-us": {
"role": {
"documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
"label": "Debt Instrument, Name [Domain]",
"terseLabel": "Debt Instrument, Name [Domain]"
}
}
},
"localname": "DebtInstrumentNameDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails",
"http://rockwellmed.com/role/SubsequentEventsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DebtInstrumentTable": {
"auth_ref": [
"r46",
"r108",
"r212",
"r215",
"r216",
"r217",
"r311",
"r312",
"r314",
"r361"
],
"lang": {
"en-us": {
"role": {
"documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
"label": "Schedule of Long-term Debt Instruments [Table]",
"terseLabel": "Schedule of Long-term Debt Instruments [Table]"
}
}
},
"localname": "DebtInstrumentTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentTerm": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "Debt Instrument, Term",
"terseLabel": "Amortization period (in months)"
}
}
},
"localname": "DebtInstrumentTerm",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/SubsequentEventsDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_DebtInstrumentUnamortizedDiscount": {
"auth_ref": [
"r311",
"r314"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after accumulated amortization, of debt discount.",
"label": "Debt Instrument, Unamortized Discount",
"terseLabel": "Additional debt discount recognized"
}
}
},
"localname": "DebtInstrumentUnamortizedDiscount",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
"auth_ref": [
"r202",
"r313"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
"label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
"terseLabel": "Unamortized issuance costs and unaccreted discount"
}
}
},
"localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent": {
"auth_ref": [
"r174",
"r181",
"r182"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
"label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current",
"terseLabel": "Accrued Interest Income"
}
}
},
"localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
"auth_ref": [
"r181"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
"label": "Debt Securities, Available-for-sale, Amortized Cost, Current",
"terseLabel": "Amortized Cost"
}
}
},
"localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
"auth_ref": [
"r175"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
},
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 4.0,
"parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-sale, Realized Gain (Loss)",
"negatedLabel": "Realized Loss (Gain) on Sale of Investments Available-for-Sale",
"terseLabel": "Realized (Loss) Gain on Investments"
}
}
},
"localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
"auth_ref": [
"r177"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-sale [Table Text Block]",
"terseLabel": "Investments available for sale"
}
}
},
"localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/InvestmentsAvailableforSaleTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DeferredRevenueArrangementByTypeTable": {
"auth_ref": [
"r8"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.",
"label": "Deferred Revenue Arrangement, by Type [Table]",
"terseLabel": "Deferred Revenue Arrangement, by Type [Table]"
}
}
},
"localname": "DeferredRevenueArrangementByTypeTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DeferredRevenueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DeferredRevenueArrangementLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Deferred Revenue Arrangement [Line Items]",
"terseLabel": "Deferred Revenue Arrangement [Line Items]"
}
}
},
"localname": "DeferredRevenueArrangementLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DeferredRevenueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_Depreciation": {
"auth_ref": [
"r95",
"r188"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
"label": "Depreciation",
"terseLabel": "Depreciation expense"
}
}
},
"localname": "Depreciation",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/PropertyandEquipmentDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DepreciationDepletionAndAmortization": {
"auth_ref": [
"r95",
"r150"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
"label": "Depreciation, Depletion and Amortization",
"terseLabel": "Depreciation and Amortization"
}
}
},
"localname": "DepreciationDepletionAndAmortization",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DisaggregationOfRevenueLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Disaggregation of Revenue [Line Items]",
"terseLabel": "Disaggregation of Revenue [Line Items]"
}
}
},
"localname": "DisaggregationOfRevenueLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DisaggregationOfRevenueTable": {
"auth_ref": [
"r235",
"r240",
"r241",
"r242",
"r243",
"r244",
"r245",
"r246"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
"label": "Disaggregation of Revenue [Table]",
"terseLabel": "Disaggregation of Revenue [Table]"
}
}
},
"localname": "DisaggregationOfRevenueTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DisaggregationOfRevenueTableTextBlock": {
"auth_ref": [
"r235"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
"label": "Disaggregation of Revenue [Table Text Block]",
"terseLabel": "Disaggregation of Revenue"
}
}
},
"localname": "DisaggregationOfRevenueTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
"auth_ref": [
"r283"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for share-based payment arrangement.",
"label": "Share-based Payment Arrangement [Text Block]",
"terseLabel": "Stock-Based Compensation"
}
}
},
"localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensation"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Share-based Payment Arrangement [Abstract]",
"terseLabel": "Share-based Payment Arrangement [Abstract]"
}
}
},
"localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_DueToRelatedPartiesCurrent": {
"auth_ref": [
"r38",
"r109",
"r337"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 4.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Due to Related Parties, Current",
"terseLabel": "Other Current Liability - Related Party"
}
}
},
"localname": "DueToRelatedPartiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
"auth_ref": [
"r109",
"r337",
"r355",
"r370"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
"label": "Due to Related Parties",
"terseLabel": "Total amount due"
}
}
},
"localname": "DueToRelatedPartiesCurrentAndNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LicensingAgreementsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EarningsPerShareBasic": {
"auth_ref": [
"r74",
"r117",
"r118",
"r119",
"r120",
"r121",
"r125",
"r127",
"r129",
"r130",
"r131",
"r134",
"r135",
"r359",
"r373"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
"label": "Earnings Per Share, Basic",
"terseLabel": "Basic Net Loss per Share (in dollars per share)"
}
}
},
"localname": "EarningsPerShareBasic",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerShareDiluted": {
"auth_ref": [
"r74",
"r117",
"r118",
"r119",
"r120",
"r121",
"r127",
"r129",
"r130",
"r131",
"r134",
"r135",
"r359",
"r373"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
"label": "Earnings Per Share, Diluted",
"terseLabel": "Diluted Net Loss per Share (in dollars per share)"
}
}
},
"localname": "EarningsPerShareDiluted",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerSharePolicyTextBlock": {
"auth_ref": [
"r103",
"r132",
"r133"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
"label": "Earnings Per Share, Policy [Policy Text Block]",
"terseLabel": "Loss Per Share"
}
}
},
"localname": "EarningsPerSharePolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EmployeeRelatedLiabilitiesCurrent": {
"auth_ref": [
"r43"
],
"calculation": {
"http://rockwellmed.com/role/AccruedLiabilitiesDetails": {
"order": 3.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Employee-related Liabilities, Current",
"terseLabel": "Accrued Compensation and Benefits"
}
}
},
"localname": "EmployeeRelatedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/AccruedLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
"terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
"http://rockwellmed.com/role/StockBasedCompensationTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
"auth_ref": [
"r275"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
"terseLabel": "Unrecognized stock-based compensation expense, weighted average remaining term (in years)",
"verboseLabel": "Unrecognized stock-based compensation expense, weighted average remaining term (in years) (less than)"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
"auth_ref": [
"r275"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
"label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
"terseLabel": "Unrecognized stock-based compensation expense"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
"auth_ref": [
"r275"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
"label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
"terseLabel": "Unrecognized stock-based compensation expenses"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeStockOptionMember": {
"auth_ref": [
"r272"
],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
"label": "Share-based Payment Arrangement, Option [Member]",
"terseLabel": "Options to purchase common stock"
}
}
},
"localname": "EmployeeStockOptionMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Equity [Abstract]",
"terseLabel": "Equity [Abstract]"
}
}
},
"localname": "EquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_EquityComponentDomain": {
"auth_ref": [
"r112",
"r113",
"r114",
"r116",
"r122",
"r124",
"r136",
"r179",
"r211",
"r218",
"r277",
"r278",
"r279",
"r285",
"r286",
"r303",
"r304",
"r305",
"r306",
"r307",
"r308",
"r379",
"r380",
"r381"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
"label": "Equity Component [Domain]",
"terseLabel": "Equity Component [Domain]"
}
}
},
"localname": "EquityComponentDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueAdjustmentOfWarrants": {
"auth_ref": [
"r95",
"r207"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 11.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
},
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 3.0,
"parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
"label": "Fair Value Adjustment of Warrants",
"negatedTerseLabel": "Warrant Modification Expense",
"terseLabel": "Warrant Modification Expense"
}
}
},
"localname": "FairValueAdjustmentOfWarrants",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FinanceLeaseInterestExpense": {
"auth_ref": [
"r317",
"r325",
"r335"
],
"calculation": {
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails": {
"order": 1.0,
"parentTag": "rmti_FinanceLeaseExpense",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of interest expense on finance lease liability.",
"label": "Finance Lease, Interest Expense",
"terseLabel": "Interest on lease obligations"
}
}
},
"localname": "FinanceLeaseInterestExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FinanceLeaseInterestPaymentOnLiability": {
"auth_ref": [
"r320",
"r329"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of interest paid on finance lease liability.",
"label": "Finance Lease, Interest Payment on Liability",
"terseLabel": "Operating cash flows from finance leases"
}
}
},
"localname": "FinanceLeaseInterestPaymentOnLiability",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Finance Lease, Liability, Payment, Due [Abstract]",
"terseLabel": "Finance"
}
}
},
"localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FinanceLeaseLiability": {
"auth_ref": [
"r316",
"r334"
],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails": {
"order": 1.0,
"parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
"label": "Finance Lease, Liability",
"terseLabel": "Finance lease liabilities"
}
}
},
"localname": "FinanceLeaseLiability",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FinanceLeaseLiabilityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Finance Lease Liability [Abstract]",
"terseLabel": "Finance leases"
}
}
},
"localname": "FinanceLeaseLiabilityAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
"auth_ref": [
"r334"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
"label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
"terseLabel": "Finance Lease Maturities"
}
}
},
"localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FinanceLeaseLiabilityPaymentsDue": {
"auth_ref": [
"r334"
],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
"label": "Finance Lease, Liability, Payment, Due",
"totalLabel": "Total"
}
}
},
"localname": "FinanceLeaseLiabilityPaymentsDue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
"auth_ref": [
"r334"
],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1": {
"order": 4.0,
"parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Finance Lease, Liability, to be Paid, Year One",
"terseLabel": "Year ending December 31, 2022"
}
}
},
"localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
"auth_ref": [
"r334"
],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1": {
"order": 3.0,
"parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Finance Lease, Liability, to be Paid, Year Four",
"terseLabel": "Year ending December 31, 2025"
}
}
},
"localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
"auth_ref": [
"r334"
],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1": {
"order": 2.0,
"parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Finance Lease, Liability, to be Paid, Year Three",
"terseLabel": "Year ending December 31, 2024"
}
}
},
"localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
"auth_ref": [
"r334"
],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1": {
"order": 6.0,
"parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Finance Lease, Liability, to be Paid, Year Two",
"terseLabel": "Year ending December 31, 2023"
}
}
},
"localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
"auth_ref": [
"r334"
],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1": {
"order": 1.0,
"parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
"label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
"terseLabel": "Year ending December 31, 2021 (remaining)"
}
}
},
"localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
"auth_ref": [
"r334"
],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails": {
"order": 2.0,
"parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
"label": "Finance Lease, Liability, Undiscounted Excess Amount",
"negatedTerseLabel": "Less present value discount"
}
}
},
"localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FinanceLeasePrincipalPayments": {
"auth_ref": [
"r319",
"r329"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow for principal payment on finance lease.",
"label": "Finance Lease, Principal Payments",
"terseLabel": "Financing cash flows from finance leases"
}
}
},
"localname": "FinanceLeasePrincipalPayments",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
"auth_ref": [
"r317",
"r325",
"r335"
],
"calculation": {
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails": {
"order": 2.0,
"parentTag": "rmti_FinanceLeaseExpense",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
"label": "Finance Lease, Right-of-Use Asset, Amortization",
"terseLabel": "Amortization of right-of-use assets"
}
}
},
"localname": "FinanceLeaseRightOfUseAssetAmortization",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
"auth_ref": [
"r332",
"r335"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average discount rate for finance lease calculated at point in time.",
"label": "Finance Lease, Weighted Average Discount Rate, Percent",
"terseLabel": "Weighted-average discount rate \u2013 finance leases"
}
}
},
"localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
"auth_ref": [
"r331",
"r335"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Finance Lease, Weighted Average Remaining Lease Term",
"terseLabel": "Weighted-average remaining lease term \u2013 finance leases"
}
}
},
"localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
"auth_ref": [
"r298",
"r299",
"r300",
"r301"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 7.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
"label": "Foreign Currency Transaction Gain (Loss), before Tax",
"negatedLabel": "Foreign Currency Translation Adjustment"
}
}
},
"localname": "ForeignCurrencyTransactionGainLossBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GainLossOnDispositionOfAssets1": {
"auth_ref": [
"r95"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 10.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
"label": "Gain (Loss) on Disposition of Assets",
"negatedTerseLabel": "Loss on Disposal of Assets"
}
}
},
"localname": "GainLossOnDispositionOfAssets1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeneralAndAdministrativeExpense": {
"auth_ref": [
"r77"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 3.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
"label": "General and Administrative Expense",
"terseLabel": "General and Administrative"
}
}
},
"localname": "GeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_Goodwill": {
"auth_ref": [
"r186",
"r187",
"r350"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 5.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
"label": "Goodwill",
"terseLabel": "Goodwill"
}
}
},
"localname": "Goodwill",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GrossProfit": {
"auth_ref": [
"r75",
"r106",
"r151",
"r153",
"r156",
"r159",
"r161",
"r178",
"r297"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 1.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
"label": "Gross Profit",
"totalLabel": "Gross Profit"
}
}
},
"localname": "GrossProfit",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeStatementAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Income Statement [Abstract]",
"terseLabel": "Income Statement [Abstract]"
}
}
},
"localname": "IncomeStatementAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_IncreaseDecreaseInAccountsPayable": {
"auth_ref": [
"r94"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 5.0,
"parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
"label": "Increase (Decrease) in Accounts Payable",
"terseLabel": "Increase in Accounts Payable"
}
}
},
"localname": "IncreaseDecreaseInAccountsPayable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccountsReceivable": {
"auth_ref": [
"r94"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 3.0,
"parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
"label": "Increase (Decrease) in Accounts Receivable",
"negatedLabel": "(Increase) Decrease in Accounts Receivable, net"
}
}
},
"localname": "IncreaseDecreaseInAccountsReceivable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
"auth_ref": [
"r94"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 8.0,
"parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
"label": "Increase (Decrease) in Contract with Customer, Liability",
"terseLabel": "Decrease in Deferred License Revenue"
}
}
},
"localname": "IncreaseDecreaseInContractWithCustomerLiability",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInInsuranceLiabilities": {
"auth_ref": [
"r94"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 6.0,
"parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) in insurance liability balances during the period.",
"label": "Increase (Decrease) in Insurance Liabilities",
"verboseLabel": "Decrease in Settlement Payable"
}
}
},
"localname": "IncreaseDecreaseInInsuranceLiabilities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInInventories": {
"auth_ref": [
"r94"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 1.0,
"parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
"label": "Increase (Decrease) in Inventories",
"negatedLabel": "Increase in Inventory"
}
}
},
"localname": "IncreaseDecreaseInInventories",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOperatingCapital": {
"auth_ref": [
"r94"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 8.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.",
"label": "Increase (Decrease) in Operating Capital",
"negatedTotalLabel": "Changes in Assets and Liabilities"
}
}
},
"localname": "IncreaseDecreaseInOperatingCapital",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Increase (Decrease) in Operating Capital [Abstract]",
"terseLabel": "Changes in Assets and Liabilities:"
}
}
},
"localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
"auth_ref": [
"r94"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 7.0,
"parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
"label": "Increase (Decrease) in Other Operating Liabilities",
"terseLabel": "Decrease in Other Liabilities"
}
}
},
"localname": "IncreaseDecreaseInOtherOperatingLiabilities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
"auth_ref": [
"r94"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 4.0,
"parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
"label": "Increase (Decrease) in Prepaid Expense and Other Assets",
"negatedLabel": "Decrease (Increase) in Prepaid and Other Assets"
}
}
},
"localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
"terseLabel": "Increase (Decrease) in Shareholders' Equity"
}
}
},
"localname": "IncreaseDecreaseInStockholdersEquityRollForward",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "stringItemType"
},
"us-gaap_InterestExpense": {
"auth_ref": [
"r71",
"r149",
"r310",
"r313",
"r360"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 2.0,
"parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
"label": "Interest Expense",
"negatedTerseLabel": "Interest Expense"
}
}
},
"localname": "InterestExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestExpenseDebt": {
"auth_ref": [
"r79",
"r205"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
"label": "Interest Expense, Debt",
"terseLabel": "Interest expense"
}
}
},
"localname": "InterestExpenseDebt",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestPaidNet": {
"auth_ref": [
"r90",
"r92",
"r98"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
"label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
"terseLabel": "Cash Paid for Interest"
}
}
},
"localname": "InterestPaidNet",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryCurrentTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
"label": "Inventory, Current [Table]",
"terseLabel": "Inventory, Current [Table]"
}
}
},
"localname": "InventoryCurrentTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/InventoryDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_InventoryDisclosureAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Inventory Disclosure [Abstract]",
"terseLabel": "Inventory Disclosure [Abstract]"
}
}
},
"localname": "InventoryDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_InventoryDisclosureTextBlock": {
"auth_ref": [
"r185"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
"label": "Inventory Disclosure [Text Block]",
"terseLabel": "Inventory"
}
}
},
"localname": "InventoryDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/Inventory"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_InventoryFinishedGoodsNetOfReserves": {
"auth_ref": [
"r26",
"r184"
],
"calculation": {
"http://rockwellmed.com/role/InventoryDetails": {
"order": 3.0,
"parentTag": "rmti_CurrentAndNonCurrentInventory",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
"label": "Inventory, Finished Goods, Net of Reserves",
"terseLabel": "Finished Goods"
}
}
},
"localname": "InventoryFinishedGoodsNetOfReserves",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/InventoryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryLIFOReservePeriodCharge": {
"auth_ref": [
"r52",
"r53",
"r54",
"r183"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.",
"label": "Inventory, LIFO Reserve, Period Charge",
"terseLabel": "Increase in Inventory Reserves"
}
}
},
"localname": "InventoryLIFOReservePeriodCharge",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Inventory [Line Items]",
"terseLabel": "Inventory [Line Items]"
}
}
},
"localname": "InventoryLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/InventoryDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_InventoryNet": {
"auth_ref": [
"r3",
"r50"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 3.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
"label": "Inventory, Net",
"terseLabel": "Inventory, net"
}
}
},
"localname": "InventoryNet",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://rockwellmed.com/role/InventoryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryNoncurrent": {
"auth_ref": [
"r51"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 2.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
"label": "Inventory, Noncurrent",
"terseLabel": "Inventory, noncurrent",
"verboseLabel": "Inventory, Non-Current"
}
}
},
"localname": "InventoryNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://rockwellmed.com/role/InventoryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryRawMaterialsNetOfReserves": {
"auth_ref": [
"r28",
"r184"
],
"calculation": {
"http://rockwellmed.com/role/InventoryDetails": {
"order": 1.0,
"parentTag": "rmti_CurrentAndNonCurrentInventory",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
"label": "Inventory, Raw Materials, Net of Reserves",
"terseLabel": "Raw Materials"
}
}
},
"localname": "InventoryRawMaterialsNetOfReserves",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/InventoryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryWorkInProcessNetOfReserves": {
"auth_ref": [
"r27",
"r184"
],
"calculation": {
"http://rockwellmed.com/role/InventoryDetails": {
"order": 2.0,
"parentTag": "rmti_CurrentAndNonCurrentInventory",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
"label": "Inventory, Work in Process, Net of Reserves",
"terseLabel": "Work in Process"
}
}
},
"localname": "InventoryWorkInProcessNetOfReserves",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/InventoryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentIncomeInterest": {
"auth_ref": [
"r78",
"r148"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 1.0,
"parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
"label": "Investment Income, Interest",
"terseLabel": "Interest Income"
}
}
},
"localname": "InvestmentIncomeInterest",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Investments, Debt and Equity Securities [Abstract]",
"terseLabel": "Investments, Debt and Equity Securities [Abstract]"
}
}
},
"localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.",
"label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]",
"terseLabel": "Investments - Available-for-Sale"
}
}
},
"localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/InvestmentsAvailableforSale"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LeaseCost": {
"auth_ref": [
"r333",
"r335"
],
"calculation": {
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lease cost recognized by lessee for lease contract.",
"label": "Lease, Cost",
"totalLabel": "Total rent expense"
}
}
},
"localname": "LeaseCost",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LeaseCostAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Lease, Cost [Abstract]",
"terseLabel": "Other information"
}
}
},
"localname": "LeaseCostAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LeaseCostTableTextBlock": {
"auth_ref": [
"r333"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
"label": "Lease, Cost [Table Text Block]",
"terseLabel": "Summary of Lease Costs"
}
}
},
"localname": "LeaseCostTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LeaseholdImprovementsMember": {
"auth_ref": [
"r189"
],
"lang": {
"en-us": {
"role": {
"documentation": "Additions or improvements to assets held under a lease arrangement.",
"label": "Leasehold Improvements [Member]",
"terseLabel": "Leasehold Improvements"
}
}
},
"localname": "LeaseholdImprovementsMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/PropertyandEquipmentDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_LeasesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Leases [Abstract]",
"terseLabel": "Leases [Abstract]"
}
}
},
"localname": "LeasesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_LesseeFinanceLeasesTextBlock": {
"auth_ref": [
"r336"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
"label": "Lessee, Finance Leases [Text Block]",
"terseLabel": "Leases"
}
}
},
"localname": "LesseeFinanceLeasesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/Leases"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LesseeLeaseDescriptionLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Lessee, Lease, Description [Line Items]",
"terseLabel": "Lessee, Lease, Description [Line Items]"
}
}
},
"localname": "LesseeLeaseDescriptionLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LesseeLeaseDescriptionTable": {
"auth_ref": [
"r324"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about lessee's leases.",
"label": "Lessee, Lease, Description [Table]",
"terseLabel": "Lessee, Lease, Description [Table]"
}
}
},
"localname": "LesseeLeaseDescriptionTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LesseeLeasesPolicyTextBlock": {
"auth_ref": [
"r322"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
"label": "Lessee, Leases [Policy Text Block]",
"terseLabel": "Leases"
}
}
},
"localname": "LesseeLeasesPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
"auth_ref": [
"r334"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
"label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
"terseLabel": "Operating Lease Maturities"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
"auth_ref": [
"r334"
],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
"label": "Lessee, Operating Lease, Liability, to be Paid",
"totalLabel": "Total"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
"auth_ref": [
"r334"
],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1": {
"order": 5.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
"terseLabel": "Year ending December 31, 2022"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
"auth_ref": [
"r334"
],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1": {
"order": 6.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
"terseLabel": "Year ending December 31, 2025"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
"auth_ref": [
"r334"
],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1": {
"order": 1.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
"terseLabel": "Year ending December 31, 2024"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
"auth_ref": [
"r334"
],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1": {
"order": 4.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
"terseLabel": "Year ending December 31, 2023"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
"auth_ref": [
"r334"
],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails_1": {
"order": 3.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
"label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
"terseLabel": "Year ending December 31, 2021 (remaining)"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
"auth_ref": [
"r334"
],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails": {
"order": 1.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
"label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
"negatedLabel": "Less present value discount"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseTermOfContract": {
"auth_ref": [
"r323"
],
"lang": {
"en-us": {
"role": {
"documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Lessee, Operating Lease, Term of Contract",
"terseLabel": "Lease term"
}
}
},
"localname": "LesseeOperatingLeaseTermOfContract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_LesseeOperatingLeasesTextBlock": {
"auth_ref": [
"r336"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
"label": "Lessee, Operating Leases [Text Block]",
"terseLabel": "Leases"
}
}
},
"localname": "LesseeOperatingLeasesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/Leases"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_Liabilities": {
"auth_ref": [
"r42",
"r106",
"r155",
"r178",
"r292",
"r294",
"r295",
"r297"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
"label": "Liabilities",
"totalLabel": "Total Liabilities"
}
}
},
"localname": "Liabilities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"auth_ref": [
"r25",
"r106",
"r178",
"r297",
"r354",
"r367"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
"label": "Liabilities and Equity",
"totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Liabilities and Equity [Abstract]",
"terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
}
}
},
"localname": "LiabilitiesAndStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesCurrent": {
"auth_ref": [
"r44",
"r106",
"r178",
"r292",
"r294",
"r295",
"r297"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 3.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
"label": "Liabilities, Current",
"totalLabel": "Total Current Liabilities"
}
}
},
"localname": "LiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebt": {
"auth_ref": [
"r16",
"r203",
"r353",
"r364"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
"label": "Long-term Debt",
"terseLabel": "Outstanding balance, net of unamortized issuance costs and unaccreted discount"
}
}
},
"localname": "LongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtCurrent": {
"auth_ref": [
"r41"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 5.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
"label": "Long-term Debt, Current Maturities",
"terseLabel": "Term Loan - Net of Issuance Costs"
}
}
},
"localname": "LongTermDebtCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
"auth_ref": [
"r110",
"r198"
],
"calculation": {
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": {
"order": 3.0,
"parentTag": "us-gaap_DebtInstrumentCarryingAmount",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year One",
"terseLabel": "2022"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
"auth_ref": [
"r110",
"r198"
],
"calculation": {
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": {
"order": 2.0,
"parentTag": "us-gaap_DebtInstrumentCarryingAmount",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year Four",
"terseLabel": "2025"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
"auth_ref": [
"r110",
"r198"
],
"calculation": {
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": {
"order": 1.0,
"parentTag": "us-gaap_DebtInstrumentCarryingAmount",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year Three",
"terseLabel": "2024"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
"auth_ref": [
"r110",
"r198"
],
"calculation": {
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": {
"order": 4.0,
"parentTag": "us-gaap_DebtInstrumentCarryingAmount",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year Two",
"terseLabel": "2023"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
"auth_ref": [
"r110"
],
"calculation": {
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": {
"order": 5.0,
"parentTag": "us-gaap_DebtInstrumentCarryingAmount",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
"label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
"terseLabel": "2021"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtNoncurrent": {
"auth_ref": [
"r46"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 4.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
"label": "Long-term Debt, Excluding Current Maturities",
"terseLabel": "Term Loan, Net of Issuance Costs"
}
}
},
"localname": "LongTermDebtNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongtermDebtTypeAxis": {
"auth_ref": [
"r46"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of long-term debt.",
"label": "Long-term Debt, Type [Axis]",
"terseLabel": "Long-term Debt, Type [Axis]"
}
}
},
"localname": "LongtermDebtTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LongtermDebtTypeDomain": {
"auth_ref": [
"r46",
"r199"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
"label": "Long-term Debt, Type [Domain]",
"terseLabel": "Long-term Debt, Type [Domain]"
}
}
},
"localname": "LongtermDebtTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_MachineryAndEquipmentMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
"label": "Machinery and Equipment [Member]",
"terseLabel": "Machinery and Equipment"
}
}
},
"localname": "MachineryAndEquipmentMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/PropertyandEquipmentDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_MediumTermNotesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Debt instruments with maturities ranging from five to ten years.",
"label": "Medium-term Notes [Member]",
"terseLabel": "Term loan"
}
}
},
"localname": "MediumTermNotesMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails",
"http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"auth_ref": [
"r91"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 1.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
"label": "Net Cash Provided by (Used in) Financing Activities",
"totalLabel": "Cash (Used In) Provided By Financing Activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
"terseLabel": "Cash Flows From Financing Activities:"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"auth_ref": [
"r91"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 2.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
"label": "Net Cash Provided by (Used in) Investing Activities",
"totalLabel": "Cash Provided By Investing Activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
"terseLabel": "Cash Flows From Investing Activities:"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r91",
"r93",
"r96"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 3.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "Net Cash Provided by (Used in) Operating Activities",
"terseLabel": "Net cash used in operating activities",
"totalLabel": "Cash Used In Operating Activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Cash Flows From Operating Activities:"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetIncomeLoss": {
"auth_ref": [
"r0",
"r66",
"r68",
"r72",
"r96",
"r106",
"r115",
"r117",
"r118",
"r119",
"r120",
"r123",
"r124",
"r128",
"r151",
"r153",
"r156",
"r159",
"r161",
"r178",
"r297",
"r357",
"r371"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
},
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
"order": 1.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
},
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
"label": "Net Income (Loss) Attributable to Parent",
"totalLabel": "Net Loss",
"verboseLabel": "Net Loss"
}
}
},
"localname": "NetIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
"label": "New Accounting Pronouncements, Policy [Policy Text Block]",
"terseLabel": "Adoption of Recent Accounting Pronouncements"
}
}
},
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NonUsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Countries excluding the United States of America (US).",
"label": "Non-US [Member]",
"verboseLabel": "Rest of World"
}
}
},
"localname": "NonUsMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Noncash Investing and Financing Items [Abstract]",
"terseLabel": "Supplemental Disclosure of Noncash Investing and Financing Activities:"
}
}
},
"localname": "NoncashInvestingAndFinancingItemsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "stringItemType"
},
"us-gaap_NotesPayableToBanksMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "A written promise to pay a note to a bank.",
"label": "Notes Payable to Banks [Member]",
"terseLabel": "Notes Payable to Banks"
}
}
},
"localname": "NotesPayableToBanksMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/SubsequentEventsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_OfficeEquipmentMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
"label": "Office Equipment [Member]",
"terseLabel": "Information Technology\u00a0& Office Equipment"
}
}
},
"localname": "OfficeEquipmentMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/PropertyandEquipmentDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_OperatingIncomeLoss": {
"auth_ref": [
"r151",
"r153",
"r156",
"r159",
"r161"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 2.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net result for the period of deducting operating expenses from operating revenues.",
"label": "Operating Income (Loss)",
"totalLabel": "Operating Loss"
}
}
},
"localname": "OperatingIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseCost": {
"auth_ref": [
"r326",
"r335"
],
"calculation": {
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails": {
"order": 1.0,
"parentTag": "us-gaap_OperatingLeaseExpense",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
"label": "Operating Lease, Cost",
"verboseLabel": "Operating lease cost"
}
}
},
"localname": "OperatingLeaseCost",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseExpense": {
"auth_ref": [
"r318"
],
"calculation": {
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails": {
"order": 1.0,
"parentTag": "us-gaap_LeaseCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of operating lease expense. Excludes sublease income.",
"label": "Operating Lease, Expense",
"totalLabel": "Operating lease expense"
}
}
},
"localname": "OperatingLeaseExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
"terseLabel": "Operating"
}
}
},
"localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_OperatingLeaseLiability": {
"auth_ref": [
"r316"
],
"calculation": {
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails": {
"order": 2.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
"label": "Operating Lease, Liability",
"terseLabel": "Operating lease liabilities"
}
}
},
"localname": "OperatingLeaseLiability",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesFinanceLeaseandOperatingLeaseMaturitiesDetails",
"http://rockwellmed.com/role/LeasesNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Operating Lease, Liability [Abstract]",
"terseLabel": "Operating leases"
}
}
},
"localname": "OperatingLeaseLiabilityAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_OperatingLeasePayments": {
"auth_ref": [
"r321",
"r329"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
"label": "Operating Lease, Payments",
"terseLabel": "Operating cash flows from operating leases"
}
}
},
"localname": "OperatingLeasePayments",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseRightOfUseAsset": {
"auth_ref": [
"r315"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's right to use underlying asset under operating lease.",
"label": "Operating Lease, Right-of-Use Asset",
"verboseLabel": "Operating lease, right of use assets"
}
}
},
"localname": "OperatingLeaseRightOfUseAsset",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
"auth_ref": [
"r95"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 6.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
"label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
"terseLabel": "Amortization of Right of Use Asset"
}
}
},
"localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
"auth_ref": [
"r332",
"r335"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average discount rate for operating lease calculated at point in time.",
"label": "Operating Lease, Weighted Average Discount Rate, Percent",
"terseLabel": "Weighted-average discount rate \u2013 operating leases"
}
}
},
"localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
"auth_ref": [
"r331",
"r335"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Operating Lease, Weighted Average Remaining Lease Term",
"terseLabel": "Weighted-average remaining lease term \u2013 operating leases"
}
}
},
"localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
"terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
}
}
},
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
"auth_ref": [
"r1",
"r296"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
"label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
"terseLabel": "Description of Business"
}
}
},
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DescriptionofBusiness"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_OtherAccruedLiabilitiesCurrent": {
"auth_ref": [
"r7",
"r9",
"r10",
"r43"
],
"calculation": {
"http://rockwellmed.com/role/AccruedLiabilitiesDetails": {
"order": 1.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
"label": "Other Accrued Liabilities, Current",
"terseLabel": "Other Accrued Liabilities"
}
}
},
"localname": "OtherAccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/AccruedLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherAssetsNoncurrent": {
"auth_ref": [
"r37"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 1.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncurrent assets classified as other.",
"label": "Other Assets, Noncurrent",
"terseLabel": "Other Non-Current Assets"
}
}
},
"localname": "OtherAssetsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
"auth_ref": [
"r59",
"r60",
"r62"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
"order": 2.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
"label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
"terseLabel": "Unrealized Loss on Available-for-Sale Debt Instrument Investments",
"verboseLabel": "Unrealized Loss on Available-for-Sale Investments"
}
}
},
"localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
"auth_ref": [
"r58"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
"order": 3.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
"label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
"verboseLabel": "Foreign Currency Translation Adjustments"
}
}
},
"localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
"auth_ref": [
"r59",
"r62",
"r176"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
"label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
"terseLabel": "Change in Unrealized Loss on Marketable Securities Available-for-Sale"
}
}
},
"localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherMachineryAndEquipmentMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.",
"label": "Other Machinery and Equipment [Member]",
"terseLabel": "Laboratory Equipment"
}
}
},
"localname": "OtherMachineryAndEquipmentMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/PropertyandEquipmentDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_OtherNonoperatingIncomeExpense": {
"auth_ref": [
"r80"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 1.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
"label": "Other Nonoperating Income (Expense)",
"totalLabel": "Total Other Expense"
}
}
},
"localname": "OtherNonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Other Nonoperating Income (Expense) [Abstract]",
"terseLabel": "Other (Expense) Income"
}
}
},
"localname": "OtherNonoperatingIncomeExpenseAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "stringItemType"
},
"us-gaap_OtherReceivables": {
"auth_ref": [
"r55"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount due from parties in nontrade transactions, classified as other.",
"label": "Other Receivables",
"terseLabel": "Receivables, which are included in \"Trade and other receivables\""
}
}
},
"localname": "OtherReceivables",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PayablesAndAccrualsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Payables and Accruals [Abstract]",
"terseLabel": "Payables and Accruals [Abstract]"
}
}
},
"localname": "PayablesAndAccrualsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_PaymentsOfDebtIssuanceCosts": {
"auth_ref": [
"r88"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
"label": "Payments of Debt Issuance Costs",
"negatedTerseLabel": "Debt Issuance Costs"
}
}
},
"localname": "PaymentsOfDebtIssuanceCosts",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsOfFinancingCosts": {
"auth_ref": [
"r89"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow for loan and debt issuance costs.",
"label": "Payments of Financing Costs",
"terseLabel": "Closing costs"
}
}
},
"localname": "PaymentsOfFinancingCosts",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsOfStockIssuanceCosts": {
"auth_ref": [
"r89"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
"label": "Payments of Stock Issuance Costs",
"negatedLabel": "Offering Costs from the Issuance of Common Stock"
}
}
},
"localname": "PaymentsOfStockIssuanceCosts",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
"auth_ref": [
"r81",
"r83",
"r170"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Payments to Acquire Debt Securities, Available-for-sale",
"negatedTerseLabel": "Purchase of Investments Available-for-Sale"
}
}
},
"localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquireMachineryAndEquipment": {
"auth_ref": [
"r84"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow for acquisition of machinery and equipment.",
"label": "Payments to Acquire Machinery and Equipment",
"negatedLabel": "Purchase of Equipment"
}
}
},
"localname": "PaymentsToAcquireMachineryAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PreferredStockParOrStatedValuePerShare": {
"auth_ref": [
"r17"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
"label": "Preferred Stock, Par or Stated Value Per Share",
"terseLabel": "Preferred shares, par value (in dollars per share)"
}
}
},
"localname": "PreferredStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://rockwellmed.com/role/StockholdersEquityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_PreferredStockSharesAuthorized": {
"auth_ref": [
"r17"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
"label": "Preferred Stock, Shares Authorized",
"terseLabel": "Preferred shares, shares authorized (in shares)",
"verboseLabel": "Preferred stock, authorized (in shares)"
}
}
},
"localname": "PreferredStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://rockwellmed.com/role/StockholdersEquityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesIssued": {
"auth_ref": [
"r17"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
"label": "Preferred Stock, Shares Issued",
"terseLabel": "Preferred shares, shares issued (in shares)"
}
}
},
"localname": "PreferredStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://rockwellmed.com/role/StockholdersEquityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesOutstanding": {
"auth_ref": [
"r17"
],
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
"label": "Preferred Stock, Shares Outstanding",
"terseLabel": "Preferred shares, shares outstanding (in shares)"
}
}
},
"localname": "PreferredStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://rockwellmed.com/role/StockholdersEquityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockValueOutstanding": {
"auth_ref": [
"r17"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 4.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
"label": "Preferred Stock, Value, Outstanding",
"terseLabel": "Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at June 30, 2021 and December 31, 2020"
}
}
},
"localname": "PreferredStockValueOutstanding",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
"auth_ref": [
"r5",
"r32",
"r33"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 4.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
"label": "Prepaid Expense and Other Assets, Current",
"terseLabel": "Prepaid and Other Current Assets"
}
}
},
"localname": "PrepaidExpenseAndOtherAssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
"auth_ref": [
"r86"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
"label": "Proceeds from Debt, Net of Issuance Costs",
"terseLabel": "Net draw down proceeds"
}
}
},
"localname": "ProceedsFromDebtNetOfIssuanceCosts",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceOfCommonStock": {
"auth_ref": [
"r85"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from the additional capital contribution to the entity.",
"label": "Proceeds from Issuance of Common Stock",
"terseLabel": "Proceeds from the Issuance of Common Stock"
}
}
},
"localname": "ProceedsFromIssuanceOfCommonStock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
"auth_ref": [
"r86"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
"label": "Proceeds from Issuance of Long-term Debt",
"terseLabel": "Proceeds from Term Loan"
}
}
},
"localname": "ProceedsFromIssuanceOfLongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
"auth_ref": [
"r81",
"r82",
"r170"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Proceeds from Sale of Debt Securities, Available-for-sale",
"terseLabel": "Sale of Investments Available-for-Sale"
}
}
},
"localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Property, Plant and Equipment [Abstract]",
"terseLabel": "Property, Plant and Equipment [Abstract]"
}
}
},
"localname": "PropertyPlantAndEquipmentAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
"auth_ref": [
"r36",
"r191"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
"label": "Long-Lived Tangible Asset [Axis]",
"terseLabel": "Property, Plant and Equipment, Type [Axis]"
}
}
},
"localname": "PropertyPlantAndEquipmentByTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/PropertyandEquipmentDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
"auth_ref": [
"r192",
"r386",
"r387",
"r388"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
"label": "Property, Plant and Equipment Disclosure [Text Block]",
"terseLabel": "Property and Equipment"
}
}
},
"localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/PropertyandEquipment"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_PropertyPlantAndEquipmentGross": {
"auth_ref": [
"r35",
"r189"
],
"calculation": {
"http://rockwellmed.com/role/PropertyandEquipmentDetails": {
"order": 2.0,
"parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Property, Plant and Equipment, Gross",
"terseLabel": "Gross property and equipment"
}
}
},
"localname": "PropertyPlantAndEquipmentGross",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/PropertyandEquipmentDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Property, Plant and Equipment [Line Items]",
"terseLabel": "Property and equipment"
}
}
},
"localname": "PropertyPlantAndEquipmentLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/PropertyandEquipmentDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_PropertyPlantAndEquipmentNet": {
"auth_ref": [
"r12",
"r13",
"r191",
"r368"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 4.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
},
"http://rockwellmed.com/role/PropertyandEquipmentDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Property, Plant and Equipment, Net",
"terseLabel": "Property and Equipment, net",
"totalLabel": "Property and Equipment, net"
}
}
},
"localname": "PropertyPlantAndEquipmentNet",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://rockwellmed.com/role/PropertyandEquipmentDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentTextBlock": {
"auth_ref": [
"r12",
"r191"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
"label": "Property, Plant and Equipment [Table Text Block]",
"terseLabel": "Schedule of Major Classes of Property and Equipment"
}
}
},
"localname": "PropertyPlantAndEquipmentTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/PropertyandEquipmentTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_PropertyPlantAndEquipmentTypeDomain": {
"auth_ref": [
"r12",
"r189"
],
"lang": {
"en-us": {
"role": {
"documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
"label": "Long-Lived Tangible Asset [Domain]",
"terseLabel": "Property, Plant and Equipment, Type [Domain]"
}
}
},
"localname": "PropertyPlantAndEquipmentTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/PropertyandEquipmentDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PublicUtilitiesInventoryAxis": {
"auth_ref": [
"r29"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of inventory held.",
"label": "Inventory [Axis]",
"terseLabel": "Inventory [Axis]"
}
}
},
"localname": "PublicUtilitiesInventoryAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/InventoryDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_PublicUtilitiesInventoryTypeDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
"label": "Inventory [Domain]",
"terseLabel": "Inventory [Domain]"
}
}
},
"localname": "PublicUtilitiesInventoryTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/InventoryDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RepaymentsOfNotesPayable": {
"auth_ref": [
"r87"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 6.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
"label": "Repayments of Notes Payable",
"negatedTerseLabel": "Payments on Short Term Note Payable"
}
}
},
"localname": "RepaymentsOfNotesPayable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpense": {
"auth_ref": [
"r284",
"r398"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 2.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
"label": "Research and Development Expense",
"terseLabel": "Research and Product Development"
}
}
},
"localname": "ResearchAndDevelopmentExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestrictedStockMember": {
"auth_ref": [
"r132"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
"label": "Restricted Stock [Member]",
"terseLabel": "Unvested restricted stock awards",
"verboseLabel": "Restricted stock awards"
}
}
},
"localname": "RestrictedStockMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails",
"http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
"http://rockwellmed.com/role/StockBasedCompensationTables"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestrictedStockUnitsRSUMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
"label": "Restricted Stock Units (RSUs) [Member]",
"terseLabel": "Unvested restricted stock units"
}
}
},
"localname": "RestrictedStockUnitsRSUMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"auth_ref": [
"r21",
"r218",
"r280",
"r366",
"r382",
"r384"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 2.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings (Accumulated Deficit)",
"terseLabel": "Accumulated Deficit"
}
}
},
"localname": "RetainedEarningsAccumulatedDeficit",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsMember": {
"auth_ref": [
"r112",
"r113",
"r114",
"r116",
"r122",
"r124",
"r179",
"r277",
"r278",
"r279",
"r285",
"r286",
"r379",
"r381"
],
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings [Member]",
"terseLabel": "ACCUMULATED DEFICIT"
}
}
},
"localname": "RetainedEarningsMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "domainItemType"
},
"us-gaap_RevenueFromContractWithCustomerAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Revenue from Contract with Customer [Abstract]",
"terseLabel": "Revenue from Contract with Customer [Abstract]"
}
}
},
"localname": "RevenueFromContractWithCustomerAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
"auth_ref": [
"r146",
"r147",
"r152",
"r157",
"r158",
"r162",
"r163",
"r165",
"r233",
"r235",
"r349"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 1.0,
"parentTag": "us-gaap_GrossProfit",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
"label": "Revenue from Contract with Customer, Including Assessed Tax",
"terseLabel": "Net Revenue",
"verboseLabel": "Net Sales"
}
}
},
"localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/DescriptionofBusinessDetails",
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RevenueFromContractWithCustomerTextBlock": {
"auth_ref": [
"r224",
"r225",
"r226",
"r227",
"r228",
"r229",
"r231",
"r232",
"r238",
"r247"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
"label": "Revenue from Contract with Customer [Text Block]",
"terseLabel": "Revenue Recognition"
}
}
},
"localname": "RevenueFromContractWithCustomerTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognition"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RevenueRemainingPerformanceObligation": {
"auth_ref": [
"r230"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
"label": "Revenue, Remaining Performance Obligation, Amount",
"terseLabel": "Revenue performance obligation"
}
}
},
"localname": "RevenueRemainingPerformanceObligation",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
"auth_ref": [
"r330",
"r335"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
"label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
"terseLabel": "Right of use assets exchanged for finance lease liabilities"
}
}
},
"localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
"auth_ref": [
"r330",
"r335"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
"label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
"terseLabel": "Right of use assets exchanged for operating lease liabilities"
}
}
},
"localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SaleOfStockNameOfTransactionDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
"label": "Sale of Stock [Domain]",
"terseLabel": "Sale of Stock [Domain]"
}
}
},
"localname": "SaleOfStockNameOfTransactionDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockholdersEquityDetails",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "domainItemType"
},
"us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of accrued liabilities.",
"label": "Schedule of Accrued Liabilities [Table Text Block]",
"terseLabel": "Schedule of Accrued Liabilities"
}
}
},
"localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/AccruedLiabilitiesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
"auth_ref": [
"r132"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
"label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
"terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
}
}
},
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
"auth_ref": [
"r132"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
"label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
"terseLabel": "Summary of Potentially Dilutive Securities"
}
}
},
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
"auth_ref": [
"r289"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
"terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
}
}
},
"localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LicensingAgreementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
"auth_ref": [
"r252",
"r273",
"r282"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
"label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
"terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
}
}
},
"localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
"http://rockwellmed.com/role/StockBasedCompensationTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
"auth_ref": [
"r252",
"r273",
"r282"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
"label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
"terseLabel": "Schedule of total stock-based compensation expense"
}
}
},
"localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
"auth_ref": [
"r11",
"r29",
"r30",
"r31"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
"label": "Schedule of Inventory, Current [Table Text Block]",
"terseLabel": "Schedule Components of Inventory"
}
}
},
"localname": "ScheduleOfInventoryCurrentTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/InventoryTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
"auth_ref": [
"r198"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
"label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
"terseLabel": "Schedule of Principal Payments on Term Loan"
}
}
},
"localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LoansandSecurityAgreementTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
"auth_ref": [
"r36",
"r191"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
"label": "Property, Plant and Equipment [Table]",
"terseLabel": "Property, Plant and Equipment [Table]"
}
}
},
"localname": "ScheduleOfPropertyPlantAndEquipmentTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/PropertyandEquipmentDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
"auth_ref": [
"r253",
"r276"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about share-based payment arrangement.",
"label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
"terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
}
}
},
"localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
"auth_ref": [
"r256"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
"label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
"terseLabel": "Schedule of restricted stock award"
}
}
},
"localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
"auth_ref": [
"r256",
"r267",
"r268"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
"label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
"terseLabel": "Schedule of stock options activity"
}
}
},
"localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
"auth_ref": [
"r270"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
"label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
"terseLabel": "Schedule of stock option assumptions"
}
}
},
"localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfStockByClassTable": {
"auth_ref": [
"r48",
"r104",
"r137",
"r138",
"r208",
"r209",
"r210",
"r212",
"r213",
"r214",
"r215",
"r216",
"r217",
"r218"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
"label": "Schedule of Stock by Class [Table]",
"terseLabel": "Schedule of Stock by Class [Table]"
}
}
},
"localname": "ScheduleOfStockByClassTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockholdersEquityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_SellingAndMarketingExpense": {
"auth_ref": [],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 4.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
"label": "Selling and Marketing Expense",
"terseLabel": "Selling and Marketing"
}
}
},
"localname": "SellingAndMarketingExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensation": {
"auth_ref": [
"r94"
],
"calculation": {
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncash expense for share-based payment arrangement.",
"label": "Share-based Payment Arrangement, Noncash Expense",
"terseLabel": "Stock-based Compensation"
}
}
},
"localname": "ShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
"auth_ref": [
"r254"
],
"lang": {
"en-us": {
"role": {
"documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
"terseLabel": "Vesting period"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
"auth_ref": [
"r261"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
"negatedLabel": "Forfeited (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r266"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
"verboseLabel": "Forfeited (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
"auth_ref": [
"r264"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
"terseLabel": "Granted (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r264"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
"terseLabel": "Granted (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
"auth_ref": [
"r263"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
"periodEndLabel": "Unvested at end of period (in shares)",
"periodStartLabel": "Unvested at beginning of period (in shares)",
"verboseLabel": "Unvested, number of shares (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
"terseLabel": "Number of Shares"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r263"
],
"lang": {
"en-us": {
"role": {
"documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
"periodEndLabel": "Unvested at end of period (in dollars per share)",
"periodStartLabel": "Unvested at beginning of period (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
"terseLabel": "Weighted Average Grant-Date Fair Value"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
"auth_ref": [
"r265"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
"negatedLabel": "Vested (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r265"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
"terseLabel": "Vested (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
"terseLabel": "Exercise price (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
"terseLabel": "Expected stock price volatility, maximum"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
"terseLabel": "Expected stock price volatility, minimum"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
"terseLabel": "Risk-free interest rate, maximum"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
"terseLabel": "Risk-free interest rate, minimum"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
"verboseLabel": "Stock option awards"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
"auth_ref": [
"r257",
"r259"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
"terseLabel": "Outstanding performance-based restricted stock units (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
"auth_ref": [
"r260"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
"periodEndLabel": "Exercisable at end of period (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
"auth_ref": [
"r260"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
"terseLabel": "Exercisable at end of the period (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
"auth_ref": [
"r262"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
"negatedLabel": "Expired (in shares)",
"terseLabel": "Expirations (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
"auth_ref": [
"r261"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
"negatedLabel": "Forfeited (in shares)",
"terseLabel": "Forfeited (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Gross number of share options (or share units) granted during the period.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
"terseLabel": "Granted (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
"auth_ref": [
"r276"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
"terseLabel": "Outstanding"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
"auth_ref": [
"r258",
"r276"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of options outstanding, including both vested and non-vested options.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
"periodEndLabel": "Outstanding at the end of the period (in shares)",
"periodStartLabel": "Outstanding at the beginning of the period (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
"terseLabel": "Shares Underlying Options",
"verboseLabel": "Number of Shares"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
"auth_ref": [
"r257"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
"periodEndLabel": "Outstanding at the end of the period (in dollars per share)",
"periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
"terseLabel": "Weighted Average Exercise Price"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
"auth_ref": [
"r251",
"r255"
],
"lang": {
"en-us": {
"role": {
"documentation": "Award under share-based payment arrangement.",
"label": "Award Type [Domain]",
"terseLabel": "Equity Award [Domain]"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedandPerformanceBasedRestrictedStockUnitsDetails",
"http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails",
"http://rockwellmed.com/role/StockBasedCompensationTables"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
"label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
"terseLabel": "Expired (in dollar per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
"label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
"terseLabel": "Forfeited (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
"label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
"terseLabel": "Granted (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails",
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
"auth_ref": [
"r271",
"r281"
],
"lang": {
"en-us": {
"role": {
"documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
"terseLabel": "Term (years)"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
"auth_ref": [
"r276"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
"terseLabel": "Exercisable at end of the period"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
"auth_ref": [
"r276"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
"terseLabel": "Exercisable at end of the period"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
"auth_ref": [
"r269"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
"terseLabel": "Outstanding"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_ShortTermDebtTypeAxis": {
"auth_ref": [
"r40"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of short-term debt arrangement.",
"label": "Short-term Debt, Type [Axis]",
"terseLabel": "Short-term Debt, Type [Axis]"
}
}
},
"localname": "ShortTermDebtTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/SubsequentEventsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShortTermDebtTypeDomain": {
"auth_ref": [
"r38"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
"label": "Short-term Debt, Type [Domain]",
"terseLabel": "Short-term Debt, Type [Domain]"
}
}
},
"localname": "ShortTermDebtTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/SubsequentEventsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShortTermLeaseCost": {
"auth_ref": [
"r327",
"r335"
],
"calculation": {
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails": {
"order": 3.0,
"parentTag": "us-gaap_LeaseCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
"label": "Short-term Lease, Cost",
"terseLabel": "Short-term lease rent expense"
}
}
},
"localname": "ShortTermLeaseCost",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SignificantAccountingPoliciesTextBlock": {
"auth_ref": [
"r111"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
"label": "Significant Accounting Policies [Text Block]",
"terseLabel": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements"
}
}
},
"localname": "SignificantAccountingPoliciesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_StatementEquityComponentsAxis": {
"auth_ref": [
"r49",
"r112",
"r113",
"r114",
"r116",
"r122",
"r124",
"r136",
"r179",
"r211",
"r218",
"r277",
"r278",
"r279",
"r285",
"r286",
"r303",
"r304",
"r305",
"r306",
"r307",
"r308",
"r379",
"r380",
"r381"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by component of equity.",
"label": "Equity Components [Axis]",
"terseLabel": "Equity Components [Axis]"
}
}
},
"localname": "StatementEquityComponentsAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Statement [Line Items]",
"terseLabel": "Statement [Line Items]"
}
}
},
"localname": "StatementLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfCashFlowsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Cash Flows [Abstract]",
"terseLabel": "Statement of Cash Flows [Abstract]"
}
}
},
"localname": "StatementOfCashFlowsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Financial Position [Abstract]",
"terseLabel": "Statement of Financial Position [Abstract]"
}
}
},
"localname": "StatementOfFinancialPositionAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Comprehensive Income [Abstract]",
"terseLabel": "Statement of Comprehensive Income [Abstract]"
}
}
},
"localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfStockholdersEquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Stockholders' Equity [Abstract]",
"terseLabel": "Statement of Stockholders' Equity [Abstract]"
}
}
},
"localname": "StatementOfStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementTable": {
"auth_ref": [
"r112",
"r113",
"r114",
"r136",
"r349"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
"label": "Statement [Table]",
"terseLabel": "Statement [Table]"
}
}
},
"localname": "StatementTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockIssued1": {
"auth_ref": [
"r99",
"r100",
"r101"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The fair value of stock issued in noncash financing activities.",
"label": "Stock Issued",
"terseLabel": "Fair Value of Warrants issued related to Debt Financing"
}
}
},
"localname": "StockIssued1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
"auth_ref": [
"r17",
"r18",
"r211",
"r218"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of new stock issued during the period.",
"label": "Stock Issued During Period, Shares, New Issues",
"terseLabel": "Issuance of common stock, net of offering costs (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesNewIssues",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
"auth_ref": [
"r17",
"r18",
"r211",
"r218"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
"label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
"terseLabel": "Vesting of Restricted Stock Units Issued, net of taxes withheld (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
"auth_ref": [
"r17",
"r18",
"r211",
"r218"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
"label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
"terseLabel": "Stock-based Compensation expense (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodValueNewIssues": {
"auth_ref": [
"r17",
"r18",
"r211",
"r218"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
"label": "Stock Issued During Period, Value, New Issues",
"terseLabel": "Issuance of common stock, net of offering costs"
}
}
},
"localname": "StockIssuedDuringPeriodValueNewIssues",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
"auth_ref": [
"r211",
"r218"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
"label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
"terseLabel": "Vesting of Restricted Stock Units Issued, net of taxes withheld"
}
}
},
"localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquity": {
"auth_ref": [
"r18",
"r23",
"r24",
"r106",
"r169",
"r178",
"r297"
],
"calculation": {
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
"label": "Stockholders' Equity Attributable to Parent",
"periodEndLabel": "Ending balance",
"periodStartLabel": "Beginning balance",
"terseLabel": "Stockholders' equity",
"totalLabel": "Total Stockholders\u2019 Equity"
}
}
},
"localname": "StockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Stockholders' Equity Attributable to Parent [Abstract]",
"terseLabel": "Stockholders\u2019 Equity:"
}
}
},
"localname": "StockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
"auth_ref": [
"r105",
"r218",
"r219"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
"label": "Stockholders' Equity Note Disclosure [Text Block]",
"terseLabel": "Stockholders' Equity"
}
}
},
"localname": "StockholdersEquityNoteDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockholdersEquity"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SubsequentEventLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
"label": "Subsequent Event [Line Items]",
"terseLabel": "Subsequent Event [Line Items]"
}
}
},
"localname": "SubsequentEventLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/SubsequentEventsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_SubsequentEventMember": {
"auth_ref": [
"r309",
"r340"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event [Member]",
"terseLabel": "Subsequent event"
}
}
},
"localname": "SubsequentEventMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/SubsequentEventsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SubsequentEventTable": {
"auth_ref": [
"r309",
"r340"
],
"lang": {
"en-us": {
"role": {
"documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
"label": "Subsequent Event [Table]",
"terseLabel": "Subsequent Event [Table]"
}
}
},
"localname": "SubsequentEventTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/SubsequentEventsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_SubsequentEventTypeAxis": {
"auth_ref": [
"r309",
"r340"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event Type [Axis]",
"terseLabel": "Subsequent Event Type [Axis]"
}
}
},
"localname": "SubsequentEventTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/SubsequentEventsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_SubsequentEventTypeDomain": {
"auth_ref": [
"r309",
"r340"
],
"lang": {
"en-us": {
"role": {
"documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event Type [Domain]",
"terseLabel": "Subsequent Event Type [Domain]"
}
}
},
"localname": "SubsequentEventTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/SubsequentEventsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SubsequentEventsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Subsequent Events [Abstract]",
"terseLabel": "Subsequent Events [Abstract]"
}
}
},
"localname": "SubsequentEventsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_SubsequentEventsTextBlock": {
"auth_ref": [
"r339",
"r341"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
"label": "Subsequent Events [Text Block]",
"terseLabel": "Subsequent Events"
}
}
},
"localname": "SubsequentEventsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/SubsequentEvents"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SubsidiarySaleOfStockAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of sale of the entity's stock.",
"label": "Sale of Stock [Axis]",
"terseLabel": "Sale of Stock [Axis]"
}
}
},
"localname": "SubsidiarySaleOfStockAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/StockholdersEquityDetails",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "stringItemType"
},
"us-gaap_SupplementalCashFlowInformationAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Supplemental Cash Flow Information [Abstract]",
"terseLabel": "Supplemental Disclosure of Cash Flow Information:"
}
}
},
"localname": "SupplementalCashFlowInformationAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "stringItemType"
},
"us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
"auth_ref": [
"r235",
"r245"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by timing of transfer of good or service to customer.",
"label": "Timing of Transfer of Good or Service [Axis]",
"terseLabel": "Timing of Transfer of Good or Service [Axis]"
}
}
},
"localname": "TimingOfTransferOfGoodOrServiceAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
"auth_ref": [
"r235",
"r245"
],
"lang": {
"en-us": {
"role": {
"documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.",
"label": "Timing of Transfer of Good or Service [Domain]",
"terseLabel": "Timing of Transfer of Good or Service [Domain]"
}
}
},
"localname": "TimingOfTransferOfGoodOrServiceDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_TransferredAtPointInTimeMember": {
"auth_ref": [
"r245"
],
"lang": {
"en-us": {
"role": {
"documentation": "Contract with customer in which good or service is transferred at point in time.",
"label": "Transferred at Point in Time [Member]",
"terseLabel": "Product Sales \u2013 Point-in-time"
}
}
},
"localname": "TransferredAtPointInTimeMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_TransferredOverTimeMember": {
"auth_ref": [
"r245"
],
"lang": {
"en-us": {
"role": {
"documentation": "Contract with customer in which good or service is transferred over time.",
"label": "Transferred over Time [Member]",
"terseLabel": "License Fee \u2013 Over time"
}
}
},
"localname": "TransferredOverTimeMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_UseOfEstimates": {
"auth_ref": [
"r139",
"r140",
"r141",
"r142",
"r143",
"r144",
"r145"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
"label": "Use of Estimates, Policy [Policy Text Block]",
"terseLabel": "Use of Estimates"
}
}
},
"localname": "UseOfEstimates",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_VariableLeaseCost": {
"auth_ref": [
"r328",
"r335"
],
"calculation": {
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails": {
"order": 2.0,
"parentTag": "us-gaap_OperatingLeaseExpense",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
"label": "Variable Lease, Cost",
"terseLabel": "Variable lease cost"
}
}
},
"localname": "VariableLeaseCost",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/LeasesSummaryofLeaseCostsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_WarrantMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
"label": "Warrant [Member]",
"terseLabel": "Warrants to purchase common stock"
}
}
},
"localname": "WarrantMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsSummaryofPotentiallyDilutiveSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
"auth_ref": [
"r126",
"r131"
],
"lang": {
"en-us": {
"role": {
"documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
"label": "Weighted Average Number of Shares Outstanding, Diluted",
"terseLabel": "Diluted Weighted Average Shares Outstanding (in shares)"
}
}
},
"localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "sharesItemType"
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
"auth_ref": [
"r125",
"r131"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
"label": "Weighted Average Number of Shares Outstanding, Basic",
"terseLabel": "Basic Weighted Average Shares Outstanding (in shares)"
}
}
},
"localname": "WeightedAverageNumberOfSharesOutstandingBasic",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "sharesItemType"
},
"us-gaap_WorkersCompensationLiabilityCurrent": {
"auth_ref": [
"r43"
],
"calculation": {
"http://rockwellmed.com/role/AccruedLiabilitiesDetails": {
"order": 5.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Workers' Compensation Liability, Current",
"terseLabel": "Accrued Workers Compensation"
}
}
},
"localname": "WorkersCompensationLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://rockwellmed.com/role/AccruedLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
}
},
"unitCount": 8
}
},
"std_ref": {
"r0": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "205",
"URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
},
"r1": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "205",
"URI": "http://asc.fasb.org/topic&trid=2122149"
},
"r10": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
},
"r100": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
},
"r101": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
},
"r102": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
},
"r103": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
},
"r104": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(d))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r105": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(e)(1))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r106": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r107": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(m)(1)(iii))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r108": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08.(e),(f))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r109": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08.(k)(1))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r11": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
},
"r110": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-04.(a))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
},
"r111": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "235",
"URI": "http://asc.fasb.org/topic&trid=2122369"
},
"r112": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
},
"r113": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
},
"r114": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
},
"r115": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
},
"r116": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
},
"r117": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
},
"r118": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
},
"r119": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
},
"r12": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(13))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r120": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
},
"r121": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
},
"r122": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
},
"r123": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
},
"r124": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
},
"r125": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
},
"r126": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
},
"r127": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
},
"r128": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
},
"r129": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
},
"r13": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(14))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r130": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
},
"r131": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
},
"r132": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
},
"r133": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
},
"r134": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
},
"r135": {
"Name": "Accounting Standards Codification",
"Paragraph": "52",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
},
"r136": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
},
"r137": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
},
"r138": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "272",
"URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
},
"r139": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r14": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(19))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r140": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r141": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
},
"r142": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
},
"r143": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
},
"r144": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
},
"r145": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
},
"r146": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r147": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r148": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r149": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r15": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(20))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r150": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r151": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r152": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
},
"r153": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
},
"r154": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
},
"r155": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
},
"r156": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
},
"r157": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
},
"r158": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
},
"r159": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
},
"r16": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(22))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r160": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
},
"r161": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
},
"r162": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
},
"r163": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
},
"r164": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
},
"r165": {
"Name": "Accounting Standards Codification",
"Paragraph": "42",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
},
"r166": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
},
"r167": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
},
"r168": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
},
"r169": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 4.E)",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
},
"r17": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r170": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
},
"r171": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
},
"r172": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
},
"r173": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
},
"r174": {
"Name": "Accounting Standards Codification",
"Paragraph": "2A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL121698322-111563"
},
"r175": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
},
"r176": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
},
"r177": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "320",
"URI": "http://asc.fasb.org/topic&trid=2196928"
},
"r178": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
},
"r179": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
},
"r18": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r180": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
},
"r181": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
},
"r182": {
"Name": "Accounting Standards Codification",
"Paragraph": "3A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267853-210455"
},
"r183": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.L)",
"Topic": "330",
"URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e99989-122729"
},
"r184": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.BB)",
"Topic": "330",
"URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
},
"r185": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "330",
"URI": "http://asc.fasb.org/topic&trid=2126998"
},
"r186": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
},
"r187": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
},
"r188": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r189": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r19": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(3))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r190": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r191": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r192": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "360",
"URI": "http://asc.fasb.org/topic&trid=2155823"
},
"r193": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "440",
"URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
},
"r194": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "440",
"URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
},
"r195": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "440",
"URI": "http://asc.fasb.org/topic&trid=2144648"
},
"r196": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
},
"r197": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "450",
"URI": "http://asc.fasb.org/topic&trid=2127136"
},
"r198": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
},
"r199": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
},
"r2": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
},
"r20": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r200": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "20",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
},
"r201": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
},
"r202": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
},
"r203": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
},
"r204": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
},
"r205": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
},
"r206": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "470",
"URI": "http://asc.fasb.org/topic&trid=2208564"
},
"r207": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "10",
"Topic": "480",
"URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
},
"r208": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(CFRR 211.02)",
"Topic": "480",
"URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
},
"r209": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
},
"r21": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r210": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
},
"r211": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
},
"r212": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
},
"r213": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
},
"r214": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
},
"r215": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
},
"r216": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
},
"r217": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
},
"r218": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
},
"r219": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "505",
"URI": "http://asc.fasb.org/topic&trid=2208762"
},
"r22": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(4))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r220": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
},
"r221": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
},
"r222": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
},
"r223": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
},
"r224": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
},
"r225": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
},
"r226": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
},
"r227": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
},
"r228": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
},
"r229": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
},
"r23": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r230": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
},
"r231": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
},
"r232": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
},
"r233": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
},
"r234": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
},
"r235": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
},
"r236": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
},
"r237": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
},
"r238": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
},
"r239": {
"Name": "Accounting Standards Codification",
"Paragraph": "27",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130611-203046-203046"
},
"r24": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(31))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r240": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
},
"r241": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
},
"r242": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
},
"r243": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
},
"r244": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
},
"r245": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
},
"r246": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
},
"r247": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "606",
"URI": "http://asc.fasb.org/topic&trid=49130388"
},
"r248": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(i)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r249": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(d)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
},
"r25": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(32))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r250": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "80",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
},
"r251": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
},
"r252": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
},
"r253": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
},
"r254": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r255": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a),(g)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r256": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r257": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(i)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r258": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(i)-(ii)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r259": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(ii)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r26": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(1))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r260": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iii)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r261": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(3)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r262": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(4)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r263": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(i)-(ii)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r264": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r265": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r266": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(3)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r267": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r268": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r269": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r27": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(3))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r270": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r271": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(i)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r272": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r273": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r274": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)(i)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r275": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r276": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r277": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r278": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r279": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r28": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(4))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r280": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(g)(2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r281": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 14.D.2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
},
"r282": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 14.F)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
},
"r283": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "718",
"URI": "http://asc.fasb.org/topic&trid=2228938"
},
"r284": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "730",
"URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
},
"r285": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "740"
},
"r286": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(3)",
"Topic": "740"
},
"r287": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "808",
"URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
},
"r288": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "808",
"URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
},
"r289": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "808",
"URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
},
"r29": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r290": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "808",
"URI": "http://asc.fasb.org/topic&trid=5833765"
},
"r291": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r292": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r293": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c),(3)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r294": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
},
"r295": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
},
"r296": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "810",
"URI": "http://asc.fasb.org/topic&trid=2197479"
},
"r297": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
},
"r298": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
},
"r299": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
},
"r3": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
},
"r30": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(b))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r300": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
},
"r301": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
},
"r302": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
},
"r303": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
},
"r304": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r305": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r306": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r307": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r308": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
},
"r309": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
},
"r31": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(c))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r310": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
},
"r311": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
},
"r312": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
},
"r313": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
},
"r314": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
},
"r315": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
},
"r316": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
},
"r317": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
},
"r318": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
},
"r319": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
},
"r32": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(7))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r320": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
},
"r321": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
},
"r322": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
},
"r323": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(3)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
},
"r324": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
},
"r325": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
},
"r326": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
},
"r327": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
},
"r328": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
},
"r329": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(1)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
},
"r33": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(8))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r330": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(2)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
},
"r331": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(3)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
},
"r332": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(4)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
},
"r333": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
},
"r334": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
},
"r335": {
"Name": "Accounting Standards Codification",
"Paragraph": "53",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
},
"r336": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"SubTopic": "20",
"Topic": "842",
"URI": "http://asc.fasb.org/subtopic&trid=77888251"
},
"r337": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r338": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
},
"r339": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "855",
"URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
},
"r34": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.1)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r340": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "855",
"URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
},
"r341": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "855",
"URI": "http://asc.fasb.org/topic&trid=2122774"
},
"r342": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r343": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r344": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r345": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r346": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r347": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r348": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "910",
"URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
},
"r349": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.L)",
"Topic": "924",
"URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
},
"r35": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.13)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r350": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(10)(1))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r351": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(11))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r352": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(13))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r353": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(16))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r354": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(23))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r355": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.15(3),(4))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r356": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.17)",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r357": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(22))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r358": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(26))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r359": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(27))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r36": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.14)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r360": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04.9)",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r361": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "470",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
},
"r362": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(16))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r363": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r364": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(16))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r365": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r366": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r367": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r368": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(8))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r369": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.(a),19)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r37": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.17)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r370": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.17)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r371": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(18))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r372": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(22))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r373": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(23))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r374": {
"Name": "Accounting Standards Codification",
"Paragraph": "4H",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
},
"r375": {
"Name": "Accounting Standards Codification",
"Paragraph": "7A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(d)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
},
"r376": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
},
"r377": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(b)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
},
"r378": {
"Name": "Accounting Standards Codification",
"Paragraph": "29F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
},
"r379": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r38": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r380": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(1)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r381": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(2)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r382": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(i)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r383": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(ii)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r384": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(2)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r385": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "310",
"Subparagraph": "(SX 210.12-29(Footnote 4))",
"Topic": "948",
"URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
},
"r386": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "360",
"Subparagraph": "(d)",
"Topic": "958",
"URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
},
"r387": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "360",
"Topic": "958",
"URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
},
"r388": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "360",
"Topic": "958",
"URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
},
"r389": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column B))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r39": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a),20,24)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r390": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column C))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r391": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column D))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r392": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column E))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r393": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column F))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r394": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column G))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r395": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column H))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r396": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column I))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r397": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Footnote 2))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r398": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "985",
"URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
},
"r399": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b"
},
"r4": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
},
"r40": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r400": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "d1-1"
},
"r401": {
"Name": "Form 10-Q",
"Number": "240",
"Publisher": "SEC",
"Section": "308",
"Subsection": "a"
},
"r402": {
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-1"
},
"r403": {
"Name": "Regulation 12B",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r404": {
"Name": "Regulation S-T",
"Number": "232",
"Publisher": "SEC",
"Section": "405"
},
"r41": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19,20)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r42": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19-26)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r43": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r44": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.21)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r45": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22(a)(1))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r46": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r47": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.25)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r48": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.28,29)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r49": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-31)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r5": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
},
"r50": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.6(a))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r51": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.6(d))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r52": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.6a)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r53": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.6b)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r54": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.6c)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r55": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.8)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r56": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.9)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r57": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
},
"r58": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
},
"r59": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
},
"r6": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
},
"r60": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
},
"r61": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
},
"r62": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
},
"r63": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
},
"r64": {
"Name": "Accounting Standards Codification",
"Paragraph": "14A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
},
"r65": {
"Name": "Accounting Standards Codification",
"Paragraph": "17B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
},
"r66": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
},
"r67": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
},
"r68": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
},
"r69": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
},
"r7": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
},
"r70": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
},
"r71": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(210.5-03(11))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r72": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(20))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r73": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(24))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r74": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(25))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r75": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.1,2)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r76": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.2(a),(d))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r77": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.4)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r78": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7(b))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r79": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.8)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r8": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
},
"r80": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.9)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r81": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
},
"r82": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
},
"r83": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
},
"r84": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
},
"r85": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
},
"r86": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
},
"r87": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
},
"r88": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
},
"r89": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
},
"r9": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
},
"r90": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
},
"r91": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
},
"r92": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
},
"r93": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
},
"r94": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
},
"r95": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
},
"r96": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
},
"r97": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
},
"r98": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
},
"r99": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
}
},
"version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001628280-21-017141-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-017141-xbrl.zip
M4$L#!!0 ( +&)$%/HO/)T.N ! #[G%0 1 <FUT:2TR,#(Q,#8S,"YH
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M2)&&U+L%(!88_[0W .A$_,8 UC_M$RS\YTJO>7+:*JAR\-E1M_#SX^+Q'
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M@L:BD&9&H=8)D8F9H%P.$01!E2R])63,D[4Q.I?0R84AT[1#K9/:#,0P$ 1
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M""088BYMH[7,FR5GS0%GU<.XSZ""!61 ;<@=)N:-B"B322E%DXUBCMLE\RX
M\RZ\Y^Z$Y-IDS309=Q8-ENTP+/'LRV*1DS6 J-_-.+5;HZXE;%0Q>NE8@L)9
M07";-!A);V,.BE3EDK.6R3ISR[S6)^E"-K)T!2Q=RL&2*Q\"6?<<.=0A[+3X
M:K%FQGT&P5/GK#51^< M$9KN1 J$%Q-G/.P &LX"\#%M82-@7L6M%$8)4(,
M"LG(^^A5L@D]\[CDK*5QGUOF+<4$=8(<@HP0M/56T4]*QNADI:A#K??%5XLU
M,^XSX.(<-(/,O,\!7&*8E8\R.RZS\0$7(&7O2RY>2)267.D\D:1/S(%EWLEL
M=30>,U/(Y$(ZRHL1=)X^KW!GN,G2BH02"'O9*#TZ[@+3@-XLI%^Z8#'>&6P
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MP27GP*5!J6(0R0$G5PAC'79++\N_/E3F%=X)K1&4)[4(,3L7)/T+"B79=K<
M^;4+H!9K9MRGS\4&=="9O/4<$G@.*(/RT4**(GFM%F"A=@&XN):PL=02UH'Q
M$(KS8S,**1-(*T34.LD%2&9<&O>%95ZMM4]&<ZY]A.@]DA-D=;;&VNQ)-2Z9
M=PXXJV;&?0:>N_'"AJ1XY)YP:O+<*F/0&QUS!%A(B+J0*$V%(#@D(+="@D2'
MPMADN3?D):<LZ[#$/7=56!=U1=D&+4O5U6BB@LA(Z'U2BJ6$I1J3JD.]L+GC
ME85W Z4DOT\3%97AX &L%8%+1K;"2^EL'>H=S:.EF$%.)EC&!#<)0)"E*"Z8
MI$^<<DE%68MZ+7,G_8NZ/!FTE]HDE526D -''R1WP+,S5ML@E[PR]Y9B^DR#
M!"2(%XSR2H/,P@>7A,,$/ECO75W@Q<S%?08+%CQ T% L@P$M=-G?$8+%(,K.
M#E>'#.SY$K[ID] +)8UD'*W,$"0AM6@\<*Z=]S$P4Q.-/7/AFT4A,BFD)]^,
M*08V.VMEV1_'0A8IA]H$%.='^*9/0B$$CTGJ$!%!INBYMIKYP*&4J]'RKPTQ
MQU7Y9^T:-=M$)3I7?%%N?WSD1^)BDD=M4 ;/#' -7FN>DQ7D[Y2N"7Q $L:%
MY$N2_"U)6,5%)?D$2))S@.BDS"Z3HG/<DBLA,\%#)TNPDLVWE#POYB=U3TF?
M7&SAR762_([G=.1?"5O]HX#=M-T]Q';S$_;IRW41EXA\4)3=J@P8A162X%Y0
MBJMH%1?S2YNQ<7E]YNF,M_UFJ]EOIMY&^P-]O].]N$:GO6XSTY2$RV,U(4Y,
M'B!Y(4AF()&1L>AXT%RZQ*)1;J&(L];$UD6/M%M-B.,8<A]0JL %>;W,1AX=
MH),NI*P#+!1Q5E]OU(0LPC.OLRF[0A@)#U@C%7.9\V!*PG*N 5FZ'7K>_L7K
M%DW!:CNN__NL>5K&^/UB[^+TLR7R5PE[Z:C3BALGI]W.AP$0KPM4<Y%PF$4-
MLM0&X=(3>,9(KQUSP@@[OU"M)J2:'(0#K=!PRV*(&:+PEO' ,PBC@B>O1RV8
M5&UB.&JV$ZG":R?61*J$-58"]^ -@#+@DG3,<*8<3:R#N&!2-7U234ZJN/;<
M8^),V@R$MSV&;)P0-B6O&-H%DZKMG,FEK9\\2>TDZH2E<ZWT-@J3C#.9\+AV
MFBV8/$V32).3)!%I_IFG^4NN--,A:(X9G9+6!".%7S1)ZA^E;IV-E',,4.=2
M?-Y##M):\(E<*,%BC*#4H@G5;.@U.?GRP%%YEOV@5XJW""+[3%<H:QC&#.IZ
M<9KCP5I%>3%_A)NK6-[UI0L.%6=W6[H8GGI%T9_)'T4 (#2OB8@@G?"H4EFU
M)XQOD.MQ3^AY;^L]EQ2=39=OS@A ,H;9<0XRH LR1><AD8Y508X;M<][K^BY
MI>CT6T>+:&R,&:WE"L!RIW/RR43".)$([6NR0CR?%)U1JE3.VF9A=5&M63FC
M [D2)8D#%+E_-4FXF5N*SB#_AG,L^RZBY1JB J)P$IZ1#<40I)3SBV3GBI"3
M0JUG[>:0,.VS<B^7<WZ2L'?63<]&8]#+\0#C(^/W983;5^/*<D( I@C[@A"$
MF1(7)IO$6.0A#?*HN1YI8ZYK2/)WV/;8/OR]V3D]PNX)AG36+]D\]XQ_]9TU
M,9UZ@S=^1A-K[RSC69=NY,XPKR)J:;4EUR5$P^N/?V=#S=E@7V<B,]I(*2R'
M(+0W1#DT)*<1K1R5C:DU]IT=-6> >QVZJ$J#=5*V*BGOHC,N)4 I.4I=?Y0T
M(VK.*$-9<V-=YN2.@N*\K/@:P;)+(6DB<OV]F-E1<P99RYQ(5"RF$0C<(WIE
MA3<VI.0#JCE>LYH;(MY+1)V(H9'T)0%10QB5N5(9E1!-UIJHQ><XF6(>Z3*Y
MR+D)/CEM0$5 2,DX<,E(G7)V+,?X1<%/7CL"[9ZU7P\HLWK83?>5U?(3BH]/
MQF&()G-FD0N1+3BO'8\22J*_MCI+8^KO,$R?D+.)DWN?F;,:B9ADP9+E*7(;
M./E^ANL8ZN\KS(20TW<38E8E\U9"M($D,3C&@5!F8")QKIFH/["<=]4Z,>_=
MY1Q%5$ZRTC7*YI0X&@%1E_U4"^#OS820TW?U@C!6*NF,DA("2U[S8BNE]0E$
M5G.<)CH/]+N?/21\X NX%(4C$*I1(<ODO)&,<;)\H;9^P;1),LED:F>#(M"H
MK1B$MR3C9,"22B'YS,>+@&ZL[ESMQ.6/U&Q-7]^YN^L[-ZD%^I1BSIX)7U!(
M1,&#R>A93JQX"/7W"69 R9DX!4FAYI'TH2C1R;*-BV<!UC&=C FUJ8LX7Y2<
M3?EJK9PA+&EE= DF<%8+3(7W#KA[0*D0<U&)J?OWP&SY*MCB#E8$(K<=HU"
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M9@T;%,_E;BD=?T<.[B8F'1(A@TW<B* ,#F2%(6*(*"/)O%A-\<Z(8;9**N)
M=4"5T40K0G:HR7(X;S(73"?TP3/GL7;*:I;K\_>COV+@VL2R397,1] V>RM+
M_U,D;U@H5SOK/J,-;_=BZY5+4<E82N8G*"GXJ30_]67=58$)->A-.W?$F9SD
MA!!* Z\L#)+M5\YR;0/9&.DRXSSDVEG^F1-G@CC )E.J<J/@*A!*EEZXX(#H
M8YV6-O#:X8"9$V>"J" *'W@2";+-I=J-]TG$'$'K*%.PHKYA@4E0Z9O7OJW
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MA;^D,M8HJ2J&G%5 AIE<*A,JEHW-E@E%<[CR;+]L!/[,+H\X]F:>V^SX%N:
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M6Y=;:W^T-O<.":^N*L*N[.#E)FQ^>O-IDY[EL\+MXN#X]];^'MWGN_7S_;W
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M\4X/S1IU>/3__5./.-_ACJ\6LCSKQ<^J6"HEC/3:&",5N5S>>TC&RBR,U1%
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MS% ,5" ZY"B5".BF0; E#KLQ^>#U S'%1^=\DIYV5)>=I;RLGPAY65Y*2];
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M"CM/XO@*TM/]M,CU"^$Q ]9%3$5,14Q%3$5,3T=,LYC.5@8)4>6M8I^<6ZR
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M=]%@X#J9DP8X!L:$5Y@ OX,].2_[_F..3L)5\BV6XYW(=U*,!UN/A02/L&*
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M"Y]+$3-_2XB:01 Q'V&SF&GOK;<,Z\+GM>/S]CC(FSA]Z[U326H8!'+2 +0
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MX$8Z 4J!2=9C4TM5J'?%,%VHMXBIB.D1-*2V@,$R(JFDD#F5>1,-]LG E9J
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MFY(FFZN9:V'-PIKKP)JSI*U@XUPPE$DL03NI5'16**H% 84]+>&&I1'B5-<
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M_);) ,Q#S#EA+,'4+_E)L8/-QB&.$3CP<DO>4Y&@UXW=)IW>N#@=;]E/J9Z
MU%-[TAWG*UH$NP*"_37/1'AB/@F?4$Q!YR(?%#DL+?*.4NT%M32XK2=L&^/S
MP6975J,N+3(;9"1YS#!POXFS+0S<% ;FV_5@'&02"*M $0<Z@XP2%$E!L (V
MXW3*$:?;6JW ''KK,+!*4\MZ\1RUG.?8T5'N/QPZ+_J=J5AT=F%]/E^?Y]23
MLKD MWRRUMX.<Q#'>4'_' X^=T,,OYWFE9V#N]FRMHAW)<1;K&[&$M74*(0=
M-8B+&)'E'",3O?42#JU209>H;<Y6X+->&^:S0@/-8P:&55IO6F!8 V"842$G
M8,6BL,BRW+F0"($L$1CE<FJ1)JPISSU'Y381*RC_OWY<:+G-9TWXSP5VGLQ_
MGO<&7T:=Y\/!<=UW:)$"7:]4[U48Z[5J\%Y6$[V503ZV>LY_3H;^*'LEV]Y4
MFV'[^].>EA5Z,]CU_SOI#N/9EC>S9CBY-4Y[[%WIV%NH@I<2''J."Z1+F8J@
M@ ]CCY'$"EON@L )P[''MI6\B26P]4FNL6C?I3VO%>U;%NVY-"\N6 PLH!0T
MB+:R+*=Y,82%9,XFHICFA=$*TC:TNA<AO<6&F9L;R[FNG&0X@"D-HZQIY%5Y
MF5KD6B%R+93!DXD&AG%NC)- %\\))38XC)13F@D>&$D)D$ML$WWC3IIMK/;Z
MRO>=$I-6OF]9ON>*]BINHLS1CSS8;&L#^29,(VH%CS9%^,Q41GBS09T*'K3=
MY!F0]9-K=]=\''K4R@ODG5.6]JT_@B$.3W?[8;HB+1)="8D6JN11+JE00"V(
M]X!$.C'DL,7(NT2E%QIK+K>>T"4TH[5]/ B977F%O%9F;T=F9^S!"*&85QXY
MD=E#I!%EO0!QH5*RRLID<9;9S<@Y?P#]C38F7/P[852-=[WSV^E2/^+C#!E?
M/F%K:J&Y($YBNIIMG,3UT/?;0KD>J92@&AA3,,X 8W(.&4XYXL$0)R1UG-&2
M0<_.^XL:(;H/4G ]M7%M KC:T/55P-'*V5Z+.;>'.3/&%XPW(?>Q%)9AP!R=
MD"/6H& UPU$1[TC,589PBSAW9L5:$TIWN<BPY]V^[?M51(9=)7[OOCN\WT%D
MV(8[8!NC?R?E7?(F#H\[?PQLO_6XWG,E[WEGS(O1:)*+_[Y,?PSZAWF-6O?+
ME8_3Q3(4.-#@DD8I$9/[# 2DHV7(&$8E5P*H$&FK>#\":;XO_VHKTJL1Z1E#
MCMYC:65"FNN<R)D<<C)(Y*B-6"AM? [CI'1;+"')K4?U[NICN7&GV?V=IX/1
M-7N>;JYO9@VY1NVP>9GRZC2+4]:F1:0K(=)"A8E,,")U#ME@<ZN0%) S!*.@
M:5*1&2'MZEJ%M"[6A^UBO7)X>2O,*Q#F&;T0D6.C,45"$X<X401IK#BRU@N!
M&=72^M)EG6^&T_7A&3+J?=\!47Q]-!B.*V/&P6 <V_9D:T(T7L63*3KEA6E;
M)EX+F!;*.>@4%>=6(AYX[ILH<HZ+-T@(JE+TR032FC(V5H;O-9"K%==5B>M<
MD07JE27"(T%,1-QRBZQ*"@GNC(Y*>Y] 7-6Z%-]_;.:)17?(^"C.;!6#U'DZ
M.#[.]&(\\/]T_MWY<^)Z7=]YF1(\K'_8VC$N0B;+5&)8)@V0PP,)CL%6%YA&
M$ 8M#+]5GTFU:&7-6N"Z$G"]7TB3YUQ880B2FC/$F0U( U5$5G,JK$Y>8=9:
M,QZ!,)O$) X4A-<93DS246K"L04%F)&H]>V[3%J)OH%$S^6@V20-U02QP$%]
ML 0C(SE!EF,5/:7",[WU1&\3?KX6_\-HM[X)C*1A%Y6OY,YXR>:J3&O(2Z9:
M5%FAUB9[?0!;J-RC.-:!"(8LC3A'<<!/";2J:*E.BL04*6U-'YLJQU<Q?:R
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M@^G6D_/&V4TNG=""UT,%KQ6H&BUXK3MXS;07DZ1C7DHDJ):(2R^0#2HAKZ/
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MZA7<NL@Q%,QA=?<H=3_]V)5HM3,?]O'FV!&!(D==R&%(P#0 M::&^L\5:9
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M"4_M#J?[!S:;C]VR YIO[P =/)!O)VW9E:,^F7;V_"Y:AAW9D"P#GFC@ @.
M)N-1-Y1=-WVT.\V[?5B%U'7^+$U67KP H<E"58]G)D+YTK,"9/OQN&OS'IL.
M>LF#\L0.RKS,WJ@WZ!\B>/'CL@[P+'\$]X:5Z.:]_3GV!Y-1Y[B@6T:7:GX^
MVV$W_[U:SH)9 $.YM6^]RX\&QWE:$IQL,-!1'.=WV^GD6<M3\^K_V..37_<Z
M)]V3F#=1F<6I4,:O)[!;\^!J +A'66IMG[</&!A-C* %1TW!YA-)^!+%U;<
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M$!9,@ J.M7$\E[$_#Q@PTX6G@" WRP:<!]24HJ+9K'O!,0@:5R$.XVB/*RH
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M:,EP7 UAS$#8AX/)X5'#N"IE>P9S4WUZ.__DBP(X;9[>G6N>'G)077YHA/T
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M'[.).P<^=.M-.\R$-CO<0V4,S2%'-4W-8 ODJ?UC&$HB]RQ_:=R L\SX.ZX
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M\URJR%9*;PFE!?J4XRK*GP][ Y?/_^YH.*E9?M&,; 5<Y2M7K9HO[ _&FL]
M:+ZN3IRH0E>G/'6.9X)V.AD75;?7/>Y6)3ZV"R^KM>9REC4QPJ!A Z;#]3E;
MQ@Y]U?!K(<QC7LONATISGQ'DZG 8AD*DLJ6O#O*HCY.9E@I'&^A0?TUL+D.2
MWV&[,SJ*/=BML'H(>%\.5ZN8= Z?+[XK>(&>'78.LTK>KT)?LQ8TF@XD!_7F
M<+?)L*JZ"-PT^FI@S60#V:FT_\9+G@6Q#SI4?@Q\5 ?9SLWQLGF:GX7RIGX"
M(\N75QRSN@9.R&G6T><ZBW3&6KLE1<'7VGFCXA=O\#0HU]=1E04NBL'4 N&#
M+5Z;!EPI907<912G=I1SV^YLF&!Y<-_6C'.ZA9:O<IFK$I0\/V$NGI\SV%KN
M=/IT6+P1*%S=,M]3/?@["[0PJAXPH<8>M#C<$I*=M;>J9<Q4*_O?V4[*_/GL
M7JIWRDZG\] 2#I8B3:4N+ #,XC0N6X%%=+H(D+PMEOWYN(K/@TS&JCC2_ISA
MIY@<AQ&.@%IT8/X7HC0F^:H<LFX[PU(I%;;P3(<YCN.C0<5I,[D]JXO7X=0G
M0&-_!56TML4U<N2;(*?I%[\WKK++"T!6%J**^E>OE,<$CR]8.HRSX64UM>Y<
M7BOSH_'<EW<Z>Y6LE'T/FD, 08@P527I !:BKBF</Z[G&HAJ=1868Q!0[ S;
MP%]'W1HR3O*@?37&&@3@KW4(78G.GWOM*DWH[/EQQG3:6XA/:A2<81.?-)V[
M8A-;87@>Q^L;GL?N,F?U]4R.=KW/5M=<IQ"X(&AUHS4)T,/[LYH;IP=O]K]^
M^/2,?GCWGA_LO?IG_]T^?P_/.7AWT/NP=_AM__>_/^7KSSJ']M^\(/O?GA_O
MO_G0^_#I$,/XOK[_=G3T\O=]\I[^#<_>__+AW3Z,]7EV#GW;/_S(!&8X!(EP
MM!IQP372B>5Z0YP)Y8*W'I\-=PO!,B&T22QH3B5Q1-,4,8[<1N>,.QN@!\I_
MM]"6^03A[<[KR3%LQB+\<RO4F2U1IUFC(CBOJG-M_N/AH \_^X:^?R_.[[OG
MS'>4Y*4,^L<3L#AAS">L02/D N>:3MP1AD7NJ(PEE\&;#6#<RRMW7*$NQS(G
M1+>$U %MF/FPQO4CZB4^&0+^YXS-)HLG4QWX/)Z,J^O/9_O =MHM.\!.4TS?
M[KS>Z?R^N_MGDVA:&4#S:=T]GAMM=]8.JB*)V4M@JQ.@LD8#(YK41SG\[7E.
MNB,8_55MT F<(/ ;)GD,K^)A#J[+MWJ-_E]S"KW=Z<!07B]&)C[[ZJLBYG!F
M''='Q=+;#/WULVEV;*6 ]&<<U16YLHO&JWIR1^4HKW-9:A7Q.L53'@!SNV"3
M ALHVPYH+!![NSP"]()KY[;US'75&-9+YN!1-D%6&M6/PR_R]W+2V"6?Y^?K
M])9HVUM_;GELV:2%KRP-<;SI&*KLALN\?XY]2;W!EZL%N31/:G3$2B@JY;W2
MY6N'8,B;N#RM3,RH6_6AR'Z4# ^9NV4*7'F"YKY[SC!=+B[:<Q\.K]$HGW;%
M-)RS1+,79W8<S@S C50V1M7M!2-S5AWJ0(/SLU!Y64?-C1LW<7/5-1<(9BN3
MY.85<LAVXTOZ7.AU<_]*::V<@#%,'Y>3IO+M\POLP4UR)E+]#%(_(SM0%UW#
M#3A7KU2]QV4%>>E#<-&&ROD#*]+]W&1U-]BX# ZW9SI/-Y?PBI6Z,+]9ZF4[
M>W)4):UJGT!1VJ=G4'G3XDJ.X^4N_.IMKWW0CHZ*5E(B!FRH D7ZGX GE='-
M3MGOO/BYM8/O73"KL[?-_N]8C"YE>J;'<RT-TQSKW>I0>E5\&_E :X[1_YD^
M-G5SR-9EGC[*+I/Y> 8X,.O.'Z"P-1MLP3PS'<@BQ$P<R&H7]G<<-5*?75:5
ML>D+@%WO% V^],]\=2ZP]TVN1I'?J>:WI7I'(09GZG? )W UT-?NY^SZ^:,R
M&CY6_^!\"<;;T@"+!O(RG='^3JM_'[4&^.6CY$Z$&!/2(%F(&ZF0@WE&6%ON
ME?)>&'E6H[LL/IVGV',8T\#H'.6?1L!-/?FU36I>Y'8ZNR!+.4ZUKIH /S25
M;.JSH#979X&T?LZP5N _9B-4OQ[?W'BK2,<?)(O=XB9].XHOTS,0R_QJHT>X
M&0]V/TH2O!0L(,FLS^8(CHP-"3E*F:=")67IV<VX?M8M6,F\D:=K^2//X@:D
M F:)KU3+!;IZ%5Y2"5OF25E;* ?VC!355&FTD#L]J +!8C./1:IGD2"CBG$7
M[\G,\%K%3,S%?^8,O=$HUK2YB>]LE.^PT'VNLML<5JZ?Y=>,EP1M+'G;RM)_
M?BB9'O=S>N1<M&3UO6+OJ.GNKA]712@J9EW9F4,7WG+8!(X,1G,SL\1L/(]B
MMPM<?^0B)/&/;*4?M4?JP5\?G1-."X$1,2:BG#B,#,8>:6TU23I1(OA9&R$-
M25/X7%,9.15)6XLMD%ZE>+)P#E\!]9; R#T!8;4G'@C\33E)PU6:*,I>><LZ
M['C./OUZ#"!@AZ"0/QV$8MX>SYOV=E_/3'N:T^VIVW0]RC0OKMU]3/I.YVT=
MR=T==0XGW6(FWNZ4MBI-7&".Q&M@- ?5]KO-\62K=2GVB_FL@/F@O6QWF#H;
MZV4L9TQ5O2P[M&=1B]^Q.8RJRF^V4\IVHT%"DU&L3I#J "DCF:86Y'2_GJ\3
MR=UI.8.:39.Z7V-SP31E?9H@4?V]JJ16'W?Y(.KFP/2<C5ZKW-77:F7ZK-I;
M/*IU[U4W& X'7XII">ZST_EC8:#=.J"B\<&6P7;K]L3U"9<K)):_3P>;8_KK
M@VP6O[)D8K+M^CB?>]D[O>0-=[)A8&ZQJO79G@U@,/^RLSI+S2/KFR_PE27#
MJ#-DBE5S:,OG)92ZN+CKTWKY\/X&=:1$FE1_;$[V*N:WGRM S6^CDD;2U$SX
MP7G]W1#/1Q>L:=I@S398\Y$&:U[-=;PYA&KYV_Z0!#]YT9^>G5/MZ9)G[KQ=
M*?9B7:'5#XY=AON:+!1K=A]5OV6KTJ _,\G/\IR*Y:J8VH?CJK!IS1Z.JB*^
MA8?D4+J<!)(/GVE28SZ5>SD6<!K_GY-S&G93<A'["Q[PHE!5 VZ\"_E,.>S#
M;(_.G%+]7 -LX12K?,3+CJ\EA\P=&KN:*C1_QN'K(S@G6[WQX,M'&UVBF 7$
MDN((MCQ#%D>&)#7.*.5MT.2LWNBB4"F2D,.^.#'.<B)2HD%0'+A6YZIEK9^U
MK#1KAWW0*1OA 2B+H-AUJ,3KIM U(G=^KN]CDK9G)K\P*7F"B\[P#%R^MM!E
MEAI KZC'#QH!(&\FUXTJ_>S/UW,UY+N5*I;K!WO _@4%H)_QS(Z+LSE'W?<'
MQ1<P	?J)X+-RSHW]1ZK0. ?GAU,]8SU^]T?IO>=GIXE.^6#_?FKAK&5)]-
M"Z6CFR]7)L_*'CCPH$QD96.NTED>2DE$SBB10]_+(5<ZD):LS$$=O-'Y CI4
M#OX?^FY)S2M7Y'Y3E=MFL/AM^+C2DV9NW?G2:PO?+2.LJSCWRT)5)V(54MLL
M8CUAL90G_8$ZM)$HL)SA_!"NGU0[I:FC-[?9S\[SN8U4><M&]<9K3 N?N]-<
MZ.E-W6GYO1I_-HK PH/^E/>WJTILET=6]=VS%:ODTLP,UHV9NMFXEQCM ]G7
MTST]NV#YENY,^H7F%2_GJ$:@DD%<3^V7)DHCIU2@:AX^+]:;+B$K@WX)N*EK
M+5:U%;>K8(N<F+*]!"F7+$=W-(T;7,+\5E^*^DP$MC^*8=*++],N/+5YUUD8
MY+-J*X>JXOD4-E^FLS3Q,1/$W#?( 0]D/B"IO4-<:X6T(0PQEEB0A&I0F<X5
M)PW>,HN)US9RJ; C4FE/;!22I\CY68(X%YPZ)Y-3B>V=UMNL[#+8EX/C.F)L
M;K/-9S1TZMXJ=1C9V>B@^5.V=)&HMO"9[5LNS\$^@UZ.>/OETL'><^>%*$?!
M\I3('\W1D_\J?19GQK32W!&.DIX]&<5?FA]^;;J@=_OE0"@7_;IHDLAFNS-]
M'<N)57T\LTCMX,HJ5?=/KY]<?[Q3/CK3K++Z3-$=Q2[^&.^0"S_[WFT)V9'$
M7.NVW_],W-)@Z>4&](,>]1?U%YY^U9S[ZI)NP)79Z6Z:WNI+*5VS0I6Y3M!"
M]].;SLA<U^99#]3<Y+2J3GY!"]3UGJY\L)UM$7O=%WYL$X>OLKO.-]QU ,!S
MC;XWH=?VRR8\99!32/Q1;4N<4LD+=Q+]\3Q<>FLL;4N^0<VW*YI\IM2DTTPR
MK9P)+O% B>&!@/:$E<21Z.1^4&H27Z' Y V9ZFX)^5F7-AO7):QU2^_W7_>/
M7_5R*XWWQV^_[;_YZQL0U>Z'3V]//WSR7PX^/?MR\&87'[S[^Y]S+;WA>1]^
M?_OU?6[K#<\]V#OX]/+W_QP?O('_SS4NW^R2_;V_R(=WK])^MV[G_1I_^<@3
MIDZ$A'3*/5J("LCHW-7;6JX(%EJ9W-!G&RN\K6_>UONJTG7=IMU71+V;'2@M
MG/P 3C@E+%F!*56!*YD,MQ[+Z"0C5GB9SC3U:N%DP^#DVQ1.,(TJ6H:1C%HC
MGC'%FJ!0(-2H2 WVSF0XH51L"WF^Q/N:PLF5V50J_]LH-O6VU(",85J0)-8]
M%CKV2XZNNQ:;6C(/#Q+A6&+"1$*3XH0SRVST@45BHY7&FR1;PK3)"'<Z1YAH
M"IQQ[Y"6!",N)$%62X8XIAP;ZKP2;NN)TMO+FII=$=Z6H\BM$J(SC[P6YWDL
M0N^(5@G+P#UUW'$.#$?):'' CC/BSO8J;85^PX1^1FL2H]ZR$)$&?3CWD["@
M+WF-@+UZ*KG 7N6F-5R"CK1.4O\8K$ 7\Y8LO=>C+4NFX4$B&&4\2BLC)H%Q
M82G\GXG>!<695I28EK9L,((=/)VC+4):YH&;(ALU19QSA9RG$4DF<KB;])&
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M3PM9%U S;YAF-%G.,$_<.9\"Y\D2!3M84=52L\V&K#F[DE<8:R40K"P!:J:
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M%-NNNP37/K*ZK^,%<]0=S5Q,<WT52Y.J^JW/K\!/U?= B)N+\[T +9^6Y@D
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MTPT_.F4 ,I\>=?MV.T]DUY9;O!Y,X.CY'SAV;(;=;(?)SH8,WF?B>B\X=/+
M&N NK9+KEC8S>G*&<%QR\_QFO^9XR_^.MC<^\GGRGPZ&)[6&/=TUU;>F3;$O
M7J.+SX[%A5N@"36"+O*ETFMHYTS6Q^8>(\]K;N F(_AL-/_.9Z.F%]CL%)PK
M\E(OUT_YNH6UF7UQ)MIYXS6<Y-A^JBR&]3XYWWMZGEE/+52+8>E+@I?JE1TU
MEK*R\MLUT\YAF\76D&/RESWUI%<'E'Z!+74TF(QBW5NZZ)'-7/UP$%,%;&8O
M;A37*HA^2ER&U?8_&9_A,)7*5\?IP$?-G>=V>7=1@YR%(9<,HJIUZ#".)\-^
M'58?\A9LS'IEX"YK -OS>BS<87@8<_K27">M1E)/;#<LA!.5439-=_J#JFM5
M]9R9DC-K S:JTPLBH/(T5JLS/CW)X-LKC<%G5]0".7W%ZJ$V,^-FRYZ4PZ[0
M][P7Z[[B3<QPZ526M\#*PTK/LIPP&09[NL!P=JL^:7]60WH#(WJ9IJ_\R,C,
MP1[<Y\M'2EDP/CDDHP *(SA#EG"!-'%1,\.\T+E^&SX;$=J!N1T5"5Y4R9>N
M=UR;U=Z;,QX\O@7G!SFBV 4NJ4"&^)#9*T?64%PR+ITPVBB-MYYPL73!'Y(S
M +:"/83C\'!JJ*GA_ 'PB%N.V5^<NI>I#O]]DVGG8P[8/]C]Z(DU$?.(0O <
M5$+/D*;,(LRU"4Q3;8@Z&TM@HE612:(5,QQKJYT)*7I-.;%)N0L#]G.ZX6PE
M*N_KR;!;CN/#.#@<VI.CHG95)M#MBMY-#_&\;2KZ!WP['\GG&4WI;_O]9( V
MAFHAAHJT,51M#-4CC:'Z84S4&=PC0#23,#X"Z^#4$T<D"8GP7%V46VPN:O?Y
M0[S\3@O1I1.\,<U!F=@Q@JZ\WZ;>(53?0F]0KJ]WUX<R5@(++=0M#-;@ZUWY
M4"9VD\9J=@R5J^QE>\DJ?L?=$'KQUMJ&7C'$YD4VAPTF<,]0S-)O=U[O=$*&
MUN&H\]._?EY>N&<Z"T1L9I_>-T?#&#O[\+VC4>=9/P?E-4U[.Y=L2OO# F.;
M.C>ONU\O.S-W5/CR=D3FDHSKSR8NYK?3SN]3[:VS"VK"95H7W[B'G=R12PGH
M.FV9[Q<'O?6&G*N<[K47SXS0[53?R52_BE60]KO!L!=N,N=W.JTM8+2[N 6,
M-0.,.^IP<J],J<07UT;PB_NPK:(Q0GN/]A[K>H\5Z42E7*W:4>+'0G^O):.;
M')W7\SDZG3]S(!'*YEUXUDTZ2BTMG+UVD_"O&[WBAM8$GXS"F:#HH(D2BCG)
MDN#"<X>5,DR38&+TUO+:A<TO"(I&[(I%Z%XT"4:[=;;M&_MU&@7--M/1717Y
M/G[5/=C[A^S__HQ\^-2#^[XZVO_TV]%[^G<NBOSI_9OW7S\<_^?XPQLOSA;Y
M_O#["_SRS=LO[]_\?0SOP0Y^?W:Z__OS3Q_>O?]Z< QC_/3\^/WQAQZ,=;'3
MM>6<>24\2AAKQ"5CR 6J$*-)<I=[;3&^]822=6H<MR(]K$6DAXI(QC+-F,8J
M6IX4M\J21)5/%+,41&P1:?T0:=9V()=MY[!L*& =$:<D(*N40,Y0A9GGDE/:
M(E*+2/?^;E=!)&Y%],DJ)R0W!KL8.=/&68,CC?XR'&F^:\JW"/S;CHY:G+IS
MG")3G***"B&=0I:Z'*PM(](L:J0X5\X)YP5/5?T>0G]ML:K%J@W!*E#:C.71
M)$,YCX(YEY(.F'.7K/=3K+HHR;5E3_> 2FRN&3A1P)8<,DZ /I>S1XQ-!.&H
M7-2))&L E3@S+2*UB+0AB&13##Y@4.:4X5Y9:X54@DHA X7?6T1:0T024T1*
MSM%$9$(X4 J(A!4R(3$4;%!&",T4#RTBM8AT[^]V%7U.>J<BUC;2P$V45C@J
M@PF@$SB32+@$(K7ZW%K@U%? J,H:OON1,2:9-;FA"\>(>XJ1#@2H%-%":1HL
M"W0=-;H5A1E<P?EXKQ$'=0V<SO,8IZ['ETW)I6LU*U\R'YO>NW>)7L<!K:SP
MPMG$I8B::V.PPE$'!N E6ZOXFJ'3P=,Y/QUVVE&F%"+8YNI&T2#+ 9N$X%HE
M;JSV((_BQGW#OP,-MT6B+AN;\>@E.&$CG=2&*BZYP-CQJ+6F)C(EF?*TM2)O
MBES/O%W&1DRT<XA(E^TUWB"C/$>>&.U-3$ Z^,HX1RO<ZRO<,C&''>P%ZQ*W
M@>I(! U!4.42\-++"'<KQG<LQG/.(&UEE(FB)(-''/N(M/$.N1@8(]$J16A[
M/#]L"<82L)I'D$ZLX60.#@LGF+$!1B@53:V9<OTD>.8X(1[T(\XDXB8YQ&5@
M(,$,H^1@/4V(0E*22XJH5H0?K@@GRG20B8CD%,=:VF!,<)9))4E2Y#(BW#+L
MM1#LF?]!I\B=$Q$Q &@XFI-$<#(S%$RBB:>(.<4MPWX$PJVX",QH0DE@L.:@
M73$OJ =A-D0:U9[/:RC&\^;Y0*45GEDDN N(:XZ1$<8AEG2PEEA@773=3NB[
MSPNZ5]-\R?#ME)3 IH+"M0SR5\T1?7A@A2U6,GK!X7CBUGK++/R%,^^Q%!&;
MUARP;F#U>LY:G_L0<*(,@@,'H(HH@IQ4'H$ZR"0/SB<'(DH56Y$7\2K)U/<9
M$-$*_^6$GRI,K:;,)\FU("9JFBM 8^V"$J9UU:VA\,],^MYHJK%G"%-)$7?<
M(>LQ8(&GQ#!MI(MDE0DLK? _*.%WTE#J,:%.&YXT<UH#Z0V12\>D(;X5_O43
M_IDC@''OM&0*"9TDG/S&("V\0X$G')@B06"["D= *_L/4?:9)PP3G(,]'.>!
M6F6Q49I& LHM";$U4:R?[,]<",)J0QCA2#+C$:=1(\.H0,19XB0)S#L'LB]D
M*_RM\"\)*F98,&] ^K'C/DA'4^8 P/Q!\Z=6ML*_?L(_<S,P!;(>&44T!(VX
M30*9&"W\0X@P(09OY2K3'%KA?U#"3PV-UC#'B.%<6*X94<HQHZ6&XV-J[VN%
M?XV$?]XY@:F(5@:* N$<SGX'9S^E&$7FDDO4X$3%2IP3=R7^CZ%VX=.Y3N@_
M]%=<XMUOKVCF"NO7M8-L![GY@VP++OZHX.)5B-?#YE;21XI]#%)APC&1AFM*
M70*&)8%*.7W%O(G^Y#@,QO7G+>VZ8]JU4+Q0!VX5E2A%@JL2//"K1RHD"HMN
M,$V@<Q&^#<K9&N5KWH-F]; %G%,I2;#8FQ XI<&89(2V(.512:]Q*^ ;)> S
M5RJQ+&CK->+&$<2YR5F/0B%B$G7,4B*E!0%GVYBNRJC:"O@:"K@7TD3# .$U
MK#_!5G-&'(O&8>^C:D_PS1+PF;O48R^4YQXY+0SB,7!DK/%(6!.UD5+CD 5\
MFXE5A4JU\KV&\NVX]QY;Q[!/7 %#MY02H[R%8SQR<YD*3ZU\KX]\SURB6"</
M-"R@8)6' UQ)9(42R 99ZJ'*P-36$VJVL>:M@#]< 2=6Q: %I491'F,);% @
MXU('K;%;WN>^%?!U%? YMZ>-5HJ@D:8,&+K"&&D9(G)<"94LY4P8$'"Y3>FJ
M7!^M@*^A@#N>N)5*:@("'JRU+*H88U!)"6R(;@5\HP1\WK7I%7<F>H88#B#B
M$3-D"8.#G"5%J([8ZQS/O*W%.DEX6Q2M+8KV8]@R<&I)E226H'C@H&RN=XTC
M22YG7AC6!ENO&3:]G"^*)BBH$0DH1Z(A ?EP ADO/0+50EMBA%'8;3WA^L:9
M%FU:]_J*L C!,8,CSR+L*=%1<L7@UY"\ !+2BO#ZB?#,PL^)<T:(A*A,0"Z2
M),@F3I%/(AD5>=866Q%^X"*L763&)\6LD%SX9+F6P#@]: \I$'Y5_UU;=N7>
M!'MFV4]"$M#]"1*!!,1QKM80C4&1X."=%C;ZMK#A8Q!N;HS6*@CG,>=26JT)
MI<)3'B(AQ+>1S6LHQC,#ODLF.*T=\E+#^2Q<1#I6-5B8E8IKG.C6$Z-(*\(/
M5X0]<=A+)6Q@E@<O+%!M%YR(.EJ'G6U%>/U$>&:B5T;S8&- ,7F%N&4&64TX
MXE)9G^O=!1]:$7[@(JPH,3+RY#T+'+ <&!C\+T:E9-2,LK:RX:8(]KQI7@+!
M=AQ'Q%7N6*(H1DYQA917Q#L<8HBKZT'9ED6[65FT*V4;M=F2WT6SY"7F"3N7
M/#<1VR1<8,D0EI3S]C(U4EIOX[I VGSA-(6CS95V$9;*Y33*A&S$$C'J" @"
MPTI7$?U:KBI>J$VD?E#0$(U-@47F(C:@G3K#DI9!.9NPL)A=QAW00L/Z0,/,
M4X )X0D6%#GO#>),!F2YQTA2K)VC/L*:EUP 06ZLR;30\!"A@8".JQ+3-%K&
M [,Z,&<-,1Y+;IUJTX0V"QIFO@9I .(YL8C)# W)1V1\X-G603@S*I+<1&F5
M600M,CPH9,!<,A)H5%8F+HW0B5KG$_$4>TRD:*,7-PH99NX+"L0 )RF1"PKP
MP$?X*28 "DLMY5K#/V'K"</;6+3E6%MH6.:^E!XKR;G AG&KN8TA8O@/UHE(
M&JYJ.&VAX7ZA8>86,0P'[@EH$<EBQ --*)?:0HHF(Y7'7&B6:[1O$]-6:VVA
M81DT"&:9R<UCJ.<Z$".]#E($X)])<'V9@HTM-*P/-,P[5A)1#C1!CY2FN16\
M)$A[&5$BL)I6&A9SN^55YCRT!=U6(+P'<=RI)>6J;JUZ_JLY^X7!)(?!Q/7B
M= UN!G1K5U'J7_<X00_F!%!,6HUQ)(9B;H5V7%-!E!**62SL53MRMR? /9X
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M2FOC%&L==AN&M2]GM):J5+HYH!15QMI 6L=A2TGK+2>@D)#BS=?MN;:%FM;
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MC'DA83A"$>XXUYIZPC!X%(XQHV?I>5\BP_(@P_CXPN$H3:(<$1\5XE18 6I
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MX=03\&K G2$<''?&+3:Y9& I3G"XX<8Z2XA:]ZTP1M+?;"P8N4LVLXDGMZY
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MHK BQB-% T<<4X$,81H)@Z47CO$0Q N0;QA!C/82<,%B*SF!#03"V-5,"$3
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MFI_8_O$6V]_-5=:>U>@VK]%OC?W=#_6B70[]RJKGM53],I'K9T*@TFB.&&S
M^;!"(A,E12(809237/"<Z[(JS(,9%>?5D<<^K+@CH[S$NA+KGOZ0HL2Z16/=
M.*\/2X>=8!QI&B3BA"6D8[!(6B(E#S8)&3/6$7*]P>.28MV""E.6&IF^MSL_
MLKO^3Z?MXRUEI72^QYX*RR\;GA9$Z'6!07GFMUO#>2]!Z-X@5)\PN*(T2M.8
M4,)4(1X4138%C!PVCEJ+A9-F99W*1;%T+5'Z1ZFIB\[Y*C5UX9HZ-A>"9U8K
MBY'Q@8!K1!1H*B/(VJ# /8HQ:+VR3M2#C84%:NI;B%!]J+?JW:-,U-%N7R]3
MG0EDICSU*P29)XS,C-:D6)(2?^Z-/Y-EF"I(49!X:JTCN"M.(.V\0$('38P(
MSE(%^+-JF%R0N[)$T9=2C9\CZ%"J\:+4>&Q&&$^CQ](AQ95 W-$B,5PCG83.
M/>0I]2RKL<8/-OD7J,9OC/%BM]VSC85GG;[9$/'B)^CUP/GC666=9J_^;I@^
MM=$*M79K^(\+?"]1? X4K[V?,,8",=;AX!##N?,.EQ*9G--'4L0R;\HVVI5U
ML:J,>:J<]J4Y2'OLJI\21DL8?4*KN(311</HV!CFRJMH"4$J&)5S6A,RP@JD
M/ N&*L&H)QE&L7X],'KONB&UU$F[-U5W#$HX<DJO;9U-EN?\:Q[U#CF'/'BB
M1>(V4$UAW\5>""*"%H3>8"6)^SB]H.#^2LF??)EZ?>]\\WS= R:(5LD29+'G
MB,<40#>#1CAA6 5M!"$1'-6UZ^T%*R!>C;RBD]G;.><:/H2&<[M:L8U&_L#I
M4=T?54[AW4XL*#LJO79E%T2P*#!H=P850'#AG[%R<F1A-7WL%]H%US[,9>JY
MI"OG>W?L::4YRI'("W]QF;7*[=+9R^[>^*;C,5].."]&N;1B&]^RO&Z(G=VO
MOZJ[>V=Y3+6- P?;B#'!HJA( @.=6.028XAR'Z6VAH>!]%XO.1U)[VLHN<NU
MG*7 +J' GA_B!8AH@4\7M8]3\ L6MUOO9E"%]^<1A! =Y]%1:HCFT0<+XR%>
M$F8B#DJ810K"#%'FMR8?M<WJV8&,3$GI"(HV,L1]IA#!CB&".<7166RX7UG'
M:]>9YR8WX NI^"W OGC6A0WR]TH:G9D>YCDO2F$K\==)?4 37E14PWYL6X>Y
M^KJHVOX23WJ#<HBBO@KVZ(OZ"'B!K<XE709;XKQEPA.:NQ;K0(+AUH '%Y/T
MO(29!8G1[J>S ^.L]@(SQ!PSB).(D:4DY+ZHFACL0+]Y%J/KQPU3Q6CCG^VA
MO%R48'=BTX) @:B 3#52I0$?!7'JQ59VEBHNGK7!/!N86]E06]8=Z>X<VS<G
M0,?;^,"KI!(Q$:4 NQ,77"(3<M/Q8*WW&I9&BRQ UUWT20&ZV3J_MSB)F6KV
MAR;7T"[B^>CII-VM%_T0"I<#/(L_1@6"1=AIXEO#. $>?\6Z;KO1[]W\E6M%
M;<]D^Q%V978F?L[.92#H!9?!46=<QW<8D>M$^P-0!)[PG6V<VK/NRK\OF\E@
M(P]'I+*9?'7"!M.R7M36W6AK/_UL3J\&_+SS_G^_;_W]=Z6ZM;G]?N/OU<IV
M[3WXE;7-RI>O?W[9WMS>^+R]]67IGZ/6SEL[;-_OV]D[Z19-HEI%E*M0/C#&
M;,N#CE:^]."%@GSD+D=HJ"17?:%GE?[?OK9L/]3AD7Z?I@9S>7//M%3J*:DZ
M_NFT3V*G=_9/PQ9A[JW_]NLG>?67CKJ#5,<$6$?[QQN_JA^W6&VW\:.6-\'C
M+;Z_^=?1_NY1O;:Y\6OO?$/4CH]^7-L$OW]H5C>W3O=V/=GY_HG )EBO[A[]
MJ#8_-'8^;N/JYH?CZN8/NO/Q<ZH>;] #(L'F!A,$46(HXI)I!):31AQKC&-4
MWL(F>(6Z@X%_%R365G+-P6ERL$Q,><JU48K*=)6M8;0&A9%TL0#WX/&X^\:7
M!XJ#B_ 9&Y@.7!AJ++<R,<$5)UP%_NB\'S=*WQN6.7:@!97$.H5BL&"Y,Y4M
M]YB0X90GQCEADKX.QH][4T,-SQ4*JF'U1[=R,JE"<21%E^,@^7L#]H]L3KXH
M_@\PGM;PP("Z!P&(4NHQ.#6$N1^OR%W=5A^% $0871* E 0@)0'(K-#\=[3=
M>-1NA,IV$]#UYQ67H*R.+ZOCIT?NJ,-.)L4M%ICSR+5B IM$B%?!29L64&]R
MH]E8M'U8EK2<^QJ/P[2<<+27HWKG^\V=CUMG, :ZL_NMOM?\_&./5G_M'V^3
MZCD8C\T]=BTMA^;4FZ/C6G./[^W^U:AM[HG:][_J^Q\_'^^=@S%Z_/6\>OSI
M;/\X7&8!T03,3N<MBE(2<'$$10Z,!T08I=1;R[#!.4>=F$65FBQ-\F+) E+B
MW'PX9P(F-+O:3! N"'-22QO@;X,-550OH""GQ+E%XMPX_9!1(ZR-&OE<=\]E
MD,C *B*6I/)<,1ZP?V$X-Z/?\A+ IVK]$;S8N18/N[/"]W57 '(IK"(:!Q\2
M#]1I3#Q)G"KA77!$E(;54@'.)-N'9CQAI0UR5C'$@Y7(^220E#C%)(3VF7)(
MK$K-YP.<QS.1YJC(?=UJ1[6"Y2...\6Y4-Q$9K B6!@8HN&AW.>73.W&^[Q@
M1A!#$F*!)<2IB,AR:Y$ E#0T46)44:W%U9PUMR5'QVQJMMT:Z$!6L=WHCUIP
MW\.SX?&F;9[\4=E)*??XF&>7?Z,$ $0ZXFPDF.G$1="NZ$.;FW1')[#5Y?:_
M5#@T2>$1D@R!"-CTF<S^AF5(Y[H*&L#W,,E':HNXBN8/[H144G@LKP93S:1A
M5D:;#]B9TX&JJ(Q*'@Q"(W%I22R9!D^0@%FB)9,6:6ECD?R!M/<422RC=)AS
MXXN(@6;7RZ*6EKWC)5D2?UO7[MBBN*&,"%P 2@"LP [&$PWGCELP$)(U@FGE
M%:-N5J;/$C46AAJ7V"*H28J(E!N_XH"X (_?:J>1HIP![#,FO5M9EVK.*&/I
M]#]^<-_@G H'!K9S/'FF-7<1PX:-0PA<S,S,66K6(C5KO!][A0,WX,\K31GL
MQ]SDNA:/0B+>6A&-I>:9-.NA?OU#[.>''4.^:(U] IK+4ID7I\R3:0>4.\R(
M9P@6+S<?40JY1#2R3!B7A/-%*K)9Y?AZR>.2'L>5NO]*6(!*W7\,W1]OY)8'
M8;35R"2L$:P615HKBH*3R0EJE>(XZSY1+Z;QT'Q>]TNAQMSPOM_L#YA:-N-)
M!]2DB.N_3B?\M^6R/"8F?W+NX>]&S'\ (&T,FF47K]\(5B5.S8-3E_IU4,UT
M4!RYH,%&<0$C#0N.+-@N@E'!O-+@<*QJ=?T$__?2CW\^Y7Q\TZ!4SN=1S@DZ
M08$M%YHA34E$L,PIM^@02$MFB#6!$\RS<HHI%/F/J9QOX8A_>O%JT;/[GI99
MR0#[!!.TW B_7-;7C8@]R3%4@O8,H#V9%,&UE\YP@K#U!,%*662D!,^/:"P)
M2SY0O[).5P5], ?LPM7G952CE$!: NE26<HED"X.2"?.PECDT6J'>,Y(X5A;
MY*CD*,0D+;>9;\]E()5\P?ULEYM,^U96L!=#KSV=Z.5NXI9)3S13/&;*IX)]
M+5I_-&+#Z!UU8BP,]V[]5Z4)MSGJ5B(\<[B)DR-#P( V>4XF[WN1Q=R3V&_R
MV9>%PN\YF&3.#X@)V'/GD&=,(YZL159YCV#&:8Q4Z,#H7)N$8M)FXB-B*.96
M:,<U%40IH9C%PM+A,O)R&1>YC!)\&L=M1#38 A/&3+.2>2YR<1]F'-?,,)>
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M:_)T$_1ZT/U)V#E+8'\XL%]JF(E%#-1S1 D89&":":3!2D,DJ2"4CU*( [B
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M&U.2.E$M,\ G893T1B5'!>,"-N9%,A>6RW[?9==:4!ZE0%I+C<"<5<@I&A$
MMS#,29=T/I];NVY!W0P0BR$Q7JML7K6\.H/*L,I-5OY]:(]3\AQ0D"63DQ -
MR?/ 4N3.,&U#Q#></BQ,.M^L,-9V/YT?R!@5=HHC0\$&X9CG3MS:(^T2YT%3
M'_+^)*?PYHZWH]MHV>9RY@BQ41,7-)$\" X %JG#8*A:[QEC-T102TEXN"1\
M%0<$?.@HG4"1YY(A:E1NWP:X%+VQT1K# DB"FB()@V6_+ [3Z?C69J'76_9
M"/ACE?_S_VA*\1\@MWT0\MU._? 0@' +4+)7O$7^J+2][W>Z(.]AZ"1>0\L3
M\#<[&4LG^<8*U5F%@?H?I['1J)RV^PUP;<$/=# ;(_3MQ!-[5KE1MT 'X'*+
M=1&V:Q_NC'!^SL/*S_9/[&1:-WL8=]+7@6__(<8+!4/TK6G8\0]Q @+9KB+
MB#G&$?>.(YW (7"PRSN&A1,Y=$ZONP+_,]K()\(DKT*56CF6*&^))=I*J'=[
MG;KK7_!]-.J^Z-1@+\<6O]N6LP6K)UQK9?2O"V5;^7V18<? >>2>8\%IXI0R
MV#P)54E%C /Q,15A1SE4)2+OM6658<?IJK0#USD(5"K#)9C)BCC$A:<HYZV
M_2Q@1;0V(?*5=3[%:GZ$N&/QO<%'+H4@QQ*:XX,W!OHN1_?FDD,KG=&8)"FT
MX 8,.1&L9&! YV;Q09&[PGOS'#[?T\7#;TP\P<7[53L\4 G,)@H>'1-8(+!F
M"=*91B]A;'1("CQ[-I<W;U3 2BK&J";<4^D4+*M5 #_!:G9W=YARJ1]KJ0-G
MPGEG<G_VA'C2&!FPK%"0S.4J'I=2S#5UJW@*N<=U?)H[NF>L"0)<)K @N(C"
MF6"4B9%;QHAEL@SS/'.8I_JK>GA@/ ^1*(]$\A;!SJ60%8$B'"3XO.!M"SI?
MFR%')5':) *BQ@4AVDJN*$X&[ ,)TE &=9=AV:,VQ! '_C2 -BR[8L@)V :"
M,<&!WH+[)7+X_WKN_<WQEI&M\511OFNV]+W"? %,?IR-%$4M)\Y:)S1U2OL8
MG;="EV&^1Y/*+5S;.&"9L9>D@(3-!U$V&@3K@)&7!NQ'F3N=)7 ^UZZW_UY\
MH ]N+"UL5^ I*7"B,( CMV"XPCA 0H@N WU/<_[ :Y\.I XY$TLA$BQ'/!:I
MD"0@0[@"Z\4[R7-KS+7K3$&5^T7\!J&&]8)7_\88QE+'+/ZRK;[MG!7/=TOL
MXB)0D1&Y?W("SMV%1]@=!"V^]%N5?XXLR/0P;C'QP@7<=E=^7RW /G^B2.\L
MLE=\NPDR[>LP2^<QAR!3D<7X6X!7SKH X+]7?LO #J^=G'7:)T?M[LD1O%SQ
M==",_':]5=ENP<?7*E\O@I394^V.=I2IHUF=?/D41" ')_.GXR_?Z'?K/R/H
M[+@[0'[ZR:$.4NM.;*?7@EOFQYHZ]-'85HL+3,YQ<<OA? X3?8K4'IB2\<#6
MX-N#WB_P8(-;CF9PN"R7%VY!<2'E7312<1&XY3$JPTU43,:4#,X) %>-,E+&
MA1:(;7L4+*X0&6QUEB%!/#C>*3%DL]U-F-8Z67"_+9EN<8WP;"!R(\F. $+U
MG)Z=Y0<^$6$O:8'4#>+<W4%4L7UF&T6+(A"/5NP-LL36*AN5O]H !94-N*YM
M^4+<FO5>+\9!EEFGWATT)FH6R-FM@. U+\EEOOI8JE<'HSKL@U07'[NJ:/%7
M]/T+:;])L2ZC[JU-@(?0QW,!Y4F[6TC:N\(^!%D;MR;ZG\M9K</<=CS^BG7=
M=J/?N_DKU_K!/!.\$WYE=B9^'G7&W6P.(W*=:'\@FV"P[VSCU)YU5_Y].1!?
M;XTNKG(@_NJSS[L3/M'$3$^=_[SS_G^_;_W]=Z6ZM;G]?N/OU<IV[3V(>&VS
M\N7KGU^V-[<W/F]O?5GZYZBU>['8/\%"#'DCR)3BK:+(HG!Z/M1;H*J@+Y4O
M/7BA4/*[CEJ&\G[UM.59!?FWKRW;#W5XI-^G2?3TGMEWY:Y?R75G/K_-P*L
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M4XC)5Y[D&.)+NP\#^=]V)]Y\&#%]4*N77G_,XXB),<YU*#$QOF<ZE>#2:"_
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M+G0!9*]A\Y-&T) "_"ON;/)[.[[7+KXU^-+J(&Z;/Y"3CG/:<[%K]+N%IE@
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MV'GC&&RH-F%GK/2<:2NUQE>B]?"JT=^^5)<")5L)FC#;26&8&<\00I%A@S
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M,MJR$<A2(/OVI70(;X7,R!Z=!EM/@IGG-%6(6"D#P\)[ [8>9]==O ?Q(RU
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MS[_QVMEG6OOT3_WPMG9>W6W OS]([?8#O+9'[U-5H++UZJ?J=>VL5C\Z.*%
M:_'1]S_/JO3P>O][OHYOK'IPB _/CH8SC*0GW&%.D),4YR(-AIP0#@6:YXXF
M[YAC98;1JF<8C;G=M#H91I/N14V&GJ6;OP+8V7?S130D$ *PF8A W"J+M* 4
M>:RPL<$1S<):9A@M-,P]MCLU&9><3W7SLI--9GGB.A)%O>#<1J.Q%U8P2EU0
MD;A.0F:Y1[6"@#F8FZ0M59YXBX3G%G$"M-,DEU,R$Z7)<VV#G!G9?,/2X,G8
M:-E@X76SH]:AP<*D?'8R@"[Y[ K \\ L>QV()\(CBX/, ^T#<DPEQ)0WDE$2
M6;0S3:A:[K8-"[R9=7 :*RD'C/_-&I&#[(_M7H$R5LZC;5^UX!V7U;("B '*
M!P</GJ%XK1)RP2N<[21K7<5> (D^;\+CO<V'P8,N/I3U-.^(_2PRN?/'9]XZ
M8H 4PB/R[\)5J]AWFQD>%3_^Z=Q()R.=+">:3-Q1HG:P1P 1N);<!D"$//]2
M)HZL803AW,-,4 &>KMK8[C?G[RE-=Q=TJ[+3SNO_L-7")ABEKAOVF&3VY>:%
M3@9E005-?3)6<FV,4PFT04;KO,/&V3(1;CGDSI-C+XADS HD".=@B31'FD>&
M0D@R6 H\1>E'D]DJUQ% K14;N;M3Y;*9@:A8X L?40?B.B*V52EPLE=[,N)S
M,Y--D,00<5(R&LX=<TXYCAWG%'#.^ZC+.IUE$],S+XZM8@+\5X]BX@YQ'!,R
MF!!D/8]""Z.B#8_6VE2N;4X>B5E"L]F\C*WS^D6Q5/=24/YONUA[,*_O3^LQ
M5;[Z>@09K>RG5/=Y#_VBORUJ.OA:B'9[4+B[D@MF_LKWQ+DKY7Y 2BJQT_BL
MXFXJ_V><69O3"3@2<V@F+-=,1O=W/]\<<Y4 /@E&RN4N;#1JD%$@]3$Z%B0(
M9DIN8QMO\8<""L2T ;]L#2<IY8_EI:^#Q!6?&V3(71;*<Y+1SV:[GC_PKH#B
M^K^QGUOT7\-MI[H. .X?8AUP_:O+QP]YD-#Q1DR;R'M/9^#G::N?CG(")J45
M[0]D$USL.]NXMC?MC?\>=B_ M^B>7.7N6_?OO7.'VT4ZR*.)8_-_,(_TDMM_
M_S_?/_SU5Z7Z87?O_<Y?FY6]VGL@A+7=RM=O?WS=V]W;^;+WX>O"WT>M>0DG
M XQ^W\QN7<9+^*WP1 M^\1$P^\+7;:/R]1)>*,SF<UE]77GOMUA; $'^[=N%
MO0K95/QGE$3?4_H.D-J4O"/:"RD8-YX:DA@7*JKH/(D8=VP$'!/#3L9S(?,D
M/VF=P($;1DW0WAF)G9=<PF\O:$8WY&XO3./$K['U+YAB5)B@ROTVBI6B6>&+
MFRE&RJ,+A/F4 F=4&TW KU'894K,M"N;*<ZCF>+U<7*468LC4CB%W$S1($,P
M6$Y@?50[21FG8S=37,APT;.YS^VN?#_B%65>6#9;+!.ART3H,A&Z3(0N6RTN
M5:M%$CR1*@#1\@Y8J-3):9:L$5823H4I6RW.OV;ORUGUX.@4OIM4OW]FU8//
M^# ?<UZ%__)G3VZJ](.HT4/QH&;O4_57[?QCH[;[#:[7_ZKMPKG.3NCA[0D]
M GZWO[MW>WCP@QV=-883H1-6DEN,D1 N(DY$1%IH@;##1FGAN0M\8YM*L<G-
MPUC)PN3SE8G09:O%>=8[3X:>9>+("F#G0*M%P1(SG")*&$><:H*TU08)Z9/E
M(@J'\S;QEERW1.C%&]L\6O$+97B+7HM+Q!,G"LLM'F$LEKJ]*ONW\\6\P5SF
MD#-+%#=(4>V +\:,>8HCC;GBVIOH<FMN1O F%F_;@.Q5LI%7MPWKI$QH2GR8
M(R4:AH"2%\T8(_J\*!+NF0,G4O.,$8E&9+#P"- A8LN]((;EO7>S@AT*EX7Z
M_%,X!].$SY:+^4S297I%J$]GJ4OJ,PFL#;8:S+F_3.3" !P4XLQR9)A3R!#A
M*-;81._ W:-D$ZC0%#VFGP"6-PJ$O3XL+%OAT/*PGF'M+UG/C.%AH/M=LM)[
M0Y%DQ(!GI'+W.\^ ^ECFL9>$*Y:C04S/*!I4!GR6:;S&FX9\UI/XK%S:_ES!
MK?9^@/M$)J.S ;PYE3CBDAODHB$H2)\B9B2/F]K8)D!]Y SF6I<!GS+@4\ZC
M6&AHZ/,>%I)R1$F4$I>(I^B14U$AP8F56!M#/-_8YEN:K%ZT9Z')SOSG48Q5
MN[XDU&D\YB1,#((%;I2*7% +1A)SZ\!X)L&5=V4Q[LIBXF!65:"P^M9(1+6/
MB LBD!&*(2T,"X[Q1#W(,^-T4^(99U4M0<>?UQQ.,3T$+1R.SW9$Q7@/:.78
MZV0 729NK0 \]RFK%4H;;# B/%#$G5'(&9>0H328$ /FP8 WNT74$F/S2\95
MO*BTMBSHFOUDBY'UK_,M\3)FBQ,Q88679).58CU3-"4E?Y4*KU>Z6%E6>)45
M7BM2X;4XHS/+41>SB45X[PFQ,5%E#3?":"*U5Y$PDS A/I6C+N9/=G^0P_-#
M7/O^C1]]_T:.#C)A_?.T]OTS$-:=&[BFF]K!'CZD1XW[9!>^IWYT]AF..87O
M^Z<!Y/<&OH,<[1Z=5W?_!!*\1ZI IH_._QFN\!*< :^U">5=&L2M<,AB:A&U
MRC(14TS*;FQSR3:5?KAWLS"%"BM2X?6F^/&6%5Z+"9R/!PHF0\\R4+ "V-D/
M%%#&(Z-8(H=I3OG#/L]:UX@('(B,6O \)HAOT:4!SODG_+RIXI<57B_(]LF-
M"IVRR?+(I<0N :SYD*+TT@=CBPU]W-O07]AQ%2M9X34GS!NL\&+.1&]$1#BP
MB'CT ED2)2+PNK-@_JCR&]M$ZTTS_=[5.B;\+"8T/)'P,QT^E!5>JX(1@Y.^
M"7,6"\2#!UYD.?B4DAD4I%9$TF2%HCG7&9L% HCY5WB]J::7%5YK0WU6LL)K
M3K#6K_#Z53T[$<>)"(^3X4B0F! G@2-G).!;,I@H'8./ >@/YIM$/JSD**N\
M%C%99.(JKZ5A/NM9Y34WB+CM0\2/7\<N).<XD\BKG-UGJ 0/244D'9/62*V3
M"3DJ-*(48ITJO=Z4_9257NM$@%:UTFON'.CZ6"<N<W4/4DE2Q'542$O"$2$!
M6RHQ!ND _D/U)A_1UZPL]5I89%AI_K.&I5YS)S_7QS0J36/4 L4B \S'AD,
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MF=9J8^,\2B 6%BE&#_3%"H<89< 1<Z&BD89H*EP"5D'OMMCK8\-K['L_B
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M39",*48&/0$C;[V'N9H(L K^\PA-+YWHV:% WXG6QC*C@D%1.Y(G P&M%@E
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M4>=%9W"-D8R@9"0-7-C$C,N(L4B!VI+)K &3>8V [9,- &>#4\.Q6E)2F?&
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M(L JN'GK.;1J;BC0]_6HU H6&R.-I4.<X HH!12D@1P D.*!%" ;_%9=9HM
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MB"NJD1/4(NF-#T(Q^+<8%8[-&N+D!$':-9A9M<B!VG6;634WQ.@':DDP"6R
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M:'XEGO]L-&]B;&]5QI7?%9;%%6PC,HTLLOW/QUP$CQEVB/ L@@.#-*$421=
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MJMI+$7TU$66UZ^/H2%2",*2Y8N 740-^D:8HMZK*RQS/&K"G;')0"\6H"
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M1<U25K "<MLOR/5<U4?1RSNN=!./"V+6JU8H_BA*%H:>T(K7-])1#><LD ;
M9-(!T@5K.7=>#Z$1W^A)C9<Z0&BB\""49A9XER4F:1H LB4A- A).GFN]V<R
MERWG9I#E"N<]/#\D^[NGC>KYM_P]I_L''^M5^'RM^._SKRH]:E1O_SB[G^5:
M^_2E?G3VC>]_^G9S=)#OZ8.H?M^[ 6I&\W^UW0^W1^??;JN?:GD:\V#+.4V
M8&ODB:*(>Z60Y<DBG0PGS#A@S""W2N#%;DIPIV!EVY:)<6(=V[8\#9"/US-.
MAI)EP[GE@,>!L3X65C4(@C1S#.7P ;+>2Q0)]8)X%H+JC'!=8&P<JQEQST6$
M.WD&3N?UR1F-55EHZ'VS62IO14PGF:4R42BO3&I=4A0>;,&A=*"&$88,S<E6
MVFODN/"(Y>S(J)))5&UL,R5&DM0Y35*9C(*N=VO^"9C7E"A03E)9,A08X&(D
M&LEQ0B20A+A('CFM#(J>:\4,"PS/B(N5LQ^F"L4-M!I[G4#<DI&=":)PE&@O
MO#521\YUX$80(:0UUI,HHC*C$\[**-SR0-O0L#C*<)!:8(2I V@++#<&I1QQ
M8#G1684EIX\3G!E[FBL1@EOK^-N*!]\F \<R^+8<J-@G?-@FI[R3B$6L$4]&
M >$+"6%N*6,N&J/-?()OK]DJF9>MDF=\E>O N9]H[SL+SKTJ[7W?CGH_V>JI
M[.S[5O:E/CBB.3+"*,[[.E0A+@38EP@_5 C*&$M(,'XI.SR5W?#FS<&7O1O>
MW*GXG*&R).BS ] ^06<Q!L580@XGASBF'FD%!)U9(9T'D6 :+R6 CFB1]TQ+
MO)7.2\>3Y:6/+#N9;Z:Z,5N<B D3U26;+*/\F=QO*?FK)*J_TL7*,E&]3%0O
M$]5?)U%]T6:C+]$661)66$JIQLSRA(E-C(7D7. Q!(-CII[$E(GJK\$U?[##
M[W_6#\__.=O?A<^<?:GG9G6'M,J/OG^&:]BYKAU42?6L?TR/:^X?!/C[S_K1
M]RK/=8.U3WN_]N&>#F]/&T>[?]:KNSND>OOMIJ@C'$Q4C]QC$:Q%)F"!N#<,
MZ1P;SGW0(L..IZ0WMIG6FX2*Q4W&7*Q=LO5RTM<Q47TRE"SWRI8#'ONNN.%>
M,\HX2EP2Q!--R/HHD774$*EM9)'G,1IJ51+55R+O^U.GH?F:Y7V/R?.B8UA:
M;8SP7#NMHY74.FP9DY1:]DQ/N;(]^U)A6G]_!C[CC[423+-D4-+*(\Z#0D[8
M@"RCTF%--&=T8UOBF90G+E[Z]]3*OTB(-^:XH5&WN+#T;.*YB-.!V^RSV8<!
MK.1JL\.U'E>[J>Y6C[V0VBDF$;#P@'C@"3E#P:45$5.N@,E)DE.;^-2N;)G+
M/A8C^]B;NC!-8&X).=F8M7A+1<I6<$[)?,&K7XL'X+5S')+$RA.*9"(1<:T9
M\#&KD!0N"!.82IF4/1:*>WDYWFCX6.1 VRKSL5&W6/*QU^9C(["K)&6SP[4!
M4G9XK"0.0AJ/8-$-XDXEI#U-*+&$N?5*A1AF&D,KPV13%QA.MH'Z,+=\W0H,
MO?,B>L^H-H);P4V 'R#QSD7N*2>CQ]F6NZ=+A&Z#J<XQ8)VDB4B')#)E2\@(
MHQ U3!&?7++<SSJ.MA@%AE-&V-:SP'"\FU]8%CCIINEDX%ANFBX'*O8W3:62
ME B'D;#6(BZ\03I/Q<$J.!$%-=[QF4;AEJ# \!D/>)QSO&*!X=M>Y3IP[B<*
M#&?!N=>XP'!&U+LL,%Q$^S+4UB,*81B/'FFI".)<)61-B(@K1;A/QGA,9E8?
M,XE^O7:!X6S(]WH6&$[T#)84)U^!BI<%ADL+H'V"'D+ -&J"I \Y(IL4TMYH
ME)1T5*2H!9]=@>$\ 71$@>&]R6_/%1RNQ-#TYTH4\T#B,<9T4L:"L91+B3%G
M/.A(6. 2>T:(L)*--S>]&)IX<75^#0+1CA?E_-DQAT#MX?V=8YPLD]%1Q(1F
MN6Q#HYR*CB0.+!+E+ Z@P1?UQL.)F\7PX<?S$D9,3)^N-6A>_C8H%?Q6KO44
MLX:KK'IR[&S@7C&&(C,F)SA)Y/*8"2I9HMH')RD=/7SZ/[,=D/X:D#265!(=
M4Y#.6Q4],!AEHC"2,JX$L81Z^8(AZ:54SD J*4@E"<D&RQE*4<4LE089:2VB
M"H-+!NX8H$662OF$5(X-2U/F%)0","L!J($ ,,F99!01[#GBQFMD0I(H&2\L
M..2"*9D%8$3:TFQGH!^<9N0)5QWIJ5]4GAUZGH$G7,4\)?1>=X>*;]4O@;#9
M7(?N@79:.-]#'.LAV$FGZ"2?J)D2^">M=J]E1)8>>W%3<8")YWFW'9X ^MEJ
MNDX8L/A<U;;\:85U!VUU[J1WW#4\HDIWA&=QI;;=CNUVYX*+T]0;]<M1'2KZ
M]W %1S<J[2OXDDO@IL4'[]XL+@SX:O^:X/$_W^RBDH=7P]6W[BZNW9W:/7R#
M+SM9+*8UM)\<9'\:6W%L^CJ3SF//T-9RSOSKLEY/"]8;82D%1\QZD<M6.,A1
MKECFG."<9,28!M;;?$AZKRX&^,BSF% ,O>ZH\E5WQ9XC,/=FB8\>M%VL&0F2
M.FY#"L;Q!-Z4 -_;&B R)E<3FF.I-I[N 9/'MKZZ)SJZ&P6A6QV=[ 8!GA@1
M#'Z("TP*3TGBX"MHL %*.O D"5CLH%XP(OA][EOCFJUB OE _&BWWO:-9ONJ
MM3BS@&^Z"G'V9Z-VM@>V$5[?/12UL\_T\.#T]/!@CQQ^A_.>?<A]GVYJ!R?L
MOD)4S[_1ZMF'7[4#N*ZS'_"YH]/]3Q]/JV?_G![2?^I@;W$5SK._&U(."=4^
M'QNA.%,>(\%RJSTI''**PI\&F#!)C 8J-N[ .>QD*"-<LZ"M]0J<.N.IMC3Y
MY$1BAD5CP_W9P7\!G%VTL]7:.0'+W!V2?2^J,B3\(^=-/_^UPY>IHF8^DA"M
M21PS:F/P-%G)9$I,<-#SQ=..OUO-3#TJG4<6AQ[8\ZV=[H\47[ @U" AR7VK
M*C]M"SA'9B.5$3("I.7RM/(>[*#]L5GYZZ_WE=\V.G]M_*?2&;_>Z]FBLGG'
MM/);)@D;Q:]WIX$/7Y[:RPZ[:@^QJ?C+-Z[:@ P5L,F-<%T/@-SY@@L2<D?8
MX*ORD9F$U"\Z!CT+Y0#&-Z]:E0-X)EF4 =<4_ST3H;R26Y7]B\J^OVSF;D3%
M91*].7P1N5]0S*<N'D35@K%H5;HLH/.M>W\//)7B'G-DE>+?.X^C4OVZ4[Q
M?O_/X$,KCMUM 1TZLS>53U<_+^TF?$.^ _B&_0[%O,<PMRI_7[7:5_"H>GP6
M3MZYX+Q:]=@>ON!'692]>_[WO.[HC4G6T40)M[E7M"0RI(SL1$EA,J@3#<98
MH=XO$Y"JUOEE_5UGEW0_[810SQ=G&WUU6IS0_]QQ_P,Y-@9CS:)%B2B'@$-@
M9'P@2&@CHK"*% G5A1\U(OQW]S@K=XL,'A!@?JON0"Y<;#2O![4C"T^C"V@#
MCE"[V2C"]Z UV?3_O&DU?YXVVS]!66/EMZZ$?_WX]YUH@\#%1@-<M2OX:M O
M(%399;F^R%]ZTQ7ZKM]SIQCY@__60S>(E#&GV"W*%_)_QG !N,12J6 4B"P/
M!%BD V<@20'RC#$K7("'TGHO</UT5N[N53QH?ND\MK\[NO;^JM7*6UL7 8B_
M[_RQ.!1^WI)[N\..C09+S[5 0 %M'HM+D#/<(X9#R&TMC1$@N63K8:[L79@
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M57>..18<B M#,H+#PBFXNIJQ #IN>4I"O!C\D8X>5PJ>OO@PS@U$'GIP%1W
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M+_'0D S=8A%JO!A,_ND=./0Q$-G&4W Z\MD_AUA#2].Q&+9 'LSX/6\S#ZU
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MW-UN!2RPV)P K*PP/OGH-".!>^ZLD5;C1*BVCD<;2M%Y!=$Y^$:/C>&&@6%
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MF,3I(NUUSXCHK!3LC.FR+Q7LC.N8O_*0MA)V)H6=OBON>0Q*,(.$EP [+"1
MG!QL3!A61 O#HP/8(2O8.JZ$G16%G9EGW):P,Q/8&=C9\%0:ECQ&,D2!8(T2
MTBIO=.0Z66^UU"IM;&NQ@OVS2MA94=B9>2)Q"3NS@9T^VPD8>*<@'N&@&>)$
M6 0V02,3A/*4)FH)S[ S=95^F5 \HY!5>G(,W3C/8.&Q=+(\EN7 TC</6(UJ
MHMA%U/V+O^K6U1OURYL26\?"UL^# 2Q+DW;4.R2B\8A+PY&AR>4V*+"0U!/J
MY<8V)0LT_V!.R2A+A4*3I9PL!PJ]0?QJT@:O)39-CTU]WL<\ER&PA,"6Y%:O
M(5>0$8V<=LI0YF0P9A$'M)0 50+4F[>++Z%H:BBZBWP=[/TZMC98+1-#T44%
M8,09<E$XA"VS@F@1!=<;VVSJIA E#I4XM#RAKY(HO1TZW=RA$S[F1(=D,$6$
M!9NIDLJ],12*.$FE3231TT6D2NN0V=61_QF&R99QRZ',ZYI3F.SO5AV$[:=M
ME#L/$P'KM\'H&,.&R;S?("DCB!.@?YJFA!SW-% :E)9J8UM,7>]0[G<N$NE;
M*O!9@NA8"4E30U(_*.82H<Y'@8PF"7$'3,]ZFDM,I25<R"A86,3Y1R4NE;CT
M9D&Q$H&F1:"A6)@6TGF"(TI,8\0E )%-FB E"*PB3RI)L;%MRC2P$GZ6!7[>
M(!96@M+4H#08 O/&Z,2B0H+EV:Y&,^2HU(A)B57DS*9D%Y$8K4.FV)?\>Z69
M*E?M6+'M=KQL5^(O?VHO3F+(BG._R+'2Z,:%ZV7ZV-+N1[Q!7.S%'4$*B=Q/
MW]IQ)XOCOKNT<.EA[^)#5RP_-EO#F;SE3L5D,'TX&%#+'BH6*2"N<]^WX!4R
M>2N527@A:4R2][F'"%>SZB%2;J0N!'E<*N!:T)A:B5ESQ*Q^Q"VJ)#SXM\C+
M"-YN,!BYI 42&BL? PL\S'S^9XE:)6HM0<2MI%L+"%T#!9N*,<\IUL@RKQ'W
MF6YA:9&/,GHE>6)6;FRS3:;*!/\2N)8%N.84JRLQ:XZ8-=!F$B?B!(V(4IP0
MIU8@%X)$DIM$.)>1,K6(=&L=4MF>C^,-I;1-%,5;QIV4,KOM%;/;7H+#@_LJ
M)0I/AL)^*%"G-<&*4G!ZI4#<46".Q# 4B39,B22-$< <29GZ5B+3TB#3XH3I
MGL8K7.+5R_"JSQJEM@P3S1 3)&?J$H&,M :QE 1EP!P]=HNX^UMB5IF7,M>T
MN))-S0N=^BESA]?'R5+&F7!(4"4!GR1%3F*&/!'1F3S,.,J-;:54B4TE-BT)
M-BU0'*Y$K)D@UET^W2$^9A%63'",)!$Y5<,2I)63R*8@@#2#J5&SZ[Y1YM.-
MY?1\+_Z( 5FX*GL2*ZUX#DK13Y^[C*WS2K$VY/=G!PC,Z"DM%)8-^H:UJW,X
MW@^#EP!#S)P$B\L$#]HYQZ/2+%&E): 8.][K\ZD!E()+\>_"5>LFVM;3G1][
M:[336:(OO14JWLR#YDF)2B] I9/!J)100N"0VY,Y;0&3!,Y3]11B@44O;!#!
MY?W,K;M.D-VEWUZ443%+KS98D00:8[SV8/89M6#^M4G)86V=4KQ0&URJS0*H
MS<"66H@X4I.0PM$@CC68<@O6(R43P9H+GS#9V*9;O%2;TMJLN=H,9,\8)JQC
M>><CD;P'0@QRP4MPW"46.D5&O2BM36EM2K4Y&4S@4!+T@TF*B,Y3 DATR#%'
MD7<1%H]:%11_WMJL0SK%>&[<T]V"9O2,E@L?7L&L#D:22G28"3K\&'+A:'!"
M,X-T ,O*1>+P6YXB3%4@%OX,+FQLBQD9U1D.:UT9I7D%HUHJS6LHS4#3%Q=$
M<EPB;7 $D\I :8C/KAPGAB3J<"Y!P5NX5)KIMSY*2[/$2C/0IX0=$VF,Y%HB
M'W1"7%.&3% 861IX(D:ZF#==2UOS>FI3VIHE49N[G;_JKV-&I$W$2D0] 1O#
M(ZB-B?'_;^_=NYM&LO7AKZ+%;^:<\"[+K:LEP3FL%0CT9(8D-(3I0__#*DFE
M6"!+'LE.")_^W7M7E2Z^)'8(Q$DTL[H;;$LJ5>W+L^]ZY''7]@,_&46H;6[7
M?'L(4;@XK2)XIYE6LAG?/OQF;;<]*W,E=DH\7)V@F<\G(2^?W%S/-JD$UPQA
M6Q 3!_*8WL,IO>-EQ/-9G2J@6[W$N%YB?-GO#,%.XL3F#M-!GR(F#4W=MT>)
M'IN1%=BF'W@6F'2CH;4;U3IWP01__ZDNX0<G.*[.1%HI.+9!&KW@N$O!T9BU
MAFTX'G-#/0I')@X?L_60,::/XL"+8\LP'=-$P>$_2L%A](+C5PB.'G'<$\'1
MBLQ:+.")'20ZB[$)<F1;(#A&GNZY/HML;GMQXCQ>Q-$+CAYQ](*C)3@:Q,&,
MP$TBP!DCEEBZ8W-?#QS?!<3A!)$3<M?C<8\X'GL8?K4?9\/X^U6B<=.*EYVB
MBKOSXESAZNT%XP\+QM<='\[(=]U19.M6Z 1@BL6.'IA>I$=&Y(6>Y1@\3CJA
MDKNM]+@_/IQ-HT(/3FS\2D2U;>OU7IC\!&'2H"PSCJ(D,GT]\IFM.X8UTGW+
M2G00*#%/0LOE#M^QTK&[1UJ]0-E9WTXO.GZNZ&B2-H[,SY[A)O!/K(_\$?:L
MC#TPT0Q'=\+ <IT(E ,S'B\2Z05'CT1Z<7*-.&F269S/3FRY4<R8'KF!JSO<
M!BP2L5CW@B@*?>:[<1CU6&25U^>W&0LS_H+V!)DCS>>,-N5_?HO3\RO3OF[4
MM68]D]0='8[8;%["?T]Q9:?PN)=9$7V]GVR1\7^\O_SKSW@:6L[HT_?]B^,O
M1RX\U_CKS^.OQP<OO_[UY>NW3Z='W_XZ_6H>__[7^-/IRR]'?_Z5 %E_/_KC
M\\A,3#^Q$SU@M@<6NQWJS+)C/79#V&G7MUTC>*)Q$!Y3V-99.>=7I^K=PIF]
MY57%^9J>N/W9-6<7,=>P?3"0?(Z5A5YDZ\Q!&84#/,V1"4<7+YT=,)V2"A-6
MGJ6Y/BNFSSRE>-,\!FWQS!Z15K\+!\F;.9PPUR9IGD[F$ZV$Y;!,F\KI9J!Q
M8[X\Z(F=E9R+'[ 2F\J""LUH1/I>FFNS<3&')<75TV>U@"+ALWHS7'IWDENU
MD"Y*>"P*Z(Q-*_Y,_>%YG%;3C%T^2W-Z$[KHN;R7$,5XNT4A35LMOGY^D<:S
M\3,_&!JVBPA#NLGE@\6WYI# QX+F$-]YYM W1FN_-H;FVN^NNJUIP8)N=MNK
MOQM9-[ORVL5Z&]WV1T,1/RDA&S$:+^](F7LK&;&6P#N<Q[Z#VR8AQZ/+8_[$
M6:GQ'->K'?"(HSVDV>9 0SVO[=5%J4^WC7Y*V8N2&6%P561IK.'[W*^>;S>;
MT;?AR^^L6;!M=]V;^=J6&U1>"2+5J%11Z0'[>Y*\2=$^_D25(@^BW]OAQ:?)
MD?/I] _KKR]PO],_;%B/<W3P]?+H=/_RY'3?/)J\OC@^_60L&LJ?OKQ,/WT?
MCX\/_IH<P]J/#^(OGT[/+DY.#[\='1RZ1P<?+S_!]<=?WB=U[.^#<?$9$[AM
ML'1U9F+)?N3Z.ANYL6Z:D>^!/9# /T]>^*,?]KEMQ1L[/C_F@4BWFTV6N>_2
M;=M>E[<EW5:Z-7JI=HM2[7LCU2)O%!A6I+/(Y[K#8Z;[CA=@MKD1F"%+0,0]
M>6$ZMY7L]7.EVF/(Q+H*B5I]QM7M"Z>-!_AMA,H.YOP8%G5ZP;-S?@0K'#^4
MF?:_2'JE+4QFV&&2F-S70S\.<51RHH>!E^A^P!(>&Z'K.0Q')8\,>S?"%GTP
M\MX"CYYQ?YAQ&]AAP:D8B1GI+G8,=/S8U$,TJ_C(\D*/1:;E ^/:AK%#;/O8
MW5QV7Y1_#\ %GN#I1=&+IFU$TV4;4XP<+[&"0+>"D.D.<[ A#DBJ( Z9RUPW
M].P$,87EWY:G9X?\.0^7I7<54_3\>B-^;: $YRX+^0C@O\V 7[T ^]T;MF[Z
MB6/Z01*9KH508I>X];'[*9S>3[$3(2(E?\8EY[T$VD("';]J(0;7]"/3B+$N
M##M/!H&O!VPTTBW?=PPS")TX D4V+MDS/0^B/N,%WI^W9Y?&\0PPE"M ^#>
M]F-$^#S4 S]T=<_RDI$=.PF+PUM!#+WSX=80@]L['W8),;PIYGW0=2L!U$XE
MX5%@!MPW=(=;$9@LL:]CI%5/HA$@"=]+ I,_>>&,=J3#1N]@N.^ H6?7[=FU
MP0MVXGM&& >Z'22V#D=CZ;YI6KK- M>V37OD<*/W,/QZ'5FWLM82456ARB@>
MCW?A5PN=<C)+KP8*I\5+_HZE\7XRXV4O>VXB>]H9#C&+;=,)?3UQ<!2,X8]T
M-DH<(*3$2**0F]$H>/(B>( CT7NFO56F70D3>F:]!69M)5-:H6T'H:LSSF,
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M0LGC:O(5"[[3ZQ>CB+OAV)8;H^?5V^+4!%*YGC,* V3I/< ZL-_+U$ Y0
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MO#@G_?$6I+WV 6SJ'+'U6]D X,T<[GDXT-Z^T_:>U#]^\I26$^& (E@&B&5
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M=<9Q8IEV&!F UP'3IL%9I"X<6P&D>^,O+ _XY]RQF ],FZ"8',]/; 9IJI8
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M=8<E@6/&OF5'SI,7]HK<X+\K8EM5]214;08R!OY>,P5Q"W <'P:"SR./^3?
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ML55"!]97T7S&*\0>]41:H]2EK:'FCM>G.>A: ?N:+ #2WL.--+DRI20D7@&
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MT'-*E2 ]@[0F$98:E].&CPI'Y?B.9SR7[*GA !STD^*D^!(5,8_&.;PH8#:
M #.DRH'VAI>('-]=EO#DHH*G Y6_2@G<:7M/ #0^>5K/ 6A@B!HW75L7-#,-
MW4PHCG%.G"1ZA"R 16;-W!Y:2\P3C*3D$?*8-@%V2:= VL!\:+P*SJ).M6+6
MF7JL4(; $G.0&F,.K#B.4(TVW7O2"8%B>'G05]+%9'K/0<&=8]SF3V$]D-PK
M\KH9U.P"Q> 7M%[FR&@@ /&K#'"U7K%SW.$QGQ1Q*EUKH,61/&F3%&['-_^:
MQCE'&:)^!R201O4HKX\YMOP2GI2' 4^YF+F$^Y?#MF<#M$RTVC)!X086$AYE
M;:3@*74LEC:H;/4OAEO66RNIGTN]3^@!S!E%QO6YPLY]Y60BA"!8KSX:XHU*
MP8ZTK$D&NXGR]%RX5L6OJ=>RR#"XX$(KB+%C\;E SPL+:JPC[$"6QD1H]:-#
M4AUR]I7VCB;(6, FR$8*!=5,@U<NL@S+^21E2%7UFB_&A<3]:NU9D9^)= ?<
M<;2GQW ;V/,4"1<44#&O1>HO'@)%M'-7,Z!$ SX%5_]=S_.9\-I@I5-0X5]!
MPR2/0<3BI$O)S>."4&<R)]=[Q6=XH,.A1FU!X?R(1,C[@-R0$N(4#\EP+"5O
M(U&")QR%E&A93K]#NV. R0CT)/*?+#]7D#RB#F"T& #,62G" O $AK=JQ"2Q
M2<>07/L:0D'EF/].0<@9684(DV#3Y6 +Z>@0!$^H):_;K==T6<W1Z!!LJPA0
M2OF6[=7JF$Y8?9G@8TGT-:LWH+;BG.!?J^TO"J$$S@KS'86^S. TZWE:C?]!
M3/M (4W-@ALO!GH0Z)61K5L'KB\=./F9.J[,A=NCJ@8AH9AYD>/37(ZUK[IM
M:5<-K"/ABF-$6@[FI57#45Q(N4R-Y>&>)+_PO-[_%YM,GQ]HTW3*D2MJ?YKT
MAIVCH7PFO"SPYG7P#=0JD^, E]7WDKQ"((%N,6JQUX@HFOY'SB2@2<#>."!R
M7O+6T-0.G!"9$BP7%MW2I@D'0'UWL8W6 ]&J2A?*Z3! O6>87Z+0B>#KU8!D
M-=J0FXS&R70N"%5R= 1X%,^M0O2-0Y]P*%DZNU2=M9N1@=H*^2$LJ;GR'0A-
MWB9E2E:Q7#+K"53)YXC4&*[T<I]?4.<7..OS"W8G56 %^]S1?BTBN@%*W!!^
M)G6)<-W_;6348^!)JN3"R4;C: <+;>%MPP 11W 9WA,IEEQR3F-PYAB#CLU
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MXK!+HRU-78#Z$&H:_:@\EE[_&"06$KEP]2N" F:B],(91Q&^5;3!.X]SV8"
M$>*5DJLF _+YJC"DRL;GPKJJ#:(Z<8OF\F)%(BQ"KH".N':9%313NBA#$885
MDOARR7>D(O]@APGW6N,"H!\.:M9<_'PE1HW0T"]%&HAR5ZD;G#&@N += G#F
M>?MMB"46Q0-AZ6K)124,M?I]4)VW341A_V!D_ RW\[)*9"H7O*H8#XA34-"
M',"K$'^,4?< Y\LHK?";Q0K@*0_7,GEOE/AY=7O]7X4)5KN2/RCWRVN<DU?G
M RH/\P/@YT7U1A*0P]NBVXWRTVH/U+F</SW%&6X476ME!4AV!';BBA>S2QU(
M"HEU1B8S?B"B_&S&]+@$+)$KOW1',<G@AK*G!V@(XTB4HKQ<@#8JQ4"%.&3,
M$5'.E!?(6K5)*#XE!)52[!+6F[/SE":0B8G<S<]PA326I>2-2J!1W8H,@.;)
M-;@ DRA[H M/V@Y:^;29CTC*50VD^V:U9!A/45?'@Y_*0>UY2V ']T2]A6#
MF (4UF!2W+H=:5:B<&&K6J^>+IO?TA6H\&8-AL%PG&&$G7#!M1@3SGL"YZQ'
M;*K2Q53@055#B/RWSH;5CI-\7H+@1>F"AZT$&UFK 86P M:[2+67:E?X!%)
MQWW<'9Z*QU13,@)4 60HEL=D> #A>I&B@2;[4-(.QL/Q$">DJ>3$!=;OT.;
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M'<$6 @"U7W*OS'Q:A^ <\?:*P;O!.PI_+7DV%^_6#%<7+FM,$HIME\:;U4W
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M'&LDVTNN-^66=6J>,I2$CPZ=$Z+$O4D151)TN$K(JMI0V*O&W];N$["J"$M
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M3]C_]_''72?W]1F+#XCFVR_)NB^Y0/CVT+L1X0NC=HGZ?P#?KQ7P:44TWW
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MN])KLU]DO\A^YFL_\_4AC)X$DV%DFO<H376'Z_G[F:\]XVW.>.; <^V>\1X
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M4 V+E% EP0 *JD1A.S8PEWR6]OO01Z3:DP"$>^*KU:?.@&Y6CB$Y,*-!-RI
ML\4)2>D5HYV=P&6$[VC7\*(V&*,MPYT^$QEI< \FO-8+'+*(XI"DA4N\4OFV
M93N7>15R'&JOS\D#3(KZ MGTC.4_Y%A"72?.AQP$[54!M0#!-@37WK3&'2.5
M/RF %<ZU-J4I)UPKM9G>^]KP_..)S9L_)=WIEL/L=U&]MGJ_UG+, N,UY@T0
M\3BED ]*!\F]&&LL"4S&YV J\E;LJ6T!DT0#8A:,H1A 8'?!.$3?-;1>+66
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MNOTCKZ%A)59S 57/_K'?MDOHU]&OXPMEK&%'/HYHN8FTF1K10""[,YZG@[-
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M=R9NZR-HY.URGGU+WBY]N4+>+OFL?KE;:F<\4.YZ#]1O81%?PG_<GVXO\'
M4$L#!!0 ( +&)$%,)%GTTD1$ *B\ 1 <FUT:2TR,#(Q,#8S,"YX
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M8-1^WJKE3S6"]>FA^]0;3 0 :23&$_C_U_[#9#R\&S[V1]W) -Z6Q'8OUG*
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M#G2Y;OB,[SK@U_CE'OT%KXDC]M/'Q<4ML5<PHR+4FH@KN*R 1:M3/0#')W[
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MVO8X<-76_DL(*K?J&_0*9O8%(\>?FS#K&;(9<LG_B2KE6I6AK%R]Y&(%]24
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M2P,$% @ L8D04YFO7A@H'@ CB@! !4 !R;71I+3(P,C$P-C,P7V-A
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MQI9G87%(<.I?U5\\);M&:NOI\EF8S[^0Y[^*!$966:D$0RC(R(<TB8-CO K
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MH^QJYR'' (U#&51B4G1QW.^&M582D_W%=%-#2>VI(8?-14FM"@2LRUPL(81
M+[VLF_^STR)WJ7_;N2$'_XMEP-N):9^N4<XI":4B>)$4* P6HF$(SNEZ*)35
M4G5I1[FI:]1B\!=1>96T1,M#J-N+="$/(Y()"#P8< 4I-%()0Y_M]G>B&M*Z
M46/NW.\$;BN=-JVL[QCNMWUF1XS3R *3$+)BI"/J69]91#()2J:D?5+YNRSN
M+8U]U[[EH+;^=>)%1R%T5*<7)W>\PX3CTYHR'@4CM?9&@U6V=J:,%,3XD""Q
MZ$O4G#GLU$?O?G!#6B[:NW[9458=6?1VCL=AG)]CP?D<\WG&CL*6*X?0CV1R
M3G$B>^U-0XR/Y*0$BHN%4X%Y*073>S+4Z\ =4@>MO3.MN3SWH,'.SQX:F4)>
MKQ&>-"GYO2K4GA6VD.551I/Q->3&[EE]G2/;<!7IAS2"?<34D3VOIHN3^:H7
M_Y7>S$QRA5E9<%YG4%K5<Y0U!^Z*D469F-*>LJTWP=MPK>@OQJ.=!=8S-JW:
M\:O#=P4@&J^8C BV1-*5UF3PFBRVL%*'Q'S)V*7^?P.,@UH:VCNMVHBN([?N
M/ )B1!BY=C3Z5!O)*Y\D^8%DD&E6C F2:PK<]L.O.W$.:K%H[QQK)\)V#83"
MXK#^J1M>3L,$5]'%8CD?IR7F^@'Y?-^^<>6;9_4@U\=YWAWIQ>=T&*8?\5U8
MXHM2,"U'*DJ913URF6S]68-?+T*$I&ATD8L269_SL/<ZS$[%\9=K0E<W"EC&
MO*(9%#YP4#(J\$&0X2-'/&;NK&!=ZEO6ASBDC." V7Y#-7H/#O3>P''39A:T
MV7G4$I2IVY2="Q"TS6 5*R4K(66?HM%M-X$^< >#'YZCNW+@(389<4<D2L&!
M6;6 $X*</%0%+"_":([9NT%M,GK@]@0_/$=WY4!OCMZDYVT63B0O($0EZZG)
M])M1":0A%U$EB=%W*2_<UM9ON'[U#H]/YB3[!1Z49[.CH]ETM5%B\6'V-GQY
M<70\F7U!K*[SX6Q2B?(A?,;:TK]P8H>$X,DY5XEE"#8FT(JL'M-8F]"MM9:U
MU>U_A(WSNU+IF_6M_D+JLHG^U6)Q4G-&EZ"7L_3GR"(I%98#L%)[\03K(6I>
M5VN9=;H$$767H/E>9$/R1SJSJH^T.I/HZOE[(QJ<B!P3N*0UU.W2$!V]#,:A
MML(%(;K$M/=#&Y++\* TVEI>S?LK')2*X0+9JKAS%+B*5G %QJT:.@4/KA0/
MF=CN0^#<^2[KHG=@^A%VT#6G3B,1=>#,2@%^BR@:4Z1* 8R4Q&(;R;@ZPT"S
M5(*S#CGO4G%[%ZA!+7#NG34["JGA(3W'EYC>S)9XN>)*8RQ>N4BWYX2&UV,^
MZJE\C&6M<_+9JB[NSFV !K6.N2>Z-!%.SQ9ZE_L^G^,RC">+;^^Y7G^\:]=H
MT/SN;EP[=K9;A3;G1VD_G>8WL_/-8LO+NXZLT,PXYD$(Y4@^H="C7-MX.JU8
MW4QM^;WS<O]MFNVP?A<^_1:6.!^'R6+5IO%\"^^J:D=D- JXK0W-;")'*.8(
M'DW029=D;:<JK/N@#6&EH#$3;MU5W48^[7?F_S&;_UG+O\B+7GP'#)D.4M8E
M<,<2^4"^!O&U9[P5*2M13VKLTC=D#6Q#B)?WQ9Q&$FI/G9?U9+%#S*NS4+X%
MIC5R+:O3G##6S*H"IY@$J1EJAT$ITY<ZMV,;0HR\+^HTDE!/]X-X?8SSY9=P
MI0?G#I[(79=KX)2LC;91Y]V+^[V=A!53+F]*PAP9%E!%19Q 5CN+9P=>% XE
M<<%\J25PO;*9MX+:>4-S2B='53*8U^FS=2N444HB)I$8<&7(9^<T0YZ1MVU9
MH2<U6D^^>X_):36 02TT-*/AM3W0#R'NEKGBF^&LSAH;>2=9J3HU8#71@E.$
MAZ5J7&XRS9 MIE>/WCM@#<%UZLZKAI+I:?R(_O,3S%>*3W<P?;=?K('A6Q-I
M([-W_6[G_M$HY(B"Z0A.*/)X49+'FU$"YAA5LMPDUDNMWXRHR4D=MX]7< H!
M.<6%<=6-7(<$03B$2&Z@3#;;P/L=%;/FH!^VQ*\-5VX\-Z.-6-IL]KWYY.]W
MN+*=-R T7F>.-;UH#&E/%P.XU2J&CHYIZ5+XOE_WK642&]UX2.:E+36ZBZ&9
M7W)1EG$[+.V$3=+0^)%&K70]Y("5 %YFC3I)"C"[5!;=BVP(T7E?S=)6.&V4
MR_E(?Y^>SDX2*3[,JQW'Q\M+3%;Z*$.T8$@Y$":WJL5PP#EW]"<;7]Q:ZN3>
M6PUI&VX'!=)VJINIC)IDQ/GB:G_BRXTJET;/H4TB6_*:BP8E335Z2H/.5J4H
MM5.E2U)O#6Q#ZM?:1VVT%E#/L&;5^&+QOL[7_,NLK%ZNUL=WB&[NO6:#(&<S
MW"V6(,]6FW%UIXNNIX&DQ!(S@)PY4,D(BDL#Q;W&<>.2TYS;M53M#1??N:_7
ME4N^FBY)?2V6%[@S,^CYJC]P"J"\8N!=UA!4[>&JE3&Q3U>OVS$-(4YI(N=K
MC;L:R:%=P[<K@.[H[#M*A,>(&$'HF$$):\%KX4FLEN=HDX_8)2>V)KXA1"_=
M"=-*/IV:?%\,5TGO1')DS7P19"WIA_-$:RY8=MK:(OH<<78CFK9#K$9EQ%UP
M.I D1?*Y-@PS$+E$"*:D6@3$$^\2@UV',@0UV8X+=[<=WWCJF['\7V$^KI5?
M7V%DX[Q%94$JE^L:/H(SJ""JK(.35O@^AV5>0S($M=>/ +M-?#/Y?[U]B+GV
M'.=@9=0U>Q@@A"@A^R1XSKQ(T26)?8N\6RGL8G6P.B-HS1&400LN*@'DE*I
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MEZE+CX==@0\IGS($'NXNW37CXO/WZX](4?D__O8_4$L#!!0 ( +&)$%/:
MI8O^<%D $$?! 5 <FUT:2TR,#(Q,#8S,%]D968N>&UL[+U9<UM)DB[X
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M.E<=W^4_Y[^:#JJ*$#,O8*TAQ;$HA%"_>"%$9J151JF;J6F/DG?8P&L@HKM
M,HV ]!]X<I:OB11!:6NX!X980PRV@%?(P40M'%DB5K:Q!SM1]T/": T!W461
M;7H<?<C3V6089SG-_^Q%9<G\'"7VE#R<G='?#(HJ0;HDP1329E6,!KQV'(H*
M*?+"DPM-#(FU*?\AT==(L'>1Z5J>;YWH1\VB<T:"M-Y6^NFB+R6 YK;DJ))G
MO)'C>#W"?TA<MA'K75CZI\*RAHX&U^KD=#9^D=)<+GCR'H=I.'J)7X8S//D'
M3DC_G/T^3L,R/ ]>O_[VA138/+#%2^V$)L00;)1S"D+B @IS(F7',[?VL8!5
M#W0<)L V+:![W+5KN_9OD/]I@?PW"^2?;Z&!+!Z3C95),= 78I+C/( ((12T
MP7,66QQR*U-ZF*#;C.#N@5H_H8%E^L'\ZZ_$LU3M;]H:\UTR0..B,+'0J1OJ
M]I"E>B\YD-D<$RN>&V<VKNK=3^MAPZVU\.X!W-KAARY;Y'[2YZL]^E(_DN9*
MC)P.9_ECGGP=QGR^\ \YCH_/!3S@&15=F!ZD).:J^@61*S"&3*JBK RYB<6[
MH?4=-K!W$23W;(:UHS$/!HU1%A:%1D"MZ&K(/D 05H$N$M$)FXR6VXWA]Q*)
M9DEGGH6A%3()2J !1\<2%*M-P."%3$U4E\<BT6MD+7VJT95!=$&DXBS$>>C$
MU4/6D>$<?*9]()*RJ)IF+,W)Z/&@N)'AVCP99PU>WI= \=-YON)?X\F8#HR_
M_3R;G.7K'XY'L_QM]OID_L*__3S-Q_5#;W X1U<]I<:C>J2]^#:<#C3C,0DZ
M<)+%4H]'!)>=!ZV#,T5;865JBH[[J.H1+ ^D'C\ GB=(>QEPUN9Z@T2<!9I>
MS6_>3D0-%I*A^X3$O53UJ6 LR^A^ CK2V_<BO6;PX40-@AG@"Y&.C\-!D"G
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MMG_)K\+<]M[+*Y\J)J.5HX.,3C%0'!UXE1-8Q6R2SED97:>[?><##BOQOUO
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M FC@]/D=XV?2_R;?;R[[TD5.\'=,1,B^%G!SHL^GE*#>R%I@D'ZQ:4D_V'B
MIL/#1E\":'!N')4RC'F1*%V4D:QX8,$*J(5\X )*,O5S(-LA9PQ-+IA[J3D\
M/*S/] :NE:/9YSQY"*FH7&1>!["Z#EUQ1*2K:1&>V>*)7);:!! >(^P \=&G
M*);Z9?H,;+[*Y[,/+[H,K!'37/*D]<.974A<B&0Z&V-VF&KH68G,D"<G5=$Y
M1)N5S8,ESUS7QWGKH2\F$QP=YP4O3M%*668@R3J6REDZ)G*VM:LP$X4IKD.7
M^8U/<'T^2EO/O=7H8QY^S6E04RV<I+WDC*,E<U\ _>@@["!"\%2QSKKY>_8
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M(KS1J.=FZ^/$F0U*)_"B9#I)/)TDA1OPS&A;(FU\'W>*H0\N9P>/]WXQW5M
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M_!&IE\3+T?'\/9_RY+0JCZ/9A+3 2=P<TV[K(CD:>7)@3<F07&2"9U(5*I)
M![C'2=N\1Z-/E"Q:<CV+HD'X\<4DXU'YD/'D]72&,SHYQT3M[/N 6R$L7>"U
MM3^O\[ 5!!D<E"AKHWAI36E2W[",H,,"1B]L[UN;N8U3NCI_&XYJ0M#\V[=#
M#,,3NJ@'KA:(,9.! %K'2@@-Z-$2&S*B\BH893NI+]W>=QB";\7@O@-Z#Y+X
MH184'I4_Z!?$H=GT79X-:N6*JP>6YRJ#8LQ4EW\"KGF.V=()IKJ%]U9]\X^"
MBW69WJ"0Z#:]U\"-E@MMG 3E= E0B0&9 _,.EG+5;ATK,6=L82>PT!(GTQO
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ML1:A)V@L(>A -$'N_NN3+B]T//!;;6P=)8G>3H[&IU\O^J(%@K&)+@ *^K:
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M[T5TA!K '#I;]Q#XV%LNF[]NOZ1X37__V_\!4$L#!!0 ( +&)$%-*Y8$W
M6=\ !Q&"0 5 <FUT:2TR,#(Q,#8S,%]L86(N>&ULW+U[<]PXEB?Z_WP*
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M"A )H.=% N)$+Z]I0@7T! YBC!FE'K'AE&XQ<V.2ZQ)J3>&OE:J@U=6.2\X
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M2B86,N=&'8W*U2Q=Y\&VZZOK'G$B-J#;GN8,"N7HQSDUBHVZ6VC6&H^P(G,
M:-@#G?-B)S[1L<;A\$C'_M:Y5:SXD%7U.J1%N0&?8<*IZ3L1*0HQB3A,/)Q
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M1 CA).:0>0$U34=B2,*00T6Q+S0UAJ1_<=@#:7-CPN?5$Z?%/5#+[%L!S "
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M)V_4QSQ=\?21+FM=;]1NEO[;]4I(L0A((H7T"<1(*8AE1"'S: YH1P%$6>8
M46M.GX=-<YLZM@"HYHI5!8'YB)L\??T3KW<QZR37:E8I,\ D>-1*W%?G7>RI
MS26Z,F>?#23FWL<6E'9JTK_+Y5)^-6DPVL 'L,RH%EV!T_S'@6[G,:@V4^(\
M-)W1S%LG1=T\)T7=;)*BME]*C0NH@3'7;K4LJK$!OSP]9TP]/V%6)I7T?
M]0,V*#6SD?G=7O$6\/8/^A8Z^!;ST'B&+LP?]JUT\Y[F-?Z=3MI,5)W.%YR)
MP<=<SIFIUB\ZH$YRV=XE++::029A$ 0L@AZ-&,0J2*"F#%.3.HE]%?M>@JU<
M3AMA<_,%:_7<SOL[P;0[ZA\*HI']E38W:N=(H!@I+-<&DR%/]SOE37JP;V/Y
M_IF^U3T]<S%-&Z-KSO.U%%O)4J_6>2[-=D[(E%Z@>I!+TW7>CP2DPK0'\[''
M?<QXDC@5FN@6-S?"J'L\->J"+7T=\R^[,;9CD>&0&_NL]Q1HVL.LE1TPE=(*
ME$&3)[LE3ILN:67]08*DW5V.36G*QWQQ^U^+(!),R 1#%'H<8@_'D&',84+\
MT),B9I):\47SO+D1PE]S^BB_IBMI>F5^IY8\T(+3_:'W,'GD+_GVS7]=?QZ@
MJ\RN81V'@.9*;1XBU4_0_+3=3*9YSC1M9':5WC20V?MUOTGW@]2+BN+^8YY]
M3859.GPII-AJ9'#-R_1K]54N&-(@^,J#A,D0XD $,/&4T+!X>EY6^I?,6Y19
M29=V$["]:*=O;Z/ F#NYQ;V)2Q'@W787CF>%W29EAS&(8QI)XON02JJ=((;U
MFBD(M1/DQ4A([1]AX91:--(83,!_6G/ S3BLS3BD*Y!MQH&./PYVCM(XZ(Y,
MM0;8Z@5OU39'#C]\J5'^T>UU=_:BW!$;TJ-RD#ZI=^6.RKZGU>,)?2MAO9(F
MP63Y;B7D]_\MGQ9<^C2(*(&A%\<0"Y]#ZDD&!98!B;BBE%M%BYR4,#=F:DH_
M-5J"2DV@]70MB+4/9#?G# +/R-3BC$R/NE@GK+^X,M;^<R>NC77"K,/J6*<N
M[.<>7K?136^SW 0\/&\UF]WBK8WG9@,!<QS0F(10($(@YL33_@D)(,>)2?1"
M(4JL6@SVE#\W*GBW^BJ+LJKU S:F0)7E\+-UH%COH0AY& LB8"!,E%Z"M-.8
M!#'D3'OK,D:,QHE;Y8L1!V.:A(OG*M'C0F_G'8X(Y\@\7IV7/BMXM?=NFR#(
M$7;8>N(UI(/HJL*D7F)/?/9=Q;Z/&3J';U,'S[2?;SXLZ?L1B:EF,HY"B!%#
M,*$X@B%62<)IY/O$J@)C+^ESFUSVFGX""-YGJSO86<1@@#'H)K?1D1W[R.!\
M9M)6@<9G$\9$?*C<L N1GT]NF-L(#)@8UH%@_\2P8P^=26)8A[WVB6%=#^G9
MJ:"I8?%;6MZ_6A=E]B#S3])$M&YDM:X8I5@%#'$84>GI&4-BR&C"81P3XDGF
M^Z%R*G1I+WINTT6K+7@M'[,BM6U#V -S._=W'"1'GAY:I<$WK35HU3;Y%T;Q
M;6(:W/UUQVO0+@+VTJ=M'>",RD&_ /<G]'!U?TN_9P^_IOP^O:.KC[DYK"B?
M;E;R5VEB^!8!]X(X"".8$(0@)C2"E/$ $AH'A 4A3PBW=FR[9<V-ERIM33^F
M6E_0*@RTQ@Y>U1F +;S6X6 ;F82Z$ ._U^J>#I!SAL[!_1P.PHF<S<N@=/,L
M[<#I]"///&(ZK]'.EAT?T?(6QV"?O%Q\UB])51SMKS*[R^GC?<KI\OI[6BP2
M'TE)C/,720IQ$OF0>!3# "<<,1Q@+*Q8M5/*W/AT6S_PN]'0D@NZL>PFT,$0
M&IDZ7<"QCRJR,;[#&=/W;SEB^E_[3EBW@&F"D&QLW(0F65W<LZ#OFA7R[VO]
MX#=?S;G*<P@\]BE%$0Z@4D$(L514>U.>A#3T0JS]*\&PTU+OI*2Y??'/BH):
M4\=JN"<1M5O(#8+3R-_] 40C)1.<Q6+0RJPGA4U;/_6<S0=53L_>T*=H2=\V
MFTWI5,MZJ9OF1(2*T!><P"@D$<2>$'JQ1@74*S421T0QGECUF7\)Y>=&8$.4
M9W[Y-\)BB3GC<1Z;@ <L[>WPNMATS7KY-\>E4LU\WZ")ENP?KH<J:_,R4':7
MR9E8IPG+[KP,VKME?%Y(AQ[NC'F.:>!SJW7C]_)6OS7M?ISR8M\/90AC1O0Z
M)Q$19%@QJ#P5H5 (%27VY==.RYF;DW#;5K"Y N5]F@M0UBH[\'H'J!:3]S!0
MC3S/5BB]KU!J] 25HGWVA3O@<IBQAH%MHLFE/WQN<\]Y4#JGB8[;IV/T\S;L
MD*_%Y?UVA$Q49Q74>2W^S[J.MGWN\+W@DBHO2# ,A>9(C!(%J6 $4AY1EE L
M8^XO5O*.:EZ_M=\<ZA1J]6(G]8M]('K$95939^?73*0JY;7__>:[F0@= V*[
M(4^X)WW) T@QUDMC1 SD"84^11X)@M GH56UWN&PGG(M.Q'(=GMS@T$W\K3U
M')D-GC4U!>Q:78?;HK."9,AMNFZ!DV[56=F^OUUG=U,_[G[S\+C,GJ3\+/.O
M*9?''?0/695&H?UNXXL7MR;#=_OOK[*B_)"5_RW+3Y)G=ZOT'U)4M3H;MWWA
M<\^+D.0P"4RW8QEH^@\H@[[R(^R;4L8R=B&D2;2>&[%]6>4;/>L"E<TV#=_>
MSI$UTSD>04SS&MA1YNP&=\*=N<V.V_.2N JQK6W=W8B[ L9(_=<2/,D2/-MY
M-5CUX1<9DB&I?QK%)YU")AV+_:EH6N'#I$SN9LU<<[V.-27\I/AKGA6%856Z
M-"K\E::K7Z3*<GE+OR\P5HDG4 *YQQ3$OE[ ))$?0Q9&V$L(D]*S"ET95*LY
M3DFUFL#H>5E27[]QLIM3)D=_Y#G#*@%PRRQ0V07VQNL*L,HVH(T;+TWP(JS'
M3![LI]B+IA1>A.6Y1,/+'MXSFJB-4KI1IC[&VV7VK7@^EN.AX DFD"C-O-C4
M.DHP"Z (2&1Z>4<A<5HV= F;&[5N=*UZ:YIR,)6ZSN>I5D#;D>A0\(WM3_='
MSCW<R *202..NN1-&W1D8?E!W)'-/3T+'6>K.[/!;3CL5UHV'/9)/M8+JF*K
MW/*[U7]+FK_5[]M"^#Z*9"0@QA)!C'P*DR0.(1<(BX@+GQ"G:AF]M)@;\^A7
M+W0LC-P+?#O2&1W2D=EHDQ)>%;F_ HT-3U? * N,M@.64KX$K$%K+/=29-KB
MRY=@=5"5^:*'7=[YW<C](#6OMFV>S1J[6'"]>)5QDL"$)GH1&]($TD 1&#(E
MA*8^7^*D;^OWXR+G1F:FF)[(Z3<@LF\K\-CHW[_/^PF@[;AL6/A&)J[=3N\U
M>1DTM5.U:?M>Z3Q.L_=N?,;J]GY"ZHNU>^]&H:O?^YD[>T1$?9)?Y6HMFST[
MLU.G?Y3I5RD6.,:,^R0V!<=\B*/$AXGOQ9!1R7S):,@\9AT1=5K.W,CERZ,>
M/;W.:%C>(;*G \MN*AD0H9'YHU$2;&D)6C6'0<HA!FH8Q*:*@;J76QWD-&L4
MJ:C*>V@$\T9M(+2/L;H#I;[V4>9I)JJ6=N:?#^E2%F6VDC\-%"MU'KS.6*F.
MVZ>+E3IOPTZLE,7EO9VV*N_VHQ[Q\GHEWOQ]G3[6D:^W^HE5IF?,@X#'OH!,
MF*Q9PCED)%)08A*J0,3*2YS"=RQDSHU96Y6O0*4TH"L!-FI? :.V4VJM"_S6
MOMR0H$ZQ"GU?$<>M_GUJ&EM67>('R\'M@<O 3MQ9L5-[<;8X'''CK&_MT_ V
M6^J?,S.A?)5;@09-'Y!/,GU@:_V)UQMU[^4=73;A<\7"XX0A0D*8(,PAQEB3
ME%E5^DD04KW:)&%H'_I^@2)SXZL=4P#=CMZ@3?>;?-L<,[$OC4&.\3H7#Z"%
M=SG1L(S,>+LCLA-/T_8C^K0_(I4M;:SH5"/BTLETFI&9R,W])!_UXZI<\'+'
MX\UE?6;]2$TA&)-E4IB.$MH/MOV8AO)\!P"\N]_G!<^?L$GGY2CL=M8<X'D]
MYCVS[5J89IU5Z)*>RGS?9PCI"4SX>BHC 20HY! %@E/&D,0(64]EN\^>V^Q4
M:5?U.:_U<V"V/= LIH_^4(P\(]0H5"V,+T3!@;+[HS$1"UNCXL:<Q^WN),.]
M6Z;CM^.Z[E#6B4MZMVC)'AZR517S6(50%C?KLBCU(C==W2T"QCB7?@1CCK2/
M+7T?:II2D/EQ$,0D\)/0*O+03MS<N.I-TZ*D4AE4.E_510GT6_JL-O@A78&B
M^O6/SGU=NM#O9KCA,1V9]"SA'+0!C 4REW>#Z1(R=6L8"X./](FQN:MG!/0F
M3ZBXS:Z%J#8PZ?(C3<6[U2OZF)9T>3QT>SL,^Y/\^SHMTK(-]OY8;3-O;8DN
M5"QB%4D&%5$*XB")(".$PH@3&9@3(26P8X>3:31W^4"GZ8SR>2N?Y]61?!['
MT.J)7@"[K=(9#NK(K'O]\=VKJ^.E=+8W(MH\GG<KGE>E]LT13I74LV76@('9
MTX[#H*';$ZD^;7#WM.-Q$/X]L?B>@9U5O_O=_@:;NN#-5U6\7DOCH=]^RQ:A
MC/W \SF,C,^,PR"&)$(F9CSV/,4"%89.(4^.\N?F3E=!AK)VF5]+7I5[ &Z
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M=A4V]XH^IB8PZ5,CP27*P19UBYB'$; <F\0V,&J5P49GL%$:_&Z3I-H?58<
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M]FJ'>P1(.UJY#)Z1.<01F1ZEX4\9/VPA^ ,I$Y=]/V7E89'WDU?V;,0MZLP
MNOQ(4_%NU20A-4=G"5+40PS!6%$,,:$"$DX0E %#$8X(I=BIKF*GM+E]]=>O
M7[^[?7?SX?H]^'C][C5\]P&\NO[X[O;ZO6,C[$Z([4A@,.!&YH-G/8%1%*:K
M35K;\&GI5J ,VE.Z4^"T7:%M;#_HZVQU4T\B.=KR^8-^5QHGFGHB8HDYU@PC
M!+&0'&H2T5Y$@D.?T<"/J-,!YSF!LZ.3XWW:KX!1N>?RY2SHENPR()1C$\QE
M* [4]?X0FO%;UV_)G$'_^4,$[)K('[FOY\(D+>C=76Y"/ZLF]$WJS_MT)=^5
M\J%8> &+"0H1#+7? G$H/$AQ@DTVCN\S&<:)<,K&.2=P;GRSJV^]S5BGOOUN
M= :5TJZ+F'.@6RYI!H1R[ 7.92BZ+W@LH1ET^7-.YK2+(4L$#I9&MO?U3 5<
MTJ*X456'O^?W'84X(4*OB# *0TTMFF2(+Q3DRO1A]Q,J L\IY>^8E+DQ2Z5D
M=;Q<=>?L3R?',;7CD(N1&IDX^H#DGGK7!<*@*79'!4V;2M=EZT'*7.?%/0+;
MZYB*&_6\A'J.$%VHF(<480Y1+ .((R^ "<88>C$/B/ 2/XFI=6Q[EZ2Y,<%S
MI E]7OC3/H'NG?AV,\*@J(W,"A,!YA#R/A1P$T6]?Y)-X5I3EE^"53>>0]6;
ML0&I,Q*^\P'3!</;V+$3#V]UPU A\9NDQF9?:D&YBJ7I8X BH;TK(AFD#$LH
MDBA)9.@CR385G&_MLX_/2[9Z\7>S#V\GR$A^=6^"IHHJL+LH9)/LW[N1H<4(
MV/EB P'ZHI'RS\G,C<ICALJ?@F?<6/D#J2\<+'\*A?/1\B?O[-5O<:E_SLSS
MOLJMN,26^LQQ&UTNS:^:\,1B$?@T"E020.4AO?:+?0H)8@GT*4N2B%(N"';H
MQ.BLP'S]P+^O::XE+I_T-[51&[3%)IW:$;H/BX6?.#+88R\JM[7?:S]2#\&-
M ELFM+'D8P/OU"%RU &8K'?DT /AVE>R-XIG.DZZ/W?*7I2]K=[K4MG_.7W#
M+/[/NJA+^-QFICS9BJ=+^4&6>F[+'N3[K-"_?T6+^X]Y]C454OSR]*608FNF
MN^9:V<K)V]2T8F%,,/855#C6LY!D'B0*$\AC@6@4$9Q(JW[ 8RHYMYEJRT9P
MFX&-E54HMK'0_-;\;.P$QCS]&6\YA\\6_MDU"F2$-\#./7_I<1UY4MP>TG)_
M2&L3P0_&R!_-GZMQ;0TUJ5<_5(.<KGX\.LJC5$P;<T"&C7<90<^)PV3&0_HP
MNF9$6?VFG;H"L'Q?KYHTO\JBW-1T(T'H18)!3\8!Q($701(@ 1%F211%*.2*
MN,P>';+F-@FTZH%LU=1VR]@RK0\.'?=0NA"V8^>!<!N99!LMVTIO&P0'+_EF
M <>0%-<E;E*FLK![GW!L;NG'&\W9^5NMY;%ZNQO_@P>>=CM#"04F(<3Z69 I
MP6%,N&0D\$7$K(HZ.<J=&Y^T(2%F5,'Q&M2]R]S:#H4=V8P \,C$,Q"VSCSD
MB-20G&0K>E)^<L1CGZM<;^]3>ZY.>ZH2R4TWN#SEI115","75;HI!Q9)%:+$
M#Z$D'H68,P))@@5,>((\WV>"2F37C,!!JLL'-5V_O%K7NL4U6!MM 01%D_A7
M%Z.@5>=7ESILEJ/ O$C*!,$((1.3&020Q(& (E8\"4(2Q=R^_<_P8S#-K/&B
M(V"Q63X\KB-/%FW2:J4QV *X#L*JE.Y57- .4I=*@X-#.]'.]XH.55K0"8'N
M.H-VCYJPZ*"3;;L5"-UN[>??_TKY?;J2N>D29.JL/)H7IWV)?<QQK"@4B4 0
M,^1!@A6&42!40B(OIM)I7Z!#UMP8>:-J%5>Q4=;-8>_"ULY)'PBQD;GV!%@C
MY/E9X#&D^]TE;E*7V\+N?3?;YI:>C2%,]:5/DLOTJRE06"Q0Y(6)4@0B2CS-
M$XF"VG?&,-#^&TD2'*G0J0S OH"YD<.6:E?@VWW*[P'-3;52OER+Z@0!_.DV
MIT)6WT-6E6C+M\QQ[!NQ#[<==5P"XLA\41>MV])MP#81)ZP>M$/$OHQIFT.<
ML/"@+\2IZ_KWO\I6E?-1EQ*\69=%J=_O='6W2(2D+(H(]'T3]8Z2 #(9<LB#
M(/%\@J7O.6W^=0F;&QG4NH*BTO.J^2_(GA4&/Z3MGW]T[VMU$O, 85_X)($A
M5:;%&&:0*B:@2A#!-%(<A^'B4>9IIEU&FI?3(K\O>#S\?Y%WZ6IE<&9T61U,
MC(.W0HRR("0P"% (L8AC2!&5AB0HCG@LF) -WF]6EGU/AD6[%3L>UF_J%WI<
MH.VFMZ&@&WFJ:]BATO.J*<)Z!;9T';;YVCE$ANZU=E+>Y*W5SEE^K)/:V7OZ
M397_2?/43+G5:=RKK"@7E#&?\5C/BG'$(,::-BB2 O(D"H@?$RR(4P+Z@82Y
M38JM@LV9.M<JNC'$(89VM' 1,B-SP0:4YN3\51<JSI__2<N'_.8/A4SZH9^T
M<?_K/GUAC].D[</U-J #>3C63A;1WI<O])*71I 0Q2%!/"0DX$'B^S9M$$\)
M</J@)\@W:H,^>O0_/(FAQ;'#A<B,_$'O1<*<"X"Q0\7AY.!"="8Z)G!$R>WH
MH ."SG."8_=-=RC0H?7."4#7=7W#>0JI;[J_7HG7\JM<9M6V8/ONQ8('A"8(
MQ@'5:QRIU_'4Y#;%2D21C+$7QHE;$$^'M+GY+*VRU:;=QSP3:UZ"+;5=@W6Z
M@+9S9@:#;V0>W$%N2]/A0P*M$!DV *=+X,1A-Q:V'P;;V-S4L[70FA7R[VOS
MO*_/!UN^$BCR0P$]&2B(HXA"(F4,$4-^&/@J4G;='3NES(T[GI4$)KK)D2N.
M VG'$1?#,S(W;"%3*3C"H6 G!(.VB#DJ:-I.+EVV'C1<Z;QXXGYB3:N6K6V6
MWV1Z=U]*<?U5YO1..S@RYVDA/^8IEPL_1#P*.85^@ G$FE0@"3F"-. )CG"8
M"!^[;V]/I/T\=\JWE >TK(JFL,WF>::J7]3:5#N[PJ1&YH7Y5;W+Z[C).]F;
MPH(0Q1&'L30MYQ"-(<4,PT@BY!-.E:"1Z\;\;-^3\??XC[PETIQB_V'?#\MY
M='XC/O;,?'E#NDW+N2WKKT!K/V@ "T"H()@!DWG^HW9++K-.:K^QV@SUV\\
M!NLOUU-\/P?J0U;*MK?K;?8+7?VMC1D.)/*1YWD0"<X@YJ&OO1T9PMCG"541
M33S?JG;@64ES6SU5BK9]B4UF=J6KVVQR&E8[_A\$K)$9^SA.(ZRHSH(Q)!6>
M%C8I>9VU>9]NSM\P4*35];J\S_+T'U(L(C\@,8\8Y DRF=I4P"2.%/0IE3*6
MD=1<<5&@U;.LN9'$\3@KNM%WP&B4+<#MR&,@&$>FCV.Q*.!9TQ$C40[A(
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M_KT@U*DIK+7DN;'&]:M77W[]\O[Z]LUK<'/['V\^_5_JWG5);AR[>51O@[
M=G=$84R EX?E7KTI:/6J4C54^'O_Z1@:N4GJS,FKRH6W[Z _"2]V0"3)#%
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ME.SU*"F[%+"PZS9X'BOC_L9B*/F;+?X/._RKXQ6/+SX 0OOW@=BH'7YX820
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MA:*" :1]2NQ@I9H!0-%6B"3,I$1YK53?_[QH^/-:NFVM2^,%8^@\R.Y[H#T
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MZV<M:U?I_AN?SEQ8^NUB^9G/CL^YI':QIVCN2D\SN_(K7$WJ3%FW!N4I99!
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MJ6<:: JS2RW$AM#$V=I/"ZXCD9,0FAI;5!6N-[K8VKPN*-K4,BN$=W3MTEH
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MTO>KE5X_"#=V6KV;VP765[?^>KM8OIW.G51\>?)XIZLJ#((9HA@P0Y3+3\D
MQSH'B' C*4.&JZ!JLITM&1O9EATI]?97.N&N+ZM$UWU098D04W4CF96ZK;.Z
M(]-0=9'N8^<9Z!UB1/J.!+L^@(4!MA=)V8VDZ8=3R6UZ4@Y+W9=*J;(/H=R;
M 8T:4NYLS+ QYULQ.PE*W_S F$6Y]Z)</WW?75('P4JB_["HU^[549)=CM%J
MK]C'ATWI:10YS(V2.3!8:8 AA8";G (.64H4@D**""6^XQH]-O[>+Z%BG9G2
ML[$O0QV>/#EHLIE/+<'_8,FD$D'\,49A\<BOA1_?CVVP!PPZ[W?X(/=(?$_.
M!J>K*+0K;EKU/*G/X.WU_2[9Z[V]MNQ_WY73^QFM_NNP1[9[!%7=^QD)OQKQ
M/;4]\(?OU+*C6+;]4AL]76\L*_RFW6?=+HV^Z27_HG^V#U^_YFO]ED^7?^.S
MC9XHK16D.09%H2' !<J!2#,!-$RYT6D&=1Y8BGD<'0MAU&'.#=;66[IT7T6U
MF,WX<N4^I=47<J@/9-S7I^=/Z(N]$N/_R)Y^69-*A&]MT:FW?^W'=@^@NZ2!
M**DQ2DJ0$H=2XF!*2IQ&\#'N9=Q'\;F.V[-_C@]Z+Z,9[9/?CW6WR@Z>M[4\
MU%N;Y=JK^KA:;9ZJGQU5Q464Y[+0!5#:'98KM 240 HTDA#FK""I\LK9[L>\
ML:UPF]Z5ROWE(G91+6+XK@==-02C#*?GQ_;%!JGOC^;>^+1\&"O-@>T'<-O%
M9*^/O99+[F< ^M$0C&+A"XD'QD3WLFI@U%;"O@JNK/V;^;K\.ED"Y'(]_:;M
MYX:_VBR7UI*)8E3K5"E M*5V+%,#.$H%D!DIA!1*"^VE)WNMH;$Q=65KLF>L
M\V%Y4IOK1])7T6VGVYB8]4R<7>'R9CY?+'8<MFI(;*7E7[XLOOV[?43%7_8O
MQ[1U]?&#$)!O)QLJ\;X^C!3*"N3+[Y-?/T\(TX1Q:$".! .8<0E8QG. I):0
M:H-3COUB-[N'CB]N\NM?/E].C;@$3?O<[=;=GF?IKQ_>/;YYG7Q^O']\\_GV
M.7G:QY;95U]<S<#Z'\>S<.^!@\RWTPXT,^O,;[HMMS[H]2N^^OIQN?@V55K]
M]/W7E=ORW!;_NW=SMDQ!V!Y"SXG1'(L4:%(8@#DC@/)4@2++J4"YE#D-.NL2
M;L+8/L;._.3M;/''*GEK!V^OMN7.]O\(6S=U&!>_M5&_:/=,$$X1J02[,=]%
M"']P/4BF\Q_/XMZ+2$!W$&.N83I8,>@ZI3M*QVN1&Y[45877KEE<R3S+'E5T
MS!U3W.D0["(2F! M&(9 :RX AB8%-$,0I#CC4-.,Z["2=]XMCXT$]PW_MSHV
M'ZK,ZPNZ9QBH#RC[CO"<0;$ZT;VSNZ=2R<%PQ97U]6U\8(G?0$Q.Y7Y#'Q O
M;+Z_"[ ?K:G9\OM1;)6E2!>%P<!@H@%.4P:X=>4 LL2&D<1$0'1KJ#S,I-%1
MW(7P^"KAM?VW!\<#!ZU[0+R_H1APY_CLF>#FX&_3D\%#W=V@[3N\'6C5BX>T
MNZ'H$\;N^.2NI5/GI4?ZVW3]]=7&TL:37G[29C-7N[1[*(G"2+N<7"<OA5,.
M!)$&I()F:<X0$CH-2T'R:'5\<:Y:.;7,N5_J]689NMOH@[4?8T;&KV=*;*Q-
M_K#F)HV]=TEE<1\G%@+PB5MZ]7JS ]=@]<;AM!BK_ZW=J*<1B'I<W$OK>R[U
M+UQ^G<[U\OO]O$SZ>':_GB!AD,@$!")#!N#"+F9YP>P?:5IPR*4RQ59-RX]]
M_!KVFD"'LEH]$]!'^Z"O[HR/=?"V9H91D"?F?BP4$<=AB&@K2;9>)+7)R=;F
MLI3A=5B#N2@,I9ATY-GRH(P4AL8Q*07>W74W_Y/^,G6!NDH/>6)$J@0Q&IB4
M*V"7G]3Z]WD!5$IXEA%.E/ J:W6I@;$M).OMZ)V1I3IWZ*;]$8B^F_7=H1EF
MD]X7E0Y[\^>[?O.>_-%C!]Z+/]^ITSWX"]=UC#=MQ$K_8V.YX(TKA/!HGU(K
MZ&N!,VI2#93U*@!.,PZ8+ Q@:8$I(Y(C&%3X_6)+8YO4.T.3TM+$F=JQ/L%E
M>#T#/C% ZSN.TPVO\ C--2RB!EXN-C9L/.5:GT_")%=ON+&<Y8,Y#85OMZZ%
M8<S^/P8%A-+53D) X#0'M( ZU1HR1;S4PH):'1U_-$:7V;WG]H&Z5AWP&P3?
M3;7(T/:^H18!U>YE,7U0ZJ4\9FO#+U,FTP>+B^4RO6[NQE';-()2UN'H@(O;
MJG/)5I^L'1^U?2GMXAWFRG D4J!<K 0CI@&'2((<:>B4PG*6YR%T%6K V)BK
ML1CP^E"=JFU.ENY<W;_^"T40_C59;--S2GV;P-AN\"CY\5F?V/=,;;MTI]+V
M,X<;&_L3UX&[I.Y"/)KK"EY,Q@NV85#RZXK0,0]V?D[7@I=RZ1IZK:O_OIN7
M1P)W5NRDJ2:2&&YY+P4B%9ESWAC@A40@9QK2W*2&ID%L&-#VV(BP,=DI2%5'
MD=]WU? *&0$_INL)UYY)KK$Z^:&Q^\<=NGL,Z(%SASJ9P8C%K9?IW_S =3.#
M<3FMGQG^B YJK[]-_UP\_3*57Z=?^/SCTGD@Z^^/?RQJ_4U20"ITKISTAUUW
M8LD I9@":(I<98BFBGN=#O9H:VQ455I[ES3V)HW!B;4X0-KT"L#MS!09MIZ9
MJ VQ+JJP5Z +T(:-!^% "K&W01DF!NL'3JLD[)5'#"<,Z]>7 WE8SUL&5G"J
M$Z[V%*6.7-HW?UH_=KK2'Y=3J3\M9C.S6+H;)X03*F1AOY<8$X ES !EN?4V
M"=$Y-T61X2!O<_@NC.Y+<+QJ; Q/2LL'$F7J_D9XQBU'/<Y]!T%O%UO:JDD<
M:!=>>7?ZB:V^V$B.0CZI>R_^.:22;AZE:+)(MUO2I3[%C=;>?_FR+'/EWLW7
MR^E\-96E*M-VET?F2$$7GI$T=]5Y:&&_GUB#(N4F0TI!5E#_,A?]&CNV+^76
MW&1K[Q6]N.''UV/%-:)1Z_F[MQNPZ6@'+*0&R'@&;J"%XH?[6"5!AH&NO;)(
MSS8,6*!D�/ZYP,U&;'/607O?RPF&_W.-_-Y>+)>@AE8=+M9,]R*7A*(4!$
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MQC2 B H#62HQ":K)=;&EL:T(G'E;9:?D=V=B!ZF]\Z!ZNNTQH.K;SPY!J9/
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M#^:3EHLO<^>X?]3+Z<)>MUJOWD_G^MU:/ZTFUK\616$44%!I@'.= R:(LGX
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MD2^I=7-N+(U$1<$4!$0R%[AU>LA"(9 C(QA/,Y(67E[;2X_DD,[?SL1QC67
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M%C>7&[KP^(%+#[5W\K0,T97KN_D$9^L2UT[)ZO5&5^O>S7*")3:I0@Q(E2*
M(<F!D+0 ]H=VT8FRE%&O#?C0AL=&&F6P15=B&,>Z%R3,<_#&WL^=Z /1GBGE
M4G'R.W<J2^CR--9=$]_:1*ABUA6KF%Z(=]N#NB:AB!S[*\'W=R^AMM.E?N=R
M%?1J_8FO]6OKE99')ISNO2(0*NXT@6 N '8%SVFJ"R!YP03.BSQ704>K_)H=
M&U>]FUL_G5L0:WN3I378Q;2DVP;\$I@5Z0F]'UG%![3OH'NI5[:UN(P35: Z
MHY/*ZNCB_F$PQ2[5YM'RX*7;_-$X5\HMX.Z.\?V-6.E_;&P#;[YMQ86%E"3-
M( 62D!1@@3B@14I H1!5E&94:QX4F3_3R-BX9V=C4AK93:SY+)R>4? ;0>H[
M?AV*3WB\N06 J)'B<^T,&^-MZ>E)=+;MVFYSOO%R'A?W\A^;Z5+??^/3F7OP
MV\72'?_XK&4=,G,<-"%&I28O,H *S &VO@C@1MB5%7+%+(1412J:DDR/_JP0
M:(;77#BLK?0X &]\M _ZZBHDN+#L_)MN9!JVG0%FL02N.V%,$CI(?B33!^;#
M\$]C>:E_4=E>R8SL++X[ GW5!GHP/76$+B9SA9HP**EUQ.>8[[H^ID.N]ZT;
M7S^[U"RM+A75:(Z>;/C,!<;1Q&"*%,888 4+@+DJ ">6456F2&;_R'CJ53?[
M)8P?F[M6FQ^0<COT:+<3\MC'L&]O<MNMR\D0/]7)$&=R(9I4B*1&H*U^T1X*
M916C!(WXI0E(V![QRS-0YO8X7Z*P].T7&L76/.ZA;1HNH?N%T#[(['XI&[JM
M%=_PI7OJZJ->EE9]7,RF\ONC_G/]DT7U[Y."(5A 5]4KH\SZ-$Y(07!WJI\7
M*84BESBH0L>5]L;FAKQ?K%8NB%J13-@*[QJT?BNZB(#UO1]?6[K#ZRZIK$U^
MK__KS$Y*NR/&E3P1BKE0N];DH LSS_X?+\1\;^L8=W8B295VX7XTNVQI=5XM
M9D(*E.6("V"01 #G!0-<F0P0K0K&=5ZD*"PL'6[#V/BG[,*YK.)::^J&JM\=
M!L@ST-TO[$.L7%:UO.I=Q6.KN_-IV_LZ5=S8]Z&IK+UI^5:$Q\V[XQDUK-[!
MC&&C[MUQ.@G*W_"H&'D$]38=TRFEE@49Q^ZH78H!U0@!0ZDQ)E6&Z"#?ZTP;
MH^,[^56KS:R,MA\F_!X4M>^T=W<.XB[) :/;N8N#V8VY +UMYYUKY@5W^5LW
M\]HNO>%\W@G9G*XF?SI>3;[YQV:Z_K[W CRLO^KEXU<^WU]GKM[5AXN/EIOE
M+U_SM7[+I\ORL,<$H[2 # D@4Y<TP"D%3"F[,$2$<JU4FFNOK.S1]6QL'-B$
MJYQKIQ:S&5^N7(Y4Y>:%>GEC 3GDJ. 8[!T3O]]^LK!"Y^!S4.*3K"U NW.'
M%4:NW$"%TMUIR+2\)'%0)0ZK7LXDCFG\HQ]A'$7GAC_Q.(IN7_+V1V=@-U]A
M6_#=U3N=+59V%7HO5F6T>)()6B"5(8 S9=<2'$*[JL@Q,(2@(N,%SW60'&M+
M6V/[GFY-37:V)K\WU@8N(MHP]OO$14*NYX].5]""&=\#CI@<W-;<H*SHT>]C
MGO*YI4.:C-M&<L>/'RT?V:7DPUS_4IXBFI@TRT@&,[?90P%610XH0PP8"#7'
M2 F8>0EXM+8R-K8H=W^=6N!=8J;+U=KI SJ# Y(*+@+JD3(2 Z:>J6%[7KW4
M.W-6)M;,Y/?*4$\^;0<J($TB!F #Y3-T!2XLX^ :(*VI 1=O'FX/_YK]!YOM
M5R_N6NC=+KO%8LE=P? ]1W!'O+MM7*$QR0B7 !&= 8RH CPK*#"($,%21GB8
MS%% VV/CSO=3:;WG4FJ]$:,+%*\( =[/W>H)SIXY]L#J@X7^OCO6RW9Z!\#B
M5FOW;W[@ZNW!N)Q6<P]_1-3J[M4!AH."R]O5BU'2$.O9 2=@[[*7)6"Y932>
M,\X)-I29H-VF<!/&1F=E&?*WL\4?J\25&DBVIN_5'O^/*#7>V\;%C^;Z1;MG
MMKM2\_T<[KVL1;N#.$ 9^#8KQE .W@,ES[+P/D_JZM<]/2WFY>Y^M9=?5QB&
MNE 9+22@@C. !=5 "*T!+ S"4.1%@8,*Q%]H9W0$5YI9YP_=U?]-IJ6MW3.+
M+H'LZZ_=#%WOOEF)6FGB+D$H=CWF*SC$=;G.-S6P>]7:WU-7JOWRCOQ@V>A^
MKMQ_7&S_&Y^Y)<R]9:GE\KLEI&HK4PN&<)YRP GC3@); 5%( ;1"6!>,28:#
MRL5[M3HZ[G#?:SY7U8=[S^Y LO!"W),Z8N/8-Y%<@O#.J?XV5L?>8@U"*2K-
M>#4\+.F$8'%"04$W=ZE5=&&Y>"_ETG+=)SU]$AL[T]W/'LR[CW6YS94UZO-&
MS,I@C/ZT^,YGZ^]OM5Y-,%&DX"H%#+K#'!DJ@*4J!7*&I.&0%H1!_ZI$D:T;
M'<$=A�:YOU<5DN=_'4B#@X[8(<#FQ5]N.)LNJIXG1OM4W^WD'//8@7G)D
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M.&,L*X#!4#DAM1Q0DVN@*<N50!QF65"IH@OMC,V%.5*@2'YWEB:EJ3<I=^R
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M @,%]TYD?K<]N7/NE=#6PYJJNV3;'R<05?4H<5V*'0*\!=;X$<).UKQ /$6
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MS=X73K%?Z+(\K^M&LM>/T+ULS]'PC"[%Q[CO<-$^O&<("
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M0Q;'%-*4YBS3SSY'3LJ*3J-/C0AJHTX531OCN\42P_7+W&;'CB>"81Z82$Z
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M4BE42&2Y*EC$B7V?W N#3&V[X$P15=M0RB6-]Q*B_93G"Z?0:0)!(7)(=O8
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MS7I#EV-BNALO(!.9,4! 9"V3"'S@%3J-X!2D W;KB+A-97@XF#C)A-<\_DD
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M?MN-.X^W-''P@WF@E@\W&O=:#2+\8-K33L+3 -2+C\L5D9RY)/4=]XI+'Y;
MOY&?Z4+<*4V2_RUI^4$_27,2%URHU.B712:Y6W#(5,1A0J+4M(:/<6'?W\M^
MW*EQ^CX>5<^;YU(:93&'G6Q7U/M)-R"6@2FU-1K45G=45V=&E.F-!,;V&:BM
M!\9\8.P/ [%#ZF48J$?*OO0+N5L&ICMPO4F8#K<;+P_3W<>#5,P!EP=22+CX
MNMGK-*S$9_W=^E5_V]KS?XZ*0N2X@$AD&"))<\@2SF&A<$IC([[-G'(Y0Q@Y
MM5=)6T3>!H4#TS$"S*7#!M@KSE#@%U17[R5 ]D<X[$8MJQ]BY[1JXV] VKG
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MZ3_^9?L;_3^S+/J/?_G_4$L#!!0 ( +&)$%.$CY@Z$HD &V"!@ 5
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MRNCNCIC':=@.(P.^%>U,P$,"ROO98HF3_W?\=>52.:TE63X'LO@(BOX!Z*P
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M8@X6E<K=I5K<6WP[@ S_=O, D?:,B9.S/$TUA_GU!#^/G(DF&,4@RTQ@UJ:
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M9+'(R\4UJUX+XZ,24&(1%*@'">@" T<&TB)*5^(C#NKAK-XEHY^:]V:8N+)
M'<B\QZ/IBOH7N/AR,DWUKU?_=3[^AA,2U>)D^0+G\PN*V/\#)^?U^E=J*3&!
MBXG.6QY-38//$%.4W'E70GJD3/YP(&U%7;_X.D3]L]:Z& # 3K[AF+X]R:]G
M\X_$T?I&<9P7+W-8WOSK*G=%6AYU8AJD3>3T)QL SH0PD3IC?$\/G(=UX'-
MVHW.?EHW- !=2_T, 7XQUL+ Q8<<,^THXO-=7E[G2;GB9#;E\E53E<@!/86:
MY#06*XNTSCS2YJ$#K#U!5#_M'UH JRO)[XTBBC'"K",<O9E^([IG\PMB8D01
M2M12.0A9,PH_>4W;UK0'G-$V&RZD?"33]7#<W":BGVX0#7"RMV0'8%W>S_-7
M'*=7?W[-TT6FL_MT^84"VY5PK@VFY\01$M2+6KV6"?"R-BDK7B7N61*AB>^T
M!6W]=)%H@*&N]3 :-TE/I'79[670#(B#HQ#"(+,IS4Z>ID+\X\E0785R>T"
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MI5B%#'/FM'5"+B"#"S(HR95[I#5A!U[^0UKZ?5 ]"JH.U< 0/38QOB0R_DT
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MK<18)C5S2QZUM:)-!/@D5?W>U76/H>Y4, \W9^>LN8B:8.).T&Z5K4&0E'$
M:K4 *[1/,@@C1),V,H^3T^\U5_<(ZD#H X#.%J-/UHP%$\F:^@Q9E7JOHC.$
MH#T4YW3$XG+437)QMZ:PWVNJ!B:JB6H&@+F/YV$Q3F.<7]3WCG5@N_(BG73*
M<<\H_!!8XU@-@>FT&KQ2;*H'>YMX;1-% WFBZB!6ZT3F0P#/#?GO\(R^O/52
M<+7I4A"ZD)95J07SF1OP7#$0.G+EL<JP#8J>):WG"*X;#-Q'5K<*Z1%B]=YZ
M]//L_/.7Y<M\[0OJXJ/V2+N.&9*--1F<B0:DUXE+XZ3&>U[4P_OO1S^Y9S!T
MK+995S+L&P#OS\-D'$\+K4QNW9H!"B(S:DMNG**MKT)P$(SSD!3#:(*3N"4(
M'OOTG@^9AD X6)9#.'"N#N&WY.V_H2_)7!*6T:""7.J#,S(+9$%)'DQ'SXM(
M,35QA1^2,I#<@0[ODO>3\@!P0A[Y/.,BO\R7?[^9/GRP^3";3%[/YG_@/(T"
MST$H'L%9CW4;:' D)N ^),9-9J[-",8=Z1S(I?.>L'A0-MM.1P. X).=J2E"
ME.@YL2&*JA<3##!K0UL4M4-R\ QO4I%T<*?PEE5)[="P2]/P752S-\R^TAD\
M2[2AYLN.SL6',TX9XU9( R$;"TK'!+4<'8HGOIR.A:DF;0#VG +:L@+I:, Z
M4 V#@=/=I.YB.8_%2I)#(HGDZ ')BP 4B#H7&8IK<CCNGE'?LG[H:"#:7_B#
MR*?L++W:HH^IWH.HE0>KBB?GE:QQ<CEH[2.SMDG/RZ-FU+?LW7LTQ/:B\L&#
M_8 D:A=LBII5IZ..*Q$^@<?,P;HBR.763.LF[F&/.?4M&P\/8B,<"0Z#V!8K
M"5\.>'IY7F^;WE\Z*"MG^UW^8_6CQ:BZ1#'S M8:<K6+0@CU#R^$R(S\\"@;
MU2=N0U[OS8V/Z[9VJZX!!. ;N%IU$;QA2@2EK>$>&"(QE6T!KY"#B5HXBONL
M;!.);T5=[_V1^X;@ <H:+@(O]]6'O%C.QW&Y'AA[4D6XLO@DSI+'RW/ZG5%1
M)4B7))A2&_#$:,!KQZ&HD"(O/+G0J,+@0,I[[[_<-W(;*7FXJ%YMU:WX1<VB
M<T:NZV9C)'>FE ":VY*C2I[Q1B\VAQ'>>Z.XOC'=1L5]OS'?.-R+Y>QN*NKX
M*A5UW6GXEUD:EW%<Z?RJ :,M7FHG-*&M/LHZI^I<;P&%.9&RXYG?'XZWX37Z
M,#KZ[TG7')W'UM8 ;.TM;C_--J1)K[E=S].5Q6.RL<HTUI17DJGC/( ((12T
MP7/6),]X9TK[[X)W-'/:5HL#@.F3/M!5/\F\JA2G7;A2\@AK@UH3"YT.H>Y$
M6>J=-@>G?4RL>&Y<DVJN/6CMOX=>WR=_9YH< %BWV8V/<[H2SNG7^B5Y]B3W
MQ7B9U],R+^7T(<?9Y^GJ$T<\HZ)#WH.4I M5_T#D"HRA<+4H*T-N<K-P)/[Z
M[^@W*/M];,0,XI[WR40*E(5%H1%0U^*;[$/M.ZU %XGHA$U&RQ;X/SS'Y9_B
M4:XSW1R8E?!JFEJEN+"D,\_"$ -,@A)HP-'Q \5J$S!X(5,37W?/%!?^3_'&
M=: >.D53;QUY3C[^_?7;T]]:=S6]7N;(W78>9Z_[WCHO</'E]63VQ^*F(6^)
M0:+V8.IH396\!6^, -J(/G/-I1:M6^H\(*KC3CJ)>T&.,4+PD==FP J<K)M/
ML>"$3PK;I%,-M)/.81AXIH'.+K(>0&BRN2C,2(^A2#JF;9UGK$L"Y$Q!DBQ'
MY5RVO$W[I8.*,8_5.&<G-6]=C+F+S(< GN=KAT)QVC*C0<A .\N2[^<E"^ *
ML<.R<EZW<9B^VV+,G3"P>S'F+@KI^YWDT?HQ#!R+UP64(2=2%5? )<%!!Q&2
MBLF@WN[U8^]:O#Z+,G=2W[.U>+O(LF\PG"R77_(9SG^O+W]WN(A.8Q1,@]>L
MRB34<5,Y@M0I2\5YM$QNA8B-2PR^1'-O6'0CU2&<10]+Q3(OTM1VP-$H49^$
M,UE2])!JHV"7* AMW/[O[4YUFL?J(W&0ZW*8E > DW=Y6?W_]_/9MS%%EC]?
M_+K(Z<WT]&K6X0EMJV^7V>)7T8'DR2@G"?K<UUDJE@3&,QW+6J)7D05L-M]A
M1U('XB+O"8Z'52DM-34,+-ZJNPE6YV13 )9-'1ME!7BA+%@KA,+,97%-RN<&
M-$:DM<J?K'O:1?Z#> NY\TA47W6F<3S)=YCZ--M5GL8I34>\!$\^("A!>]=+
M4>?G)4[2S"2))E-%6C#3[[%[9##WCH8!&-27F5:.XY6*Z>M)7A>[G)S-YLOQ
M/RZ3!RBXCKH("276'J%8_9]@XJK4A1M73Z8FC5FW(:Y?\]L_A&:-]3D C&Y(
M:6%:V.P]'3=2ULZU44- "L6EL;7-#I*PVER4[9]_U,QR#@Z''>AL ,A[C>/Y
M*J'Z1KZG99T%2.Z/"R)*Q\G?80B*!%3+K&K:JE02M;+9-KGO?Y*J?FOP!X?#
M[C0X #B^F7XC^F?SB[=O7I]^(,W.OZTSE%[0=ON<1U%:X[/6P R9<X6B0(@6
M0>8D=43F4#:9\_4<8?V6V0\.E)WJ<0"XO);3VYK8\J&.W#TM),*3Q2(O;WL>
M5QG^2F=14N#@;*@IJ11".B=J?[P0,D\BL]0D[6Q70ONMBA\<;IOJ>0 XOLW"
M:7D]GB))?/KYQ6RQ7) /_7*\B+/S>FXX&T6RI38I#U6(+@ FCZ MER[2N<%%
MDXNG;0GLMRQ^<+AMHM<!X/5O.)Y6:9Y.B86OL\7XDL'5=ESPD4I1\:@L(#%1
M<_X-B2Q$8LDQ8837I4W7S:?)ZK=>?G#8[%"'NR/27R)RFC_7IOF?.KQ5"LM;
M383NM1?ZD'$R_D=.5ZR/2BPE>$3@6&I+(9[!T48$[Q5ZXXNAXZ+-_=(N9/9;
M+C\XX#;4\:% [B;VW]@+Z(JGGW.AWZG-?UCF!6MR=LIUU&G(!M!H27Y."B8D
M6:)J4B>W XW]%L8/#KVMM#L(Z#XL-;@6X[H2ZEJ&M 6%U6C ..] >9T !5/U
M*CC0\>)-+K8%<K<GL>>B^<$AMY%R!^#./N3L)%XZYB3W//ZVRL59T<Z2I9 2
M>4WV=. 8+Q"#5TE@\%XW>6W=AKBA=6?N!AC/XN] +0W49%Y=THUK3ROOB[!.
M@4"105DF@%B(P(O$H)DR=#P<!W2WJ!I:R^8CH6U?O0P49N_G^2N.T\LU1>N;
MLY/IY0BSRS!PY"RSK*"$9)VN$J3M)#T#=(JGZ#%FWB2?;C]RA]8&^DC [%R3
M T7LE;E_CQ<K6Q^,UEDP!%GY4CH5\%%ET,Y)IYW56C5Z='J&LJ$U=S[R<;R/
M?@;I!;Z9+LXI/HOY[1C#>+)RI4<EAJRE%.!-H8U4[\0\*@LRZ%*$83&D)IW'
MMR-O:.V4CW8V'ZBI7K-$5^4=3\AN]>IUQ=G%R)84B](>4A015*BIAU&EFCP0
M4D#/M+L7B6PHHMEZR:%U.^X450VE/TBKMO(*;KB[M6$4,SE6-U;PVK!)>@&H
MT)$P52R1<1?CD09=;:1Q:$V/CV3?NM'9(.'X8C9=2>RW\?++B_/%<G:6YS>[
M3?AH'?<<?*D)*4S4TC;I(:!S06<9'1[IM'V2SJ%U-#X2++O3W2"A>5^*H[SJ
M6ZL-,%$[UZ:2(.C@Z0! %Z4SH? CW0'>)VUH[8>/91</T=#!S]8S6O'(E8XC
M1<8]8<W0RRE=3J +P2O0WI/%ETJ8-DW?MR>QWUN8X]>EM=#<_N:P-2;K+>AB
M@R"+=-%@6;U2TM[.M,N1^*3-)[G*2;C 6I5%[DCJ0*J\W[:LONU*4P,XFM_C
MQ56#S?A?Y^-YWCPXK&:'C&+Q%.C2CK:!/&-5A 4OZ9_T13!!&X>A28'$CG0.
MLH*W,]C,CJ?#X22@D31CSFGQFL1]V0SD&3:M1ZL,0^!6*U"<&?","6 L*(W6
M2>V:=+[8E=!!%N@VPVI++0[1GOZ"I(!IGE^<3%/MV_FU_GB44G6960*)3(,R
MOH /@0/YTCJF9&P(30H=MR-OD'[FT:SGX1H;Q"O?]F(<H93&.I;!8Y3$FV44
M-"8/7'G!M0N2:^S7N^SWW>_(B&RDN>%&/M?E&X\(,IGHO1(2+#=U.+PA]UUE
M 847ELB95P&/V7?H"5+[M9K'B7RZTM003NI;GDB=O%'?.$_+V]GT,_FL9RO?
MPT7TF$N!*'0B1SD$0"LU2*-T#I9);9I[D(^3-LCXIC-P/.$S=J"I(6!O[7.<
MEDK]%4^KXK61\%HD8^JS9UZU=@\0<HZ@R?O(Q2L>7)-WF2=H&F2$T@QM'>EF
M.)'SA_SUFJ=WLV6^3B,2M#.2IFVBF:X3,(,#5RSYM%)E9T-RY$:T@-HF@@89
M=[3"62=:&0[('C?2MZ:AC(0QR 3)J83:6DZH.IS2UAZM6B!G0A37YNKP.<H&
M&5P<]S#=5T^#.DNOAZC=&.R@H\3B$1)W%(:Y^C(D)()QB,DHCC8WO:Y^C*A^
M$PE[.TT/U$ZO=RJK1#8RV.?S^ 47-_ME->#ITXR8?'7V=3*[R+GF:]0I/23)
M3_AG?9M$GXU($IBK4_J4M!"*2 0<*V7D(7%_KQ!Z0TKA7LOWFUYX)*P=23O#
M.6NWE^LHDL&.P5KP+HEZ023 H<N0-'FL/$>4ODDF__8D]IMW>&1SV$AS [C:
MJVS5_Z\WYM]PDE?%@U<CR^L/3J;I[C=N_>9EIZR'24AQ<E[WZJL_:6-//^</
MM(U>E9+K_2J&H)3@X'@=VA"+@D""!QF8HVVLM6_3%NVX;/;KF79\I3A@A'SO
M^V<48O+*<PX^"?*D&")]Y0JHG(S7/,;HVPS]/(3J?AWA(:%[)_T=.,J1^)XO
M!P#9[*5$&S68&&MNH*D=D R'R+TIF3G#3).'G?:0;>9/#PJRN^AO*+-LS[]^
MG:P$B).K^8=OIF4V/[M4X96'I\EU+TBNE_9(>["DFEF/ KA 9454PO,F'52V
MI*]?C[EC$+;0R0!NI=Y,Z;-H[]1AY>3TCZ(PM$68 9'0U*"!_'HKB)OH4XKH
M0K%-4BSNT='WO+\&NGY0R;"_X > FW>S:23)W.1Z3--U<+C:;#?C6DD:6:&%
M5*I_:U4!#(4#T[8DHLSRTN1J<VL*^ZW<ZCH?HHE>!@"X5?UC;>@_SU_R=#'^
MEB^[8/TZG:_[_?W]\L+LIJOEK1:!\_&"?O3RO([,NPS1;GJLH:KM59T%XV*H
M(RD"[3QR;"7YN.36QH2B28YC,XYZ3KIH@\#[_: ' 8<![(OKYXJ<^,ADY:R/
M"D(H1+N+'KRHC2^CQXPEZM F$>@V$3TG81P%?7L+O3/ _.M/#\1+!\COJQ^M
M?E+_JP^Y_%#__O7#F^O/GQ/E?^3)Y"RGO]"&N?STEWD1Y^.O]5-FY>=SVAQY
ML;A+\V)\1C[1<R] CW_03S=DW2=X_7EW,+ OB?G/99ZFG'X\\*29?\;INF7W
MB]ET,9N,$ZYG&;V_1?YU.V^<7!_BM_HL<LM)]0H4JU7YS CR#2WM'%<+7'U.
MRC3IR]H)]0<?UH<047NB3V:+<S+'I-&?)Y=O_<H[@0E\YDB>MLG@%:/=9H1&
MP5U&QP<GS4<8Z?=H/CZR'QS;?0+C>S*^+_,2QY/N;/#5YS4SQ8\2/"B+[+C1
M3J<Z+;2.4LZ^ 'V+4UB5 [K,3=+_O!;Y0_Z6I^>Y9E,]UK+C^H&J]@JD_Z7+
MYM.8N3>R]FRC.#1(!D%C'=V'3B*JS-L4?^U!ZS^#7=T%GP^3--NJM\= 9Y4U
M\Y\9YS4W*\^_C6,>N22*]4:!B758BO(9L#A/@&**B>*UOS]]>4.RTMW/[3=T
MZ0]%AXJX1W2D/!Z]FB['RXMWYV<AST_+50[58F0-^LAK_.XPDT>@?4V:TJ"M
M#K(@3^*Q9F:+*P.VR/$OGV???J(E+FT7?7'?9#VQ?+])XOV!J2N-#-1;>SO^
MK_-Q(NYPFM8MAS[DQ>Q\'O->WMJ3G]>%M[8]P0=Z:RLK<KW:R</5;LT@B"8*
M[P"E,[4MF(/ B@3K5&(Z^QSU=N9[F]4..G=N+W"]46@_I=6LI%MAB,LJXJJ3
MU>HRB:QE2$H"YR$)M$DI)G?FZ(D%^_%WVFCXSBG40N#?H24Y(/S;YF-;VY46
MP>#VX(O61ADEUIJD"$I' VAU!'0B"$VN+1K;NWFY\=Q)5-.<7N%\2@[ZXB3&
M\[/S24W$?IG+.(Z7(\536(T&E'3LU@L7!2YQ"5JZY#T7I5$3CN=)&[H9V@4)
M#T.J3A4SE*>B6E9 GU@SI)87HQA=D-XE,"SZ6E<@P>5D(:88#":A%&]RK_J0
ME'YBK^- Z4#!#P ZCZ3@D; ^?IG-E[6V_?*Y;14[C#Q+Q8FB@!DG007-(6A6
MR!-@(:@8HU)-K-7V)/83F1T':HT4U??]SV^S^>\W/5YKOA1G3H8H IC$4VWS
MRL$%9J $SY5/GB&6K0[Y!Q_=3S%#6WAT(,0!6*$=6JW&;(WU00"/-3W=H0 ?
MLP/-C30N1R=SD^X4'3?)[;RJX#A6J)&B!AK(_8R+\6)6;E^K?3P_.\/YQ:Q\
M''^>CLE;Q.ER/1RGIAS-)N0_Y@76O/68[_QH/IO2E_'R(FZ?^*\A-5V$C<<2
M5D=/CP_IN&F=5E3.]<Z!%47>/P]T=)8@P6+4JK93P](D57HS20<'"$_)_^;N
M)1#C K,&D9&1[QHTA3W6@!.L))>8TVT>4K<CK]^GP([P\B""Z%XS_^V,Z=4O
M#LNH7E,U;./ZN/#:&UE6A!5,:RB1UTWCR$.M]\HL!I8R*U:TJ4=I9V17.CHM
M]Q:XN/SS9BLS(^C_F (;BJE]7!VYYDE#B-ZQE)(SI<F@D>W(&ZR1W04O]XUL
M \T,(&CZM78:>;58CL]P2?ZVT<B$1P/!B%5QB01?M*\CHU(T,D>,32JP[Y+1
M;Z9%(_P<(.D!X.1M30S*JU%WB_N05YY7UV75^ZAVXL^K%/=:J\9";=[+O6_2
M@.\)FOI-KVB$H*YT, X73V;O,_S58.C!U8TVSJ=SH!UHJ;KD@%%(0UH'9D5
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MG$-)#JQDY"D9DE63C)U=B/QN;.,NV'I0&-%*:]^?C3L@#6^+3VULY5JFX>T
M11DQU](]4$Q6A* 5(J#ULEYPX,5N<FMUE#,W,G9;+ZL/L*+V6+YXGQ>=_HH
M,1D520 ,*S4_VB!@H$U:+&9BQS*#3:Z5=R?UNS%YN^!L-Y-WL 8'<%%XGZ=[
M',=X?G8^P25YLG/R8F]\W.K8_EPM2JY51\Q%*[35X 0Z4#(*",$[*&AM3KHP
M:9O MA/J^\V8/Q*2CZ_G[QC<-6"[8;HPEU+A'(0)L=836W!*D0RL#C)8[8-O
M$M1W0GV_3<8&#N[]];P[N/TEN*>U5'3]NXW]BQCGYSF]J7D@I(230G^?3":S
M/^H],/W.S9OIU='%-4ICO0&!OH[GU0X"$0Y9>R9"3*;(-C-#N^6CW[KT87@F
M374_0,M^(XJ[@KEB3\?$.-<18D;:V[4=A'.60V1%>Y?)59--[E1VI',KZ.KO
M'+HM==?AJVCWEPE3PO3%OG<&E_]Q5U<#CY#2X0W ZM-?CA=Q,EN<S_,U:C3Z
M6N=;()LL*#8B)?J:-,]]L8KEA-DT>Q[90%,7STKW/OK6)1AJ)S%'T$43OR5Z
MB@5U!L00.69I1&[VJK:)J/[C]B[0\=B[32=J&/!=Y(J_PUY7;G]$IZ:D\<O)
M)L@$FZTPHH IVM8<!@G(LP(65)$E)2R^R;U#0X/R,7[)Z7R23\OU(NN#\/X-
M>\S1!0I2 HMU+)+D@(P%VBX!L^8\I[1-O<3.O&]+X' -S2ZHN6]HFJAGZ$;G
MP.>..Y_1J=EI_92Q"4'*1"9T+* =P4B%Q"&$I(&QZ%EQUC*S3>OX(=F=1^$\
M<LF+VN<3K HU+$0/+M6.?10N>JML#J')E<"CU S7HNR"AXVNR]Z"'T \_OX\
M3,;QUV7-8Z70[9JG=9]X81@3""75H<M!:PH6#9*]9=DZKTV.30;2/4740+"T
MO\YGC10P8#!]HO]^7<@F1<U5,#5,J.GXIM2B:V6 )9N3M#H'UL0 /T]:O\#J
M#@9;XFM/G?1= /AI/J9%Q_&:CW41HU;,!5LT^$367"D"@2N:0M+ F"Z*>QG2
M<R[/4PL,$QW[*G'6L42'@HJ78YQ<+'!Y/6A1V9)*?=,WG RSHS]0J@PABVA#
MUL@5VPD5]Q;HL52O$[4]AH-#9#@4')R\?[.FWLA@>1 .V*HZUD6BWJ4,EH44
M0PJ"WW\:>P8!UQ_=8R%=,]WO)[<!>![7DGA[78B3M/9)J 3DR=.AF7P![QT"
M%NLT"H]!-TD_?4A*_WDJW;JL!PI[2'#Y@'_\0J9N3C9O\2XO:Q_H19Y_RXN1
M]$P(1 8R%#I4%8G*1QOKN+V<D952MFJRMC]\-I(VD AH3^5OPE(WFA@2MGZ;
MS7]_,WT_G\6\N,>2B=)K%BQ8X\A08VT'$X2$Q%'6=)5:G-P47)MI&XBQZAA=
M'>EB2/!Z/9Z.%U]RJF/+[[%DM4G<> &97!B*%T4 +YP$9NL]>:0SW/.F\-I,
M6_]I;2W@U9$N^G:?UQ["R32]FTW7_[CF<82Q6F)&CD),M%$D,^!LH@B3A,8C
M-\D9N94K_>0R_2>!=0"0CJ6Y/RYF2YQT:W:(E[C.[W$B>!8EB<(X@K9V&C#Z
M!$**&!W+J.4VW0+W-S,WM/2??]7"K.PIZR&=4K4%2]1:U+;Q()6@6$/S!(B&
M_M!)Q:)E<NWJ(J^(V H@YKL#R([2'>A[-?EE7_-\>8&7B8M?:R;C/F_6CWY.
M%^_6SQ/8T=OUU4+O)SB]RN-<K793".HY13U<@%%8N_619^&**6 9N1)T:D09
MFQC=9RD[^/%HTP*/988QU"&4HD!:X4!YM.!+2"24Z+V6@3RL)@F)NQ#9\Y-!
MITAZ\*K42EG?D87:/Z/OB4]K9:T:YOD]CS26;)&.:2A8'ZBD<X!<:S"9!T(;
MSYX==[<VMUDWX"\Z<8W<@;%U5++R]G)Z1?:*SG\A>6I3A/8\:4.W3[N@9FO[
MM)]BOB.K=$#*WU,?U\HNM4P$W.((+$*([!(DY'4,1&VKG+R!S(K-2>48PO?I
M3-UDNV[>":MW(,:2\3S1)BN%PA!=2JT'<D#!9HI<2J;:F*=M"1RZD=H%09M3
MDCM4T@""_XW<_+Q*6%FE-#D;HO+:0B$OD%@*&9PS$6S D$P6,6XU-*"[G7=#
M6[^0:P.*;8_'/34T9-#=RI$JU6T()8(PM0M"U!Y"# :BH(.?:V^9;I//^CQM
M [5S^^)A:W=L/^4, &]O,R[RE]DDO3G[.I]]6PUON!H#9)/+CJ)G8"@L*.88
MT#\1A#>L1"NB;O.\^P1- \77OOJ?M5'& '#U"Y(LIWE^<5M,5TE9M-4<$Y%B
ME#J_C!,_/J4$U=QK@4'Z^_,@N\'5$S3UFR[0&E==*6, N#HM91SS?29T413]
M%0\L6(JQC57@ J[*ZH+A.F<,34[$1ZGI-S>@-98.5\ 04%3G@C^U*U"YR+P.
M8+5BH!PQY6K1@F>V>&*/I=!DM/9SA/6;5M <6UVJ90 PVRBOF_=3RUEMA:K!
M.D_'>N8!7)8>'*_M]A5*Y>11??FWPTCW[3=^W$\_0T;<JO/82!FN"O<*$JO<
M,,O N\(A"#1><5>?ZX^*MA59 W7J]P3!MAC;72,#P->M7G8O,Q$1QRL]T=>3
MO%+8-*V[DJZ^OY'YD<FZI#JCSXO$ZS&AP&OEP5J3:>,*'U@3N]<5 P,-&+K!
M;"]:'D1+PXVLU!0EZ6W)DF28ZMN_THJ.&EY;ZT;T'HD>[IO,$7J*J($&&XUM
MYZ[:&$#FZ>V--.(I899.D:M2G19T"$&FVOE31V^D$B4V0=)M(@8:2G2#G+VE
M/= G\G5#S:M1;>/]$G8>^90N'L2?(ZZK=W"\6&7_U-.GKHB3FWZ0R@:;5!80
MG1?D1J&$D(H#RS#7Q"RM<YOTE,TT=>!JU2'*B_425RO<D?-C:6I>,!F=-;1C
M(J'=9-HQ0A#:;2*?TGH38Y/;U3WI[=GY[PA3CWA0S97WW9BJ_3,,-WY6&[/5
M,KOP": 5+5$I1,@Y:U#!6#KC; %CB\FD?J5EFSN@=L;KYOIF@Y1O(!^29RY*
M"9X+PKTD.7CN AC&LXM9*.^:)"]M3^)P3=0NR-F<MM.IBKX;JW1 AN'F#VMC
MEYIF%SX!+YNMC*1;"(H54+XP"M\]A>_91!9XR*C-=V*8U@-O%YF068<GOLS?
M\F2VBC@^Y-5-QRUY7W7^CEZ78BBF3$+2:5PD!U?_\(E._Z(Y.0'N.:SLL_!P
M#<XNB+A31=I2] .X%WU%9F-VD?-FAE(PY$N2T<R^3O<HN5[TI@":"65324:V
M&2/X+&4]WV1V#+8V"NF[HGU])/PZ_38[IV.;5O^08QY_75YS4\CB9$;<A!(\
MJ.CHL"XDL.)]L2%F'31N9:J>7:KG&\<6QJE;\0[ '-4^(?1A+V9G7_-TL79!
M+G? 5?^D$7<<O> >C/(2E""^G-$U\DQ&A,1,*DW*F;>@K>>KR48FJ6NE# !G
MJX2-A_[J%3=$+>,*-4@I=7V;)VD)EL![1E\;Z6*;1+^GR>JWR4(K='6HB@$
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MG[760M\7VS\C>13SOV><++]$$NCI_#-.UVG%ZYJ?(I/G.B0HTH2:0VP@:,G
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MS\35L;!TBZY^<R.. ZA]U3 5+V8G9W-IH\?ZEGP9".96)Y*W2 <P44N0!9A
MC4@I.=/D?>$)FOIM]M0]FKH2_["0M/'DUL$S::*#',MJX)L%K-N$ E:.)$*F
M<VM$'>1+->O[U!19G:AC6 B[<Y"S$H3*-H,K)H&JQA<I#H&8E?'$0RRFS47"
MX_1LA23[72)I;[$/$3VW3VU9<O1U4 .MK$$E;HBK+,%YZV0TCBG7I)[G*:*V
MPI'[CG&TKP+Z?N>LKWV+ZRJW3X2'1<V26C\"KE@;I2RYY9ZL:NVMIY3WX% %
MR!A$U$);[;>K,]UBL:V XH</E";"'0)89I?2^9#K2S"A_9+'LUI^.=(V!ALC
M I.U;W6=J1>2%9""*#ZC1K]EWOHS"VUW(<F^(Y1T)=4A)XK^C(N<;K<8WCM+
M].$G=98B^@R1'>6'WN0#GY;;BZU;PK^8+9:+E7T(E9SWEQ4*-]U34>>$/ECP
MA8=J,S0$76S-G8C,19%<FWS2P\@^N)9YV]5_OKWZ3<*U<5J%P!Q$[E;W^IHL
MK4V@;8A>6:^D;U)*>"#=/5>U'@^I#XJCCZCO[\IN[C^T[,G/:V=#&PXO.Q"?
M3#%V.9;*J5QG7!OPL5X=J.!M<HG.[C:]#WJUI#=/]%>S2#[F^;=QS#?;Z391
M)Y/51])7I^6FSO=]GH]GEY1>/NYS8W,V',$:G^M<'%];= 6((JMLG.$N-*X!
MZ)";[]KJ[H+JS=4&?6%C /<K)W_@/-46'ZL<-Z63338JR,80\4HY<"YH,#D6
ME^DXXZ[):]0=*H92C] ;*NY/ =A;10/ UP:IW50[+WZ^>.#:K#B^87N:ZH#J
M6[V.LG>Q*'*SM+$>5+9(NSYQ"-:BB-K55B!-[&\#9OI%^P'8NF]-^U;T ,#^
M(=.Q-([+]3/S58O&%#-COH! QT!%PA6F'($%3G];4TJ;DN1'J>G9N/8.DEG7
M&NN_[\;Z?%J)[!X_OT['U_W<@D<3M4^ FHEZ!!6HS45 :_2R\&)M3L]%53NL
MUW/QQE" UDI#_<..?)PRFY_A]'G&+$O.^ER[D IB3"L+SJ:\2I%0U0/B66P%
MO>W7[#DS?%#P:Z2IWM]H;NVJ%2.G7U=2KA*\XJ=DD;)R" YU 24* CI3(&E>
MM$LFDQ1W-GH;%NLW9VY8D.M:-WUC[?X6VL13U$H@;1+PK!!/B4FHV3I 9KQH
MJ:Q N=TAN^6"_6;6#0MS+70T@*"BFVN(F]?;E&(*_W][7];D5HZC^W[_"^YP
M7UYNA+N6"4]4V14N3_?,DX(+:"LZ+=7D4EV>7W]!Y>+,M#)31SK4X9$]2W=Z
MDTC@ PB0P =9%$2A4QT=2**E:)>VKS!DYP)3K$4Z,O(^>FD.[N66:$J8=& E
MHROD[G$-=<FL2 /NNG8%!<1:[:0-YNQS5KM-99K^LK^/9]9)<=KZ!6 OT'1E
M/=MWOBUCN#['T^7RS^7EYXW_^K)].J4M%\$"AD1*T3%"0%<'V?!4>(J<,MVV
M-C/*/J8]8_JTE.,#I%/[N!_.W@LU+VJQ_K5J+BZN/EW_WN/=(W-.UDFMPF>*
M0(N%(&T"8YBD1(!$XMOP-8VZC6FO6'JWCB/!HU/CN*^$^[M_PAUX4;Q724.Q
MJ,@=5-X$82)D:]!0EL:Y;)*3'+[T:2]]>C>"AC"851W;EPJ6=.]W\:_ZXR&3
MJ _XMG8U<,,WVT>%7!#.EZ0]B%@$Q>R9PI'$?>UH"<JX'(QMTN9XBA5RUN3D
MF-\$=+$2)M5'+2? 9AVE)%\B]#R2YME7R U!]7$JY(9@HX/PYF&)3.4V5KQX
MD,K4TH!(9R4%:^"Y0IXE%J&;9+8G7R$W"!7/5L@-45$'^&KRB,*$QLRU!BZY
M R5KKUU)!0I9?,S1",V;C/(Y]0JY0=@Z1H7<$$5/_8AZ_U'XP8N<<BI(YFD3
MO)Y17E+J6]_FO$R>26Z=>5QVO,,K_>!GTGE5O0U2_%-/\WMKH2<H/5/.HIGF
MJ*,#(>L(@LB0\ED,$(0M(AI,SL3!P#JPZ&ATF(VHU3V*UH:(N"?4/%4=H+*Q
M6+0#)Q/%(76TN@NN#E1WC-G >'@\GJ%QQ=#H[PM'P,L8PIT:+(_+21[6+ADK
MM+(6(J\#<&4L$!7G$(,1J(72TNV&DN>^Y01+:/<^M4;31F^P>N1:'^R+I&6T
M30A,4:BMN/5DAIQ!"4ZP('S2EN^%LF>^=,(S;#P=#ZA^W5O@G0/I_AE-7M=&
MG<G/>E4H:RD)O+ 1G)!"9&9UY+O%UR/77[<YVB:!T;[B[@U%3YW<@G,ZGLDR
M"M8'>Z,C!%TDE)1Y3!3QD?<^>F'KZ(_+1\3/&(+NX/9J[!?($)@JWE$ZX;2H
M4V@#>6"TD)UU(CGF4,N'./M>G3J#&]HI8=*!E=SLC*Q^Z\9_NGX;76CED_>>
MTF@GZX 0.CV\BAQ8L%DZZ:/,V +\NRWOM.I&!R'H\7O#^.H<L9_O& 4-6X/H
MT0L9GOV6=@4,NV^NC\(%Y'7Z5%($L4HYK6N[LM<*F$Z%LA;+'3M!DK27ZHUV
MN:FX/MA2$0P]B8[Q0$*,E1+7UAU+2[[ 959B$]:3T78PZP*%(>@=6G/6!@,]
M!!0/7B6]82YJ$2%+3P<-JRWDQ2>0"8L72NALF@3-718E'!4)SQ8B#%%+!YAJ
M<N%+N2NGA#F#=EQ3TE $)0U&@!36&Q\T-]@DI#WU0H1!V#I&(<(017< ]NW$
M+T%GK7TB0$7&0"$SX*U58!,/,:B03!MBOV^%JF<02':BZAFBL>XY4QY<!#KG
MM'7&0RZ2U8M 3[Q6FJ$*A;'HW#RI;2JR>//O%X<]X%<4UUUX/Q>%/13<OYR
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M&=_,GIIL:?:- =;T/1(.8D"Y:,5(T]7>-QQD3&JA$D$#4DY1U:0)03C%*1B
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M8VN<NZR' EFXS'+6T4'TO-1J<A*$9@5B5L8FAR(W/)Q:[&C&.=FHH&UWVW\
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MNHW$NP3/^W^M;WD*=%&%T_D0BR3#\UF"3Q1*%B&<4I$+(\+^X+G[GNGRK$[
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MNA^-FM=N3^-MDU+=V7!*#E+S;IR20V3> 7*V\QL*HX,*H@ Y7%UG(/#*ZEL
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MJ/\1PP7^O__S_P%02P,$% @ L8D04_/[L(W$!P %", !H !R;71I
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MKUNLL>*9M;^>PF,$3.6VI]SSAD;]&=X7\6^N'/T/4$L#!!0 ( +&)$%,Y
M6;G5 @ &LE : <FUT:2TR,#(Q,#8S,'@Q,'%E>#,Q,BYH=&WM6FEO
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M+L-+@6#O^X&@9(G*$&3"RSJH=> /S5%M-^I5EH!1."DN?(]U*3 F@+,1P3I
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M^')G,DZI@3M G_0I89I;L<07$*]XI+0J%J03=DU+N\U#T:,L;)1;33?TK<]
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MP2Z+[2X/O/A3?8;7D/P+42?_!5!+ P04 " "QB1!3MLR(KR\% #D$P
M&@ ')M=&DM,C R,3 V,S!X,3!Q97@S,C$N:'1M[5AM<QHW$/[>7['%T[S,
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M:B\[\5%KV6[Y46=Y]%N 3GHH7N@HO>/T66W#4F=-C?UN,W0/6YGN;5FLU]W
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M_LO>Q!W_"5!+ 0(4 Q0 ( +&)$%/HO/)T.N ! #[G%0 1
M " 0 !R;71I+3(P,C$P-C,P+FAT;5!+ 0(4 Q0 ( +&)$%,)%GTT
MD1$ *B\ 1 " 6G@ 0!R;71I+3(P,C$P-C,P+GAS9%!+
M 0(4 Q0 ( +&)$%.9KUX8*!X (XH 0 5 " 2GR 0!R
M;71I+3(P,C$P-C,P7V-A;"YX;6Q02P$"% ,4 " "QB1!3VJ6+_G!9 !!
M'P0 %0 @ &$$ ( <FUT:2TR,#(Q,#8S,%]D968N>&UL4$L!
M A0#% @ L8D04TKE@3=9WP '$8) !4 ( !)VH" ')M
M=&DM,C R,3 V,S!?;&%B+GAM;%!+ 0(4 Q0 ( +&)$%.$CY@Z$HD &V"
M!@ 5 " ;-) P!R;71I+3(P,C$P-C,P7W!R92YX;6Q02P$"
M% ,4 " "QB1!3\_NPC<0' 4(P &@ @ 'XT@, <FUT
M:2TR,#(Q,#8S,'@Q,'%E>#,Q,2YH=&U02P$"% ,4 " "QB1!3.5FYU0 (
M !K)0 &@ @ 'TV@, <FUT:2TR,#(Q,#8S,'@Q,'%E>#,Q
M,BYH=&U02P$"% ,4 " "QB1!3MLR(KR\% #D$P &@
M@ $LXP, <FUT:2TR,#(Q,#8S,'@Q,'%E>#,R,2YH=&U02P4& D "0!B
) @ D^@#
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>